|('DB01148', 'MONDO:0005280', ['prostatitis'], 'for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitisurethrotrigonitis')|
|('DB01359', 'MONDO:0005280', ['prostatitis'], 'penbutolol is indicated in the treatment of mild to moderate arterial hypertension it may be used alone or in combination with other antihypertensive agents especially thiazidetype diureticspenbutolol is contraindicated in patients with cardiogenic shock sinus bradycardia second and third degree atrioventricular conduction block bronchial asthma and those with known hypersensitivity')|
|('DB01359', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'penbutolol is indicated in the treatment of mild to moderate arterial hypertension it may be used alone or in combination with other antihypertensive agents especially thiazidetype diureticspenbutolol is contraindicated in patients with cardiogenic shock sinus bradycardia second and third degree atrioventricular conduction block bronchial asthma and those with known hypersensitivity')|
|('DB00246', 'MONDO:0005280', ['prostatitis'], 'in its oral form ziprasidone is approved for the treatment of schizophrenia as monotherapy for acute treatment of manic or mixed episodes related to bipolar i disorder and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar i disorderl7342 the injectable formulation is approved only for treatment of acute agitation in schizophrenial7342')|
|('DB00246', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'in its oral form ziprasidone is approved for the treatment of schizophrenia as monotherapy for acute treatment of manic or mixed episodes related to bipolar i disorder and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar i disorderl7342 the injectable formulation is approved only for treatment of acute agitation in schizophrenial7342')|
|('DB00246', 'MONDO:0001866', ['bipolar I disorder'], 'in its oral form ziprasidone is approved for the treatment of schizophrenia as monotherapy for acute treatment of manic or mixed episodes related to bipolar i disorder and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar i disorderl7342 the injectable formulation is approved only for treatment of acute agitation in schizophrenial7342')|
|('DB04878', 'MONDO:0001866', ['bipolar I disorder'], 'for the treatment of diabetes it is specifically used for lowering postprandial blood glucose levels thereby reducing the risk of macrovascular complications')|
|('DB06589', 'MONDO:0001866', ['bipolar I disorder'], 'treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients previously treated with chemotherapy ')|
|('DB06589', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients previously treated with chemotherapy ')|
|('DB00133', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'used as a natural moisturizing agent in some cosmetics and skin care products')|
|('DB00972', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'intranasal azelastine is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and olderl8240 ophthalmic azelastine solution is indicated for the treatment of itchy eyes associated with allergic conjunctivitisl8270')|
|('DB00972', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'intranasal azelastine is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and olderl8240 ophthalmic azelastine solution is indicated for the treatment of itchy eyes associated with allergic conjunctivitisl8270')|
|('DB00972', 'MONDO:0006004', ['vasomotor rhinitis'], 'intranasal azelastine is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and olderl8240 ophthalmic azelastine solution is indicated for the treatment of itchy eyes associated with allergic conjunctivitisl8270')|
|('DB00322', 'MONDO:0006004', ['vasomotor rhinitis'], 'for palliative management of gastrointestinal adenocarcinoma metastatic to the liver when given by continuous regional intraarterial infusion in carefully selected patients who are considered incurable by surgery or other means also for the palliative management of liver cancer usually administered by hepatic intraarterial infusion')|
|('DB00322', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'for palliative management of gastrointestinal adenocarcinoma metastatic to the liver when given by continuous regional intraarterial infusion in carefully selected patients who are considered incurable by surgery or other means also for the palliative management of liver cancer usually administered by hepatic intraarterial infusion')|
|('DB00833', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'for the treatment of certain infections caused by bacteria such as pneumonia and ear lung skin throat and urinary tract infections')|
|('DB00748', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'for symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis as well as allergic conjunctivitis caused by foods and inhaled allergens also for the relief of allergic reactions to blood or plasma and the symptomatic management of mild uncomplicated allergic skin manifestations of urticaria and angioedema')|
|('DB00748', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis as well as allergic conjunctivitis caused by foods and inhaled allergens also for the relief of allergic reactions to blood or plasma and the symptomatic management of mild uncomplicated allergic skin manifestations of urticaria and angioedema')|
|('DB00748', 'MONDO:0006004', ['vasomotor rhinitis'], 'for symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis as well as allergic conjunctivitis caused by foods and inhaled allergens also for the relief of allergic reactions to blood or plasma and the symptomatic management of mild uncomplicated allergic skin manifestations of urticaria and angioedema')|
|('DB00748', 'MONDO:0005492', ['urticaria'], 'for symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis as well as allergic conjunctivitis caused by foods and inhaled allergens also for the relief of allergic reactions to blood or plasma and the symptomatic management of mild uncomplicated allergic skin manifestations of urticaria and angioedema')|
|('DB00748', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis as well as allergic conjunctivitis caused by foods and inhaled allergens also for the relief of allergic reactions to blood or plasma and the symptomatic management of mild uncomplicated allergic skin manifestations of urticaria and angioedema')|
|('DB00318', 'MONDO:0005492', ['urticaria'], 'codeine sulfate is a form of this drug that is commonly used it is available in tablet form fda label and indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate fda labelthe solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above l5521 l5524 ')|
|('DB00666', 'MONDO:0005492', ['urticaria'], 'for treatment of central precocious puberty true precocious puberty gnrhdependent precocious precocity complete isosexual precocity in children of both sexes and for the treatment of endometriosis')|
|('DB00666', 'MONDO:0019165', ['precocious puberty, central [OMIMPS:176400]', 'CPP [Orphanet:759]', 'gonadotropin-dependent precocious puberty []', 'gonadotropin-dependant precocious puberty [Orphanet:759]', 'central precocious puberty'], 'for treatment of central precocious puberty true precocious puberty gnrhdependent precocious precocity complete isosexual precocity in children of both sexes and for the treatment of endometriosis')|
|('DB00666', 'MONDO:0000088', ['sexual precocity [GARD:0007446,https://rarediseases.org/rare-diseases/precocious-puberty/]', 'pubertas praecox [https://rarediseases.org/rare-diseases/precocious-puberty/]', 'precocious puberty'], 'for treatment of central precocious puberty true precocious puberty gnrhdependent precocious precocity complete isosexual precocity in children of both sexes and for the treatment of endometriosis')|
|('DB00666', 'MONDO:0005133', ['endometriosis'], 'for treatment of central precocious puberty true precocious puberty gnrhdependent precocious precocity complete isosexual precocity in children of both sexes and for the treatment of endometriosis')|
|('DB00732', 'MONDO:0000088', ['sexual precocity [GARD:0007446,https://rarediseases.org/rare-diseases/precocious-puberty/]', 'pubertas praecox [https://rarediseases.org/rare-diseases/precocious-puberty/]', 'precocious puberty'], 'for use as an adjunct to general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation')|
|('DB06151', 'MONDO:0000088', ['sexual precocity [GARD:0007446,https://rarediseases.org/rare-diseases/precocious-puberty/]', 'pubertas praecox [https://rarediseases.org/rare-diseases/precocious-puberty/]', 'precocious puberty'], 'acetylcysteine is used mainly as a mucolytic and in the management of paracetamol acetaminophen overdose')|
|('DB00218', 'MONDO:0000088', ['sexual precocity [GARD:0007446,https://rarediseases.org/rare-diseases/precocious-puberty/]', 'pubertas praecox [https://rarediseases.org/rare-diseases/precocious-puberty/]', 'precocious puberty'], 'for the treatment of sinus and lung infections such as sinusitis pneumonia and secondary infections in chronic bronchitis also for the treatment of bacterial conjunctivitis pinkeye')|
|('DB00218', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of sinus and lung infections such as sinusitis pneumonia and secondary infections in chronic bronchitis also for the treatment of bacterial conjunctivitis pinkeye')|
|('DB00218', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of sinus and lung infections such as sinusitis pneumonia and secondary infections in chronic bronchitis also for the treatment of bacterial conjunctivitis pinkeye')|
|('DB00218', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'for the treatment of sinus and lung infections such as sinusitis pneumonia and secondary infections in chronic bronchitis also for the treatment of bacterial conjunctivitis pinkeye')|
|('DB00208', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'used in patients who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked to try to prevent another thrombotic stroke')|
|('DB00208', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'used in patients who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked to try to prevent another thrombotic stroke')|
|('DB06725', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of acute mild to moderate pain as well as pain and inflammation of the joints caused by certain types of rheumatic diseases')|
|('DB01105', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of obesity')|
|('DB01078', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment and management of congestive cardiac insufficiency arrhythmias and heart failure')|
|('DB01078', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment and management of congestive cardiac insufficiency arrhythmias and heart failure')|
|('DB00264', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'metoprolol is indicated for the treatment of angina heart failure myocardial infarction atrial fibrillation atrial flutter and hypertensiona175141some offlabel uses of metoprolol include supraventricular tachycardia and thyroid storma175141all the indications of metoprolol are part of cardiovascular diseases these conditions correspond to a number of diseases that involve the function of the heart and blood vessels the underlying causes of these conditions are variable and can be due to genetic disposition lifestyle decisions such as smoking obesity diet and lack of exercise and comorbidity with other conditions such as diabetes the cardiovascular diseases are the leading cause of death on a global scalel5533')|
|('DB00264', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'metoprolol is indicated for the treatment of angina heart failure myocardial infarction atrial fibrillation atrial flutter and hypertensiona175141some offlabel uses of metoprolol include supraventricular tachycardia and thyroid storma175141all the indications of metoprolol are part of cardiovascular diseases these conditions correspond to a number of diseases that involve the function of the heart and blood vessels the underlying causes of these conditions are variable and can be due to genetic disposition lifestyle decisions such as smoking obesity diet and lack of exercise and comorbidity with other conditions such as diabetes the cardiovascular diseases are the leading cause of death on a global scalel5533')|
|('DB00264', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'metoprolol is indicated for the treatment of angina heart failure myocardial infarction atrial fibrillation atrial flutter and hypertensiona175141some offlabel uses of metoprolol include supraventricular tachycardia and thyroid storma175141all the indications of metoprolol are part of cardiovascular diseases these conditions correspond to a number of diseases that involve the function of the heart and blood vessels the underlying causes of these conditions are variable and can be due to genetic disposition lifestyle decisions such as smoking obesity diet and lack of exercise and comorbidity with other conditions such as diabetes the cardiovascular diseases are the leading cause of death on a global scalel5533')|
|('DB00264', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'metoprolol is indicated for the treatment of angina heart failure myocardial infarction atrial fibrillation atrial flutter and hypertensiona175141some offlabel uses of metoprolol include supraventricular tachycardia and thyroid storma175141all the indications of metoprolol are part of cardiovascular diseases these conditions correspond to a number of diseases that involve the function of the heart and blood vessels the underlying causes of these conditions are variable and can be due to genetic disposition lifestyle decisions such as smoking obesity diet and lack of exercise and comorbidity with other conditions such as diabetes the cardiovascular diseases are the leading cause of death on a global scalel5533')|
|('DB01115', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the management of vasospastic angina chronic stable angina hypertension and raynauds phenomenon may be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension longacting agents ')|
|('DB00304', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'oral desogestrel is used in combination with ethinylestradiol as a contraceptive agent for the prevention of pregnancyfda labeldesogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulationl5698')|
|('DB00302', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use in patients with hemophilia for short term use two to eight days to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction it can also be used for excessive bleeding in menstruation surgery or trauma cases')|
|('DB00302', 'MONDO:0018660', ['hemophilia'], 'for use in patients with hemophilia for short term use two to eight days to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction it can also be used for excessive bleeding in menstruation surgery or trauma cases')|
|('DB00302', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for use in patients with hemophilia for short term use two to eight days to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction it can also be used for excessive bleeding in menstruation surgery or trauma cases')|
|('DB00432', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2 in ophthalmic solutionstrifluridine in combination with tipiracil as oral tablets is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf biological therapy and if ras wildtype an antiegfr therapy fda label')|
|('DB00432', 'MONDO:0004768', ['keratoconjunctivitis'], 'trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2 in ophthalmic solutionstrifluridine in combination with tipiracil as oral tablets is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf biological therapy and if ras wildtype an antiegfr therapy fda label')|
|('DB00432', 'MONDO:0003085', ['keratitis'], 'trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2 in ophthalmic solutionstrifluridine in combination with tipiracil as oral tablets is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf biological therapy and if ras wildtype an antiegfr therapy fda label')|
|('DB00432', 'MONDO:0004992', ['cancer'], 'trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2 in ophthalmic solutionstrifluridine in combination with tipiracil as oral tablets is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf biological therapy and if ras wildtype an antiegfr therapy fda label')|
|('DB00360', 'MONDO:0004992', ['cancer'], 'for the treatment of tetrahydrobiopterin bh4 deficiency')|
|('DB01553', 'MONDO:0004992', ['cancer'], 'used primarily as an antianxiety agent typically used short term and may be given as a single dose of up to 100mcgkg to reduce anxiety and tension experienced prior to surgery ')|
|('DB01553', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used primarily as an antianxiety agent typically used short term and may be given as a single dose of up to 100mcgkg to reduce anxiety and tension experienced prior to surgery ')|
|('DB00341', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'seasonal allergic rhinitis indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed grass and tree pollens in adults and children 2 years of age and above symptoms treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing and redness of the eyes fda label perennial allergic rhinitis this drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites animal dander and molds in adults and children 6 months of age and older symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing fda label chronic urticaria cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older it markedly reduces the occurrence severity and duration of hives and significantly reduces pruritus fda label')|
|('DB00341', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'seasonal allergic rhinitis indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed grass and tree pollens in adults and children 2 years of age and above symptoms treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing and redness of the eyes fda label perennial allergic rhinitis this drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites animal dander and molds in adults and children 6 months of age and older symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing fda label chronic urticaria cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older it markedly reduces the occurrence severity and duration of hives and significantly reduces pruritus fda label')|
|('DB00341', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'seasonal allergic rhinitis indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed grass and tree pollens in adults and children 2 years of age and above symptoms treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing and redness of the eyes fda label perennial allergic rhinitis this drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites animal dander and molds in adults and children 6 months of age and older symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing fda label chronic urticaria cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older it markedly reduces the occurrence severity and duration of hives and significantly reduces pruritus fda label')|
|('DB00341', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'seasonal allergic rhinitis indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed grass and tree pollens in adults and children 2 years of age and above symptoms treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing and redness of the eyes fda label perennial allergic rhinitis this drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites animal dander and molds in adults and children 6 months of age and older symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing fda label chronic urticaria cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older it markedly reduces the occurrence severity and duration of hives and significantly reduces pruritus fda label')|
|('DB01158', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'for use in the prophylaxis and therapy of ventricular fibrillation also used in the treatment of lifethreatening ventricular arrhythmias such as ventricular tachycardia that have failed to respond to adequate doses of a firstline antiarrhythmic agent such as lidocaine')|
|('DB01158', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'for use in the prophylaxis and therapy of ventricular fibrillation also used in the treatment of lifethreatening ventricular arrhythmias such as ventricular tachycardia that have failed to respond to adequate doses of a firstline antiarrhythmic agent such as lidocaine')|
|('DB01414', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'cefacetrile is a broadspectrum first generation cephalosporin antibiotic effective in grampositive and gramnegative bacterial infections')|
|('DB01611', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported treatment of uncomplicated malaria caused by p falciparum p malariae p ovale or p vivax chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis and chronic rheumatoid arthritisl8072')|
|('DB01611', 'MONDO:0005136', ['induced malaria', 'malaria'], 'hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported treatment of uncomplicated malaria caused by p falciparum p malariae p ovale or p vivax chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis and chronic rheumatoid arthritisl8072')|
|('DB01611', 'MONDO:0019558', ['DLE [NCIT:C26820]', 'discoid lupus erythematosus'], 'hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported treatment of uncomplicated malaria caused by p falciparum p malariae p ovale or p vivax chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis and chronic rheumatoid arthritisl8072')|
|('DB01611', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported treatment of uncomplicated malaria caused by p falciparum p malariae p ovale or p vivax chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis and chronic rheumatoid arthritisl8072')|
|('DB01611', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported treatment of uncomplicated malaria caused by p falciparum p malariae p ovale or p vivax chronic discoid lupus erythematosus systemic lupus erythematosus acute rheumatoid arthritis and chronic rheumatoid arthritisl8072')|
|('DB00960', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the management of hypertension edema ventricular tachycardias and atrial fibrillation')|
|('DB00960', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the management of hypertension edema ventricular tachycardias and atrial fibrillation')|
|('DB01203', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'nadolol is indicated to treat angina pectoris and hypertensionl7922 another product formulated with bendroflumethiazide is indicated to treat hypertensionl7925')|
|('DB00849', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the relief of anxiety tension and apprehension also used as an anticonvulsant for the treatment of epilepsy')|
|('DB00849', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the relief of anxiety tension and apprehension also used as an anticonvulsant for the treatment of epilepsy')|
|('DB00849', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the relief of anxiety tension and apprehension also used as an anticonvulsant for the treatment of epilepsy')|
|('DB06827', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'viomycin is an essential component in the drug cocktail currently used to fight infections of mycobacterium tuberculosis')|
|('DB01132', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus fda label')|
|('DB01132', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus fda label')|
|('DB01173', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'indicated as an adjunct to rest physical therapy and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions')|
|('DB00479', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'the amikacin sulfate injection is indicated in the shortterm treatment of serious bacterial infections due to susceptible strains of gramnegative bacteria including pseudomonas species escherichia coli species of indolepositive and indolenegative proteus providencia species klebsiellaenterobacterserratia species as well as acinetobacter mimaherellea speciesf1954clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia including neonatal sepsis in serious infections of the respiratory tract bones and joints central nervous system including meningitis and skin and soft tissue intraabdominal infections including peritonitis and in burns and postoperative infections including postvascular surgeryf1954clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to the above organisms aminoglycosides including amikacin are not indicated in uncomplicated firsttime episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxicf1954in september 2018 a new indication with a new dosage route was approved for this drug amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria mycobacterium avium complex mac in a limited population of patients with the disease who do not respond to conventional treatment refractory diseasel4673 this indication is approved under accelerated approval based on achieving sputum culture conversion defined as 3 consecutive negative monthly sputum cultures by month 6 of treatment clinical benefit has not yet been establishedlabelimportant notes regarding staphylococcus and sensitivity testingstaphylococcus aureus including methicillinresistant strains is the principal grampositive organism sensitive to amikacinthe use of amikacin in the treatment of staphylococcal infections should be restricted only to secondline therapy and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibioticsf1949bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin amikacin may be used as initial therapy in suspected gramnegative infections and therapy may be initiated before obtaining the results of susceptibility testinglabelf1949f1954')|
|('DB00479', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'the amikacin sulfate injection is indicated in the shortterm treatment of serious bacterial infections due to susceptible strains of gramnegative bacteria including pseudomonas species escherichia coli species of indolepositive and indolenegative proteus providencia species klebsiellaenterobacterserratia species as well as acinetobacter mimaherellea speciesf1954clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia including neonatal sepsis in serious infections of the respiratory tract bones and joints central nervous system including meningitis and skin and soft tissue intraabdominal infections including peritonitis and in burns and postoperative infections including postvascular surgeryf1954clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to the above organisms aminoglycosides including amikacin are not indicated in uncomplicated firsttime episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxicf1954in september 2018 a new indication with a new dosage route was approved for this drug amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria mycobacterium avium complex mac in a limited population of patients with the disease who do not respond to conventional treatment refractory diseasel4673 this indication is approved under accelerated approval based on achieving sputum culture conversion defined as 3 consecutive negative monthly sputum cultures by month 6 of treatment clinical benefit has not yet been establishedlabelimportant notes regarding staphylococcus and sensitivity testingstaphylococcus aureus including methicillinresistant strains is the principal grampositive organism sensitive to amikacinthe use of amikacin in the treatment of staphylococcal infections should be restricted only to secondline therapy and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibioticsf1949bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin amikacin may be used as initial therapy in suspected gramnegative infections and therapy may be initiated before obtaining the results of susceptibility testinglabelf1949f1954')|
|('DB00479', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'the amikacin sulfate injection is indicated in the shortterm treatment of serious bacterial infections due to susceptible strains of gramnegative bacteria including pseudomonas species escherichia coli species of indolepositive and indolenegative proteus providencia species klebsiellaenterobacterserratia species as well as acinetobacter mimaherellea speciesf1954clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia including neonatal sepsis in serious infections of the respiratory tract bones and joints central nervous system including meningitis and skin and soft tissue intraabdominal infections including peritonitis and in burns and postoperative infections including postvascular surgeryf1954clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to the above organisms aminoglycosides including amikacin are not indicated in uncomplicated firsttime episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxicf1954in september 2018 a new indication with a new dosage route was approved for this drug amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria mycobacterium avium complex mac in a limited population of patients with the disease who do not respond to conventional treatment refractory diseasel4673 this indication is approved under accelerated approval based on achieving sputum culture conversion defined as 3 consecutive negative monthly sputum cultures by month 6 of treatment clinical benefit has not yet been establishedlabelimportant notes regarding staphylococcus and sensitivity testingstaphylococcus aureus including methicillinresistant strains is the principal grampositive organism sensitive to amikacinthe use of amikacin in the treatment of staphylococcal infections should be restricted only to secondline therapy and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibioticsf1949bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin amikacin may be used as initial therapy in suspected gramnegative infections and therapy may be initiated before obtaining the results of susceptibility testinglabelf1949f1954')|
|('DB00479', 'MONDO:0005275', ['lung disease'], 'the amikacin sulfate injection is indicated in the shortterm treatment of serious bacterial infections due to susceptible strains of gramnegative bacteria including pseudomonas species escherichia coli species of indolepositive and indolenegative proteus providencia species klebsiellaenterobacterserratia species as well as acinetobacter mimaherellea speciesf1954clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia including neonatal sepsis in serious infections of the respiratory tract bones and joints central nervous system including meningitis and skin and soft tissue intraabdominal infections including peritonitis and in burns and postoperative infections including postvascular surgeryf1954clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to the above organisms aminoglycosides including amikacin are not indicated in uncomplicated firsttime episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxicf1954in september 2018 a new indication with a new dosage route was approved for this drug amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria mycobacterium avium complex mac in a limited population of patients with the disease who do not respond to conventional treatment refractory diseasel4673 this indication is approved under accelerated approval based on achieving sputum culture conversion defined as 3 consecutive negative monthly sputum cultures by month 6 of treatment clinical benefit has not yet been establishedlabelimportant notes regarding staphylococcus and sensitivity testingstaphylococcus aureus including methicillinresistant strains is the principal grampositive organism sensitive to amikacinthe use of amikacin in the treatment of staphylococcal infections should be restricted only to secondline therapy and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibioticsf1949bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin amikacin may be used as initial therapy in suspected gramnegative infections and therapy may be initiated before obtaining the results of susceptibility testinglabelf1949f1954')|
|('DB00479', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the amikacin sulfate injection is indicated in the shortterm treatment of serious bacterial infections due to susceptible strains of gramnegative bacteria including pseudomonas species escherichia coli species of indolepositive and indolenegative proteus providencia species klebsiellaenterobacterserratia species as well as acinetobacter mimaherellea speciesf1954clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia including neonatal sepsis in serious infections of the respiratory tract bones and joints central nervous system including meningitis and skin and soft tissue intraabdominal infections including peritonitis and in burns and postoperative infections including postvascular surgeryf1954clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to the above organisms aminoglycosides including amikacin are not indicated in uncomplicated firsttime episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxicf1954in september 2018 a new indication with a new dosage route was approved for this drug amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria mycobacterium avium complex mac in a limited population of patients with the disease who do not respond to conventional treatment refractory diseasel4673 this indication is approved under accelerated approval based on achieving sputum culture conversion defined as 3 consecutive negative monthly sputum cultures by month 6 of treatment clinical benefit has not yet been establishedlabelimportant notes regarding staphylococcus and sensitivity testingstaphylococcus aureus including methicillinresistant strains is the principal grampositive organism sensitive to amikacinthe use of amikacin in the treatment of staphylococcal infections should be restricted only to secondline therapy and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibioticsf1949bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin amikacin may be used as initial therapy in suspected gramnegative infections and therapy may be initiated before obtaining the results of susceptibility testinglabelf1949f1954')|
|('DB00050', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the inhibition of premature lh surges in women undergoing controlled ovarian stimulation')|
|('DB00426', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of acute herpes zoster shingles also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in hiv infected patients')|
|('DB00426', 'MONDO:0005770', ['Genital herpes simplex', 'Herpes Genitalis', 'venereal herpes', 'Virus-Genital Herpes', 'genital herpes'], 'for the treatment of acute herpes zoster shingles also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in hiv infected patients')|
|('DB00385', 'MONDO:0005770', ['Genital herpes simplex', 'Herpes Genitalis', 'venereal herpes', 'Virus-Genital Herpes', 'genital herpes'], 'for the treatment of cancer of the bladder')|
|('DB00385', 'MONDO:0004992', ['cancer'], 'for the treatment of cancer of the bladder')|
|('DB01114', 'MONDO:0004992', ['cancer'], 'for the treatment of rhinitis urticaria allergy common cold asthma and hay fever')|
|('DB01114', 'MONDO:0003014', ['rhinitis'], 'for the treatment of rhinitis urticaria allergy common cold asthma and hay fever')|
|('DB01114', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of rhinitis urticaria allergy common cold asthma and hay fever')|
|('DB01114', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the treatment of rhinitis urticaria allergy common cold asthma and hay fever')|
|('DB06707', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used as a topical nasal decongestant and vasoconstrictor in dentistry')|
|('DB04930', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of infestation with isarcoptes scabieii scabies')|
|('DB04930', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for the treatment of infestation with isarcoptes scabieii scabies')|
|('DB00421', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'spironolactone is indicated for the treatment of new york heart association class iiiiv heart failure management of edema in cirrhotic adults not responsive to fluid and sodium restrictions primary hyperaldosteronism shortterm preoperatively primary hyperaldosteronism longterm in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micromacronodular adrenal hyperplasia as an addon therapy in hypertension and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequatelabelspironolactone has antiandrogenic activity which leads to many of its off label uses spironolactone is used off label in the treatment of hirsutism female pattern hair loss and adult acne vulgarisa178135spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing malepattern hair growtha178138')|
|('DB00421', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'spironolactone is indicated for the treatment of new york heart association class iiiiv heart failure management of edema in cirrhotic adults not responsive to fluid and sodium restrictions primary hyperaldosteronism shortterm preoperatively primary hyperaldosteronism longterm in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micromacronodular adrenal hyperplasia as an addon therapy in hypertension and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequatelabelspironolactone has antiandrogenic activity which leads to many of its off label uses spironolactone is used off label in the treatment of hirsutism female pattern hair loss and adult acne vulgarisa178135spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing malepattern hair growtha178138')|
|('DB00421', 'MONDO:0001422', ['Conn syndrome', 'primary aldosteronism', 'primary hyperaldosteronism', 'primary aldosteronism'], 'spironolactone is indicated for the treatment of new york heart association class iiiiv heart failure management of edema in cirrhotic adults not responsive to fluid and sodium restrictions primary hyperaldosteronism shortterm preoperatively primary hyperaldosteronism longterm in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micromacronodular adrenal hyperplasia as an addon therapy in hypertension and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequatelabelspironolactone has antiandrogenic activity which leads to many of its off label uses spironolactone is used off label in the treatment of hirsutism female pattern hair loss and adult acne vulgarisa178135spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing malepattern hair growtha178138')|
|('DB00421', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'spironolactone is indicated for the treatment of new york heart association class iiiiv heart failure management of edema in cirrhotic adults not responsive to fluid and sodium restrictions primary hyperaldosteronism shortterm preoperatively primary hyperaldosteronism longterm in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micromacronodular adrenal hyperplasia as an addon therapy in hypertension and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequatelabelspironolactone has antiandrogenic activity which leads to many of its off label uses spironolactone is used off label in the treatment of hirsutism female pattern hair loss and adult acne vulgarisa178135spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing malepattern hair growtha178138')|
|('DB08847', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in france as a combination product for the treatment of small superficial wounds')|
|('DB00345', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to measure effective renal plasma flow erpf and to determine the functional capacity of the tubular excretory mechanism')|
|('DB04942', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in leukemia unspecified')|
|('DB01164', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels for the treatment of magnesium intoxication due to overdosage of magnesium sulfate and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic ecg pending correction of the increased potassium level in the extracellular fluid')|
|('DB00802', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the management of postoperative pain and the maintenance of general anesthesia')|
|('DB00651', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema')|
|('DB00651', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema')|
|('DB00651', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema')|
|('DB00852', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB00852', 'MONDO:0006004', ['vasomotor rhinitis'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB00852', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB00852', 'MONDO:0005961', ['sinusitis'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB00852', 'MONDO:0021925', ['tracheobronchitis [NCIT:C122784]', 'tracheobronchitis'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB00852', 'MONDO:0004745', ['Mentulagra', 'priapism'], 'for the treatment of nasal congestion sinus congestion eustachian tube congestion and vasomotor rhinitis and as an adjunct to other agents in the optimum treatment of allergic rhinitis croup sinusitis otitis media and tracheobronchitis also used as firstline therapy of priapism')|
|('DB04575', 'MONDO:0021925', ['tracheobronchitis [NCIT:C122784]', 'tracheobronchitis'], 'used in hormone replacement therapy treating symptoms of menopause such as hot flashes also used to treat breast and prostate cancer')|
|('DB04575', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used in hormone replacement therapy treating symptoms of menopause such as hot flashes also used to treat breast and prostate cancer')|
|('DB00621', 'MONDO:0021925', ['tracheobronchitis [NCIT:C122784]', 'tracheobronchitis'], 'use to promote weight gain after weight loss following extensive surgery')|
|('DB00198', 'MONDO:0021925', ['tracheobronchitis [NCIT:C122784]', 'tracheobronchitis'], 'according to fda prescribing information oseltamivir is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours f3094 in particular this agent is indicated in adults and children including fullterm neonates who present with symptoms typical of influenza when influenza virus is circulating in the community efficacy has been demonstrated when treatment is initiated within two days of the first onset of symptomsf3097oseltamivir is also indicated for the prophylaxis of influenza in patients one year and older f3094 specifically postexposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community qualifies for such prophylactic therapy oseltamivir would only be indicated for postexposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak f3097')|
|('DB00198', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'according to fda prescribing information oseltamivir is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours f3094 in particular this agent is indicated in adults and children including fullterm neonates who present with symptoms typical of influenza when influenza virus is circulating in the community efficacy has been demonstrated when treatment is initiated within two days of the first onset of symptomsf3097oseltamivir is also indicated for the prophylaxis of influenza in patients one year and older f3094 specifically postexposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community qualifies for such prophylactic therapy oseltamivir would only be indicated for postexposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak f3097')|
|('DB00198', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'according to fda prescribing information oseltamivir is indicated for the treatment of acute uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours f3094 in particular this agent is indicated in adults and children including fullterm neonates who present with symptoms typical of influenza when influenza virus is circulating in the community efficacy has been demonstrated when treatment is initiated within two days of the first onset of symptomsf3097oseltamivir is also indicated for the prophylaxis of influenza in patients one year and older f3094 specifically postexposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community qualifies for such prophylactic therapy oseltamivir would only be indicated for postexposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak f3097')|
|('DB00653', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'used for immediate control of lifethreatening convulsions in the treatment of severe toxemias preeclampsia and eclampsia of pregnancy and in the treatment of acute nephritis in children also indicated for replacement therapy in magnesium deficiency especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia also used in uterine tetany as a myometriat relaxant')|
|('DB00653', 'MONDO:0005081', ['gestational hypertension', 'hypertension induced by pregnancy', 'pre-eclamptic toxaemia', 'preeclampsia', 'preeclampsia/eclampsia', 'pregnancy associated hypertension', 'pregnancy toxemia', 'proteinuric hypertension of pregnancy', 'toxaemia of pregnancy', 'preeclampsia'], 'used for immediate control of lifethreatening convulsions in the treatment of severe toxemias preeclampsia and eclampsia of pregnancy and in the treatment of acute nephritis in children also indicated for replacement therapy in magnesium deficiency especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia also used in uterine tetany as a myometriat relaxant')|
|('DB00653', 'MONDO:0001754', ['Eclampsia in puerperium', 'Eclampsia, postpartum', 'Postpartum eclampsia', 'eclampsia'], 'used for immediate control of lifethreatening convulsions in the treatment of severe toxemias preeclampsia and eclampsia of pregnancy and in the treatment of acute nephritis in children also indicated for replacement therapy in magnesium deficiency especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia also used in uterine tetany as a myometriat relaxant')|
|('DB00653', 'MONDO:0006844', ['magnesium deficiency'], 'used for immediate control of lifethreatening convulsions in the treatment of severe toxemias preeclampsia and eclampsia of pregnancy and in the treatment of acute nephritis in children also indicated for replacement therapy in magnesium deficiency especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia also used in uterine tetany as a myometriat relaxant')|
|('DB01064', 'MONDO:0006844', ['magnesium deficiency'], 'for the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis')|
|('DB01064', 'MONDO:0020755', ['heart block'], 'for the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis')|
|('DB01064', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis')|
|('DB01064', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis')|
|('DB00266', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for decreasing blood clotting often used along with heparin for treatment of deep vein thrombosis')|
|('DB00201', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birtht716l9851 in addition it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with cns depressant drugsl9899 caffeine has a broad range of over the counter uses and is found in energy supplements athletic enhancement products pain relief products as well as cosmetic productst716l9854l9872')|
|('DB00201', 'MONDO:0020567', ['apnea of prematurity'], 'caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birtht716l9851 in addition it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with cns depressant drugsl9899 caffeine has a broad range of over the counter uses and is found in energy supplements athletic enhancement products pain relief products as well as cosmetic productst716l9854l9872')|
|('DB00201', 'MONDO:0019091', ['BPD [Orphanet:70589]', 'bronchopulmonary dysplasia'], 'caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birtht716l9851 in addition it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with cns depressant drugsl9899 caffeine has a broad range of over the counter uses and is found in energy supplements athletic enhancement products pain relief products as well as cosmetic productst716l9854l9872')|
|('DB00201', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birtht716l9851 in addition it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with cns depressant drugsl9899 caffeine has a broad range of over the counter uses and is found in energy supplements athletic enhancement products pain relief products as well as cosmetic productst716l9854l9872')|
|('DB00335', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated forlabel1 management of hypertension alone and in combination with other antihypertensives2 management of angina pectoris associated with coronary atherosclerosis3 management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmhgofflabel uses include1 secondary prevention of myocardial infarctiona1781562 management of heart failurea1781533 management of atrial fibrillationa1781414 management of supraventricular tachycardiaa1781625 management of ventricular arrythmias such as congenital longqt and arrhythmogenic right ventricular cardiomyopathya1781686 management of symptomatic thyrotoxicosis in combination with methimazolea1781477 prophylaxis of migraine headachesa1781718 management of alcohol withdrawala178174a178177')|
|('DB00335', 'MONDO:0004781', ['acute myocardial infarction'], 'indicated forlabel1 management of hypertension alone and in combination with other antihypertensives2 management of angina pectoris associated with coronary atherosclerosis3 management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmhgofflabel uses include1 secondary prevention of myocardial infarctiona1781562 management of heart failurea1781533 management of atrial fibrillationa1781414 management of supraventricular tachycardiaa1781625 management of ventricular arrythmias such as congenital longqt and arrhythmogenic right ventricular cardiomyopathya1781686 management of symptomatic thyrotoxicosis in combination with methimazolea1781477 prophylaxis of migraine headachesa1781718 management of alcohol withdrawala178174a178177')|
|('DB00173', 'MONDO:0004781', ['acute myocardial infarction'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00964', 'MONDO:0004781', ['acute myocardial infarction'], 'for prevention or reduction of intraoperative and postoperative increases in intraocular pressure iop before and after ocular laser surgery when used prophylactically also used as a shortterm adjunctive therapy in patients with openangle glaucoma who are on maximally tolerated medical therapy requiring additional iop reduction')|
|('DB00964', 'MONDO:0005041', ['glaucoma'], 'for prevention or reduction of intraoperative and postoperative increases in intraocular pressure iop before and after ocular laser surgery when used prophylactically also used as a shortterm adjunctive therapy in patients with openangle glaucoma who are on maximally tolerated medical therapy requiring additional iop reduction')|
|('DB00993', 'MONDO:0005041', ['glaucoma'], 'for use in rheumatoid arthritis preventing renal transplant rejection crohns disease and colitis')|
|('DB00993', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for use in rheumatoid arthritis preventing renal transplant rejection crohns disease and colitis')|
|('DB00993', 'MONDO:0005292', ['colitis'], 'for use in rheumatoid arthritis preventing renal transplant rejection crohns disease and colitis')|
|('DB00492', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for treating mild to moderate hypertension use as an adjunct in treating congestive heart failure and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00492', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for treating mild to moderate hypertension use as an adjunct in treating congestive heart failure and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00492', 'MONDO:0005015', ['diabetes mellitus'], 'for treating mild to moderate hypertension use as an adjunct in treating congestive heart failure and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00492', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'for treating mild to moderate hypertension use as an adjunct in treating congestive heart failure and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB01070', 'MONDO:0005015', ['diabetes mellitus'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0001068', ['osteomalacia'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0001220', ['hypoparathyroidism'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0019992', ['pseudohypoparathyroidism'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0006946', ['renal rickets', 'renal osteodystrophy'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0000313', ['hypophosphatemia'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB01070', 'MONDO:0006022', ['acidosis [MONDO:ambiguous]', 'acidosis disorder'], 'used for the prevention and treatment of rickets or osteomalacia and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism also used for the treatment of vitamin d dependent rickets rickets or osteomalacia secondary to longterm high dose anticonvulsant therapy early renal osteodystrophy osteoporosis in conjunction with calcium and hypophosphatemia associated with fanconi syndrome with treatment of acidosis')|
|('DB00803', 'MONDO:0000313', ['hypophosphatemia'], 'for the treatment of acute or chronic infections due to sensitive strains of certain gramnegative bacilli particularly ipseudomonas aeruginosai')|
|('DB00546', 'MONDO:0000313', ['hypophosphatemia'], 'for the treatment of anxiety and status epilepticus')|
|('DB00546', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety and status epilepticus')|
|('DB00546', 'MONDO:0002125', ['Grand mal status', 'status epilepticus'], 'for the treatment of anxiety and status epilepticus')|
|('DB00648', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for treatment of inoperable adrenocortical tumours cushings syndrome')|
|('DB00648', 'MONDO:0003009', ['Cushing syndrome', 'Cushings syndrome', 'hyperaldosteronism', 'hyperaldosteronism'], 'for treatment of inoperable adrenocortical tumours cushings syndrome')|
|('DB00284', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for treatment and management of diabetes type ii used in combination therapy as a second or third line agent')|
|('DB00446', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in treatment of cholera as it destroys the vibrios and decreases the diarrhea it is effective against tetracyclineresistant vibrios it is also used in eye drops or ointment to treat bacterial conjunctivitis')|
|('DB00446', 'MONDO:0015766', ['Cholera', 'Cholera - Vibrio cholerae', 'Cholera due to Vibrio cholerae', 'Vibrio cholerae', 'cholera'], 'used in treatment of cholera as it destroys the vibrios and decreases the diarrhea it is effective against tetracyclineresistant vibrios it is also used in eye drops or ointment to treat bacterial conjunctivitis')|
|('DB00446', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'used in treatment of cholera as it destroys the vibrios and decreases the diarrhea it is effective against tetracyclineresistant vibrios it is also used in eye drops or ointment to treat bacterial conjunctivitis')|
|('DB00590', 'MONDO:0015766', ['Cholera', 'Cholera - Vibrio cholerae', 'Cholera due to Vibrio cholerae', 'Vibrio cholerae', 'cholera'], 'doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy which may include urinary frequency urgency and nocturia among other symptoms in addition doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertensionl7282 offlabel uses of doxazosin include the treatment of pediatric hypertensiona180634 and the treatment of ureteric calculia180637')|
|('DB00892', 'MONDO:0015766', ['Cholera', 'Cholera - Vibrio cholerae', 'Cholera due to Vibrio cholerae', 'Vibrio cholerae', 'cholera'], 'used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed')|
|('DB00892', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed')|
|('DB06810', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of testicular cancer as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer')|
|('DB06810', 'MONDO:0005447', ['childhood neoplasm of the testis', 'neoplasm of testis', 'pediatric testicular neoplasm', 'testicular tumor', 'testis cancer', 'testis neoplasm', 'testicular cancer'], 'for the treatment of testicular cancer as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer')|
|('DB06810', 'MONDO:0004992', ['cancer'], 'for the treatment of testicular cancer as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer')|
|('DB05246', 'MONDO:0005447', ['childhood neoplasm of the testis', 'neoplasm of testis', 'pediatric testicular neoplasm', 'testicular tumor', 'testis cancer', 'testis neoplasm', 'testicular cancer'], 'for the control of absence petit mal seizures that are refractory to other drugs')|
|('DB01029', 'MONDO:0005447', ['childhood neoplasm of the testis', 'neoplasm of testis', 'pediatric testicular neoplasm', 'testicular tumor', 'testis cancer', 'testis neoplasm', 'testicular cancer'], 'irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes elevated serum creatinine and proteinurial7456 a combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapyl7459')|
|('DB01029', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes elevated serum creatinine and proteinurial7456 a combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapyl7459')|
|('DB01029', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes elevated serum creatinine and proteinurial7456 a combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapyl7459')|
|('DB00755', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0012883', ['acute myeloblastic leukaemia type 3', 'acute myeloblastic leukemia type 3', 'acute myeloid leukaemia M3', 'acute myeloid leukemia M3', 'acute promyelocytic leukaemia', 'acute promyelocytic leukemia'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0005083', ['psoriasis'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0006566', ['keratosis'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0007239', ['bullous congenital ichthyosiform erythroderma', 'Bullous ichthyosiform erythroderma', 'Epidermolytic palmoplantar hyperkeratosis', 'epidermolytic hyperkeratosis'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB00755', 'MONDO:0007417', ['Dariers disease', 'DARIER-WHITE DISEASE', 'Keratosis follicularis', 'darier disease'], 'for the the induction of remission in patients with acute promyelocytic leukemia apl frenchamericanbritish fab classification m3 including the m3 variant for the topical treatment of acne vulgaris flat warts and other skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis dariers disease and basal cell carcinomas for palliative therapy to improve fine wrinkling mottled hyperpigmentation roughness associated with photodamage')|
|('DB08792', 'MONDO:0007417', ['Dariers disease', 'DARIER-WHITE DISEASE', 'Keratosis follicularis', 'darier disease'], 'diloxanide is used alone as a primary agent in the treatment of asymptomatic cyst passers intestinal amebiasis caused by entamoeba histolytica diloxanide may also be used concurrently or sequentially with other agents such as the nitroimidazoles eg metronidazole in the treatment of invasive or extraintestinal forms of amebiasis')|
|('DB08792', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'diloxanide is used alone as a primary agent in the treatment of asymptomatic cyst passers intestinal amebiasis caused by entamoeba histolytica diloxanide may also be used concurrently or sequentially with other agents such as the nitroimidazoles eg metronidazole in the treatment of invasive or extraintestinal forms of amebiasis')|
|('DB04711', 'MONDO:0007417', ['Dariers disease', 'DARIER-WHITE DISEASE', 'Keratosis follicularis', 'darier disease'], 'iodipamide is used as a contrast agent for cholecystography and intravenous cholangiography')|
|('DB00405', 'MONDO:0007417', ['Dariers disease', 'DARIER-WHITE DISEASE', 'Keratosis follicularis', 'darier disease'], 'for treatment and relief of symptoms of allergies hay fever and colds')|
|('DB00405', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for treatment and relief of symptoms of allergies hay fever and colds')|
|('DB00923', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the treatment of infections caused by susceptible organisms')|
|('DB01165', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the treatment of infections respiratory tract kidney skin soft tissue uti urethral and cervical gonorrhoea')|
|('DB01165', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of infections respiratory tract kidney skin soft tissue uti urethral and cervical gonorrhoea')|
|('DB01377', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'indicated for overthecounter use as a supplement for cardiovascular and neuromuscular health and as an antacid for relief of acid indigestion and upset stomach')|
|('DB00682', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'indicated forlabell66161 prophylaxis and treatment of venous thromboembolism and related pulmonary embolism2 prophylaxis and treatment of thromboembolism associated with atrial fibrillation3 prophylaxis and treatment of thromboembolism associated with cardiac valve replacement4 use as adjunct therapy to reduce mortality recurrent myocardial infarction and thromboembolic events post myocardial infarctionofflabel uses include1 secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillationa179182')|
|('DB00682', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'indicated forlabell66161 prophylaxis and treatment of venous thromboembolism and related pulmonary embolism2 prophylaxis and treatment of thromboembolism associated with atrial fibrillation3 prophylaxis and treatment of thromboembolism associated with cardiac valve replacement4 use as adjunct therapy to reduce mortality recurrent myocardial infarction and thromboembolic events post myocardial infarctionofflabel uses include1 secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillationa179182')|
|('DB00682', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'indicated forlabell66161 prophylaxis and treatment of venous thromboembolism and related pulmonary embolism2 prophylaxis and treatment of thromboembolism associated with atrial fibrillation3 prophylaxis and treatment of thromboembolism associated with cardiac valve replacement4 use as adjunct therapy to reduce mortality recurrent myocardial infarction and thromboembolic events post myocardial infarctionofflabel uses include1 secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillationa179182')|
|('DB00682', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'indicated forlabell66161 prophylaxis and treatment of venous thromboembolism and related pulmonary embolism2 prophylaxis and treatment of thromboembolism associated with atrial fibrillation3 prophylaxis and treatment of thromboembolism associated with cardiac valve replacement4 use as adjunct therapy to reduce mortality recurrent myocardial infarction and thromboembolic events post myocardial infarctionofflabel uses include1 secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillationa179182')|
|('DB00594', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'for use as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension')|
|('DB00594', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for use as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension')|
|('DB00549', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the prophylaxis and chronic treatment of asthma')|
|('DB00549', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the prophylaxis and chronic treatment of asthma')|
|('DB00430', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for treatment of severe infections caused by susceptible bacteria such as p aeruginosa')|
|('DB00158', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'folic acid is indicated for the treatment of folic acid deficiency megaloblastic anemia and in anemias of nutritional origins pregnancy infancy or childhood')|
|('DB00158', 'MONDO:0002280', ['anaemia', 'anemia'], 'folic acid is indicated for the treatment of folic acid deficiency megaloblastic anemia and in anemias of nutritional origins pregnancy infancy or childhood')|
|('DB00652', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the relief of moderate to severe pain')|
|('DB01144', 'MONDO:0002280', ['anaemia', 'anemia'], 'for adjunctive treatment of chronic simple openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure')|
|('DB01144', 'MONDO:0005041', ['glaucoma'], 'for adjunctive treatment of chronic simple openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure')|
|('DB06414', 'MONDO:0005041', ['glaucoma'], 'indicated as an adjunct therapy in the treatment of adult hiv1 infections resistant to therapy with other nnrtis and antiretroviral agents ')|
|('DB00130', 'MONDO:0005041', ['glaucoma'], 'used for nutritional supplementation also for treating dietary shortage or imbalanceused to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older fda label')|
|('DB00967', 'MONDO:0005041', ['glaucoma'], 'for the relief of symptoms of seasonal allergic rhinitis perennial nonseasonal allergic rhinitis desloratidine is also used for the sympomatic treatment of pruritus and urticaria hives associated with chronic idiopathic urticaria')|
|('DB00967', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the relief of symptoms of seasonal allergic rhinitis perennial nonseasonal allergic rhinitis desloratidine is also used for the sympomatic treatment of pruritus and urticaria hives associated with chronic idiopathic urticaria')|
|('DB00967', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the relief of symptoms of seasonal allergic rhinitis perennial nonseasonal allergic rhinitis desloratidine is also used for the sympomatic treatment of pruritus and urticaria hives associated with chronic idiopathic urticaria')|
|('DB00967', 'MONDO:0005492', ['urticaria'], 'for the relief of symptoms of seasonal allergic rhinitis perennial nonseasonal allergic rhinitis desloratidine is also used for the sympomatic treatment of pruritus and urticaria hives associated with chronic idiopathic urticaria')|
|('DB00967', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'for the relief of symptoms of seasonal allergic rhinitis perennial nonseasonal allergic rhinitis desloratidine is also used for the sympomatic treatment of pruritus and urticaria hives associated with chronic idiopathic urticaria')|
|('DB01342', 'MONDO:0005492', ['urticaria'], 'for the treatment of hypertension')|
|('DB00543', 'MONDO:0005492', ['urticaria'], 'for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions may also be used to treat depression accompanied by anxiety or agitation')|
|('DB00543', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions may also be used to treat depression accompanied by anxiety or agitation')|
|('DB00962', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of shortterm treatment of insomnia in adults')|
|('DB00962', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of shortterm treatment of insomnia in adults')|
|('DB01578', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'metrizamide is used for lumbar thoracic cervical and total columnar myelography to determine the presence of abnormalities in the spinal column spinal canal and central nervous system cns as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain for computerized tomography ct of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms known or suspected or vascular diseases congenital or acquired that may cause changes in normal vascular anatomy or physiology metrizamide is also indicated in adults for intravenous digital arteriography of head and neck')|
|('DB01578', 'MONDO:0021140', ['inborn []', 'congenital'], 'metrizamide is used for lumbar thoracic cervical and total columnar myelography to determine the presence of abnormalities in the spinal column spinal canal and central nervous system cns as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain for computerized tomography ct of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms known or suspected or vascular diseases congenital or acquired that may cause changes in normal vascular anatomy or physiology metrizamide is also indicated in adults for intravenous digital arteriography of head and neck')|
|('DB01578', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'metrizamide is used for lumbar thoracic cervical and total columnar myelography to determine the presence of abnormalities in the spinal column spinal canal and central nervous system cns as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain for computerized tomography ct of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms known or suspected or vascular diseases congenital or acquired that may cause changes in normal vascular anatomy or physiology metrizamide is also indicated in adults for intravenous digital arteriography of head and neck')|
|('DB01124', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'for treatment of niddm noninsulindependent diabetes mellitus in conjunction with diet and exercise')|
|('DB01124', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for treatment of niddm noninsulindependent diabetes mellitus in conjunction with diet and exercise')|
|('DB01124', 'MONDO:0005015', ['diabetes mellitus'], 'for treatment of niddm noninsulindependent diabetes mellitus in conjunction with diet and exercise')|
|('DB01018', 'MONDO:0005015', ['diabetes mellitus'], 'for use alone or in combination with other classes of antihypertensive agents in the management of hypertension has also been used for the treatment of attention deficit hyperactivity disorder adhd in pediatric patients')|
|('DB01018', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'for use alone or in combination with other classes of antihypertensive agents in the management of hypertension has also been used for the treatment of attention deficit hyperactivity disorder adhd in pediatric patients')|
|('DB00154', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB01066', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'for the treatment of mild to moderate infections in adults and adolescents 12 years of age or older which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis communityacquired pneumonia pharyngitistonsillitis and uncomplicated skin and skinstructure infections')|
|('DB01066', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of mild to moderate infections in adults and adolescents 12 years of age or older which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis communityacquired pneumonia pharyngitistonsillitis and uncomplicated skin and skinstructure infections')|
|('DB01066', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of mild to moderate infections in adults and adolescents 12 years of age or older which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis communityacquired pneumonia pharyngitistonsillitis and uncomplicated skin and skinstructure infections')|
|('DB01594', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety or anxiety associated with depressive symptoms')|
|('DB01594', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety or anxiety associated with depressive symptoms')|
|('DB01435', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'antipyrine is an analgesic often used to test effects of other drugs on liver enzymesin combination with benzocaine in otic solutions antipyrine is indicated for the symptomatic relief of acute otitis media arising from various etiologies ')|
|('DB01435', 'MONDO:0024330', ['acute otitis Media [NCIT:C84354]', 'infectious otitis Media [NCIT:C84354]', 'middle Ear infection [NCIT:C84354]', 'AOM [NCIT:C84354]', 'infectious otitis media'], 'antipyrine is an analgesic often used to test effects of other drugs on liver enzymesin combination with benzocaine in otic solutions antipyrine is indicated for the symptomatic relief of acute otitis media arising from various etiologies ')|
|('DB01146', 'MONDO:0024330', ['acute otitis Media [NCIT:C84354]', 'infectious otitis Media [NCIT:C84354]', 'middle Ear infection [NCIT:C84354]', 'AOM [NCIT:C84354]', 'infectious otitis media'], 'for use in the treatment of allergic rhinitis hay fever and allergic skin disorders')|
|('DB01146', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for use in the treatment of allergic rhinitis hay fever and allergic skin disorders')|
|('DB00841', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'indicated when parenteral therapy is necessary for inotropic support in the shortterm treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures')|
|('DB01357', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'mestranol was used as one of the first oral contraceptives')|
|('DB01440', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'used as a general anesthetic to treat conditions such as insomnia clinical depression narcolepsy and alcoholism and to improve athletic performance ')|
|('DB01440', 'MONDO:0012048', ['clinical depression', 'unipolar depression', 'endogenous depression'], 'used as a general anesthetic to treat conditions such as insomnia clinical depression narcolepsy and alcoholism and to improve athletic performance ')|
|('DB01440', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'used as a general anesthetic to treat conditions such as insomnia clinical depression narcolepsy and alcoholism and to improve athletic performance ')|
|('DB00359', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for the treatment of rheumatic fever and meningococcal meningitis')|
|('DB00359', 'MONDO:0017767', ['ACUTE RHEUMATIC FEVER', 'RhF - Rheumatic fever', 'rheumatic fever'], 'for the treatment of rheumatic fever and meningococcal meningitis')|
|('DB00359', 'MONDO:0018059', ['meningococcal meningitis'], 'for the treatment of rheumatic fever and meningococcal meningitis')|
|('DB01139', 'MONDO:0017767', ['ACUTE RHEUMATIC FEVER', 'RhF - Rheumatic fever', 'rheumatic fever'], 'for treatment of infections caused by susceptible bacteria')|
|('DB00230', 'MONDO:0017767', ['ACUTE RHEUMATIC FEVER', 'RhF - Rheumatic fever', 'rheumatic fever'], 'pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain associated with spinal cord injury and as adjunctive therapy for the treatment of partialonset seizures in patients 1 month of age and olderl7066')|
|('DB00230', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain associated with spinal cord injury and as adjunctive therapy for the treatment of partialonset seizures in patients 1 month of age and olderl7066')|
|('DB00230', 'MONDO:0043797', ['spinal cord injury [MESH:D013119,MONDO:patterns/location]', 'injury of spinal cord [MONDO:design_pattern]', 'spinal cord injury'], 'pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain associated with spinal cord injury and as adjunctive therapy for the treatment of partialonset seizures in patients 1 month of age and olderl7066')|
|('DB00951', 'MONDO:0043797', ['spinal cord injury [MESH:D013119,MONDO:patterns/location]', 'injury of spinal cord [MONDO:design_pattern]', 'spinal cord injury'], 'for the treatment of all forms of tuberculosis in which organisms are susceptible')|
|('DB00951', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all forms of tuberculosis in which organisms are susceptible')|
|('DB00951', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of all forms of tuberculosis in which organisms are susceptible')|
|('DB00260', 'MONDO:0018076', ['tuberculosis'], 'used in combination with up to 5 other drugs as a treatment for mycobacterium avium complex mac and is also used to treat tuberculosis tb')|
|('DB01382', 'MONDO:0018076', ['tuberculosis'], 'glycodiazine is used concomitantly with insulin for the treatment of noninsulindependent type 2 diabetes mellitus ')|
|('DB01382', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'glycodiazine is used concomitantly with insulin for the treatment of noninsulindependent type 2 diabetes mellitus ')|
|('DB01433', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used mainly in the treatment of narcotic dependence')|
|('DB00324', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the ophthalmic treatment of corticosteroidresponsive inflammation of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe')|
|('DB06817', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of hiv1 infection in conjunction with other antiretrovirals')|
|('DB00853', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme also used as maintenance therapy for glioblastoma multiforme')|
|('DB00853', 'MONDO:0016684', ['anaplastic astrocytoma', 'grade III Astrocytic tumor', 'anaplastic astrocytoma'], 'for the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme also used as maintenance therapy for glioblastoma multiforme')|
|('DB00853', 'MONDO:0020690', ['adult glioblastoma multiforme [NCIT:C9094]', 'glioblastoma [NCIT:C9094]', 'grade iv adult astrocytic tumor [NCIT:C9094]', 'grade iv adult astrocytic neoplasm [NCIT:C9094]', 'adult glioblastoma [NCIT:C9094]', 'adult glioblastoma'], 'for the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme also used as maintenance therapy for glioblastoma multiforme')|
|('DB06717', 'MONDO:0020690', ['adult glioblastoma multiforme [NCIT:C9094]', 'glioblastoma [NCIT:C9094]', 'grade iv adult astrocytic tumor [NCIT:C9094]', 'grade iv adult astrocytic neoplasm [NCIT:C9094]', 'adult glioblastoma [NCIT:C9094]', 'adult glioblastoma'], 'for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy')|
|('DB06717', 'MONDO:0004992', ['cancer'], 'for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy')|
|('DB00733', 'MONDO:0004992', ['cancer'], 'for the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis')|
|('DB00733', 'MONDO:0029000', ['poisoning'], 'for the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis')|
|('DB00733', 'MONDO:0009688', ['myasthenia gravis'], 'for the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis')|
|('DB01231', 'MONDO:0029000', ['poisoning'], 'for use in the prevention and symptomatic treatment of peripheral labyrinthine vertigo and associated nausea and vomiting that occur in such conditions as menieres disease and surgery of the middle and inner ear also for the control of nausea and vomiting associated with postoperative states malignant neoplasms labyrinthine disturbances antineoplastic agent therapy radiation sickness and infectious diseases')|
|('DB00151', 'MONDO:0029000', ['poisoning'], 'for the prevention of liver damage and kidney damage associated with overdoses of acetaminophen')|
|('DB01394', 'MONDO:0029000', ['poisoning'], 'colchicine is indicated for the prophylaxis and treatment of gout flares  it is also indicated in familial mediterranean fever fmf in children and adults of 4 years of age and older it is important to note that this medication is not a pain reliever to be used for other painful conditions consider analgesics for this purposel8138 some offlabel uses of colchicine include the treatment of the manifestations of behcets syndrome pericarditis and postpericardiotomy syndromea183932a183935')|
|('DB01394', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'colchicine is indicated for the prophylaxis and treatment of gout flares  it is also indicated in familial mediterranean fever fmf in children and adults of 4 years of age and older it is important to note that this medication is not a pain reliever to be used for other painful conditions consider analgesics for this purposel8138 some offlabel uses of colchicine include the treatment of the manifestations of behcets syndrome pericarditis and postpericardiotomy syndromea183932a183935')|
|('DB01076', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0018328', ['HoFH [Orphanet:391665]', 'homozygous familial hypercholesterolemia'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005439', ['familial hyperbetalipoproteinaemia', 'familial hypercholesteremia', 'Fredrickson type IIa hyperlipoproteinemia', 'Fredrickson type IIa lipidaemia', 'hyperbetalipoproteinemia', 'type II hyperlipidemia', 'familial hypercholesterolemia'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005015', ['diabetes mellitus'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005311', ['atherosclerosis'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0005350', ['AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1', 'abdominal aortic aneurysm'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01076', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'atorvastatin is approved for the treatment of several types of dyslipidemias including primary hyperlipidemia and mixed dyslipidemia in adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modificationsa177397dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025 atorvastatin is indicated in combination with dietary modifications to prevent cardiovascular events in patients with cardiac risk factors andor abnormal lipid profilesa177397atorvastatin can be used as a preventive agent for myocardial infarction stroke revascularization and angina in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factorsa177397atorvastatin can also be used as a preventive agent for nonfatal myocardial infarction fatal and nonfatal stroke revascularization procedures hospitalization for congestive heart failure and angina in patients with coronary heart diseasea177397prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00464', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves')|
|('DB00148', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB06237', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'treatment of erectile dysfunction in males ')|
|('DB06237', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'treatment of erectile dysfunction in males ')|
|('DB00614', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'for the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms')|
|('DB00614', 'MONDO:0043579', ['enteritis of small intestine []', 'small intestine inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'enteritis [NCIT:C26765]', 'inflammation of small intestine []', 'enteritis'], 'for the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms')|
|('DB08918', 'MONDO:0043579', ['enteritis of small intestine []', 'small intestine inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'enteritis [NCIT:C26765]', 'inflammation of small intestine []', 'enteritis'], 'levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder mdd ')|
|('DB08918', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder mdd ')|
|('DB08877', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'treatment of intermediate or highrisk myelofibrosis including primary myelofibrosis postpolycythemia vera postpv myelofibrosis and postessential thrombocythemia postet myelofibrosis lexicomp myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis the excessive formation of connective tissue')|
|('DB08877', 'MONDO:0044903', ['myelofibrosis [NCIT:C3248]', 'myelofibrosis'], 'treatment of intermediate or highrisk myelofibrosis including primary myelofibrosis postpolycythemia vera postpv myelofibrosis and postessential thrombocythemia postet myelofibrosis lexicomp myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis the excessive formation of connective tissue')|
|('DB08877', 'MONDO:0009692', ['Agnogenic myeloid metaplasia', 'Aleukemic myelosis', 'bone Marrow Fibrosis', 'Megakaryocytic myelosclerosis', 'myelosclerosis', 'primary myelofibrosis', 'primary myelofibrosis'], 'treatment of intermediate or highrisk myelofibrosis including primary myelofibrosis postpolycythemia vera postpv myelofibrosis and postessential thrombocythemia postet myelofibrosis lexicomp myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis the excessive formation of connective tissue')|
|('DB08815', 'MONDO:0044903', ['myelofibrosis [NCIT:C3248]', 'myelofibrosis'], 'treatment of schizophrenia ')|
|('DB08815', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'treatment of schizophrenia ')|
|('DB00455', 'MONDO:0044903', ['myelofibrosis [NCIT:C3248]', 'myelofibrosis'], 'loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis wheal formation urticaria and other allergic dermatologic conditionsa176435a176438l8486 ')|
|('DB00455', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis wheal formation urticaria and other allergic dermatologic conditionsa176435a176438l8486 ')|
|('DB00455', 'MONDO:0005492', ['urticaria'], 'loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis wheal formation urticaria and other allergic dermatologic conditionsa176435a176438l8486 ')|
|('DB00661', 'MONDO:0005492', ['urticaria'], 'verapamil is indicated in the treatment of vasopastic ie prinzmetals angina unstable angina and chronic stable angina it is also indicated to treat hypertension for the prophylaxis of repetitive paroxysmal supraventricular tachycardia and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutterl8791 given intravenously it is indicated for the treatment of various supraventricular tachyarrhythmias including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutterl10481verapamil is commonly used offlabel for prophylaxis of cluster headachesa13983')|
|('DB00661', 'MONDO:0006021', ['angina inversa', 'Prinzmetals angina', 'Prinzmetals variant angina', 'variant angina', 'variant angina pectoris', 'prinzmetal angina'], 'verapamil is indicated in the treatment of vasopastic ie prinzmetals angina unstable angina and chronic stable angina it is also indicated to treat hypertension for the prophylaxis of repetitive paroxysmal supraventricular tachycardia and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutterl8791 given intravenously it is indicated for the treatment of various supraventricular tachyarrhythmias including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutterl10481verapamil is commonly used offlabel for prophylaxis of cluster headachesa13983')|
|('DB00661', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'verapamil is indicated in the treatment of vasopastic ie prinzmetals angina unstable angina and chronic stable angina it is also indicated to treat hypertension for the prophylaxis of repetitive paroxysmal supraventricular tachycardia and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutterl8791 given intravenously it is indicated for the treatment of various supraventricular tachyarrhythmias including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutterl10481verapamil is commonly used offlabel for prophylaxis of cluster headachesa13983')|
|('DB00881', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failurel8420 quinapril in combination with hydrochlorothiazide is indicated for the treatment of hypertensionl8423')|
|('DB00713', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'used in the treatment of resistant staphylococci infections')|
|('DB01238', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'aripiprazole is indicated for manic and mixed episodes associated with bipolar i disorder irritability associated with autism spectrum disorder treatment of schizophrenia treatment of tourettes disorder and as an adjunctive treatment of major depressive disorderlabel an injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar manialabel')|
|('DB01238', 'MONDO:0001866', ['bipolar I disorder'], 'aripiprazole is indicated for manic and mixed episodes associated with bipolar i disorder irritability associated with autism spectrum disorder treatment of schizophrenia treatment of tourettes disorder and as an adjunctive treatment of major depressive disorderlabel an injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar manialabel')|
|('DB01238', 'MONDO:0005260', ['autism', 'autistic disorder of childhood onset', 'childhood autism', 'infantile autism', 'Kanners syndrome', 'autism'], 'aripiprazole is indicated for manic and mixed episodes associated with bipolar i disorder irritability associated with autism spectrum disorder treatment of schizophrenia treatment of tourettes disorder and as an adjunctive treatment of major depressive disorderlabel an injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar manialabel')|
|('DB01238', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'aripiprazole is indicated for manic and mixed episodes associated with bipolar i disorder irritability associated with autism spectrum disorder treatment of schizophrenia treatment of tourettes disorder and as an adjunctive treatment of major depressive disorderlabel an injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar manialabel')|
|('DB00300', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'tenofovir is indicated in combination with other antiretroviral agents for the management of hiv1 infection in adults and pediatric patients 2 years of age and older it is also indicated for the treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older fda label this drug is also a component of multiple products used for the management of hiv1 infection f3418 f3421 safety and effectiveness of tenofovir disoproxil in pediatric patients younger than 2 years of age has not been established to this date fda label')|
|('DB00300', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'tenofovir is indicated in combination with other antiretroviral agents for the management of hiv1 infection in adults and pediatric patients 2 years of age and older it is also indicated for the treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older fda label this drug is also a component of multiple products used for the management of hiv1 infection f3418 f3421 safety and effectiveness of tenofovir disoproxil in pediatric patients younger than 2 years of age has not been established to this date fda label')|
|('DB00228', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'used for the induction and maintenance of general anaesthesia during surgery and cesarean section and also used for analgesia during vaginal delivery')|
|('DB00228', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'used for the induction and maintenance of general anaesthesia during surgery and cesarean section and also used for analgesia during vaginal delivery')|
|('DB08910', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy')|
|('DB00781', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'polymyxin b is indicated for the treatment of infections of the urinary tract meninges and blood stream caused by susceptible strains of ipseudomonas aeruginosaifda label')|
|('DB01579', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'used in the management of exogenous obesity as a short term adjunct a few weeks in a regimen of weight reduction based on caloric restriction')|
|('DB00204', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for the maintenance of normal sinus rhythm delay in time to recurrence of atrial fibrillationatrial flutter afafl in patients with atrial fibrillationatrial flutter of greater than one week duration who have been converted to normal sinus rhythm')|
|('DB00303', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms 1 complicated intraabdominal infections due to iescherichia colii iclostridium clostridioformei ieubacterium lentumi ipeptostreptococcusi species ibacteroides fragilisi ibacteroides distasonisi ibacteroides ovatusi ibacteroides thetaiotaomicroni or ibacteroides uniformisi 2 complicated skin and skin structure infections including diabetic foot infections without osteomyelitis due to istaphylococcus aureusi methicillin susceptible isolates only istreptococcus agalactiaei istreptococcus pyogenesi iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ibacteroides fragilisi ipeptostreptococcusi species iporphyromonas asaccharolyticai or iprevotella biviai 3 community acquired pneumonia due to istreptococcus pneumoniaei penicillin susceptible isolates only including cases with concurrent bacteremia ihaemophilus influenzaei betalactamase negative isolates only or imoraxella catarrhalisi 4 complicated urinary tract infections including pyelonephritis due to iescherichia colii including cases with concurrent bacteremia or iklebsiella pneumoniaei 5 acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections due to istreptococcus agalactiaei iescherichia colii ibacteroides fragilisi iporphyromonas asaccharolyticai ipeptostreptococcusi species or iprevotella biviai')|
|('DB00303', 'MONDO:0005246', ['osteomyelitis'], 'for the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms 1 complicated intraabdominal infections due to iescherichia colii iclostridium clostridioformei ieubacterium lentumi ipeptostreptococcusi species ibacteroides fragilisi ibacteroides distasonisi ibacteroides ovatusi ibacteroides thetaiotaomicroni or ibacteroides uniformisi 2 complicated skin and skin structure infections including diabetic foot infections without osteomyelitis due to istaphylococcus aureusi methicillin susceptible isolates only istreptococcus agalactiaei istreptococcus pyogenesi iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ibacteroides fragilisi ipeptostreptococcusi species iporphyromonas asaccharolyticai or iprevotella biviai 3 community acquired pneumonia due to istreptococcus pneumoniaei penicillin susceptible isolates only including cases with concurrent bacteremia ihaemophilus influenzaei betalactamase negative isolates only or imoraxella catarrhalisi 4 complicated urinary tract infections including pyelonephritis due to iescherichia colii including cases with concurrent bacteremia or iklebsiella pneumoniaei 5 acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections due to istreptococcus agalactiaei iescherichia colii ibacteroides fragilisi iporphyromonas asaccharolyticai ipeptostreptococcusi species or iprevotella biviai')|
|('DB00303', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'for the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms 1 complicated intraabdominal infections due to iescherichia colii iclostridium clostridioformei ieubacterium lentumi ipeptostreptococcusi species ibacteroides fragilisi ibacteroides distasonisi ibacteroides ovatusi ibacteroides thetaiotaomicroni or ibacteroides uniformisi 2 complicated skin and skin structure infections including diabetic foot infections without osteomyelitis due to istaphylococcus aureusi methicillin susceptible isolates only istreptococcus agalactiaei istreptococcus pyogenesi iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ibacteroides fragilisi ipeptostreptococcusi species iporphyromonas asaccharolyticai or iprevotella biviai 3 community acquired pneumonia due to istreptococcus pneumoniaei penicillin susceptible isolates only including cases with concurrent bacteremia ihaemophilus influenzaei betalactamase negative isolates only or imoraxella catarrhalisi 4 complicated urinary tract infections including pyelonephritis due to iescherichia colii including cases with concurrent bacteremia or iklebsiella pneumoniaei 5 acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections due to istreptococcus agalactiaei iescherichia colii ibacteroides fragilisi iporphyromonas asaccharolyticai ipeptostreptococcusi species or iprevotella biviai')|
|('DB00303', 'MONDO:0006939', ['pyelonephritis'], 'for the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms 1 complicated intraabdominal infections due to iescherichia colii iclostridium clostridioformei ieubacterium lentumi ipeptostreptococcusi species ibacteroides fragilisi ibacteroides distasonisi ibacteroides ovatusi ibacteroides thetaiotaomicroni or ibacteroides uniformisi 2 complicated skin and skin structure infections including diabetic foot infections without osteomyelitis due to istaphylococcus aureusi methicillin susceptible isolates only istreptococcus agalactiaei istreptococcus pyogenesi iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ibacteroides fragilisi ipeptostreptococcusi species iporphyromonas asaccharolyticai or iprevotella biviai 3 community acquired pneumonia due to istreptococcus pneumoniaei penicillin susceptible isolates only including cases with concurrent bacteremia ihaemophilus influenzaei betalactamase negative isolates only or imoraxella catarrhalisi 4 complicated urinary tract infections including pyelonephritis due to iescherichia colii including cases with concurrent bacteremia or iklebsiella pneumoniaei 5 acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections due to istreptococcus agalactiaei iescherichia colii ibacteroides fragilisi iporphyromonas asaccharolyticai ipeptostreptococcusi species or iprevotella biviai')|
|('DB00774', 'MONDO:0006939', ['pyelonephritis'], 'used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00774', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00774', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00498', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for the treatment of pulmonary embolism cardiomyopathy atrial fibrillation and flutter cerebral embolism mural thrombosis and thrombophili also used for anticoagulant prophylaxis')|
|('DB00498', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for the treatment of pulmonary embolism cardiomyopathy atrial fibrillation and flutter cerebral embolism mural thrombosis and thrombophili also used for anticoagulant prophylaxis')|
|('DB00498', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the treatment of pulmonary embolism cardiomyopathy atrial fibrillation and flutter cerebral embolism mural thrombosis and thrombophili also used for anticoagulant prophylaxis')|
|('DB00498', 'MONDO:0006809', ['cerebral embolism', 'Cerebral embolism with cerebral infarction', 'intracranial embolism'], 'for the treatment of pulmonary embolism cardiomyopathy atrial fibrillation and flutter cerebral embolism mural thrombosis and thrombophili also used for anticoagulant prophylaxis')|
|('DB00493', 'MONDO:0006809', ['cerebral embolism', 'Cerebral embolism with cerebral infarction', 'intracranial embolism'], 'used to treat gonorrhoea meningitis and severe infections including infections of the kidney pyelonephritis and urinary system also used before an operation to prevent infection after surgery')|
|('DB00493', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'used to treat gonorrhoea meningitis and severe infections including infections of the kidney pyelonephritis and urinary system also used before an operation to prevent infection after surgery')|
|('DB01267', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the treatment of schizophrenia')|
|('DB01267', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of schizophrenia')|
|('DB01395', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'drospirenone in combination with ethinyl estradiol is indicated as an oral contraceptive for the prevention of pregnancy  in addition to its use for contraceptive effects this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorderl7973l7976  the drug has approved indications for combination with estrogens for the treatment of menopauseassociated symptoms such as vasomotor symptoms and vulvovaginal atrophy drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been postmenopausal for at least a year and are not candidates for other therapiesl7997l8075   it can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraceptionl8078when used for the treatment of acne vulgaris drospirenonecontaining contraceptives should only be used in women ≥14 years of age who have experienced menarche desire oral contraception and do not have any contraindications to oral contraceptivesl7976 offlabel uses for this drug include the treatment of menstrual irregularities dysmenorrhea hirsutism and endometriosisa2439a182576')|
|('DB01395', 'MONDO:0005298', ['osteoporosis'], 'drospirenone in combination with ethinyl estradiol is indicated as an oral contraceptive for the prevention of pregnancy  in addition to its use for contraceptive effects this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorderl7973l7976  the drug has approved indications for combination with estrogens for the treatment of menopauseassociated symptoms such as vasomotor symptoms and vulvovaginal atrophy drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been postmenopausal for at least a year and are not candidates for other therapiesl7997l8075   it can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraceptionl8078when used for the treatment of acne vulgaris drospirenonecontaining contraceptives should only be used in women ≥14 years of age who have experienced menarche desire oral contraception and do not have any contraindications to oral contraceptivesl7976 offlabel uses for this drug include the treatment of menstrual irregularities dysmenorrhea hirsutism and endometriosisa2439a182576')|
|('DB01395', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'drospirenone in combination with ethinyl estradiol is indicated as an oral contraceptive for the prevention of pregnancy  in addition to its use for contraceptive effects this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorderl7973l7976  the drug has approved indications for combination with estrogens for the treatment of menopauseassociated symptoms such as vasomotor symptoms and vulvovaginal atrophy drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been postmenopausal for at least a year and are not candidates for other therapiesl7997l8075   it can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraceptionl8078when used for the treatment of acne vulgaris drospirenonecontaining contraceptives should only be used in women ≥14 years of age who have experienced menarche desire oral contraception and do not have any contraindications to oral contraceptivesl7976 offlabel uses for this drug include the treatment of menstrual irregularities dysmenorrhea hirsutism and endometriosisa2439a182576')|
|('DB01395', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'drospirenone in combination with ethinyl estradiol is indicated as an oral contraceptive for the prevention of pregnancy  in addition to its use for contraceptive effects this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorderl7973l7976  the drug has approved indications for combination with estrogens for the treatment of menopauseassociated symptoms such as vasomotor symptoms and vulvovaginal atrophy drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been postmenopausal for at least a year and are not candidates for other therapiesl7997l8075   it can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraceptionl8078when used for the treatment of acne vulgaris drospirenonecontaining contraceptives should only be used in women ≥14 years of age who have experienced menarche desire oral contraception and do not have any contraindications to oral contraceptivesl7976 offlabel uses for this drug include the treatment of menstrual irregularities dysmenorrhea hirsutism and endometriosisa2439a182576')|
|('DB00537', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'ciprofloxacin is only indicated in infections caused by susceptible bacterial6469l6472l6475l6478l6481l6484l6487l6490l6493ciprofloxacin immediate release tablets oral suspensions and intravenous injections are indicated for the treatment of skin and skin structure infections bone and joint infections complicated intraabdominal infections nosocomial pneumonia febrile neutropenia adults who have inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections including acute exacerbations of chronic bronchitis urinary tract infections complicated urinary tract infections in pediatrics complicated pyelonephritis in pediatrics and acute sinusitisl6481l6478a ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis external6469l6484 ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis external6490 a ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis external6493a ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitisl6472 a ciprofloxacin eye ointment is indicated for bacterial conjunctivitisl6475a ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections complicated urinary tract infections and acute uncomplicated pyelonephritisl6487')|
|('DB00537', 'MONDO:0005280', ['prostatitis'], 'ciprofloxacin is only indicated in infections caused by susceptible bacterial6469l6472l6475l6478l6481l6484l6487l6490l6493ciprofloxacin immediate release tablets oral suspensions and intravenous injections are indicated for the treatment of skin and skin structure infections bone and joint infections complicated intraabdominal infections nosocomial pneumonia febrile neutropenia adults who have inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections including acute exacerbations of chronic bronchitis urinary tract infections complicated urinary tract infections in pediatrics complicated pyelonephritis in pediatrics and acute sinusitisl6481l6478a ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis external6469l6484 ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis external6490 a ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis external6493a ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitisl6472 a ciprofloxacin eye ointment is indicated for bacterial conjunctivitisl6475a ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections complicated urinary tract infections and acute uncomplicated pyelonephritisl6487')|
|('DB00537', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'ciprofloxacin is only indicated in infections caused by susceptible bacterial6469l6472l6475l6478l6481l6484l6487l6490l6493ciprofloxacin immediate release tablets oral suspensions and intravenous injections are indicated for the treatment of skin and skin structure infections bone and joint infections complicated intraabdominal infections nosocomial pneumonia febrile neutropenia adults who have inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections including acute exacerbations of chronic bronchitis urinary tract infections complicated urinary tract infections in pediatrics complicated pyelonephritis in pediatrics and acute sinusitisl6481l6478a ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis external6469l6484 ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis external6490 a ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis external6493a ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitisl6472 a ciprofloxacin eye ointment is indicated for bacterial conjunctivitisl6475a ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections complicated urinary tract infections and acute uncomplicated pyelonephritisl6487')|
|('DB00537', 'MONDO:0024330', ['acute otitis Media [NCIT:C84354]', 'infectious otitis Media [NCIT:C84354]', 'middle Ear infection [NCIT:C84354]', 'AOM [NCIT:C84354]', 'infectious otitis media'], 'ciprofloxacin is only indicated in infections caused by susceptible bacterial6469l6472l6475l6478l6481l6484l6487l6490l6493ciprofloxacin immediate release tablets oral suspensions and intravenous injections are indicated for the treatment of skin and skin structure infections bone and joint infections complicated intraabdominal infections nosocomial pneumonia febrile neutropenia adults who have inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections including acute exacerbations of chronic bronchitis urinary tract infections complicated urinary tract infections in pediatrics complicated pyelonephritis in pediatrics and acute sinusitisl6481l6478a ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis external6469l6484 ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis external6490 a ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis external6493a ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitisl6472 a ciprofloxacin eye ointment is indicated for bacterial conjunctivitisl6475a ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections complicated urinary tract infections and acute uncomplicated pyelonephritisl6487')|
|('DB00537', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'ciprofloxacin is only indicated in infections caused by susceptible bacterial6469l6472l6475l6478l6481l6484l6487l6490l6493ciprofloxacin immediate release tablets oral suspensions and intravenous injections are indicated for the treatment of skin and skin structure infections bone and joint infections complicated intraabdominal infections nosocomial pneumonia febrile neutropenia adults who have inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections including acute exacerbations of chronic bronchitis urinary tract infections complicated urinary tract infections in pediatrics complicated pyelonephritis in pediatrics and acute sinusitisl6481l6478a ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis external6469l6484 ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis external6490 a ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis external6493a ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitisl6472 a ciprofloxacin eye ointment is indicated for bacterial conjunctivitisl6475a ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections complicated urinary tract infections and acute uncomplicated pyelonephritisl6487')|
|('DB01384', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of all conditions in which corticosteroid therapy is indicated except adrenaldeficiency states for which its lack of sodiumretaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone')|
|('DB01384', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all conditions in which corticosteroid therapy is indicated except adrenaldeficiency states for which its lack of sodiumretaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone')|
|('DB00554', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for treatment of osteoarthritis and rheumatoid arthritis')|
|('DB00554', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for treatment of osteoarthritis and rheumatoid arthritis')|
|('DB00554', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for treatment of osteoarthritis and rheumatoid arthritis')|
|('DB00826', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of fungal blepharitis conjunctivitis and keratitis caused by susceptible organisms including ifusarium solanii keratitis')|
|('DB00826', 'MONDO:0003799', ['conjunctivitis'], 'for the treatment of fungal blepharitis conjunctivitis and keratitis caused by susceptible organisms including ifusarium solanii keratitis')|
|('DB00826', 'MONDO:0003085', ['keratitis'], 'for the treatment of fungal blepharitis conjunctivitis and keratitis caused by susceptible organisms including ifusarium solanii keratitis')|
|('DB00846', 'MONDO:0003085', ['keratitis'], 'for relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses particularly dry scaling localized lesions')|
|('DB00846', 'MONDO:0045042', ['localized'], 'for relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses particularly dry scaling localized lesions')|
|('DB01183', 'MONDO:0045042', ['localized'], 'for the complete or partial reversal of narcotic depression including respiratory depression induced by opioids including natural and synthetic narcotics propoxyphene methadone and the narcoticantagonist analgesics nalbuphine pentazocine and butorphanol it is also indicated for the diagnosis of suspected acute opioid overdose it may also be used as an adjunctive agent to increase blood pressure in the management of septic shock')|
|('DB00699', 'MONDO:0045042', ['localized'], 'for the treatment of senile dementia migraines of vascular origin transient ischemia platelet hyperaggregability and macular degeneration')|
|('DB00699', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'for the treatment of senile dementia migraines of vascular origin transient ischemia platelet hyperaggregability and macular degeneration')|
|('DB00433', 'MONDO:0045042', ['localized'], 'indicated for the symptomatic treatment of severe nausea and vomitinglabelindicated for the management of manifestations of psychotic disorders such as schizophrenia and generalized nonpsychotic anxiety the use of prochlorperazine for the management of generalized nonpsychotic anxiety is typically not a firstline therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weekslabell6634offlabel uses include use in emergency settings for adult and pediatric migraines the american headache society recommends the use of prochlorperazine as the firstline medication in this setting in pediatric migraines a nonsteroidal antiinflammatory agent is often used in combination with dopamine antagonistl6637')|
|('DB00433', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'indicated for the symptomatic treatment of severe nausea and vomitinglabelindicated for the management of manifestations of psychotic disorders such as schizophrenia and generalized nonpsychotic anxiety the use of prochlorperazine for the management of generalized nonpsychotic anxiety is typically not a firstline therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weekslabell6634offlabel uses include use in emergency settings for adult and pediatric migraines the american headache society recommends the use of prochlorperazine as the firstline medication in this setting in pediatric migraines a nonsteroidal antiinflammatory agent is often used in combination with dopamine antagonistl6637')|
|('DB00530', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'erlotinib is indicated for the treatment of metastatic nonsmall cell lung cancer nsclc with tumors showing epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations fda label  in combination with firstline treatment for patients diagnosed with locally advanced unresectable or metastatic pancreatic cancer fda labelthe safety and efficacy of erlotinib have not been established for patients with nsclc whose tumors show other egfr mutations additionally it is not recommended for use in combination with platinumbased chemotherapy fda label')|
|('DB00530', 'MONDO:0004992', ['cancer'], 'erlotinib is indicated for the treatment of metastatic nonsmall cell lung cancer nsclc with tumors showing epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations fda label  in combination with firstline treatment for patients diagnosed with locally advanced unresectable or metastatic pancreatic cancer fda labelthe safety and efficacy of erlotinib have not been established for patients with nsclc whose tumors show other egfr mutations additionally it is not recommended for use in combination with platinumbased chemotherapy fda label')|
|('DB00530', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'erlotinib is indicated for the treatment of metastatic nonsmall cell lung cancer nsclc with tumors showing epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations fda label  in combination with firstline treatment for patients diagnosed with locally advanced unresectable or metastatic pancreatic cancer fda labelthe safety and efficacy of erlotinib have not been established for patients with nsclc whose tumors show other egfr mutations additionally it is not recommended for use in combination with platinumbased chemotherapy fda label')|
|('DB00824', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'used in the management of symptoms of asthma also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency sickle cell disease and diabetic neuropathy')|
|('DB00824', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used in the management of symptoms of asthma also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency sickle cell disease and diabetic neuropathy')|
|('DB00305', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for treatment of malignant neoplasm of lip oral cavity pharynx digestive organs peritoneum female breast and urinary bladder also used as an adjunct to ab externo glaucoma surgery')|
|('DB00305', 'MONDO:0006517', ['malignant childhood neoplasm [NCIT:C4005]', 'malignant neoplasm [NCIT:C4005]', 'childhood cancer [NCIT:C4005]', 'childhood neoplasm, malignant [MONDO:patterns/malignant]', 'malignant pediatric neoplasm [NCIT:C4005]', 'malignant childhood tumor [NCIT:C4005]', 'malignant pediatric tumor [NCIT:C4005]', 'childhood malignant neoplasm [NCIT:C4005]', 'pediatric cancer [NCIT:C4005]', 'childhood malignant neoplasm'], 'for treatment of malignant neoplasm of lip oral cavity pharynx digestive organs peritoneum female breast and urinary bladder also used as an adjunct to ab externo glaucoma surgery')|
|('DB00305', 'MONDO:0005041', ['glaucoma'], 'for treatment of malignant neoplasm of lip oral cavity pharynx digestive organs peritoneum female breast and urinary bladder also used as an adjunct to ab externo glaucoma surgery')|
|('DB01369', 'MONDO:0005041', ['glaucoma'], 'for the treatment of bacterial infections usually in combination with dalfopristin')|
|('DB01063', 'MONDO:0005041', ['glaucoma'], 'for the treatment of disorganized and psychotic thinking also used to help treat false perceptions eg hallucinations or delusions')|
|('DB00287', 'MONDO:0005041', ['glaucoma'], 'travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension f3061 f3064 l5146travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to  18 years with ocular hypertension or paediatric glaucoma l5146')|
|('DB00287', 'MONDO:0006875', ['ocular hypertension'], 'travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension f3061 f3064 l5146travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to  18 years with ocular hypertension or paediatric glaucoma l5146')|
|('DB00799', 'MONDO:0006875', ['ocular hypertension'], 'used to treat psoriasis acne and sun damaged skin photodamage')|
|('DB00799', 'MONDO:0005083', ['psoriasis'], 'used to treat psoriasis acne and sun damaged skin photodamage')|
|('DB01229', 'MONDO:0005083', ['psoriasis'], 'used in the treatment of kaposis sarcoma and cancer of the lung ovarian and breast abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic nonsmall cell lung cancer')|
|('DB01229', 'MONDO:0004992', ['cancer'], 'used in the treatment of kaposis sarcoma and cancer of the lung ovarian and breast abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic nonsmall cell lung cancer')|
|('DB00531', 'MONDO:0004992', ['cancer'], 'cyclophosphamide is indicated for the treatment of malignant lymphomas multiple myeloma leukemias mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma and carcinoma of the breast it is also indicated for the treatment of biopsyproven minimal change nephrotic syndrome in pediatric patients ')|
|('DB00531', 'MONDO:0009691', ['Mycosis fungoides', 'mycosis fungoides lymphoma', 'mycosis fungoides'], 'cyclophosphamide is indicated for the treatment of malignant lymphomas multiple myeloma leukemias mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma and carcinoma of the breast it is also indicated for the treatment of biopsyproven minimal change nephrotic syndrome in pediatric patients ')|
|('DB00531', 'MONDO:0005072', ['neuroblastoma'], 'cyclophosphamide is indicated for the treatment of malignant lymphomas multiple myeloma leukemias mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma and carcinoma of the breast it is also indicated for the treatment of biopsyproven minimal change nephrotic syndrome in pediatric patients ')|
|('DB00531', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'cyclophosphamide is indicated for the treatment of malignant lymphomas multiple myeloma leukemias mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma and carcinoma of the breast it is also indicated for the treatment of biopsyproven minimal change nephrotic syndrome in pediatric patients ')|
|('DB00441', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy metastatic ovarian cancer inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancer and locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas ')|
|('DB00441', 'MONDO:0004992', ['cancer'], 'gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy metastatic ovarian cancer inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancer and locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas ')|
|('DB00441', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy metastatic ovarian cancer inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancer and locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas ')|
|('DB00441', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy metastatic ovarian cancer inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancer and locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas ')|
|('DB00441', 'MONDO:0004970', ['adenocarcinomas', 'adenocarcinoma'], 'gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy metastatic ovarian cancer inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancer and locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas ')|
|('DB00726', 'MONDO:0004970', ['adenocarcinomas', 'adenocarcinoma'], 'for the treatment of depression and depression accompanied by anxiety agitation or sleep disturbance')|
|('DB00726', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of depression and depression accompanied by anxiety agitation or sleep disturbance')|
|('DB00726', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'for the treatment of depression and depression accompanied by anxiety agitation or sleep disturbance')|
|('DB06218', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old injection is indicated for short term use when oral therapy is not feasible ')|
|('DB06218', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old injection is indicated for short term use when oral therapy is not feasible ')|
|('DB00742', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used for the promotion of diuresis before irreversible renal failure becomes established the reduction of intracranial pressure the treatment of cerebral edema and the promotion of urinary excretion of toxic substances')|
|('DB00742', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'used for the promotion of diuresis before irreversible renal failure becomes established the reduction of intracranial pressure the treatment of cerebral edema and the promotion of urinary excretion of toxic substances')|
|('DB00527', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks')|
|('DB04855', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'dronedarone is indicated for the management of atrial fibrillation af in patients in sinus rhythm with a history of paroxysmal or persistent af to reduce the risk of hospitalizationl9007')|
|('DB04855', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'dronedarone is indicated for the management of atrial fibrillation af in patients in sinus rhythm with a history of paroxysmal or persistent af to reduce the risk of hospitalizationl9007')|
|('DB01329', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'indicated for the treatment of following infections caused by susceptible bacterialabel1 respiratory tract infections caused by s pneumoniae h influenzae s aureus penicillinase and nonpenicillinase producing strains s pyogenes group a betahemolytic streptococci p aeruginosa klebsiella pneumoniae e coli proteus mirabilis and enterobacter species2 peritonitis and other intraabdominal infections caused by e coli p aeruginosa and anaerobic gramnegative bacilli including bacteroides fragilis3 bacterial septicemia caused by s pneumoniae s agalactiae s aureus pseudomonas aeruginosa e coli klebsiella spp klebsiella pneumoniae proteus species indolepositive and indolenegative clostridium spp and anaerobic grampositive cocci4 infections of the skin and skin structures caused by s aureus penicillinase and nonpenicillinase producing strains s pyogenes and p aeruginosa5 pelvic inflammatory disease endometritis and other infections of the female genital tract caused by n gonorrhoeae s epidermidis s agalactiae e coli clostridium spp bacteroides species including bacteroides fragilis and anaerobic grampositive cocci6 urinary tract infections caused by escherichia coli and pseudomonas aeruginosa7 enterococcal infections although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intraabdominal infections infections of the skin and skin structures pelvic inflammatory disease endometritis and other infections of the female genital tract and urinary tract infections the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility and are moderately resistant to cefoperazone however in vitro susceptibility testing may not correlate directly with in vivo results despite this cefoperazone therapy has resulted in clinical cures of enterococcal infections chiefly in polymicrobial infections cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone')|
|('DB01329', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'indicated for the treatment of following infections caused by susceptible bacterialabel1 respiratory tract infections caused by s pneumoniae h influenzae s aureus penicillinase and nonpenicillinase producing strains s pyogenes group a betahemolytic streptococci p aeruginosa klebsiella pneumoniae e coli proteus mirabilis and enterobacter species2 peritonitis and other intraabdominal infections caused by e coli p aeruginosa and anaerobic gramnegative bacilli including bacteroides fragilis3 bacterial septicemia caused by s pneumoniae s agalactiae s aureus pseudomonas aeruginosa e coli klebsiella spp klebsiella pneumoniae proteus species indolepositive and indolenegative clostridium spp and anaerobic grampositive cocci4 infections of the skin and skin structures caused by s aureus penicillinase and nonpenicillinase producing strains s pyogenes and p aeruginosa5 pelvic inflammatory disease endometritis and other infections of the female genital tract caused by n gonorrhoeae s epidermidis s agalactiae e coli clostridium spp bacteroides species including bacteroides fragilis and anaerobic grampositive cocci6 urinary tract infections caused by escherichia coli and pseudomonas aeruginosa7 enterococcal infections although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intraabdominal infections infections of the skin and skin structures pelvic inflammatory disease endometritis and other infections of the female genital tract and urinary tract infections the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility and are moderately resistant to cefoperazone however in vitro susceptibility testing may not correlate directly with in vivo results despite this cefoperazone therapy has resulted in clinical cures of enterococcal infections chiefly in polymicrobial infections cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone')|
|('DB01329', 'MONDO:0000922', ['PID', 'pelvic inflammatory disease'], 'indicated for the treatment of following infections caused by susceptible bacterialabel1 respiratory tract infections caused by s pneumoniae h influenzae s aureus penicillinase and nonpenicillinase producing strains s pyogenes group a betahemolytic streptococci p aeruginosa klebsiella pneumoniae e coli proteus mirabilis and enterobacter species2 peritonitis and other intraabdominal infections caused by e coli p aeruginosa and anaerobic gramnegative bacilli including bacteroides fragilis3 bacterial septicemia caused by s pneumoniae s agalactiae s aureus pseudomonas aeruginosa e coli klebsiella spp klebsiella pneumoniae proteus species indolepositive and indolenegative clostridium spp and anaerobic grampositive cocci4 infections of the skin and skin structures caused by s aureus penicillinase and nonpenicillinase producing strains s pyogenes and p aeruginosa5 pelvic inflammatory disease endometritis and other infections of the female genital tract caused by n gonorrhoeae s epidermidis s agalactiae e coli clostridium spp bacteroides species including bacteroides fragilis and anaerobic grampositive cocci6 urinary tract infections caused by escherichia coli and pseudomonas aeruginosa7 enterococcal infections although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intraabdominal infections infections of the skin and skin structures pelvic inflammatory disease endometritis and other infections of the female genital tract and urinary tract infections the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility and are moderately resistant to cefoperazone however in vitro susceptibility testing may not correlate directly with in vivo results despite this cefoperazone therapy has resulted in clinical cures of enterococcal infections chiefly in polymicrobial infections cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone')|
|('DB01329', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of following infections caused by susceptible bacterialabel1 respiratory tract infections caused by s pneumoniae h influenzae s aureus penicillinase and nonpenicillinase producing strains s pyogenes group a betahemolytic streptococci p aeruginosa klebsiella pneumoniae e coli proteus mirabilis and enterobacter species2 peritonitis and other intraabdominal infections caused by e coli p aeruginosa and anaerobic gramnegative bacilli including bacteroides fragilis3 bacterial septicemia caused by s pneumoniae s agalactiae s aureus pseudomonas aeruginosa e coli klebsiella spp klebsiella pneumoniae proteus species indolepositive and indolenegative clostridium spp and anaerobic grampositive cocci4 infections of the skin and skin structures caused by s aureus penicillinase and nonpenicillinase producing strains s pyogenes and p aeruginosa5 pelvic inflammatory disease endometritis and other infections of the female genital tract caused by n gonorrhoeae s epidermidis s agalactiae e coli clostridium spp bacteroides species including bacteroides fragilis and anaerobic grampositive cocci6 urinary tract infections caused by escherichia coli and pseudomonas aeruginosa7 enterococcal infections although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intraabdominal infections infections of the skin and skin structures pelvic inflammatory disease endometritis and other infections of the female genital tract and urinary tract infections the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility and are moderately resistant to cefoperazone however in vitro susceptibility testing may not correlate directly with in vivo results despite this cefoperazone therapy has resulted in clinical cures of enterococcal infections chiefly in polymicrobial infections cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone')|
|('DB08924', 'MONDO:0000922', ['PID', 'pelvic inflammatory disease'], 'used as an appetite suppressant')|
|('DB01197', 'MONDO:0000922', ['PID', 'pelvic inflammatory disease'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB01197', 'MONDO:0006947', ['Renovascular hypertension', 'renovascular hypertension'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB01197', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB01197', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB01197', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB01197', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'for the treatment of essential or renovascular hypertension usually administered with other drugs particularly thiazide diuretics may be used to treat congestive heart failure in combination with other drugs eg cardiac glycosides diuretics betaadrenergic blockers may improve survival in patients with left ventricular dysfunction following myocardial infarction may be used to treat nephropathy including diabetic nephropathy ')|
|('DB00641', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005439', ['familial hyperbetalipoproteinaemia', 'familial hypercholesteremia', 'Fredrickson type IIa hyperlipoproteinemia', 'Fredrickson type IIa lipidaemia', 'hyperbetalipoproteinemia', 'type II hyperlipidemia', 'familial hypercholesterolemia'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005015', ['diabetes mellitus'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005311', ['atherosclerosis'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0005350', ['AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1', 'abdominal aortic aneurysm'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00641', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldl‑c apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlcf4655 f4658this includes the treatment of primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh as an adjunct to other lipidlowering treatments as well as adolescent patients with heterozygous familial hypercholesterolemia hefhf4655 f4658simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction stroke and the need for revascularization procedures it is primarily used in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular diseasef4655 f4658prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01241', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'gemfibrozil is indicated to treat patients with types iv and v hyperlipidemia who have elevated serum triglycerides usually above 2000mgdl elevated vldl cholesterol fasting chylomicrons are at risk of developing pancreatitis and do not adequately respond to dietary restrictionsl8525 gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with type iib hyperlipidemia without history or symptoms of coronary heart disease who do not adequately respond to weight loss diet exercise and other medications and have low hdl raised ldl and raised triglyceridesl8525')|
|('DB01241', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'gemfibrozil is indicated to treat patients with types iv and v hyperlipidemia who have elevated serum triglycerides usually above 2000mgdl elevated vldl cholesterol fasting chylomicrons are at risk of developing pancreatitis and do not adequately respond to dietary restrictionsl8525 gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with type iib hyperlipidemia without history or symptoms of coronary heart disease who do not adequately respond to weight loss diet exercise and other medications and have low hdl raised ldl and raised triglyceridesl8525')|
|('DB01241', 'MONDO:0004982', ['pancreatitis'], 'gemfibrozil is indicated to treat patients with types iv and v hyperlipidemia who have elevated serum triglycerides usually above 2000mgdl elevated vldl cholesterol fasting chylomicrons are at risk of developing pancreatitis and do not adequately respond to dietary restrictionsl8525 gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with type iib hyperlipidemia without history or symptoms of coronary heart disease who do not adequately respond to weight loss diet exercise and other medications and have low hdl raised ldl and raised triglyceridesl8525')|
|('DB01241', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'gemfibrozil is indicated to treat patients with types iv and v hyperlipidemia who have elevated serum triglycerides usually above 2000mgdl elevated vldl cholesterol fasting chylomicrons are at risk of developing pancreatitis and do not adequately respond to dietary restrictionsl8525 gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with type iib hyperlipidemia without history or symptoms of coronary heart disease who do not adequately respond to weight loss diet exercise and other medications and have low hdl raised ldl and raised triglyceridesl8525')|
|('DB08912', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test fda labeltafinlar in combination with db08911 is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test the use in combination is based on the demonstration of durable response rate improvement in diseaserelated symptoms or overall survival has not been demonstrated for tafinlar in combination with trametinib fda labelin may 2018 tafinlar dabrafenib and mekinist db08911 have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2712')|
|('DB08912', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test fda labeltafinlar in combination with db08911 is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test the use in combination is based on the demonstration of durable response rate improvement in diseaserelated symptoms or overall survival has not been demonstrated for tafinlar in combination with trametinib fda labelin may 2018 tafinlar dabrafenib and mekinist db08911 have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2712')|
|('DB08912', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test fda labeltafinlar in combination with db08911 is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test the use in combination is based on the demonstration of durable response rate improvement in diseaserelated symptoms or overall survival has not been demonstrated for tafinlar in combination with trametinib fda labelin may 2018 tafinlar dabrafenib and mekinist db08911 have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2712')|
|('DB08912', 'MONDO:0006468', ['anaplastic thyroid cancer [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland cancer [NCIT:C3878]', 'anaplastic thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid tumor [NCIT:C3878]', 'anaplastic carcinoma of thyroid [NCIT:C3878]', 'undifferentiated carcinoma of thyroid [NCIT:C3878]', 'thyroid gland undifferentiated (anaplastic) carcinoma [NCIT:C3878]', 'undifferentiated thyroid carcinoma [NCIT:C3878]', 'pleomorphic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland carcinosarcoma [NCIT:C3878]', 'anaplastic thyroid carcinoma [GARD:0000664,MONDO:ambiguous,NCIT:C3878]', 'undifferentiated carcinoma of the thyroid gland [NCIT:C3878]', 'undifferentiated carcinoma of the thyroid [NCIT:C3878]', 'sarcomatoid thyroid gland carcinoma [NCIT:C3878]', 'Dedifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of the thyroid [NCIT:C3878]', 'anaplastic carcinoma of the thyroid gland [NCIT:C3878]', 'metaplastic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland undifferentiated carcinoma [MONDO:patterns/location]', 'thyroid gland undifferentiated (anaplastic) carcinoma'], 'tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test fda labeltafinlar in combination with db08911 is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test the use in combination is based on the demonstration of durable response rate improvement in diseaserelated symptoms or overall survival has not been demonstrated for tafinlar in combination with trametinib fda labelin may 2018 tafinlar dabrafenib and mekinist db08911 have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2712')|
|('DB03255', 'MONDO:0006468', ['anaplastic thyroid cancer [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland cancer [NCIT:C3878]', 'anaplastic thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid tumor [NCIT:C3878]', 'anaplastic carcinoma of thyroid [NCIT:C3878]', 'undifferentiated carcinoma of thyroid [NCIT:C3878]', 'thyroid gland undifferentiated (anaplastic) carcinoma [NCIT:C3878]', 'undifferentiated thyroid carcinoma [NCIT:C3878]', 'pleomorphic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland carcinosarcoma [NCIT:C3878]', 'anaplastic thyroid carcinoma [GARD:0000664,MONDO:ambiguous,NCIT:C3878]', 'undifferentiated carcinoma of the thyroid gland [NCIT:C3878]', 'undifferentiated carcinoma of the thyroid [NCIT:C3878]', 'sarcomatoid thyroid gland carcinoma [NCIT:C3878]', 'Dedifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of the thyroid [NCIT:C3878]', 'anaplastic carcinoma of the thyroid gland [NCIT:C3878]', 'metaplastic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland undifferentiated carcinoma [MONDO:patterns/location]', 'thyroid gland undifferentiated (anaplastic) carcinoma'], 'phenol is primarily indicated for minor sore throat pain sore mouth minor mouth irritation and pain associated with canker sores additionally phenol is indicated in the treatment of focal spasticity ')|
|('DB00366', 'MONDO:0006468', ['anaplastic thyroid cancer [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland cancer [NCIT:C3878]', 'anaplastic thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid tumor [NCIT:C3878]', 'anaplastic carcinoma of thyroid [NCIT:C3878]', 'undifferentiated carcinoma of thyroid [NCIT:C3878]', 'thyroid gland undifferentiated (anaplastic) carcinoma [NCIT:C3878]', 'undifferentiated thyroid carcinoma [NCIT:C3878]', 'pleomorphic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland carcinosarcoma [NCIT:C3878]', 'anaplastic thyroid carcinoma [GARD:0000664,MONDO:ambiguous,NCIT:C3878]', 'undifferentiated carcinoma of the thyroid gland [NCIT:C3878]', 'undifferentiated carcinoma of the thyroid [NCIT:C3878]', 'sarcomatoid thyroid gland carcinoma [NCIT:C3878]', 'Dedifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of the thyroid [NCIT:C3878]', 'anaplastic carcinoma of the thyroid gland [NCIT:C3878]', 'metaplastic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland undifferentiated carcinoma [MONDO:patterns/location]', 'thyroid gland undifferentiated (anaplastic) carcinoma'], 'used alone as a shortterm sleep aid in combination with other drugs as a nighttime cold and allergy relief drug also used in combination with vitamin b6 pyridoxine to prevent morning sickness in pregnant women')|
|('DB00366', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used alone as a shortterm sleep aid in combination with other drugs as a nighttime cold and allergy relief drug also used in combination with vitamin b6 pyridoxine to prevent morning sickness in pregnant women')|
|('DB01141', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated for the treatment of candidemia acute disseminated candidiasis and certain other invasive icandidai infections as well as esophageal candidiasis and prophylaxis of icandidai infections in patients undergoing hematopoietic stem cell transplantation micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy alone or in combination with other antifungals for the treatment of invasive aspergillosisindicated for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation')|
|('DB01141', 'MONDO:0044070', ['candidemia []', 'candidemia'], 'indicated for the treatment of candidemia acute disseminated candidiasis and certain other invasive icandidai infections as well as esophageal candidiasis and prophylaxis of icandidai infections in patients undergoing hematopoietic stem cell transplantation micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy alone or in combination with other antifungals for the treatment of invasive aspergillosisindicated for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation')|
|('DB01141', 'MONDO:0042233', ['invasive candidiasis []', 'disseminated candidiasis []', 'disseminated candidiasis'], 'indicated for the treatment of candidemia acute disseminated candidiasis and certain other invasive icandidai infections as well as esophageal candidiasis and prophylaxis of icandidai infections in patients undergoing hematopoietic stem cell transplantation micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy alone or in combination with other antifungals for the treatment of invasive aspergillosisindicated for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation')|
|('DB01141', 'MONDO:0002026', ['Disseminated candidiasis', 'systemic candidiasis', 'candidiasis'], 'indicated for the treatment of candidemia acute disseminated candidiasis and certain other invasive icandidai infections as well as esophageal candidiasis and prophylaxis of icandidai infections in patients undergoing hematopoietic stem cell transplantation micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy alone or in combination with other antifungals for the treatment of invasive aspergillosisindicated for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation')|
|('DB01141', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of candidemia acute disseminated candidiasis and certain other invasive icandidai infections as well as esophageal candidiasis and prophylaxis of icandidai infections in patients undergoing hematopoietic stem cell transplantation micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy alone or in combination with other antifungals for the treatment of invasive aspergillosisindicated for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation')|
|('DB06712', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the management of vasospastic angina chronic stable angina and hypertension')|
|('DB00402', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'eszopiclone is indicated for the treatment of insomnial6769')|
|('DB00793', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to treat fungal tinea skin infections such as athletes foot jock itch ringworm and tinea versicolor')|
|('DB00793', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'used to treat fungal tinea skin infections such as athletes foot jock itch ringworm and tinea versicolor')|
|('DB08887', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'icosapent ethyl is used as adjunct therapy to reduce triglyceride tg levels in adults with severe 500 mgdl hypertriglyceridemia ')|
|('DB08887', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'icosapent ethyl is used as adjunct therapy to reduce triglyceride tg levels in adults with severe 500 mgdl hypertriglyceridemia ')|
|('DB01587', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'ketazolam could be used for the treatment of anxiety in approved countries it is indicated for the treatment of anxiety tension irritability and similar stress related symptoms')|
|('DB01587', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'ketazolam could be used for the treatment of anxiety in approved countries it is indicated for the treatment of anxiety tension irritability and similar stress related symptoms')|
|('DB00296', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in obstetric anesthesia and regional anesthesia for surgery')|
|('DB01426', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for use as an antiarrhythmic agent')|
|('DB00868', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the symptomatic relief of cough has also been applied locally in the oral cavity in adults by releasing the drug from the liquidfilled capsules to provide oropharyngeal anesthesia for conscious intubation')|
|('DB01193', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of hypertension and ventricular premature beats in adults')|
|('DB06803', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of tapeworm and intestinal fluke infections taenia saginata beef tapeworm taenia solium pork tapeworm diphyllobothrium latum fish tapeworm fasciolopsis buski large intestinal fluke niclosamide is also used as a molluscicide in the control of schistosomiasis')|
|('DB06803', 'MONDO:0015260', ['Diphyllobothrium infection', 'fish tapeworm', 'diphyllobothriasis'], 'for the treatment of tapeworm and intestinal fluke infections taenia saginata beef tapeworm taenia solium pork tapeworm diphyllobothrium latum fish tapeworm fasciolopsis buski large intestinal fluke niclosamide is also used as a molluscicide in the control of schistosomiasis')|
|('DB06803', 'MONDO:0015254', ['schistosomiasis'], 'for the treatment of tapeworm and intestinal fluke infections taenia saginata beef tapeworm taenia solium pork tapeworm diphyllobothrium latum fish tapeworm fasciolopsis buski large intestinal fluke niclosamide is also used as a molluscicide in the control of schistosomiasis')|
|('DB01001', 'MONDO:0015260', ['Diphyllobothrium infection', 'fish tapeworm', 'diphyllobothriasis'], 'salbutamol is indicated for i the symptomatic relief and prevention of bronchospasm due to bronchial asthma chronic bronchitis reversible obstructive airway disease and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor andor ii the acute prophylaxis against exerciseinduced bronchospasm and other stimuli known to induce bronchospasmlabelf3265f3268')|
|('DB01001', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'salbutamol is indicated for i the symptomatic relief and prevention of bronchospasm due to bronchial asthma chronic bronchitis reversible obstructive airway disease and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor andor ii the acute prophylaxis against exerciseinduced bronchospasm and other stimuli known to induce bronchospasmlabelf3265f3268')|
|('DB01001', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'salbutamol is indicated for i the symptomatic relief and prevention of bronchospasm due to bronchial asthma chronic bronchitis reversible obstructive airway disease and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor andor ii the acute prophylaxis against exerciseinduced bronchospasm and other stimuli known to induce bronchospasmlabelf3265f3268')|
|('DB01142', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB01142', 'MONDO:0045042', ['localized'], 'oral doxepin is approved for the following indications treatment of depression andor anxietya177163 treatment of depression andor anxiety associated with different conditions including alcoholism organic disease and manicdepressive disorderst249 treatment of psychotic depressive disorders with associated anxietyt249 treatment of involutional depressiont249  treatment of manicdepressive disordert249 treatment of insomnia characterized by difficulties with sleep maintenancea177163topical doxepin is also approved for shortterm up to 8 days management of moderate pruritus in adult patients with atopic dermatitis pruritus or lichen simplex chronicust249offlabel doxepin is used topically for the management of neuropathic paina177172depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities this condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environmentl5980anxiety is a normal reaction of the body towards a normal danger when the anxious state is exacerbated or appears on situations without danger it is defined as an anxiety disorder this disorders can appear in different forms such as phobias panic obsessivecompulsive disorder and posttraumatic stress disorderl5983insomnia is a sleep disorder that directly affects the quality of life of the individual it is characterized by the complication either to fall asleep or to stay asleep this condition can be occasional or chronicl5986pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch it can be localized or generalized and it can appear in an acute or chronic mannerl5989neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptorsl5992')|
|('DB08932', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'macitentan is indicated for patients with pulmonary arterial hypertension')|
|('DB08932', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'macitentan is indicated for patients with pulmonary arterial hypertension')|
|('DB00321', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0002050', ['depressive disorder'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0000022', ['sleep enuresis [NCIT:C118172]', 'enuresis, nocturnal []', 'bedwetting []', 'nocturnal enuresis'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0008449', ['spina bifida'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0005546', ['fibromyalgia'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB00321', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'this drug in indicated for the following conditions fda labelmajor depressive disorder in adultsmanagement of neuropathic pain in adultsprophylactic treatment of chronic tensiontype headache ctth in adultsprophylactic treatment of migraine in adultstreatment of nocturnal enuresis in children aged 6 years and above when organic pathology including spina bifida and related disorders have been excluded and no response has been achieved to all other nondrug and drug treatments including antispasmodics and vasopressinrelated products this product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis fda labelofflabel uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia and insomnia ')|
|('DB01046', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of chronic idiopathic constipation in the adult population also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older')|
|('DB01046', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of chronic idiopathic constipation in the adult population also used for the treatment of irritable bowel syndrome with constipation in women who are 18 years of age or older')|
|('DB00232', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension also used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy')|
|('DB00232', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension also used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy')|
|('DB00232', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension also used as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy')|
|('DB00645', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'used to provide topical anesthesia of accessible mucous membranes prior to examination endoscopy or instrumentation or other procedures involving the esophagus larynx mouth pharynx or throat respiratory tract or trachea urinary tract or vagina also used to suppress the gag reflex andor other laryngeal and esophageal reflexes to facilitate dental examination or procedures including oral surgery endoscopy or intubation also used for relief of canker sores cold sores or fever blister')|
|('DB00645', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used to provide topical anesthesia of accessible mucous membranes prior to examination endoscopy or instrumentation or other procedures involving the esophagus larynx mouth pharynx or throat respiratory tract or trachea urinary tract or vagina also used to suppress the gag reflex andor other laryngeal and esophageal reflexes to facilitate dental examination or procedures including oral surgery endoscopy or intubation also used for relief of canker sores cold sores or fever blister')|
|('DB01403', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of psychosis particular those of schizophrenia and manic phases of bipolar disorder')|
|('DB01403', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of psychosis particular those of schizophrenia and manic phases of bipolar disorder')|
|('DB01403', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'for the treatment of psychosis particular those of schizophrenia and manic phases of bipolar disorder')|
|('DB00409', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia')|
|('DB00659', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation')|
|('DB00659', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation')|
|('DB00942', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for treatment and management of parkinsons disease')|
|('DB00380', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mgm2 and would benefit from continued doxorubicin therapy also approved for the treatment of extravasation from intravenous anthracyclines')|
|('DB00380', 'MONDO:0004994', ['Cardiomyopathies', 'cardiomyopathy'], 'for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mgm2 and would benefit from continued doxorubicin therapy also approved for the treatment of extravasation from intravenous anthracyclines')|
|('DB00380', 'MONDO:0004992', ['cancer'], 'for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mgm2 and would benefit from continued doxorubicin therapy also approved for the treatment of extravasation from intravenous anthracyclines')|
|('DB08933', 'MONDO:0004992', ['cancer'], 'luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by trichophyton rubrum and epidermophyton floccosum specifically tinea pedis cruris and corporis ')|
|('DB08933', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by trichophyton rubrum and epidermophyton floccosum specifically tinea pedis cruris and corporis ')|
|('DB00516', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'used to prevent or reduce the severity of allergic contact dermatitis due to urushiol the allergenic resin of poison ivy poison oak and poison sumac')|
|('DB00516', 'MONDO:0006525', ['allergic contact dermatitis'], 'used to prevent or reduce the severity of allergic contact dermatitis due to urushiol the allergenic resin of poison ivy poison oak and poison sumac')|
|('DB00940', 'MONDO:0006525', ['allergic contact dermatitis'], 'for the treatment of peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm and reflex neurogenic bladder in children')|
|('DB00940', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm and reflex neurogenic bladder in children')|
|('DB00940', 'MONDO:0004982', ['pancreatitis'], 'for the treatment of peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm and reflex neurogenic bladder in children')|
|('DB00940', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'for the treatment of peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm and reflex neurogenic bladder in children')|
|('DB01591', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence urgency and frequencyl7511')|
|('DB01331', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'for the treatment of serious infections caused by susceptible strains microorganisms')|
|('DB00315', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'for the acute treatment of adult migraine with or without auras')|
|('DB01437', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'for the treatment of insomnia')|
|('DB01437', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of insomnia')|
|('DB00384', 'MONDO:0005667', ['sphincter of oddi dysfunction', 'biliary dyskinesia'], 'triamterene is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome also in steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronisml6166triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be riskedl6169 triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazidest28')|
|('DB00384', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'triamterene is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome also in steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronisml6166triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be riskedl6169 triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazidest28')|
|('DB00384', 'MONDO:0005377', ['nephrotic syndrome'], 'triamterene is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome also in steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronisml6166triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be riskedl6169 triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazidest28')|
|('DB00190', 'MONDO:0005377', ['nephrotic syndrome'], 'carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic parkinson disease postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxicationfda labelthe combination therapy is administered for the reduction of levodopadriven nausea and vomitingfda labelthe product of carbidopa should be used in patients where the combination therapy of carbidopalevodopa provide less than the adequate daily dosagefda labelas well carbidopa can be used in patients where the dosages of carbidopa and levodopa require individual titrationfda label')|
|('DB00190', 'MONDO:0006966', ['disorder presenting primarily with parkinsonism', 'secondary Parkinsonism', 'secondary parkinsonism', 'Symptomatic parkinsonism', 'secondary parkinson disease'], 'carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic parkinson disease postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxicationfda labelthe combination therapy is administered for the reduction of levodopadriven nausea and vomitingfda labelthe product of carbidopa should be used in patients where the combination therapy of carbidopalevodopa provide less than the adequate daily dosagefda labelas well carbidopa can be used in patients where the dosages of carbidopa and levodopa require individual titrationfda label')|
|('DB00190', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic parkinson disease postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxicationfda labelthe combination therapy is administered for the reduction of levodopadriven nausea and vomitingfda labelthe product of carbidopa should be used in patients where the combination therapy of carbidopalevodopa provide less than the adequate daily dosagefda labelas well carbidopa can be used in patients where the dosages of carbidopa and levodopa require individual titrationfda label')|
|('DB05812', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used in combination with prednisone for the treatment of metastatic castrationresistant prostate cancer ')|
|('DB05812', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used in combination with prednisone for the treatment of metastatic castrationresistant prostate cancer ')|
|('DB00473', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as a local anesthetic for surface application infiltration or nerve block')|
|('DB00660', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes')|
|('DB00741', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammationl10529l10532 hydrocortisone tablets are indicated for certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal and other conditionsl10535 a hydrocortisone enema is indicated for ulcerative colitisl10538 a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infectionsl7772 and a topical cream with acyclovir is indicated to treat cold soresl7321')|
|('DB00741', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammationl10529l10532 hydrocortisone tablets are indicated for certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal and other conditionsl10535 a hydrocortisone enema is indicated for ulcerative colitisl10538 a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infectionsl7772 and a topical cream with acyclovir is indicated to treat cold soresl7321')|
|('DB00741', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammationl10529l10532 hydrocortisone tablets are indicated for certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal and other conditionsl10535 a hydrocortisone enema is indicated for ulcerative colitisl10538 a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infectionsl7772 and a topical cream with acyclovir is indicated to treat cold soresl7321')|
|('DB00091', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0005083', ['psoriasis'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0004768', ['keratoconjunctivitis'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0005377', ['nephrotic syndrome'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0005376', ['membranous nephropathy', 'membranous glomerulonephritis'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB00091', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'cyclosporine is officially approved for different conditions listed below prophylaxis of organ rejection in kidney liver and heart allogeneic transplants for this indication it can be used concomitantly with azathioprine and corticosteroids treatment of patients with severe active rheumatoid arthritis when the patient no longer responds to methotrexate  concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone treatment of adult nonimmunocompromised patients with severe recalcitrant plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicatedfda label its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years oldl5158 prevention of graft rejection following bone marrow transplantation and in the treatment of graftversushost disease gvhd treatment of steroid dependent and steroidresistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and childrenf3091away from all this approved and reviewed indications cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis blistering disorders and connective tissue diseasesa174085')|
|('DB06710', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency it is also used in women to treat breast cancer breast pain swelling due to pregnancy and with the addition of estrogen it can treat symptoms of menopause')|
|('DB06710', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency it is also used in women to treat breast cancer breast pain swelling due to pregnancy and with the addition of estrogen it can treat symptoms of menopause')|
|('DB06710', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency it is also used in women to treat breast cancer breast pain swelling due to pregnancy and with the addition of estrogen it can treat symptoms of menopause')|
|('DB06710', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency it is also used in women to treat breast cancer breast pain swelling due to pregnancy and with the addition of estrogen it can treat symptoms of menopause')|
|('DB00476', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for1 management of major depressive disorderlabel2 management of generalized anxiety disorderlabel3 management of diabetic peripheral neuropathylabel4 management of fibromyalgialabel5 management of chronic musculoskeletal painlabel6 management of osteoarthritis of the knee in adultsl63647 management of chronic lower back pain in adultsl63648 management of stress urinary incontinence in adult womenl6367offlabel uses include1 management of chemotherapyinduced peripheral neuropathya1786032 management of stress urinary incontinence in adult men after prostatectomy until recovery is completel6370')|
|('DB00476', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'indicated for1 management of major depressive disorderlabel2 management of generalized anxiety disorderlabel3 management of diabetic peripheral neuropathylabel4 management of fibromyalgialabel5 management of chronic musculoskeletal painlabel6 management of osteoarthritis of the knee in adultsl63647 management of chronic lower back pain in adultsl63648 management of stress urinary incontinence in adult womenl6367offlabel uses include1 management of chemotherapyinduced peripheral neuropathya1786032 management of stress urinary incontinence in adult men after prostatectomy until recovery is completel6370')|
|('DB00476', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'indicated for1 management of major depressive disorderlabel2 management of generalized anxiety disorderlabel3 management of diabetic peripheral neuropathylabel4 management of fibromyalgialabel5 management of chronic musculoskeletal painlabel6 management of osteoarthritis of the knee in adultsl63647 management of chronic lower back pain in adultsl63648 management of stress urinary incontinence in adult womenl6367offlabel uses include1 management of chemotherapyinduced peripheral neuropathya1786032 management of stress urinary incontinence in adult men after prostatectomy until recovery is completel6370')|
|('DB06268', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'investigated for usetreatment in pulmonary hypertension connective tissue diseases hypertension and congestive heart failure')|
|('DB06268', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'investigated for usetreatment in pulmonary hypertension connective tissue diseases hypertension and congestive heart failure')|
|('DB01355', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical diagnostic or therapeutic procedures associated with minimal painful stimuli')|
|('DB00630', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women treatment of glucocorticoidinduced osteoporosis and pagets disease of bonefda labela959a176750 however alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance 35mlminfda label')|
|('DB00630', 'MONDO:0005298', ['osteoporosis'], 'alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women treatment of glucocorticoidinduced osteoporosis and pagets disease of bonefda labela959a176750 however alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance 35mlminfda label')|
|('DB00630', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women treatment of glucocorticoidinduced osteoporosis and pagets disease of bonefda labela959a176750 however alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance 35mlminfda label')|
|('DB00451', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'levothyroxine is indicated as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism it is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer')|
|('DB00451', 'MONDO:0021140', ['inborn []', 'congenital'], 'levothyroxine is indicated as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism it is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer')|
|('DB00451', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'levothyroxine is indicated as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism it is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer')|
|('DB00451', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'levothyroxine is indicated as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism it is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer')|
|('DB08930', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with hiv1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kga7520 the fda combination therapy approval of dolutegravir and rilpivirine is indicated for adults with hiv1 infections whose virus is currently suppressed  50 copiesml on a stable regimen for at least six months without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapyl1031')|
|('DB00656', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0001627', ['dementia'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00656', 'MONDO:0005546', ['fibromyalgia'], 'trazodone is indicated for the treatment of major depressive disorder mddl3484 it has been used offlabel for adjunct therapy in alcohol dependence and offlabel to treat anxiety and insomnial3484 it may also be used offlabel to treat symptoms of dementia alzheimer’s disease schizophrenia eating disorders and fibromyalgia due to its effects on various neurotransmitter receptorsa31634')|
|('DB00586', 'MONDO:0005546', ['fibromyalgia'], 'diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis rheumatoid arthritis and akylosing spondylitis as well as injuryrelated inflammation due to surgery and physical trauma it is often used in combination with misoprostol as a gastroprotective agent in patients with high risk of developing nsaidinduced ulcers')|
|('DB00586', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis rheumatoid arthritis and akylosing spondylitis as well as injuryrelated inflammation due to surgery and physical trauma it is often used in combination with misoprostol as a gastroprotective agent in patients with high risk of developing nsaidinduced ulcers')|
|('DB00586', 'MONDO:0003937', ['spondylitis'], 'diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis rheumatoid arthritis and akylosing spondylitis as well as injuryrelated inflammation due to surgery and physical trauma it is often used in combination with misoprostol as a gastroprotective agent in patients with high risk of developing nsaidinduced ulcers')|
|('DB00586', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis rheumatoid arthritis and akylosing spondylitis as well as injuryrelated inflammation due to surgery and physical trauma it is often used in combination with misoprostol as a gastroprotective agent in patients with high risk of developing nsaidinduced ulcers')|
|('DB00830', 'MONDO:0003937', ['spondylitis'], 'used as an anorectic in the treatment of obesity')|
|('DB00711', 'MONDO:0003937', ['spondylitis'], 'used for the treatment of certain filarial diseases including tropical pulmonary eosinophilia loiasis and lymphatic filariasis caused by infection with iwuchereria bancroftii ibrugia malayii or ibrugia timorii')|
|('DB00711', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'used for the treatment of certain filarial diseases including tropical pulmonary eosinophilia loiasis and lymphatic filariasis caused by infection with iwuchereria bancroftii ibrugia malayii or ibrugia timorii')|
|('DB00711', 'MONDO:0005761', ['Bancroftian elephantiasis', 'Bancroftian filarial chyluria', 'Elephantiasis of eyelid', 'elephantiasis of eyelid', 'Lymphatic filariasis', 'filarial elephantiasis'], 'used for the treatment of certain filarial diseases including tropical pulmonary eosinophilia loiasis and lymphatic filariasis caused by infection with iwuchereria bancroftii ibrugia malayii or ibrugia timorii')|
|('DB00420', 'MONDO:0005761', ['Bancroftian elephantiasis', 'Bancroftian filarial chyluria', 'Elephantiasis of eyelid', 'elephantiasis of eyelid', 'Lymphatic filariasis', 'filarial elephantiasis'], 'used as an adjunct for short term treatment of moderate and severe psychomotor agitation also used to treat agitation or restlessness in the elderly')|
|('DB01588', 'MONDO:0005761', ['Bancroftian elephantiasis', 'Bancroftian filarial chyluria', 'Elephantiasis of eyelid', 'elephantiasis of eyelid', 'Lymphatic filariasis', 'filarial elephantiasis'], 'for the treatment of anxiety disorders')|
|('DB01588', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety disorders')|
|('DB00904', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'in the adult patient populationi orally administered ondansetron tablets and orally disintegrating tablets odt are indicated for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including high dose ie greater than or equal to 50 mgm2 cisplatin therapy and radiotherapy and the prevention and treatment of postoperative nausea and vomitingii intravenously administered ondansetron injection formulations are indicated for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including high dose ie greater than or equal to 50 mgm2 cisplatin therapy and the prevention and treatment of postoperative nausea and vomitingin the pediatric 418 years of age patient populationi ondansetron was effective and well tolerated when given to children 412 years of age for the treatment of postchemotherapy induced nausea and vomitingii ondansetron tablets ondansetron odt ondansetron injection are not indicated for the treatment of children 3 years of age or youngeriii ondansetron tablets ondansetron odt ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postradiotherapy induced nausea and vomiting andiv ondansetron tablets ondansetron odt ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomitingin the geriatric 65 years of age patient populationi efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of postchemotherapy and radiotherapyinduced nausea and vomiting andii clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population ')|
|('DB00904', 'MONDO:0004992', ['cancer'], 'in the adult patient populationi orally administered ondansetron tablets and orally disintegrating tablets odt are indicated for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including high dose ie greater than or equal to 50 mgm2 cisplatin therapy and radiotherapy and the prevention and treatment of postoperative nausea and vomitingii intravenously administered ondansetron injection formulations are indicated for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including high dose ie greater than or equal to 50 mgm2 cisplatin therapy and the prevention and treatment of postoperative nausea and vomitingin the pediatric 418 years of age patient populationi ondansetron was effective and well tolerated when given to children 412 years of age for the treatment of postchemotherapy induced nausea and vomitingii ondansetron tablets ondansetron odt ondansetron injection are not indicated for the treatment of children 3 years of age or youngeriii ondansetron tablets ondansetron odt ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postradiotherapy induced nausea and vomiting andiv ondansetron tablets ondansetron odt ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomitingin the geriatric 65 years of age patient populationi efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of postchemotherapy and radiotherapyinduced nausea and vomiting andii clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population ')|
|('DB08865', 'MONDO:0004992', ['cancer'], 'crizotinib is used for the treatment of locally advanced or metastatic nonsmall cell lung cancer nsclc that is anaplasticlymphoma kinase alkpositive as detected by a fdaapproved test ')|
|('DB04948', 'MONDO:0004992', ['cancer'], 'lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment it is the first nonopioid medication for the symptomatic management of opioid discontinuationl2801opioid withdrawal syndrome is a debilitating manifestation of opioid dependencea33085 this condition is extremely unpleasant lasting several days with some of the main features being abdominal pain nausea diarrhea mydriasis lacrimation and piloerection these symptoms are often observed after abrupt reductions in the opioid dose and can be resolved by readministration of the opioida33088')|
|('DB04948', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment it is the first nonopioid medication for the symptomatic management of opioid discontinuationl2801opioid withdrawal syndrome is a debilitating manifestation of opioid dependencea33085 this condition is extremely unpleasant lasting several days with some of the main features being abdominal pain nausea diarrhea mydriasis lacrimation and piloerection these symptoms are often observed after abrupt reductions in the opioid dose and can be resolved by readministration of the opioida33088')|
|('DB06813', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'treatment of relapsed or refractory peripheral tcell lymphoma ')|
|('DB06813', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'treatment of relapsed or refractory peripheral tcell lymphoma ')|
|('DB04835', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for treatmentexperienced adult patients infected with only ccr5tropic hiv1 detectable who have evidence of viral replication and hiv1 strains resistant to multiple antiretroviral agents')|
|('DB01189', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use as an inhalation agent for induction andor maintenance of anesthesia for inpatient and outpatient surgery in adults')|
|('DB00843', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'donepezil is indicated for the management of mild to moderate alzheimer’s disease at doses of 5 mg or 10 mgl7916 it is also indicated for the management of moderate to severe alzheimer’s disease in a higher dose of 10 mg or 23 mg administered once dailyl7916 offlabel uses include the management of vascular dementia parkinsons diseaseassociated dementia and lewy body dementia among othersa182333t668 when combined with memantine the extendedrelease form of donepezil is indicated to treat the symptoms of moderate to severe demential7937')|
|('DB00843', 'MONDO:0004648', ['Multi Infarct Dementia', 'multifocal dementia', 'vascular dementia'], 'donepezil is indicated for the management of mild to moderate alzheimer’s disease at doses of 5 mg or 10 mgl7916 it is also indicated for the management of moderate to severe alzheimer’s disease in a higher dose of 10 mg or 23 mg administered once dailyl7916 offlabel uses include the management of vascular dementia parkinsons diseaseassociated dementia and lewy body dementia among othersa182333t668 when combined with memantine the extendedrelease form of donepezil is indicated to treat the symptoms of moderate to severe demential7937')|
|('DB00843', 'MONDO:0001627', ['dementia'], 'donepezil is indicated for the management of mild to moderate alzheimer’s disease at doses of 5 mg or 10 mgl7916 it is also indicated for the management of moderate to severe alzheimer’s disease in a higher dose of 10 mg or 23 mg administered once dailyl7916 offlabel uses include the management of vascular dementia parkinsons diseaseassociated dementia and lewy body dementia among othersa182333t668 when combined with memantine the extendedrelease form of donepezil is indicated to treat the symptoms of moderate to severe demential7937')|
|('DB00843', 'MONDO:0007488', ['Dementia with Lewy bodies', 'Diffuse Lewy body disease', 'Lewy body disease', 'Senile dementia of the Lewy body type', 'lewy body dementia'], 'donepezil is indicated for the management of mild to moderate alzheimer’s disease at doses of 5 mg or 10 mgl7916 it is also indicated for the management of moderate to severe alzheimer’s disease in a higher dose of 10 mg or 23 mg administered once dailyl7916 offlabel uses include the management of vascular dementia parkinsons diseaseassociated dementia and lewy body dementia among othersa182333t668 when combined with memantine the extendedrelease form of donepezil is indicated to treat the symptoms of moderate to severe demential7937')|
|('DB08905', 'MONDO:0007488', ['Dementia with Lewy bodies', 'Diffuse Lewy body disease', 'Lewy body disease', 'Senile dementia of the Lewy body type', 'lewy body dementia'], 'for the treatment of estrogenreceptor positive breast cancer in postmenopausal women')|
|('DB08905', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for the treatment of estrogenreceptor positive breast cancer in postmenopausal women')|
|('DB00373', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], ' ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or openangle glaucoma the oral form of this drug is used to treat high blood pressurel6724l6727 in certain cases timolol is used in the prevention of migraine headachesa179530l6742 ')|
|('DB00373', 'MONDO:0006875', ['ocular hypertension'], ' ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or openangle glaucoma the oral form of this drug is used to treat high blood pressurel6724l6727 in certain cases timolol is used in the prevention of migraine headachesa179530l6742 ')|
|('DB00373', 'MONDO:0005041', ['glaucoma'], ' ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or openangle glaucoma the oral form of this drug is used to treat high blood pressurel6724l6727 in certain cases timolol is used in the prevention of migraine headachesa179530l6742 ')|
|('DB00450', 'MONDO:0005041', ['glaucoma'], 'droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures')|
|('DB00770', 'MONDO:0005041', ['glaucoma'], 'for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival also for the treatment of erectile dysfunction due to neurogenic vasculogenic psychogenic or mixed etiology')|
|('DB00770', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival also for the treatment of erectile dysfunction due to neurogenic vasculogenic psychogenic or mixed etiology')|
|('DB00770', 'MONDO:0021140', ['inborn []', 'congenital'], 'for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival also for the treatment of erectile dysfunction due to neurogenic vasculogenic psychogenic or mixed etiology')|
|('DB00770', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival also for the treatment of erectile dysfunction due to neurogenic vasculogenic psychogenic or mixed etiology')|
|('DB01224', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'quetiapine is used in the symptomatic treatment of schizophrenia  in addition it may be used for the management of acute manic or mixed episodes in patients with bipolar i disorder as a monotherapy or combined with other drugs it may be used to manage depressive episodes in bipolar disorder in addition to the above indications quetiapine is used in combination with antidepressant drugs for the treatment of major depressionl8546some offlabel uses for this drug include the management of posttraumatic stress disorder ptsd generalized anxiety disorder and psychosis associated with parkinsons diseasea185438a185447t685')|
|('DB01224', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'quetiapine is used in the symptomatic treatment of schizophrenia  in addition it may be used for the management of acute manic or mixed episodes in patients with bipolar i disorder as a monotherapy or combined with other drugs it may be used to manage depressive episodes in bipolar disorder in addition to the above indications quetiapine is used in combination with antidepressant drugs for the treatment of major depressionl8546some offlabel uses for this drug include the management of posttraumatic stress disorder ptsd generalized anxiety disorder and psychosis associated with parkinsons diseasea185438a185447t685')|
|('DB01224', 'MONDO:0001866', ['bipolar I disorder'], 'quetiapine is used in the symptomatic treatment of schizophrenia  in addition it may be used for the management of acute manic or mixed episodes in patients with bipolar i disorder as a monotherapy or combined with other drugs it may be used to manage depressive episodes in bipolar disorder in addition to the above indications quetiapine is used in combination with antidepressant drugs for the treatment of major depressionl8546some offlabel uses for this drug include the management of posttraumatic stress disorder ptsd generalized anxiety disorder and psychosis associated with parkinsons diseasea185438a185447t685')|
|('DB01224', 'MONDO:0001942', ['generalized anxiety disorder'], 'quetiapine is used in the symptomatic treatment of schizophrenia  in addition it may be used for the management of acute manic or mixed episodes in patients with bipolar i disorder as a monotherapy or combined with other drugs it may be used to manage depressive episodes in bipolar disorder in addition to the above indications quetiapine is used in combination with antidepressant drugs for the treatment of major depressionl8546some offlabel uses for this drug include the management of posttraumatic stress disorder ptsd generalized anxiety disorder and psychosis associated with parkinsons diseasea185438a185447t685')|
|('DB01240', 'MONDO:0001942', ['generalized anxiety disorder'], 'for the longterm intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond adequately to conventional therapy')|
|('DB01240', 'MONDO:0001999', ['primary pulmonary hypertension'], 'for the longterm intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond adequately to conventional therapy')|
|('DB01240', 'MONDO:0005149', ['pulmonary hypertension'], 'for the longterm intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond adequately to conventional therapy')|
|('DB01240', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the longterm intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond adequately to conventional therapy')|
|('DB06715', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'potassium iodide is oral antithyroid agent used in the prevention of radioactive iodine uptake into the thyroid gland during a nuclear radiation emergency potassium iodide may be used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution')|
|('DB06715', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'potassium iodide is oral antithyroid agent used in the prevention of radioactive iodine uptake into the thyroid gland during a nuclear radiation emergency potassium iodide may be used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution')|
|('DB06715', 'MONDO:0010138', ['thyrotoxicosis'], 'potassium iodide is oral antithyroid agent used in the prevention of radioactive iodine uptake into the thyroid gland during a nuclear radiation emergency potassium iodide may be used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution')|
|('DB00560', 'MONDO:0010138', ['thyrotoxicosis'], 'for the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions complicated skin and skin structure infections caused by iescherichia colii ienterococcus faecalisi vancomycinsusceptible isolates only istaphylococcus aureusi methicillinsusceptible and resistant isolates istreptococcus agalactiaei istreptococcus anginosusi grp includes is anginosusi is intermediusi and is constellatusi istreptococcus pyogenesi and ibacteroides fragilisi complicated intraabdominal infections caused by icitrobacter freundiii ienterobacter cloacaei iescherichia colii iklebsiella oxytocai iklebsiella pneumoniaei ienterococcus faecalisi vancomycinsusceptible isolates only istaphylococcus aureusi methicillinsusceptible isolates only istreptococcus anginosusi grp includes is anginosusi is intermediusi and is constellatusi ibacteroides fragilisi ibacteroides thetaiotaomicroni ibacteroides uniformisi ibacteroides vulgatusi iclostridium perfringensi and ipeptostreptococcus microsi')|
|('DB00123', 'MONDO:0010138', ['thyrotoxicosis'], 'supplemental llysine has putative antiherpes simplex virus activity there is preliminary research suggesting that it may have some antiosteoporotic activity')|
|('DB00123', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'supplemental llysine has putative antiherpes simplex virus activity there is preliminary research suggesting that it may have some antiosteoporotic activity')|
|('DB01127', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for topical application in the treatment of tinea pedis tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi imicrosporum canisi imicrosporum audouinii imicrosporum gypseumi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis and in the treatment of tinea versicolor')|
|('DB01127', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for topical application in the treatment of tinea pedis tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi imicrosporum canisi imicrosporum audouinii imicrosporum gypseumi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis and in the treatment of tinea versicolor')|
|('DB01127', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for topical application in the treatment of tinea pedis tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi imicrosporum canisi imicrosporum audouinii imicrosporum gypseumi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis and in the treatment of tinea versicolor')|
|('DB01127', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'for topical application in the treatment of tinea pedis tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi imicrosporum canisi imicrosporum audouinii imicrosporum gypseumi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis and in the treatment of tinea versicolor')|
|('DB01127', 'MONDO:0000879', ['cutaneous candidiasis'], 'for topical application in the treatment of tinea pedis tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi imicrosporum canisi imicrosporum audouinii imicrosporum gypseumi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis and in the treatment of tinea versicolor')|
|('DB01261', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'sitagliptin is indicated for the management of glycemic control in type 2 diabetes mellitus along with diet and exerciselabel')|
|('DB01261', 'MONDO:0005015', ['diabetes mellitus'], 'sitagliptin is indicated for the management of glycemic control in type 2 diabetes mellitus along with diet and exerciselabel')|
|('DB00445', 'MONDO:0005015', ['diabetes mellitus'], 'for use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer')|
|('DB00445', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer')|
|('DB01182', 'MONDO:0005015', ['diabetes mellitus'], 'used to prolong the time to recurrence of paroxysmal atrial fibrillationflutter paf associated with disabling symptoms in patients without structural heart disease also used for the treatment of lifethreatening documented ventricular arrhythmias such as sustained ventricular tachycardia')|
|('DB01182', 'MONDO:0018608', ['Pure idiopatic dysautonomia [Orphanet:441]', 'Bradbury Eggleston syndrome [GARD:0010428]', 'PAF [Orphanet:441]', 'Bradbury-Eggleston syndrome [Orphanet:441]', 'Pure dysautonomia [Orphanet:441]', 'idiopathic orthostatic hypotension [Orphanet:441]', 'pure autonomic failure'], 'used to prolong the time to recurrence of paroxysmal atrial fibrillationflutter paf associated with disabling symptoms in patients without structural heart disease also used for the treatment of lifethreatening documented ventricular arrhythmias such as sustained ventricular tachycardia')|
|('DB01182', 'MONDO:0005477', ['ventricular tachycardia'], 'used to prolong the time to recurrence of paroxysmal atrial fibrillationflutter paf associated with disabling symptoms in patients without structural heart disease also used for the treatment of lifethreatening documented ventricular arrhythmias such as sustained ventricular tachycardia')|
|('DB00368', 'MONDO:0018608', ['Pure idiopatic dysautonomia [Orphanet:441]', 'Bradbury Eggleston syndrome [GARD:0010428]', 'PAF [Orphanet:441]', 'Bradbury-Eggleston syndrome [Orphanet:441]', 'Pure dysautonomia [Orphanet:441]', 'idiopathic orthostatic hypotension [Orphanet:441]', 'pure autonomic failure'], 'mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine also used as a vasopressor medication for patients with critical hypotension')|
|('DB00368', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine also used as a vasopressor medication for patients with critical hypotension')|
|('DB00458', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0005452', ['hyperorexia nervosa', 'bulimia nervosa'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0003763', ['traumatic stress disorder', 'acute stress disorder'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00458', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older fda label may also be used offlabel to manage panic disorders with or without agoraphobia as a second line agent for adhd in children and adolescents to manage bulimia nervosa for shortterm management of acute depressive episodes in bipolar disorder and schizophrenia for the treatment of acute stress disorder and posttraumatic stress disorder and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy l1349l1348a31900l1351l1352l1353a31904 ')|
|('DB00632', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'for the topical treatment of recurrent oralfacial herpes simplex episodes cold sores or fever blisters')|
|('DB00632', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the topical treatment of recurrent oralfacial herpes simplex episodes cold sores or fever blisters')|
|('DB00936', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'key additive in many skincare products for the treatment of acne psoriasis callouses corns keratosis pilaris and warts')|
|('DB00936', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'key additive in many skincare products for the treatment of acne psoriasis callouses corns keratosis pilaris and warts')|
|('DB00936', 'MONDO:0021036', ['KP [NCIT:C124070]', 'keratosis pilaris'], 'key additive in many skincare products for the treatment of acne psoriasis callouses corns keratosis pilaris and warts')|
|('DB00326', 'MONDO:0021036', ['KP [NCIT:C124070]', 'keratosis pilaris'], 'for treatment of mild hypocalcemia due to neonatal tetany tetany due to parathyroid deficiency or vitamin d deficiency and alkalosis as prophylaxis of hypocalcemia during exchange transfusions in the treatment of intestinal malabsorption and to replenish electrolytes')|
|('DB01392', 'MONDO:0021036', ['KP [NCIT:C124070]', 'keratosis pilaris'], 'indicated as a sympatholytic and mydriatic impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins')|
|('DB01392', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated as a sympatholytic and mydriatic impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins')|
|('DB00155', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00567', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'cephalexin is indicated for the treatment of certain infections caused by susceptible bacterialabell6550l6553 these infections include respiratory tract infections otitis media skin and skin structure infections bone infections and genitourinary tract infectionslabell6550l6553')|
|('DB00567', 'MONDO:0005441', ['otitis media'], 'cephalexin is indicated for the treatment of certain infections caused by susceptible bacterialabell6550l6553 these infections include respiratory tract infections otitis media skin and skin structure infections bone infections and genitourinary tract infectionslabell6550l6553')|
|('DB00358', 'MONDO:0005441', ['otitis media'], 'for the treatment of mild to moderate acute malaria caused by mefloquineuinesusceptible strains of iplasmodium falciparumi both chloroquinesusceptible and resistant strains or by iplasmodium vivaxi also for the prophylaxis of iplasmodium falciparumi and iplasmodium vivaxi malaria infections including prophylaxis of chloroquineresistant strains of iplasmodium falciparumi')|
|('DB00358', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of mild to moderate acute malaria caused by mefloquineuinesusceptible strains of iplasmodium falciparumi both chloroquinesusceptible and resistant strains or by iplasmodium vivaxi also for the prophylaxis of iplasmodium falciparumi and iplasmodium vivaxi malaria infections including prophylaxis of chloroquineresistant strains of iplasmodium falciparumi')|
|('DB08916', 'MONDO:0005136', ['induced malaria', 'malaria'], 'afatinib is a kinase inhibitor indicated as monotherapy l2937 for the firstline fda label treatment of a epidermal growth factor receptor egfr tki tyrosine kinase inhibitornaive adult patients with locally advanced or metastatic nonsmall cell lung cancer nsclc whose tumours have nonresistant egfr mutations as detected by an fdaapproved test fda label and b adult patients with locally advanced or metastatic nsclc of squamous histology progressing on or after platinumbased chemotherapy fda label l2937recently as of january 2018 the us fda approved a supplemental new drug application for boehringer ingelheims gilotrif afatinib for the first line treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have nonresistant epidermal growth factor receptor egfr mutations as detected by an fdaapproved test l2939 the new label includes data on three additional egfr mutations l861q g719x and s768i l2939')|
|('DB08916', 'MONDO:0004992', ['cancer'], 'afatinib is a kinase inhibitor indicated as monotherapy l2937 for the firstline fda label treatment of a epidermal growth factor receptor egfr tki tyrosine kinase inhibitornaive adult patients with locally advanced or metastatic nonsmall cell lung cancer nsclc whose tumours have nonresistant egfr mutations as detected by an fdaapproved test fda label and b adult patients with locally advanced or metastatic nsclc of squamous histology progressing on or after platinumbased chemotherapy fda label l2937recently as of january 2018 the us fda approved a supplemental new drug application for boehringer ingelheims gilotrif afatinib for the first line treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have nonresistant epidermal growth factor receptor egfr mutations as detected by an fdaapproved test l2939 the new label includes data on three additional egfr mutations l861q g719x and s768i l2939')|
|('DB01198', 'MONDO:0004992', ['cancer'], 'for the shortterm treatment of insomnia')|
|('DB01198', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the shortterm treatment of insomnia')|
|('DB00684', 'MONDO:0004992', ['cancer'], 'for the treatment of pseudomonas aeruginosa lung infections also being investigated for use in the treatment of sinus infections')|
|('DB00509', 'MONDO:0004992', ['cancer'], 'used to lower high cholesterol levels in the blood')|
|('DB01223', 'MONDO:0004992', ['cancer'], 'for the treatment of bronchospasm due to asthma emphysema and chronic bronchitis')|
|('DB01223', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the treatment of bronchospasm due to asthma emphysema and chronic bronchitis')|
|('DB01223', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of bronchospasm due to asthma emphysema and chronic bronchitis')|
|('DB01223', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of bronchospasm due to asthma emphysema and chronic bronchitis')|
|('DB13179', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of bacterial infection')|
|('DB08604', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'triclosan is used in a variety of common household products including soaps mouthwashes dish detergents toothpastes deodorants and hand sanitizers  it is also used in health care settings in surgical scrubs and personnel hand washes')|
|('DB08604', 'MONDO:0021137', ['common []', 'not rare'], 'triclosan is used in a variety of common household products including soaps mouthwashes dish detergents toothpastes deodorants and hand sanitizers  it is also used in health care settings in surgical scrubs and personnel hand washes')|
|('DB08604', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'triclosan is used in a variety of common household products including soaps mouthwashes dish detergents toothpastes deodorants and hand sanitizers  it is also used in health care settings in surgical scrubs and personnel hand washes')|
|('DB00407', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'for prevention of deep vein thrombosis which may result in pulmonary embolism following knee surgery')|
|('DB00551', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'used in addition to antibiotics or medical procedures to treat chronic ureasplitting urinary infections')|
|('DB08807', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'for the management of hypertension edema ventricular tachycardias and atrial fibrillation')|
|('DB08807', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the management of hypertension edema ventricular tachycardias and atrial fibrillation')|
|('DB00538', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'gadoversetamide is an mri contrast agent used for mri diagnostic procedures to provide increased enhancement and visualization of lesions of the brain spine and liver including tumors')|
|('DB01093', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'for the symptomatic relief of patients with interstitial cystitis')|
|('DB01093', 'MONDO:0018301', ['interstitial cystitis'], 'for the symptomatic relief of patients with interstitial cystitis')|
|('DB00680', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'used to treat irregular heartbeats arrhythmias and maintain a normal heart rate')|
|('DB00768', 'MONDO:0007127', ['Ankylosing vertebral hyperostosis', 'DISH', 'Disseminated idiopathic skeletal hyperostosis', 'diffuse idiopathic skeletal hyperostosis'], 'olopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solutionl6781in nasal spray olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and olderl6784')|
|('DB00768', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'olopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solutionl6781in nasal spray olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and olderl6784')|
|('DB01268', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate')|
|('DB01268', 'MONDO:0011719', ['GANT', 'gastrointestinal stromal tumour', 'GIST', 'Stromal tumor of gastrointestinal tract', 'Stromal tumour of gastrointestinal tract', 'gastrointestinal stromal tumor'], 'for the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate')|
|('DB00782', 'MONDO:0011719', ['GANT', 'gastrointestinal stromal tumour', 'GIST', 'Stromal tumor of gastrointestinal tract', 'Stromal tumour of gastrointestinal tract', 'gastrointestinal stromal tumor'], 'for the treatment of enuresis it has also been used for hyperhidrosis and cramps or spasms of the stomach intestines or bladder')|
|('DB00782', 'MONDO:0024290', ['enuresis [NCIT:C34588]', 'enuresis'], 'for the treatment of enuresis it has also been used for hyperhidrosis and cramps or spasms of the stomach intestines or bladder')|
|('DB00782', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of enuresis it has also been used for hyperhidrosis and cramps or spasms of the stomach intestines or bladder')|
|('DB09020', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], ' indicated for cleansing of the colon as a preparation for colonoscopy in adults ')|
|('DB01274', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'a bronchodilator used for the long term symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema ')|
|('DB01274', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'a bronchodilator used for the long term symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema ')|
|('DB01274', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'a bronchodilator used for the long term symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema ')|
|('DB00882', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'used mainly in female infertility due to anovulation eg due to polycystic ovary syndrome to induce ovulation ')|
|('DB00882', 'MONDO:0008487', ['Multicystic ovaries', 'PCOS', 'Polycystic Ovarian disease', 'Polycystic ovaries', 'polycystic ovary', 'Polycystic ovary syndrome', 'Stein-Leventhal synd.', 'Stein-Leventhal syndrome', 'polycystic ovary syndrome'], 'used mainly in female infertility due to anovulation eg due to polycystic ovary syndrome to induce ovulation ')|
|('DB00191', 'MONDO:0008487', ['Multicystic ovaries', 'PCOS', 'Polycystic Ovarian disease', 'Polycystic ovaries', 'polycystic ovary', 'Polycystic ovary syndrome', 'Stein-Leventhal synd.', 'Stein-Leventhal syndrome', 'polycystic ovary syndrome'], 'phentermine is indicated alone or in combination with topiramate as a shortterm adjunct not pass a few weeks in a regimen of weight reduction based on exercise behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index bmi greater than 30 kgm2 or greater than 27 kgm2 in presence of other risk factors such as controller hypertension diabetes or hyperlipidemiafda labelexogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants this condition commonly causes an increase in fat storage it is an epidemic condition in the united states where over twothirds of adults are overweight or obese and one in three americans is obese in the world the incidence of obesity has nearly doubleda174391')|
|('DB01393', 'MONDO:0008487', ['Multicystic ovaries', 'PCOS', 'Polycystic Ovarian disease', 'Polycystic ovaries', 'polycystic ovary', 'Polycystic ovary syndrome', 'Stein-Leventhal synd.', 'Stein-Leventhal syndrome', 'polycystic ovary syndrome'], 'for the treatment of primary hyperlipidaemia types iia iib iii iv and v fredrickson classification corresponding to groups i ii and iii of the european atherosclerosis society guidelines  when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response also for the treatment of secondary hyperlipidaemias eg severe hypertriglyceridemias when sufficient improvement does not occur after correction of the underlying disorder eg diabetes mellitus')|
|('DB01393', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of primary hyperlipidaemia types iia iib iii iv and v fredrickson classification corresponding to groups i ii and iii of the european atherosclerosis society guidelines  when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response also for the treatment of secondary hyperlipidaemias eg severe hypertriglyceridemias when sufficient improvement does not occur after correction of the underlying disorder eg diabetes mellitus')|
|('DB01032', 'MONDO:0008487', ['Multicystic ovaries', 'PCOS', 'Polycystic Ovarian disease', 'Polycystic ovaries', 'polycystic ovary', 'Polycystic ovary syndrome', 'Stein-Leventhal synd.', 'Stein-Leventhal syndrome', 'polycystic ovary syndrome'], 'for the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics ')|
|('DB01032', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics ')|
|('DB01032', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics ')|
|('DB00949', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia andor liver failure is deemed acceptable in light of the benefits conferred by its use')|
|('DB00949', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia andor liver failure is deemed acceptable in light of the benefits conferred by its use')|
|('DB00949', 'MONDO:0015909', ['aplastic anemia'], 'for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia andor liver failure is deemed acceptable in light of the benefits conferred by its use')|
|('DB08808', 'MONDO:0015909', ['aplastic anemia'], 'used to manage hypertension and tachycardia also used to treat glaucoma')|
|('DB08808', 'MONDO:0005041', ['glaucoma'], 'used to manage hypertension and tachycardia also used to treat glaucoma')|
|('DB00795', 'MONDO:0015909', ['aplastic anemia'], 'for the treatment of crohns disease and rheumatoid arthritis as a secondline agent')|
|('DB00795', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of crohns disease and rheumatoid arthritis as a secondline agent')|
|('DB01068', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB01068', 'MONDO:0005384', ['localisation-related epilepsy', 'partial epilepsy', 'partial epilepsy'], 'clonazepam is indicated as monotherapy or as an adjunct in the treatment of lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures fda label f3787 furthermore clonazepam may also be of some value in patients with absence spells petit mal who have failed to respond to succinimides fda label f3787 additionally clonazepam is also indicated for the treatment of panic disorder with or without agoraphobia as defined in the dsmv fda labelalternatively some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults especially absence seizures petit mal including atypical absence primary or secondarily generalised tonicclonic grand mal tonic or clonic seizures partial focal seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus and associated abnormal movements l5572 f3796 such regional label data also has clonazepam indicated for most types of epilepsy in infants and children especially absences petit mal myoclonic seizures and tonicclonic fits whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy f3796                                                                                                                                                                     ')|
|('DB00240', 'MONDO:0005384', ['localisation-related epilepsy', 'partial epilepsy', 'partial epilepsy'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB01251', 'MONDO:0005384', ['localisation-related epilepsy', 'partial epilepsy', 'partial epilepsy'], 'used in the treatment of diabetes mellitus type 2')|
|('DB01251', 'MONDO:0005015', ['diabetes mellitus'], 'used in the treatment of diabetes mellitus type 2')|
|('DB00226', 'MONDO:0005015', ['diabetes mellitus'], 'used to treat and control hypertension')|
|('DB01051', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of infections due to staphylococci and other susceptible organisms')|
|('DB01175', 'MONDO:0005015', ['diabetes mellitus'], 'escitalopram is indicated for both acute and maintenance treatment of major depressive disorder mdd and for the acute treatment of generalized anxiety disorder gadl8513 it is additionally indicated for symptomatic relief of obsessivecompulsive disorder ocd in canadal8516')|
|('DB01175', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'escitalopram is indicated for both acute and maintenance treatment of major depressive disorder mdd and for the acute treatment of generalized anxiety disorder gadl8513 it is additionally indicated for symptomatic relief of obsessivecompulsive disorder ocd in canadal8516')|
|('DB01175', 'MONDO:0001942', ['generalized anxiety disorder'], 'escitalopram is indicated for both acute and maintenance treatment of major depressive disorder mdd and for the acute treatment of generalized anxiety disorder gadl8513 it is additionally indicated for symptomatic relief of obsessivecompulsive disorder ocd in canadal8516')|
|('DB01013', 'MONDO:0001942', ['generalized anxiety disorder'], 'for shortterm topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroidresponsive dermatoses of the scalp')|
|('DB01048', 'MONDO:0001942', ['generalized anxiety disorder'], 'for the treatment of hiv1 infection in combination with other antiretroviral agents')|
|('DB00328', 'MONDO:0001942', ['generalized anxiety disorder'], 'oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease moderate to severe ankylosing spondylitis moderate to severe osteoarthritis acute painful shoulder bursitis andor tendinitis and acute gouty arthritisa177871l6778 intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management eg fluid restriction diuretics digitalis respiratory support etc is ineffectivel10553')|
|('DB00328', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease moderate to severe ankylosing spondylitis moderate to severe osteoarthritis acute painful shoulder bursitis andor tendinitis and acute gouty arthritisa177871l6778 intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management eg fluid restriction diuretics digitalis respiratory support etc is ineffectivel10553')|
|('DB00328', 'MONDO:0003937', ['spondylitis'], 'oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease moderate to severe ankylosing spondylitis moderate to severe osteoarthritis acute painful shoulder bursitis andor tendinitis and acute gouty arthritisa177871l6778 intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management eg fluid restriction diuretics digitalis respiratory support etc is ineffectivel10553')|
|('DB00328', 'MONDO:0004857', ['tendinitis'], 'oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease moderate to severe ankylosing spondylitis moderate to severe osteoarthritis acute painful shoulder bursitis andor tendinitis and acute gouty arthritisa177871l6778 intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management eg fluid restriction diuretics digitalis respiratory support etc is ineffectivel10553')|
|('DB00328', 'MONDO:0011827', ['Patent ductus Botalli', 'patent ductus arteriosus'], 'oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease moderate to severe ankylosing spondylitis moderate to severe osteoarthritis acute painful shoulder bursitis andor tendinitis and acute gouty arthritisa177871l6778 intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management eg fluid restriction diuretics digitalis respiratory support etc is ineffectivel10553')|
|('DB00922', 'MONDO:0011827', ['Patent ductus Botalli', 'patent ductus arteriosus'], 'for short term treatment of acutely decompensated severe chronic heart failure chf also being investigated for usetreatment in heart disease')|
|('DB00922', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for short term treatment of acutely decompensated severe chronic heart failure chf also being investigated for usetreatment in heart disease')|
|('DB00471', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'montelukast is indicated fora the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 and also include indications for preventing day and nighttime symptoms and the treatment of acetylsalicylic acidsensitive asthmal6304b the prevention of exerciseinduced bronchoconstriction eib in patients who are 6 years of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 andc the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and olderl6301 although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and olderl6304l6307furthermore some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma including the prevention of day and nighttime symptoms the treatment of acetylsalicylic acid based asthma and the prevention of exerciseinduced bronchoconstriction in adult and pediatric patients aged 2 and olderl6328 between the ages 2 and 5l6325 or between the ages of 6 and 14 yearsl6331moreover when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthmal6304l6328 for instance montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stabilityl6304l6328additionally in patients who continue to experience asthma symptoms montelukast can also be combined with an as required shortacting betaagonist an inhaled corticosteroid or inhaled corticosteroid paired with a longacting betaagonistl6304l6328')|
|('DB00471', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'montelukast is indicated fora the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 and also include indications for preventing day and nighttime symptoms and the treatment of acetylsalicylic acidsensitive asthmal6304b the prevention of exerciseinduced bronchoconstriction eib in patients who are 6 years of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 andc the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and olderl6301 although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and olderl6304l6307furthermore some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma including the prevention of day and nighttime symptoms the treatment of acetylsalicylic acid based asthma and the prevention of exerciseinduced bronchoconstriction in adult and pediatric patients aged 2 and olderl6328 between the ages 2 and 5l6325 or between the ages of 6 and 14 yearsl6331moreover when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthmal6304l6328 for instance montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stabilityl6304l6328additionally in patients who continue to experience asthma symptoms montelukast can also be combined with an as required shortacting betaagonist an inhaled corticosteroid or inhaled corticosteroid paired with a longacting betaagonistl6304l6328')|
|('DB00471', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'montelukast is indicated fora the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 and also include indications for preventing day and nighttime symptoms and the treatment of acetylsalicylic acidsensitive asthmal6304b the prevention of exerciseinduced bronchoconstriction eib in patients who are 6 years of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 andc the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and olderl6301 although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and olderl6304l6307furthermore some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma including the prevention of day and nighttime symptoms the treatment of acetylsalicylic acid based asthma and the prevention of exerciseinduced bronchoconstriction in adult and pediatric patients aged 2 and olderl6328 between the ages 2 and 5l6325 or between the ages of 6 and 14 yearsl6331moreover when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthmal6304l6328 for instance montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stabilityl6304l6328additionally in patients who continue to experience asthma symptoms montelukast can also be combined with an as required shortacting betaagonist an inhaled corticosteroid or inhaled corticosteroid paired with a longacting betaagonistl6304l6328')|
|('DB00471', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'montelukast is indicated fora the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 and also include indications for preventing day and nighttime symptoms and the treatment of acetylsalicylic acidsensitive asthmal6304b the prevention of exerciseinduced bronchoconstriction eib in patients who are 6 years of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 andc the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and olderl6301 although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and olderl6304l6307furthermore some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma including the prevention of day and nighttime symptoms the treatment of acetylsalicylic acid based asthma and the prevention of exerciseinduced bronchoconstriction in adult and pediatric patients aged 2 and olderl6328 between the ages 2 and 5l6325 or between the ages of 6 and 14 yearsl6331moreover when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthmal6304l6328 for instance montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stabilityl6304l6328additionally in patients who continue to experience asthma symptoms montelukast can also be combined with an as required shortacting betaagonist an inhaled corticosteroid or inhaled corticosteroid paired with a longacting betaagonistl6304l6328')|
|('DB00471', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'montelukast is indicated fora the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 and also include indications for preventing day and nighttime symptoms and the treatment of acetylsalicylic acidsensitive asthmal6304b the prevention of exerciseinduced bronchoconstriction eib in patients who are 6 years of age and olderl6301 although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and olderl6304l6307 andc the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and olderl6301 although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and olderl6304l6307furthermore some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma including the prevention of day and nighttime symptoms the treatment of acetylsalicylic acid based asthma and the prevention of exerciseinduced bronchoconstriction in adult and pediatric patients aged 2 and olderl6328 between the ages 2 and 5l6325 or between the ages of 6 and 14 yearsl6331moreover when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthmal6304l6328 for instance montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stabilityl6304l6328additionally in patients who continue to experience asthma symptoms montelukast can also be combined with an as required shortacting betaagonist an inhaled corticosteroid or inhaled corticosteroid paired with a longacting betaagonistl6304l6328')|
|('DB00783', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0002146', ['hypogonadism'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00783', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'estradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the prevention of postmenopausal osteoarthritis it is also used for the treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB01143', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for reduction in the cumulative renal toxicity in patients with ovarian cancer using cisplatin and moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer')|
|('DB01143', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'for reduction in the cumulative renal toxicity in patients with ovarian cancer using cisplatin and moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer')|
|('DB01143', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'for reduction in the cumulative renal toxicity in patients with ovarian cancer using cisplatin and moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer')|
|('DB01196', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'for the palliative treatment of patients with metastatic andor progressive carcinoma of the prostate')|
|('DB01199', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'used as a diagnosis agent for myasthenia gravis and also to facilitate the intubation after induction of anesthesia in surgical procedure')|
|('DB01199', 'MONDO:0009688', ['myasthenia gravis'], 'used as a diagnosis agent for myasthenia gravis and also to facilitate the intubation after induction of anesthesia in surgical procedure')|
|('DB01017', 'MONDO:0009688', ['myasthenia gravis'], 'for the treatment of infections caused by susceptible strains of microorganisms such as rocky mountain spotted fever typhus fever and the typhus group q fever rickettsial pox and tick fevers caused by rickettsiae upper respiratory tract infections caused by istreptococcus pneumoniaei and for the treatment of asymptomatic carriers of ineisseria meningitidisi')|
|('DB01017', 'MONDO:0001195', ['Spotted fever group rickettsial disease', 'spotted fever'], 'for the treatment of infections caused by susceptible strains of microorganisms such as rocky mountain spotted fever typhus fever and the typhus group q fever rickettsial pox and tick fevers caused by rickettsiae upper respiratory tract infections caused by istreptococcus pneumoniaei and for the treatment of asymptomatic carriers of ineisseria meningitidisi')|
|('DB01017', 'MONDO:0001246', ['endemic flea-borne typhus', 'Endemic Typhus fever', 'epidemic louse-borne typhus', 'Exanthematic Typhus fever', 'Flea typhus', 'Louse-borne [epidemic] typhus', 'Moscow typhus', 'Murine [endemic] typhus', 'Typhus fever', 'typhus'], 'for the treatment of infections caused by susceptible strains of microorganisms such as rocky mountain spotted fever typhus fever and the typhus group q fever rickettsial pox and tick fevers caused by rickettsiae upper respiratory tract infections caused by istreptococcus pneumoniaei and for the treatment of asymptomatic carriers of ineisseria meningitidisi')|
|('DB01017', 'MONDO:0019186', ['Infection due to Coxiella burnetii', 'q fever'], 'for the treatment of infections caused by susceptible strains of microorganisms such as rocky mountain spotted fever typhus fever and the typhus group q fever rickettsial pox and tick fevers caused by rickettsiae upper respiratory tract infections caused by istreptococcus pneumoniaei and for the treatment of asymptomatic carriers of ineisseria meningitidisi')|
|('DB01614', 'MONDO:0019186', ['Infection due to Coxiella burnetii', 'q fever'], 'acepromazine was first used in humans in the 1950s as an antipsychotic agent it is now rarely used in humans acepromazine is frequently used in animals as a sedative and antiemetic its principal value is in quietening and calming anxious animals')|
|('DB00390', 'MONDO:0019186', ['Infection due to Coxiella burnetii', 'q fever'], 'digoxin is indicated in the following conditions 1 for the treatment of mild to moderate heart failure in adult patientsl6775 2 to increase myocardial contraction in children diagnosed with heart failurel6775 3 to maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillationl6775in adults with heart failure when it is clinically possible digoxin should be administered in conjunction with a diuretic and an angiotensinconverting enzyme ace inhibitor for optimum effectsl6775')|
|('DB00390', 'MONDO:0005256', ['moderate heart failure'], 'digoxin is indicated in the following conditions 1 for the treatment of mild to moderate heart failure in adult patientsl6775 2 to increase myocardial contraction in children diagnosed with heart failurel6775 3 to maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillationl6775in adults with heart failure when it is clinically possible digoxin should be administered in conjunction with a diuretic and an angiotensinconverting enzyme ace inhibitor for optimum effectsl6775')|
|('DB00390', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'digoxin is indicated in the following conditions 1 for the treatment of mild to moderate heart failure in adult patientsl6775 2 to increase myocardial contraction in children diagnosed with heart failurel6775 3 to maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillationl6775in adults with heart failure when it is clinically possible digoxin should be administered in conjunction with a diuretic and an angiotensinconverting enzyme ace inhibitor for optimum effectsl6775')|
|('DB06287', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of renal cell carcinoma rcc also investigated for usetreatment in breast cancer lymphoma unspecified rheumatoid arthritis and multiple myeloma')|
|('DB06287', 'MONDO:0005549', ['adenocarcinoma of kidney [NCIT:C9385]', 'kidney adenocarcinoma [NCIT:C9385]', 'renal cell carcinoma [NCIT:C9385]', 'RCC [NCIT:C9385]', 'adenocarcinoma of the kidney [NCIT:C9385]', 'carcinoma, renal cell, malignant [NCIT:C9385]', 'renal cell carcinoma, stage unspecified [NCIT:C9385]', 'renal cell adenocarcinoma [NCIT:C9385]', 'renal cell cancer [NCIT:C9385]', 'renal cell adenocarcinoma'], 'for the treatment of renal cell carcinoma rcc also investigated for usetreatment in breast cancer lymphoma unspecified rheumatoid arthritis and multiple myeloma')|
|('DB06287', 'MONDO:0004992', ['cancer'], 'for the treatment of renal cell carcinoma rcc also investigated for usetreatment in breast cancer lymphoma unspecified rheumatoid arthritis and multiple myeloma')|
|('DB06287', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of renal cell carcinoma rcc also investigated for usetreatment in breast cancer lymphoma unspecified rheumatoid arthritis and multiple myeloma')|
|('DB00756', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for use as a surgical scrub and a bacteriostatic skin cleanser it may also be used to control an outbreak of grampositive infection where other infection control procedures have been unsuccessful')|
|('DB00467', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of adults ge18 years of age with the following infections caused by susceptible strains of the designated microorganisms 1 uncomplicated urethral or cervical gonorrhea due to ineisseria gonorrhoeaei 2 uncomplicated urinary tract infections cystitis due to iescherichia colii istaphylococcus epidermidisi or istaphylococcus saprophyticusi and 3 complicated urinary tract infections due to iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ipseudomonas aeruginosai istaphylococcus epidermidisi or ienterobacter cloacaei')|
|('DB00467', 'MONDO:0006032', ['cystitis'], 'for the treatment of adults ge18 years of age with the following infections caused by susceptible strains of the designated microorganisms 1 uncomplicated urethral or cervical gonorrhea due to ineisseria gonorrhoeaei 2 uncomplicated urinary tract infections cystitis due to iescherichia colii istaphylococcus epidermidisi or istaphylococcus saprophyticusi and 3 complicated urinary tract infections due to iescherichia colii iklebsiella pneumoniaei iproteus mirabilisi ipseudomonas aeruginosai istaphylococcus epidermidisi or ienterobacter cloacaei')|
|('DB00903', 'MONDO:0006032', ['cystitis'], 'for the treatment of high blood pressure and edema caused by diseases like congestive heart failure liver failure and kidney failure')|
|('DB00903', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for the treatment of high blood pressure and edema caused by diseases like congestive heart failure liver failure and kidney failure')|
|('DB00903', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of high blood pressure and edema caused by diseases like congestive heart failure liver failure and kidney failure')|
|('DB00903', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'for the treatment of high blood pressure and edema caused by diseases like congestive heart failure liver failure and kidney failure')|
|('DB00771', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain diverticulitis and irritable bowel syndrome')|
|('DB00771', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain diverticulitis and irritable bowel syndrome')|
|('DB00771', 'MONDO:0004235', ['diverticulitis'], 'for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain diverticulitis and irritable bowel syndrome')|
|('DB00771', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain diverticulitis and irritable bowel syndrome')|
|('DB01178', 'MONDO:0004235', ['diverticulitis'], 'used in the management of anxiety and in the treatment of muscle spasm')|
|('DB01178', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in the management of anxiety and in the treatment of muscle spasm')|
|('DB00238', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for use in combination with other antiretroviral drugs in the ongoing treatment of hiv1 infection')|
|('DB00634', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of bacterial vaginitis keratitis acute conjunctivitis and blepharitis')|
|('DB00634', 'MONDO:0003085', ['keratitis'], 'for the treatment of bacterial vaginitis keratitis acute conjunctivitis and blepharitis')|
|('DB00634', 'MONDO:0003799', ['conjunctivitis'], 'for the treatment of bacterial vaginitis keratitis acute conjunctivitis and blepharitis')|
|('DB00634', 'MONDO:0004785', ['blepharitis'], 'for the treatment of bacterial vaginitis keratitis acute conjunctivitis and blepharitis')|
|('DB00927', 'MONDO:0003799', ['conjunctivitis'], 'for the treatment of peptic ulcer disease pud and gastroesophageal reflux disease gerd')|
|('DB00927', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of peptic ulcer disease pud and gastroesophageal reflux disease gerd')|
|('DB00927', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of peptic ulcer disease pud and gastroesophageal reflux disease gerd')|
|('DB00355', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of the following infections caused by susceptible gramnegative microorganisms urinary tract infections lower respiratory tract infections septicemia skin and skinstructure infections intraabdominal infections and gynecologic infections')|
|('DB01009', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for symptomatic treatment of acute and chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma sprains and strains postoperative including dental surgery or postpartum pain')|
|('DB01009', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for symptomatic treatment of acute and chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma sprains and strains postoperative including dental surgery or postpartum pain')|
|('DB01009', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'for symptomatic treatment of acute and chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma sprains and strains postoperative including dental surgery or postpartum pain')|
|('DB01009', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for symptomatic treatment of acute and chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma sprains and strains postoperative including dental surgery or postpartum pain')|
|('DB01222', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate crohn’s diseasel10601l10604 various inhaled budesonide products are indicated for prophylactic therapy in asthmal10607l10613l10619 and reducing exacerbations of copdl10619 a budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergiesl10616 extended release capsules are indicated to induce remission of mild to moderate ulcerative colitisl10622 and a rectal foam is used for mild to moderate distal ulcerative colitisl10625')|
|('DB01222', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate crohn’s diseasel10601l10604 various inhaled budesonide products are indicated for prophylactic therapy in asthmal10607l10613l10619 and reducing exacerbations of copdl10619 a budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergiesl10616 extended release capsules are indicated to induce remission of mild to moderate ulcerative colitisl10622 and a rectal foam is used for mild to moderate distal ulcerative colitisl10625')|
|('DB01222', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate crohn’s diseasel10601l10604 various inhaled budesonide products are indicated for prophylactic therapy in asthmal10607l10613l10619 and reducing exacerbations of copdl10619 a budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergiesl10616 extended release capsules are indicated to induce remission of mild to moderate ulcerative colitisl10622 and a rectal foam is used for mild to moderate distal ulcerative colitisl10625')|
|('DB01044', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of bronchitis sinusitis communityacquired pneumonia and skin infections abscesses wounds caused by s pneumoniae h influenzae s aureus m pneumoniae c pneumoniae l pneumophila s pyogenes')|
|('DB01044', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of bronchitis sinusitis communityacquired pneumonia and skin infections abscesses wounds caused by s pneumoniae h influenzae s aureus m pneumoniae c pneumoniae l pneumophila s pyogenes')|
|('DB01044', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of bronchitis sinusitis communityacquired pneumonia and skin infections abscesses wounds caused by s pneumoniae h influenzae s aureus m pneumoniae c pneumoniae l pneumophila s pyogenes')|
|('DB04920', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable')|
|('DB00369', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids')|
|('DB00369', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids')|
|('DB00369', 'MONDO:0017769', ['acquired immunodeficiency'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids')|
|('DB01262', 'MONDO:0017769', ['acquired immunodeficiency'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB01262', 'MONDO:0009532', ['MDS', 'Miller-Dieker syndrome', 'miller-dieker lissencephaly syndrome'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB01262', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB01262', 'MONDO:0005272', ['RA [NCIT:C2872]', 'aregenerative anemia [NCIT:C2872]', 'refractory anemia'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB01262', 'MONDO:0002280', ['anaemia', 'anemia'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB01262', 'MONDO:0020311', ['chronic myelomonocytic leukemia'], 'for treatment of patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups scores ≥05')|
|('DB00672', 'MONDO:0020311', ['chronic myelomonocytic leukemia'], 'for treatment of niddm in conjunction with diet and exercise ')|
|('DB00672', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for treatment of niddm in conjunction with diet and exercise ')|
|('DB00596', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB01169', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for induction of remission and consolidation in patients with acute promyelocytic leukemia apl and whose apl is characterized by the presence of the t1517 translocation or pmlraralpha gene expression')|
|('DB01169', 'MONDO:0012883', ['acute myeloblastic leukaemia type 3', 'acute myeloblastic leukemia type 3', 'acute myeloid leukaemia M3', 'acute myeloid leukemia M3', 'acute promyelocytic leukaemia', 'acute promyelocytic leukemia'], 'for induction of remission and consolidation in patients with acute promyelocytic leukemia apl and whose apl is characterized by the presence of the t1517 translocation or pmlraralpha gene expression')|
|('DB00434', 'MONDO:0012883', ['acute myeloblastic leukaemia type 3', 'acute myeloblastic leukemia type 3', 'acute myeloid leukaemia M3', 'acute myeloid leukemia M3', 'acute promyelocytic leukaemia', 'acute promyelocytic leukemia'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB00434', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB00434', 'MONDO:0003014', ['rhinitis'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB00434', 'MONDO:0003799', ['conjunctivitis'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB00434', 'MONDO:0005492', ['urticaria'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB00434', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for treatment of perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma cold urticaria dermatographism and as therapy for anaphylactic reactions adjunctive to epinephrine')|
|('DB01248', 'MONDO:0005492', ['urticaria'], 'for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy also used as a single agent in the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy it is also used in combination with prednisone in the treatment of patients with androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer ')|
|('DB01248', 'MONDO:0004992', ['cancer'], 'for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy also used as a single agent in the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy it is also used in combination with prednisone in the treatment of patients with androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer ')|
|('DB01248', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy also used as a single agent in the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy it is also used in combination with prednisone in the treatment of patients with androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer ')|
|('DB01248', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy also used as a single agent in the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy it is also used in combination with prednisone in the treatment of patients with androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer ')|
|('DB01248', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy also used as a single agent in the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy it is also used in combination with prednisone in the treatment of patients with androgen independent hormone refractory metastatic prostate cancer furthermore docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer ')|
|('DB01140', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of the following infections skin uti ent caused by is pneumoniae h influenzae staphylococci s pyogenesi group a betahemolytic streptococci ie coli p mirabilis klebsiellai sp coagulasenegative staphylococci and istreptococcus pyogenesi')|
|('DB01006', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy also for firstline treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy')|
|('DB01006', 'MONDO:0004992', ['cancer'], 'for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy also for firstline treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy')|
|('DB00797', 'MONDO:0004992', ['cancer'], 'for the treatment of pulmonary artery anomalies')|
|('DB00780', 'MONDO:0004992', ['cancer'], 'phenelzine is indicated for the treatment of nonendogenous neurotic or atypical depression for patients that do not tolerate other forms of therapyl1356 atypical depression has a high prevalence rate starts in early life tends to last longer is more likely to occur in people with bipolar disorder has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior it is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service the featuring symptoms of the atypical feature include mood reactivity two or more of this symptoms 1 increased appetite 2 increased sleep 3 leaden paralysis and 4 interpersonal rejection sensitivity and should not have melancholic or catatonic features of depressiona31917neurotic depression is a depression of an emotionally unstable person it is a secondary condition to major personality disorder neuroses and drug use disorders likewise a primary depression with a family history of depression spectrum disease would fit in this categorya31922a nonendogenous depression is characterized by a disturbance in mood and general outlook the physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily livinga31924')|
|('DB00780', 'MONDO:0001485', ['Atypical depression', 'atypical depressive disorder'], 'phenelzine is indicated for the treatment of nonendogenous neurotic or atypical depression for patients that do not tolerate other forms of therapyl1356 atypical depression has a high prevalence rate starts in early life tends to last longer is more likely to occur in people with bipolar disorder has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior it is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service the featuring symptoms of the atypical feature include mood reactivity two or more of this symptoms 1 increased appetite 2 increased sleep 3 leaden paralysis and 4 interpersonal rejection sensitivity and should not have melancholic or catatonic features of depressiona31917neurotic depression is a depression of an emotionally unstable person it is a secondary condition to major personality disorder neuroses and drug use disorders likewise a primary depression with a family history of depression spectrum disease would fit in this categorya31922a nonendogenous depression is characterized by a disturbance in mood and general outlook the physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily livinga31924')|
|('DB00780', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'phenelzine is indicated for the treatment of nonendogenous neurotic or atypical depression for patients that do not tolerate other forms of therapyl1356 atypical depression has a high prevalence rate starts in early life tends to last longer is more likely to occur in people with bipolar disorder has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior it is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service the featuring symptoms of the atypical feature include mood reactivity two or more of this symptoms 1 increased appetite 2 increased sleep 3 leaden paralysis and 4 interpersonal rejection sensitivity and should not have melancholic or catatonic features of depressiona31917neurotic depression is a depression of an emotionally unstable person it is a secondary condition to major personality disorder neuroses and drug use disorders likewise a primary depression with a family history of depression spectrum disease would fit in this categorya31922a nonendogenous depression is characterized by a disturbance in mood and general outlook the physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily livinga31924')|
|('DB00780', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'phenelzine is indicated for the treatment of nonendogenous neurotic or atypical depression for patients that do not tolerate other forms of therapyl1356 atypical depression has a high prevalence rate starts in early life tends to last longer is more likely to occur in people with bipolar disorder has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior it is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service the featuring symptoms of the atypical feature include mood reactivity two or more of this symptoms 1 increased appetite 2 increased sleep 3 leaden paralysis and 4 interpersonal rejection sensitivity and should not have melancholic or catatonic features of depressiona31917neurotic depression is a depression of an emotionally unstable person it is a secondary condition to major personality disorder neuroses and drug use disorders likewise a primary depression with a family history of depression spectrum disease would fit in this categorya31922a nonendogenous depression is characterized by a disturbance in mood and general outlook the physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily livinga31924')|
|('DB00391', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'sulpiride is indicated for the treatment of schizophrenia')|
|('DB00391', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'sulpiride is indicated for the treatment of schizophrenia')|
|('DB00957', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'for the prevention of pregnancy')|
|('DB00141', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'for the treatment and prevention of osteoarthritis by itself or in combination with chondroitin sulfate')|
|('DB00141', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment and prevention of osteoarthritis by itself or in combination with chondroitin sulfate')|
|('DB00683', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'intravenous indicated for promoting preoperative sedation anxiolysis anesthesia induction or amnesiaf2434intramuscular indicated for the treatment of status epilepticus in adultsfda labelnasal indicated for the acute treatment of intermittent stereotypic episodes of frequent seizure activity ie seizure clusters acute repetitive seizures that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and olderl6559')|
|('DB00683', 'MONDO:0002125', ['Grand mal status', 'status epilepticus'], 'intravenous indicated for promoting preoperative sedation anxiolysis anesthesia induction or amnesiaf2434intramuscular indicated for the treatment of status epilepticus in adultsfda labelnasal indicated for the acute treatment of intermittent stereotypic episodes of frequent seizure activity ie seizure clusters acute repetitive seizures that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and olderl6559')|
|('DB00683', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'intravenous indicated for promoting preoperative sedation anxiolysis anesthesia induction or amnesiaf2434intramuscular indicated for the treatment of status epilepticus in adultsfda labelnasal indicated for the acute treatment of intermittent stereotypic episodes of frequent seizure activity ie seizure clusters acute repetitive seizures that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and olderl6559')|
|('DB01297', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used in the emergency treatment of cardiac arrhythmias')|
|('DB06706', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'isometheptene is a sympathomimetic drug which causes vasoconstriction it is used for treating migraines and tension headaches')|
|('DB01123', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'topical antiseptic used mainly in wound dressings')|
|('DB06201', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'adjunct therapy for treatment of seizures associated with lennoxgastaut syndrome   ')|
|('DB00340', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used for the symptomatic treatment of parkinsonism')|
|('DB00553', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the treatment of psoriasis and vitiligo')|
|('DB00553', 'MONDO:0005083', ['psoriasis'], 'for the treatment of psoriasis and vitiligo')|
|('DB00553', 'MONDO:0008661', ['vitiligo'], 'for the treatment of psoriasis and vitiligo')|
|('DB01043', 'MONDO:0005083', ['psoriasis'], 'memantine is used to manage moderate to severe alzheimers dementia fda label a more recent systemic review and metaanalysis a177106 indicates that memantine is beneficial as a first line drug for the treatment of alzheimers dementia  cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia a177106')|
|('DB01043', 'MONDO:0001627', ['dementia'], 'memantine is used to manage moderate to severe alzheimers dementia fda label a more recent systemic review and metaanalysis a177106 indicates that memantine is beneficial as a first line drug for the treatment of alzheimers dementia  cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia a177106')|
|('DB01043', 'MONDO:0004975', ['Alzheimer disease', 'Alzheimers dementia', 'alzheimer disease'], 'memantine is used to manage moderate to severe alzheimers dementia fda label a more recent systemic review and metaanalysis a177106 indicates that memantine is beneficial as a first line drug for the treatment of alzheimers dementia  cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia a177106')|
|('DB01249', 'MONDO:0001627', ['dementia'], 'iodixanol is a contrast agent during coronary angiography')|
|('DB00929', 'MONDO:0001627', ['dementia'], 'misoprostol is indicated as a tablet to reduce the risk of nsaid induced gastric ulcers but not duodenal ulcers in high risk patientsl7616 misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcersl7619 misoprostol is used off label for the management of miscarriages prevention of post partum hemorrhage and is also used alone or in combination with mifepristone in other countries for first trimester abortionsa181589a181583a181697')|
|('DB00929', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'misoprostol is indicated as a tablet to reduce the risk of nsaid induced gastric ulcers but not duodenal ulcers in high risk patientsl7616 misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcersl7619 misoprostol is used off label for the management of miscarriages prevention of post partum hemorrhage and is also used alone or in combination with mifepristone in other countries for first trimester abortionsa181589a181583a181697')|
|('DB00929', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'misoprostol is indicated as a tablet to reduce the risk of nsaid induced gastric ulcers but not duodenal ulcers in high risk patientsl7616 misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcersl7619 misoprostol is used off label for the management of miscarriages prevention of post partum hemorrhage and is also used alone or in combination with mifepristone in other countries for first trimester abortionsa181589a181583a181697')|
|('DB00929', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'misoprostol is indicated as a tablet to reduce the risk of nsaid induced gastric ulcers but not duodenal ulcers in high risk patientsl7616 misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcersl7619 misoprostol is used off label for the management of miscarriages prevention of post partum hemorrhage and is also used alone or in combination with mifepristone in other countries for first trimester abortionsa181589a181583a181697')|
|('DB04894', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with aidsrelated diarrhea')|
|('DB04894', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with aidsrelated diarrhea')|
|('DB00418', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the shortterm treatment of intractable insomnia for patients habituated to barbiturates')|
|('DB01130', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB01656', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'roflumilast is indicated as a treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm')|
|('DB01656', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'roflumilast is indicated as a treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm')|
|('DB01656', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'roflumilast is indicated as a treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm')|
|('DB00361', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], ' vinorelbine tartrate is indicated for adults in the treatment of advanced nonsmall cell lung cancer nsclc as a single therapy or in combination with other chemotherapeutic drugs l1998used in relapsed or refractory hodgkin lymphoma in combination with other chemotherapy agents l2011 for the treatment of desmoid tumor or aggressive fibromatosis in combination with methotrexate l2011for the treatment of recurrent or metastatic squamous cell head and neck cancer l2011for the treatment of recurrent ovarian cancer l2011for the treatment of metastatic breast cancer in patients previously treated with anthracyline andor taxane therapy l2011for the treatment of her2positive trastuzumabresistant advanced breast cancer in patients previously treated with a taxane in combination with trastuzumab and everolimus l2011')|
|('DB00361', 'MONDO:0004992', ['cancer'], ' vinorelbine tartrate is indicated for adults in the treatment of advanced nonsmall cell lung cancer nsclc as a single therapy or in combination with other chemotherapeutic drugs l1998used in relapsed or refractory hodgkin lymphoma in combination with other chemotherapy agents l2011 for the treatment of desmoid tumor or aggressive fibromatosis in combination with methotrexate l2011for the treatment of recurrent or metastatic squamous cell head and neck cancer l2011for the treatment of recurrent ovarian cancer l2011for the treatment of metastatic breast cancer in patients previously treated with anthracyline andor taxane therapy l2011for the treatment of her2positive trastuzumabresistant advanced breast cancer in patients previously treated with a taxane in combination with trastuzumab and everolimus l2011')|
|('DB00361', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], ' vinorelbine tartrate is indicated for adults in the treatment of advanced nonsmall cell lung cancer nsclc as a single therapy or in combination with other chemotherapeutic drugs l1998used in relapsed or refractory hodgkin lymphoma in combination with other chemotherapy agents l2011 for the treatment of desmoid tumor or aggressive fibromatosis in combination with methotrexate l2011for the treatment of recurrent or metastatic squamous cell head and neck cancer l2011for the treatment of recurrent ovarian cancer l2011for the treatment of metastatic breast cancer in patients previously treated with anthracyline andor taxane therapy l2011for the treatment of her2positive trastuzumabresistant advanced breast cancer in patients previously treated with a taxane in combination with trastuzumab and everolimus l2011')|
|('DB00361', 'MONDO:0007608', ['desmoid fibromatosis [NCIT:C9182]', 'deep fibromatosis [NCIT:C9182]', 'desmoid type fibromatosis [Orphanet:873]', 'desmoid-type fibromatosis [NCIT:C9182]', 'aggressive fibromatosis [NCIT:C9182,Orphanet:873]', 'desmoid tumor [NCIT:C9182]', 'deep fibromatosis/desmoid tumor [NCIT:C9182]', 'desmoid tumor'], ' vinorelbine tartrate is indicated for adults in the treatment of advanced nonsmall cell lung cancer nsclc as a single therapy or in combination with other chemotherapeutic drugs l1998used in relapsed or refractory hodgkin lymphoma in combination with other chemotherapy agents l2011 for the treatment of desmoid tumor or aggressive fibromatosis in combination with methotrexate l2011for the treatment of recurrent or metastatic squamous cell head and neck cancer l2011for the treatment of recurrent ovarian cancer l2011for the treatment of metastatic breast cancer in patients previously treated with anthracyline andor taxane therapy l2011for the treatment of her2positive trastuzumabresistant advanced breast cancer in patients previously treated with a taxane in combination with trastuzumab and everolimus l2011')|
|('DB00361', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], ' vinorelbine tartrate is indicated for adults in the treatment of advanced nonsmall cell lung cancer nsclc as a single therapy or in combination with other chemotherapeutic drugs l1998used in relapsed or refractory hodgkin lymphoma in combination with other chemotherapy agents l2011 for the treatment of desmoid tumor or aggressive fibromatosis in combination with methotrexate l2011for the treatment of recurrent or metastatic squamous cell head and neck cancer l2011for the treatment of recurrent ovarian cancer l2011for the treatment of metastatic breast cancer in patients previously treated with anthracyline andor taxane therapy l2011for the treatment of her2positive trastuzumabresistant advanced breast cancer in patients previously treated with a taxane in combination with trastuzumab and everolimus l2011')|
|('DB00764', 'MONDO:0004992', ['cancer'], 'the inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy the nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis')|
|('DB00764', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'the inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy the nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis')|
|('DB00764', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'the inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy the nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis')|
|('DB00211', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of symptomatic orthostatic hypotension oh')|
|('DB00211', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment of symptomatic orthostatic hypotension oh')|
|('DB01035', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment of lifethreatening ventricular arrhythmias')|
|('DB00566', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 microgdl may also be used to treat mercury or arsenic poisoning')|
|('DB00566', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 microgdl may also be used to treat mercury or arsenic poisoning')|
|('DB00566', 'MONDO:0029000', ['poisoning'], 'for the treatment of lead poisoning in pediatric patients with blood lead levels above 45 microgdl may also be used to treat mercury or arsenic poisoning')|
|('DB00935', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for treatment of nasal congestion and redness associated with minor irritations of the eye')|
|('DB00913', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for treatment and management of pain systemic and for use as an anesthesia adjunct')|
|('DB00958', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents one established combination regimen consists of paraplatin and cyclophosphamide it is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have been previously treated with cisplatin ')|
|('DB00958', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents one established combination regimen consists of paraplatin and cyclophosphamide it is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have been previously treated with cisplatin ')|
|('DB00958', 'MONDO:0005140', ['Ovarian carcinoma', 'ovarian carcinoma'], 'for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents one established combination regimen consists of paraplatin and cyclophosphamide it is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have been previously treated with cisplatin ')|
|('DB01162', 'MONDO:0005140', ['Ovarian carcinoma', 'ovarian carcinoma'], 'terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertensionfda label')|
|('DB00728', 'MONDO:0005140', ['Ovarian carcinoma', 'ovarian carcinoma'], 'for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation')|
|('DB01128', 'MONDO:0005140', ['Ovarian carcinoma', 'ovarian carcinoma'], 'for treatment together with surgery or lhrh analogue of advanced prostatic cancer')|
|('DB01128', 'MONDO:0004992', ['cancer'], 'for treatment together with surgery or lhrh analogue of advanced prostatic cancer')|
|('DB00161', 'MONDO:0005140', ['Ovarian carcinoma', 'ovarian carcinoma'], 'promotes mental vigor muscle coordination and calm emotions may also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria')|
|('DB00161', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'promotes mental vigor muscle coordination and calm emotions may also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria')|
|('DB00161', 'MONDO:0009861', ['Follings disease', 'maternal phenylketonuria', 'phenylalaninemia', 'PKU', 'phenylketonuria'], 'promotes mental vigor muscle coordination and calm emotions may also be of use in a minority of patients with hepatic encephalopathy and in some with phenylketonuria')|
|('DB00216', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'for the acute treatment of migraine with or without aura in adults')|
|('DB00216', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'for the acute treatment of migraine with or without aura in adults')|
|('DB00291', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB00291', 'MONDO:0005059', ['leukemia'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB00291', 'MONDO:0005377', ['nephrotic syndrome'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB00291', 'MONDO:0004638', ['diffuse lymphoma [DOID:8675,MTHICD9_2006:202.8]', 'malignant lymphoma [DOID:8675]', 'lymphosarcoma [NCIT:C26919]', 'lymphosarcoma'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB00291', 'MONDO:0018906', ['follicular lymphoma'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB00291', 'MONDO:0005190', ['primary macroglobulinemia', 'macroglobulinemia'], 'for treatment of chronic lymphatic lymphocytic leukemia  childhood minimalchange nephrotic syndrome and malignant lymphomas including lymphosarcoma giant follicular lymphoma hodgkins disease  nonhodgkins lymphomas and waldenström’s macroglobulinemia')|
|('DB01242', 'MONDO:0018906', ['follicular lymphoma'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0005244', ['peripheral neuropathy', 'peripheral neuropathy'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0013189', ['trichotillomania'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB01242', 'MONDO:0001780', ['premature ejaculation'], 'may be used to treat obsessivecompulsive disorder and disorders with an obsessivecompulsive component eg depression schizophrenia tourette’s disorderunlabeled indications include depression panic disorder chronic pain eg central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy and associated narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation and premenstrual syndrome ')|
|('DB00622', 'MONDO:0001780', ['premature ejaculation'], 'used for the management of patients with chronic stable angina and for the treatment of hypertension')|
|('DB00690', 'MONDO:0001780', ['premature ejaculation'], 'for shortterm and intermittent use in patients with recurring insomnia and poor sleeping habits')|
|('DB00915', 'MONDO:0001780', ['premature ejaculation'], 'for the chemoprophylaxis prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus also for the treatment of parkinsonism and druginduced extrapyramidal reactions')|
|('DB00915', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the chemoprophylaxis prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus also for the treatment of parkinsonism and druginduced extrapyramidal reactions')|
|('DB04898', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of acute deep vein thrombosis')|
|('DB01209', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'indicated in the treatment of moderate to severe pain')|
|('DB00947', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy as monotherapy or in combination with other antineoplastic agents')|
|('DB00947', 'MONDO:0004992', ['cancer'], 'for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy as monotherapy or in combination with other antineoplastic agents')|
|('DB00954', 'MONDO:0004992', ['cancer'], 'for the treatment of the following mildtomoderate infections caused by susceptible strains of microorganisms acute bacterial exacerbations of chronic bronchitis secondary bacterial infection of acute bronchitis communityacquired pneumonia pharyngitistonsilitis and uncomplicated skin and skin structure infections')|
|('DB00954', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of the following mildtomoderate infections caused by susceptible strains of microorganisms acute bacterial exacerbations of chronic bronchitis secondary bacterial infection of acute bronchitis communityacquired pneumonia pharyngitistonsilitis and uncomplicated skin and skin structure infections')|
|('DB00954', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of the following mildtomoderate infections caused by susceptible strains of microorganisms acute bacterial exacerbations of chronic bronchitis secondary bacterial infection of acute bronchitis communityacquired pneumonia pharyngitistonsilitis and uncomplicated skin and skin structure infections')|
|('DB00954', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of the following mildtomoderate infections caused by susceptible strains of microorganisms acute bacterial exacerbations of chronic bronchitis secondary bacterial infection of acute bronchitis communityacquired pneumonia pharyngitistonsilitis and uncomplicated skin and skin structure infections')|
|('DB06751', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'used in the treatment of functional bowel disorders and alleviating pain in renal colic')|
|('DB00274', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of infections caused by susceptible organisms')|
|('DB00210', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the topical treatment of comedo papular and pustular acne acne vulgaris of the face chest or back')|
|('DB00210', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'for the topical treatment of comedo papular and pustular acne acne vulgaris of the face chest or back')|
|('DB00210', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for the topical treatment of comedo papular and pustular acne acne vulgaris of the face chest or back')|
|('DB00171', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00730', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for the treatment of strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans and trichinosis')|
|('DB00730', 'MONDO:0005974', ['disseminated strongyloidiasis', 'Infection by Strongyloides', 'strongyloidiasis'], 'for the treatment of strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans and trichinosis')|
|('DB00730', 'MONDO:0018500', ['cutaneous larva migrans'], 'for the treatment of strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans and trichinosis')|
|('DB00730', 'MONDO:0005988', ['Infection by Toxascaris', 'Toxocara infection', 'visceral larva migrans', 'toxocariasis'], 'for the treatment of strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans and trichinosis')|
|('DB00730', 'MONDO:0019444', ['trichinosis [Orphanet:863]', 'trichinellosis'], 'for the treatment of strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans and trichinosis')|
|('DB00854', 'MONDO:0005988', ['Infection by Toxascaris', 'Toxocara infection', 'visceral larva migrans', 'toxocariasis'], 'for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate')|
|('DB01612', 'MONDO:0005988', ['Infection by Toxascaris', 'Toxocara infection', 'visceral larva migrans', 'toxocariasis'], 'for the rapid relief of angina pectoris')|
|('DB01213', 'MONDO:0005988', ['Infection by Toxascaris', 'Toxocara infection', 'visceral larva migrans', 'toxocariasis'], 'antizol is indicated as an antidote for ethylene glycol such as antifreeze or methanol poisoning or for use in suspected ethylene glycol or methanol ingestion either alone or in combination with hemodialysis')|
|('DB01213', 'MONDO:0017860', ['methanol poisoning'], 'antizol is indicated as an antidote for ethylene glycol such as antifreeze or methanol poisoning or for use in suspected ethylene glycol or methanol ingestion either alone or in combination with hemodialysis')|
|('DB00584', 'MONDO:0017860', ['methanol poisoning'], 'indicated for the management of essential or renovascular hypertension l6586 as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics for an additive effectlabelindicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalislabelindicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of ≤ to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failurelabel')|
|('DB00584', 'MONDO:0006947', ['Renovascular hypertension', 'renovascular hypertension'], 'indicated for the management of essential or renovascular hypertension l6586 as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics for an additive effectlabelindicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalislabelindicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of ≤ to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failurelabel')|
|('DB00584', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'indicated for the management of essential or renovascular hypertension l6586 as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics for an additive effectlabelindicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalislabelindicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of ≤ to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failurelabel')|
|('DB00812', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of backache and ankylosing spondylitis')|
|('DB00812', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'for the treatment of backache and ankylosing spondylitis')|
|('DB06210', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow in this they differ from the previously discussed agents that act by attempting to curtail platelet destruction ')|
|('DB00431', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of patients infested with sarcoptes scabiei or pediculosis capitis who have either failed to respond to adequate doses or are intolerant of other approved therapies')|
|('DB00431', 'MONDO:0003471', ['head louse infestation', 'Pediculosis capitis', 'Pediculus capitis', 'Pediculus capitis infestation', 'pediculus humanus capitis infestation'], 'for the treatment of patients infested with sarcoptes scabiei or pediculosis capitis who have either failed to respond to adequate doses or are intolerant of other approved therapies')|
|('DB00231', 'MONDO:0003471', ['head louse infestation', 'Pediculosis capitis', 'Pediculus capitis', 'Pediculus capitis infestation', 'pediculus humanus capitis infestation'], 'temazepam is specifically indicated only for the shortterm management of insomnia fda label l5539 furthermore such management is generally predominantly associated with the symptomatic relief of transient and shortterm insomnia characterized by difficulty in falling asleep frequent nocturnal awakenings andor early morning awakenings f3718 in particular the official prescribing information for temazepam typically specifies that the instructions issued for dispensed prescriptions of the medication should indicate specifically that patients are only expected to use the therapy for short periods of time  usually 710 days in general fda label f3718 subsequently treatment with temazepam should usually not exceed 7 to 10 consecutive days and nor should it be prescribed in quantities exceeding a onemonth supply f3718some regional prescribing information also notes that temazepam may be used for premedication prior to minor surgery or other related procedures l5539')|
|('DB00231', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'temazepam is specifically indicated only for the shortterm management of insomnia fda label l5539 furthermore such management is generally predominantly associated with the symptomatic relief of transient and shortterm insomnia characterized by difficulty in falling asleep frequent nocturnal awakenings andor early morning awakenings f3718 in particular the official prescribing information for temazepam typically specifies that the instructions issued for dispensed prescriptions of the medication should indicate specifically that patients are only expected to use the therapy for short periods of time  usually 710 days in general fda label f3718 subsequently treatment with temazepam should usually not exceed 7 to 10 consecutive days and nor should it be prescribed in quantities exceeding a onemonth supply f3718some regional prescribing information also notes that temazepam may be used for premedication prior to minor surgery or other related procedures l5539')|
|('DB00644', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery andor irradiation')|
|('DB00644', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'for evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery andor irradiation')|
|('DB00175', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00175', 'MONDO:0002525', ['dyslipidemia', 'fatty acid metabolism disorder', 'inherited lipid metabolism disorder'], 'pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease its use includes the reduction of risk on myocardial infarction undergoing myocardial revascularization procedures and cardiovascular mortalityt274as well pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease this indication includes the reduction of risk of total mortality by reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke and stroketransient ischemic attack as well as to slow the progression of coronary atherosclerosist274the term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flowl6028as adjunctive therapy to diet pravastatin is used in patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type iia and iib patients with elevated serum triglycerides including type iv hyperlipidemia patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with lowdensity lipoprotein ldl cholesterol higher than 190 mgdl after diet modifications or ldl levels higher than 160 mgdl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factorst274in patients that do not respond adequately to diet pravastatin is used to treat patients with primary dysbetalipoproteinemia type iii hyperlipidemiat274 dyslipidemia is defined as an elevation of plasma cholesterol triglycerides or both as well as to the presence of low levels of highdensity lipoprotein this condition represents an increased risk for the development of atherosclerosisl6025')|
|('DB00700', 'MONDO:0002525', ['dyslipidemia', 'fatty acid metabolism disorder', 'inherited lipid metabolism disorder'], 'for improvement of survival of stable patients with left ventricular systolic dysfunction ejection fraction 40 and clinical evidence of congestive heart failure after an acute myocardial infarction')|
|('DB00700', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for improvement of survival of stable patients with left ventricular systolic dysfunction ejection fraction 40 and clinical evidence of congestive heart failure after an acute myocardial infarction')|
|('DB00700', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for improvement of survival of stable patients with left ventricular systolic dysfunction ejection fraction 40 and clinical evidence of congestive heart failure after an acute myocardial infarction')|
|('DB04841', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'used in the prophylaxis of migraine occlusive peripheral vascular disease vertigo of central and peripheral origin and as an adjuvant in the therapy of epilepsy')|
|('DB04841', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'used in the prophylaxis of migraine occlusive peripheral vascular disease vertigo of central and peripheral origin and as an adjuvant in the therapy of epilepsy')|
|('DB04841', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used in the prophylaxis of migraine occlusive peripheral vascular disease vertigo of central and peripheral origin and as an adjuvant in the therapy of epilepsy')|
|('DB00412', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB00412', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB09018', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'bromopride in indicated in the treatment of nausea and vomiting including ponv postoperative nausea and vomiting gastroesophageal reflux disease gerdgord as well as endoscopy preparation and radiographic studies of the gi tract ')|
|('DB09018', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'bromopride in indicated in the treatment of nausea and vomiting including ponv postoperative nausea and vomiting gastroesophageal reflux disease gerdgord as well as endoscopy preparation and radiographic studies of the gi tract ')|
|('DB00655', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for management of perimenopausal and postmenopausal symptoms')|
|('DB00187', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention')|
|('DB00187', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention')|
|('DB00187', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention')|
|('DB08871', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer ')|
|('DB08871', 'MONDO:0004992', ['cancer'], 'for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer ')|
|('DB08871', 'MONDO:0024880', ['metastatic malignant neoplasm [NCIT:C36263]', 'metastatic neoplasm, malignant [MONDO:patterns/malignant]', 'metastatic cancer [NCIT:C36263]', 'malignant metastatic neoplasm []', 'metastatic malignant neoplasm'], 'for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer ')|
|('DB00804', 'MONDO:0004992', ['cancer'], 'dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndromel7967')|
|('DB00842', 'MONDO:0004992', ['cancer'], 'for the treatment of anxiety disorders and alcohol withdrawal ')|
|('DB00842', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety disorders and alcohol withdrawal ')|
|('DB00842', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'for the treatment of anxiety disorders and alcohol withdrawal ')|
|('DB01088', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used for the treatment of pulmonary arterial hypertension')|
|('DB01088', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'used for the treatment of pulmonary arterial hypertension')|
|('DB08911', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'trametinib is indicated for the treatment of unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test fdain may 2018 it was approved for use with db08912 for the treatment of treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2726')|
|('DB08911', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'trametinib is indicated for the treatment of unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test fdain may 2018 it was approved for use with db08912 for the treatment of treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2726')|
|('DB08911', 'MONDO:0006468', ['anaplastic thyroid cancer [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland cancer [NCIT:C3878]', 'anaplastic thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid tumor [NCIT:C3878]', 'anaplastic carcinoma of thyroid [NCIT:C3878]', 'undifferentiated carcinoma of thyroid [NCIT:C3878]', 'thyroid gland undifferentiated (anaplastic) carcinoma [NCIT:C3878]', 'undifferentiated thyroid carcinoma [NCIT:C3878]', 'pleomorphic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland carcinosarcoma [NCIT:C3878]', 'anaplastic thyroid carcinoma [GARD:0000664,MONDO:ambiguous,NCIT:C3878]', 'undifferentiated carcinoma of the thyroid gland [NCIT:C3878]', 'undifferentiated carcinoma of the thyroid [NCIT:C3878]', 'sarcomatoid thyroid gland carcinoma [NCIT:C3878]', 'Dedifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of the thyroid [NCIT:C3878]', 'anaplastic carcinoma of the thyroid gland [NCIT:C3878]', 'metaplastic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland undifferentiated carcinoma [MONDO:patterns/location]', 'thyroid gland undifferentiated (anaplastic) carcinoma'], 'trametinib is indicated for the treatment of unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test fdain may 2018 it was approved for use with db08912 for the treatment of treat anaplastic thyroid cancer caused by an abnormal braf v600e gene l2726')|
|('DB00482', 'MONDO:0006468', ['anaplastic thyroid cancer [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated (anaplastic) thyroid gland cancer [NCIT:C3878]', 'anaplastic thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated thyroid tumor [NCIT:C3878]', 'anaplastic carcinoma of thyroid [NCIT:C3878]', 'undifferentiated carcinoma of thyroid [NCIT:C3878]', 'thyroid gland undifferentiated (anaplastic) carcinoma [NCIT:C3878]', 'undifferentiated thyroid carcinoma [NCIT:C3878]', 'pleomorphic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland carcinosarcoma [NCIT:C3878]', 'anaplastic thyroid carcinoma [GARD:0000664,MONDO:ambiguous,NCIT:C3878]', 'undifferentiated carcinoma of the thyroid gland [NCIT:C3878]', 'undifferentiated carcinoma of the thyroid [NCIT:C3878]', 'sarcomatoid thyroid gland carcinoma [NCIT:C3878]', 'Dedifferentiated thyroid gland carcinoma [NCIT:C3878]', 'undifferentiated carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of thyroid gland [NCIT:C3878]', 'anaplastic carcinoma of the thyroid [NCIT:C3878]', 'anaplastic carcinoma of the thyroid gland [NCIT:C3878]', 'metaplastic thyroid gland carcinoma [NCIT:C3878]', 'thyroid gland undifferentiated carcinoma [MONDO:patterns/location]', 'thyroid gland undifferentiated (anaplastic) carcinoma'], 'celecoxib is indicated for symptomatic treatment of adult osteoarthritis oa and adult rheumatoid arthritis ral7646 celecoxib is not a substitute for aspirin for cardiovascular event prophylaxisl7586l7646 it may be also be used to treat acute pain from various sources juvenile rheumatoid arthritis in children over 2 ankylosing spondylitis and primary dysmenorrhea in addition celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposisl7646')|
|('DB00482', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'celecoxib is indicated for symptomatic treatment of adult osteoarthritis oa and adult rheumatoid arthritis ral7646 celecoxib is not a substitute for aspirin for cardiovascular event prophylaxisl7586l7646 it may be also be used to treat acute pain from various sources juvenile rheumatoid arthritis in children over 2 ankylosing spondylitis and primary dysmenorrhea in addition celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposisl7646')|
|('DB00482', 'MONDO:0005185', ['Juvenile rheumatoid arthritis (AQ) [NCIT:C27179]', 'JRA [NCIT:C27179]', 'Juvenile rheumatoid arthritis [NCIT:C27179]', 'chronic childhood arthritis'], 'celecoxib is indicated for symptomatic treatment of adult osteoarthritis oa and adult rheumatoid arthritis ral7646 celecoxib is not a substitute for aspirin for cardiovascular event prophylaxisl7586l7646 it may be also be used to treat acute pain from various sources juvenile rheumatoid arthritis in children over 2 ankylosing spondylitis and primary dysmenorrhea in addition celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposisl7646')|
|('DB00482', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'celecoxib is indicated for symptomatic treatment of adult osteoarthritis oa and adult rheumatoid arthritis ral7646 celecoxib is not a substitute for aspirin for cardiovascular event prophylaxisl7586l7646 it may be also be used to treat acute pain from various sources juvenile rheumatoid arthritis in children over 2 ankylosing spondylitis and primary dysmenorrhea in addition celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposisl7646')|
|('DB01106', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'as an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis also used as a nasal spray for allergic rhinitis')|
|('DB01106', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'as an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis also used as a nasal spray for allergic rhinitis')|
|('DB00640', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'used as an initial treatment for the termination of paroxysmal supraventricular tachycardia pvst including that associated with accessory bypass tracts and is a drug of choice for terminating stable narrowcomplex supraventricular tachycardias svt also used as an adjunct to thallous chloride ti 201 myocardial perfusion scintigraphy thallium stress test in patients who are unable to exercise adequately as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined stable narrowcomplex svt')|
|('DB00872', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'for the treatment of euvolemic or hypervolemic hyponatremia eg the syndrome of inappropriate secretion of antidiuretic hormone or in the setting of hypothyroidism adrenal insufficiency pulmonary disorders etc in hospitalized patients')|
|('DB00872', 'MONDO:0006802', ['syndrome of Inappropriate Antidiuretic Hormone Secretion', 'syndrome of inappropriate secretion of ADH', 'syndrome of inappropriate secretion of antidiuretic hormone', 'syndrome of inappropriate vasopressin secretion', 'inappropriate adh syndrome'], 'for the treatment of euvolemic or hypervolemic hyponatremia eg the syndrome of inappropriate secretion of antidiuretic hormone or in the setting of hypothyroidism adrenal insufficiency pulmonary disorders etc in hospitalized patients')|
|('DB00872', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for the treatment of euvolemic or hypervolemic hyponatremia eg the syndrome of inappropriate secretion of antidiuretic hormone or in the setting of hypothyroidism adrenal insufficiency pulmonary disorders etc in hospitalized patients')|
|('DB00410', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'indicated for the treatment of impetigo and secondary skin infections leading to traumatic skin lesions due to staphylococcus aureus and streptococcus pyogenesl10580 ')|
|('DB00410', 'MONDO:0004592', ['impetigo'], 'indicated for the treatment of impetigo and secondary skin infections leading to traumatic skin lesions due to staphylococcus aureus and streptococcus pyogenesl10580 ')|
|('DB00327', 'MONDO:0004592', ['impetigo'], 'hydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain due to its addictive potential and overdose risk hydromorphone is only prescribed when other firstline treatments have faileda176468the who has proposed a threestep ladder for the management of pain in which it is suggested to start with a nonopioid medication followed by addition of weak opioids to the nonopioid treatment for moderate pain and finishing in the use of strong opioids such as hydromorphone along with the existing regimen for cases of severe paina176471offlabel hydromorphone can be administered for the suppression of refractory cougha176468')|
|('DB00327', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'hydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain due to its addictive potential and overdose risk hydromorphone is only prescribed when other firstline treatments have faileda176468the who has proposed a threestep ladder for the management of pain in which it is suggested to start with a nonopioid medication followed by addition of weak opioids to the nonopioid treatment for moderate pain and finishing in the use of strong opioids such as hydromorphone along with the existing regimen for cases of severe paina176471offlabel hydromorphone can be administered for the suppression of refractory cougha176468')|
|('DB01558', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the shortterm treatment of insomnia shortterm treatment of anxiety or panic attacks if a benzodiazepine is required and the alleviation of the symptoms of alcohol and opiatewithdrawal')|
|('DB01558', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the shortterm treatment of insomnia shortterm treatment of anxiety or panic attacks if a benzodiazepine is required and the alleviation of the symptoms of alcohol and opiatewithdrawal')|
|('DB01558', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the shortterm treatment of insomnia shortterm treatment of anxiety or panic attacks if a benzodiazepine is required and the alleviation of the symptoms of alcohol and opiatewithdrawal')|
|('DB01045', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of tuberculosis and tuberculosisrelated mycobacterial infections')|
|('DB01045', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of tuberculosis and tuberculosisrelated mycobacterial infections')|
|('DB00134', 'MONDO:0018076', ['tuberculosis'], 'used for protein synthesis including the formation of same lhomocysteine lcysteine taurine and sulfate')|
|('DB00631', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic lymphoblastic leukemia after at least two prior regimens it is designated as an orphan drug by the fda for this use')|
|('DB00631', 'MONDO:0005059', ['leukemia'], 'for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic lymphoblastic leukemia after at least two prior regimens it is designated as an orphan drug by the fda for this use')|
|('DB01567', 'MONDO:0005059', ['leukemia'], 'used for the shortterm treatment of anxiety disorders')|
|('DB01567', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used for the shortterm treatment of anxiety disorders')|
|('DB00307', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used orally for the treatment of skin manifestations of cutaneous tcell lymphoma ctcl in patients who are refractory to at least one prior systemic therapy also used topically for the treatment of skin lesions in early stage ia and ib ctcl in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies')|
|('DB00307', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'used orally for the treatment of skin manifestations of cutaneous tcell lymphoma ctcl in patients who are refractory to at least one prior systemic therapy also used topically for the treatment of skin lesions in early stage ia and ib ctcl in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies')|
|('DB00834', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the medical termination of intrauterine pregnancy through 49 days pregnancy also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery')|
|('DB00834', 'MONDO:0002909', ['hyperglycemia'], 'for the medical termination of intrauterine pregnancy through 49 days pregnancy also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery')|
|('DB00834', 'MONDO:0006640', ['Adrenocortical hyperfunction', 'hyperadrenalism', 'hypercortisolism', 'adrenal gland hyperfunction'], 'for the medical termination of intrauterine pregnancy through 49 days pregnancy also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery')|
|('DB00834', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the medical termination of intrauterine pregnancy through 49 days pregnancy also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery')|
|('DB00834', 'MONDO:0001076', ['Glucose: intolerance', 'Glucose: malabsorption', 'Malabsorption of glucose', 'glucose intolerance'], 'for the medical termination of intrauterine pregnancy through 49 days pregnancy also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery')|
|('DB05109', 'MONDO:0001076', ['Glucose: intolerance', 'Glucose: malabsorption', 'Malabsorption of glucose', 'glucose intolerance'], 'indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in europe russia and south korea approved for orphan drug status by the us fda for treatment of soft tissue sarcomas and ovarian cancer investigated for usetreatment in cancertumors unspecified gastric cancer ovarian cancer pediatric indications sarcoma and solid tumors')|
|('DB05109', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in europe russia and south korea approved for orphan drug status by the us fda for treatment of soft tissue sarcomas and ovarian cancer investigated for usetreatment in cancertumors unspecified gastric cancer ovarian cancer pediatric indications sarcoma and solid tumors')|
|('DB05109', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in europe russia and south korea approved for orphan drug status by the us fda for treatment of soft tissue sarcomas and ovarian cancer investigated for usetreatment in cancertumors unspecified gastric cancer ovarian cancer pediatric indications sarcoma and solid tumors')|
|('DB05109', 'MONDO:0004992', ['cancer'], 'indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in europe russia and south korea approved for orphan drug status by the us fda for treatment of soft tissue sarcomas and ovarian cancer investigated for usetreatment in cancertumors unspecified gastric cancer ovarian cancer pediatric indications sarcoma and solid tumors')|
|('DB00140', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'for the treatment of ariboflavinosis vitamin b2 deficiency')|
|('DB00140', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'for the treatment of ariboflavinosis vitamin b2 deficiency')|
|('DB01080', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'for use as an adjunct in treatment resistant epilepsy refractory complex partial seizures and secondary generalized seizures it is also used as monotherapy in infantile spasms in west syndrome')|
|('DB06701', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'dexmethylphenidate is used as a treatment for adhd ideally in conjunction with psychological educational behavioral or other forms of treatmenta177187label')|
|('DB00875', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'for use in the treatment of schizophrenia and depression')|
|('DB00875', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for use in the treatment of schizophrenia and depression')|
|('DB00845', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of lepromatous leprosy including dapsoneresistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum')|
|('DB00845', 'MONDO:0041751', ['lepromatous leprosy [MONDO:cjm,PMID:27219008]', 'multibacillary leprosy []', 'multibacillary leprosy'], 'for the treatment of lepromatous leprosy including dapsoneresistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum')|
|('DB01622', 'MONDO:0041751', ['lepromatous leprosy [MONDO:cjm,PMID:27219008]', 'multibacillary leprosy []', 'multibacillary leprosy'], 'for the treatment of all types of acute and chronic schizophrenia including those which did not respond to the usual neuroleptics manic syndromes')|
|('DB01622', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all types of acute and chronic schizophrenia including those which did not respond to the usual neuroleptics manic syndromes')|
|('DB00937', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'used in the management of exogenous obesity as a shortterm adjunct a few weeks in a regimen of weight reduction based on caloric restriction')|
|('DB00761', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for use as an electrolyte replenisher and in the treatment of hypokalemia')|
|('DB04953', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'adjuvant treatment of partialonset seizures ')|
|('DB00694', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for remission induction in acute nonlymphocytic leukemia myelogenous monocytic erythroid of adults and for remission induction in acute lymphocytic leukemia of children and adults')|
|('DB00694', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'for remission induction in acute nonlymphocytic leukemia myelogenous monocytic erythroid of adults and for remission induction in acute lymphocytic leukemia of children and adults')|
|('DB00694', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'for remission induction in acute nonlymphocytic leukemia myelogenous monocytic erythroid of adults and for remission induction in acute lymphocytic leukemia of children and adults')|
|('DB01094', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'for lowering cholesterol and possibly otherwise favorably affecting lipids iin vitroi research also suggests the possibility that hesperetin might have some anticancer effects and that it might have some antiaromatase activity as well as activity again')|
|('DB02959', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'for use as an antidepressant appetite suppressant and sleep aid')|
|('DB01236', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery')|
|('DB00495', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'used in combination with other antiretroviral agents for the treatment of human immunovirus hiv infections')|
|('DB04571', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'trioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo')|
|('DB04571', 'MONDO:0008661', ['vitiligo'], 'trioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo')|
|('DB00946', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'used for the prevention and treatment of thromboembolic disease including venous thrombosis thromboembolism and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation af')|
|('DB00946', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'used for the prevention and treatment of thromboembolic disease including venous thrombosis thromboembolism and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation af')|
|('DB00946', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'used for the prevention and treatment of thromboembolic disease including venous thrombosis thromboembolism and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation af')|
|('DB01034', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for use as a biochemical tool cerulenin is shown to cause dramatic weight loss in animals')|
|('DB00183', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'used as a diagnostic aid for evaluation of gastric acid secretory function')|
|('DB01416', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms')|
|('DB01320', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery it can also be substituted shortterm for oral phenytoin')|
|('DB01320', 'MONDO:0002125', ['Grand mal status', 'status epilepticus'], 'for the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery it can also be substituted shortterm for oral phenytoin')|
|('DB01320', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery it can also be substituted shortterm for oral phenytoin')|
|('DB01347', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'saprisartan is used in the treatment of hypertension and heart failure')|
|('DB01347', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'saprisartan is used in the treatment of hypertension and heart failure')|
|('DB00688', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal hepatic or cardiac transplants it should be used with cyclosporine and corticosteroidsl7363 mycophenolate mofetil may also be used offlabel as a secondline treatment for autoimmune hepatitis that has not responded adequately to firstline therapya180814 other offlabel uses of this drug include lupusassociated nephritis and dermatitis in childrena180817')|
|('DB00688', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal hepatic or cardiac transplants it should be used with cyclosporine and corticosteroidsl7363 mycophenolate mofetil may also be used offlabel as a secondline treatment for autoimmune hepatitis that has not responded adequately to firstline therapya180814 other offlabel uses of this drug include lupusassociated nephritis and dermatitis in childrena180817')|
|('DB00688', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal hepatic or cardiac transplants it should be used with cyclosporine and corticosteroidsl7363 mycophenolate mofetil may also be used offlabel as a secondline treatment for autoimmune hepatitis that has not responded adequately to firstline therapya180814 other offlabel uses of this drug include lupusassociated nephritis and dermatitis in childrena180817')|
|('DB00688', 'MONDO:0001166', ['nephritis'], 'mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal hepatic or cardiac transplants it should be used with cyclosporine and corticosteroidsl7363 mycophenolate mofetil may also be used offlabel as a secondline treatment for autoimmune hepatitis that has not responded adequately to firstline therapya180814 other offlabel uses of this drug include lupusassociated nephritis and dermatitis in childrena180817')|
|('DB00688', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal hepatic or cardiac transplants it should be used with cyclosporine and corticosteroidsl7363 mycophenolate mofetil may also be used offlabel as a secondline treatment for autoimmune hepatitis that has not responded adequately to firstline therapya180814 other offlabel uses of this drug include lupusassociated nephritis and dermatitis in childrena180817')|
|('DB04946', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'treatment of acute schizophrenia ')|
|('DB03147', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'used to treat eye diseases caused by vitamin b2 deficiency such as keratitis and blepharitis')|
|('DB03147', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'used to treat eye diseases caused by vitamin b2 deficiency such as keratitis and blepharitis')|
|('DB03147', 'MONDO:0004785', ['blepharitis'], 'used to treat eye diseases caused by vitamin b2 deficiency such as keratitis and blepharitis')|
|('DB01438', 'MONDO:0004573', ['ariboflavinosis', 'vitamin B2 deficiency', 'ariboflavinosis'], 'phenazopyridine hydrochloride is indicated to relieve uncomfortable symptoms that occur as a consequence of mucosal irritation of the lower urinary tract in adults  the irritation may be a result of trauma surgery endoscopic procedures infection or the insertion of instruments or urinary cathetersl7826 phenazopyridine may be used in combination with antimicrobial therapy but is not used as an antimicrobial agent it contributes to the relief of discomfort and pain before antimicrobial therapy begins to take effect  it is important to note that the duration of treatment with this drug should last a maximum of 2 daysl7826 phenazopyridine is available in many countries as an over the counter druga182147')|
|('DB01438', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'phenazopyridine hydrochloride is indicated to relieve uncomfortable symptoms that occur as a consequence of mucosal irritation of the lower urinary tract in adults  the irritation may be a result of trauma surgery endoscopic procedures infection or the insertion of instruments or urinary cathetersl7826 phenazopyridine may be used in combination with antimicrobial therapy but is not used as an antimicrobial agent it contributes to the relief of discomfort and pain before antimicrobial therapy begins to take effect  it is important to note that the duration of treatment with this drug should last a maximum of 2 daysl7826 phenazopyridine is available in many countries as an over the counter druga182147')|
|('DB01075', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'diphenhydramine is a firstgeneration histamine h1 receptor antagonist h1 antihistamine that is widely available as a nonprescription overthecounter otc medication as an otc medication diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing runny nose itchywatery eyes itching of nose or throat insomnia pruritis urticaria insect bitesstings allergic rashes and nausea l5263 l5266 l5269 f3379 a174541additionally when the use of oral diphenhydramine is impractical there are also prescriptiononly formulations such as diphenhydramine injection products that are effective in adults and pediatric patients other than premature infants and neonates fori the amelioration of allergic reactions to blood or plasma in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated f3352ii the active treatment of motion sickness f3352 andiii use in parkinsonism when oral therapy is impossible or contraindicated as follows parkinsonism in the elderly who are unable to tolerate more potent agents mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents f3352')|
|('DB01075', 'MONDO:0005492', ['urticaria'], 'diphenhydramine is a firstgeneration histamine h1 receptor antagonist h1 antihistamine that is widely available as a nonprescription overthecounter otc medication as an otc medication diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing runny nose itchywatery eyes itching of nose or throat insomnia pruritis urticaria insect bitesstings allergic rashes and nausea l5263 l5266 l5269 f3379 a174541additionally when the use of oral diphenhydramine is impractical there are also prescriptiononly formulations such as diphenhydramine injection products that are effective in adults and pediatric patients other than premature infants and neonates fori the amelioration of allergic reactions to blood or plasma in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated f3352ii the active treatment of motion sickness f3352 andiii use in parkinsonism when oral therapy is impossible or contraindicated as follows parkinsonism in the elderly who are unable to tolerate more potent agents mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents f3352')|
|('DB01075', 'MONDO:0100053', ['anaphylactic shock []', 'systemic anaphylaxis [PMID:18596587]', 'anaphylaxis'], 'diphenhydramine is a firstgeneration histamine h1 receptor antagonist h1 antihistamine that is widely available as a nonprescription overthecounter otc medication as an otc medication diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing runny nose itchywatery eyes itching of nose or throat insomnia pruritis urticaria insect bitesstings allergic rashes and nausea l5263 l5266 l5269 f3379 a174541additionally when the use of oral diphenhydramine is impractical there are also prescriptiononly formulations such as diphenhydramine injection products that are effective in adults and pediatric patients other than premature infants and neonates fori the amelioration of allergic reactions to blood or plasma in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated f3352ii the active treatment of motion sickness f3352 andiii use in parkinsonism when oral therapy is impossible or contraindicated as follows parkinsonism in the elderly who are unable to tolerate more potent agents mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents f3352')|
|('DB01075', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'diphenhydramine is a firstgeneration histamine h1 receptor antagonist h1 antihistamine that is widely available as a nonprescription overthecounter otc medication as an otc medication diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing runny nose itchywatery eyes itching of nose or throat insomnia pruritis urticaria insect bitesstings allergic rashes and nausea l5263 l5266 l5269 f3379 a174541additionally when the use of oral diphenhydramine is impractical there are also prescriptiononly formulations such as diphenhydramine injection products that are effective in adults and pediatric patients other than premature infants and neonates fori the amelioration of allergic reactions to blood or plasma in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated f3352ii the active treatment of motion sickness f3352 andiii use in parkinsonism when oral therapy is impossible or contraindicated as follows parkinsonism in the elderly who are unable to tolerate more potent agents mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents f3352')|
|('DB00491', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for use as an adjunct to diet to improve glycemic control in patients with noninsulindependent diabetes mellitus niddm whose hyperglycemia cannot be managed with diet alone')|
|('DB00491', 'MONDO:0005015', ['diabetes mellitus'], 'for use as an adjunct to diet to improve glycemic control in patients with noninsulindependent diabetes mellitus niddm whose hyperglycemia cannot be managed with diet alone')|
|('DB00491', 'MONDO:0002909', ['hyperglycemia'], 'for use as an adjunct to diet to improve glycemic control in patients with noninsulindependent diabetes mellitus niddm whose hyperglycemia cannot be managed with diet alone')|
|('DB00261', 'MONDO:0002909', ['hyperglycemia'], 'for the treatment of patients with thrombocythemia secondary to myeloproliferative disorders to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombohemorrhagic events')|
|('DB00343', 'MONDO:0002909', ['hyperglycemia'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB00343', 'MONDO:0006021', ['angina inversa', 'Prinzmetals angina', 'Prinzmetals variant angina', 'variant angina', 'variant angina pectoris', 'prinzmetal angina'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB00343', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB00343', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB00343', 'MONDO:0004994', ['Cardiomyopathies', 'cardiomyopathy'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB00343', 'MONDO:0003634', ['proteinuria'], 'oralindicated for the management of hypertension to lower blood pressure alone or in combination with other antihypertensive agentsl10556indicated for use to improve exercise tolerance in patients with chronic stable anginal10556indicated for the management of variant angina prinzmetals anginal6298intravenousindicated for the shortterm management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular ratel6292indicated for the rapid conversion of paroxysmal supraventricular tachycardias psvt to sinus rhythm this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndromel6292offlabelindicated for offlabel uses in anal fissures as topical formulation migraine prophylaxis cramps in lower leg related to rest pulmonary hypertensionl6289 idiopathic dilated cardiomyopathy and proteinuria associated with diabetic nephropathyl6298')|
|('DB01107', 'MONDO:0003634', ['proteinuria'], 'for the treatment of insomnia')|
|('DB01107', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of insomnia')|
|('DB00207', 'MONDO:0003634', ['proteinuria'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0002345', ['cervicitis'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0001797', ['Ulcus molle, skin', 'chancroid'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB00207', 'MONDO:0005441', ['otitis media'], 'azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin fda labelazithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below recommended dosages duration of therapy and considerations for various patient populations may vary among these infections refer to the fda label and indications section of this drug entry for detailed information fda label adultsacute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaeacute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapyuncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes or streptococcus agalactiae abscesses usually require surgical drainageurethritis and cervicitis due to chlamydia trachomatis or neisseria gonorrhoeaegenital ulcer disease in men due to haemophilus ducreyi chancroid due to the small number of women included in clinical trials the efficacy of azithromycin in the treatment of chancroid in women has not been establishedpediatric patientsacute otitis media caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniaecommunityacquired pneumonia due to chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapypharyngitistonsillitis caused by streptococcus pyogenes as an alternative to firstline therapy in individuals who cannot use firstline therapy')|
|('DB08796', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of cough')|
|('DB01390', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease uncontrolled diabetes circulatory insufficiency due to shock or severe dehydration extracorporeal circulation of blood cardiac arrest and severe primary lactic acidosis also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate further indicated in the treatment of certain drug intoxications including barbiturates where dissociation of the barbiturateprotein complex is desired in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments')|
|('DB01390', 'MONDO:0000440', ['metabolic acidosis'], 'sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease uncontrolled diabetes circulatory insufficiency due to shock or severe dehydration extracorporeal circulation of blood cardiac arrest and severe primary lactic acidosis also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate further indicated in the treatment of certain drug intoxications including barbiturates where dissociation of the barbiturateprotein complex is desired in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments')|
|('DB01390', 'MONDO:0006022', ['acidosis [MONDO:ambiguous]', 'acidosis disorder'], 'sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease uncontrolled diabetes circulatory insufficiency due to shock or severe dehydration extracorporeal circulation of blood cardiac arrest and severe primary lactic acidosis also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate further indicated in the treatment of certain drug intoxications including barbiturates where dissociation of the barbiturateprotein complex is desired in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments')|
|('DB00507', 'MONDO:0006022', ['acidosis [MONDO:ambiguous]', 'acidosis disorder'], 'for the treatment of diarrhea in adults and children caused by the protozoa igiardia lambliai  and for the treatment of diarrhea in children caused by the protozoan  icryptosporidium parvumi fda labelnitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by cryptosporidium parvum in patients with hivimmunodeficiency fda label a31973 a31976 ')|
|('DB00507', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of diarrhea in adults and children caused by the protozoa igiardia lambliai  and for the treatment of diarrhea in children caused by the protozoan  icryptosporidium parvumi fda labelnitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by cryptosporidium parvum in patients with hivimmunodeficiency fda label a31973 a31976 ')|
|('DB01005', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for management of melanoma resistant chronic myelocytic leukemia and recurrent metastatic or inoperable carcinoma of the ovary and sicklecell anemia')|
|('DB01005', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for management of melanoma resistant chronic myelocytic leukemia and recurrent metastatic or inoperable carcinoma of the ovary and sicklecell anemia')|
|('DB01005', 'MONDO:0005059', ['leukemia'], 'for management of melanoma resistant chronic myelocytic leukemia and recurrent metastatic or inoperable carcinoma of the ovary and sicklecell anemia')|
|('DB01005', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for management of melanoma resistant chronic myelocytic leukemia and recurrent metastatic or inoperable carcinoma of the ovary and sicklecell anemia')|
|('DB01005', 'MONDO:0002280', ['anaemia', 'anemia'], 'for management of melanoma resistant chronic myelocytic leukemia and recurrent metastatic or inoperable carcinoma of the ovary and sicklecell anemia')|
|('DB00182', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'amphetamine is indicated for the treatment of attentiondeficithyperactivity disorders adhd as well as for the treatment of central nervous system disorders such as narcolepsya18540 adhd is a complex disorder associated with the substantial heterogeneity in etiology clinical presentation and treatment outcome adhd comes from a complex interplay between interdependent genetic and nongenetic factors which cause complex mental disorders in children and teenagersa174271on the other hand narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepinessa174274amphetamine is also being used nowadays offlabel for the treatment of obesity depression and chronic paina174268 a174283')|
|('DB00182', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'amphetamine is indicated for the treatment of attentiondeficithyperactivity disorders adhd as well as for the treatment of central nervous system disorders such as narcolepsya18540 adhd is a complex disorder associated with the substantial heterogeneity in etiology clinical presentation and treatment outcome adhd comes from a complex interplay between interdependent genetic and nongenetic factors which cause complex mental disorders in children and teenagersa174271on the other hand narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepinessa174274amphetamine is also being used nowadays offlabel for the treatment of obesity depression and chronic paina174268 a174283')|
|('DB00182', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'amphetamine is indicated for the treatment of attentiondeficithyperactivity disorders adhd as well as for the treatment of central nervous system disorders such as narcolepsya18540 adhd is a complex disorder associated with the substantial heterogeneity in etiology clinical presentation and treatment outcome adhd comes from a complex interplay between interdependent genetic and nongenetic factors which cause complex mental disorders in children and teenagersa174271on the other hand narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepinessa174274amphetamine is also being used nowadays offlabel for the treatment of obesity depression and chronic paina174268 a174283')|
|('DB00182', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'amphetamine is indicated for the treatment of attentiondeficithyperactivity disorders adhd as well as for the treatment of central nervous system disorders such as narcolepsya18540 adhd is a complex disorder associated with the substantial heterogeneity in etiology clinical presentation and treatment outcome adhd comes from a complex interplay between interdependent genetic and nongenetic factors which cause complex mental disorders in children and teenagersa174271on the other hand narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepinessa174274amphetamine is also being used nowadays offlabel for the treatment of obesity depression and chronic paina174268 a174283')|
|('DB01595', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'used to treat shortterm sleeping problems insomnia such as difficulty falling asleep frequent awakenings during the night and earlymorning awakening')|
|('DB01595', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used to treat shortterm sleeping problems insomnia such as difficulty falling asleep frequent awakenings during the night and earlymorning awakening')|
|('DB06623', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'investigated for usetreatment in fibromyalgia')|
|('DB04837', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used in the treatment of dry cough')|
|('DB01237', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for management of symptoms related to hay fever and other types of allergy and used to help bring up phlegm thin secretions and make a cough productive')|
|('DB01237', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for management of symptoms related to hay fever and other types of allergy and used to help bring up phlegm thin secretions and make a cough productive')|
|('DB00290', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for palliative treatment in the management malignant neoplasm trachea bronchus lung squamous cell carcinoma and lymphomas')|
|('DB00290', 'MONDO:0006517', ['malignant childhood neoplasm [NCIT:C4005]', 'malignant neoplasm [NCIT:C4005]', 'childhood cancer [NCIT:C4005]', 'childhood neoplasm, malignant [MONDO:patterns/malignant]', 'malignant pediatric neoplasm [NCIT:C4005]', 'malignant childhood tumor [NCIT:C4005]', 'malignant pediatric tumor [NCIT:C4005]', 'childhood malignant neoplasm [NCIT:C4005]', 'pediatric cancer [NCIT:C4005]', 'childhood malignant neoplasm'], 'for palliative treatment in the management malignant neoplasm trachea bronchus lung squamous cell carcinoma and lymphomas')|
|('DB00290', 'MONDO:0005096', ['epidermoid carcinoma', 'malignant squamous cell tumor', 'squamous carcinoma', 'squamous cell cancer', 'squamous cell Epithelioma', 'squamous cell carcinoma'], 'for palliative treatment in the management malignant neoplasm trachea bronchus lung squamous cell carcinoma and lymphomas')|
|('DB01616', 'MONDO:0005096', ['epidermoid carcinoma', 'malignant squamous cell tumor', 'squamous carcinoma', 'squamous cell cancer', 'squamous cell Epithelioma', 'squamous cell carcinoma'], 'used to relieve cramps or spasms of the stomach and intestines it is also useful in treating irritable bowel syndrome ibs and similar conditions it can also be used to help relieve period pain alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor mg132 on breast cancer cells ')|
|('DB01616', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'used to relieve cramps or spasms of the stomach and intestines it is also useful in treating irritable bowel syndrome ibs and similar conditions it can also be used to help relieve period pain alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor mg132 on breast cancer cells ')|
|('DB01616', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to relieve cramps or spasms of the stomach and intestines it is also useful in treating irritable bowel syndrome ibs and similar conditions it can also be used to help relieve period pain alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor mg132 on breast cancer cells ')|
|('DB01616', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'used to relieve cramps or spasms of the stomach and intestines it is also useful in treating irritable bowel syndrome ibs and similar conditions it can also be used to help relieve period pain alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor mg132 on breast cancer cells ')|
|('DB00985', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'dimenhydrinate is indicated for the prevention and treatment of nausea vomiting or vertigo of motion sickness')|
|('DB01016', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'glyburide is indicated alone or as part of combination product with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusl8120l8123')|
|('DB01016', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'glyburide is indicated alone or as part of combination product with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusl8120l8123')|
|('DB00744', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older')|
|('DB00744', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older')|
|('DB00995', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used in the treatment of active progressive or destructive forms of inflammatory arthritis such as adult rheumatoid arthritis')|
|('DB00995', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in the treatment of active progressive or destructive forms of inflammatory arthritis such as adult rheumatoid arthritis')|
|('DB00989', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of mild to moderate dementia associated with parkinsons disease or of the alzheimers type')|
|('DB00565', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for inpatients and outpatients as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the icu')|
|('DB08811', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of anxiety and alcohol withdrawal')|
|('DB08811', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety and alcohol withdrawal')|
|('DB08811', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'for the treatment of anxiety and alcohol withdrawal')|
|('DB04861', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'nebivolol is indicated to treat hypertensiona2762a182579l7985l7988')|
|('DB00126', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used to treat vitamin c deficiency scurvy delayed wound and bone healing urine acidification and in general as an antioxidant it has also been suggested to be an effective antiviral agent')|
|('DB00126', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to treat vitamin c deficiency scurvy delayed wound and bone healing urine acidification and in general as an antioxidant it has also been suggested to be an effective antiviral agent')|
|('DB00620', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0019558', ['DLE [NCIT:C26820]', 'discoid lupus erythematosus'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0006583', ['Necrobiosis lipoidica', 'necrobiosis lipoidica'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0045042', ['localized'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0006554', ['Granuloma annulare', 'Granulome annulare', 'granuloma annulare'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0040698', ['subacute bursitis []', 'subacute bursitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0004855', ['Inflammation of tendon sheath', 'tenosynovitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0002400', ['synovitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005340', ['Circumscribed alopecia', 'alopecia areata'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0009691', ['Mycosis fungoides', 'mycosis fungoides lymphoma', 'mycosis fungoides'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0006594', ['pemphigus'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0020108', ['Autoimmune haemolytic anaemia', 'Autoimmune hemolytic anaemia', 'autoimmune hemolytic anaemia', 'Autoimmune hemolytic anemia', 'autoimmune hemolytic anemia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0002280', ['anaemia', 'anemia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0020113', ['red cell aplasia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0002049', ['thrombocytopenia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0044684', ['TBM [Orphanet:499004]', 'tubercular meningitis [Orphanet:499004]', 'tuberculous meningitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0019198', ['Sympathetic uveitis', 'sympathetic ophthalmia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0043494', ['artery inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'inflammation of artery []', 'arteritis [NCIT:C34399]', 'arteritis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0016367', ['dermatopolymyositis', 'Polymyositis with skin involvement', 'dermatomyositis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0000004', ['Adrenal Cortical Insufficiency', 'Corticoadrenal insufficiency', 'adrenocortical insufficiency'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0043579', ['enteritis of small intestine []', 'small intestine inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'enteritis [NCIT:C26765]', 'inflammation of small intestine []', 'enteritis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005292', ['colitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0022202', ['disseminated'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0018076', ['tuberculosis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0006955', ['rheumatic carditis', 'rheumatic heart disease'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0003937', ['spondylitis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005059', ['leukemia'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0003634', ['proteinuria'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0018170', ['idiopathic nephrotic syndrome'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00620', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata discoid lupus erythematosus keloids and necrobiosis lipoidica diabeticoruml8246 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8246triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosesl8249l8258 a triamcinolone acetonide 10mgml or 40mgml injection is indicated intraarticularly for acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl8252l8255 the same 10mgml injection is indicated by the intralesional route for the treatment of alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum and tumors of an aponeurosis or tendonl8252 this formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus and psoriatic plaquesl8252 the 40mgml injection is indicated intramuscularly for controlling severe allergic conditions such as asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial or seasonal allergic rhinitis serum sickness and transfusion reactions treatment of bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia incancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis acute exacerbations of multiple sclerosis or cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis and systemic lupus erythematosus adjunct treatment of adrenocortical insufficiency regional enteritis ulcerative colitis fulminating or disseminated pulmonary tuberculosis acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative management of leukemia and lymphoma induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosusl8255 a triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditionsl8261 the intravitreal injection is also used for visualization during vitrectomyl8261 an extended release suspension is indicated intraarticularly for management of pain in osteoarthritis of the kneel8264')|
|('DB00811', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'indicated for the treatment of chronic hepatitis c virus hcv infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response svr typically added to improve svr and reduce relapse rates a19644the addition of ribavirin in technivie therapy indicated for treating hcv genotype 1a and 4 infections is recommended in patients with or without cirrhosis resistance viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined ')|
|('DB00811', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'indicated for the treatment of chronic hepatitis c virus hcv infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response svr typically added to improve svr and reduce relapse rates a19644the addition of ribavirin in technivie therapy indicated for treating hcv genotype 1a and 4 infections is recommended in patients with or without cirrhosis resistance viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined ')|
|('DB00811', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of chronic hepatitis c virus hcv infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response svr typically added to improve svr and reduce relapse rates a19644the addition of ribavirin in technivie therapy indicated for treating hcv genotype 1a and 4 infections is recommended in patients with or without cirrhosis resistance viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined ')|
|('DB00184', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation')|
|('DB00751', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for the prevention of itching associated with allergic conjunctivitis')|
|('DB00595', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'oxytetracycline is indicated for treatment of infections caused by a variety of gram positive and gram negative microorganisms including imycoplasma pneumoniae pasteurella pestis escherichia coli haemophilus influenzaei respiratory infections and idiplococcus pneumoniaei')|
|('DB01021', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'used in the treatment of oedema including that associated with heart failure and hypertension')|
|('DB01021', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'used in the treatment of oedema including that associated with heart failure and hypertension')|
|('DB06204', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'the immediaterelease formulation of tapentadol is indicated for the relief of moderate to severe acute pain the longacting formulation serves as a continuous aroundtheclock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy ')|
|('DB00677', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for use in the eye to treat certain types of glaucoma and other eye conditions such as accommodative esotropia')|
|('DB00677', 'MONDO:0005041', ['glaucoma'], 'for use in the eye to treat certain types of glaucoma and other eye conditions such as accommodative esotropia')|
|('DB00677', 'MONDO:0004896', ['Convergence in manifest squint', 'crossed eyes', 'Internal Strabismus', 'esotropia'], 'for use in the eye to treat certain types of glaucoma and other eye conditions such as accommodative esotropia')|
|('DB01581', 'MONDO:0005041', ['glaucoma'], 'a sulfanilamide that is used as an antibacterial agent it can be used to treat bronchitis prostatitis and urinary tract infections')|
|('DB01581', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'a sulfanilamide that is used as an antibacterial agent it can be used to treat bronchitis prostatitis and urinary tract infections')|
|('DB01581', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'a sulfanilamide that is used as an antibacterial agent it can be used to treat bronchitis prostatitis and urinary tract infections')|
|('DB00424', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for treatment of bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis and pancreatitis also used to treat certain heart conditions to control the symptoms of parkinsons disease and rhinitis')|
|('DB00424', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for treatment of bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis and pancreatitis also used to treat certain heart conditions to control the symptoms of parkinsons disease and rhinitis')|
|('DB00424', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for treatment of bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis and pancreatitis also used to treat certain heart conditions to control the symptoms of parkinsons disease and rhinitis')|
|('DB00424', 'MONDO:0004982', ['pancreatitis'], 'for treatment of bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis and pancreatitis also used to treat certain heart conditions to control the symptoms of parkinsons disease and rhinitis')|
|('DB00424', 'MONDO:0003014', ['rhinitis'], 'for treatment of bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis and pancreatitis also used to treat certain heart conditions to control the symptoms of parkinsons disease and rhinitis')|
|('DB00121', 'MONDO:0004982', ['pancreatitis'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00351', 'MONDO:0004982', ['pancreatitis'], 'for the treatment of anorexia cachexia or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome aids also used for the palliative management of recurrent inoperable or metastatic breast cancer endometrial cancer and prostate cancer in canada and some other countries')|
|('DB00351', 'MONDO:0017769', ['acquired immunodeficiency'], 'for the treatment of anorexia cachexia or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome aids also used for the palliative management of recurrent inoperable or metastatic breast cancer endometrial cancer and prostate cancer in canada and some other countries')|
|('DB00351', 'MONDO:0004992', ['cancer'], 'for the treatment of anorexia cachexia or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome aids also used for the palliative management of recurrent inoperable or metastatic breast cancer endometrial cancer and prostate cancer in canada and some other countries')|
|('DB00351', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of anorexia cachexia or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome aids also used for the palliative management of recurrent inoperable or metastatic breast cancer endometrial cancer and prostate cancer in canada and some other countries')|
|('DB00519', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of mild to moderate hypertension as an adjunct in the treatment of congestive heart failure chf to improve survival following myocardial infarction mi in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00519', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of mild to moderate hypertension as an adjunct in the treatment of congestive heart failure chf to improve survival following myocardial infarction mi in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00519', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of mild to moderate hypertension as an adjunct in the treatment of congestive heart failure chf to improve survival following myocardial infarction mi in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00519', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of mild to moderate hypertension as an adjunct in the treatment of congestive heart failure chf to improve survival following myocardial infarction mi in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB00519', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'for the treatment of mild to moderate hypertension as an adjunct in the treatment of congestive heart failure chf to improve survival following myocardial infarction mi in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy ')|
|('DB06699', 'MONDO:0005015', ['diabetes mellitus'], 'degaralix is used for the management of advanced prostate cancer ')|
|('DB06699', 'MONDO:0004992', ['cancer'], 'degaralix is used for the management of advanced prostate cancer ')|
|('DB01012', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on hemodialysis or peritoneal dialysis also for the treatment of hypercalcemia in patients with parathyroid carcinoma')|
|('DB01012', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on hemodialysis or peritoneal dialysis also for the treatment of hypercalcemia in patients with parathyroid carcinoma')|
|('DB01012', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on hemodialysis or peritoneal dialysis also for the treatment of hypercalcemia in patients with parathyroid carcinoma')|
|('DB00703', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for treatment of chronic openangle glaucoma and acute angleclosure glaucoma')|
|('DB00703', 'MONDO:0005041', ['glaucoma'], 'for treatment of chronic openangle glaucoma and acute angleclosure glaucoma')|
|('DB00809', 'MONDO:0005041', ['glaucoma'], 'indicated to induce mydriasis dilation of the pupil and cycloplegia paralysis of the ciliary muscle of the eye in diagnostic procedures such as measurement of refractive errors and examination of the fundus of the eye')|
|('DB00809', 'MONDO:0005555', ['Ciliary muscle paresis', 'Cycloplegic paralysis of accommodation', 'Paresis of accommodation', 'cycloplegia'], 'indicated to induce mydriasis dilation of the pupil and cycloplegia paralysis of the ciliary muscle of the eye in diagnostic procedures such as measurement of refractive errors and examination of the fundus of the eye')|
|('DB00664', 'MONDO:0005555', ['Ciliary muscle paresis', 'Cycloplegic paralysis of accommodation', 'Paresis of accommodation', 'cycloplegia'], 'for the treatment of urinary tract infection and chronic bronchitis')|
|('DB00664', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of urinary tract infection and chronic bronchitis')|
|('DB00664', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of urinary tract infection and chronic bronchitis')|
|('DB01022', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of haemorrhagic conditions in infants antidote for coumarin anticoagulants in hypoprothrombinaemia')|
|('DB00349', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for treatment and management of epilepsy and seizures associated with lennoxgastaut syndrome a difficulttotreat form of childhood epilepsy ')|
|('DB00349', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for treatment and management of epilepsy and seizures associated with lennoxgastaut syndrome a difficulttotreat form of childhood epilepsy ')|
|('DB00277', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases such as emphysema and chronic bronchitis')|
|('DB00277', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases such as emphysema and chronic bronchitis')|
|('DB00292', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used in the induction of general anesthesia')|
|('DB01037', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'monotherapy for initial treatment of parkinsons disease as well as an adjunct therapy in patients with a decreased response to levodopacarbadopa also used for the palliative treatment of mild to moderate alzheimers disease and at higher doses for the treatment of depression')|
|('DB01133', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for treatment of pagets disease of bone osteitis deformans')|
|('DB01133', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'for treatment of pagets disease of bone osteitis deformans')|
|('DB06689', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'for the treatment of patients with esophageal varices that have recently bled to prevent rebleeding')|
|('DB06689', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'for the treatment of patients with esophageal varices that have recently bled to prevent rebleeding')|
|('DB01170', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'for the treatment of moderate and severe hypertension either alone or as an adjunct and for the treatment of renal hypertension')|
|('DB01170', 'MONDO:0001105', ['renal hypertension'], 'for the treatment of moderate and severe hypertension either alone or as an adjunct and for the treatment of renal hypertension')|
|('DB00606', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00606', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00606', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00362', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for use in the treatment of the following fungal infections candidemia and other forms of icandidai infections intraabdominal abscess and peritonitis aspergillus infections and esophageal candidiasis also considered an alternative treatment for oropharyngeal canaidiasis')|
|('DB00362', 'MONDO:0044070', ['candidemia []', 'candidemia'], 'for use in the treatment of the following fungal infections candidemia and other forms of icandidai infections intraabdominal abscess and peritonitis aspergillus infections and esophageal candidiasis also considered an alternative treatment for oropharyngeal canaidiasis')|
|('DB00362', 'MONDO:0005227', ['abscess'], 'for use in the treatment of the following fungal infections candidemia and other forms of icandidai infections intraabdominal abscess and peritonitis aspergillus infections and esophageal candidiasis also considered an alternative treatment for oropharyngeal canaidiasis')|
|('DB00362', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'for use in the treatment of the following fungal infections candidemia and other forms of icandidai infections intraabdominal abscess and peritonitis aspergillus infections and esophageal candidiasis also considered an alternative treatment for oropharyngeal canaidiasis')|
|('DB00362', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'for use in the treatment of the following fungal infections candidemia and other forms of icandidai infections intraabdominal abscess and peritonitis aspergillus infections and esophageal candidiasis also considered an alternative treatment for oropharyngeal canaidiasis')|
|('DB00605', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'for acute or longterm use in the relief of signs and symptoms of osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis and acute gouty arthritis')|
|('DB00605', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for acute or longterm use in the relief of signs and symptoms of osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis and acute gouty arthritis')|
|('DB00605', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for acute or longterm use in the relief of signs and symptoms of osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis and acute gouty arthritis')|
|('DB00605', 'MONDO:0003937', ['spondylitis'], 'for acute or longterm use in the relief of signs and symptoms of osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis and acute gouty arthritis')|
|('DB00605', 'MONDO:0004857', ['tendinitis'], 'for acute or longterm use in the relief of signs and symptoms of osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis and acute gouty arthritis')|
|('DB00139', 'MONDO:0004857', ['tendinitis'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB01397', 'MONDO:0004857', ['tendinitis'], 'magnesium salicylate is a common analgesic and nonsteroidal antiinflammatory drug nsaid used to treat mild to moderate muscular pain')|
|('DB00836', 'MONDO:0004857', ['tendinitis'], 'for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis also used for reducing the volume of discharge from ileostomies')|
|('DB00836', 'MONDO:0044751', ['diarrheal disease, chronic [MONDO:patterns/chronic]', 'chronic diarrhea []', 'chronic diarrheal disease'], 'for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis also used for reducing the volume of discharge from ileostomies')|
|('DB00836', 'MONDO:0005265', ['inflammatory bowel disease'], 'for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis also used for reducing the volume of discharge from ileostomies')|
|('DB00836', 'MONDO:0002269', ['cholera morbus', 'infectious colitis, enteritis and gastroenteritis', 'gastroenteritis'], 'for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis also used for reducing the volume of discharge from ileostomies')|
|('DB06695', 'MONDO:0002269', ['cholera morbus', 'infectious colitis, enteritis and gastroenteritis', 'gastroenteritis'], 'dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery based on renovate remodel and remobilize trialsa177463a6978a6977 in 2010 it was approved in the us and canada for prevention of stroke and systemic embolism in patients with atrial fibrillation approval based on the rely triallabela177463')|
|('DB06695', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery based on renovate remodel and remobilize trialsa177463a6978a6977 in 2010 it was approved in the us and canada for prevention of stroke and systemic embolism in patients with atrial fibrillation approval based on the rely triallabela177463')|
|('DB06695', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery based on renovate remodel and remobilize trialsa177463a6978a6977 in 2010 it was approved in the us and canada for prevention of stroke and systemic embolism in patients with atrial fibrillation approval based on the rely triallabela177463')|
|('DB00754', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the control of tonicclonic grand mal and complex partial psychomotor seizures')|
|('DB00973', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'ezetimibe is indicated to reduce elevated totalc ldlc apo b and nonhdlc in patients with primary hyperlipidemia alone or in combination with an hmgcoa reductase inhibitor statin reduce elevated totalc ldlc apo b and nonhdlc in patients with mixed hyperlipidemia in combination with fenofibrate reduce elevated totalc and ldlc in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin and to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia fda label')|
|('DB00973', 'MONDO:0018328', ['HoFH [Orphanet:391665]', 'homozygous familial hypercholesterolemia'], 'ezetimibe is indicated to reduce elevated totalc ldlc apo b and nonhdlc in patients with primary hyperlipidemia alone or in combination with an hmgcoa reductase inhibitor statin reduce elevated totalc ldlc apo b and nonhdlc in patients with mixed hyperlipidemia in combination with fenofibrate reduce elevated totalc and ldlc in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin and to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia fda label')|
|('DB00973', 'MONDO:0008863', ['phytosterolemia', 'sitosterolemia'], 'ezetimibe is indicated to reduce elevated totalc ldlc apo b and nonhdlc in patients with primary hyperlipidemia alone or in combination with an hmgcoa reductase inhibitor statin reduce elevated totalc ldlc apo b and nonhdlc in patients with mixed hyperlipidemia in combination with fenofibrate reduce elevated totalc and ldlc in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin and to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia fda label')|
|('DB00120', 'MONDO:0008863', ['phytosterolemia', 'sitosterolemia'], 'lphenylalanine may be helpful in some with depression it may also be useful in the treatment of vitiligo there is some evidence that lphenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs')|
|('DB00120', 'MONDO:0008661', ['vitiligo'], 'lphenylalanine may be helpful in some with depression it may also be useful in the treatment of vitiligo there is some evidence that lphenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs')|
|('DB00120', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'lphenylalanine may be helpful in some with depression it may also be useful in the treatment of vitiligo there is some evidence that lphenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs')|
|('DB00149', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress')|
|('DB00149', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress')|
|('DB00419', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of adult patients with mild to moderate type 1 nonneuropathic gauchers disease for whom enzyme replacement therapy is not a therapeutic option eg due to constraints such as allergy hypersensitivity or poor venous access now approved in some countries for the treatment of progressive neurological symptoms in adult and pediatric patients with niemannpick disease type c npc ')|
|('DB00419', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'for the treatment of adult patients with mild to moderate type 1 nonneuropathic gauchers disease for whom enzyme replacement therapy is not a therapeutic option eg due to constraints such as allergy hypersensitivity or poor venous access now approved in some countries for the treatment of progressive neurological symptoms in adult and pediatric patients with niemannpick disease type c npc ')|
|('DB01396', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'for the treatment and management of congestive cardiac insufficiency arrhythmias and heart failure')|
|('DB01396', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment and management of congestive cardiac insufficiency arrhythmias and heart failure')|
|('DB00571', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'propranolol is indicated to treat hypertensionl6907l6904 propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma and proliferating infantile hemangiomal6904l6907')|
|('DB00571', 'MONDO:0021661', ['coronary artery arteriosclerosis (disease) [MONDO:patterns/location]', 'arteriosclerosis disorder of coronary artery [MONDO:design_pattern]', 'coronary atherosclerosis [NCIT:C35505]', 'coronary artery arteriosclerosis disorder [MONDO:design_pattern,MONDO:patterns/location]', 'coronary atherosclerosis'], 'propranolol is indicated to treat hypertensionl6907l6904 propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma and proliferating infantile hemangiomal6904l6907')|
|('DB00571', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'propranolol is indicated to treat hypertensionl6907l6904 propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma and proliferating infantile hemangiomal6904l6907')|
|('DB00571', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'propranolol is indicated to treat hypertensionl6907l6904 propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma and proliferating infantile hemangiomal6904l6907')|
|('DB00952', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'for the acute treatment of migraine attacks with or without aura in adults')|
|('DB00916', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB00916', 'MONDO:0002154', ['trichomoniasis'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB00916', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB00916', 'MONDO:0021137', ['common []', 'not rare'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB00916', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB00916', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'metronidazole is indicated for the treatment of confirmed trichomoniasis caused by trichomonas vaginalis except for in the first trimester of pregnancy and the patients sexual partners bacterial vaginosisl7432 certain types of amebiasis and various anaerobic infectionsa181057  the above anaerobic infections may occur on the skin and skin structures the abdomen the heart reproductive organs central nervous system and the respiratory system some may also be present in the bloodstream in cases of septicemia common infections treated by metronidazole are bacteroides species infections clostridium infections and fusobacterium infections as well as peptococcus and peptostreptococcus infectionsl3754 it is also used offlabel in the treatment of crohns disease and rosacea as a prophylactic agent after surgerya181039 and in the treatment of helicobacter pylori infectiona181045 it has also been studied in the prevention of preterm births and to treat periodontal diseasea1391a181078')|
|('DB01601', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated in combination with other antiretroviral agents for the treatment of hivinfection')|
|('DB01627', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lincomycin is an antibiotic used in the treatment of staphylococcal streptococcal and ibacteroides fragilisi infections')|
|('DB00692', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as an aid for the diagnosis of pheochromocytoma and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia stress or operative manipulation of the tumor phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking mao inhibitors or by clonidine withdrawal syndrome other indications include the prevention of dermal necrosis and sloughing following iv administration or extravasation of norepinephrine decrease in impedance to left ventricular ejection and the infarct size in patients with mi associated with left ventricular failure treatment of erectile dysfunction through selfinjection of small doses combined with papaverine hydrochloride into the corpus cavernosum and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen benzodiazepinesand nitroglycerin ')|
|('DB00692', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'used as an aid for the diagnosis of pheochromocytoma and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia stress or operative manipulation of the tumor phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking mao inhibitors or by clonidine withdrawal syndrome other indications include the prevention of dermal necrosis and sloughing following iv administration or extravasation of norepinephrine decrease in impedance to left ventricular ejection and the infarct size in patients with mi associated with left ventricular failure treatment of erectile dysfunction through selfinjection of small doses combined with papaverine hydrochloride into the corpus cavernosum and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen benzodiazepinesand nitroglycerin ')|
|('DB00911', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'for the treatment of trichomoniasis caused by it vaginalisi in both female and male patients also for the treatment of giardiasis caused by ig duodenalisi in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by ie histolyticai in both adults and pediatric patients older than three years of age')|
|('DB00911', 'MONDO:0002154', ['trichomoniasis'], 'for the treatment of trichomoniasis caused by it vaginalisi in both female and male patients also for the treatment of giardiasis caused by ig duodenalisi in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by ie histolyticai in both adults and pediatric patients older than three years of age')|
|('DB00911', 'MONDO:0001103', ['beaver feaver', 'Infection by Giardia lamblia', 'giardiasis'], 'for the treatment of trichomoniasis caused by it vaginalisi in both female and male patients also for the treatment of giardiasis caused by ig duodenalisi in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by ie histolyticai in both adults and pediatric patients older than three years of age')|
|('DB00911', 'MONDO:0005227', ['abscess'], 'for the treatment of trichomoniasis caused by it vaginalisi in both female and male patients also for the treatment of giardiasis caused by ig duodenalisi in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by ie histolyticai in both adults and pediatric patients older than three years of age')|
|('DB00679', 'MONDO:0005227', ['abscess'], 'for the treatment of schizophrenia and generalized anxiety disorder')|
|('DB00679', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of schizophrenia and generalized anxiety disorder')|
|('DB00679', 'MONDO:0001942', ['generalized anxiety disorder'], 'for the treatment of schizophrenia and generalized anxiety disorder')|
|('DB00712', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'flurbiprofen tablets are indicated for the acute or longterm symptomatic treatment of rheumatoid arthritis osteorarthritis and anklosing spondylitis it may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation eg bursitis tendonitis soft tissue trauma topical ophthalmic formulations may be used preoperatively to prevent intraoperative miosis ')|
|('DB00712', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'flurbiprofen tablets are indicated for the acute or longterm symptomatic treatment of rheumatoid arthritis osteorarthritis and anklosing spondylitis it may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation eg bursitis tendonitis soft tissue trauma topical ophthalmic formulations may be used preoperatively to prevent intraoperative miosis ')|
|('DB00712', 'MONDO:0003937', ['spondylitis'], 'flurbiprofen tablets are indicated for the acute or longterm symptomatic treatment of rheumatoid arthritis osteorarthritis and anklosing spondylitis it may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation eg bursitis tendonitis soft tissue trauma topical ophthalmic formulations may be used preoperatively to prevent intraoperative miosis ')|
|('DB00712', 'MONDO:0002471', ['bursitis'], 'flurbiprofen tablets are indicated for the acute or longterm symptomatic treatment of rheumatoid arthritis osteorarthritis and anklosing spondylitis it may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation eg bursitis tendonitis soft tissue trauma topical ophthalmic formulations may be used preoperatively to prevent intraoperative miosis ')|
|('DB00262', 'MONDO:0002471', ['bursitis'], 'for the treatment of brain tumors multiple myeloma hodgkins disease and nonhodgkins lymphomas')|
|('DB01349', 'MONDO:0002471', ['bursitis'], 'tasosartan is infrequently in the treatment of hypertension and heart failure')|
|('DB01349', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'tasosartan is infrequently in the treatment of hypertension and heart failure')|
|('DB00948', 'MONDO:0002471', ['bursitis'], 'used to treat serious gramndashnegative infections of the lungs urinary tract and skin')|
|('DB00902', 'MONDO:0002471', ['bursitis'], 'used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders')|
|('DB00902', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders')|
|('DB00413', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'this drug is indicated for the symptomatic treatment of parkinson’s disease fda label  this drug can be administered as monotherapy or in conjunction with levodopa it is also indicated for symptomatic treatment of moderate to severe primary restless legs syndrome rls fda label  ')|
|('DB01039', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'fenofibrate is indicated as adjunctive therapy to diet to reduce elevated ldlc totalc triglycerides and apo b and to increase hdlc adults with primary hypercholesterolemia or mixed dyslipidemial8588l8591 fenofibrate is also indicated to treat adults with severe hypertriglyceridemial8588l8591')|
|('DB06288', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders mania in bipolar disorder and depression')|
|('DB00521', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'for the treatment of intraocular hypertension and chronic openangle glaucoma')|
|('DB00521', 'MONDO:0005041', ['glaucoma'], 'for the treatment of intraocular hypertension and chronic openangle glaucoma')|
|('DB00541', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'treatment of acute lymphocytic leukemia all hodgkin lymphoma nonhodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine is indicated for the treatment of relapsed philadelphia chromosomenegative ph acute lymphoblastic leukemia all ')|
|('DB00541', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'treatment of acute lymphocytic leukemia all hodgkin lymphoma nonhodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine is indicated for the treatment of relapsed philadelphia chromosomenegative ph acute lymphoblastic leukemia all ')|
|('DB00541', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'treatment of acute lymphocytic leukemia all hodgkin lymphoma nonhodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine is indicated for the treatment of relapsed philadelphia chromosomenegative ph acute lymphoblastic leukemia all ')|
|('DB00541', 'MONDO:0005212', ['rhabdomyosarcoma'], 'treatment of acute lymphocytic leukemia all hodgkin lymphoma nonhodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine is indicated for the treatment of relapsed philadelphia chromosomenegative ph acute lymphoblastic leukemia all ')|
|('DB00541', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'treatment of acute lymphocytic leukemia all hodgkin lymphoma nonhodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal vincristine is indicated for the treatment of relapsed philadelphia chromosomenegative ph acute lymphoblastic leukemia all ')|
|('DB00963', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'for the treatment of postoperative inflammation in patients who have undergone cataract extraction')|
|('DB00963', 'MONDO:0005129', ['cataract'], 'for the treatment of postoperative inflammation in patients who have undergone cataract extraction')|
|('DB00696', 'MONDO:0005129', ['cataract'], 'for use as therapy to abort or prevent vascular headache eg migraine migraine variants or so called histaminic cephalalgia')|
|('DB00716', 'MONDO:0005129', ['cataract'], 'for the treatment of mild to moderate asthma')|
|('DB01121', 'MONDO:0005129', ['cataract'], 'used to control certain seizures in the treatment of epilepsy')|
|('DB01121', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used to control certain seizures in the treatment of epilepsy')|
|('DB01137', 'MONDO:0005129', ['cataract'], 'for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms icorynebacteriumi species istaphylococus aureusi istaphylococcus epidermidisi istreptococcus pneumoniaei istreptococcusi groups cfg viridans group streptococci iacinetobacter lwoffiii ihaemophilus influenzaei iserratia marcescensi')|
|('DB01137', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms icorynebacteriumi species istaphylococus aureusi istaphylococcus epidermidisi istreptococcus pneumoniaei istreptococcusi groups cfg viridans group streptococci iacinetobacter lwoffiii ihaemophilus influenzaei iserratia marcescensi')|
|('DB00966', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'used alone or in combination with other classes of antihypertensives for the treatment of hypertension also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus as well as the treatment of congestive heart failure only in patients who cannot tolerate ace inhibitors')|
|('DB00966', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'used alone or in combination with other classes of antihypertensives for the treatment of hypertension also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus as well as the treatment of congestive heart failure only in patients who cannot tolerate ace inhibitors')|
|('DB00966', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used alone or in combination with other classes of antihypertensives for the treatment of hypertension also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus as well as the treatment of congestive heart failure only in patients who cannot tolerate ace inhibitors')|
|('DB00966', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'used alone or in combination with other classes of antihypertensives for the treatment of hypertension also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus as well as the treatment of congestive heart failure only in patients who cannot tolerate ace inhibitors')|
|('DB06781', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of inflammation and pain associated with ocular surgery')|
|('DB01180', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of hypertension')|
|('DB09014', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'captodiame is indicated for the treatment of anxiety ')|
|('DB09014', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'captodiame is indicated for the treatment of anxiety ')|
|('DB00658', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the control of serum phosphorus in patients with chronic kidney disease ckd on hemodialysis')|
|('DB00658', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the control of serum phosphorus in patients with chronic kidney disease ckd on hemodialysis')|
|('DB00604', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease')|
|('DB00604', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease')|
|('DB00259', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of vulvovaginitis caused by icandida albicansi')|
|('DB00259', 'MONDO:0007019', ['Vulvo-vaginitis', 'vulvovaginitis'], 'for the treatment of vulvovaginitis caused by icandida albicansi')|
|('DB00539', 'MONDO:0007019', ['Vulvo-vaginitis', 'vulvovaginitis'], 'for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptorpositive or receptorunknown tumors toremifene is currently under investigation as a preventative agent for prostate cancer in men with highgrade prostatic intraepithelial neoplasia and no evidence of prostate cancer')|
|('DB00539', 'MONDO:0004992', ['cancer'], 'for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptorpositive or receptorunknown tumors toremifene is currently under investigation as a preventative agent for prostate cancer in men with highgrade prostatic intraepithelial neoplasia and no evidence of prostate cancer')|
|('DB00539', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptorpositive or receptorunknown tumors toremifene is currently under investigation as a preventative agent for prostate cancer in men with highgrade prostatic intraepithelial neoplasia and no evidence of prostate cancer')|
|('DB00539', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptorpositive or receptorunknown tumors toremifene is currently under investigation as a preventative agent for prostate cancer in men with highgrade prostatic intraepithelial neoplasia and no evidence of prostate cancer')|
|('DB00539', 'MONDO:0005193', ['pin - prostatic intraepithelial neoplasia [NCIT:C4064]', 'prostate intraepithelial neopl. [NCIT:C4064]', 'prostate intraepithelial neoplasia (pin) [NCIT:C4064]', 'prostatic intraepithelial neoplasia [NCIT:C4064]', 'pin [NCIT:C4064]', 'prostate intraepithelial neoplasia'], 'for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptorpositive or receptorunknown tumors toremifene is currently under investigation as a preventative agent for prostate cancer in men with highgrade prostatic intraepithelial neoplasia and no evidence of prostate cancer')|
|('DB00984', 'MONDO:0005193', ['pin - prostatic intraepithelial neoplasia [NCIT:C4064]', 'prostate intraepithelial neopl. [NCIT:C4064]', 'prostate intraepithelial neoplasia (pin) [NCIT:C4064]', 'prostatic intraepithelial neoplasia [NCIT:C4064]', 'pin [NCIT:C4064]', 'prostate intraepithelial neoplasia'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB00984', 'MONDO:0004989', ['carcinoma of breast', 'Mammary carcinoma', 'breast carcinoma'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB00984', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB00984', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB00598', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'labetalol injections are indicated to control blood pressure in severe hypertensionl7727 labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertensionl7730')|
|('DB01422', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'nitroxoline is an antibiotic agent')|
|('DB00331', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'metformin tablet metformin is indicated as an adjunct to diet and exercise to increase glycemic control in adults and pediatric patients 10 years of age and older diagnosed with type 2 diabetes mellitus fda labelmetformin extendedrelease tablet xrthe extendedrelease form is indicated as an adjunct to diet and exercise to improve glycemic control in only adults with type 2 diabetes mellitus safety in children has not been determined to this date fda label')|
|('DB00331', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'metformin tablet metformin is indicated as an adjunct to diet and exercise to increase glycemic control in adults and pediatric patients 10 years of age and older diagnosed with type 2 diabetes mellitus fda labelmetformin extendedrelease tablet xrthe extendedrelease form is indicated as an adjunct to diet and exercise to improve glycemic control in only adults with type 2 diabetes mellitus safety in children has not been determined to this date fda label')|
|('DB00331', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'metformin tablet metformin is indicated as an adjunct to diet and exercise to increase glycemic control in adults and pediatric patients 10 years of age and older diagnosed with type 2 diabetes mellitus fda labelmetformin extendedrelease tablet xrthe extendedrelease form is indicated as an adjunct to diet and exercise to improve glycemic control in only adults with type 2 diabetes mellitus safety in children has not been determined to this date fda label')|
|('DB01059', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of urinary tract infection')|
|('DB01059', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of urinary tract infection')|
|('DB06274', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis also investigated for use in the treatment of pain acute or chronic')|
|('DB00188', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies')|
|('DB00961', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for production of local or regional analgesia and anesthesia by local infiltration peripheral nerve block techniques and central neural techniques including epidural and caudal blocks')|
|('DB00818', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for induction andor maintenance of anaesthesia and for management of refractory status epilepticus ')|
|('DB00980', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of insomnia characterized by difficulty with sleep onset')|
|('DB00980', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of insomnia characterized by difficulty with sleep onset')|
|('DB00194', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for treatment of chickenpox  varicella herpes zoster and herpes simplex')|
|('DB00194', 'MONDO:0005700', ['varicella', 'chickenpox'], 'for treatment of chickenpox  varicella herpes zoster and herpes simplex')|
|('DB00194', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'for treatment of chickenpox  varicella herpes zoster and herpes simplex')|
|('DB01204', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'for the treatment of secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis')|
|('DB01204', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for the treatment of secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis')|
|('DB00878', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'for reduction of pocket depth in patients with adult periodontitis used as an adjunct to scaling and root planing procedures also for prevention of dental caries oropharyngeal decontamination in critically ill patients hand hygiene in healthcare personnel general skin cleanser and catheter site preparation and care')|
|('DB00878', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'for reduction of pocket depth in patients with adult periodontitis used as an adjunct to scaling and root planing procedures also for prevention of dental caries oropharyngeal decontamination in critically ill patients hand hygiene in healthcare personnel general skin cleanser and catheter site preparation and care')|
|('DB04572', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'thiotepa is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation hpct in haematological diseases in adult and paediatric patients also when high dose chemotherapy with hpct support it is appropriate for the treatment of solid tumours in adult and paediatric patients')|
|('DB00363', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'for use in patients with treatmentresistant schizophrenia')|
|('DB00363', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for use in patients with treatmentresistant schizophrenia')|
|('DB00615', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'for the prevention of disseminated imycobacterium aviumi complex mac disease in patients with advanced hiv infection')|
|('DB00615', 'MONDO:0022202', ['disseminated'], 'for the prevention of disseminated imycobacterium aviumi complex mac disease in patients with advanced hiv infection')|
|('DB01338', 'MONDO:0022202', ['disseminated'], 'used as a muscle relaxant during anesthesia and surgical procedures')|
|('DB00035', 'MONDO:0022202', ['disseminated'], ' indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void intranasal  indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region intranasalparenteral indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 or mild to moderate classic von willebrands disease type i with factor viii levels greater than 5 during surgical procedures and postoperatively to maintain hemostasis parenteral')|
|('DB00035', 'MONDO:0004782', ['diabetes insipidus'], ' indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void intranasal  indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region intranasalparenteral indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 or mild to moderate classic von willebrands disease type i with factor viii levels greater than 5 during surgical procedures and postoperatively to maintain hemostasis parenteral')|
|('DB00035', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], ' indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void intranasal  indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region intranasalparenteral indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 or mild to moderate classic von willebrands disease type i with factor viii levels greater than 5 during surgical procedures and postoperatively to maintain hemostasis parenteral')|
|('DB00035', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], ' indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void intranasal  indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region intranasalparenteral indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5 or mild to moderate classic von willebrands disease type i with factor viii levels greater than 5 during surgical procedures and postoperatively to maintain hemostasis parenteral')|
|('DB00724', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults also indicated for the treatment of external genital and perianal wartscondyloma acuminata in individuals 12 years old and above')|
|('DB00724', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults also indicated for the treatment of external genital and perianal wartscondyloma acuminata in individuals 12 years old and above')|
|('DB01154', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'used for the production of complete anaesthesia of short duration for the induction of general anaesthesia and for inducing a hypnotic state')|
|('DB00765', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for use in the treatment of patients with pheochromocytoma for preoperative preparation of patients for surgery management of patients when surgery is contraindicated and chronic treatment of patients with malignant pheochromocytoma')|
|('DB02638', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'commonly used to stop bleeding of varices in the food pipe oesophagus')|
|('DB02638', 'MONDO:0008638', ['varices', 'Varix', 'Venous ectasia', 'Venous varices', 'varicose disease'], 'commonly used to stop bleeding of varices in the food pipe oesophagus')|
|('DB00167', 'MONDO:0008638', ['varices', 'Varix', 'Venous ectasia', 'Venous varices', 'varicose disease'], 'the branchedchain amino acids may have antihepatic encephalopathy activity in some they may also have anticatabolic and antitardive dyskinesia activity')|
|('DB00167', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'the branchedchain amino acids may have antihepatic encephalopathy activity in some they may also have anticatabolic and antitardive dyskinesia activity')|
|('DB01033', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for remission induction and maintenance therapy of acute lymphatic leukemia')|
|('DB01033', 'MONDO:0005059', ['leukemia'], 'for remission induction and maintenance therapy of acute lymphatic leukemia')|
|('DB00517', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for use in conjunction with antacids or histamine hsub2subreceptor antagonists in the treatment of peptic ulcer to reduce further gastric acid secretion and delay gastric emptying')|
|('DB00172', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'lproline is extremely important for the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles')|
|('DB00821', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for use as a pain reliever in the treatment of joint pain and postsurgical pain')|
|('DB00308', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm')|
|('DB00308', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm')|
|('DB00308', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm')|
|('DB00200', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'for treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepaticbiliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets or other restrictive diets also for the treatment of known or suspected cyanide poisoning')|
|('DB00200', 'MONDO:0008228', ['Addisons anaemia', 'ANEMIA PERNICIOUS', 'Biermers anaemia', 'Biermers anemia', 'pernicious anaemia', 'pernicious anemia'], 'for treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepaticbiliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets or other restrictive diets also for the treatment of known or suspected cyanide poisoning')|
|('DB00200', 'MONDO:0020696', ['vitamin b12 deficiency [NCIT:C131684]', 'hypocobalaminemia [NCIT:C131684]', 'cobalamin deficiency []', 'vitamin b12 deficiency'], 'for treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepaticbiliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets or other restrictive diets also for the treatment of known or suspected cyanide poisoning')|
|('DB00200', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepaticbiliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets or other restrictive diets also for the treatment of known or suspected cyanide poisoning')|
|('DB00200', 'MONDO:0018754', ['cyanide poisoning'], 'for treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepaticbiliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets or other restrictive diets also for the treatment of known or suspected cyanide poisoning')|
|('DB00646', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'nystatin is available in oral formulations for the treatment andor prevention of oral candidiasis aka thrush intestinal candidiasis and anal candidiasisl10686l10728 it is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infectionsl10728 a combination product containing nystatin alongside neomycin gramicidin d and triamcinolone viaderm kc® is indicated in the treatment of corticosteroidresponsive dermatoses caused by bacterial or candidal infections and for pruritus anivulvael10731 it is also available in combination with metronidazole for the treatment of mixed infections due to trichomonas vaginalis and candida albicansl10776nystatin is also sometimes used offlabel for the prevention of invasive candidiasis in low birth weight neonatesa188565 though it is generally reserved as a secondline option after fluconazole')|
|('DB00646', 'MONDO:0005886', ['Candidiasis of mouth', 'Oral moniliasis', 'thrush', 'Thrush, oral', 'oral candidiasis'], 'nystatin is available in oral formulations for the treatment andor prevention of oral candidiasis aka thrush intestinal candidiasis and anal candidiasisl10686l10728 it is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infectionsl10728 a combination product containing nystatin alongside neomycin gramicidin d and triamcinolone viaderm kc® is indicated in the treatment of corticosteroidresponsive dermatoses caused by bacterial or candidal infections and for pruritus anivulvael10731 it is also available in combination with metronidazole for the treatment of mixed infections due to trichomonas vaginalis and candida albicansl10776nystatin is also sometimes used offlabel for the prevention of invasive candidiasis in low birth weight neonatesa188565 though it is generally reserved as a secondline option after fluconazole')|
|('DB00646', 'MONDO:0002026', ['Disseminated candidiasis', 'systemic candidiasis', 'candidiasis'], 'nystatin is available in oral formulations for the treatment andor prevention of oral candidiasis aka thrush intestinal candidiasis and anal candidiasisl10686l10728 it is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infectionsl10728 a combination product containing nystatin alongside neomycin gramicidin d and triamcinolone viaderm kc® is indicated in the treatment of corticosteroidresponsive dermatoses caused by bacterial or candidal infections and for pruritus anivulvael10731 it is also available in combination with metronidazole for the treatment of mixed infections due to trichomonas vaginalis and candida albicansl10776nystatin is also sometimes used offlabel for the prevention of invasive candidiasis in low birth weight neonatesa188565 though it is generally reserved as a secondline option after fluconazole')|
|('DB00646', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'nystatin is available in oral formulations for the treatment andor prevention of oral candidiasis aka thrush intestinal candidiasis and anal candidiasisl10686l10728 it is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infectionsl10728 a combination product containing nystatin alongside neomycin gramicidin d and triamcinolone viaderm kc® is indicated in the treatment of corticosteroidresponsive dermatoses caused by bacterial or candidal infections and for pruritus anivulvael10731 it is also available in combination with metronidazole for the treatment of mixed infections due to trichomonas vaginalis and candida albicansl10776nystatin is also sometimes used offlabel for the prevention of invasive candidiasis in low birth weight neonatesa188565 though it is generally reserved as a secondline option after fluconazole')|
|('DB00646', 'MONDO:0042233', ['invasive candidiasis []', 'disseminated candidiasis []', 'disseminated candidiasis'], 'nystatin is available in oral formulations for the treatment andor prevention of oral candidiasis aka thrush intestinal candidiasis and anal candidiasisl10686l10728 it is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infectionsl10728 a combination product containing nystatin alongside neomycin gramicidin d and triamcinolone viaderm kc® is indicated in the treatment of corticosteroidresponsive dermatoses caused by bacterial or candidal infections and for pruritus anivulvael10731 it is also available in combination with metronidazole for the treatment of mixed infections due to trichomonas vaginalis and candida albicansl10776nystatin is also sometimes used offlabel for the prevention of invasive candidiasis in low birth weight neonatesa188565 though it is generally reserved as a secondline option after fluconazole')|
|('DB00529', 'MONDO:0042233', ['invasive candidiasis []', 'disseminated candidiasis []', 'disseminated candidiasis'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids and for treatment of acyclovirresistant mucocutaneous hsv infections in immunocompromised patients')|
|('DB00529', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids and for treatment of acyclovirresistant mucocutaneous hsv infections in immunocompromised patients')|
|('DB00529', 'MONDO:0017769', ['acquired immunodeficiency'], 'for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome aids and for treatment of acyclovirresistant mucocutaneous hsv infections in immunocompromised patients')|
|('DB00934', 'MONDO:0017769', ['acquired immunodeficiency'], 'for treatment of depression including the depressed phase of bipolar depression psychotic depression and involutional melancholia and may also be helpful in treating certain patients suffering severe depressive neurosis')|
|('DB00934', 'MONDO:0024613', ['bipolar affective disorder, current episode depression []', 'bipolar depression [NCIT:C34424]', 'bipolar depression'], 'for treatment of depression including the depressed phase of bipolar depression psychotic depression and involutional melancholia and may also be helpful in treating certain patients suffering severe depressive neurosis')|
|('DB00934', 'MONDO:0005379', ['depressive neurosis', 'neurosis', 'neurotic depression', 'Neurotic depression reactive type', 'Neurotic depressive state', 'Psychoneurosis', 'reactive depression', 'neurotic disorder'], 'for treatment of depression including the depressed phase of bipolar depression psychotic depression and involutional melancholia and may also be helpful in treating certain patients suffering severe depressive neurosis')|
|('DB00181', 'MONDO:0024613', ['bipolar affective disorder, current episode depression []', 'bipolar depression [NCIT:C34424]', 'bipolar depression'], 'baclofen is administered for the relief of signs and symptoms of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and associated  pain and clonus in addition to muscular rigidity fda labelpatients receiving this drug should have reversible spasticity for baclofen to promote the restoration of residual function this drug is not indicated in the treatment of skeletal muscle spasm caused by rheumatic disorders the efficacy of baclofen in stroke cerebral palsy and parkinsons disease has not been determined and therefore baclofen is not recommended for these conditions fda label')|
|('DB00181', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'baclofen is administered for the relief of signs and symptoms of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and associated  pain and clonus in addition to muscular rigidity fda labelpatients receiving this drug should have reversible spasticity for baclofen to promote the restoration of residual function this drug is not indicated in the treatment of skeletal muscle spasm caused by rheumatic disorders the efficacy of baclofen in stroke cerebral palsy and parkinsons disease has not been determined and therefore baclofen is not recommended for these conditions fda label')|
|('DB00181', 'MONDO:0006497', ['infantile cerebral palsy', 'cerebral palsy'], 'baclofen is administered for the relief of signs and symptoms of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and associated  pain and clonus in addition to muscular rigidity fda labelpatients receiving this drug should have reversible spasticity for baclofen to promote the restoration of residual function this drug is not indicated in the treatment of skeletal muscle spasm caused by rheumatic disorders the efficacy of baclofen in stroke cerebral palsy and parkinsons disease has not been determined and therefore baclofen is not recommended for these conditions fda label')|
|('DB00798', 'MONDO:0006497', ['infantile cerebral palsy', 'cerebral palsy'], 'for treatment of serious infections caused by susceptible strains of the following microorganisms ip aeruginosai iproteusi species indolepositive and indolenegative ie colii iklebsiellaenterobactorserratiai species icitrobacteri species and istaphylococcusi species coagulasepositive and coagulasenegative')|
|('DB00177', 'MONDO:0006497', ['infantile cerebral palsy', 'cerebral palsy'], 'valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions it is also indicated for the treatment of heart failure nyha class iiiv and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensinconverting enzyme inhibitor acei is not appropriatef4703f4706')|
|('DB00177', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions it is also indicated for the treatment of heart failure nyha class iiiv and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensinconverting enzyme inhibitor acei is not appropriatef4703f4706')|
|('DB00177', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions it is also indicated for the treatment of heart failure nyha class iiiv and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensinconverting enzyme inhibitor acei is not appropriatef4703f4706')|
|('DB01233', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis in addition to the treatment of gastroesophageal reflux disease gerd in patients who have failed to respond to traditional therapyl8414 in the intravenous injection form it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine  in some cases the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract and metoclopramide is used to facilitate emptying in these cases allowing for adequate diagnostic visualizationl8417some offlabel uses of metoclopramide include the management of radiationinduced nausea and vomiting gastric bezoars intractable hiccups and migraine paina184961a184964a184967a40105')|
|('DB01233', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis in addition to the treatment of gastroesophageal reflux disease gerd in patients who have failed to respond to traditional therapyl8414 in the intravenous injection form it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine  in some cases the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract and metoclopramide is used to facilitate emptying in these cases allowing for adequate diagnostic visualizationl8417some offlabel uses of metoclopramide include the management of radiationinduced nausea and vomiting gastric bezoars intractable hiccups and migraine paina184961a184964a184967a40105')|
|('DB01235', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in parkinsons patients who are already being treated with carbidopa and levodopafda label levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of parkinsons disease postencephalitic parkinsonism and symptomatic parkinsonism following carbon monoxide intoxication or manganese intoxicationf4579')|
|('DB01235', 'MONDO:0006966', ['disorder presenting primarily with parkinsonism', 'secondary Parkinsonism', 'secondary parkinsonism', 'Symptomatic parkinsonism', 'secondary parkinson disease'], 'levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in parkinsons patients who are already being treated with carbidopa and levodopafda label levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of parkinsons disease postencephalitic parkinsonism and symptomatic parkinsonism following carbon monoxide intoxication or manganese intoxicationf4579')|
|('DB00378', 'MONDO:0006966', ['disorder presenting primarily with parkinsonism', 'secondary Parkinsonism', 'secondary parkinsonism', 'Symptomatic parkinsonism', 'secondary parkinson disease'], 'used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency also used to prevent natural abortion in patients who have a history of habitual abortions')|
|('DB08884', 'MONDO:0006966', ['disorder presenting primarily with parkinsonism', 'secondary Parkinsonism', 'secondary parkinsonism', 'Symptomatic parkinsonism', 'secondary parkinson disease'], 'gadoxetate is used as a contrast medium for magnetic resonance imaging mri to detect and characterize lesions in the liver ')|
|('DB00801', 'MONDO:0006966', ['disorder presenting primarily with parkinsonism', 'secondary Parkinsonism', 'secondary parkinsonism', 'Symptomatic parkinsonism', 'secondary parkinson disease'], 'used to relieve anxiety nervousness and tension associated with anxiety disorders')|
|('DB00801', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used to relieve anxiety nervousness and tension associated with anxiety disorders')|
|('DB00877', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the prophylaxis of organ rejection in patients receiving renal transplants')|
|('DB00945', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0021167', ['Inflammatory disorder of muscle', 'myositis'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0002400', ['synovitis'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0002471', ['bursitis'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0004781', ['acute myocardial infarction'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00945', 'MONDO:0018922', ['CAD [Orphanet:56425]', 'CAS [Orphanet:56425]', 'cold agglutinin syndrome [Orphanet:56425]', 'chronic cold agglutinin disease [Orphanet:56425]', 'cold agglutinin disease'], 'pain fever and inflammationacetylsalicylic acid asa in the regular tablet form immediaterelease is indicated to relieve pain fever and inflammation associated with many conditions including the flu the common cold neck and back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns and various injuries it is also used for symptomatic pain relief after surgical and dental procedures fda label the extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia sensitivity to light and phonophobia sensitivity to soundfda labelother indicationsasa is also indicated for various other purposes due to its ability to inhibit platelet aggregation these include reducing the risk of cardiovascular death in suspected cases of myocardial infarction mi fda label reducing the risk of a first nonfatal myocardial infarction in patients and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction fda labelfor reducing the risk of transient ischemic attacks tia and to prevent atherothrombotic cerebral infarction in conjunction with other treatments fda labelfor the prevention of thromboembolism after hip replacement surgery fda label for decreasing platelet to platelet adhesion following carotid endarterectomy aiding in the prevention of transient ischemic attacks tia fda labelused for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site fda label important note regarding use of the extendedrelease formulation f4405in the setting of acute myocardial infarction or before percutaneous interventions the extendedrelease form of acetylsalicylic acid should not be used use immediaterelease formulations in scenarios requiring rapid onset of action label f4405 the extendedrelease form is taken to decrease the incidence of mortality and myocardial infarction mi for individuals diagnosed with chronic coronary artery disease cad including patients with previous myocardial infarction mi or unstable angina or with chronic stable angina additionally the extendedrelease form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia f4405 ')|
|('DB00816', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'for the treatment of bronchospasm chronic bronchitis asthma and emphysema')|
|('DB00816', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the treatment of bronchospasm chronic bronchitis asthma and emphysema')|
|('DB00816', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of bronchospasm chronic bronchitis asthma and emphysema')|
|('DB00160', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'used for protein synthesis')|
|('DB00747', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of excessive salivation colicky abdominal pain bradycardia sialorrhoea diverticulitis irritable bowel syndrome and motion sickness')|
|('DB00747', 'MONDO:0004235', ['diverticulitis'], 'for the treatment of excessive salivation colicky abdominal pain bradycardia sialorrhoea diverticulitis irritable bowel syndrome and motion sickness')|
|('DB00747', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for the treatment of excessive salivation colicky abdominal pain bradycardia sialorrhoea diverticulitis irritable bowel syndrome and motion sickness')|
|('DB00357', 'MONDO:0004235', ['diverticulitis'], 'for the suppression of adrenal function in selected patients with cushings syndrome malignant neoplasm of the female breast and carcinoma in situ of the breast')|
|('DB00357', 'MONDO:0003009', ['Cushing syndrome', 'Cushings syndrome', 'hyperaldosteronism', 'hyperaldosteronism'], 'for the suppression of adrenal function in selected patients with cushings syndrome malignant neoplasm of the female breast and carcinoma in situ of the breast')|
|('DB00357', 'MONDO:0021079', ['neoplasm (disease) of childhood [MONDO:patterns/childhood]', 'pediatric neoplasm [NCIT:C6283]', 'pediatric neoplasm (disease) [MONDO:patterns/childhood]', 'neoplasm [NCIT:C6283]', 'pediatric tumor [NCIT:C6283]', 'childhood neoplasm (disease) []', 'childhood neoplasm [NCIT:C6283]', 'childhood tumor [NCIT:C6283]', 'childhood neoplasm'], 'for the suppression of adrenal function in selected patients with cushings syndrome malignant neoplasm of the female breast and carcinoma in situ of the breast')|
|('DB00357', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the suppression of adrenal function in selected patients with cushings syndrome malignant neoplasm of the female breast and carcinoma in situ of the breast')|
|('DB01610', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections')|
|('DB00869', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma also used prophylatically for the inhibition of perioperative iop increase before neodynium yttrium aluminum garnet laser posterior capsulotomy')|
|('DB00869', 'MONDO:0006875', ['ocular hypertension'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma also used prophylatically for the inhibition of perioperative iop increase before neodynium yttrium aluminum garnet laser posterior capsulotomy')|
|('DB00869', 'MONDO:0005041', ['glaucoma'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma also used prophylatically for the inhibition of perioperative iop increase before neodynium yttrium aluminum garnet laser posterior capsulotomy')|
|('DB00860', 'MONDO:0005041', ['glaucoma'], 'prednisolone is indicated to treat endocrine rheumatic and hematologic disorders collagen dermatologic ophthalmic respiratory and gastrointestinal diseases allergic and edematous states and other conditions like tuberculous meningitisl9542')|
|('DB00309', 'MONDO:0005041', ['glaucoma'], 'for the treatment of acute leukaemia malignant lymphoma hodgkins disease acute erythraemia and acute panmyelosis')|
|('DB00309', 'MONDO:0004638', ['diffuse lymphoma [DOID:8675,MTHICD9_2006:202.8]', 'malignant lymphoma [DOID:8675]', 'lymphosarcoma [NCIT:C26919]', 'lymphosarcoma'], 'for the treatment of acute leukaemia malignant lymphoma hodgkins disease acute erythraemia and acute panmyelosis')|
|('DB00309', 'MONDO:0019455', ['APMF [NCIT:C4344,ONCOTREE:APMF]', 'acute myelodysplasia with myelofibrosis [Orphanet:86843]', 'acute myelofibrosis [Orphanet:86843]', 'acute (malignant) myelosclerosis [NCIT:C4344]', 'acute panmyelosis [NCIT:C4344]', 'acute myelosclerosis [Orphanet:86843]', 'acute (malignant) myelofibrosis [NCIT:C4344]', 'acute panmyelosis with myelofibrosis'], 'for the treatment of acute leukaemia malignant lymphoma hodgkins disease acute erythraemia and acute panmyelosis')|
|('DB01086', 'MONDO:0004638', ['diffuse lymphoma [DOID:8675,MTHICD9_2006:202.8]', 'malignant lymphoma [DOID:8675]', 'lymphosarcoma [NCIT:C26919]', 'lymphosarcoma'], 'for general use as a lubricant and topical anesthetic on esophagus larynx mouth nasal cavity rectum respiratory tract or trachea urinary tract vagina it is also used to suppress gag reflex')|
|('DB01583', 'MONDO:0004638', ['diffuse lymphoma [DOID:8675,MTHICD9_2006:202.8]', 'malignant lymphoma [DOID:8675]', 'lymphosarcoma [NCIT:C26919]', 'lymphosarcoma'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0010140', ['isolated TRH deficiency [Orphanet:238670]', 'isolated TSH-releasing factor deficiency [Orphanet:238670]', 'isolated TRF deficiency [Orphanet:238670]', 'isolated thyrotropin-releasing factor deficiency [Orphanet:238670]', 'isolated protirelin deficiency [Orphanet:238670]', 'isolated thyroliberin deficiency [Orphanet:238670]', 'tertiary hypothyroidism [NCIT:C121741]', 'isolated prothyroliberin deficiency [Orphanet:238670]', 'isolated thyrotropin-releasing hormone deficiency'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0005397', ['goitre', 'goiter'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0007699', ['Chronic Lymphocytic Thyroiditis', 'Hashimoto thyroiditis', 'Hashimotos Disease', 'Hashimotos syndrome', 'Hashimotos thyroiditis', 'Lymphocytic Thyroiditis', 'hashimoto thyroiditis'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0010138', ['thyrotoxicosis'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB01583', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'may be used to treat primary secondary or tertiary hypothyroidism may also be used to suppress thyroid stimulating hormone tsh secretion in patients with simple nontoxic goiter subacute or chronic lymphocytic thyroiditis multinodular goiter and in the management of thyroid cancer may be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism may also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy')|
|('DB00706', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasialabeltamsulosin is also used off label for the treatment of ureteral stones prostatitis and female voiding dysfunctiona178339l6259')|
|('DB00706', 'MONDO:0005280', ['prostatitis'], 'tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasialabeltamsulosin is also used off label for the treatment of ureteral stones prostatitis and female voiding dysfunctiona178339l6259')|
|('DB00268', 'MONDO:0005280', ['prostatitis'], 'for the treatment of the signs and symptoms of parkinsons disease and for the treatment of primary moderatesevere restless legs syndrome fda label')|
|('DB00268', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'for the treatment of the signs and symptoms of parkinsons disease and for the treatment of primary moderatesevere restless legs syndrome fda label')|
|('DB01023', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'for the treatment of mild to moderate essential hypertension ')|
|('DB00895', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'for use as a adjunct in assessing the risk of administering penicillin benzylpenicillin or penicillin g')|
|('DB00609', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'for use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed')|
|('DB00609', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'for use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed')|
|('DB06804', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'nonoxynol 9 is a surfactant spermicide used for contraception in spermicidal creams jellies foams gel and lubricants it is also used in conjuction with other methods of contraception including condoms cervical caps and diaphragms')|
|('DB00996', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'in the united states gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partialonset seizures with or without secondary generalization in patients 3 years of age and olderl8717 in europe gabapentin is indicated for adjunctive therapy in the treatment of partialonset seizures with or without secondary generalization in patients 6 years of age and older and as monotherapy in patients 12 years of age and older it is also used in adults for the treatment of various types of peripheral neuropathic pain such as painful diabetic neuropathyl8732')|
|('DB00996', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'in the united states gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partialonset seizures with or without secondary generalization in patients 3 years of age and olderl8717 in europe gabapentin is indicated for adjunctive therapy in the treatment of partialonset seizures with or without secondary generalization in patients 6 years of age and older and as monotherapy in patients 12 years of age and older it is also used in adults for the treatment of various types of peripheral neuropathic pain such as painful diabetic neuropathyl8732')|
|('DB01010', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease it may also be used for evaluating emergency treatment in myasthenic crises')|
|('DB01010', 'MONDO:0009688', ['myasthenia gravis'], 'for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease it may also be used for evaluating emergency treatment in myasthenic crises')|
|('DB01084', 'MONDO:0009688', ['myasthenia gravis'], 'for the temporary relief of the signs and symptoms of allergic conjunctivitis')|
|('DB00573', 'MONDO:0009688', ['myasthenia gravis'], 'for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis also for the relief of mild to moderate pain')|
|('DB00573', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis also for the relief of mild to moderate pain')|
|('DB00573', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis also for the relief of mild to moderate pain')|
|('DB00896', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis')|
|('DB00896', 'MONDO:0006651', ['anterior uveitis'], 'for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis')|
|('DB01071', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of hay fever urticaria hives and allergic rhinitis')|
|('DB01071', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the treatment of hay fever urticaria hives and allergic rhinitis')|
|('DB01071', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of hay fever urticaria hives and allergic rhinitis')|
|('DB00813', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction maintenance and recovery from general or regional anesthesialabel these injections are also used with a neuroleptic for premedication induction and as an adjunct to maintenance of anesthesialabel finally fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patientslabelfentanyl sublingual tablets transmucosal lozenges buccal tablets sublingual sprays transdermal systems and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain managementl6598l6601l6604l6607l922l6610')|
|('DB00813', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction maintenance and recovery from general or regional anesthesialabel these injections are also used with a neuroleptic for premedication induction and as an adjunct to maintenance of anesthesialabel finally fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patientslabelfentanyl sublingual tablets transmucosal lozenges buccal tablets sublingual sprays transdermal systems and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain managementl6598l6601l6604l6607l922l6610')|
|('DB00813', 'MONDO:0004992', ['cancer'], 'fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction maintenance and recovery from general or regional anesthesialabel these injections are also used with a neuroleptic for premedication induction and as an adjunct to maintenance of anesthesialabel finally fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patientslabelfentanyl sublingual tablets transmucosal lozenges buccal tablets sublingual sprays transdermal systems and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain managementl6598l6601l6604l6607l922l6610')|
|('DB01072', 'MONDO:0004992', ['cancer'], 'used in combination with other antiretroviral agents for the treatment of hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission')|
|('DB01072', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'used in combination with other antiretroviral agents for the treatment of hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission')|
|('DB00789', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for use with magnetic resonance imaging mri in adults and pediatric patients 2 years of age and older to visualize lesions with abnormal vascularity in the brain intracranial lesions spine and associated tissues as well as lesions with abnormal vascularity in the head and neck also used to facilitate the visualization of lesions with abnormal vascularity in the body excluding the heart')|
|('DB00588', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisfda labelas well as inflammatory and pruritic dermatosesf4355 a fluticasone propionate nasal spray is indicated for managing nonallergic rhinitisf4358')|
|('DB00588', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisfda labelas well as inflammatory and pruritic dermatosesf4355 a fluticasone propionate nasal spray is indicated for managing nonallergic rhinitisf4358')|
|('DB00344', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of depression ')|
|('DB00701', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of hiv1 infection in combination with other antiretroviral agents')|
|('DB01053', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for use in the treatment of severe infections caused by penicillin gsusceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia meningitis pericarditis endocarditis and severe pneumonia')|
|('DB01053', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for use in the treatment of severe infections caused by penicillin gsusceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia meningitis pericarditis endocarditis and severe pneumonia')|
|('DB01053', 'MONDO:0005025', ['endocarditis'], 'for use in the treatment of severe infections caused by penicillin gsusceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia meningitis pericarditis endocarditis and severe pneumonia')|
|('DB00647', 'MONDO:0005025', ['endocarditis'], 'for the relief of mild to moderate pain')|
|('DB00398', 'MONDO:0005025', ['endocarditis'], 'sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma  ')|
|('DB00398', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma  ')|
|('DB00440', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00440', 'MONDO:0005280', ['prostatitis'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00440', 'MONDO:0021666', ['Ear infection [NCIT:C27193]', 'otitis [NCIT:C27193]', 'ear infection'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00440', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00440', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00440', 'MONDO:0019121', ['Pneumocystis carinii pneumonia', 'Pneumocystis jirovecii pneumonia', 'Pneumocystis pneumonia', 'Pneumocystosis', 'Pneumocystosis pneumonia', 'pulmonary pneumocystosis', 'pneumocystosis'], 'for the treatment of urinary tract infections uncomplicated pyelonephritis with sulfamethoxazole and mild acute prostatitis may be used as pericoital with sulfamethoxazole or continuous prophylaxis in females with recurrent cystitis may be used as an alternative to treat asymptomatic bacteriuria during pregnancy only before the last 6 weeks of pregnancy other uses include alternative agent in respiratory tract infections otitis sinusitus bronchitis and pneumonia treatment of pneumocystis jirovecii pneumonia acute or prophylaxis nocardia infections and travellers diarrhea')|
|('DB00857', 'MONDO:0019121', ['Pneumocystis carinii pneumonia', 'Pneumocystis jirovecii pneumonia', 'Pneumocystis pneumonia', 'Pneumocystosis', 'Pneumocystosis pneumonia', 'pulmonary pneumocystosis', 'pneumocystosis'], 'terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by trichophyton species microsporum canis epidermophyton floccosuml9068 and tinea speciesl9065 terbinafine hydrochloride also treats yeast infections of the skin caused by candida species and malassezia furfurl9068')|
|('DB00857', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by trichophyton species microsporum canis epidermophyton floccosuml9068 and tinea speciesl9065 terbinafine hydrochloride also treats yeast infections of the skin caused by candida species and malassezia furfurl9068')|
|('DB00469', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for the treatment of rheumatoid arthritis osteoarthritis backache and pain')|
|('DB00469', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of rheumatoid arthritis osteoarthritis backache and pain')|
|('DB01155', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of bacterial infection caused by susceptible strains such as is pneumoniaei ih influenzaei ih parainfluenzaei or im catarrhalisi is pneumoniaei including multidrug resistant strains mdrsp im pneumoniaei ic pneumoniaei or ik pneumoniaei')|
|('DB00371', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety')|
|('DB00371', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety')|
|('DB00282', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of moderate or severe hypercalcemia associated with malignancy')|
|('DB00487', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of uncomplicated gonococcal urethritis in males and for gramnegativebacterial infections in the gastrointestinal system and the genitourinary tract')|
|('DB00487', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for the treatment of uncomplicated gonococcal urethritis in males and for gramnegativebacterial infections in the gastrointestinal system and the genitourinary tract')|
|('DB00233', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for the treatment of tuberculosis')|
|('DB00233', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of tuberculosis')|
|('DB06213', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'diagnostic agent for radionuclide myocardial perfusion imaging mpi ')|
|('DB00819', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies chronic simple openangle glaucoma')|
|('DB00819', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies chronic simple openangle glaucoma')|
|('DB00819', 'MONDO:0005041', ['glaucoma'], 'for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies chronic simple openangle glaucoma')|
|('DB00938', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00938', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00938', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB01036', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of overactive bladder with symptoms of urinary frequency urgency or urge incontinence')|
|('DB01036', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of overactive bladder with symptoms of urinary frequency urgency or urge incontinence')|
|('DB00306', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for use as a sedative and hypnotic')|
|('DB01062', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'oxybutynin is indicated for the symptomatic treatment of overactive bladder which causes urge urinary incontinence and frequency and urgency  oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptomsl8648 on occasion oxybutynin may be used offlabel to relieve bladder spasms associated with ureteral stents or urinary catheterst689')|
|('DB01062', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'oxybutynin is indicated for the symptomatic treatment of overactive bladder which causes urge urinary incontinence and frequency and urgency  oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptomsl8648 on occasion oxybutynin may be used offlabel to relieve bladder spasms associated with ureteral stents or urinary catheterst689')|
|('DB01062', 'MONDO:0008449', ['spina bifida'], 'oxybutynin is indicated for the symptomatic treatment of overactive bladder which causes urge urinary incontinence and frequency and urgency  oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptomsl8648 on occasion oxybutynin may be used offlabel to relieve bladder spasms associated with ureteral stents or urinary catheterst689')|
|('DB01221', 'MONDO:0008449', ['spina bifida'], 'ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures if skeletal muscle relaxation is needed it should be combined with a muscle relaxant if the surgical procedure involves visceral pain it should be supplemented with an agent that obtunds visceral pain ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agentsl1336 fda labelreports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower dosesa31873 these reports have increased the interest for ketamine in this area and several clinical trials are launched for this indicationl1337 a31874')|
|('DB01221', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures if skeletal muscle relaxation is needed it should be combined with a muscle relaxant if the surgical procedure involves visceral pain it should be supplemented with an agent that obtunds visceral pain ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agentsl1336 fda labelreports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower dosesa31873 these reports have increased the interest for ketamine in this area and several clinical trials are launched for this indicationl1337 a31874')|
|('DB01365', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to maintain blood pressure in hypotensive states')|
|('DB08816', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with st elevation')|
|('DB08816', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with st elevation')|
|('DB08816', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with st elevation')|
|('DB08816', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with st elevation')|
|('DB00689', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for treatment of severe infections caused by susceptible bacteria')|
|('DB01166', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'indicated for the alleviation of symptoms of intermittent claudication pain in the legs that occurs with walking and disappears with rest')|
|('DB01166', 'MONDO:0005295', ['Charcots syndrome', 'Intermittent claudication', 'intermittent vascular claudication'], 'indicated for the alleviation of symptoms of intermittent claudication pain in the legs that occurs with walking and disappears with rest')|
|('DB00721', 'MONDO:0005295', ['Charcots syndrome', 'Intermittent claudication', 'intermittent vascular claudication'], 'used as a local anesthetic primarily in oral surgery')|
|('DB00610', 'MONDO:0005295', ['Charcots syndrome', 'Intermittent claudication', 'intermittent vascular claudication'], 'for the treatment and prevention of hypotension due to hemorrhage spinal anesthesia and shock associated with brain damage')|
|('DB00610', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment and prevention of hypotension due to hemorrhage spinal anesthesia and shock associated with brain damage')|
|('DB06738', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment of all types of severe pain such as postoperative cancer kidney stones and fractures')|
|('DB06738', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all types of severe pain such as postoperative cancer kidney stones and fractures')|
|('DB06738', 'MONDO:0004992', ['cancer'], 'for the treatment of all types of severe pain such as postoperative cancer kidney stones and fractures')|
|('DB00897', 'MONDO:0004992', ['cancer'], 'for the shortterm treatment of insomnia')|
|('DB00897', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the shortterm treatment of insomnia')|
|('DB00548', 'MONDO:0004992', ['cancer'], 'for the topical treatment of mildtomoderate inflammatory acne vulgaris')|
|('DB00959', 'MONDO:0004992', ['cancer'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0002471', ['bursitis'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0004855', ['Inflammation of tendon sheath', 'tenosynovitis'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0002400', ['synovitis'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0005340', ['Circumscribed alopecia', 'alopecia areata'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0019558', ['DLE [NCIT:C26820]', 'discoid lupus erythematosus'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0006572', ['lichen ruber planus', 'Lichen, ruber planus', 'lichen planus'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0006583', ['Necrobiosis lipoidica', 'necrobiosis lipoidica'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB00959', 'MONDO:0045042', ['localized'], 'oral and intramuscular methylprednisolone are indicated for a number of endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system and other disordersl10785l10788 intraarticular and soft tissue injections are indicated for short term treatment of acute gouty arthritis acute and subactute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis and synovitis of osteoarthritisl10788 intralesional injections are indicated for alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus and psoriatic plaques necrobiosis lipoidica diabeticorum and localized hypertrophic infiltrated inflammatory lesions of granuloma annularel10788')|
|('DB01409', 'MONDO:0045042', ['localized'], 'tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in copd and to prevent exacerbations of copdl7084 a combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of copdl7087 a tiotropium inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 12 or more years oldl7090 a tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 6 or more years oldl7093')|
|('DB01409', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in copd and to prevent exacerbations of copdl7084 a combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of copdl7087 a tiotropium inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 12 or more years oldl7090 a tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 6 or more years oldl7093')|
|('DB01409', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in copd and to prevent exacerbations of copdl7084 a combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of copdl7087 a tiotropium inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 12 or more years oldl7090 a tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 6 or more years oldl7093')|
|('DB01409', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in copd and to prevent exacerbations of copdl7084 a combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of copdl7087 a tiotropium inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 12 or more years oldl7090 a tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in copd to prevent exacerbations of copd and to treat asthma in patients 6 or more years oldl7093')|
|('DB00602', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of intestinal ie nondisseminated strongyloidiasis due to the nematode parasite istrongyloides stercoralisi also for the treatment of onchocerciasis river blindness due to the nematode parasite ionchocerca volvulusi can be used to treat scabies caused by isarcoptes scabieii')|
|('DB00602', 'MONDO:0005974', ['disseminated strongyloidiasis', 'Infection by Strongyloides', 'strongyloidiasis'], 'for the treatment of intestinal ie nondisseminated strongyloidiasis due to the nematode parasite istrongyloides stercoralisi also for the treatment of onchocerciasis river blindness due to the nematode parasite ionchocerca volvulusi can be used to treat scabies caused by isarcoptes scabieii')|
|('DB00602', 'MONDO:0017137', ['Infection by Onchocerca volvulus', 'Onchocerca volvulus infection', 'volvulosis', 'onchocerciasis'], 'for the treatment of intestinal ie nondisseminated strongyloidiasis due to the nematode parasite istrongyloides stercoralisi also for the treatment of onchocerciasis river blindness due to the nematode parasite ionchocerca volvulusi can be used to treat scabies caused by isarcoptes scabieii')|
|('DB00602', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of intestinal ie nondisseminated strongyloidiasis due to the nematode parasite istrongyloides stercoralisi also for the treatment of onchocerciasis river blindness due to the nematode parasite ionchocerca volvulusi can be used to treat scabies caused by isarcoptes scabieii')|
|('DB00602', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for the treatment of intestinal ie nondisseminated strongyloidiasis due to the nematode parasite istrongyloides stercoralisi also for the treatment of onchocerciasis river blindness due to the nematode parasite ionchocerca volvulusi can be used to treat scabies caused by isarcoptes scabieii')|
|('DB06800', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy ')|
|('DB01356', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'lithium is used as a mood stabilizer and is used for treatment of depression and mania it is often used in bipolar disorder treatment')|
|('DB01208', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for the treatment of adults with the following infections caused by susceptible strains microorganisms communityacquired pneumonia caused by ichlamydia pneumoniaei ihaemophilus influenzaei ihaemophilus parainfluenzaei imoraxella catarrhalisi imycoplasma pneumoniaei or istreptococcus pneumoniaei and acute bacterial exacerbations of chronic bronchitis caused by ichlamydia pneumoniaei ienterobacter cloacaei ihaemophilus influenzaei ihaemophilus parainfluenzaei iklebsiella pneumoniaei imoraxella catarrhalisi istaphylococcus aureusi or istreptococcus pneumoniaei')|
|('DB01208', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of adults with the following infections caused by susceptible strains microorganisms communityacquired pneumonia caused by ichlamydia pneumoniaei ihaemophilus influenzaei ihaemophilus parainfluenzaei imoraxella catarrhalisi imycoplasma pneumoniaei or istreptococcus pneumoniaei and acute bacterial exacerbations of chronic bronchitis caused by ichlamydia pneumoniaei ienterobacter cloacaei ihaemophilus influenzaei ihaemophilus parainfluenzaei iklebsiella pneumoniaei imoraxella catarrhalisi istaphylococcus aureusi or istreptococcus pneumoniaei')|
|('DB01208', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of adults with the following infections caused by susceptible strains microorganisms communityacquired pneumonia caused by ichlamydia pneumoniaei ihaemophilus influenzaei ihaemophilus parainfluenzaei imoraxella catarrhalisi imycoplasma pneumoniaei or istreptococcus pneumoniaei and acute bacterial exacerbations of chronic bronchitis caused by ichlamydia pneumoniaei ienterobacter cloacaei ihaemophilus influenzaei ihaemophilus parainfluenzaei iklebsiella pneumoniaei imoraxella catarrhalisi istaphylococcus aureusi or istreptococcus pneumoniaei')|
|('DB00243', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'ranolazine is indicated for the treatment of chronic angina it can be used in conjunction with nitrates betablockers angiotensin receptor blockers antiplatelet drugs calcium channel blockerslipidlowering drugs ace inhibitorsl3580ranolazine has also been used offlabel for the treatment of some arrhythmias such as ventricular tachycardia however this use does not have a lot of supporting evidencea174940 the use of ranolazine has been researched in the treatment of acute coronary syndrome microvascular coronary dysfunction arrhythmia and glycemic controla174898')|
|('DB00243', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ranolazine is indicated for the treatment of chronic angina it can be used in conjunction with nitrates betablockers angiotensin receptor blockers antiplatelet drugs calcium channel blockerslipidlowering drugs ace inhibitorsl3580ranolazine has also been used offlabel for the treatment of some arrhythmias such as ventricular tachycardia however this use does not have a lot of supporting evidencea174940 the use of ranolazine has been researched in the treatment of acute coronary syndrome microvascular coronary dysfunction arrhythmia and glycemic controla174898')|
|('DB00243', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ranolazine is indicated for the treatment of chronic angina it can be used in conjunction with nitrates betablockers angiotensin receptor blockers antiplatelet drugs calcium channel blockerslipidlowering drugs ace inhibitorsl3580ranolazine has also been used offlabel for the treatment of some arrhythmias such as ventricular tachycardia however this use does not have a lot of supporting evidencea174940 the use of ranolazine has been researched in the treatment of acute coronary syndrome microvascular coronary dysfunction arrhythmia and glycemic controla174898')|
|('DB00243', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'ranolazine is indicated for the treatment of chronic angina it can be used in conjunction with nitrates betablockers angiotensin receptor blockers antiplatelet drugs calcium channel blockerslipidlowering drugs ace inhibitorsl3580ranolazine has also been used offlabel for the treatment of some arrhythmias such as ventricular tachycardia however this use does not have a lot of supporting evidencea174940 the use of ranolazine has been researched in the treatment of acute coronary syndrome microvascular coronary dysfunction arrhythmia and glycemic controla174898')|
|('DB00243', 'MONDO:0007263', ['arrhythmia [NCIT:C2881]', 'cardiac rhythm disease'], 'ranolazine is indicated for the treatment of chronic angina it can be used in conjunction with nitrates betablockers angiotensin receptor blockers antiplatelet drugs calcium channel blockerslipidlowering drugs ace inhibitorsl3580ranolazine has also been used offlabel for the treatment of some arrhythmias such as ventricular tachycardia however this use does not have a lot of supporting evidencea174940 the use of ranolazine has been researched in the treatment of acute coronary syndrome microvascular coronary dysfunction arrhythmia and glycemic controla174898')|
|('DB00695', 'MONDO:0007263', ['arrhythmia [NCIT:C2881]', 'cardiac rhythm disease'], 'furosemide is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome in adults and pediatric patientsl7958 oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medicationsl9659intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desiredl7958')|
|('DB00695', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'furosemide is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome in adults and pediatric patientsl7958 oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medicationsl9659intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desiredl7958')|
|('DB00695', 'MONDO:0005377', ['nephrotic syndrome'], 'furosemide is indicated for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome in adults and pediatric patientsl7958 oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medicationsl9659intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desiredl7958')|
|('DB00792', 'MONDO:0005377', ['nephrotic syndrome'], 'used for the symptomatic relief of hypersensitivity reactions coughs and the common cold')|
|('DB00792', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'used for the symptomatic relief of hypersensitivity reactions coughs and the common cold')|
|('DB00792', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used for the symptomatic relief of hypersensitivity reactions coughs and the common cold')|
|('DB00235', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'indicated for the treatment of congestive heart failure')|
|('DB00235', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'indicated for the treatment of congestive heart failure')|
|('DB00411', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'primarily used in the treatment of glaucoma but is also used during ophthalmic surgery')|
|('DB00411', 'MONDO:0005041', ['glaucoma'], 'primarily used in the treatment of glaucoma but is also used during ophthalmic surgery')|
|('DB00129', 'MONDO:0005041', ['glaucoma'], 'used for nutritional supplementation also for treating dietary shortage or imbalance it has been claimed that ornithine improves athletic performance has anabolic effects has woundhealing effects and is immunoenhancing')|
|('DB00129', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for nutritional supplementation also for treating dietary shortage or imbalance it has been claimed that ornithine improves athletic performance has anabolic effects has woundhealing effects and is immunoenhancing')|
|('DB01181', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as a component of various chemotherapeutic regimens as thirdline therapy for recurrent or refractory germ cell testicular cancer also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer as well as in conjunction with surgery andor radiation therapy in the treatment of various soft tissue sarcomas other indications include treatment of osteosarcoma bladder cancer ovarian cancer small cell lung cancer and nonhodgkins lymphoma')|
|('DB01181', 'MONDO:0004992', ['cancer'], 'used as a component of various chemotherapeutic regimens as thirdline therapy for recurrent or refractory germ cell testicular cancer also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer as well as in conjunction with surgery andor radiation therapy in the treatment of various soft tissue sarcomas other indications include treatment of osteosarcoma bladder cancer ovarian cancer small cell lung cancer and nonhodgkins lymphoma')|
|('DB01181', 'MONDO:0002974', ['cervical neoplasm', 'cervix cancer', 'cervix uteri cancer', 'neoplasm of uterine cervix', 'tumor of the Cervix Uteri', 'uterine cervical neoplasm', 'cervical cancer'], 'used as a component of various chemotherapeutic regimens as thirdline therapy for recurrent or refractory germ cell testicular cancer also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer as well as in conjunction with surgery andor radiation therapy in the treatment of various soft tissue sarcomas other indications include treatment of osteosarcoma bladder cancer ovarian cancer small cell lung cancer and nonhodgkins lymphoma')|
|('DB01181', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'used as a component of various chemotherapeutic regimens as thirdline therapy for recurrent or refractory germ cell testicular cancer also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer as well as in conjunction with surgery andor radiation therapy in the treatment of various soft tissue sarcomas other indications include treatment of osteosarcoma bladder cancer ovarian cancer small cell lung cancer and nonhodgkins lymphoma')|
|('DB01181', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'used as a component of various chemotherapeutic regimens as thirdline therapy for recurrent or refractory germ cell testicular cancer also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer as well as in conjunction with surgery andor radiation therapy in the treatment of various soft tissue sarcomas other indications include treatment of osteosarcoma bladder cancer ovarian cancer small cell lung cancer and nonhodgkins lymphoma')|
|('DB00888', 'MONDO:0004992', ['cancer'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00888', 'MONDO:0004638', ['diffuse lymphoma [DOID:8675,MTHICD9_2006:202.8]', 'malignant lymphoma [DOID:8675]', 'lymphosarcoma [NCIT:C26919]', 'lymphosarcoma'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00888', 'MONDO:0005571', ['Erythrocythemia', 'polycythemia'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00888', 'MONDO:0009691', ['Mycosis fungoides', 'mycosis fungoides lymphoma', 'mycosis fungoides'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00888', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00888', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'for the palliative treatment of hodgkins disease stages iii and iv lymphosarcoma chronic myelocytic or chronic lymphocytic leukemia polycythemia vera mycosis fungoides and bronchogenic carcinoma also for the palliative treatment of metastatic carcinoma resulting in effusion')|
|('DB00330', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'for use as an adjunct in the treatment of pulmonary tuberculosis')|
|('DB00330', 'MONDO:0006052', ['pulmonary tuberculosis'], 'for use as an adjunct in the treatment of pulmonary tuberculosis')|
|('DB00905', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'bimatoprost is used for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertensionthese patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatmentsl6877bimatoprost is also indicated to treat eyelash hypotrichosisl6910')|
|('DB00905', 'MONDO:0005041', ['glaucoma'], 'bimatoprost is used for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertensionthese patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatmentsl6877bimatoprost is also indicated to treat eyelash hypotrichosisl6910')|
|('DB00623', 'MONDO:0005041', ['glaucoma'], 'for management of manifestations of psychotic disorders')|
|('DB04574', 'MONDO:0005041', ['glaucoma'], 'estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause it is also used to treat hypoestrogenism due to hypogonadism castration or primary ovarian failure and prevent postmenopausal osteoporosis')|
|('DB04574', 'MONDO:0002146', ['hypogonadism'], 'estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause it is also used to treat hypoestrogenism due to hypogonadism castration or primary ovarian failure and prevent postmenopausal osteoporosis')|
|('DB04574', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause it is also used to treat hypoestrogenism due to hypogonadism castration or primary ovarian failure and prevent postmenopausal osteoporosis')|
|('DB04574', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause it is also used to treat hypoestrogenism due to hypogonadism castration or primary ovarian failure and prevent postmenopausal osteoporosis')|
|('DB01101', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen may also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to or recurred or relasped during or following anthracyclinecontaining chemotherapy capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage iii colon cancer when monotherapy with fluroprymidine is preferred the use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated')|
|('DB01101', 'MONDO:0004992', ['cancer'], 'for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen may also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to or recurred or relasped during or following anthracyclinecontaining chemotherapy capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage iii colon cancer when monotherapy with fluroprymidine is preferred the use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated')|
|('DB00425', 'MONDO:0004992', ['cancer'], 'this drug is indicated for the shortterm treatment of insomnia in adults characterized by difficulties with sleep initiation fda label ')|
|('DB00425', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'this drug is indicated for the shortterm treatment of insomnia in adults characterized by difficulties with sleep initiation fda label ')|
|('DB01411', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used as an adjunct to the standard therapy of inhaled steroids with inhaled long andor shortacting betaagonists ')|
|('DB00461', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'indicated forlabel1 symptomatic relief in rheumatoid arthritis2 symptomatic relief in osteoarthritis')|
|('DB00294', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'etonogestrel is administered in subdermal implants as longacting reversible contraception it is known to be effective in postpartum insertion including breastfeeding womena175990etonogestrel is part of the longacting contraceptive implants that prevent pregnancy the implants effect can remain for 5 yearsl5698')|
|('DB00294', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'etonogestrel is administered in subdermal implants as longacting reversible contraception it is known to be effective in postpartum insertion including breastfeeding womena175990etonogestrel is part of the longacting contraceptive implants that prevent pregnancy the implants effect can remain for 5 yearsl5698')|
|('DB00504', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the complete or partial reversal of narcotic depression including respiratory depression induced by opioids')|
|('DB00552', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of hairy cell leukaemia refractory to alpha interferon')|
|('DB00722', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'lisinopril is indicated for the treatment of acute myocardial infarction hypertension in patients ≥6 years and as an adjunct therapy for heart failurel8384l8387 a combination product with hydrochlorothiazide is indicated for the treatment of hypertensionl8390')|
|('DB00722', 'MONDO:0004781', ['acute myocardial infarction'], 'lisinopril is indicated for the treatment of acute myocardial infarction hypertension in patients ≥6 years and as an adjunct therapy for heart failurel8384l8387 a combination product with hydrochlorothiazide is indicated for the treatment of hypertensionl8390')|
|('DB01264', 'MONDO:0004781', ['acute myocardial infarction'], 'darunavir coadministered with ritonavir and with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus hiv infection in antiretroviral treatmentexperienced adult patients such as those with hiv1 strains resistant to more than one protease inhibitor')|
|('DB00180', 'MONDO:0004781', ['acute myocardial infarction'], 'for the maintenance treatment of asthma as a prophylactic therapy')|
|('DB00180', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the maintenance treatment of asthma as a prophylactic therapy')|
|('DB08842', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0006626', ['diabetic neuropathy'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0005244', ['peripheral neuropathy', 'peripheral neuropathy'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0001627', ['dementia'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0019037', ['progressive supranuclear ophthalmoplegia', 'Steele-Richardson-Olszewski syndrome', 'progressive supranuclear palsy'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0004992', ['cancer'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0024613', ['bipolar affective disorder, current episode depression []', 'bipolar depression [NCIT:C34424]', 'bipolar depression'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB08842', 'MONDO:0005372', ['male infertility'], 'acetylcarnitine is not approved for any indication in the united states and canada but it is approved and indicated in italy for cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy and nutritional supplementation portugal for mental function disorders argentina for cerebral vasculopathy nutritional supplementation and peripheral neuropathy chile for dementia philippines for cerebrovascular disorders and mental function disorders australia for nutritional supplementation and india for nutritional supplementation to increase sperm count acetylcarnitine also has several potential therapeutic indications for which it is still being investigated in norway acetylcarnitine is in a phase iv trial for prophylactic treatment of migraines in italy acetylcarnitine is in a phase ii trial for use in patients with type 2 diabetes mellitus a phase iii trial for alleviating fatigue in patients with chronic hepatitis c and for use in patients with minimal hepatic encephalopathy in the united states acetylcarnitine is in a phase ii trial for the neurodegenerative disorder progressive supranuclear palsy a phase ii and iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy a phase i and ii trial for treating patients in septic shock a phase ii trial for bipolar depression a phase ii trial to reduce oxidative stress in patients with sickle cell disease a phase i and ii trial for chronic fatigue syndrome and a study for preventing nerve damage in hiv patients in china acetylcarnitine is in a phase iii trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy in the united kingdom acetylcarnitine is being investigated for preventing nerve damage in hiv patients and in israel acetylcarnitine is being studied for the treatment of male infertility ')|
|('DB00520', 'MONDO:0004992', ['cancer'], 'for the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies')|
|('DB00520', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'for the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies')|
|('DB00520', 'MONDO:0000240', ['invasive aspergillosis'], 'for the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies')|
|('DB01559', 'MONDO:0000240', ['invasive aspergillosis'], 'for the treatment of anxiety disorders')|
|('DB01559', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety disorders')|
|('DB00165', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'pyridoxine is indicated for the treatment of vitamin b6 deficiency and for the prophylaxis of db00951induced peripheral neuropathy it is also approved by health canada for the treatment of nausea and vomiting in pregnancy in a combination product with db00366 as the commercially available product diclectin')|
|('DB00165', 'MONDO:0005244', ['peripheral neuropathy', 'peripheral neuropathy'], 'pyridoxine is indicated for the treatment of vitamin b6 deficiency and for the prophylaxis of db00951induced peripheral neuropathy it is also approved by health canada for the treatment of nausea and vomiting in pregnancy in a combination product with db00366 as the commercially available product diclectin')|
|('DB00152', 'MONDO:0005244', ['peripheral neuropathy', 'peripheral neuropathy'], 'for the treatment of thiamine and niacin deficiency states korsakovs alcoholic psychosis wernickekorsakov syndrome delirium and peripheral neuritis')|
|('DB00152', 'MONDO:0019975', ['Niacin deficiency', 'Niacin-tryptophan deficiency', 'Pellagra', 'pellagra'], 'for the treatment of thiamine and niacin deficiency states korsakovs alcoholic psychosis wernickekorsakov syndrome delirium and peripheral neuritis')|
|('DB00152', 'MONDO:0002122', ['peripheral neuritis', 'neuritis'], 'for the treatment of thiamine and niacin deficiency states korsakovs alcoholic psychosis wernickekorsakov syndrome delirium and peripheral neuritis')|
|('DB06696', 'MONDO:0019975', ['Niacin deficiency', 'Niacin-tryptophan deficiency', 'Pellagra', 'pellagra'], 'arbekacin is used for the short term treatment of multiresistant bacterial infections such as methicillinresistant istaphylococcus aureusi mrsa')|
|('DB06696', 'MONDO:0100073', ['MRSA []', 'methicillin-resistant staphylococcus aureus infectious disease'], 'arbekacin is used for the short term treatment of multiresistant bacterial infections such as methicillinresistant istaphylococcus aureusi mrsa')|
|('DB00776', 'MONDO:0019975', ['Niacin deficiency', 'Niacin-tryptophan deficiency', 'Pellagra', 'pellagra'], 'in the united states oxcarbazepine is indicated as monotherapy in the treatment of partialonset seizures in patients 4 years of age and older and as adjunctive therapy in the treatment of partialonset seizures in patients 2 years of age and olderl8627 in canada oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partialonset seizures in patients 6 years of age and olderl8630')|
|('DB02703', 'MONDO:0019975', ['Niacin deficiency', 'Niacin-tryptophan deficiency', 'Pellagra', 'pellagra'], 'for the treatment of bacterial infections')|
|('DB01160', 'MONDO:0019975', ['Niacin deficiency', 'Niacin-tryptophan deficiency', 'Pellagra', 'pellagra'], 'used for aborting secondtrimester pregnancy between the twelfth to eighteenth week of gestation and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life also used at lowdoses for medically indicated induction of labor at term also injected intraarterially for use as a vasodilator to assist in angiography')|
|('DB01160', 'MONDO:0021140', ['inborn []', 'congenital'], 'used for aborting secondtrimester pregnancy between the twelfth to eighteenth week of gestation and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life also used at lowdoses for medically indicated induction of labor at term also injected intraarterially for use as a vasodilator to assist in angiography')|
|('DB00316', 'MONDO:0021140', ['inborn []', 'congenital'], 'in general acetaminophen is used for the treatment of mild to moderate pain and reduction of feverf4124 it is available over the counter in various forms the most common being oral formsacetaminophen injection is indicated for the management of mild to moderate pain the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of feverlabelbecause of its low risk of causing allergic reactions this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies including bronchial asthmaticsf4124 specific dosing guidelines should be followed when administering acetaminophen to childrenl5780')|
|('DB00316', 'MONDO:0021137', ['common []', 'not rare'], 'in general acetaminophen is used for the treatment of mild to moderate pain and reduction of feverf4124 it is available over the counter in various forms the most common being oral formsacetaminophen injection is indicated for the management of mild to moderate pain the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of feverlabelbecause of its low risk of causing allergic reactions this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies including bronchial asthmaticsf4124 specific dosing guidelines should be followed when administering acetaminophen to childrenl5780')|
|('DB01020', 'MONDO:0021137', ['common []', 'not rare'], 'for the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris hypertension and myocardial infarction')|
|('DB01020', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris hypertension and myocardial infarction')|
|('DB01020', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris hypertension and myocardial infarction')|
|('DB00714', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the acute intermittent treatment of hypomobility off episodes endofdose wearing off and unpredictable onoff episodes associated with advanced parkinsons disease')|
|('DB00438', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of patients with infections caused by susceptible strains of organisms in the following diseases lower respiratory tract infectionsskin and skin structure infections urinary tract infections bacterial septicemia bone and joint infections gynecologic infections intra abdominal infections including peritonitis and central nervous system infections including meningitis')|
|('DB00438', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'for the treatment of patients with infections caused by susceptible strains of organisms in the following diseases lower respiratory tract infectionsskin and skin structure infections urinary tract infections bacterial septicemia bone and joint infections gynecologic infections intra abdominal infections including peritonitis and central nervous system infections including meningitis')|
|('DB00438', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the treatment of patients with infections caused by susceptible strains of organisms in the following diseases lower respiratory tract infectionsskin and skin structure infections urinary tract infections bacterial septicemia bone and joint infections gynecologic infections intra abdominal infections including peritonitis and central nervous system infections including meningitis')|
|('DB01428', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'used as an ingredient in sunscreen and other cosmetics')|
|('DB00150', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'tryptophan may be useful in increasing serotonin production promoting healthy sleep managing depression by enhancing mental and emotional wellbeing managing pain tolerance and managing weight')|
|('DB01195', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'in new zealand and america flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmiasl8878 in the united states it is also indicated to prevent paroxysmal atrial fibrillation and fluttera186886l5056')|
|('DB00626', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'bacitracin is indicated in topical formulations for acute and chronic localized skin infectionsa181997 occasionally it is also used intramuscularly for infantile streptococcal pneumonia and empyemaa181997 bacitracin is also formulated as an ointment with neomycin and polymyxin b for over the counter usea181997l7769 a bacitracin ointment formulated with neomycin and polymyxin b along with hydrocortisone is indicated for the treatment of corticosteroid responsive dermatoses with secondary infectionl7772')|
|('DB00626', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'bacitracin is indicated in topical formulations for acute and chronic localized skin infectionsa181997 occasionally it is also used intramuscularly for infantile streptococcal pneumonia and empyemaa181997 bacitracin is also formulated as an ointment with neomycin and polymyxin b for over the counter usea181997l7769 a bacitracin ointment formulated with neomycin and polymyxin b along with hydrocortisone is indicated for the treatment of corticosteroid responsive dermatoses with secondary infectionl7772')|
|('DB00523', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for topical treatment of cutaneous lesions in patients with aidsrelated kaposis sarcoma')|
|('DB00624', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadisml8983l8935l8938l8986l8989l8992l8995')|
|('DB00280', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia ventricular preexcitation and cardiac dysrhythmias it is a class ia antiarrhythmic drug')|
|('DB00280', 'MONDO:0005477', ['ventricular tachycardia'], 'for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia ventricular preexcitation and cardiac dysrhythmias it is a class ia antiarrhythmic drug')|
|('DB08864', 'MONDO:0005477', ['ventricular tachycardia'], 'rilpivirine in combination with other agents is indicated for the treatment of hiv1 infections in antiretroviral treatmentnaive patients with hiv1 rna ≤100000 copiesml and cd4 cell count 200 cellsmm3l1030 the fda combination therapy approval of rilpivirine and dolutegravir is indicated for adults with hiv1 infections whose virus is currently suppressed  50 copiesml on a stable regimen for at least six months without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapyl1031')|
|('DB01104', 'MONDO:0005477', ['ventricular tachycardia'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0021137', ['common []', 'not rare'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0001942', ['generalized anxiety disorder'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0005546', ['fibromyalgia'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB01104', 'MONDO:0006626', ['diabetic neuropathy'], 'sertraline is indicated for the management of major depressive disorder mdd posttraumatic stress disorder ptsd obsessivecompulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd and social anxiety disorder sadl9016 common offlabel uses for sertraline include the prevention of post stroke depressiona187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy and neurocardiogenic syncopel5227')|
|('DB00671', 'MONDO:0006626', ['diabetic neuropathy'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0005441', ['otitis media'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0001039', ['chronic tonsillitis', 'Throat infection - tonsillitis', 'tonsillitis'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB00671', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms 1 uncomplicated urinary tract infections caused by iescherichia colii and iproteus mirabilisi 2 otitis media caused by ihaemophilus influenzaei betalactamase positive and negative strains imoraxella catarrhalisi most of which are betalactamase positive and is pyogenesi 3 pharyngitis and tonsillitis caused by is pyogenesi 4 acute bronchitis and acute exacerbations of chronic bronchitis caused by istreptococcus pneumoniaei and ihaemophilus influenzaei betalactamase positive and negative strains and 5 uncomplicated gonorrhea cervicalurethral caused by ineisseria gonorrhoeaei penicillinase and nonpenicillinaseproducing strains')|
|('DB04890', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for the symptomatic treatment of itchy eyes caused by igeinduced mast cell degranulation due to allergic conjunctivitis')|
|('DB00131', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB06702', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for the treatment of overactive bladder with symptoms of urinary frequency urgency or urge incontinence')|
|('DB06702', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of overactive bladder with symptoms of urinary frequency urgency or urge incontinence')|
|('DB00760', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms bcomplicated skin and skin structure infectionsb due to istaphylococcus aureusi blactamase and nonblactamase producing methicillinsusceptible isolates only istreptococcus pyogenesi istreptococcus agalactiaei viridans group streptococci ienterococcus faecalisi excluding vancomycinresistant isolates ipseudomonas aeruginosai iescherichia colii iproteus mirabilisi ibacteroides fragilisi and ipeptostreptococcusi species bcomplicated appendicitis and peritonitisb caused by viridans group streptococci iescherichia colii iklebsiella pneumoniaei ipseudomonas aeruginosai ibacteroides fragilisi ib thetaiotaomicroni and ipeptostreptococcusi species also for use in the treatment of bacterial meningitis caused by istreptococcus pneumoniaei ihaemophilus influenzaei blactamase and nonblactamaseproducing isolates and ineisseria meningitidisi')|
|('DB00760', 'MONDO:0005649', ['acute appendicitis', 'acute appendicitis with generalized peritonitis', 'acute appendicitis with peritoneal abscess', 'appendicitis'], 'for use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms bcomplicated skin and skin structure infectionsb due to istaphylococcus aureusi blactamase and nonblactamase producing methicillinsusceptible isolates only istreptococcus pyogenesi istreptococcus agalactiaei viridans group streptococci ienterococcus faecalisi excluding vancomycinresistant isolates ipseudomonas aeruginosai iescherichia colii iproteus mirabilisi ibacteroides fragilisi and ipeptostreptococcusi species bcomplicated appendicitis and peritonitisb caused by viridans group streptococci iescherichia colii iklebsiella pneumoniaei ipseudomonas aeruginosai ibacteroides fragilisi ib thetaiotaomicroni and ipeptostreptococcusi species also for use in the treatment of bacterial meningitis caused by istreptococcus pneumoniaei ihaemophilus influenzaei blactamase and nonblactamaseproducing isolates and ineisseria meningitidisi')|
|('DB00760', 'MONDO:0006670', ['bacterial meningitis'], 'for use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms bcomplicated skin and skin structure infectionsb due to istaphylococcus aureusi blactamase and nonblactamase producing methicillinsusceptible isolates only istreptococcus pyogenesi istreptococcus agalactiaei viridans group streptococci ienterococcus faecalisi excluding vancomycinresistant isolates ipseudomonas aeruginosai iescherichia colii iproteus mirabilisi ibacteroides fragilisi and ipeptostreptococcusi species bcomplicated appendicitis and peritonitisb caused by viridans group streptococci iescherichia colii iklebsiella pneumoniaei ipseudomonas aeruginosai ibacteroides fragilisi ib thetaiotaomicroni and ipeptostreptococcusi species also for use in the treatment of bacterial meningitis caused by istreptococcus pneumoniaei ihaemophilus influenzaei blactamase and nonblactamaseproducing isolates and ineisseria meningitidisi')|
|('DB01150', 'MONDO:0006670', ['bacterial meningitis'], 'for the treatment of the following infections respiratory skin soft tissue uti ent caused by s pneumoniae h influenzae staphylococci s pyogenes group a betahemolytic streptococci e coli p mirabilis klebsiella sp coagulasenegative staph')|
|('DB00192', 'MONDO:0006670', ['bacterial meningitis'], 'for the treatment of lifethreatening dysrhythmias and sustained ventricular tachycardia')|
|('DB00192', 'MONDO:0005477', ['ventricular tachycardia'], 'for the treatment of lifethreatening dysrhythmias and sustained ventricular tachycardia')|
|('DB01354', 'MONDO:0006670', ['bacterial meningitis'], 'used mainly for sedation and hypnosis')|
|('DB00336', 'MONDO:0006670', ['bacterial meningitis'], 'for the treatment of bacterial skin infections including pyodermas infected dermatoses and infections of cuts wounds burns and ulcers due to susceptible organisms')|
|('DB00336', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of bacterial skin infections including pyodermas infected dermatoses and infections of cuts wounds burns and ulcers due to susceptible organisms')|
|('DB04876', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'used to reduce hyperglycemia in type 2 diabetes mellitus')|
|('DB04876', 'MONDO:0002909', ['hyperglycemia'], 'used to reduce hyperglycemia in type 2 diabetes mellitus')|
|('DB04876', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used to reduce hyperglycemia in type 2 diabetes mellitus')|
|('DB00295', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'morphine is used for the management of chronic moderatetosevere paina176050opioids including morphine can manage pain effectively when used for a short amount of time the use of opioids for longer periods needs to be monitored as they can develop a physical dependence addiction disorder and drug abusel5728')|
|('DB00295', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'morphine is used for the management of chronic moderatetosevere paina176050opioids including morphine can manage pain effectively when used for a short amount of time the use of opioids for longer periods needs to be monitored as they can develop a physical dependence addiction disorder and drug abusel5728')|
|('DB01609', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of chronic iron overload due to blood transfusions transfusional hemosiderosis in patients 2 years of age and older')|
|('DB01609', 'MONDO:0001436', ['haemosiderosis', 'hemosiderosis'], 'for the treatment of chronic iron overload due to blood transfusions transfusional hemosiderosis in patients 2 years of age and older')|
|('DB00600', 'MONDO:0001436', ['haemosiderosis', 'hemosiderosis'], 'used topically to treat the loss of skin color vitiligo')|
|('DB00738', 'MONDO:0001436', ['haemosiderosis', 'hemosiderosis'], 'for the treatment of pneumonia due to ipneumocystis cariniii')|
|('DB00738', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of pneumonia due to ipneumocystis cariniii')|
|('DB01003', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the management of patients with bronchial asthma also used in the treatment of vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB01003', 'MONDO:0019085', ['Spring catarrh [Orphanet:70476]', 'vernal keratoconjunctivitis'], 'for the management of patients with bronchial asthma also used in the treatment of vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB01003', 'MONDO:0003799', ['conjunctivitis'], 'for the management of patients with bronchial asthma also used in the treatment of vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB00393', 'MONDO:0003799', ['conjunctivitis'], 'for use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage sah from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits')|
|('DB00393', 'MONDO:0005099', ['subarachnoid hemorrhage [MONDO:ambiguous]', 'subarachnoid hemorrhage'], 'for use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage sah from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits')|
|('DB06795', 'MONDO:0005099', ['subarachnoid hemorrhage [MONDO:ambiguous]', 'subarachnoid hemorrhage'], 'indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn woundslabel')|
|('DB06795', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn woundslabel')|
|('DB00497', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'oxycodone is indicated for the treatment of moderate to severe painlabel there is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended periodlabel')|
|('DB00346', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'for the reduction of urinary obstruction and relief of associated manifestations eg sensation of incomplete bladder emptying or straining urgency interrupted or weak stream in patients with symptomatic beningn prostatic hyperplasia')|
|('DB00346', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'for the reduction of urinary obstruction and relief of associated manifestations eg sensation of incomplete bladder emptying or straining urgency interrupted or weak stream in patients with symptomatic beningn prostatic hyperplasia')|
|('DB01192', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'for the treatment of moderatetosevere pain')|
|('DB05013', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'for the topical treatment of actinic keratosis')|
|('DB05013', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'for the topical treatment of actinic keratosis')|
|('DB01325', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'used to treat hypertension')|
|('DB01147', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'used to treat infections caused by penicillinaseproducing staphylococci including pneumococci group a betahemolytic streptococci and penicillin gsensitive and penicillin gresistant staphylococci')|
|('DB01619', 'MONDO:0003330', ['Obstructive Uropathy', 'urinary obstruction', 'urinary tract obstruction'], 'used to treat sneezing runny nose itching watery eyes hives rashes itching and other symptoms of allergies and the common cold')|
|('DB01619', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used to treat sneezing runny nose itching watery eyes hives rashes itching and other symptoms of allergies and the common cold')|
|('DB00186', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'lorazepam is fdaapproved for the shortterm relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxietyassociated insomnia it is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedationamnesia and for the treatment of status epilepticust385some offlabel indications of lorazepam include rapid tranquilization of an agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapyassociated anticipatory nausea and vomiting and psychogenic catatoniat385')|
|('DB00186', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'lorazepam is fdaapproved for the shortterm relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxietyassociated insomnia it is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedationamnesia and for the treatment of status epilepticust385some offlabel indications of lorazepam include rapid tranquilization of an agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapyassociated anticipatory nausea and vomiting and psychogenic catatoniat385')|
|('DB00186', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'lorazepam is fdaapproved for the shortterm relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxietyassociated insomnia it is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedationamnesia and for the treatment of status epilepticust385some offlabel indications of lorazepam include rapid tranquilization of an agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapyassociated anticipatory nausea and vomiting and psychogenic catatoniat385')|
|('DB00186', 'MONDO:0006642', ['alcohol withdrawal delirium'], 'lorazepam is fdaapproved for the shortterm relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxietyassociated insomnia it is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedationamnesia and for the treatment of status epilepticust385some offlabel indications of lorazepam include rapid tranquilization of an agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapyassociated anticipatory nausea and vomiting and psychogenic catatoniat385')|
|('DB00186', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'lorazepam is fdaapproved for the shortterm relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxietyassociated insomnia it is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedationamnesia and for the treatment of status epilepticust385some offlabel indications of lorazepam include rapid tranquilization of an agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapyassociated anticipatory nausea and vomiting and psychogenic catatoniat385')|
|('DB00928', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0044873', ['myelodysplastic syndrome [NCIT:C68744]', 'childhood MDS [NCIT:C68744]', 'childhood myelodysplastic syndrome [NCIT:C68744]', 'childhood myelodysplastic syndrome'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0005272', ['RA [NCIT:C2872]', 'aregenerative anemia [NCIT:C2872]', 'refractory anemia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0001475', ['neutropenia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0002049', ['thrombocytopenia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0005059', ['leukemia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB00928', 'MONDO:0020311', ['chronic myelomonocytic leukemia'], 'for treatment of patients with the following frenchamericanbritish myelodysplastic syndrome subtypes refractory anemia or refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions refractory anemia with excess blasts refractory anemia with excess blasts in transformation now classified as acute myelogenous leukemia with multilineage dysplasia and chronic myelomonocytic leukemia')|
|('DB08874', 'MONDO:0005059', ['leukemia'], 'treatment of clostridium difficileassociated diarrhea')|
|('DB00994', 'MONDO:0005059', ['leukemia'], 'topical uses include treatment for superficial eye infections caused by susceptible bacteria used in combination with other antiinfectives treatment of otitis externa caused by susceptible bacteria treatment or prevention of bacterial infections in skin lesions and use as a continuous shortterm irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters f3634f3637f3640f3643 may be used orally to treat hepatic encephalopathy as a perioperative prophylactic agent and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic e coli epec f3643')|
|('DB00994', 'MONDO:0004795', ['swimmers ear', 'otitis externa'], 'topical uses include treatment for superficial eye infections caused by susceptible bacteria used in combination with other antiinfectives treatment of otitis externa caused by susceptible bacteria treatment or prevention of bacterial infections in skin lesions and use as a continuous shortterm irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters f3634f3637f3640f3643 may be used orally to treat hepatic encephalopathy as a perioperative prophylactic agent and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic e coli epec f3643')|
|('DB00994', 'MONDO:0001882', ['bacteriuria'], 'topical uses include treatment for superficial eye infections caused by susceptible bacteria used in combination with other antiinfectives treatment of otitis externa caused by susceptible bacteria treatment or prevention of bacterial infections in skin lesions and use as a continuous shortterm irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters f3634f3637f3640f3643 may be used orally to treat hepatic encephalopathy as a perioperative prophylactic agent and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic e coli epec f3643')|
|('DB00994', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'topical uses include treatment for superficial eye infections caused by susceptible bacteria used in combination with other antiinfectives treatment of otitis externa caused by susceptible bacteria treatment or prevention of bacterial infections in skin lesions and use as a continuous shortterm irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters f3634f3637f3640f3643 may be used orally to treat hepatic encephalopathy as a perioperative prophylactic agent and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic e coli epec f3643')|
|('DB01625', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB01625', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB01625', 'MONDO:0001272', ['Functional diarrhea', 'Functional diarrhoea', 'functional diarrhoea', 'functional diarrhea'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB01625', 'MONDO:0001428', ['pylorospasm'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB01625', 'MONDO:0002269', ['cholera morbus', 'infectious colitis, enteritis and gastroenteritis', 'gastroenteritis'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB01625', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'for the treatment of a wide range of gastrointestinal disorders including such conditions as peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable or spastic colon pyloroduodenal irritability pylorospasm acute nonspecific gastroenteritis biliary dyskinesia and chronic cholelithiasis duodenitis gastrointestinal spasm it may also be used to treat genitourinary spasm')|
|('DB00576', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'for the treatment of urinary tract infection')|
|('DB00576', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of urinary tract infection')|
|('DB00146', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0010931', ['vitamin D receptor signaling defect rickets [NCIT:C131076]', 'vitamin D dependent rickets 2b [NCIT:C131076]', 'hereditary 1,25 dihydroxyvitamin D-resistant rickets with abnormal vitamin D receptor without alopecia [NCIT:C131076]', 'vitamin D resistant rickets [NCIT:C131076]', 'vitamin D-dependent rickets type II without alopecia [MONDO:cjm]', 'vitamin d-dependent rickets, type 2b'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0000313', ['hypophosphatemia'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0001220', ['hypoparathyroidism'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0006946', ['renal rickets', 'renal osteodystrophy'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0024327', ['chronic renal failure [NCIT:C9438]', 'CRF - chronic renal failure [NCIT:C9438]', 'Chronic renal disease [NCIT:C9438]', 'chronic kidney failure []', 'chronic renal failure disease [NCIT:C9438-modified]', 'kidney failure, chronic [MONDO:patterns/chronic]', 'chronic renal failure syndrome'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00146', 'MONDO:0005298', ['osteoporosis'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB08934', 'MONDO:0024327', ['chronic renal failure [NCIT:C9438]', 'CRF - chronic renal failure [NCIT:C9438]', 'Chronic renal disease [NCIT:C9438]', 'chronic kidney failure []', 'chronic renal failure disease [NCIT:C9438-modified]', 'kidney failure, chronic [MONDO:patterns/chronic]', 'chronic renal failure syndrome'], 'sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include either ribavirin alone or ribavirin and peginterferon alfawhen used in combination with db09027 as the combination product harvoni sofosbuvir has the following indications treatment of genotypes 1 4 5 or 6 infection without cirrhosis or with compensated cirrhosis in combination with db00811 for genotype 1 infection with decompensated cirrhosis or in combination with db00811 for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosiswhen used in combination with db11613 as the combination product epclusa sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotypes 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosisresistance reduced susceptibility to sofosbuvir has been associated with the ns5b substitution mutation s282t a19634')|
|('DB08934', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include either ribavirin alone or ribavirin and peginterferon alfawhen used in combination with db09027 as the combination product harvoni sofosbuvir has the following indications treatment of genotypes 1 4 5 or 6 infection without cirrhosis or with compensated cirrhosis in combination with db00811 for genotype 1 infection with decompensated cirrhosis or in combination with db00811 for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosiswhen used in combination with db11613 as the combination product epclusa sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotypes 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosisresistance reduced susceptibility to sofosbuvir has been associated with the ns5b substitution mutation s282t a19634')|
|('DB08934', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include either ribavirin alone or ribavirin and peginterferon alfawhen used in combination with db09027 as the combination product harvoni sofosbuvir has the following indications treatment of genotypes 1 4 5 or 6 infection without cirrhosis or with compensated cirrhosis in combination with db00811 for genotype 1 infection with decompensated cirrhosis or in combination with db00811 for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosiswhen used in combination with db11613 as the combination product epclusa sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotypes 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosisresistance reduced susceptibility to sofosbuvir has been associated with the ns5b substitution mutation s282t a19634')|
|('DB08934', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include either ribavirin alone or ribavirin and peginterferon alfawhen used in combination with db09027 as the combination product harvoni sofosbuvir has the following indications treatment of genotypes 1 4 5 or 6 infection without cirrhosis or with compensated cirrhosis in combination with db00811 for genotype 1 infection with decompensated cirrhosis or in combination with db00811 for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosiswhen used in combination with db11613 as the combination product epclusa sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotypes 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosisresistance reduced susceptibility to sofosbuvir has been associated with the ns5b substitution mutation s282t a19634')|
|('DB00734', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'risperidone is indicated for the treatment of schizophrenia acute manic or mixed episodes associated with bipolar i disorder and irritability associated with autistic disorderl4697l4700risperidone has additional indications through health canada for the shortterm symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the alzheimer type unresponsive to nonpharmacological approachesf4700risperidone is also used offlabel for a number of conditions including as an adjunct to antidepressants in treatmentresistant depressiona177226 ')|
|('DB00734', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'risperidone is indicated for the treatment of schizophrenia acute manic or mixed episodes associated with bipolar i disorder and irritability associated with autistic disorderl4697l4700risperidone has additional indications through health canada for the shortterm symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the alzheimer type unresponsive to nonpharmacological approachesf4700risperidone is also used offlabel for a number of conditions including as an adjunct to antidepressants in treatmentresistant depressiona177226 ')|
|('DB00734', 'MONDO:0001866', ['bipolar I disorder'], 'risperidone is indicated for the treatment of schizophrenia acute manic or mixed episodes associated with bipolar i disorder and irritability associated with autistic disorderl4697l4700risperidone has additional indications through health canada for the shortterm symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the alzheimer type unresponsive to nonpharmacological approachesf4700risperidone is also used offlabel for a number of conditions including as an adjunct to antidepressants in treatmentresistant depressiona177226 ')|
|('DB01056', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are lifethreatening')|
|('DB01056', 'MONDO:0005477', ['ventricular tachycardia'], 'for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are lifethreatening')|
|('DB06777', 'MONDO:0005477', ['ventricular tachycardia'], 'chenodiol is indicated for patients with radiolucent stones in wellopacifying gallbladders in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age chenodiol will not dissolve calcified radiopaque or radiolucent bile pigment stones')|
|('DB06777', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'chenodiol is indicated for patients with radiolucent stones in wellopacifying gallbladders in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age chenodiol will not dissolve calcified radiopaque or radiolucent bile pigment stones')|
|('DB01551', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'dihydrocodeine is used for the treatment of moderate to severe pain including postoperative and dental pain 2 it  can also be used to treat chronic pain 1 breathlessness and coughing in heroin addicts dihydrocodeine has been used as a substitute drug in doses up to 2500mgday to treat addiction httpwwwncbinlmnihgovpmcarticlespmc2014322 ')|
|('DB01551', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'dihydrocodeine is used for the treatment of moderate to severe pain including postoperative and dental pain 2 it  can also be used to treat chronic pain 1 breathlessness and coughing in heroin addicts dihydrocodeine has been used as a substitute drug in doses up to 2500mgday to treat addiction httpwwwncbinlmnihgovpmcarticlespmc2014322 ')|
|('DB01551', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dihydrocodeine is used for the treatment of moderate to severe pain including postoperative and dental pain 2 it  can also be used to treat chronic pain 1 breathlessness and coughing in heroin addicts dihydrocodeine has been used as a substitute drug in doses up to 2500mgday to treat addiction httpwwwncbinlmnihgovpmcarticlespmc2014322 ')|
|('DB05521', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'telaprevir when used in combination with db00811 db00008 and db00022 is indicated for use in the treatment of chronic hcv genotype 1 infection in adults fda label')|
|('DB00392', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use in the treatment of parkinsons disease and also used to control severe reactions to certain medicines such as reserpine')|
|('DB00817', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of bacterial infection of respiratory tract urinary tract gi cns and immuno compromised patients')|
|('DB00220', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in combination with other antiviral drugs in the treatment of hiv in both adults and children')|
|('DB00735', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the topical treatment of tinea pedis tinea cruris and tinea corporis caused by the organisms itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi and iepidermophyton floccosumi')|
|('DB00735', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for the topical treatment of tinea pedis tinea cruris and tinea corporis caused by the organisms itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi and iepidermophyton floccosumi')|
|('DB00735', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for the topical treatment of tinea pedis tinea cruris and tinea corporis caused by the organisms itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi and iepidermophyton floccosumi')|
|('DB00735', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'for the topical treatment of tinea pedis tinea cruris and tinea corporis caused by the organisms itrichophyton rubrumi itrichophyton mentagrophytesi itrichophyton tonsuransi and iepidermophyton floccosumi')|
|('DB00627', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00627', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00627', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00627', 'MONDO:0005311', ['atherosclerosis'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00627', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00627', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injectionsl7550l7553l7556l7559 niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemial7562l7565 it can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemial7562l7565 niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemial7562l7565 finally niacin is indicated to treat severe hypertriglyceridemial7562l7565')|
|('DB00490', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'indicated for the management of anxiety disorders or the shortterm relief of the symptoms of anxietyl4478')|
|('DB00490', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'indicated for the management of anxiety disorders or the shortterm relief of the symptoms of anxietyl4478')|
|('DB01430', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of chronic obstructive pulmonary disease')|
|('DB01430', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of chronic obstructive pulmonary disease')|
|('DB00871', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema also used acute iv and subq therapy in selected women to inhibit uterine contractions in preterm labor tocolysis and prolong gestation when beneficial')|
|('DB00871', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema also used acute iv and subq therapy in selected women to inhibit uterine contractions in preterm labor tocolysis and prolong gestation when beneficial')|
|('DB00871', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema also used acute iv and subq therapy in selected women to inhibit uterine contractions in preterm labor tocolysis and prolong gestation when beneficial')|
|('DB00285', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'venlafaxine is indicated in the management of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia and panic disorder with or without agoraphobia venlafaxine is also used offlabel for prophylaxis of migraine headaches a177229 for reduction of vasomotor symptoms associated with menopause a177238 and for management of neuropathic pain although there is only minimal evidence of efficacy for this condition a177232 it is also considered a secondline option for management of obsessivecompulsive disorder ocd a177226 a177235 ')|
|('DB00285', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'venlafaxine is indicated in the management of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia and panic disorder with or without agoraphobia venlafaxine is also used offlabel for prophylaxis of migraine headaches a177229 for reduction of vasomotor symptoms associated with menopause a177238 and for management of neuropathic pain although there is only minimal evidence of efficacy for this condition a177232 it is also considered a secondline option for management of obsessivecompulsive disorder ocd a177226 a177235 ')|
|('DB00285', 'MONDO:0001942', ['generalized anxiety disorder'], 'venlafaxine is indicated in the management of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia and panic disorder with or without agoraphobia venlafaxine is also used offlabel for prophylaxis of migraine headaches a177229 for reduction of vasomotor symptoms associated with menopause a177238 and for management of neuropathic pain although there is only minimal evidence of efficacy for this condition a177232 it is also considered a secondline option for management of obsessivecompulsive disorder ocd a177226 a177235 ')|
|('DB00285', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'venlafaxine is indicated in the management of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia and panic disorder with or without agoraphobia venlafaxine is also used offlabel for prophylaxis of migraine headaches a177229 for reduction of vasomotor symptoms associated with menopause a177238 and for management of neuropathic pain although there is only minimal evidence of efficacy for this condition a177232 it is also considered a secondline option for management of obsessivecompulsive disorder ocd a177226 a177235 ')|
|('DB00285', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'venlafaxine is indicated in the management of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia and panic disorder with or without agoraphobia venlafaxine is also used offlabel for prophylaxis of migraine headaches a177229 for reduction of vasomotor symptoms associated with menopause a177238 and for management of neuropathic pain although there is only minimal evidence of efficacy for this condition a177232 it is also considered a secondline option for management of obsessivecompulsive disorder ocd a177226 a177235 ')|
|('DB00556', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'used as an ultrasound contrast imaging in cardiology and radiology')|
|('DB05389', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections cancertumors unspecified hiv infection and inflammatory disorders unspecified')|
|('DB05389', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections cancertumors unspecified hiv infection and inflammatory disorders unspecified')|
|('DB00427', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0003014', ['rhinitis'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0003799', ['conjunctivitis'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0005492', ['urticaria'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB00427', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'for the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis allergic conjunctivitis and mild uncomplicated allergic skin manifestations of urticaria and angioedema also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold')|
|('DB01400', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone')|
|('DB01400', 'MONDO:0009688', ['myasthenia gravis'], 'neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone')|
|('DB00691', 'MONDO:0009688', ['myasthenia gravis'], 'for the treatment of hypertension')|
|('DB05381', 'MONDO:0009688', ['myasthenia gravis'], 'histamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function')|
|('DB00906', 'MONDO:0009688', ['myasthenia gravis'], 'for the treatment of partial seizures')|
|('DB00245', 'MONDO:0009688', ['myasthenia gravis'], 'benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism it can also be used for the control of extrapyramidal disorders due to neuroleptic drugst203the extrapyramidal symptoms are defined as druginduced disorders that include symptoms of dystonia akathisia parkinsonism bradykinesia tremors and dyskinesiaa175120 parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to parkinsons disease such as tremors slow movement and stiffness the parkinsonism includes a large number of disorders and some of them have not been clearly definedl5509')|
|('DB00245', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism it can also be used for the control of extrapyramidal disorders due to neuroleptic drugst203the extrapyramidal symptoms are defined as druginduced disorders that include symptoms of dystonia akathisia parkinsonism bradykinesia tremors and dyskinesiaa175120 parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to parkinsons disease such as tremors slow movement and stiffness the parkinsonism includes a large number of disorders and some of them have not been clearly definedl5509')|
|('DB00245', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism it can also be used for the control of extrapyramidal disorders due to neuroleptic drugst203the extrapyramidal symptoms are defined as druginduced disorders that include symptoms of dystonia akathisia parkinsonism bradykinesia tremors and dyskinesiaa175120 parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to parkinsons disease such as tremors slow movement and stiffness the parkinsonism includes a large number of disorders and some of them have not been clearly definedl5509')|
|('DB00597', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'gadoteridol is an mri contrast agent used for contrast enhancement of the brain spine and surrounding tissues resulting in improved visualization compared with unenhanced mri of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier gadoteridol can also be used for whole body contrast enhanced mri including the head neck liver breast musculoskeletal system and soft tissue pathologies')|
|('DB00480', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone it is also indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities')|
|('DB00480', 'MONDO:0002280', ['anaemia', 'anemia'], 'lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone it is also indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities')|
|('DB00480', 'MONDO:0009532', ['MDS', 'Miller-Dieker syndrome', 'miller-dieker lissencephaly syndrome'], 'lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone it is also indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities')|
|('DB04840', 'MONDO:0009532', ['MDS', 'Miller-Dieker syndrome', 'miller-dieker lissencephaly syndrome'], 'for the treatment of moderate and severe hypertension either alone or as an adjunct and for the treatment of renal hypertension')|
|('DB04840', 'MONDO:0001105', ['renal hypertension'], 'for the treatment of moderate and severe hypertension either alone or as an adjunct and for the treatment of renal hypertension')|
|('DB00356', 'MONDO:0009532', ['MDS', 'Miller-Dieker syndrome', 'miller-dieker lissencephaly syndrome'], 'for the relief of discomfort associated with acute painful musculoskeletal conditions')|
|('DB00179', 'MONDO:0009532', ['MDS', 'Miller-Dieker syndrome', 'miller-dieker lissencephaly syndrome'], 'used for the treatment of actinic keratoses precancerous skin growths that can become malignant if left untreated')|
|('DB00179', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used for the treatment of actinic keratoses precancerous skin growths that can become malignant if left untreated')|
|('DB01135', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to provide skeletal muscle relaxation as an adjunct to general anesthesia for endotracheal intubation or to facilitate mechanical ventilation')|
|('DB00503', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated in combination with other antiretroviral agents for the treatment of hiv1 infection')|
|('DB01288', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'fenoterol is used for the treatment of asthma')|
|('DB01288', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'fenoterol is used for the treatment of asthma')|
|('DB00215', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of depression as indicated by the fda label fda label offlabel indications include but are not limited to treatment of sexual dysfunction poststroke behavioural changes ethanol abuse obsessivecompulsive disorder ocd in children and diabetic neuropathy fda label a321 a322 a323 a324 a174406 a174409 a174412')|
|('DB00215', 'MONDO:0002046', ['alcohol abuse', 'Ethanol abuse', 'alcohol abuse'], 'for the treatment of depression as indicated by the fda label fda label offlabel indications include but are not limited to treatment of sexual dysfunction poststroke behavioural changes ethanol abuse obsessivecompulsive disorder ocd in children and diabetic neuropathy fda label a321 a322 a323 a324 a174406 a174409 a174412')|
|('DB00215', 'MONDO:0006626', ['diabetic neuropathy'], 'for the treatment of depression as indicated by the fda label fda label offlabel indications include but are not limited to treatment of sexual dysfunction poststroke behavioural changes ethanol abuse obsessivecompulsive disorder ocd in children and diabetic neuropathy fda label a321 a322 a323 a324 a174406 a174409 a174412')|
|('DB00723', 'MONDO:0006626', ['diabetic neuropathy'], 'indicated for the treatment and management of hypotension')|
|('DB00723', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'indicated for the treatment and management of hypotension')|
|('DB00535', 'MONDO:0006626', ['diabetic neuropathy'], 'cefdinir is indicated to treat acute bacterial otitis media acute maxillary sinusitis communityacquired ca pneumonia acute bacterial exacerbations of chronic bronchitis pharyngitistonsillitis  and uncomplicated skin and skin structure infections in children and adultsl7330a180739the organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinirl7330 various betalactamase producing organisms may be treated as indicated in certain sections belowrespiratoryacute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhaliscommunityacquired pneumonia caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisear nose and throat acute bacterial otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pneumoniae penicillinsusceptible onlytonsillitis caused by streptococcus pyogenespharyngitis caused by streptococcus pyogenesacute maxillary sinusitis caused by haemophilus pneumoniae and streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisskin and skin structure infectionsuncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes')|
|('DB00535', 'MONDO:0002186', ['acute antritis', 'acute maxillary sinusitis'], 'cefdinir is indicated to treat acute bacterial otitis media acute maxillary sinusitis communityacquired ca pneumonia acute bacterial exacerbations of chronic bronchitis pharyngitistonsillitis  and uncomplicated skin and skin structure infections in children and adultsl7330a180739the organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinirl7330 various betalactamase producing organisms may be treated as indicated in certain sections belowrespiratoryacute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhaliscommunityacquired pneumonia caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisear nose and throat acute bacterial otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pneumoniae penicillinsusceptible onlytonsillitis caused by streptococcus pyogenespharyngitis caused by streptococcus pyogenesacute maxillary sinusitis caused by haemophilus pneumoniae and streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisskin and skin structure infectionsuncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes')|
|('DB00535', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'cefdinir is indicated to treat acute bacterial otitis media acute maxillary sinusitis communityacquired ca pneumonia acute bacterial exacerbations of chronic bronchitis pharyngitistonsillitis  and uncomplicated skin and skin structure infections in children and adultsl7330a180739the organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinirl7330 various betalactamase producing organisms may be treated as indicated in certain sections belowrespiratoryacute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhaliscommunityacquired pneumonia caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisear nose and throat acute bacterial otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pneumoniae penicillinsusceptible onlytonsillitis caused by streptococcus pyogenespharyngitis caused by streptococcus pyogenesacute maxillary sinusitis caused by haemophilus pneumoniae and streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisskin and skin structure infectionsuncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes')|
|('DB00535', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'cefdinir is indicated to treat acute bacterial otitis media acute maxillary sinusitis communityacquired ca pneumonia acute bacterial exacerbations of chronic bronchitis pharyngitistonsillitis  and uncomplicated skin and skin structure infections in children and adultsl7330a180739the organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinirl7330 various betalactamase producing organisms may be treated as indicated in certain sections belowrespiratoryacute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhaliscommunityacquired pneumonia caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisear nose and throat acute bacterial otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pneumoniae penicillinsusceptible onlytonsillitis caused by streptococcus pyogenespharyngitis caused by streptococcus pyogenesacute maxillary sinusitis caused by haemophilus pneumoniae and streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisskin and skin structure infectionsuncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes')|
|('DB00535', 'MONDO:0005842', ['maxillary sinusitis'], 'cefdinir is indicated to treat acute bacterial otitis media acute maxillary sinusitis communityacquired ca pneumonia acute bacterial exacerbations of chronic bronchitis pharyngitistonsillitis  and uncomplicated skin and skin structure infections in children and adultsl7330a180739the organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinirl7330 various betalactamase producing organisms may be treated as indicated in certain sections belowrespiratoryacute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhaliscommunityacquired pneumonia caused by haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisear nose and throat acute bacterial otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pneumoniae penicillinsusceptible onlytonsillitis caused by streptococcus pyogenespharyngitis caused by streptococcus pyogenesacute maxillary sinusitis caused by haemophilus pneumoniae and streptococcus pneumoniae penicillinsusceptible only and moraxella catarrhalisskin and skin structure infectionsuncomplicated skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes')|
|('DB01340', 'MONDO:0005842', ['maxillary sinusitis'], 'cilazapril is an ace inhibtor class drug used in the treatment of hypertension and heart failure')|
|('DB01340', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'cilazapril is an ace inhibtor class drug used in the treatment of hypertension and heart failure')|
|('DB00832', 'MONDO:0005842', ['maxillary sinusitis'], 'for the treatment of epilepsy')|
|('DB00832', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the treatment of epilepsy')|
|('DB00990', 'MONDO:0005842', ['maxillary sinusitis'], 'for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy')|
|('DB00990', 'MONDO:0004992', ['cancer'], 'for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy')|
|('DB01194', 'MONDO:0004992', ['cancer'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma')|
|('DB01194', 'MONDO:0006875', ['ocular hypertension'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma')|
|('DB01194', 'MONDO:0005041', ['glaucoma'], 'for the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma')|
|('DB00132', 'MONDO:0006875', ['ocular hypertension'], 'for nutritional supplementation and for treating dietary shortage or imbalance')|
|('DB00281', 'MONDO:0006875', ['ocular hypertension'], 'lidocaine is an anesthetic of the amide group indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks f4349 l5930')|
|('DB01255', 'MONDO:0006875', ['ocular hypertension'], 'for the treatment of attentiondeficithyperactivity disorder adhd and for moderate to severe binge eating disorder in adults fda label a40246this drug is not indicated for weight loss use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects the safety and effectiveness of this drug for the treatment of obesity have not yet been determined fda label')|
|('DB01255', 'MONDO:0005451', ['eating disorder'], 'for the treatment of attentiondeficithyperactivity disorder adhd and for moderate to severe binge eating disorder in adults fda label a40246this drug is not indicated for weight loss use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects the safety and effectiveness of this drug for the treatment of obesity have not yet been determined fda label')|
|('DB01008', 'MONDO:0005451', ['eating disorder'], 'for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  myeloid myelocytic granulocytic leukemia fda has designated busulfan as an orphan drug for this use it is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases')|
|('DB01008', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  myeloid myelocytic granulocytic leukemia fda has designated busulfan as an orphan drug for this use it is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases')|
|('DB01008', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  myeloid myelocytic granulocytic leukemia fda has designated busulfan as an orphan drug for this use it is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases')|
|('DB00998', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for the acute treatment of migraine attacks with or without aura in adults')|
|('DB01410', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older')|
|('DB01410', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older')|
|('DB00737', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'indicated for the symptomatic treatment of nausea vomiting and dizziness associated with motion sicknessl6772 and management of vertigo due to various causes including radiation sickness meniere’s syndrome labyrinthitis and other vestibular disturbancesl6766')|
|('DB00470', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the treatment of anorexia associated with weight loss in patients with aids and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments')|
|('DB00470', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'for the treatment of anorexia associated with weight loss in patients with aids and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments')|
|('DB00470', 'MONDO:0004992', ['cancer'], 'for the treatment of anorexia associated with weight loss in patients with aids and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments')|
|('DB00828', 'MONDO:0004992', ['cancer'], 'for the treatment of uncomplicated urinary tract infections acute cystitis in women due to susceptible strains of iescherichia colii and ienterococcus faecalisi')|
|('DB00828', 'MONDO:0001650', ['urinary tract infection', 'acute cystitis'], 'for the treatment of uncomplicated urinary tract infections acute cystitis in women due to susceptible strains of iescherichia colii and ienterococcus faecalisi')|
|('DB01550', 'MONDO:0001650', ['urinary tract infection', 'acute cystitis'], 'fenproporex is used as an appetite suppressant and antiobesity agent 2 however due to substance abuse potential it is an illicit substance in many countries in some countries such as brazil it is still prescribed  often in the form of diet pills ie brazilian diet pills which combine amphetamines benzodiazepines antidepressants diuretics and laxatives in the united states the sale of such diet pills has been banned due to concerns over side effects and the risk of potentially fatal overdosehowever internet sales and illicit markets has lead to international availability it has been found by primary care physicians that brazilian immigrant women utilized imported diet pills at particularly high rates and sometimes suffered from side effects requiring hospitalization or experienced a loss of employment 3')|
|('DB01550', 'MONDO:0002491', ['substance abuse'], 'fenproporex is used as an appetite suppressant and antiobesity agent 2 however due to substance abuse potential it is an illicit substance in many countries in some countries such as brazil it is still prescribed  often in the form of diet pills ie brazilian diet pills which combine amphetamines benzodiazepines antidepressants diuretics and laxatives in the united states the sale of such diet pills has been banned due to concerns over side effects and the risk of potentially fatal overdosehowever internet sales and illicit markets has lead to international availability it has been found by primary care physicians that brazilian immigrant women utilized imported diet pills at particularly high rates and sometimes suffered from side effects requiring hospitalization or experienced a loss of employment 3')|
|('DB01550', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'fenproporex is used as an appetite suppressant and antiobesity agent 2 however due to substance abuse potential it is an illicit substance in many countries in some countries such as brazil it is still prescribed  often in the form of diet pills ie brazilian diet pills which combine amphetamines benzodiazepines antidepressants diuretics and laxatives in the united states the sale of such diet pills has been banned due to concerns over side effects and the risk of potentially fatal overdosehowever internet sales and illicit markets has lead to international availability it has been found by primary care physicians that brazilian immigrant women utilized imported diet pills at particularly high rates and sometimes suffered from side effects requiring hospitalization or experienced a loss of employment 3')|
|('DB01205', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced andor maintained with benzodiazepines and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures')|
|('DB00256', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of infections and to treat acne it may also be used to treat urinary tract infections gum disease and other bacterial infections such as gonorrhea and chlamydia lymecycline is also used commonly as a prophylactic treatment for infection by ibacillus anthracisi anthrax it is also effective against iyersinia pestisi and malaria and is also prescribed for the treatment of lyme disease')|
|('DB00256', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'for the treatment of infections and to treat acne it may also be used to treat urinary tract infections gum disease and other bacterial infections such as gonorrhea and chlamydia lymecycline is also used commonly as a prophylactic treatment for infection by ibacillus anthracisi anthrax it is also effective against iyersinia pestisi and malaria and is also prescribed for the treatment of lyme disease')|
|('DB00256', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of infections and to treat acne it may also be used to treat urinary tract infections gum disease and other bacterial infections such as gonorrhea and chlamydia lymecycline is also used commonly as a prophylactic treatment for infection by ibacillus anthracisi anthrax it is also effective against iyersinia pestisi and malaria and is also prescribed for the treatment of lyme disease')|
|('DB00256', 'MONDO:0019632', ['Bannwarth syndrome', 'Bannworths syndrome', 'Lyme borreliosis', 'lyme neuroborreliosis', 'neuroborreliosis', 'Neurological Lyme disease', 'lyme disease'], 'for the treatment of infections and to treat acne it may also be used to treat urinary tract infections gum disease and other bacterial infections such as gonorrhea and chlamydia lymecycline is also used commonly as a prophylactic treatment for infection by ibacillus anthracisi anthrax it is also effective against iyersinia pestisi and malaria and is also prescribed for the treatment of lyme disease')|
|('DB01418', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment and prevention of thromboembolic diseases more specifically it is indicated for the prevention of cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism in infarction and transient ischemic attacks it is used for the treatment of deep vein thrombosis and myocardial infarction')|
|('DB01418', 'MONDO:0006809', ['cerebral embolism', 'Cerebral embolism with cerebral infarction', 'intracranial embolism'], 'for the treatment and prevention of thromboembolic diseases more specifically it is indicated for the prevention of cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism in infarction and transient ischemic attacks it is used for the treatment of deep vein thrombosis and myocardial infarction')|
|('DB01418', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for the treatment and prevention of thromboembolic diseases more specifically it is indicated for the prevention of cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism in infarction and transient ischemic attacks it is used for the treatment of deep vein thrombosis and myocardial infarction')|
|('DB01418', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'for the treatment and prevention of thromboembolic diseases more specifically it is indicated for the prevention of cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism in infarction and transient ischemic attacks it is used for the treatment of deep vein thrombosis and myocardial infarction')|
|('DB01418', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment and prevention of thromboembolic diseases more specifically it is indicated for the prevention of cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism in infarction and transient ischemic attacks it is used for the treatment of deep vein thrombosis and myocardial infarction')|
|('DB00887', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndrome')|
|('DB00887', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndrome')|
|('DB00887', 'MONDO:0005377', ['nephrotic syndrome'], 'for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndrome')|
|('DB01244', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of hypertension and chronic stable angina classic effortassociated angina')|
|('DB00762', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of metastatic colorectal cancer firstline therapy when administered with 5fluorouracil and leucovorin also used in combination with cisplatin for the treatment of extensive small cell lung cancer irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabinebased therapy ')|
|('DB00762', 'MONDO:0004992', ['cancer'], 'for the treatment of metastatic colorectal cancer firstline therapy when administered with 5fluorouracil and leucovorin also used in combination with cisplatin for the treatment of extensive small cell lung cancer irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabinebased therapy ')|
|('DB01489', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'camazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression ')|
|('DB01489', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'camazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression ')|
|('DB00540', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'primarily indicated for the relief of symptoms of depression')|
|('DB00499', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of locally confined stage b2c and stage d2 metastatic carcinoma of the prostate')|
|('DB00499', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'for the management of locally confined stage b2c and stage d2 metastatic carcinoma of the prostate')|
|('DB01074', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'for the management of severe angina pectoris')|
|('DB00563', 'MONDO:0024879', ['metastatic carcinoma [NCIT:C3482]', 'metastatic carcinoma'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0005059', ['leukemia'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0020550', ['Gestational choriocarcinoma', 'Gestational chorionepithelioma', 'Molar pregnancy with choriocarcinoma', 'gestational choriocarcinoma'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0005073', ['melanocytic Nevus [NCIT:C7570]', 'melanotic Nevus [NCIT:C7570]', 'mole of skin [NCIT:C7570]', 'mole [NCIT:C7570]', 'nevus [NCIT:C7570]', 'melanocytic nevus'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0004992', ['cancer'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0009691', ['Mycosis fungoides', 'mycosis fungoides lymphoma', 'mycosis fungoides'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB00563', 'MONDO:0008903', ['lung cancer'], 'methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritisl7144 methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis and severe recalcitrant disabling psoriasisl7147l7150l10457other formulations are indicated to treat gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer of the head and neck advanced mycosis fungoides lung cancer and advanced nonhodgkins lymphomal7180 it is also used in the maintenance of acute lymphocytic leukemial7180 methotrexate is also given before treatment with leucovorin to prolong relapsefree survival following surgical removal of a tumour in nonmetastatic osteosarcomal7180')|
|('DB01082', 'MONDO:0008903', ['lung cancer'], 'for the treatment of tuberculosis may also be used in combination with other drugs to treat tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis and enterococcal endocarditis eg e faecalis e faecium')|
|('DB01082', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of tuberculosis may also be used in combination with other drugs to treat tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis and enterococcal endocarditis eg e faecalis e faecium')|
|('DB01082', 'MONDO:0018077', ['tularemia'], 'for the treatment of tuberculosis may also be used in combination with other drugs to treat tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis and enterococcal endocarditis eg e faecalis e faecium')|
|('DB01082', 'MONDO:0019095', ['plague'], 'for the treatment of tuberculosis may also be used in combination with other drugs to treat tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis and enterococcal endocarditis eg e faecalis e faecium')|
|('DB01082', 'MONDO:0005025', ['endocarditis'], 'for the treatment of tuberculosis may also be used in combination with other drugs to treat tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis and enterococcal endocarditis eg e faecalis e faecium')|
|('DB00396', 'MONDO:0005025', ['endocarditis'], 'gelatinized capsulesthe gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets they are also indicated for use in secondary amenorrhea fda label vaginal gelprogesterone gel 8 is indicated as progesterone supplementation or replacement as part of an assisted reproductive technology “art” treatment for infertile women with progesterone deficiency  the lower concentration progesterone gel 4 is used in the treatment of secondary amenorrhea with the use of the 8 concentration if there is no therapeutic response to the 4 gel f3898vaginal insertthis form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology art treatment program for infertile women f3901injection intramuscularthis drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer f3907 tablets contraceptivethe tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy f3904 ')|
|('DB00396', 'MONDO:0041161', ['hyperplasia of the endometrium [NCIT:C3013]', 'endometrial hyperplasia []', 'hyperplasia of endometrium [NCIT:C3013]', 'endometrial hyperplasia'], 'gelatinized capsulesthe gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets they are also indicated for use in secondary amenorrhea fda label vaginal gelprogesterone gel 8 is indicated as progesterone supplementation or replacement as part of an assisted reproductive technology “art” treatment for infertile women with progesterone deficiency  the lower concentration progesterone gel 4 is used in the treatment of secondary amenorrhea with the use of the 8 concentration if there is no therapeutic response to the 4 gel f3898vaginal insertthis form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology art treatment program for infertile women f3901injection intramuscularthis drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer f3907 tablets contraceptivethe tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy f3904 ')|
|('DB00396', 'MONDO:0001836', ['absence of menstruation', 'amenia', 'amenorrhea'], 'gelatinized capsulesthe gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets they are also indicated for use in secondary amenorrhea fda label vaginal gelprogesterone gel 8 is indicated as progesterone supplementation or replacement as part of an assisted reproductive technology “art” treatment for infertile women with progesterone deficiency  the lower concentration progesterone gel 4 is used in the treatment of secondary amenorrhea with the use of the 8 concentration if there is no therapeutic response to the 4 gel f3898vaginal insertthis form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology art treatment program for infertile women f3901injection intramuscularthis drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer f3907 tablets contraceptivethe tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy f3904 ')|
|('DB00396', 'MONDO:0002715', ['CA - cancer of uterus', 'malignant neoplasm of uterus', 'malignant uterine tumor', 'neoplasm of uterus', 'Tumour of uterus', 'uterine tumor', 'uterus neoplasm', 'uterine cancer'], 'gelatinized capsulesthe gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets they are also indicated for use in secondary amenorrhea fda label vaginal gelprogesterone gel 8 is indicated as progesterone supplementation or replacement as part of an assisted reproductive technology “art” treatment for infertile women with progesterone deficiency  the lower concentration progesterone gel 4 is used in the treatment of secondary amenorrhea with the use of the 8 concentration if there is no therapeutic response to the 4 gel f3898vaginal insertthis form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology art treatment program for infertile women f3901injection intramuscularthis drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer f3907 tablets contraceptivethe tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy f3904 ')|
|('DB00312', 'MONDO:0002715', ['CA - cancer of uterus', 'malignant neoplasm of uterus', 'malignant uterine tumor', 'neoplasm of uterus', 'Tumour of uterus', 'uterine tumor', 'uterus neoplasm', 'uterine cancer'], 'for the shortterm treatment of insomnia')|
|('DB00312', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the shortterm treatment of insomnia')|
|('DB00223', 'MONDO:0002715', ['CA - cancer of uterus', 'malignant neoplasm of uterus', 'malignant uterine tumor', 'neoplasm of uterus', 'Tumour of uterus', 'uterine tumor', 'uterus neoplasm', 'uterine cancer'], 'for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses')|
|('DB00348', 'MONDO:0002715', ['CA - cancer of uterus', 'malignant neoplasm of uterus', 'malignant uterine tumor', 'neoplasm of uterus', 'Tumour of uterus', 'uterine tumor', 'uterus neoplasm', 'uterine cancer'], 'used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1')|
|('DB00784', 'MONDO:0002715', ['CA - cancer of uterus', 'malignant neoplasm of uterus', 'malignant uterine tumor', 'neoplasm of uterus', 'Tumour of uterus', 'uterine tumor', 'uterus neoplasm', 'uterine cancer'], 'for the treatment of rheumatoid arthritis osteoarthritis dysmenorrhea and mild to moderate pain inflammation and fever')|
|('DB00784', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of rheumatoid arthritis osteoarthritis dysmenorrhea and mild to moderate pain inflammation and fever')|
|('DB00514', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for treatment and relief of dry cough')|
|('DB01041', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence')|
|('DB00525', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'tolnaftate topical is used to treat skin infections such as athletes foot jock itch and ringworm infections tolnaftate is also used along with other antifungals to treat infections of the nails scalp palms and soles of the feet the powder and powder aerosol may be used to prevent athletes foot')|
|('DB00525', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'tolnaftate topical is used to treat skin infections such as athletes foot jock itch and ringworm infections tolnaftate is also used along with other antifungals to treat infections of the nails scalp palms and soles of the feet the powder and powder aerosol may be used to prevent athletes foot')|
|('DB01600', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'tiaprofenic acid is used to treat pain especially arthritic pain')|
|('DB00169', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets or vitamin d resistant rickets hypoparathyroidism and familial hypophosphatemia f4027 f4042concurrently as one of the most commonly utilized forms of vitamin d cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease among others a176041 a176044 f4051')|
|('DB00169', 'MONDO:0010931', ['vitamin D receptor signaling defect rickets [NCIT:C131076]', 'vitamin D dependent rickets 2b [NCIT:C131076]', 'hereditary 1,25 dihydroxyvitamin D-resistant rickets with abnormal vitamin D receptor without alopecia [NCIT:C131076]', 'vitamin D resistant rickets [NCIT:C131076]', 'vitamin D-dependent rickets type II without alopecia [MONDO:cjm]', 'vitamin d-dependent rickets, type 2b'], 'cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets or vitamin d resistant rickets hypoparathyroidism and familial hypophosphatemia f4027 f4042concurrently as one of the most commonly utilized forms of vitamin d cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease among others a176041 a176044 f4051')|
|('DB00169', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets or vitamin d resistant rickets hypoparathyroidism and familial hypophosphatemia f4027 f4042concurrently as one of the most commonly utilized forms of vitamin d cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease among others a176041 a176044 f4051')|
|('DB00169', 'MONDO:0005298', ['osteoporosis'], 'cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets or vitamin d resistant rickets hypoparathyroidism and familial hypophosphatemia f4027 f4042concurrently as one of the most commonly utilized forms of vitamin d cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease among others a176041 a176044 f4051')|
|('DB00169', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets or vitamin d resistant rickets hypoparathyroidism and familial hypophosphatemia f4027 f4042concurrently as one of the most commonly utilized forms of vitamin d cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease among others a176041 a176044 f4051')|
|('DB00227', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0002525', ['dyslipidemia', 'fatty acid metabolism disorder', 'inherited lipid metabolism disorder'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0021661', ['coronary artery arteriosclerosis (disease) [MONDO:patterns/location]', 'arteriosclerosis disorder of coronary artery [MONDO:design_pattern]', 'coronary atherosclerosis [NCIT:C35505]', 'coronary artery arteriosclerosis disorder [MONDO:design_pattern,MONDO:patterns/location]', 'coronary atherosclerosis'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005015', ['diabetes mellitus'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005311', ['atherosclerosis'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0005350', ['AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1', 'abdominal aortic aneurysm'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00227', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'lovastatin is indicated to reduce the risk of myocardial infarction unstable angina and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease average to moderately elevated totalc and ldlc and below average hdlc it is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease the administration of this agent should be accompanied by the implementation of a fat and cholesterolrestricted dietf4661therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia lovastatin is indicated as an adjunct to diet for the reduction of elevated totalc and ldlc levels in patients with primary hypercholesterolemia types iia and iib2 when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequatef4661f4664lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower totalc and ldlc to target levelsf4661lovastatin is indicated as an adjunct to diet to reduce totalc ldlc and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia hefh who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present ldlc remains greater than 189 mgdl or ldlc remains greater than 160 mgdl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patientbefore administering lovastatin it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performedprescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00193', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'tramadol is approved for the management of moderate to severe pain in adultsf4676f4679tramadol is also used offlabel in the treatment of premature ejaculationa173986')|
|('DB00583', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for treatment of primary systemic carnitine deficiency a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii methyl malonic aciduria propionic acidemia and medium chain fatty acylcoa dehydrogenase deficiency used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with endstage renal disease')|
|('DB00583', 'MONDO:0011628', ['GLYCINEMIA, KETOTIC', 'ketotic glycinemia', 'KETOTIC HYPERGLYCINEMIA', 'ketotic II glycinemia', 'propionic aciduria', 'propionyl-CoA carboxylase deficiency', 'propionic acidemia'], 'for treatment of primary systemic carnitine deficiency a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii methyl malonic aciduria propionic acidemia and medium chain fatty acylcoa dehydrogenase deficiency used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with endstage renal disease')|
|('DB00222', 'MONDO:0011628', ['GLYCINEMIA, KETOTIC', 'ketotic glycinemia', 'KETOTIC HYPERGLYCINEMIA', 'ketotic II glycinemia', 'propionic aciduria', 'propionyl-CoA carboxylase deficiency', 'propionic acidemia'], 'glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy it may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic a drug used to lower blood sugar levels agent alonel10322')|
|('DB00222', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy it may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic a drug used to lower blood sugar levels agent alonel10322')|
|('DB03166', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used to treat infections in the ear canal')|
|('DB00587', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for protection against second phase inflamation in exerciseinduced bronchoconstriction and asthma')|
|('DB00587', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for protection against second phase inflamation in exerciseinduced bronchoconstriction and asthma')|
|('DB06729', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment bacterial infections')|
|('DB00720', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors')|
|('DB00720', 'MONDO:0043455', ['hypercalcemia of malignancy [NCIT:C3496]', 'humoral hypercalcemia of malignancy []', 'humoral hypercalcemia of malignancy'], 'for the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors')|
|('DB00720', 'MONDO:0043731', ['osteolysis []', 'lytic metastatic bone lesion [NCIT:C35371]', 'osteolytic lesion [NCIT:C35371]', 'lytic metastatic bone lesion'], 'for the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors')|
|('DB01586', 'MONDO:0043731', ['osteolysis []', 'lytic metastatic bone lesion [NCIT:C35371]', 'osteolytic lesion [NCIT:C35371]', 'lytic metastatic bone lesion'], 'the drug decreases the absorption of cholesterol and is used to dissolve cholesterol gallstones in patients as an alternative to a surgical procedure to remove the gallstones')|
|('DB01586', 'MONDO:0005346', ['gallstones'], 'the drug decreases the absorption of cholesterol and is used to dissolve cholesterol gallstones in patients as an alternative to a surgical procedure to remove the gallstones')|
|('DB00249', 'MONDO:0043731', ['osteolysis []', 'lytic metastatic bone lesion [NCIT:C35371]', 'osteolytic lesion [NCIT:C35371]', 'lytic metastatic bone lesion'], 'for use in keratoconjunctivitis and keratitis caused by herpes simplex virus')|
|('DB00249', 'MONDO:0003085', ['keratitis'], 'for use in keratoconjunctivitis and keratitis caused by herpes simplex virus')|
|('DB00477', 'MONDO:0003085', ['keratitis'], 'for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance')|
|('DB00477', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance')|
|('DB00477', 'MONDO:0008294', ['AIP - acute intermittent porphyria', 'porphyria intermittent acute', 'Pyrroloporphyria', 'acute intermittent porphyria'], 'for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance')|
|('DB00477', 'MONDO:0005526', ['clostridial tetanus', 'Infection due to Clostridium tetani', 'tetanus'], 'for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance')|
|('DB00477', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance')|
|('DB01042', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer alone or in combination regimens for palliative treatment of locally recurrent or unresectable intransit metastatic melanoma of the extremities as well as for the treatment of amyloidosis with prednisone')|
|('DB01042', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for the palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer alone or in combination regimens for palliative treatment of locally recurrent or unresectable intransit metastatic melanoma of the extremities as well as for the treatment of amyloidosis with prednisone')|
|('DB01042', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for the palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer alone or in combination regimens for palliative treatment of locally recurrent or unresectable intransit metastatic melanoma of the extremities as well as for the treatment of amyloidosis with prednisone')|
|('DB01042', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'for the palliative treatment of multiple myeloma and for the palliation of nonresectable epithelial carcinoma of the ovary has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer alone or in combination regimens for palliative treatment of locally recurrent or unresectable intransit metastatic melanoma of the extremities as well as for the treatment of amyloidosis with prednisone')|
|('DB04552', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'used in the treatment of rheumatoid arthritis')|
|('DB04552', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in the treatment of rheumatoid arthritis')|
|('DB01069', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'for the treatment of allergic disorders and nauseavomiting')|
|('DB01605', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'used to treat infections due to mecillinamsensitive organisms such as urinary tract infections salmonellosis and typhoid fever')|
|('DB01605', 'MONDO:0000827', ['Salmonella infection', 'salmonellosis'], 'used to treat infections due to mecillinamsensitive organisms such as urinary tract infections salmonellosis and typhoid fever')|
|('DB01605', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'used to treat infections due to mecillinamsensitive organisms such as urinary tract infections salmonellosis and typhoid fever')|
|('DB00437', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'allopurinol is indicated in fda label1 the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy2 the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present3 the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks')|
|('DB00437', 'MONDO:0005059', ['leukemia'], 'allopurinol is indicated in fda label1 the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy2 the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present3 the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks')|
|('DB00437', 'MONDO:0004992', ['cancer'], 'allopurinol is indicated in fda label1 the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy2 the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present3 the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks')|
|('DB05260', 'MONDO:0004992', ['cancer'], 'for the treatment of hypercalcemia also intended for the treatment of nonhodgkins lymphoma')|
|('DB05260', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of hypercalcemia also intended for the treatment of nonhodgkins lymphoma')|
|('DB00144', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'phosphatidylserine has demonstrated some usefulness in treating cognitive impairment including alzheimers disease ageassociated memory impairment and some nonalzheimers dementias more research is needed before phosphatidylserine can be indicated for immune enhancement or for reduction of exercise stress')|
|('DB00144', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'phosphatidylserine has demonstrated some usefulness in treating cognitive impairment including alzheimers disease ageassociated memory impairment and some nonalzheimers dementias more research is needed before phosphatidylserine can be indicated for immune enhancement or for reduction of exercise stress')|
|('DB08820', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'when used as monotherapy as the product kalydeco ivacaftor is indicated for the management of cf in patients age 2 years and older who have a mutation in the cftr gene that is responsive to ivacaftor potentiation ivacaftor received expanded approval in may 2017 for the following 33 cftr mutations e56k p67l r74w d110e d110h r117c r117h g178r e193k l206w r347h r352q a455e s549n s549r g551d g551s d579g s945l s977f f1052v k1060t a1067t g1069r r1070q r1070w f1074l d1152h g1244e s1251n s1255p d1270n and g1349dl768l6838when used in combination with the drug lumacaftor as the product orkambi ivacaftor is indicated for the management of cf patients age 6 years and older who are shown to be homozygous for the f508del mutation in the cftr genewhen used in combination with tezacaftor in the product symdeko it is used to manage cf in patients 12 years and older who have at least one mutation in the cftr gene or patients aged 12 or older who are shown to be homozygous for the f508del mutationl6814when used in combination with tezacaftor and elexacaftor in the product trikafta it is indicated for the treatment of cystic fibrosis in patients 12 years of age and older who have at least one f508del mutation in the cftr genel9395')|
|('DB08820', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'when used as monotherapy as the product kalydeco ivacaftor is indicated for the management of cf in patients age 2 years and older who have a mutation in the cftr gene that is responsive to ivacaftor potentiation ivacaftor received expanded approval in may 2017 for the following 33 cftr mutations e56k p67l r74w d110e d110h r117c r117h g178r e193k l206w r347h r352q a455e s549n s549r g551d g551s d579g s945l s977f f1052v k1060t a1067t g1069r r1070q r1070w f1074l d1152h g1244e s1251n s1255p d1270n and g1349dl768l6838when used in combination with the drug lumacaftor as the product orkambi ivacaftor is indicated for the management of cf patients age 6 years and older who are shown to be homozygous for the f508del mutation in the cftr genewhen used in combination with tezacaftor in the product symdeko it is used to manage cf in patients 12 years and older who have at least one mutation in the cftr gene or patients aged 12 or older who are shown to be homozygous for the f508del mutationl6814when used in combination with tezacaftor and elexacaftor in the product trikafta it is indicated for the treatment of cystic fibrosis in patients 12 years of age and older who have at least one f508del mutation in the cftr genel9395')|
|('DB00145', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'supplemental glycine may have antispastic activity very early findings suggest it may also have antipsychotic activity as well as antioxidant and antiinflammatory activities')|
|('DB00710', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment and prevention of osteoporosis in postmenopausal women')|
|('DB00710', 'MONDO:0005298', ['osteoporosis'], 'for the treatment and prevention of osteoporosis in postmenopausal women')|
|('DB08881', 'MONDO:0005298', ['osteoporosis'], 'vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on braf in the valine located in the exon 15 at codon 600 this mutation is denominated as v600ea31270 the v600e mutation a substitution of glutamic acid for valine accounts for 54 of the cases of cutaneous melanomaa31271 vemurafenib approval was extended in 2017 for its use as a treatment of adult patients with erdheimchester disease whose cancer cells present braf v600 mutationl1013 erdheimchester disease is an extremely rare histiocyte cell disorder that affects large bones large vessels central nervous system as well as skin and lungs it is reported an association of erdheimchester disease and v600e mutationa31272')|
|('DB08881', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on braf in the valine located in the exon 15 at codon 600 this mutation is denominated as v600ea31270 the v600e mutation a substitution of glutamic acid for valine accounts for 54 of the cases of cutaneous melanomaa31271 vemurafenib approval was extended in 2017 for its use as a treatment of adult patients with erdheimchester disease whose cancer cells present braf v600 mutationl1013 erdheimchester disease is an extremely rare histiocyte cell disorder that affects large bones large vessels central nervous system as well as skin and lungs it is reported an association of erdheimchester disease and v600e mutationa31272')|
|('DB08881', 'MONDO:0004992', ['cancer'], 'vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on braf in the valine located in the exon 15 at codon 600 this mutation is denominated as v600ea31270 the v600e mutation a substitution of glutamic acid for valine accounts for 54 of the cases of cutaneous melanomaa31271 vemurafenib approval was extended in 2017 for its use as a treatment of adult patients with erdheimchester disease whose cancer cells present braf v600 mutationl1013 erdheimchester disease is an extremely rare histiocyte cell disorder that affects large bones large vessels central nervous system as well as skin and lungs it is reported an association of erdheimchester disease and v600e mutationa31272')|
|('DB08881', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on braf in the valine located in the exon 15 at codon 600 this mutation is denominated as v600ea31270 the v600e mutation a substitution of glutamic acid for valine accounts for 54 of the cases of cutaneous melanomaa31271 vemurafenib approval was extended in 2017 for its use as a treatment of adult patients with erdheimchester disease whose cancer cells present braf v600 mutationl1013 erdheimchester disease is an extremely rare histiocyte cell disorder that affects large bones large vessels central nervous system as well as skin and lungs it is reported an association of erdheimchester disease and v600e mutationa31272')|
|('DB01580', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'used in the treatment of hypertension angina pectoris arrhythmias and anxiety')|
|('DB01580', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in the treatment of hypertension angina pectoris arrhythmias and anxiety')|
|('DB08907', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0005147', ['IDDM', 'insulin-dependent diabetes mellitus', 'type I diabetes mellitus', 'type 1 diabetes mellitus'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08907', 'MONDO:0012819', ['DIABETES MELLITUS, KETOSIS-PRONE', 'ketosis-prone diabetes mellitus', 'diabetic ketoacidosis'], 'this drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus fda labelanother indication for canagliflozin is the prevention of major cardiovascular events myocardial infarction stroke or death due to a cardiovascular cause in patients with type 2 diabetes as well as hospitalization for heart failure in patients with type 2 diabetesl5897l8917in addition to the above canagliflozin can be used to lower the risk of endstage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus diabetic nephropathy and albuminurial8917it is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis fda label ')|
|('DB08810', 'MONDO:0012819', ['DIABETES MELLITUS, KETOSIS-PRONE', 'ketosis-prone diabetes mellitus', 'diabetic ketoacidosis'], 'it is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease gerd nonulcer dyspepsia and delayed gastric emptying')|
|('DB08810', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'it is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease gerd nonulcer dyspepsia and delayed gastric emptying')|
|('DB08810', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'it is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease gerd nonulcer dyspepsia and delayed gastric emptying')|
|('DB00650', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for the treatment of osteosarcoma after high dose methotrexate therapy used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists and to treat megaloblastic anemias due to folic acid deficiency also used in combination with 5fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer')|
|('DB00650', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'for the treatment of osteosarcoma after high dose methotrexate therapy used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists and to treat megaloblastic anemias due to folic acid deficiency also used in combination with 5fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer')|
|('DB00650', 'MONDO:0004992', ['cancer'], 'for the treatment of osteosarcoma after high dose methotrexate therapy used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists and to treat megaloblastic anemias due to folic acid deficiency also used in combination with 5fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer')|
|('DB01265', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'for the treatment of chronic hepatitis b in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB01265', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'for the treatment of chronic hepatitis b in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB01265', 'MONDO:0005103', ['well-differentiated liposarcoma [NCIT:C4250]', 'well differentiated liposarcoma of deep soft tissue [NCIT:C4250]', 'WDLS [Orphanet:99971]', 'atypical lipomatous tumor [Orphanet:99971]', 'atypical lipoma [Orphanet:99971]', 'ALT [Orphanet:99971]', 'well differentiated liposarcoma [NCIT:C4250]', 'well-differentiated liposarcoma'], 'for the treatment of chronic hepatitis b in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB02187', 'MONDO:0005103', ['well-differentiated liposarcoma [NCIT:C4250]', 'well differentiated liposarcoma of deep soft tissue [NCIT:C4250]', 'WDLS [Orphanet:99971]', 'atypical lipomatous tumor [Orphanet:99971]', 'atypical lipoma [Orphanet:99971]', 'ALT [Orphanet:99971]', 'well differentiated liposarcoma [NCIT:C4250]', 'well-differentiated liposarcoma'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB02187', 'MONDO:0002234', ['vaginitis'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB02187', 'MONDO:0002146', ['hypogonadism'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB02187', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB02187', 'MONDO:0004992', ['cancer'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB02187', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and advanced androgendependent carcinoma of the prostate for palliation only')|
|('DB00978', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of bacterial infections of the respiratory tract chronic bronchitis and urinary tract and as a preoperative prophylactic to prevent urinary tract infection caused by ispneumoniaei ihinfluenzaei isaureusi ipaeruginosai ie cloacaei ip mirabilisi ic civersusi is asprphyticusi iecolii and ikpneumoniaei')|
|('DB00978', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of bacterial infections of the respiratory tract chronic bronchitis and urinary tract and as a preoperative prophylactic to prevent urinary tract infection caused by ispneumoniaei ihinfluenzaei isaureusi ipaeruginosai ie cloacaei ip mirabilisi ic civersusi is asprphyticusi iecolii and ikpneumoniaei')|
|('DB00978', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of bacterial infections of the respiratory tract chronic bronchitis and urinary tract and as a preoperative prophylactic to prevent urinary tract infection caused by ispneumoniaei ihinfluenzaei isaureusi ipaeruginosai ie cloacaei ip mirabilisi ic civersusi is asprphyticusi iecolii and ikpneumoniaei')|
|('DB00669', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'a combination sumatriptan and naproxen tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and olderl6793 sumatriptan nasal powder nasal spray subcutaneous injection and tablets are indicated to treat migraines with or without auras in adultsl6796l6799l6805l6808l6811 one of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adultsl6805 while the other subcutaneous formulation is notl6808')|
|('DB00607', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'indicated in the treatment of infections caused by penicillinaseproducing staphylococci which have demonstrated susceptibility to the drug ')|
|('DB01298', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'used orally in the treatment of acute urinary tract infections')|
|('DB05265', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'for the treatment of reflux oesophagitis and peptic ulcer disease')|
|('DB05265', 'MONDO:0006896', ['Peptic esophagitis', 'Peptic reflux disease', 'reflux esophagitis', 'Reflux oesophagitis', 'peptic esophagitis'], 'for the treatment of reflux oesophagitis and peptic ulcer disease')|
|('DB05265', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of reflux oesophagitis and peptic ulcer disease')|
|('DB00138', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'it has been claimed that lcysteine has antiinflammatory properties that it can protect against various toxins and that it might be helpful in osteoarthritis and rheumatoid arthritis more research will have to be done before lcysteine can be indicated for any of these conditions research to date has mostly been in animal models')|
|('DB00138', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'it has been claimed that lcysteine has antiinflammatory properties that it can protect against various toxins and that it might be helpful in osteoarthritis and rheumatoid arthritis more research will have to be done before lcysteine can be indicated for any of these conditions research to date has mostly been in animal models')|
|('DB00138', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'it has been claimed that lcysteine has antiinflammatory properties that it can protect against various toxins and that it might be helpful in osteoarthritis and rheumatoid arthritis more research will have to be done before lcysteine can be indicated for any of these conditions research to date has mostly been in animal models')|
|('DB00136', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0010931', ['vitamin D receptor signaling defect rickets [NCIT:C131076]', 'vitamin D dependent rickets 2b [NCIT:C131076]', 'hereditary 1,25 dihydroxyvitamin D-resistant rickets with abnormal vitamin D receptor without alopecia [NCIT:C131076]', 'vitamin D resistant rickets [NCIT:C131076]', 'vitamin D-dependent rickets type II without alopecia [MONDO:cjm]', 'vitamin d-dependent rickets, type 2b'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0000313', ['hypophosphatemia'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0001220', ['hypoparathyroidism'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0006946', ['renal rickets', 'renal osteodystrophy'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0024327', ['chronic renal failure [NCIT:C9438]', 'CRF - chronic renal failure [NCIT:C9438]', 'Chronic renal disease [NCIT:C9438]', 'chronic kidney failure []', 'chronic renal failure disease [NCIT:C9438-modified]', 'kidney failure, chronic [MONDO:patterns/chronic]', 'chronic renal failure syndrome'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB00136', 'MONDO:0005298', ['osteoporosis'], 'used to treat vitamin d deficiency or insufficiency refractory rickets vitamin d resistant rickets familial hypophosphatemia and hypoparathyroidism and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis also used in conjunction with calcium in the management and prevention of primary or corticosteroidinduced osteoporosis')|
|('DB01576', 'MONDO:0024327', ['chronic renal failure [NCIT:C9438]', 'CRF - chronic renal failure [NCIT:C9438]', 'Chronic renal disease [NCIT:C9438]', 'chronic kidney failure []', 'chronic renal failure disease [NCIT:C9438-modified]', 'kidney failure, chronic [MONDO:patterns/chronic]', 'chronic renal failure syndrome'], 'dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder adhdlabel')|
|('DB01576', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder adhdlabel')|
|('DB00674', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'for the treatment of mild to moderate dementia of the alzheimers type has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for alzheimers disease')|
|('DB00674', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of mild to moderate dementia of the alzheimers type has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for alzheimers disease')|
|('DB00908', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of ventricular preexcitation and cardiac dysrhythmias')|
|('DB00423', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'methocarbamol tablets and intramuscular injections are indicated in the united states as an adjunct to rest physical therapy and other measures for the relief of discomforts associated with acute painful musculoskeletal conditionslabell6268 oral methocarbamol in america may be given up to 1500mg 4 times daily for 23 daysa31312in canada methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasml6295 however if these combination formulations include codeine they are prescription onlyl6295')|
|('DB00675', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situl7802')|
|('DB00675', 'MONDO:0004992', ['cancer'], 'tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situl7802')|
|('DB00675', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situl7802')|
|('DB00675', 'MONDO:0006256', ['invasive mammary carcinoma [NCIT:C9245]', 'infiltrating breast carcinoma [NCIT:C9245]', 'invasive breast cancer [NCIT:C9245]', 'infiltrating carcinoma of breast [NCIT:C9245]', 'invasive carcinoma of the breast [NCIT:C9245]', 'infiltrating carcinoma of the breast [NCIT:C9245]', 'infiltrating breast cancer [NCIT:C9245]', 'invasive carcinoma of breast [NCIT:C9245]', 'invasive breast carcinoma [NCIT:C9245]', 'invasive breast carcinoma'], 'tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situl7802')|
|('DB01408', 'MONDO:0006256', ['invasive mammary carcinoma [NCIT:C9245]', 'infiltrating breast carcinoma [NCIT:C9245]', 'invasive breast cancer [NCIT:C9245]', 'infiltrating carcinoma of breast [NCIT:C9245]', 'invasive carcinoma of the breast [NCIT:C9245]', 'infiltrating carcinoma of the breast [NCIT:C9245]', 'infiltrating breast cancer [NCIT:C9245]', 'invasive carcinoma of breast [NCIT:C9245]', 'invasive breast carcinoma [NCIT:C9245]', 'invasive breast carcinoma'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema')|
|('DB01408', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema')|
|('DB01408', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema')|
|('DB01408', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema')|
|('DB01028', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for use in the induction and maintenance of general anesthesia')|
|('DB00524', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of hypertension alone or in combination with other antihypertensive drugs of a different class')|
|('DB01589', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'used to treat insomnia')|
|('DB01589', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used to treat insomnia')|
|('DB08890', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'treatment of irritable bowel syndrome ibs with constipation and chronic idiopathic constipation ')|
|('DB08890', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'treatment of irritable bowel syndrome ibs with constipation and chronic idiopathic constipation ')|
|('DB00778', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'used to treat respiratory tract urinary and soft tissue infections')|
|('DB00494', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'used as an adjunct to levodopa  carbidopa in the symptomatic treatment of patients with idiopathic parkinsons disease who experience the signs and symptoms of endofdose wearingoff')|
|('DB01129', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of acidreflux disorders gerd peptic ulcer disease h pylori eradication and prevention of gastroinetestinal bleeds with nsaid use')|
|('DB01129', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of acidreflux disorders gerd peptic ulcer disease h pylori eradication and prevention of gastroinetestinal bleeds with nsaid use')|
|('DB00320', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes')|
|('DB00320', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes')|
|('DB00786', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'for the treatment of various cancers')|
|('DB01626', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'for the treatment of moderate to severe hypertension')|
|('DB00685', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'for treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by ineisseria gonorrhoeaei as well as non gonoccocal urethritis and cervicitis due to ichlamydia trachomatisi')|
|('DB00685', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by ineisseria gonorrhoeaei as well as non gonoccocal urethritis and cervicitis due to ichlamydia trachomatisi')|
|('DB00685', 'MONDO:0002345', ['cervicitis'], 'for treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by ineisseria gonorrhoeaei as well as non gonoccocal urethritis and cervicitis due to ichlamydia trachomatisi')|
|('DB01243', 'MONDO:0002345', ['cervicitis'], 'used in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp')|
|('DB01243', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'used in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp')|
|('DB00806', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs')|
|('DB00837', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the treatment of epilepsy')|
|('DB00837', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'indicated for the treatment of epilepsy')|
|('DB01273', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for use as an aid in smoking cessation')|
|('DB00399', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of hypercalcemia of malignancy also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy in may of 2007 the drug was approved for treatment of paget’s disease')|
|('DB00399', 'MONDO:0043455', ['hypercalcemia of malignancy [NCIT:C3496]', 'humoral hypercalcemia of malignancy []', 'humoral hypercalcemia of malignancy'], 'for the treatment of hypercalcemia of malignancy also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy in may of 2007 the drug was approved for treatment of paget’s disease')|
|('DB00339', 'MONDO:0043455', ['hypercalcemia of malignancy [NCIT:C3496]', 'humoral hypercalcemia of malignancy []', 'humoral hypercalcemia of malignancy'], 'for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents')|
|('DB00429', 'MONDO:0043455', ['hypercalcemia of malignancy [NCIT:C3496]', 'humoral hypercalcemia of malignancy []', 'humoral hypercalcemia of malignancy'], 'for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion 1 failure of expulsion of the fetus during the course of treatment by another method 2 premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity 3 requirement of a repeat intrauterine instillation of drug for expulsion of the fetus 4 inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management')|
|('DB00429', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion 1 failure of expulsion of the fetus during the course of treatment by another method 2 premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity 3 requirement of a repeat intrauterine instillation of drug for expulsion of the fetus 4 inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management')|
|('DB00459', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of severe psoriasis in adults')|
|('DB01263', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for prophylaxis of invasive emaspergillusem and emcandidaem infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant hsct recipients with graftversushost disease gvhd or due to hematologic malignancies with prolonged neutropenia from chemotherapy also for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole andor fluconazole posaconazole is used as an alternative treatment for invasive aspergillosis emfusariumem infections and zygomycosis in patients who are intolerant of or whose disease is refractory to other antifungals')|
|('DB01263', 'MONDO:0005657', ['Infection due to Aspergillus', 'aspergillosis'], 'for prophylaxis of invasive emaspergillusem and emcandidaem infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant hsct recipients with graftversushost disease gvhd or due to hematologic malignancies with prolonged neutropenia from chemotherapy also for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole andor fluconazole posaconazole is used as an alternative treatment for invasive aspergillosis emfusariumem infections and zygomycosis in patients who are intolerant of or whose disease is refractory to other antifungals')|
|('DB01263', 'MONDO:0019136', ['disseminated mucormycosis', 'zygomycosis', 'zygomycosis'], 'for prophylaxis of invasive emaspergillusem and emcandidaem infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant hsct recipients with graftversushost disease gvhd or due to hematologic malignancies with prolonged neutropenia from chemotherapy also for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole andor fluconazole posaconazole is used as an alternative treatment for invasive aspergillosis emfusariumem infections and zygomycosis in patients who are intolerant of or whose disease is refractory to other antifungals')|
|('DB00478', 'MONDO:0019136', ['disseminated mucormycosis', 'zygomycosis', 'zygomycosis'], 'for the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults')|
|('DB00478', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults')|
|('DB00314', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'used in the treatment of tuberculosis in combination with other drugs')|
|('DB00314', 'MONDO:0018076', ['tuberculosis'], 'used in the treatment of tuberculosis in combination with other drugs')|
|('DB00773', 'MONDO:0018076', ['tuberculosis'], 'for use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer also used to treat other malignancies such as lymphoma nonlymphocytic leukemia and glioblastoma multiforme')|
|('DB00773', 'MONDO:0005059', ['leukemia'], 'for use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer also used to treat other malignancies such as lymphoma nonlymphocytic leukemia and glioblastoma multiforme')|
|('DB00773', 'MONDO:0020690', ['adult glioblastoma multiforme [NCIT:C9094]', 'glioblastoma [NCIT:C9094]', 'grade iv adult astrocytic tumor [NCIT:C9094]', 'grade iv adult astrocytic neoplasm [NCIT:C9094]', 'adult glioblastoma [NCIT:C9094]', 'adult glioblastoma'], 'for use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer also used to treat other malignancies such as lymphoma nonlymphocytic leukemia and glioblastoma multiforme')|
|('DB01283', 'MONDO:0020690', ['adult glioblastoma multiforme [NCIT:C9094]', 'glioblastoma [NCIT:C9094]', 'grade iv adult astrocytic tumor [NCIT:C9094]', 'grade iv adult astrocytic neoplasm [NCIT:C9094]', 'adult glioblastoma [NCIT:C9094]', 'adult glioblastoma'], 'for the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults')|
|('DB01283', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults')|
|('DB00408', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the management of the manifestations of psychotic disorders such as schizophrenia')|
|('DB00839', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for use as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus type ii whose hyperglycemia cannot be satisfactorily controlled by diet alone')|
|('DB00839', 'MONDO:0002909', ['hyperglycemia'], 'for use as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus type ii whose hyperglycemia cannot be satisfactorily controlled by diet alone')|
|('DB00388', 'MONDO:0002909', ['hyperglycemia'], 'phenylephrine injections are indicated to treat hypotension caused by shock or anesthesial9416 l9410 an ophthalmic formulation is indicated to dilate pupilsl9413 and induce vasoconstriction an intranasal formulation is used to treat congestion and a topical formulation is used to treat hemorrhoidsa187370 offlabel uses include situations that require local blood flow restriction such as the treatment of priapisma187370')|
|('DB00388', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'phenylephrine injections are indicated to treat hypotension caused by shock or anesthesial9416 l9410 an ophthalmic formulation is indicated to dilate pupilsl9413 and induce vasoconstriction an intranasal formulation is used to treat congestion and a topical formulation is used to treat hemorrhoidsa187370 offlabel uses include situations that require local blood flow restriction such as the treatment of priapisma187370')|
|('DB01174', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for the treatment of all types of seizures except absence seizures')|
|('DB01174', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all types of seizures except absence seizures')|
|('DB06684', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'vilazodone is approved for treatment of major depressive disorderlabela38477a177622')|
|('DB01336', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'metocurine is a muscle relaxant')|
|('DB00823', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the prevention of pregnancy in women who elect to use this product as a method of contraception')|
|('DB00673', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy including highdose cisplatin in combination with other antiemetic agents')|
|('DB00673', 'MONDO:0004992', ['cancer'], 'for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy including highdose cisplatin in combination with other antiemetic agents')|
|('DB01054', 'MONDO:0004992', ['cancer'], 'for the treatment of mild to moderate hypertension')|
|('DB00387', 'MONDO:0004992', ['cancer'], 'for the treatment of all forms of parkinsons disease as well as control of extrapyramidal reactions induced by antipsychotic agents')|
|('DB00387', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of all forms of parkinsons disease as well as control of extrapyramidal reactions induced by antipsychotic agents')|
|('DB00759', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'used to treat bacterial infections such as rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox and brillzinsser disease may be used to treat infections caused by chlamydiae spp b burgdorferi lyme disease and upper respiratory infections caused by typical s pneumoniae h influenzae and m catarrhalis and atypical organisms c pneumoniae m pneumoniae l pneumophila may also be used to treat acne tetracycline may be an alternative drug for people who are allergic to penicillin')|
|('DB00759', 'MONDO:0001195', ['Spotted fever group rickettsial disease', 'spotted fever'], 'used to treat bacterial infections such as rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox and brillzinsser disease may be used to treat infections caused by chlamydiae spp b burgdorferi lyme disease and upper respiratory infections caused by typical s pneumoniae h influenzae and m catarrhalis and atypical organisms c pneumoniae m pneumoniae l pneumophila may also be used to treat acne tetracycline may be an alternative drug for people who are allergic to penicillin')|
|('DB00759', 'MONDO:0019186', ['Infection due to Coxiella burnetii', 'q fever'], 'used to treat bacterial infections such as rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox and brillzinsser disease may be used to treat infections caused by chlamydiae spp b burgdorferi lyme disease and upper respiratory infections caused by typical s pneumoniae h influenzae and m catarrhalis and atypical organisms c pneumoniae m pneumoniae l pneumophila may also be used to treat acne tetracycline may be an alternative drug for people who are allergic to penicillin')|
|('DB00759', 'MONDO:0019632', ['Bannwarth syndrome', 'Bannworths syndrome', 'Lyme borreliosis', 'lyme neuroborreliosis', 'neuroborreliosis', 'Neurological Lyme disease', 'lyme disease'], 'used to treat bacterial infections such as rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox and brillzinsser disease may be used to treat infections caused by chlamydiae spp b burgdorferi lyme disease and upper respiratory infections caused by typical s pneumoniae h influenzae and m catarrhalis and atypical organisms c pneumoniae m pneumoniae l pneumophila may also be used to treat acne tetracycline may be an alternative drug for people who are allergic to penicillin')|
|('DB00759', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'used to treat bacterial infections such as rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox and brillzinsser disease may be used to treat infections caused by chlamydiae spp b burgdorferi lyme disease and upper respiratory infections caused by typical s pneumoniae h influenzae and m catarrhalis and atypical organisms c pneumoniae m pneumoniae l pneumophila may also be used to treat acne tetracycline may be an alternative drug for people who are allergic to penicillin')|
|('DB01215', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'for the shortterm management of insomnia characterized by difficulty in falling asleep frequent nocturnal awakenings andor early morning awakenings')|
|('DB01215', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the shortterm management of insomnia characterized by difficulty in falling asleep frequent nocturnal awakenings andor early morning awakenings')|
|('DB00162', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of vitamin a deficiency')|
|('DB00162', 'MONDO:0007016', ['vitamin A deficiency [MONDO:ambiguous,NCIT:C85220]', 'vitamin a deficiency'], 'for the treatment of vitamin a deficiency')|
|('DB00992', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for topical use in combination with 570 to 670 nm wavelength red light illumination in the treatment of nonhyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation debridement using a sharp dermal curette')|
|('DB00992', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'for topical use in combination with 570 to 670 nm wavelength red light illumination in the treatment of nonhyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation debridement using a sharp dermal curette')|
|('DB01415', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'indicated for the treatment of acute bacterial exacerbations of chronic bronchitis abecb acute bacterial otitis media pharyngitis and tonsilitis')|
|('DB01415', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'indicated for the treatment of acute bacterial exacerbations of chronic bronchitis abecb acute bacterial otitis media pharyngitis and tonsilitis')|
|('DB01415', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'indicated for the treatment of acute bacterial exacerbations of chronic bronchitis abecb acute bacterial otitis media pharyngitis and tonsilitis')|
|('DB00404', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'alprazolam is indicated for the management of anxiety disorder anxiety associated with depression panic disorder and panic disorder with agoraphobialabel alprazolam may also be prescribed off label for insomnia premenstrual syndrome and depressiona177973')|
|('DB00404', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'alprazolam is indicated for the management of anxiety disorder anxiety associated with depression panic disorder and panic disorder with agoraphobialabel alprazolam may also be prescribed off label for insomnia premenstrual syndrome and depressiona177973')|
|('DB00404', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'alprazolam is indicated for the management of anxiety disorder anxiety associated with depression panic disorder and panic disorder with agoraphobialabel alprazolam may also be prescribed off label for insomnia premenstrual syndrome and depressiona177973')|
|('DB00404', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'alprazolam is indicated for the management of anxiety disorder anxiety associated with depression panic disorder and panic disorder with agoraphobialabel alprazolam may also be prescribed off label for insomnia premenstrual syndrome and depressiona177973')|
|('DB00404', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'alprazolam is indicated for the management of anxiety disorder anxiety associated with depression panic disorder and panic disorder with agoraphobialabel alprazolam may also be prescribed off label for insomnia premenstrual syndrome and depressiona177973')|
|('DB00389', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of hyperthyroidism and thyrotoxicosis it is also used to prepare patients for thyroidectomy')|
|('DB00389', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'for the treatment of hyperthyroidism and thyrotoxicosis it is also used to prepare patients for thyroidectomy')|
|('DB00389', 'MONDO:0010138', ['thyrotoxicosis'], 'for the treatment of hyperthyroidism and thyrotoxicosis it is also used to prepare patients for thyroidectomy')|
|('DB00550', 'MONDO:0010138', ['thyrotoxicosis'], 'used to manage hyperthyroidism which is due to an overactive thyroid gland graves disease')|
|('DB00550', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'used to manage hyperthyroidism which is due to an overactive thyroid gland graves disease')|
|('DB01275', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertensionl8782 a combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failurel8785')|
|('DB00912', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB00912', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB00353', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the prevention and control of excessive bleeding following vaginal childbirth')|
|('DB00847', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'given intravenously or orally to treat radiation sickness the bitartrate salts cystagon® and procysbi have been used for the oral treatment of nephropathic cystinosis and cystinurea the hydrochloride salt cystaran™ is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients')|
|('DB04877', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of malaria also under investigation for the modulation of multidrug resistance in cancer cells')|
|('DB04877', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of malaria also under investigation for the modulation of multidrug resistance in cancer cells')|
|('DB04877', 'MONDO:0004992', ['cancer'], 'for the treatment of malaria also under investigation for the modulation of multidrug resistance in cancer cells')|
|('DB00663', 'MONDO:0004992', ['cancer'], 'for the treatment of contact dermatitis atopic dermatitis exczema psoriasis diaper rash and other skin conditions')|
|('DB00663', 'MONDO:0005480', ['Contact dermatitis', 'Contact dermatitis/eczema', 'Contact eczema', 'dermatitis venenata', 'Dermatitis, venenata', 'contact dermatitis'], 'for the treatment of contact dermatitis atopic dermatitis exczema psoriasis diaper rash and other skin conditions')|
|('DB00663', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of contact dermatitis atopic dermatitis exczema psoriasis diaper rash and other skin conditions')|
|('DB00663', 'MONDO:0005083', ['psoriasis'], 'for the treatment of contact dermatitis atopic dermatitis exczema psoriasis diaper rash and other skin conditions')|
|('DB00663', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'for the treatment of contact dermatitis atopic dermatitis exczema psoriasis diaper rash and other skin conditions')|
|('DB01239', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'for treatment of psychotic disorders eg schizophrenia and of acute mania occuring as part of bipolar disorders')|
|('DB01239', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for treatment of psychotic disorders eg schizophrenia and of acute mania occuring as part of bipolar disorders')|
|('DB01118', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'intravenously for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy orally for the treatment of lifethreatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia')|
|('DB01118', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'intravenously for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy orally for the treatment of lifethreatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia')|
|('DB06148', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'for the treatment of depression')|
|('DB01420', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'testosterone propionate is often used for muscle mass building the original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropausel1161 nowadays testosterone propionate is indicated for its use in heifers in order to stimulate maximal growthl1160')|
|('DB01296', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'glucosamine is usually used in the treatment of osteoarthritis although its efficacy is still in question')|
|('DB01296', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'glucosamine is usually used in the treatment of osteoarthritis although its efficacy is still in question')|
|('DB06768', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of dry scaly skin xerosis and ichthyosis vulgaris and for temporary relief of itching associated with these conditions')|
|('DB06768', 'MONDO:0024304', ['ichthyosis vulgaris [NCIT:C84778]', 'ichthyosis vulgaris'], 'for the treatment of dry scaly skin xerosis and ichthyosis vulgaris and for temporary relief of itching associated with these conditions')|
|('DB00116', 'MONDO:0024304', ['ichthyosis vulgaris [NCIT:C84778]', 'ichthyosis vulgaris'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00395', 'MONDO:0024304', ['ichthyosis vulgaris [NCIT:C84778]', 'ichthyosis vulgaris'], 'carisoprodol is indicated for the relief of discomfort related to acute painful musculoskeletal conditions fda labelimportant limitations of use fda label• should only be used for acute treatment periods up to two or three weeks • adequate evidence of effectiveness for more prolonged use has not been established • not recommended in pediatric patients less than 16 years of age')|
|('DB00395', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'carisoprodol is indicated for the relief of discomfort related to acute painful musculoskeletal conditions fda labelimportant limitations of use fda label• should only be used for acute treatment periods up to two or three weeks • adequate evidence of effectiveness for more prolonged use has not been established • not recommended in pediatric patients less than 16 years of age')|
|('DB00800', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the inhospital shortterm up to 48 hours management of severe hypertension when rapid but quickly reversible emergency reduction of blood pressure is clinically indicated including malignant hypertension with deteriorating endorgan function')|
|('DB00800', 'MONDO:0006846', ['malignant hypertension'], 'for the inhospital shortterm up to 48 hours management of severe hypertension when rapid but quickly reversible emergency reduction of blood pressure is clinically indicated including malignant hypertension with deteriorating endorgan function')|
|('DB08801', 'MONDO:0006846', ['malignant hypertension'], 'indicated as symptomatic treatment of allergic reactions urticaria allergies of the upper respiratory tract such as hey fever and perennial rhinitis food and drug allergies pruritus of various origins except pruritus due to cholestasis insect bites dimethindene is also indicated for pruritus in eruptive skin diseases such as chickenpox dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin ')|
|('DB08801', 'MONDO:0005492', ['urticaria'], 'indicated as symptomatic treatment of allergic reactions urticaria allergies of the upper respiratory tract such as hey fever and perennial rhinitis food and drug allergies pruritus of various origins except pruritus due to cholestasis insect bites dimethindene is also indicated for pruritus in eruptive skin diseases such as chickenpox dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin ')|
|('DB08801', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'indicated as symptomatic treatment of allergic reactions urticaria allergies of the upper respiratory tract such as hey fever and perennial rhinitis food and drug allergies pruritus of various origins except pruritus due to cholestasis insect bites dimethindene is also indicated for pruritus in eruptive skin diseases such as chickenpox dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin ')|
|('DB08801', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated as symptomatic treatment of allergic reactions urticaria allergies of the upper respiratory tract such as hey fever and perennial rhinitis food and drug allergies pruritus of various origins except pruritus due to cholestasis insect bites dimethindene is also indicated for pruritus in eruptive skin diseases such as chickenpox dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin ')|
|('DB01159', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the induction and maintenance of general anesthesia')|
|('DB08824', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ioflupane i123 is a spect single photon emission computerized tomography agent used to distinguish between parkinson’s syndrome tremors and essential tremor ')|
|('DB08824', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'ioflupane i123 is a spect single photon emission computerized tomography agent used to distinguish between parkinson’s syndrome tremors and essential tremor ')|
|('DB01615', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'aceprometazine is often used in combination with meprobamate for the treatment of sleep disorders')|
|('DB00704', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification also used for the management of alcohol dependence in conjunction with a behavioural modification program')|
|('DB00704', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification also used for the management of alcohol dependence in conjunction with a behavioural modification program')|
|('DB00299', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'used to treat recurrent cold sores on the lips and face from various herpesvirus invections')|
|('DB00299', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'used to treat recurrent cold sores on the lips and face from various herpesvirus invections')|
|('DB06809', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'used in combination with granulocytecolony stimulating factor gcsf filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with nonhodgkin’s lymphoma nhl and multiple myeloma mm')|
|('DB06809', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'used in combination with granulocytecolony stimulating factor gcsf filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with nonhodgkin’s lymphoma nhl and multiple myeloma mm')|
|('DB06402', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of complicated skin and skin structure infections csssi caused by grampositive bacteria like methicillinsusceptible or resistant staphylococcus aureus vancomycinsusceptible enterococcus faecalis and streptococcus pyogenes streptococcus agalactiae or streptococcus anginosus group also for the treatment of adult patients with hospitalacquired bacterial pneumonia hap and ventilatorassociated bacterial pneumonia vap known or suspected to be caused by susceptible isolates of staphylococcus aureus including methicillinsusceptible and methicillinresistant s aureus')|
|('DB06402', 'MONDO:0004652', ['gram-negative pneumonia', 'Pneumonia due to other gram-negative bacteria', 'bacterial pneumonia'], 'for the treatment of complicated skin and skin structure infections csssi caused by grampositive bacteria like methicillinsusceptible or resistant staphylococcus aureus vancomycinsusceptible enterococcus faecalis and streptococcus pyogenes streptococcus agalactiae or streptococcus anginosus group also for the treatment of adult patients with hospitalacquired bacterial pneumonia hap and ventilatorassociated bacterial pneumonia vap known or suspected to be caused by susceptible isolates of staphylococcus aureus including methicillinsusceptible and methicillinresistant s aureus')|
|('DB01250', 'MONDO:0004652', ['gram-negative pneumonia', 'Pneumonia due to other gram-negative bacteria', 'bacterial pneumonia'], 'for the treatment of inflammatory bowel disease and ulcerative colitis')|
|('DB01250', 'MONDO:0005265', ['inflammatory bowel disease'], 'for the treatment of inflammatory bowel disease and ulcerative colitis')|
|('DB01250', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'for the treatment of inflammatory bowel disease and ulcerative colitis')|
|('DB00810', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'for use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy')|
|('DB00810', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy')|
|('DB01339', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'vecuronium is a muscle relaxing agent and is used as an adjunct in general anesthesia')|
|('DB00234', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of clinical depression')|
|('DB00234', 'MONDO:0012048', ['clinical depression', 'unipolar depression', 'endogenous depression'], 'for the treatment of clinical depression')|
|('DB06771', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'treatment of bacterial conjunctivitis bacterial isolates that are susceptible to besifloxacin include cdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius ')|
|('DB06771', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'treatment of bacterial conjunctivitis bacterial isolates that are susceptible to besifloxacin include cdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius ')|
|('DB01108', 'MONDO:0006668', ['Purulent conjunctivitis', 'bacterial conjunctivitis'], 'used in the treatment of cushings syndrome it is normally used in shortterm treatment until permanent therapy is possible')|
|('DB01108', 'MONDO:0003009', ['Cushing syndrome', 'Cushings syndrome', 'hyperaldosteronism', 'hyperaldosteronism'], 'used in the treatment of cushings syndrome it is normally used in shortterm treatment until permanent therapy is possible')|
|('DB00746', 'MONDO:0003009', ['Cushing syndrome', 'Cushings syndrome', 'hyperaldosteronism', 'hyperaldosteronism'], 'used to treat acute iron or aluminum toxicity an excess of aluminum in the body in certain patients also used in certain patients with anemia who must receive many blood transfusions')|
|('DB00746', 'MONDO:0002280', ['anaemia', 'anemia'], 'used to treat acute iron or aluminum toxicity an excess of aluminum in the body in certain patients also used in certain patients with anemia who must receive many blood transfusions')|
|('DB00899', 'MONDO:0002280', ['anaemia', 'anemia'], 'for use during the induction and maintenance of general anesthesia')|
|('DB01598', 'MONDO:0002280', ['anaemia', 'anemia'], 'imipenem is indicated in combination with cilastatin with or without relebactam for the treatment of bacterial infections including respiratory skin bone gynecologic urinary tract and intraabdominal as well as septicemia and endocarditisl7526l7568')|
|('DB06698', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the reduction of episodes of vertigo association with ménières disease')|
|('DB06663', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the treatment of cushing’s disease specifically for those patients whom pituitary surgery has not been curative or is not an option')|
|('DB06663', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'for the treatment of cushing’s disease specifically for those patients whom pituitary surgery has not been curative or is not an option')|
|('DB06663', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of cushing’s disease specifically for those patients whom pituitary surgery has not been curative or is not an option')|
|('DB01623', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the management of schizophrenia')|
|('DB01623', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the management of schizophrenia')|
|('DB00195', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the management of hypertension')|
|('DB00117', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the actions of supplemental lhistidine are entirely unclear it may have some immunomodulatory as well as antioxidant activity lhistidine may be indicated for use in some with rheumatoid arthritis it is not indicated for treatment of anemia or uremia or for lowering serum cholesterol')|
|('DB00117', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'the actions of supplemental lhistidine are entirely unclear it may have some immunomodulatory as well as antioxidant activity lhistidine may be indicated for use in some with rheumatoid arthritis it is not indicated for treatment of anemia or uremia or for lowering serum cholesterol')|
|('DB00117', 'MONDO:0002280', ['anaemia', 'anemia'], 'the actions of supplemental lhistidine are entirely unclear it may have some immunomodulatory as well as antioxidant activity lhistidine may be indicated for use in some with rheumatoid arthritis it is not indicated for treatment of anemia or uremia or for lowering serum cholesterol')|
|('DB00117', 'MONDO:0007008', ['UREMIA OF renal ORIGIN', 'uremia'], 'the actions of supplemental lhistidine are entirely unclear it may have some immunomodulatory as well as antioxidant activity lhistidine may be indicated for use in some with rheumatoid arthritis it is not indicated for treatment of anemia or uremia or for lowering serum cholesterol')|
|('DB01015', 'MONDO:0007008', ['UREMIA OF renal ORIGIN', 'uremia'], 'for the treatment bacterial infections causing bronchitis prostatitis and urinary tract infections')|
|('DB01015', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment bacterial infections causing bronchitis prostatitis and urinary tract infections')|
|('DB06705', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography mra to evaluate aortoiliac occlusive disease aiod in adults with known or suspected peripheral vascular disease')|
|('DB06705', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography mra to evaluate aortoiliac occlusive disease aiod in adults with known or suspected peripheral vascular disease')|
|('DB05294', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease because vandetanib can prolong the qt interval it is contraindicated for use in patients with serious cardiac complications such as congenital long qt syndrome and uncompensated heart failure ')|
|('DB05294', 'MONDO:0022202', ['disseminated'], 'vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease because vandetanib can prolong the qt interval it is contraindicated for use in patients with serious cardiac complications such as congenital long qt syndrome and uncompensated heart failure ')|
|('DB05294', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease because vandetanib can prolong the qt interval it is contraindicated for use in patients with serious cardiac complications such as congenital long qt syndrome and uncompensated heart failure ')|
|('DB05294', 'MONDO:0002442', ['long Q-T syndrome', 'LQT', 'Romano-Ward syndrome', 'long qt syndrome'], 'vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease because vandetanib can prolong the qt interval it is contraindicated for use in patients with serious cardiac complications such as congenital long qt syndrome and uncompensated heart failure ')|
|('DB05294', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease because vandetanib can prolong the qt interval it is contraindicated for use in patients with serious cardiac complications such as congenital long qt syndrome and uncompensated heart failure ')|
|('DB00185', 'MONDO:0002442', ['long Q-T syndrome', 'LQT', 'Romano-Ward syndrome', 'long qt syndrome'], 'for the treatment of symptoms of dry mouth in patients with sjoumlgrens syndrome')|
|('DB01618', 'MONDO:0002442', ['long Q-T syndrome', 'LQT', 'Romano-Ward syndrome', 'long qt syndrome'], 'molindone is used for the management of the manifestations of psychotic disorders')|
|('DB00943', 'MONDO:0002442', ['long Q-T syndrome', 'LQT', 'Romano-Ward syndrome', 'long qt syndrome'], 'for the treatment of human immunovirus hiv infections in conjunction with other antivirals')|
|('DB00697', 'MONDO:0002442', ['long Q-T syndrome', 'LQT', 'Romano-Ward syndrome', 'long qt syndrome'], 'tizanidine is indicated for the relief of muscle spasticity which can interfere with daily activities  the general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief as it has a short duration of action fda label f4471 ')|
|('DB00697', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tizanidine is indicated for the relief of muscle spasticity which can interfere with daily activities  the general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief as it has a short duration of action fda label f4471 ')|
|('DB00697', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tizanidine is indicated for the relief of muscle spasticity which can interfere with daily activities  the general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief as it has a short duration of action fda label f4471 ')|
|('DB00125', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00288', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB08897', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'aclidinium bromide inhalation powder is indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema')|
|('DB08897', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'aclidinium bromide inhalation powder is indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema')|
|('DB08897', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'aclidinium bromide inhalation powder is indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema')|
|('DB08897', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'aclidinium bromide inhalation powder is indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema')|
|('DB00739', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'hetacillin is a betalactam antibiotic prodrug used to treat bacterial infections in the body it gets converted to ampicillin')|
|('DB01157', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for use with concurrent leucovorin administration leucovorin protection as an alternative therapy for the treatment of moderatetosevere ipneumocystis cariniii pneumonia pcp in immunocompromised patients including patients with the acquired immunodeficiency syndrome aids also used to treat several types of cancer including colon cancer')|
|('DB01157', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for use with concurrent leucovorin administration leucovorin protection as an alternative therapy for the treatment of moderatetosevere ipneumocystis cariniii pneumonia pcp in immunocompromised patients including patients with the acquired immunodeficiency syndrome aids also used to treat several types of cancer including colon cancer')|
|('DB01157', 'MONDO:0017769', ['acquired immunodeficiency'], 'for use with concurrent leucovorin administration leucovorin protection as an alternative therapy for the treatment of moderatetosevere ipneumocystis cariniii pneumonia pcp in immunocompromised patients including patients with the acquired immunodeficiency syndrome aids also used to treat several types of cancer including colon cancer')|
|('DB01157', 'MONDO:0004992', ['cancer'], 'for use with concurrent leucovorin administration leucovorin protection as an alternative therapy for the treatment of moderatetosevere ipneumocystis cariniii pneumonia pcp in immunocompromised patients including patients with the acquired immunodeficiency syndrome aids also used to treat several types of cancer including colon cancer')|
|('DB00582', 'MONDO:0004992', ['cancer'], 'for the treatment of esophageal candidiasis invasive pulmonary aspergillosis and serious fungal infections caused by iscedosporium apiospermumi and ifusariumi spp')|
|('DB00582', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'for the treatment of esophageal candidiasis invasive pulmonary aspergillosis and serious fungal infections caused by iscedosporium apiospermumi and ifusariumi spp')|
|('DB01324', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'polythiazide is a thiazide diuretic used to decrease edema and decrease blood pressure')|
|('DB01117', 'MONDO:0001648', ['Candida Esophagitis', 'Candidal esophagitis', 'Candidiasis of the esophagus', 'esophageal moniliasis', 'esophageal thrush', 'esophageal candidiasis'], 'for the treatment or prevention of ipneumocystis cariniii pneumonia in patients who are intolerant to trimethoprimsulfamethoxazole tmpsmx also indicated for the acute oral treatment of mild to moderate pcp in patients who are intolerant to tmpsmx')|
|('DB01117', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment or prevention of ipneumocystis cariniii pneumonia in patients who are intolerant to trimethoprimsulfamethoxazole tmpsmx also indicated for the acute oral treatment of mild to moderate pcp in patients who are intolerant to tmpsmx')|
|('DB00593', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of petit mal epilepsy')|
|('DB00488', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following firstline therapy with a cisplatin andor alkylating agentbased combination')|
|('DB00488', 'MONDO:0004992', ['cancer'], 'for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following firstline therapy with a cisplatin andor alkylating agentbased combination')|
|('DB01120', 'MONDO:0004992', ['cancer'], 'for the treatment of niddm in conjunction with diet and exercise ')|
|('DB01120', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of niddm in conjunction with diet and exercise ')|
|('DB00196', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'fluconazole can be administered in the treatment of the following fungal infectionsfda label 1 vaginal yeast infections caused by candida 2 systemic candida infections 3 both esophageal and oropharyngeal candidiasis  4 cryptococcal meningitis 5 uti urinary tract infection by candida 6 peritonitis inflammation of the peritoneum caused by candidaa note on fungal infection prophylaxispatients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy andor radiation therapy may be predisposed to candida infections and may receive fluconazole as prophylactic therapyfda labela note on laboratory testingobtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment it is permissible to start therapy before the results are available however adjusting the therapy once laboratory results confirm the causative organism may be necessaryfda label')|
|('DB00196', 'MONDO:0005723', ['Cryptococcal meningitis'], 'fluconazole can be administered in the treatment of the following fungal infectionsfda label 1 vaginal yeast infections caused by candida 2 systemic candida infections 3 both esophageal and oropharyngeal candidiasis  4 cryptococcal meningitis 5 uti urinary tract infection by candida 6 peritonitis inflammation of the peritoneum caused by candidaa note on fungal infection prophylaxispatients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy andor radiation therapy may be predisposed to candida infections and may receive fluconazole as prophylactic therapyfda labela note on laboratory testingobtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment it is permissible to start therapy before the results are available however adjusting the therapy once laboratory results confirm the causative organism may be necessaryfda label')|
|('DB00196', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'fluconazole can be administered in the treatment of the following fungal infectionsfda label 1 vaginal yeast infections caused by candida 2 systemic candida infections 3 both esophageal and oropharyngeal candidiasis  4 cryptococcal meningitis 5 uti urinary tract infection by candida 6 peritonitis inflammation of the peritoneum caused by candidaa note on fungal infection prophylaxispatients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy andor radiation therapy may be predisposed to candida infections and may receive fluconazole as prophylactic therapyfda labela note on laboratory testingobtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment it is permissible to start therapy before the results are available however adjusting the therapy once laboratory results confirm the causative organism may be necessaryfda label')|
|('DB00196', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'fluconazole can be administered in the treatment of the following fungal infectionsfda label 1 vaginal yeast infections caused by candida 2 systemic candida infections 3 both esophageal and oropharyngeal candidiasis  4 cryptococcal meningitis 5 uti urinary tract infection by candida 6 peritonitis inflammation of the peritoneum caused by candidaa note on fungal infection prophylaxispatients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy andor radiation therapy may be predisposed to candida infections and may receive fluconazole as prophylactic therapyfda labela note on laboratory testingobtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment it is permissible to start therapy before the results are available however adjusting the therapy once laboratory results confirm the causative organism may be necessaryfda label')|
|('DB01328', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'for the treatment of bacterial infections caused by susceptible microorganisms')|
|('DB08889', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy approval is based on response rate ')|
|('DB01131', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'for the causal prevention and suppression of malaria caused by susceptible strains of ip falciparumi and other species of plasmodium found in some geographical areas of the world')|
|('DB00921', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'buprenorphine is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate buprenorphine is also used in combination with naloxone in a fixeddose combination product for the treatment of moderate to severe opioid use disorderf4715f4718')|
|('DB00982', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the ipledge programlabell6579')|
|('DB01153', 'MONDO:0004522', ['acute generalized peritonitis', 'primary bacterial peritonitis', 'Retractile mesenteritis', 'sclerosing mesenteritis', 'peritonitis'], 'for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi')|
|('DB01153', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi')|
|('DB01245', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for use as a skeletal muscle relaxant')|
|('DB01327', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'mainly used to treat bacterial infections of the skin it can also be used to treat moderately severe bacterial infections involving the lung bone joint stomach blood heart valve and urinary tract it is clinically effective against infections caused by staphylococci and streptococci species of gram positive bacteria may be used for surgical prophylaxis if required metronidazole may be added to cover b fragilis')|
|('DB01327', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'mainly used to treat bacterial infections of the skin it can also be used to treat moderately severe bacterial infections involving the lung bone joint stomach blood heart valve and urinary tract it is clinically effective against infections caused by staphylococci and streptococci species of gram positive bacteria may be used for surgical prophylaxis if required metronidazole may be added to cover b fragilis')|
|('DB00654', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with openangle glaucoma or ocular hypertensionl8357 latanoprost may be combined in a product with netarsudil a rho kinase inhibitor for the same indicationsl8369 in addition to the above indications the canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angleclosure glaucoma that has been treated with peripheral iridotomy or laser iridoplastyl8366')|
|('DB00654', 'MONDO:0005041', ['glaucoma'], 'latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with openangle glaucoma or ocular hypertensionl8357 latanoprost may be combined in a product with netarsudil a rho kinase inhibitor for the same indicationsl8369 in addition to the above indications the canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angleclosure glaucoma that has been treated with peripheral iridotomy or laser iridoplastyl8366')|
|('DB00654', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with openangle glaucoma or ocular hypertensionl8357 latanoprost may be combined in a product with netarsudil a rho kinase inhibitor for the same indicationsl8369 in addition to the above indications the canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angleclosure glaucoma that has been treated with peripheral iridotomy or laser iridoplastyl8366')|
|('DB00591', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB00591', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB00591', 'MONDO:0005348', ['keloid'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB00591', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB00591', 'MONDO:0004728', ['diabetic macular edema'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB00591', 'MONDO:0020283', ['uveitis'], 'fluocinolone acetonide has been used extensively in different medical areasin dermatology it is extensively used for the relief of inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues and atopic dermatitisf1955it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalpl4682in ear drops it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and olderl4683as an intravitreal implant it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressurel4684fluocinolone acetonide was announced on october 15 2018 to be fda approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eyel4685some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of firstdegree hemorrhoidsa39532')|
|('DB01380', 'MONDO:0020283', ['uveitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders')|
|('DB01191', 'MONDO:0020283', ['uveitis'], 'for the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet')|
|('DB00831', 'MONDO:0020283', ['uveitis'], 'for the treatment of anxiety disorders depressive symptoms secondary to anxiety and agitation')|
|('DB00831', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety disorders depressive symptoms secondary to anxiety and agitation')|
|('DB00758', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'clopidogrel is indicated to reduce the risk of myocardial infarction for patients with nonst elevated acute coronary syndrome acs patients with stelevated myocardial infarction and in recent mi stroke or established peripheral arterial diseasel7213')|
|('DB00758', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'clopidogrel is indicated to reduce the risk of myocardial infarction for patients with nonst elevated acute coronary syndrome acs patients with stelevated myocardial infarction and in recent mi stroke or established peripheral arterial diseasel7213')|
|('DB00758', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'clopidogrel is indicated to reduce the risk of myocardial infarction for patients with nonst elevated acute coronary syndrome acs patients with stelevated myocardial infarction and in recent mi stroke or established peripheral arterial diseasel7213')|
|('DB00758', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'clopidogrel is indicated to reduce the risk of myocardial infarction for patients with nonst elevated acute coronary syndrome acs patients with stelevated myocardial infarction and in recent mi stroke or established peripheral arterial diseasel7213')|
|('DB08800', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of allergic conjunctivitis allergic rhinitis bronchial asthma and other atopic allergic conditions')|
|('DB08800', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of allergic conjunctivitis allergic rhinitis bronchial asthma and other atopic allergic conditions')|
|('DB08800', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of allergic conjunctivitis allergic rhinitis bronchial asthma and other atopic allergic conditions')|
|('DB01210', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for lowering intraocular pressure iop and may be used in patients with chronic openangle glaucoma or ocular hypertension')|
|('DB01210', 'MONDO:0005041', ['glaucoma'], 'for lowering intraocular pressure iop and may be used in patients with chronic openangle glaucoma or ocular hypertension')|
|('DB01210', 'MONDO:0006875', ['ocular hypertension'], 'for lowering intraocular pressure iop and may be used in patients with chronic openangle glaucoma or ocular hypertension')|
|('DB00247', 'MONDO:0005041', ['glaucoma'], 'for the treatment of vascular headache')|
|('DB00924', 'MONDO:0005041', ['glaucoma'], 'cyclobenzaprine is indicated as a shortterm 23 weeks adjunct therapy along with rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions it has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease or spasticity in children with cerebral palsyl8408l8411 cyclobenzaprine is also occasionally used offlabel for reducing pain and sleep disturbances in patients with fibromyalgiaa184946')|
|('DB00924', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'cyclobenzaprine is indicated as a shortterm 23 weeks adjunct therapy along with rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions it has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease or spasticity in children with cerebral palsyl8408l8411 cyclobenzaprine is also occasionally used offlabel for reducing pain and sleep disturbances in patients with fibromyalgiaa184946')|
|('DB00924', 'MONDO:0002545', ['spinal cord disease'], 'cyclobenzaprine is indicated as a shortterm 23 weeks adjunct therapy along with rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions it has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease or spasticity in children with cerebral palsyl8408l8411 cyclobenzaprine is also occasionally used offlabel for reducing pain and sleep disturbances in patients with fibromyalgiaa184946')|
|('DB00924', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'cyclobenzaprine is indicated as a shortterm 23 weeks adjunct therapy along with rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions it has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease or spasticity in children with cerebral palsyl8408l8411 cyclobenzaprine is also occasionally used offlabel for reducing pain and sleep disturbances in patients with fibromyalgiaa184946')|
|('DB06711', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'naphazoline is indicated for use as otc eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestiona176558l5804l5807')|
|('DB00866', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'for the treatment of hypertension angina and arrhythmia')|
|('DB00866', 'MONDO:0007263', ['arrhythmia [NCIT:C2881]', 'cardiac rhythm disease'], 'for the treatment of hypertension angina and arrhythmia')|
|('DB00558', 'MONDO:0100081', ['disturbances, sleep [NCIT:C3376]', 'sleep disturbances [NCIT:C3376]', 'sleep disturbance [NCIT:C3376]', 'sleep disorder'], 'for the prevention and treatment of influenza a and b')|
|('DB00558', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the prevention and treatment of influenza a and b')|
|('DB00515', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of metastatic testicular tumors metastatic ovarian tumors and advanced bladder cancer')|
|('DB00515', 'MONDO:0021068', ['ovary neoplasm []', 'neoplasm of the ovary [NCIT:C4984]', 'tumor of ovary [MONDO:patterns/neoplasm,NCIT:C4984]', 'ovarian tumor [NCIT:C4984]', 'tumor of the ovary [NCIT:C4984]', 'ovary tumor [MONDO:patterns/neoplasm]', 'ovarian neoplasm [NCIT:C4984]', 'ovary neoplasm (disease) [MONDO:patterns/location]', 'ovarian tumors [NCIT:C4984]', 'neoplasm of ovary [MONDO:patterns/neoplasm,NCIT:C4984]', 'ovarian neoplasm'], 'for the treatment of metastatic testicular tumors metastatic ovarian tumors and advanced bladder cancer')|
|('DB00515', 'MONDO:0004992', ['cancer'], 'for the treatment of metastatic testicular tumors metastatic ovarian tumors and advanced bladder cancer')|
|('DB04896', 'MONDO:0021068', ['ovary neoplasm []', 'neoplasm of the ovary [NCIT:C4984]', 'tumor of ovary [MONDO:patterns/neoplasm,NCIT:C4984]', 'ovarian tumor [NCIT:C4984]', 'tumor of the ovary [NCIT:C4984]', 'ovary tumor [MONDO:patterns/neoplasm]', 'ovarian neoplasm [NCIT:C4984]', 'ovary neoplasm (disease) [MONDO:patterns/location]', 'ovarian tumors [NCIT:C4984]', 'neoplasm of ovary [MONDO:patterns/neoplasm,NCIT:C4984]', 'ovarian neoplasm'], 'milnacipran is a selective serotonin and norepinephrine reuptake inhibitor snri indicated for the management of fibromyalgia in patients that are 18 years old or above f3925 while milnacipran may be used for the treatment of major depressive disorder mdd it is only recommended in adult patients who are 18 years old or above f3922 due to an increased risk for suicidal ideation thinking and behavior in children adolescents and young adults taking antidepressants for major depressive disorder mdd and other psychiatric disorders some regional prescribing information notes that the use of the medication is specifically for the shortterm symptomatic relief of mdd f3919 nevertheless it is important to note that the regulatory approval of andor indications listed here for milnacipran may or may not exist andor vary greatly between regions and nations f3928 f3934')|
|('DB04896', 'MONDO:0005546', ['fibromyalgia'], 'milnacipran is a selective serotonin and norepinephrine reuptake inhibitor snri indicated for the management of fibromyalgia in patients that are 18 years old or above f3925 while milnacipran may be used for the treatment of major depressive disorder mdd it is only recommended in adult patients who are 18 years old or above f3922 due to an increased risk for suicidal ideation thinking and behavior in children adolescents and young adults taking antidepressants for major depressive disorder mdd and other psychiatric disorders some regional prescribing information notes that the use of the medication is specifically for the shortterm symptomatic relief of mdd f3919 nevertheless it is important to note that the regulatory approval of andor indications listed here for milnacipran may or may not exist andor vary greatly between regions and nations f3928 f3934')|
|('DB04896', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'milnacipran is a selective serotonin and norepinephrine reuptake inhibitor snri indicated for the management of fibromyalgia in patients that are 18 years old or above f3925 while milnacipran may be used for the treatment of major depressive disorder mdd it is only recommended in adult patients who are 18 years old or above f3922 due to an increased risk for suicidal ideation thinking and behavior in children adolescents and young adults taking antidepressants for major depressive disorder mdd and other psychiatric disorders some regional prescribing information notes that the use of the medication is specifically for the shortterm symptomatic relief of mdd f3919 nevertheless it is important to note that the regulatory approval of andor indications listed here for milnacipran may or may not exist andor vary greatly between regions and nations f3928 f3934')|
|('DB04896', 'MONDO:0016217', ['sickness of disembarkment [Orphanet:210272]', 'MDD [Orphanet:210272]', 'disembarkment syndrome [Orphanet:210272]', 'MdDS [Orphanet:210272]', 'mal de debarquement'], 'milnacipran is a selective serotonin and norepinephrine reuptake inhibitor snri indicated for the management of fibromyalgia in patients that are 18 years old or above f3925 while milnacipran may be used for the treatment of major depressive disorder mdd it is only recommended in adult patients who are 18 years old or above f3922 due to an increased risk for suicidal ideation thinking and behavior in children adolescents and young adults taking antidepressants for major depressive disorder mdd and other psychiatric disorders some regional prescribing information notes that the use of the medication is specifically for the shortterm symptomatic relief of mdd f3919 nevertheless it is important to note that the regulatory approval of andor indications listed here for milnacipran may or may not exist andor vary greatly between regions and nations f3928 f3934')|
|('DB00444', 'MONDO:0016217', ['sickness of disembarkment [Orphanet:210272]', 'MDD [Orphanet:210272]', 'disembarkment syndrome [Orphanet:210272]', 'MdDS [Orphanet:210272]', 'mal de debarquement'], 'teniposide is used for the treatment of refractory acute lymphoblastic leukaemia')|
|('DB00444', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'teniposide is used for the treatment of refractory acute lymphoblastic leukaemia')|
|('DB00974', 'MONDO:0016217', ['sickness of disembarkment [Orphanet:210272]', 'MDD [Orphanet:210272]', 'disembarkment syndrome [Orphanet:210272]', 'MdDS [Orphanet:210272]', 'mal de debarquement'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB00974', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB00974', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB01083', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for obesity management including weight loss and weight maintenance when used in conjunction with a reducedcalorie diet also used to reduce the risk for weight regain after prior weight loss use of orlistat is pending revision due to reports of liverrelated adverse events')|
|('DB06766', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for the prevention of itching associated with allergic conjunctivitis')|
|('DB01085', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for the treatment of radiationinduced dry mouth xerostomia and symptoms of dry mouth in patients with sjoumlgrens syndrome')|
|('DB08828', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery and in patients who are not candidates for surgery or radiation')|
|('DB08828', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery and in patients who are not candidates for surgery or radiation')|
|('DB01172', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for treatment of infections where one or more of the following are the known or suspected pathogens ie colii iproteusi species both indolepositive and indolenegative ie aerogenes k pneumoniae s marcescensi and iacinetobacteri species')|
|('DB00796', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'may be used as a first line agent to treat uncomplicated hypertension isolated systolic hypertension and left ventricular hypertrophy may be used as a first line agent to delay progression of diabetic nephropathy candesartan may be also used as a second line agent in the treatment of congestive heart failure systolic dysfunction myocardial infarction and coronary artery disease in those intolerant of ace inhibitors')|
|('DB00796', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'may be used as a first line agent to treat uncomplicated hypertension isolated systolic hypertension and left ventricular hypertrophy may be used as a first line agent to delay progression of diabetic nephropathy candesartan may be also used as a second line agent in the treatment of congestive heart failure systolic dysfunction myocardial infarction and coronary artery disease in those intolerant of ace inhibitors')|
|('DB00796', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'may be used as a first line agent to treat uncomplicated hypertension isolated systolic hypertension and left ventricular hypertrophy may be used as a first line agent to delay progression of diabetic nephropathy candesartan may be also used as a second line agent in the treatment of congestive heart failure systolic dysfunction myocardial infarction and coronary artery disease in those intolerant of ace inhibitors')|
|('DB00796', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'may be used as a first line agent to treat uncomplicated hypertension isolated systolic hypertension and left ventricular hypertrophy may be used as a first line agent to delay progression of diabetic nephropathy candesartan may be also used as a second line agent in the treatment of congestive heart failure systolic dysfunction myocardial infarction and coronary artery disease in those intolerant of ace inhibitors')|
|('DB00796', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'may be used as a first line agent to treat uncomplicated hypertension isolated systolic hypertension and left ventricular hypertrophy may be used as a first line agent to delay progression of diabetic nephropathy candesartan may be also used as a second line agent in the treatment of congestive heart failure systolic dysfunction myocardial infarction and coronary artery disease in those intolerant of ace inhibitors')|
|('DB01452', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'diamorphine as a prescription medication in the united kingdom is indicated for use in the treatment of severe pain associated with surgical procedures myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema l4999')|
|('DB01452', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'diamorphine as a prescription medication in the united kingdom is indicated for use in the treatment of severe pain associated with surgical procedures myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema l4999')|
|('DB01452', 'MONDO:0006932', ['pulmonary edema'], 'diamorphine as a prescription medication in the united kingdom is indicated for use in the treatment of severe pain associated with surgical procedures myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema l4999')|
|('DB00988', 'MONDO:0006932', ['pulmonary edema'], 'for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction trauma endotoxic septicemia openheart surgery renal failure and chronic cardiac decompensation as in congestive failure')|
|('DB00988', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction trauma endotoxic septicemia openheart surgery renal failure and chronic cardiac decompensation as in congestive failure')|
|('DB00988', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction trauma endotoxic septicemia openheart surgery renal failure and chronic cardiac decompensation as in congestive failure')|
|('DB00932', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'for combination antiretroviral treatment of hiv1 infected adult patients with evidence of viral replication who are highly treatmentexperienced or have hiv1 strains resistant to multiple protease inhibitors')|
|('DB01628', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'for the treatment of rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain and gout')|
|('DB01628', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain and gout')|
|('DB01628', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'for the treatment of rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain and gout')|
|('DB01628', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain acute pain and gout')|
|('DB00717', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'norethisterone is indicated as an oral contraceptive when given as monotherapyl9527 or in combination with an estrogen component such as ethinylestradiol or estradioll10313l10307 in combination with an estrogen component oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderatetosevere vasomotor symptoms arising from menopausel10304 when applied via transdermal patch the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism vulvovaginal atrophy and moderatesevere vasomotor symptomsl10301norethisterone taken in combination with intramuscular leuprolide is also indicated for the symptomatic treatment of endometriosisrelated painl10310')|
|('DB00717', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'norethisterone is indicated as an oral contraceptive when given as monotherapyl9527 or in combination with an estrogen component such as ethinylestradiol or estradioll10313l10307 in combination with an estrogen component oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderatetosevere vasomotor symptoms arising from menopausel10304 when applied via transdermal patch the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism vulvovaginal atrophy and moderatesevere vasomotor symptomsl10301norethisterone taken in combination with intramuscular leuprolide is also indicated for the symptomatic treatment of endometriosisrelated painl10310')|
|('DB01110', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'for topical application in the treatment of tinea pedis athletersquos foot tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis moniliasis and in the treatment of tinea versicolor')|
|('DB01110', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for topical application in the treatment of tinea pedis athletersquos foot tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis moniliasis and in the treatment of tinea versicolor')|
|('DB01110', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'for topical application in the treatment of tinea pedis athletersquos foot tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis moniliasis and in the treatment of tinea versicolor')|
|('DB01110', 'MONDO:0000879', ['cutaneous candidiasis'], 'for topical application in the treatment of tinea pedis athletersquos foot tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis moniliasis and in the treatment of tinea versicolor')|
|('DB01110', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for topical application in the treatment of tinea pedis athletersquos foot tinea cruris and tinea corporis caused by itrichophyton rubrumi itrichophyton mentagrophytesi and iepidermophyton floccosumi in the treatment of cutaneous candidiasis moniliasis and in the treatment of tinea versicolor')|
|('DB01112', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for the treatment of many different types of bacterial infections such as bronchitis sinusitis tonsillitis ear infections skin infections gonorrhea and urinary tract infections')|
|('DB01112', 'MONDO:0005961', ['sinusitis'], 'for the treatment of many different types of bacterial infections such as bronchitis sinusitis tonsillitis ear infections skin infections gonorrhea and urinary tract infections')|
|('DB01112', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for the treatment of many different types of bacterial infections such as bronchitis sinusitis tonsillitis ear infections skin infections gonorrhea and urinary tract infections')|
|('DB00971', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for treatment of tinea versicolor tinea capitis dandruff and seborrheic dermatitis of the scalp')|
|('DB00971', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for treatment of tinea versicolor tinea capitis dandruff and seborrheic dermatitis of the scalp')|
|('DB00971', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'for treatment of tinea versicolor tinea capitis dandruff and seborrheic dermatitis of the scalp')|
|('DB01087', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'for the treatment of malaria')|
|('DB01087', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of malaria')|
|('DB00542', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'benazepril is indicated for the treatment of hypertensiona840 it may be used alone or in combination with thiazide diureticsfda label')|
|('DB06155', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kgmsup2sup or patients wih a bmi greater than 27 kgmsup2sup with associated risk factors such as type 2 diabetes or dyslipidaemia')|
|('DB00237', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'for shortterm treatment of insomnia and anxiety disorders')|
|('DB00237', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for shortterm treatment of insomnia and anxiety disorders')|
|('DB00237', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for shortterm treatment of insomnia and anxiety disorders')|
|('DB05630', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of various types of a protozoal infection called leishmaniasis which may result from sandfly bites in tropical and temperate parts of the world also investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05630', 'MONDO:0011989', ['leishmaniasis'], 'for the treatment of various types of a protozoal infection called leishmaniasis which may result from sandfly bites in tropical and temperate parts of the world also investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB00969', 'MONDO:0011989', ['leishmaniasis'], 'only for the treatment of symptoms of severe diarrheapredominant irritable bowel syndrome ibs in women with chronic symptoms generally lasting greater than 6 months who does not present with anatomic or biochemical gi abnormalities and have not responded to conventional therapy')|
|('DB00969', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'only for the treatment of symptoms of severe diarrheapredominant irritable bowel syndrome ibs in women with chronic symptoms generally lasting greater than 6 months who does not present with anatomic or biochemical gi abnormalities and have not responded to conventional therapy')|
|('DB06335', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy ')|
|('DB06335', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy ')|
|('DB00865', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the management of exogenous obesity as a short term adjunct a few weeks in a regimen of weight reduction based on caloric restriction')|
|('DB01073', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen')|
|('DB01073', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen')|
|('DB00750', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'used as a local anaesthetic and is often used in dentistry')|
|('DB00534', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'previously used as a diuretic the radiolabeled form has been used as a diagnostic and research tool')|
|('DB01299', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria it can also be used to treat various infections in livestock as wellsulfadoxine and pyrimethamine is indicated for the treatment of plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected ')|
|('DB01299', 'MONDO:0005136', ['induced malaria', 'malaria'], 'sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria it can also be used to treat various infections in livestock as wellsulfadoxine and pyrimethamine is indicated for the treatment of plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected ')|
|('DB01299', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria it can also be used to treat various infections in livestock as wellsulfadoxine and pyrimethamine is indicated for the treatment of plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected ')|
|('DB01299', 'MONDO:0005920', ['Falciparum Malaria', 'Falciparum malaria', 'Malaria fever, subtertian', 'malignant tertian fever', 'plasmodium falciparum malaria'], 'sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria it can also be used to treat various infections in livestock as wellsulfadoxine and pyrimethamine is indicated for the treatment of plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected ')|
|('DB01007', 'MONDO:0005920', ['Falciparum Malaria', 'Falciparum malaria', 'Malaria fever, subtertian', 'malignant tertian fever', 'plasmodium falciparum malaria'], 'for the local treatment of vulvovaginal candidiasis moniliasis')|
|('DB01007', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'for the local treatment of vulvovaginal candidiasis moniliasis')|
|('DB00014', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'goserelin is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate palliative treatment of advanced carcinoma of the prostate the management of endometriosis use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding use in the palliative treatment of advanced breast cancer in pre and perimenopausal women')|
|('DB00014', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'goserelin is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate palliative treatment of advanced carcinoma of the prostate the management of endometriosis use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding use in the palliative treatment of advanced breast cancer in pre and perimenopausal women')|
|('DB00014', 'MONDO:0005133', ['endometriosis'], 'goserelin is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate palliative treatment of advanced carcinoma of the prostate the management of endometriosis use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding use in the palliative treatment of advanced breast cancer in pre and perimenopausal women')|
|('DB00014', 'MONDO:0004992', ['cancer'], 'goserelin is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate palliative treatment of advanced carcinoma of the prostate the management of endometriosis use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding use in the palliative treatment of advanced breast cancer in pre and perimenopausal women')|
|('DB06700', 'MONDO:0004992', ['cancer'], 'desvenlafaxine is indicated for the treatment of major depressive disorder in adultsa6990a6991label')|
|('DB06700', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'desvenlafaxine is indicated for the treatment of major depressive disorder in adultsa6990a6991label')|
|('DB00401', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for the treatment of hypertension it may be used alone or in combination with other antihypertensive agents')|
|('DB00668', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0100053', ['anaphylactic shock []', 'systemic anaphylaxis [PMID:18596587]', 'anaphylaxis'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0000745', ['cardiopulmonary arrest', 'circulatory arrest', 'cardiac arrest'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0043789', ['serum sickness [NCIT:C79718]', 'transfusion reaction due to serum protein reaction []', 'serum sickness'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0019013', ['non histamine-induced angioedema [Orphanet:658]', 'angioneurotic edema [Orphanet:658]', 'bradykinine-induced angioedema [Orphanet:658]', 'non-histaminic angioedema'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0005338', ['glaucoma simplex', 'open angle glaucoma', 'pigmentary glaucoma', 'Wide-angle glaucoma', 'open-angle glaucoma'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB00668', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'epinephrine injection is indicated in the emergency treatment of allergic reactions type i including anaphylaxis to stinging insects eg order hymenoptera which include bees wasps hornets yellow jackets and fire ants and biting insects eg triatoma mosquitos allergen immunotherapy foods drugs diagnostic testing substances eg radiocontrast media and other allergens as well as idiopathic anaphylaxis or exerciseinduced anaphylaxis injectable epinephrine is intended for immediateurgent administration in patients who are found to be at increased risk for anaphylaxis including individuals with a history of anaphylaxis selection of the appropriate dosage strength is determined according to body weight fda label epinephrines cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock f1247epinephrine is used as a hemostatic agent it is also used in treating mucosal congestion of hay fever rhinitis and acute sinusitis to relieve bronchial asthmatic paroxysms in syncope due to complete heart block or carotid sinus hypersensitivity for symptomatic relief of serum sickness urticaria angioneurotic edema for resuscitation in cardiac arrest following anesthetic accidents in simple open angle glaucoma for relaxation of uterine musculature and to inhibit uterine contractions epinephrine injection can be utilized to prolong the action of local anesthetics f1247in addition to the above epinephrine is used as an over the counter otc agent for the intermittent symptoms of asthma such as wheezing tightness of chest and shortness of breath f2131  it is also used for the maintenance of mydriasis during intraocular surgery l4825')|
|('DB01103', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions')|
|('DB01103', 'MONDO:0001103', ['beaver feaver', 'Infection by Giardia lamblia', 'giardiasis'], 'for the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions')|
|('DB01103', 'MONDO:0005446', ['Asian Desert Cutaneous Leishmaniasis', 'diffuse cutaneous leishmaniasis', 'Leproid leishmaniasis', 'cutaneous leishmaniasis'], 'for the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions')|
|('DB00153', 'MONDO:0005446', ['Asian Desert Cutaneous Leishmaniasis', 'diffuse cutaneous leishmaniasis', 'Leproid leishmaniasis', 'cutaneous leishmaniasis'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00153', 'MONDO:0001220', ['hypoparathyroidism'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00153', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00153', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00153', 'MONDO:0000313', ['hypophosphatemia'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00153', 'MONDO:0001068', ['osteomalacia'], 'ergocalciferol is indicated for the treatment of hypoparathyroidism refractory rickets and familial hypophosphatemiafda labelhypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands this condition produces decreased calcium and increased phosphorus levelsl6082rickets is a condition produced due to a deficiency in vitamin d calcium or phosphorus however this condition can also be related to renal diseases it is characterized to present weak or soft bonesa177664familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys the presence of this condition can derive in the presence of osteomalacia bone softening and ricketsl6085')|
|('DB00561', 'MONDO:0001068', ['osteomalacia'], 'for use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease')|
|('DB00561', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease')|
|('DB01096', 'MONDO:0001068', ['osteomalacia'], 'for treatment of schistosomiasis caused by ischistosoma mansonii')|
|('DB01096', 'MONDO:0015254', ['schistosomiasis'], 'for treatment of schistosomiasis caused by ischistosoma mansonii')|
|('DB01319', 'MONDO:0015254', ['schistosomiasis'], 'indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission the use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in hiv infected adults')|
|('DB01319', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission the use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in hiv infected adults')|
|('DB01319', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission the use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in hiv infected adults')|
|('DB01319', 'MONDO:0002525', ['dyslipidemia', 'fatty acid metabolism disorder', 'inherited lipid metabolism disorder'], 'indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus hiv1 infection as well as postexposure prophylaxis of hiv infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with hiv when that exposure represents a substantial risk for hiv transmission the use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in hiv infected adults')|
|('DB00562', 'MONDO:0002525', ['dyslipidemia', 'fatty acid metabolism disorder', 'inherited lipid metabolism disorder'], 'for the treatment of high blood pressure and management of edema')|
|('DB00562', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for the treatment of high blood pressure and management of edema')|
|('DB01004', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01004', 'MONDO:0002708', ['retinitis'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01004', 'MONDO:0017769', ['acquired immunodeficiency'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01004', 'MONDO:0024354', ['Cytomegaloviral pneumonia [NCIT:C35360]', 'CMV pneumonia [NCIT:C35360]', 'Cytomegalovirus pneumonia [NCIT:C35360]', 'Cytomegalovirus caused pneumonia [MONDO:patterns/specific_infectious_disease_by_agent]', 'cytomegalovirus pneumonia []', 'cytomegalovirus pneumonia'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01004', 'MONDO:0004335', ['alimentary system disease', 'digestive system disorder', 'Gastroenteropathy', 'gastrointestinal disease', 'gastrointestinal disorder', 'GIT disease', 'digestive system disease'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01004', 'MONDO:0022202', ['disseminated'], 'for induction and maintenance in the treatment of cytomegalovirus cmv retinitis in immunocompromised patients including patients with acquired immunodeficiency syndrome aids also used in the treatment of severe cytomegalovirus cmv disease including cmv pneumonia cmv gastrointestinal disease and disseminated cmv infections in immunocompromised patients')|
|('DB01077', 'MONDO:0022202', ['disseminated'], 'for the treatment of symptomatic pagets disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury')|
|('DB01077', 'MONDO:0043797', ['spinal cord injury [MESH:D013119,MONDO:patterns/location]', 'injury of spinal cord [MONDO:design_pattern]', 'spinal cord injury'], 'for the treatment of symptomatic pagets disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury')|
|('DB00979', 'MONDO:0022202', ['disseminated'], 'used mainly to produce mydriasis and cycloplegia for diagnostic purposes')|
|('DB00979', 'MONDO:0005555', ['Ciliary muscle paresis', 'Cycloplegic paralysis of accommodation', 'Paresis of accommodation', 'cycloplegia'], 'used mainly to produce mydriasis and cycloplegia for diagnostic purposes')|
|('DB06782', 'MONDO:0005555', ['Ciliary muscle paresis', 'Cycloplegic paralysis of accommodation', 'Paresis of accommodation', 'cycloplegia'], 'for the treatment of arsenic gold and mercury poisoning indicated in acute lead poisoning when used concomitantly with edetate calcium disodium db00974')|
|('DB06782', 'MONDO:0018020', ['mercurialism [Orphanet:330021]', 'Mercury intoxication [Orphanet:330021]', 'hydrargyria [Orphanet:330021]', 'mercury poisoning'], 'for the treatment of arsenic gold and mercury poisoning indicated in acute lead poisoning when used concomitantly with edetate calcium disodium db00974')|
|('DB06782', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for the treatment of arsenic gold and mercury poisoning indicated in acute lead poisoning when used concomitantly with edetate calcium disodium db00974')|
|('DB08906', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxisfda labelf4364 the fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitisfda labela177130')|
|('DB08906', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxisfda labelf4364 the fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitisfda labela177130')|
|('DB01081', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for as adjunctive therapy in the management of diarrhea')|
|('DB00406', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of bacterial and fungal infections inside the mouth thrush and skin also for the prevention of transmission of chagas disease as a blood additive')|
|('DB00406', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'for the treatment of bacterial and fungal infections inside the mouth thrush and skin also for the prevention of transmission of chagas disease as a blood additive')|
|('DB00435', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'for the treatment of term and nearterm gt34 weeks neonates with hypoxic respiratory failure')|
|('DB00435', 'MONDO:0021113', ['acute and chronic respiratory failure', 'acute respiratory Failure', 'acute-on-chronic respiratory failure', 'chronic respiratory failure', 'respiratory insufficiency/failure', 'respiratory failure'], 'for the treatment of term and nearterm gt34 weeks neonates with hypoxic respiratory failure')|
|('DB00449', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic openangle glaucoma')|
|('DB00449', 'MONDO:0005041', ['glaucoma'], 'dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic openangle glaucoma')|
|('DB00376', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'indicated for the treatment of parkinsons disease and extrapyramidal reactions caused by drugs')|
|('DB00999', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure and corticosteroid and estrogen therapyl8447l8450 hydrochlorothiazide is also indicated alone or in combination for the management of hypertensiona185138l8447l8450')|
|('DB00999', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure and corticosteroid and estrogen therapyl8447l8450 hydrochlorothiazide is also indicated alone or in combination for the management of hypertensiona185138l8447l8450')|
|('DB00999', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure and corticosteroid and estrogen therapyl8447l8450 hydrochlorothiazide is also indicated alone or in combination for the management of hypertensiona185138l8447l8450')|
|('DB00999', 'MONDO:0002462', ['glomerulonephritis'], 'hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure and corticosteroid and estrogen therapyl8447l8450 hydrochlorothiazide is also indicated alone or in combination for the management of hypertensiona185138l8447l8450')|
|('DB00999', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure hepatic cirrhosis nephrotic syndrome acute glomerulonephritis chronic renal failure and corticosteroid and estrogen therapyl8447l8450 hydrochlorothiazide is also indicated alone or in combination for the management of hypertensiona185138l8447l8450')|
|('DB00642', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery also used as a monotherapy for the treatment of locally advanced or metastatic nonsmall cell lung cancer nsclc after prior chemotherapy')|
|('DB00642', 'MONDO:0005112', ['malignant mesothelioma of pleura', 'malignant pleural mesothelioma'], 'used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery also used as a monotherapy for the treatment of locally advanced or metastatic nonsmall cell lung cancer nsclc after prior chemotherapy')|
|('DB00642', 'MONDO:0004992', ['cancer'], 'used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery also used as a monotherapy for the treatment of locally advanced or metastatic nonsmall cell lung cancer nsclc after prior chemotherapy')|
|('DB00788', 'MONDO:0004992', ['cancer'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0002471', ['bursitis'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00788', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'naproxen is indicated for the management of rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis acute gout primary dysmenorrhea and for the relief of mild to moderate painl6582l6583a178975 further it is firstline therapy for osteoarthritis acute gouty arthritis dysmenorrhea and musculoskeletal inflammation and paina178975')|
|('DB00452', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of bacterial blepharitis bacterial bonjunctivitis corneal injuries corneal ulcers and meibomianitis for the prophylaxis of ocular infections following foreign body removal')|
|('DB00657', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension')|
|('DB00657', 'MONDO:0006846', ['malignant hypertension'], 'for the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension')|
|('DB00955', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of bacteremia septicaemia respiratory tract infections skin and softtissue infection burns wounds and perioperative infections caused by susceptible strains')|
|('DB04570', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins it is used to treat bacterial infections latamoxef  is primarily indicated in conditions like bone and joint infection gi infections gynecological infections meningitis respiratory tract infections septicaemia skin infections soft tissue infections uti ')|
|('DB04570', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins it is used to treat bacterial infections latamoxef  is primarily indicated in conditions like bone and joint infection gi infections gynecological infections meningitis respiratory tract infections septicaemia skin infections soft tissue infections uti ')|
|('DB04570', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins it is used to treat bacterial infections latamoxef  is primarily indicated in conditions like bone and joint infection gi infections gynecological infections meningitis respiratory tract infections septicaemia skin infections soft tissue infections uti ')|
|('DB06723', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for relief of heartburn and acid indigestion ')|
|('DB00394', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0006004', ['vasomotor rhinitis'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0005083', ['psoriasis'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0006572', ['lichen ruber planus', 'Lichen, ruber planus', 'lichen planus'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB00394', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older the aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasml6871indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic vasomotor rhinitis and prevent the recurrence of nasal polyps following surgical removall6880indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses in patients 13 years of age and olderl10782 corticosteroidresponsive dermatoses include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis and anogenital and senile pruritusl6886')|
|('DB08819', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'tafluprost is indicated for reducing elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension')|
|('DB08819', 'MONDO:0005041', ['glaucoma'], 'tafluprost is indicated for reducing elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension')|
|('DB08819', 'MONDO:0006875', ['ocular hypertension'], 'tafluprost is indicated for reducing elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension')|
|('DB05266', 'MONDO:0005041', ['glaucoma'], 'for the treatment of multiple sclerosis asthma and cerebrovascular disease')|
|('DB05266', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for the treatment of multiple sclerosis asthma and cerebrovascular disease')|
|('DB01337', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'used as a muscle relaxant during anesthesia and surgical procedures')|
|('DB01436', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'indicated for the management of hypocalcemia secondary hyperparathyroidism and osteodystrophy in patients with chronic renal failurelabel')|
|('DB01436', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'indicated for the management of hypocalcemia secondary hyperparathyroidism and osteodystrophy in patients with chronic renal failurelabel')|
|('DB00454', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'used to control moderate to severe pain')|
|('DB00693', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'for diagnostic imaging primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature')|
|('DB00381', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions fda label• hypertension • coronary artery disease• chronic stable angina• vasospastic angina prinzmetal’s or variant angina • angiographically documented coronary artery disease in patients without heart failure or an ejection fraction  40')|
|('DB00381', 'MONDO:0006021', ['angina inversa', 'Prinzmetals angina', 'Prinzmetals variant angina', 'variant angina', 'variant angina pectoris', 'prinzmetal angina'], 'amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions fda label• hypertension • coronary artery disease• chronic stable angina• vasospastic angina prinzmetal’s or variant angina • angiographically documented coronary artery disease in patients without heart failure or an ejection fraction  40')|
|('DB00381', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions fda label• hypertension • coronary artery disease• chronic stable angina• vasospastic angina prinzmetal’s or variant angina • angiographically documented coronary artery disease in patients without heart failure or an ejection fraction  40')|
|('DB00381', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions fda label• hypertension • coronary artery disease• chronic stable angina• vasospastic angina prinzmetal’s or variant angina • angiographically documented coronary artery disease in patients without heart failure or an ejection fraction  40')|
|('DB01214', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma')|
|('DB01214', 'MONDO:0006875', ['ocular hypertension'], 'indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma')|
|('DB01214', 'MONDO:0005338', ['glaucoma simplex', 'open angle glaucoma', 'pigmentary glaucoma', 'Wide-angle glaucoma', 'open-angle glaucoma'], 'indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma')|
|('DB00592', 'MONDO:0006875', ['ocular hypertension'], 'used as alternative treatment for ascariasis caused by iascaris lumbricoidesi roundworm and enterobiasis oxyuriasis caused by ienterobius vermicularisi pinworm it is also used to treat partial intestinal obstruction by the common roundworm a condition primarily occurring in children')|
|('DB00592', 'MONDO:0005746', ['Oxyuris vermicularis infection', 'Threadworm infection', 'enterobiasis'], 'used as alternative treatment for ascariasis caused by iascaris lumbricoidesi roundworm and enterobiasis oxyuriasis caused by ienterobius vermicularisi pinworm it is also used to treat partial intestinal obstruction by the common roundworm a condition primarily occurring in children')|
|('DB00592', 'MONDO:0021137', ['common []', 'not rare'], 'used as alternative treatment for ascariasis caused by iascaris lumbricoidesi roundworm and enterobiasis oxyuriasis caused by ienterobius vermicularisi pinworm it is also used to treat partial intestinal obstruction by the common roundworm a condition primarily occurring in children')|
|('DB01113', 'MONDO:0021137', ['common []', 'not rare'], 'for the treatment of impotence and vasospasms')|
|('DB00374', 'MONDO:0021137', ['common []', 'not rare'], 'for use as a continuous subcutaneous infusion or intravenous infusion for those not able to tolerate a subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with nyha class iiiv symptoms to diminish symptoms associated with exercise')|
|('DB00374', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'for use as a continuous subcutaneous infusion or intravenous infusion for those not able to tolerate a subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with nyha class iiiv symptoms to diminish symptoms associated with exercise')|
|('DB05039', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'for the long term oncedailydosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema')|
|('DB05039', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the long term oncedailydosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema')|
|('DB05039', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the long term oncedailydosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema')|
|('DB00987', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of acute nonlymphocytic leukemia acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia')|
|('DB00987', 'MONDO:0005059', ['leukemia'], 'for the treatment of acute nonlymphocytic leukemia acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia')|
|('DB00987', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'for the treatment of acute nonlymphocytic leukemia acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia')|
|('DB06228', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'rivaroxaban is indicated for the prevention of venous thromboembolic events vte in patients who have undergone total hips replacements and total knee replacement surgery prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation treatment of deep vein thrombosis dvt and pulmonary embolism pe to reduce risk of recurrent dvt andor pe rivaroxaban is also indicated in combination with aspirin for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease due to a lack of safety studies it is not recommended for use in those under 18 years old its use is also not recommended in those with severe renal impairment 30mlmin')|
|('DB06228', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'rivaroxaban is indicated for the prevention of venous thromboembolic events vte in patients who have undergone total hips replacements and total knee replacement surgery prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation treatment of deep vein thrombosis dvt and pulmonary embolism pe to reduce risk of recurrent dvt andor pe rivaroxaban is also indicated in combination with aspirin for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease due to a lack of safety studies it is not recommended for use in those under 18 years old its use is also not recommended in those with severe renal impairment 30mlmin')|
|('DB06228', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'rivaroxaban is indicated for the prevention of venous thromboembolic events vte in patients who have undergone total hips replacements and total knee replacement surgery prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation treatment of deep vein thrombosis dvt and pulmonary embolism pe to reduce risk of recurrent dvt andor pe rivaroxaban is also indicated in combination with aspirin for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease due to a lack of safety studies it is not recommended for use in those under 18 years old its use is also not recommended in those with severe renal impairment 30mlmin')|
|('DB06228', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'rivaroxaban is indicated for the prevention of venous thromboembolic events vte in patients who have undergone total hips replacements and total knee replacement surgery prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation treatment of deep vein thrombosis dvt and pulmonary embolism pe to reduce risk of recurrent dvt andor pe rivaroxaban is also indicated in combination with aspirin for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease due to a lack of safety studies it is not recommended for use in those under 18 years old its use is also not recommended in those with severe renal impairment 30mlmin')|
|('DB01207', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction')|
|('DB01207', 'MONDO:0004781', ['acute myocardial infarction'], 'used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction')|
|('DB06262', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for treatment of neurogenic orthostatic hypotension noh associated with various disorders including multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension and parkinsons disease also investigated for usetreatment in neurologic disorders nephropathy blood blood forming organ disorders unspecified and dizzyfainting spells')|
|('DB06262', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'for treatment of neurogenic orthostatic hypotension noh associated with various disorders including multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension and parkinsons disease also investigated for usetreatment in neurologic disorders nephropathy blood blood forming organ disorders unspecified and dizzyfainting spells')|
|('DB06262', 'MONDO:0007803', ['Multiple system atrophy', 'Shy-Drager syndrome', 'multiple system atrophy'], 'for treatment of neurogenic orthostatic hypotension noh associated with various disorders including multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension and parkinsons disease also investigated for usetreatment in neurologic disorders nephropathy blood blood forming organ disorders unspecified and dizzyfainting spells')|
|('DB00975', 'MONDO:0007803', ['Multiple system atrophy', 'Shy-Drager syndrome', 'multiple system atrophy'], 'for as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina')|
|('DB01176', 'MONDO:0007803', ['Multiple system atrophy', 'Shy-Drager syndrome', 'multiple system atrophy'], 'for prevention and treatment of nausea vomiting and dizziness associated with motion sickness and vertigo dizziness caused by other medical problems')|
|('DB01176', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for prevention and treatment of nausea vomiting and dizziness associated with motion sickness and vertigo dizziness caused by other medical problems')|
|('DB00708', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'the indications for this drug are as follows1 as an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated2 as a primary anesthetic agent for the induction and maintenance of anesthesia with 100 oxygen in patients undergoing major surgical procedures in patients who are intubated and ventilated such as cardiovascular surgery or neurosurgical procedures in the sitting position to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated3 for epidural administration as an analgesic combined with low dose usually 125 mg per administration bupivacaine usually during labor and vaginal delivery 4 the sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings including hospitals surgical centers and emergency departmentsfda label')|
|('DB04838', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'used in the treatment of various blood vessel diseases eg claudication arteriosclerosis and raynauds disease and nighttime leg cramps')|
|('DB04838', 'MONDO:0002277', ['Arteriosclerosis', 'Arteriosclerotic vascular disease', 'arteriosclerosis disorder'], 'used in the treatment of various blood vessel diseases eg claudication arteriosclerosis and raynauds disease and nighttime leg cramps')|
|('DB04838', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'used in the treatment of various blood vessel diseases eg claudication arteriosclerosis and raynauds disease and nighttime leg cramps')|
|('DB00474', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'methohexital is indicated for use as an intravenous anaesthetic it has also been commonly used to induce deep sedation')|
|('DB00474', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'methohexital is indicated for use as an intravenous anaesthetic it has also been commonly used to induce deep sedation')|
|('DB08827', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in homozygous familial hypercholesterolemia hofh patients to reduce lowdensity lipoprotein cholesterol ldlc total cholesterol tc apolipoprotein b apo b and nonhighdensity lipoprotein cholesterol nonhdlc')|
|('DB08827', 'MONDO:0005439', ['familial hyperbetalipoproteinaemia', 'familial hypercholesteremia', 'Fredrickson type IIa hyperlipoproteinemia', 'Fredrickson type IIa lipidaemia', 'hyperbetalipoproteinemia', 'type II hyperlipidemia', 'familial hypercholesterolemia'], 'used in homozygous familial hypercholesterolemia hofh patients to reduce lowdensity lipoprotein cholesterol ldlc total cholesterol tc apolipoprotein b apo b and nonhighdensity lipoprotein cholesterol nonhdlc')|
|('DB01406', 'MONDO:0005439', ['familial hyperbetalipoproteinaemia', 'familial hypercholesteremia', 'Fredrickson type IIa hyperlipoproteinemia', 'Fredrickson type IIa lipidaemia', 'hyperbetalipoproteinemia', 'type II hyperlipidemia', 'familial hypercholesterolemia'], 'for the treatment of endometriosis and fibrocystic breast disease in patients unresponsive to simple measures also used for the prophylactic treatment of all types of hereditary angioedema in males and females')|
|('DB01406', 'MONDO:0005133', ['endometriosis'], 'for the treatment of endometriosis and fibrocystic breast disease in patients unresponsive to simple measures also used for the prophylactic treatment of all types of hereditary angioedema in males and females')|
|('DB01406', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of endometriosis and fibrocystic breast disease in patients unresponsive to simple measures also used for the prophylactic treatment of all types of hereditary angioedema in males and females')|
|('DB01406', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for the treatment of endometriosis and fibrocystic breast disease in patients unresponsive to simple measures also used for the prophylactic treatment of all types of hereditary angioedema in males and females')|
|('DB00814', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for symptomatic treatment of arthritis and osteoarthritis')|
|('DB00814', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for symptomatic treatment of arthritis and osteoarthritis')|
|('DB00814', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for symptomatic treatment of arthritis and osteoarthritis')|
|('DB01367', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of the signs and symptoms of idiopathic parkinsons disease as initial monotherapy and as adjunct therapy to levodopa')|
|('DB00225', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for intravenous use in mri to visualize lesions with abnormal vascularity or those thought to cause abnormalities in the bloodbrain barrier in the brain intracranial lesions spine and associated tissues')|
|('DB01024', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants administered in combination with cyclosporine and corticosteroids')|
|('DB08896', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'regorafenib is indicated for the treatment of patients with metastatic colorectal cancer crc who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf therapy and if kras wild type an antiegfr therapy regorafenib is also indicated for the treatment of patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor gist who have been previously treated with imatinib mesylate and sunitinib malate')|
|('DB08896', 'MONDO:0004992', ['cancer'], 'regorafenib is indicated for the treatment of patients with metastatic colorectal cancer crc who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf therapy and if kras wild type an antiegfr therapy regorafenib is also indicated for the treatment of patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor gist who have been previously treated with imatinib mesylate and sunitinib malate')|
|('DB01295', 'MONDO:0004992', ['cancer'], 'for the treatment of angina pectoris and hypertension')|
|('DB00822', 'MONDO:0004992', ['cancer'], 'for the treatment and management of chronic alcoholism')|
|('DB00253', 'MONDO:0004992', ['cancer'], 'for the treatment of allergic conjunctivitis vernal conjunctivitis episcleritis and epinephrine sensitivity')|
|('DB00253', 'MONDO:0002313', ['vernal conjunctivitis'], 'for the treatment of allergic conjunctivitis vernal conjunctivitis episcleritis and epinephrine sensitivity')|
|('DB00276', 'MONDO:0002313', ['vernal conjunctivitis'], 'for treatment of acute myeloid leukaemia')|
|('DB00276', 'MONDO:0018874', ['acute myeloblastic leukaemia', 'acute myeloblastic leukemia', 'acute myelogenous leukaemia', 'acute myelogenous leukemia', 'acute myeloid leukaemia', 'AML - acute Myeloid Leukemia', 'Leukemia, Myelocytic, acute', 'acute myeloid leukemia'], 'for treatment of acute myeloid leukaemia')|
|('DB00815', 'MONDO:0002313', ['vernal conjunctivitis'], 'sls is used as a surfactant in shampoos and toothpastes sls also has microbicidal activities against both enveloped herpes simplex viruses hiv1 semliki forest virus and nonenveloped papillomaviruses reovirus rotavirus and poliovirus viruses although it has not been approved for this use')|
|('DB00815', 'MONDO:0010031', ['FALDH deficiency', 'fatty acid alcohol oxidoreductase deficiency', 'Sjogren Larsson syndrome', 'Sjogren-Larssons syndrome', 'SLS', 'sjogren-larsson syndrome'], 'sls is used as a surfactant in shampoos and toothpastes sls also has microbicidal activities against both enveloped herpes simplex viruses hiv1 semliki forest virus and nonenveloped papillomaviruses reovirus rotavirus and poliovirus viruses although it has not been approved for this use')|
|('DB00815', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sls is used as a surfactant in shampoos and toothpastes sls also has microbicidal activities against both enveloped herpes simplex viruses hiv1 semliki forest virus and nonenveloped papillomaviruses reovirus rotavirus and poliovirus viruses although it has not been approved for this use')|
|('DB01190', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of serious infections caused by susceptible anaerobic bacteria including bacteroides spp peptostreptococcus anaerobic streptococci clostridium spp and microaerophilic streptococci may be useful in polymicrobic infections such as intraabdominal or pelvic infections osteomyelitis diabetic foot ulcers aspiration pneumonia and dental infections may also be used to treat mssa and respiratory infections caused by s pneumoniae and s pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism may be used vaginally to treat vaginosis caused by gardnerella vaginosa clindamycin reduces the toxin producing effects of s aureus and s pyogenes and as such may be particularly useful for treating necrotizing fasciitis may be used topically to treat acne')|
|('DB01190', 'MONDO:0005246', ['osteomyelitis'], 'for the treatment of serious infections caused by susceptible anaerobic bacteria including bacteroides spp peptostreptococcus anaerobic streptococci clostridium spp and microaerophilic streptococci may be useful in polymicrobic infections such as intraabdominal or pelvic infections osteomyelitis diabetic foot ulcers aspiration pneumonia and dental infections may also be used to treat mssa and respiratory infections caused by s pneumoniae and s pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism may be used vaginally to treat vaginosis caused by gardnerella vaginosa clindamycin reduces the toxin producing effects of s aureus and s pyogenes and as such may be particularly useful for treating necrotizing fasciitis may be used topically to treat acne')|
|('DB01190', 'MONDO:0000265', ['aspiration pneumonia'], 'for the treatment of serious infections caused by susceptible anaerobic bacteria including bacteroides spp peptostreptococcus anaerobic streptococci clostridium spp and microaerophilic streptococci may be useful in polymicrobic infections such as intraabdominal or pelvic infections osteomyelitis diabetic foot ulcers aspiration pneumonia and dental infections may also be used to treat mssa and respiratory infections caused by s pneumoniae and s pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism may be used vaginally to treat vaginosis caused by gardnerella vaginosa clindamycin reduces the toxin producing effects of s aureus and s pyogenes and as such may be particularly useful for treating necrotizing fasciitis may be used topically to treat acne')|
|('DB01190', 'MONDO:0004835', ['necrotizing fasciitis'], 'for the treatment of serious infections caused by susceptible anaerobic bacteria including bacteroides spp peptostreptococcus anaerobic streptococci clostridium spp and microaerophilic streptococci may be useful in polymicrobic infections such as intraabdominal or pelvic infections osteomyelitis diabetic foot ulcers aspiration pneumonia and dental infections may also be used to treat mssa and respiratory infections caused by s pneumoniae and s pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism may be used vaginally to treat vaginosis caused by gardnerella vaginosa clindamycin reduces the toxin producing effects of s aureus and s pyogenes and as such may be particularly useful for treating necrotizing fasciitis may be used topically to treat acne')|
|('DB01190', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'for the treatment of serious infections caused by susceptible anaerobic bacteria including bacteroides spp peptostreptococcus anaerobic streptococci clostridium spp and microaerophilic streptococci may be useful in polymicrobic infections such as intraabdominal or pelvic infections osteomyelitis diabetic foot ulcers aspiration pneumonia and dental infections may also be used to treat mssa and respiratory infections caused by s pneumoniae and s pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism may be used vaginally to treat vaginosis caused by gardnerella vaginosa clindamycin reduces the toxin producing effects of s aureus and s pyogenes and as such may be particularly useful for treating necrotizing fasciitis may be used topically to treat acne')|
|('DB01095', 'MONDO:0004835', ['necrotizing fasciitis'], 'to be used as an adjunct to dietary therapy to prevent cardiovascular events may be used as secondary prevention in patients with coronary heart disease chd to reduce the risk of requiring coronary revascularization procedures for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with chd and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia ')|
|('DB01095', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'to be used as an adjunct to dietary therapy to prevent cardiovascular events may be used as secondary prevention in patients with coronary heart disease chd to reduce the risk of requiring coronary revascularization procedures for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with chd and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia ')|
|('DB01095', 'MONDO:0021661', ['coronary artery arteriosclerosis (disease) [MONDO:patterns/location]', 'arteriosclerosis disorder of coronary artery [MONDO:design_pattern]', 'coronary atherosclerosis [NCIT:C35505]', 'coronary artery arteriosclerosis disorder [MONDO:design_pattern,MONDO:patterns/location]', 'coronary atherosclerosis'], 'to be used as an adjunct to dietary therapy to prevent cardiovascular events may be used as secondary prevention in patients with coronary heart disease chd to reduce the risk of requiring coronary revascularization procedures for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with chd and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia ')|
|('DB00205', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of toxoplasmosis and acute malaria for the prevention of malaria in areas nonresistant to pyrimethamine')|
|('DB00205', 'MONDO:0005989', ['disseminated toxoplasmosis', 'toxoplasmosis'], 'for the treatment of toxoplasmosis and acute malaria for the prevention of malaria in areas nonresistant to pyrimethamine')|
|('DB00205', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of toxoplasmosis and acute malaria for the prevention of malaria in areas nonresistant to pyrimethamine')|
|('DB00263', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00263', 'MONDO:0018059', ['meningococcal meningitis'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00263', 'MONDO:0005441', ['otitis media'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00263', 'MONDO:0001249', ['active stage trachoma', 'trachoma dubium', 'trachoma'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00263', 'MONDO:0003799', ['conjunctivitis'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00263', 'MONDO:0001797', ['Ulcus molle, skin', 'chancroid'], 'for the treatment of severe repeated or longlasting urinary tract infections meningococcal meningitis acute otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria and other bacterial infections')|
|('DB00456', 'MONDO:0005136', ['induced malaria', 'malaria'], 'used to prevent infection during surgery and to treat many kinds of infections of the blood bone or joints respiratory tract skin and urinary tract')|
|('DB00884', 'MONDO:0005136', ['induced malaria', 'malaria'], 'risedronic acid is indicated for the treatment of osteoperosis in men treatment of pagets disease treatment and prevention of osteoperosis in postmenopausal women and treatment and prevention of glucocorticoidinduced osteoperosisfda label')|
|('DB00884', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'risedronic acid is indicated for the treatment of osteoperosis in men treatment of pagets disease treatment and prevention of osteoperosis in postmenopausal women and treatment and prevention of glucocorticoidinduced osteoperosisfda label')|
|('DB00286', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00286', 'MONDO:0002146', ['hypogonadism'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00286', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00286', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00286', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00286', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'the conjugated estrogens are indicated for several different conditions including treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure palliative treatment of breast cancer in appropriately selected patients with metastatic disease palliative treatment of androgendependent carcinoma of the prostate preventive therapy of postmenopausal osteoporosisa38238 ')|
|('DB00379', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of ventricular tachycardia and symptomatic premature ventricular beats and prevention of ventricular fibrillation')|
|('DB00379', 'MONDO:0005477', ['ventricular tachycardia'], 'for the treatment of ventricular tachycardia and symptomatic premature ventricular beats and prevention of ventricular fibrillation')|
|('DB00379', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'for the treatment of ventricular tachycardia and symptomatic premature ventricular beats and prevention of ventricular fibrillation')|
|('DB06216', 'MONDO:0005477', ['ventricular tachycardia'], 'used for treatment in psychosis schizophrenia and schizoaffective disorders manic disorders and bipolar disorders as monotherapy or in combination')|
|('DB06216', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used for treatment in psychosis schizophrenia and schizoaffective disorders manic disorders and bipolar disorders as monotherapy or in combination')|
|('DB01228', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'encainide is a class ic antiarrhythmic agent which was used for management of irregular heartbeats such as atrial fibrillation atrial flutter ventricular tachycardia and ventricular fibrillation ')|
|('DB01228', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'encainide is a class ic antiarrhythmic agent which was used for management of irregular heartbeats such as atrial fibrillation atrial flutter ventricular tachycardia and ventricular fibrillation ')|
|('DB01228', 'MONDO:0000190', ['VFib [NCIT:C50799]', 'fibrillation, ventricular [NCIT:C50799]', 'ventricular fibrillation [MONDO:ambiguous]', 'VF [NCIT:C50799]', 'ventricular fibrillation'], 'encainide is a class ic antiarrhythmic agent which was used for management of irregular heartbeats such as atrial fibrillation atrial flutter ventricular tachycardia and ventricular fibrillation ')|
|('DB00496', 'MONDO:0005310', ['atrial flutter [MONDO:ambiguous]', 'atrial flutter'], 'for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and frequency')|
|('DB00496', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and frequency')|
|('DB01280', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of pediatric and adult patients with acute tcell lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens')|
|('DB01280', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'for the treatment of pediatric and adult patients with acute tcell lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens')|
|('DB01280', 'MONDO:0000873', ['lymphoblastic lymphoma'], 'for the treatment of pediatric and adult patients with acute tcell lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens')|
|('DB01280', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of pediatric and adult patients with acute tcell lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens')|
|('DB06811', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity ')|
|('DB00159', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'epa can be used for lowering elevated triglycerides in those who are hyperglyceridemic in addition epa may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy')|
|('DB00159', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'epa can be used for lowering elevated triglycerides in those who are hyperglyceridemic in addition epa may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy')|
|('DB00159', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'epa can be used for lowering elevated triglycerides in those who are hyperglyceridemic in addition epa may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy')|
|('DB00219', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment of visceral spasms')|
|('DB00212', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment of hypertension and heart failure')|
|('DB00212', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of hypertension and heart failure')|
|('DB01161', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the production of local anesthesia by infiltration and peripheral nerve block they are not to be used for lumbar or caudal epidural anesthesia')|
|('DB08882', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'linagliptin is indicated for the treatment of type ii diabetes in addition to diet and exercisel9557 it should not be used to treat type i diabetes or in diabetic ketoacidosisl9557')|
|('DB01065', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0024381', ['jet lag [https://www.circadiansleepdisorders.org/defs.php#defJetLag]', 'circadian rhythm sleep disorder, jet lag type'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0006496', ['Plegias [MESH:D010243]', 'Plegia [MESH:D010243]', 'palsy'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0005326', ['sunburn'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB01065', 'MONDO:0004992', ['cancer'], 'used orally for jet lag insomnia shiftwork disorder circadian rhythm disorders in the blind evidence for efficacy and benzodiazepine and nicotine withdrawal evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults it has received fda orphan drug status as an oral medication for this use a number of studies have shown that melatonin may be effective for treating sleepwake cycle disturbances in children and adolescents with mental retardation autism and other central nervous system disorders it appears to decrease the time to fall asleep in children with developmental disabilities such as cerebral palsy autism and mental retardation it may also improve secondary insomnia associated with various sleepwake cycle disturbances other possible uses for which there is some evidence for include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety and sedation prostate cancer solid tumors when combined with il2 therapy in certain cancers sunburn prevention topical use tardive dyskinesia thrombocytopenia associated with cancer chemotherapy and other disorders ')|
|('DB00794', 'MONDO:0004992', ['cancer'], 'primidone is commonly indicated for the management of grand mal psychomotor and focal epileptic seizures l4645 fda label in addition it has also been studied and utilized as an effective management of essential tremor a39414 a39415 l4645')|
|('DB00794', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'primidone is commonly indicated for the management of grand mal psychomotor and focal epileptic seizures l4645 fda label in addition it has also been studied and utilized as an effective management of essential tremor a39414 a39415 l4645')|
|('DB00794', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'primidone is commonly indicated for the management of grand mal psychomotor and focal epileptic seizures l4645 fda label in addition it has also been studied and utilized as an effective management of essential tremor a39414 a39415 l4645')|
|('DB00898', 'MONDO:0003233', ['benign essential tremor', 'essential hereditary tremor', 'shaky hand syndrome', 'essential tremor'], 'for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia tic douloureux in patients for whom neurosurgical procedures are contraindicated')|
|('DB00898', 'MONDO:0004992', ['cancer'], 'for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia tic douloureux in patients for whom neurosurgical procedures are contraindicated')|
|('DB00898', 'MONDO:0008599', ['Trifacial neuralgia', 'trifocal neuralgia', 'Trigeminal neuralgia', 'trigeminal neuralgia'], 'for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia tic douloureux in patients for whom neurosurgical procedures are contraindicated')|
|('DB00907', 'MONDO:0008599', ['Trifacial neuralgia', 'trifocal neuralgia', 'Trigeminal neuralgia', 'trigeminal neuralgia'], 'for the introduction of local topical anesthesia of accessible mucous membranes of the oral laryngeal and nasal cavities')|
|('DB00457', 'MONDO:0008599', ['Trifacial neuralgia', 'trifocal neuralgia', 'Trigeminal neuralgia', 'trigeminal neuralgia'], 'this drug is indicated for the treatment of hypertension high blood pressure prazosin can be given alone or given with other blood pressurelowering drugs including diuretics or betaadrenergic blocking agents fda labelprazosin does not negatively impact lung function and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease copda176630')|
|('DB00457', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug is indicated for the treatment of hypertension high blood pressure prazosin can be given alone or given with other blood pressurelowering drugs including diuretics or betaadrenergic blocking agents fda labelprazosin does not negatively impact lung function and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease copda176630')|
|('DB00457', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'this drug is indicated for the treatment of hypertension high blood pressure prazosin can be given alone or given with other blood pressurelowering drugs including diuretics or betaadrenergic blocking agents fda labelprazosin does not negatively impact lung function and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease copda176630')|
|('DB00448', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers active duodenal ulcers erosive reflux oesophagitis symptomatic gastroesophageal reflux disease and nonsteroidal antiinflammatory drug nsaid induced gastric and duodenal ulcers a4892a177065fda label  it may be used in the maintenance and healing of several gastric conditions including duodenal ulcers nsaid related gastric ulcers and erosive esophagitisfda label lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use nsaids chronically fda label  predictably it is also useful in the management of hypersecretory conditions including zollingerellison syndrome fda label  lansoprazole is effective at eradicating h pylori when used in conjunction with amoxicillin and clarithromycin triple therapy or with amoxicillin alone dual therapy fda label')|
|('DB00448', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers active duodenal ulcers erosive reflux oesophagitis symptomatic gastroesophageal reflux disease and nonsteroidal antiinflammatory drug nsaid induced gastric and duodenal ulcers a4892a177065fda label  it may be used in the maintenance and healing of several gastric conditions including duodenal ulcers nsaid related gastric ulcers and erosive esophagitisfda label lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use nsaids chronically fda label  predictably it is also useful in the management of hypersecretory conditions including zollingerellison syndrome fda label  lansoprazole is effective at eradicating h pylori when used in conjunction with amoxicillin and clarithromycin triple therapy or with amoxicillin alone dual therapy fda label')|
|('DB00472', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00472', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00472', 'MONDO:0005452', ['hyperorexia nervosa', 'bulimia nervosa'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00472', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00472', 'MONDO:0003709', ['Fear of open spaces', 'agoraphobia'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00472', 'MONDO:0001866', ['bipolar I disorder'], 'fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder obsessive compulsive disorder and bulimia nervosa however it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is presentl7664 fluoxetine may also be used in combination with olanzapine to treat depression related to bipolar i disorder and treatment resistant depressionl7664')|
|('DB00662', 'MONDO:0001866', ['bipolar I disorder'], 'for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis')|
|('DB00662', 'MONDO:0002269', ['cholera morbus', 'infectious colitis, enteritis and gastroenteritis', 'gastroenteritis'], 'for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis')|
|('DB06292', 'MONDO:0001866', ['bipolar I disorder'], 'dapagliflozin is indicated to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exerciselabela6757a6758')|
|('DB06292', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'dapagliflozin is indicated to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exerciselabela6757a6758')|
|('DB01604', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'or the treatment of respiratory tract infections including acute bronchitis acute exacerbations of chronic bronchitis and pneumonia ear nose and throat infections gynecological infections urinary tract infections including acute uncomplicated gonococcal urethritis when caused by non penicillinaseproducing susceptible strains of the following organisms grampositive organisms eg streptococci pneumococci and staphylococci gramnegative organisms eg h influenzae n gonorrhoeae e coli p mirabilis ')|
|('DB01604', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'or the treatment of respiratory tract infections including acute bronchitis acute exacerbations of chronic bronchitis and pneumonia ear nose and throat infections gynecological infections urinary tract infections including acute uncomplicated gonococcal urethritis when caused by non penicillinaseproducing susceptible strains of the following organisms grampositive organisms eg streptococci pneumococci and staphylococci gramnegative organisms eg h influenzae n gonorrhoeae e coli p mirabilis ')|
|('DB01604', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'or the treatment of respiratory tract infections including acute bronchitis acute exacerbations of chronic bronchitis and pneumonia ear nose and throat infections gynecological infections urinary tract infections including acute uncomplicated gonococcal urethritis when caused by non penicillinaseproducing susceptible strains of the following organisms grampositive organisms eg streptococci pneumococci and staphylococci gramnegative organisms eg h influenzae n gonorrhoeae e coli p mirabilis ')|
|('DB01604', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'or the treatment of respiratory tract infections including acute bronchitis acute exacerbations of chronic bronchitis and pneumonia ear nose and throat infections gynecological infections urinary tract infections including acute uncomplicated gonococcal urethritis when caused by non penicillinaseproducing susceptible strains of the following organisms grampositive organisms eg streptococci pneumococci and staphylococci gramnegative organisms eg h influenzae n gonorrhoeae e coli p mirabilis ')|
|('DB01604', 'MONDO:0020971', ['gonococcal urethritis [NCIT:C26787]', 'gc urethritis [NCIT:C26787]', 'gonococcal urethritis'], 'or the treatment of respiratory tract infections including acute bronchitis acute exacerbations of chronic bronchitis and pneumonia ear nose and throat infections gynecological infections urinary tract infections including acute uncomplicated gonococcal urethritis when caused by non penicillinaseproducing susceptible strains of the following organisms grampositive organisms eg streptococci pneumococci and staphylococci gramnegative organisms eg h influenzae n gonorrhoeae e coli p mirabilis ')|
|('DB08798', 'MONDO:0020971', ['gonococcal urethritis [NCIT:C26787]', 'gc urethritis [NCIT:C26787]', 'gonococcal urethritis'], 'for the treatment of bacterial infection')|
|('DB06290', 'MONDO:0020971', ['gonococcal urethritis [NCIT:C26787]', 'gc urethritis [NCIT:C26787]', 'gonococcal urethritis'], 'indicated for the treatment of adults with chronic hepatitis c virus hcv infection typically in combination with sofosbuvir in patients with hcv genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa pegifnalfa and ribavirin rbv in patients with hcv genotype 1 or 4 without cirrhosis or with compensated cirrhosis resistance reduced susceptibility to simeprevir was most commonly associated with the viral ns3 q80k polymorphism amino acid substitutions at ns3 positions s122 r155 andor d168 are also shown to reduce susceptibility to simeprevir in genotype 1ab patients ')|
|('DB06290', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'indicated for the treatment of adults with chronic hepatitis c virus hcv infection typically in combination with sofosbuvir in patients with hcv genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa pegifnalfa and ribavirin rbv in patients with hcv genotype 1 or 4 without cirrhosis or with compensated cirrhosis resistance reduced susceptibility to simeprevir was most commonly associated with the viral ns3 q80k polymorphism amino acid substitutions at ns3 positions s122 r155 andor d168 are also shown to reduce susceptibility to simeprevir in genotype 1ab patients ')|
|('DB06290', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of adults with chronic hepatitis c virus hcv infection typically in combination with sofosbuvir in patients with hcv genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa pegifnalfa and ribavirin rbv in patients with hcv genotype 1 or 4 without cirrhosis or with compensated cirrhosis resistance reduced susceptibility to simeprevir was most commonly associated with the viral ns3 q80k polymorphism amino acid substitutions at ns3 positions s122 r155 andor d168 are also shown to reduce susceptibility to simeprevir in genotype 1ab patients ')|
|('DB00242', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for the treatment of active hairy cell leukemia leukemic reticuloendotheliosis as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms also used as an alternative agent for the treatment of chronic lymphocytic leukemia cll lowgrade nonhodgkins lymphoma and cutaneous tcell lymphoma')|
|('DB00242', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the treatment of active hairy cell leukemia leukemic reticuloendotheliosis as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms also used as an alternative agent for the treatment of chronic lymphocytic leukemia cll lowgrade nonhodgkins lymphoma and cutaneous tcell lymphoma')|
|('DB00242', 'MONDO:0002049', ['thrombocytopenia'], 'for the treatment of active hairy cell leukemia leukemic reticuloendotheliosis as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms also used as an alternative agent for the treatment of chronic lymphocytic leukemia cll lowgrade nonhodgkins lymphoma and cutaneous tcell lymphoma')|
|('DB00242', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'for the treatment of active hairy cell leukemia leukemic reticuloendotheliosis as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms also used as an alternative agent for the treatment of chronic lymphocytic leukemia cll lowgrade nonhodgkins lymphoma and cutaneous tcell lymphoma')|
|('DB00242', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of active hairy cell leukemia leukemic reticuloendotheliosis as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms also used as an alternative agent for the treatment of chronic lymphocytic leukemia cll lowgrade nonhodgkins lymphoma and cutaneous tcell lymphoma')|
|('DB00808', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of hypertension alone or in combination with other antihypertensive drugs as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed also used for the management of edema as a result of various causes')|
|('DB00808', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of hypertension alone or in combination with other antihypertensive drugs as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed also used for the management of edema as a result of various causes')|
|('DB00559', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'used in the treatment of pulmonary arterial hypertension pah to improve exercise ability and to decrease the rate of clinical worsening in patients with who class iii or iv symptoms')|
|('DB00559', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'used in the treatment of pulmonary arterial hypertension pah to improve exercise ability and to decrease the rate of clinical worsening in patients with who class iii or iv symptoms')|
|('DB00352', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias')|
|('DB01184', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'for management of dyspepsia heartburn epigastric pain nausea and vomiting')|
|('DB01184', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for management of dyspepsia heartburn epigastric pain nausea and vomiting')|
|('DB00910', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stage 3 and 4')|
|('DB00910', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'for treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stage 3 and 4')|
|('DB00910', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stage 3 and 4')|
|('DB06439', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'tyloxapol is an inhaled surfactant that assists in removing and liquefying and removing bronchopulmonary secretions with mucus and pus tyloxapol is administered either through nebulized solution or a stream of oxygen also investigated for usetreatment in cystic fibrosis and pediatric indications')|
|('DB00749', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for acute and longterm management of signs and symptoms of osteoarthritis and rheumatoid arthritis as well as for the management of pain')|
|('DB00749', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for acute and longterm management of signs and symptoms of osteoarthritis and rheumatoid arthritis as well as for the management of pain')|
|('DB00749', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for acute and longterm management of signs and symptoms of osteoarthritis and rheumatoid arthritis as well as for the management of pain')|
|('DB00880', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00880', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00880', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy it is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension')|
|('DB00575', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medicationsl7237l7240 a clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficientl7243 an extended release tablet of clonidine is indicated for the treatment of adhd either alone or in combination with other medicationsl7246clonidine is also used for the diagnosis of pheochromocytomaa180565 treatment of nicotine dependancea180568 and opiate withdrawala180571')|
|('DB00575', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medicationsl7237l7240 a clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficientl7243 an extended release tablet of clonidine is indicated for the treatment of adhd either alone or in combination with other medicationsl7246clonidine is also used for the diagnosis of pheochromocytomaa180565 treatment of nicotine dependancea180568 and opiate withdrawala180571')|
|('DB04938', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'ospemifene is used for the treatment of moderate to dyspareunia a symptom of vulvar and vaginal atrophy due to menopause')|
|('DB00914', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for the reatment of type ii diabetes mellitus')|
|('DB00914', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the reatment of type ii diabetes mellitus')|
|('DB01353', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for the treatment of insomnia')|
|('DB01353', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of insomnia')|
|('DB00769', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'used topically as an antiinflammatory in the treatment of steroidresponsive dermatoses')|
|('DB01608', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for use as adjunctive medication in some psychotic patients propericiazine pericyazineis used for the control of residual prevailing hostility impulsiveness and aggressiveness ')|
|('DB06616', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'treatment of chronic accelerated or blast phase philadelphia chromosomepositive ph chronic myelogenous leukemia cml with resistance or intolerance to prior therapy in adult patients ')|
|('DB06616', 'MONDO:0005059', ['leukemia'], 'treatment of chronic accelerated or blast phase philadelphia chromosomepositive ph chronic myelogenous leukemia cml with resistance or intolerance to prior therapy in adult patients ')|
|('DB00686', 'MONDO:0005059', ['leukemia'], 'for the relief of bladder pain or discomfort associated with interstitial cystitis')|
|('DB00686', 'MONDO:0018301', ['interstitial cystitis'], 'for the relief of bladder pain or discomfort associated with interstitial cystitis')|
|('DB00273', 'MONDO:0005059', ['leukemia'], 'topiramate is indicated  for the following conditions 1monotherapy for partial onset or primary generalized tonicclonic seizures for patients 2 years of age and above 2adjunctive therapy for partial onset seizures or primary generalized tonicclonic seizures for both adult and pediatric patients above 2 years old 3adjunctive therapy for seizures associated with lennoxgastaut syndrome in patients above 2 years of age 4prophylaxis of migraine in children 12 years of age and older and adultsl10544topiramate is also used offlabel as an adjunct therapy for weight managementl10550 and for mood disordersa188312')|
|('DB06203', 'MONDO:0005059', ['leukemia'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB06203', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ')|
|('DB00619', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of philadelphia chromosome positive chronic myeloid leukemia ph cml ph acute lymphoblastic leukaemia myelodysplasticmyeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome andor chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumors gist')|
|('DB00619', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'for the treatment of philadelphia chromosome positive chronic myeloid leukemia ph cml ph acute lymphoblastic leukaemia myelodysplasticmyeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome andor chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumors gist')|
|('DB00619', 'MONDO:0020333', ['Aggressive systemic mastocytosis', 'ASM', 'Lymphadenopathic mastocytosis with eosinophilia', 'aggressive systemic mastocytosis'], 'for the treatment of philadelphia chromosome positive chronic myeloid leukemia ph cml ph acute lymphoblastic leukaemia myelodysplasticmyeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome andor chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumors gist')|
|('DB00619', 'MONDO:0006147', ['CEL [NCIT:C4563]', 'chronic eosinophilic leukemia, not otherwise specified [NCIT:C4563]', 'chronic eosinophilic leukemia/hypereosinophilic syndrome [NCIT:C4563]', 'CEL/hypereosinophilic syndrome [NCIT:C4563]', 'chronic eosinophilic leukemia [NCIT:C4563]', 'eosinophilic leukemia [NCIT:C4563]', 'chronic eosinophilic leukemia, not otherwise specified'], 'for the treatment of philadelphia chromosome positive chronic myeloid leukemia ph cml ph acute lymphoblastic leukaemia myelodysplasticmyeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome andor chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumors gist')|
|('DB00619', 'MONDO:0011934', ['dermatofibrosarcoma protuberans'], 'for the treatment of philadelphia chromosome positive chronic myeloid leukemia ph cml ph acute lymphoblastic leukaemia myelodysplasticmyeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome andor chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans and malignant gastrointestinal stromal tumors gist')|
|('DB00174', 'MONDO:0011934', ['dermatofibrosarcoma protuberans'], 'used for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB08873', 'MONDO:0011934', ['dermatofibrosarcoma protuberans'], 'boceprevir when used in combination with db00811 db00008 and db00022 is indicated for use in the treatment of chronic hcv genotype 1 infection in adults fda label')|
|('DB00986', 'MONDO:0011934', ['dermatofibrosarcoma protuberans'], 'for use as a preoperative antimuscarinic to reduce salivary tracheobronchial and pharyngeal secretions to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation also used to treat chronic obstructive pulmonary disease copd')|
|('DB00986', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use as a preoperative antimuscarinic to reduce salivary tracheobronchial and pharyngeal secretions to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation also used to treat chronic obstructive pulmonary disease copd')|
|('DB00757', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including initial and repeat courses of chemotherapy also used for the prevention of postoperative nausea and vomiting this drug can be used intravenously for the treatment of postoperative nausea and vomiting')|
|('DB00757', 'MONDO:0004992', ['cancer'], 'for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy including initial and repeat courses of chemotherapy also used for the prevention of postoperative nausea and vomiting this drug can be used intravenously for the treatment of postoperative nausea and vomiting')|
|('DB00168', 'MONDO:0004992', ['cancer'], 'used as a diet supplement and sugar substitute')|
|('DB00255', 'MONDO:0004992', ['cancer'], 'used in the treatment of prostate cancer previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery')|
|('DB00255', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used in the treatment of prostate cancer previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery')|
|('DB02546', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of cutaneous manifestations in patients with cutaneous tcell lymphoma who have progressive persistent or recurrent disease on or following two systemic therapies')|
|('DB02546', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of cutaneous manifestations in patients with cutaneous tcell lymphoma who have progressive persistent or recurrent disease on or following two systemic therapies')|
|('DB06209', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB06209', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB06209', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB06209', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB06209', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB06209', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'indicated in combination with acetylsalicylic acid asa to prevent atherothrombotic events in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci may be used in patients with unstable angina ua nonst elevation myocardial infarction nstemi stelevation myocardial infarction stemi who are to be managed with pci prasugrel is not recommended in patients 75 years of age or greater those that weigh60kg and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding ')|
|('DB00917', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'for the termination of pregnancy during the second trimester from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period also used in the management of nonmetastatic gestational trophoblastic disease benign hydatidiform mole other indications include improving the cervical inducibility cervical ripening in pregnant women at or near term with a medical or obstetrical need for labor induction and the management of postpartum hemorrhage')|
|('DB00917', 'MONDO:0016784', ['gestational trophoblastic disease'], 'for the termination of pregnancy during the second trimester from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period also used in the management of nonmetastatic gestational trophoblastic disease benign hydatidiform mole other indications include improving the cervical inducibility cervical ripening in pregnant women at or near term with a medical or obstetrical need for labor induction and the management of postpartum hemorrhage')|
|('DB00917', 'MONDO:0006248', ['hydatid Mole [NCIT:C3110]', 'hydatidiform mole [MONDO:0020551,NCIT:C3110]', 'molar pregnancy [NCIT:C3110,Orphanet:99927]', 'hydatidiform mole'], 'for the termination of pregnancy during the second trimester from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period also used in the management of nonmetastatic gestational trophoblastic disease benign hydatidiform mole other indications include improving the cervical inducibility cervical ripening in pregnant women at or near term with a medical or obstetrical need for labor induction and the management of postpartum hemorrhage')|
|('DB01577', 'MONDO:0006248', ['hydatid Mole [NCIT:C3110]', 'hydatidiform mole [MONDO:0020551,NCIT:C3110]', 'molar pregnancy [NCIT:C3110,Orphanet:99927]', 'hydatidiform mole'], 'for the treatment of attention deficit disorder with hyperactivity adhd and exogenous obesity')|
|('DB01577', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for the treatment of attention deficit disorder with hyperactivity adhd and exogenous obesity')|
|('DB01186', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'indicated as adjunctive treatment to levodopacarbidopa in the management of the signs and symptoms of parkinsons disease it was withdrawn from the us and canadian markets in 2007 due to an increased risk of cardiac valvulopathy ')|
|('DB00272', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for use clinically to test gastric secretory function')|
|('DB06770', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'ulesfia benzyl alcohol lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older ulesfia lotion does not have ovicidal activity')|
|('DB08834', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'used in the treatment of cholesterol gallstones tauroursodeoxycholic acid is also being investigated for use in several conditions such as primary biliary cirrhosis pbc insulin resistance amyloidosis cystic fibrosis cholestasis and amyotrophic lateral sclerosis')|
|('DB08834', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'used in the treatment of cholesterol gallstones tauroursodeoxycholic acid is also being investigated for use in several conditions such as primary biliary cirrhosis pbc insulin resistance amyloidosis cystic fibrosis cholestasis and amyotrophic lateral sclerosis')|
|('DB08834', 'MONDO:0004976', ['ALS', 'Lou Gehrigs disease', 'motor neuron disease, bulbar', 'amyotrophic lateral sclerosis'], 'used in the treatment of cholesterol gallstones tauroursodeoxycholic acid is also being investigated for use in several conditions such as primary biliary cirrhosis pbc insulin resistance amyloidosis cystic fibrosis cholestasis and amyotrophic lateral sclerosis')|
|('DB00250', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment and management of leprosy and dermatitis herpetiformis')|
|('DB00250', 'MONDO:0005124', ['leprosy'], 'for the treatment and management of leprosy and dermatitis herpetiformis')|
|('DB00250', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'for the treatment and management of leprosy and dermatitis herpetiformis')|
|('DB00633', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting also used in pain relief anxiety reduction and analgesia')|
|('DB00633', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting also used in pain relief anxiety reduction and analgesia')|
|('DB00633', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting also used in pain relief anxiety reduction and analgesia')|
|('DB04967', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'intended for use as a radiation sensitizer in the treatment of brain cancer')|
|('DB04967', 'MONDO:0001657', ['adult brain tumor', 'adult malignant brain neoplasm', 'brain neoplasm', 'brain neoplasm, adult', 'BT - Brain tumour', 'malignant brain tumour', 'malignant primary brain neoplasm', 'malignant primary brain tumor', 'malignant tumor of adult brain', 'malignant tumor of Brain', 'neoplasm of brain', 'primary brain neoplasm', 'primary brain tumor', 'primary malignant neoplasm of brain', 'tumor of the Brain', 'brain cancer'], 'intended for use as a radiation sensitizer in the treatment of brain cancer')|
|('DB00970', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of wilms tumor childhood rhabdomyosarcoma ewings sarcoma and metastatic nonseminomatous testicular cancer as part of a combination chemotherapy andor multimodality treatment regimen')|
|('DB00970', 'MONDO:0006058', ['Wilms tumor (nephroblastoma) [NCIT:C3267]', 'Wilms tumor [MONDO:0021044,NCIT:C3267]', "Wilms' tumor [NCIT:C3267]", 'wilms tumor'], 'for the treatment of wilms tumor childhood rhabdomyosarcoma ewings sarcoma and metastatic nonseminomatous testicular cancer as part of a combination chemotherapy andor multimodality treatment regimen')|
|('DB00970', 'MONDO:0005212', ['rhabdomyosarcoma'], 'for the treatment of wilms tumor childhood rhabdomyosarcoma ewings sarcoma and metastatic nonseminomatous testicular cancer as part of a combination chemotherapy andor multimodality treatment regimen')|
|('DB00970', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'for the treatment of wilms tumor childhood rhabdomyosarcoma ewings sarcoma and metastatic nonseminomatous testicular cancer as part of a combination chemotherapy andor multimodality treatment regimen')|
|('DB00970', 'MONDO:0005447', ['childhood neoplasm of the testis', 'neoplasm of testis', 'pediatric testicular neoplasm', 'testicular tumor', 'testis cancer', 'testis neoplasm', 'testicular cancer'], 'for the treatment of wilms tumor childhood rhabdomyosarcoma ewings sarcoma and metastatic nonseminomatous testicular cancer as part of a combination chemotherapy andor multimodality treatment regimen')|
|('DB00364', 'MONDO:0005447', ['childhood neoplasm of the testis', 'neoplasm of testis', 'pediatric testicular neoplasm', 'testicular tumor', 'testis cancer', 'testis neoplasm', 'testicular cancer'], 'the sucralfate suspension fda label and tablet f4534 are used for the treatment of active duodenal ulcer for up to 8 weeks  the tablet form may be used at a lower dose for healed duodenal ulcers for the purpose of maintaining healing and preventing recurrence f4519 f4534 sucralfate is also used in the prevention andor treatment of gastroesophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer in addition to dyspepsia a177655 f4519')|
|('DB00364', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'the sucralfate suspension fda label and tablet f4534 are used for the treatment of active duodenal ulcer for up to 8 weeks  the tablet form may be used at a lower dose for healed duodenal ulcers for the purpose of maintaining healing and preventing recurrence f4519 f4534 sucralfate is also used in the prevention andor treatment of gastroesophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer in addition to dyspepsia a177655 f4519')|
|('DB00364', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'the sucralfate suspension fda label and tablet f4534 are used for the treatment of active duodenal ulcer for up to 8 weeks  the tablet form may be used at a lower dose for healed duodenal ulcers for the purpose of maintaining healing and preventing recurrence f4519 f4534 sucralfate is also used in the prevention andor treatment of gastroesophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer in addition to dyspepsia a177655 f4519')|
|('DB00364', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'the sucralfate suspension fda label and tablet f4534 are used for the treatment of active duodenal ulcer for up to 8 weeks  the tablet form may be used at a lower dose for healed duodenal ulcers for the purpose of maintaining healing and preventing recurrence f4519 f4534 sucralfate is also used in the prevention andor treatment of gastroesophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer in addition to dyspepsia a177655 f4519')|
|('DB00364', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'the sucralfate suspension fda label and tablet f4534 are used for the treatment of active duodenal ulcer for up to 8 weeks  the tablet form may be used at a lower dose for healed duodenal ulcers for the purpose of maintaining healing and preventing recurrence f4519 f4534 sucralfate is also used in the prevention andor treatment of gastroesophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer in addition to dyspepsia a177655 f4519')|
|('DB06614', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two dayslabel')|
|('DB06614', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two dayslabel')|
|('DB00500', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis including the treatment of acute flares longterm management also for treatment of juvenile rheumatoid arthritis')|
|('DB00500', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis including the treatment of acute flares longterm management also for treatment of juvenile rheumatoid arthritis')|
|('DB00500', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis including the treatment of acute flares longterm management also for treatment of juvenile rheumatoid arthritis')|
|('DB00500', 'MONDO:0005185', ['Juvenile rheumatoid arthritis (AQ) [NCIT:C27179]', 'JRA [NCIT:C27179]', 'Juvenile rheumatoid arthritis [NCIT:C27179]', 'chronic childhood arthritis'], 'for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis including the treatment of acute flares longterm management also for treatment of juvenile rheumatoid arthritis')|
|('DB00862', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used for the treatment of erectile dysfunction')|
|('DB00862', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'used for the treatment of erectile dysfunction')|
|('DB08835', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used in patients with allergic conjunctivitis')|
|('DB01168', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for use with other anticancer drugs for the treatment of stage iii and stage iv hodgkins disease')|
|('DB00334', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar i disorder including mixed or manic episodesa177014 olanzapine is also indicated in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adultsfda labelas well olanzapine is indicated in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatmentresistant depression in patients over 10 years olda177014olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar i maniafda labelschizophrenia is a complex biochemical brain disorder that affects the persons ability to differentiate reality it is usually observed as the presence of delusions hallucinations social withdrawal and disturbed thinkingl5936bipolar disorder is a mental health condition defined by periods of extreme mood disturbances it is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of manial5939')|
|('DB00334', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar i disorder including mixed or manic episodesa177014 olanzapine is also indicated in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adultsfda labelas well olanzapine is indicated in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatmentresistant depression in patients over 10 years olda177014olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar i maniafda labelschizophrenia is a complex biochemical brain disorder that affects the persons ability to differentiate reality it is usually observed as the presence of delusions hallucinations social withdrawal and disturbed thinkingl5936bipolar disorder is a mental health condition defined by periods of extreme mood disturbances it is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of manial5939')|
|('DB00334', 'MONDO:0001866', ['bipolar I disorder'], 'olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar i disorder including mixed or manic episodesa177014 olanzapine is also indicated in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adultsfda labelas well olanzapine is indicated in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatmentresistant depression in patients over 10 years olda177014olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar i maniafda labelschizophrenia is a complex biochemical brain disorder that affects the persons ability to differentiate reality it is usually observed as the presence of delusions hallucinations social withdrawal and disturbed thinkingl5936bipolar disorder is a mental health condition defined by periods of extreme mood disturbances it is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of manial5939')|
|('DB00334', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar i disorder including mixed or manic episodesa177014 olanzapine is also indicated in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adultsfda labelas well olanzapine is indicated in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatmentresistant depression in patients over 10 years olda177014olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar i maniafda labelschizophrenia is a complex biochemical brain disorder that affects the persons ability to differentiate reality it is usually observed as the presence of delusions hallucinations social withdrawal and disturbed thinkingl5936bipolar disorder is a mental health condition defined by periods of extreme mood disturbances it is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of manial5939')|
|('DB06691', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'indicated for the treatment of allergic conditions symptomatic relief of hypersensitivity reaction and treatment of pruritic skin disorders')|
|('DB06691', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'indicated for the treatment of allergic conditions symptomatic relief of hypersensitivity reaction and treatment of pruritic skin disorders')|
|('DB00745', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'to improve wakefulness in patients with excessive daytime sleepiness eds associated with narcolepsy')|
|('DB00745', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'to improve wakefulness in patients with excessive daytime sleepiness eds associated with narcolepsy')|
|('DB00889', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy including high dose cisplatin postoperation and radiation including total body irradiation and daily fractionated abdominal radiation')|
|('DB00889', 'MONDO:0004992', ['cancer'], 'for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy including high dose cisplatin postoperation and radiation including total body irradiation and daily fractionated abdominal radiation')|
|('DB01100', 'MONDO:0004992', ['cancer'], 'used for the suppression of motor and phonic tics in patients with tourettes disorder who have failed to respond satisfactorily to standard treatment')|
|('DB00278', 'MONDO:0004992', ['cancer'], 'argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia hit it is also indicated for use in patients with or at risk for hit who are undergoing percutaneous coronary intervention')|
|('DB00278', 'MONDO:0002049', ['thrombocytopenia'], 'argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia hit it is also indicated for use in patients with or at risk for hit who are undergoing percutaneous coronary intervention')|
|('DB00278', 'MONDO:0018048', ['HAT [Orphanet:3325]', 'heparin-associated thrombocytopenia [Orphanet:3325]', 'HIT [Orphanet:3325]', 'heparin-induced thrombocytopenia [MONDO:ambiguous]', 'heparin-induced thrombocytopenia type 2 [Orphanet:3325]', 'heparin-induced thrombocytopenia'], 'argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia hit it is also indicated for use in patients with or at risk for hit who are undergoing percutaneous coronary intervention')|
|('DB01466', 'MONDO:0018048', ['HAT [Orphanet:3325]', 'heparin-associated thrombocytopenia [Orphanet:3325]', 'HIT [Orphanet:3325]', 'heparin-induced thrombocytopenia [MONDO:ambiguous]', 'heparin-induced thrombocytopenia type 2 [Orphanet:3325]', 'heparin-induced thrombocytopenia'], 'ethylmorphine is an analgesic used for pain relief')|
|('DB01049', 'MONDO:0018048', ['HAT [Orphanet:3325]', 'heparin-associated thrombocytopenia [Orphanet:3325]', 'HIT [Orphanet:3325]', 'heparin-induced thrombocytopenia [MONDO:ambiguous]', 'heparin-induced thrombocytopenia type 2 [Orphanet:3325]', 'heparin-induced thrombocytopenia'], 'it was labeled by the fda for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible conditiona32913 as well as for agerelated cognitive impairmenta32926 the prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease primary neurological disease or primary mood disturbancel2637 to know more about the individual components of the ergoloid mixture please visit db13345 and db11274')|
|('DB01049', 'MONDO:0045057', ['delirium'], 'it was labeled by the fda for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible conditiona32913 as well as for agerelated cognitive impairmenta32926 the prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease primary neurological disease or primary mood disturbancel2637 to know more about the individual components of the ergoloid mixture please visit db13345 and db11274')|
|('DB01049', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'it was labeled by the fda for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible conditiona32913 as well as for agerelated cognitive impairmenta32926 the prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease primary neurological disease or primary mood disturbancel2637 to know more about the individual components of the ergoloid mixture please visit db13345 and db11274')|
|('DB04868', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'for the potential treatment of various leukemias including chronic myeloid leukemia cml')|
|('DB04868', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for the potential treatment of various leukemias including chronic myeloid leukemia cml')|
|('DB00931', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'for the treatment of acute bacterial exacerbations of chronic bronchitis')|
|('DB00931', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for the treatment of acute bacterial exacerbations of chronic bronchitis')|
|('DB00333', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'methadone is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate its recommended that use is reserved for use in patients for whom alternative treatment options eg nonopioid analgesics opioid combination products are ineffective not tolerated or would be otherwise inadequate to provide sufficient management of painf4688methadone is also indicated for detoxification treatment of opioid addiction heroin or other morphinelike drugs and for maintenance substitution treatment for opioid dependence in adults in conjunction with appropriate social and medical servicesf4685f4691')|
|('DB00475', 'MONDO:0015938', ['multisystem disorder []', 'multi-system disorder []', 'systemic disorder [MONDO:cjm]', 'systemic disease'], 'for the management of anxiety disorders or for the shortterm relief of symptoms of anxiety withdrawal symptoms of acute alcoholism and preoperative apprehension and anxiety')|
|('DB00475', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of anxiety disorders or for the shortterm relief of symptoms of anxiety withdrawal symptoms of acute alcoholism and preoperative apprehension and anxiety')|
|('DB01332', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of infections due to susceptible strains of microorganisms')|
|('DB00579', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in shortterm a few weeks treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction exercise and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared kgmsup2sup or in patients with a body mass index of 27 kgmsup2sup in the presence of risk factors such as hypertension diabetes or hyperlipidemia')|
|('DB00579', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'used in shortterm a few weeks treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction exercise and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared kgmsup2sup or in patients with a body mass index of 27 kgmsup2sup in the presence of risk factors such as hypertension diabetes or hyperlipidemia')|
|('DB01026', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis and paracoccidioidomycosisfda label in europe it is also used in the treatment of endogenous cushings syndromel7736')|
|('DB01026', 'MONDO:0005672', ['Blastomyces Dermatitidis Infection', 'Blastomycotic infection', 'Chicago disease', 'Gilchrists disease', 'Infection by Blastomyces dermatitidis', 'North American blastomycosis', 'blastomycosis'], 'ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis and paracoccidioidomycosisfda label in europe it is also used in the treatment of endogenous cushings syndromel7736')|
|('DB01026', 'MONDO:0005706', ['primary extrapulmonary coccidioidomycosis', 'coccidioidomycosis'], 'ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis and paracoccidioidomycosisfda label in europe it is also used in the treatment of endogenous cushings syndromel7736')|
|('DB01026', 'MONDO:0015908', ['Chromomycosis', 'Mossy foot disease', 'chromomycosis'], 'ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis and paracoccidioidomycosisfda label in europe it is also used in the treatment of endogenous cushings syndromel7736')|
|('DB06704', 'MONDO:0015908', ['Chromomycosis', 'Mossy foot disease', 'chromomycosis'], 'detection of primary and metastatic pheochromocytoma or neuroblastoma ')|
|('DB06704', 'MONDO:0005072', ['neuroblastoma'], 'detection of primary and metastatic pheochromocytoma or neuroblastoma ')|
|('DB00953', 'MONDO:0015908', ['Chromomycosis', 'Mossy foot disease', 'chromomycosis'], 'for treatment of acute migraine attacks with or without aura')|
|('DB00400', 'MONDO:0015908', ['Chromomycosis', 'Mossy foot disease', 'chromomycosis'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB00400', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB00400', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB00400', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB00400', 'MONDO:0000242', ['dermatophytosis of beard', 'tinea barbae'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB00400', 'MONDO:0006609', ['Complement 5 dysfunction', 'cradle cap', 'Generalized seborrheic dermatitis of infants', 'Infantile seborrheic dermatitis', 'Infantile seborrhoeic dermatitis', 'Pityriasis capitis', 'Seborrhea capitis', 'seborrhea capitis', 'Seborrhea sicca', 'Seborrhoea capitis', 'Seborrhoeic dermatitis of scalp', 'Seborrhoeic eczema of scalp', 'seborrheic infantile dermatitis'], 'for the treatment of ringworm infections of the skin hair and nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap or other conditions caused by itrichophytoni or imicrosporumi fungi')|
|('DB01145', 'MONDO:0006609', ['Complement 5 dysfunction', 'cradle cap', 'Generalized seborrheic dermatitis of infants', 'Infantile seborrheic dermatitis', 'Infantile seborrhoeic dermatitis', 'Pityriasis capitis', 'Seborrhea capitis', 'seborrhea capitis', 'Seborrhea sicca', 'Seborrhoea capitis', 'Seborrhoeic dermatitis of scalp', 'Seborrhoeic eczema of scalp', 'seborrheic infantile dermatitis'], 'for the treatment of leprosy and dermatitis herpetiformis')|
|('DB01145', 'MONDO:0005124', ['leprosy'], 'for the treatment of leprosy and dermatitis herpetiformis')|
|('DB01145', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'for the treatment of leprosy and dermatitis herpetiformis')|
|('DB00825', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'used to treat occasional minor irritation pain sore mouth and sore throat as well as cough associated with a cold or inhaled irritants')|
|('DB00581', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patientsfda labell6199l6202additionally lactulose is also employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portalsystemic encephalopathy pse including both the hepatic precoma and coma variationsfda labell6199l6202 in particular lactulose solution has been effective at managing pse resulting from surgical portacaval shunts or from chronic hepatic diseases like cirrhosisl6199moreover there have also been studies demonstrating the capacity for lactulose to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions l6202')|
|('DB00581', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patientsfda labell6199l6202additionally lactulose is also employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portalsystemic encephalopathy pse including both the hepatic precoma and coma variationsfda labell6199l6202 in particular lactulose solution has been effective at managing pse resulting from surgical portacaval shunts or from chronic hepatic diseases like cirrhosisl6199moreover there have also been studies demonstrating the capacity for lactulose to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions l6202')|
|('DB00581', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patientsfda labell6199l6202additionally lactulose is also employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portalsystemic encephalopathy pse including both the hepatic precoma and coma variationsfda labell6199l6202 in particular lactulose solution has been effective at managing pse resulting from surgical portacaval shunts or from chronic hepatic diseases like cirrhosisl6199moreover there have also been studies demonstrating the capacity for lactulose to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions l6202')|
|('DB00581', 'MONDO:0005346', ['gallstones'], 'lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patientsfda labell6199l6202additionally lactulose is also employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portalsystemic encephalopathy pse including both the hepatic precoma and coma variationsfda labell6199l6202 in particular lactulose solution has been effective at managing pse resulting from surgical portacaval shunts or from chronic hepatic diseases like cirrhosisl6199moreover there have also been studies demonstrating the capacity for lactulose to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions l6202')|
|('DB00885', 'MONDO:0005346', ['gallstones'], 'for the prevention of itching of the eyes caused by allergies such as hay fever and allergic conjunctivitis')|
|('DB00585', 'MONDO:0005346', ['gallstones'], 'for the treatment of acidreflux disorders gerd peptic ulcer disease active benign gastric ulcer and active duodenal ulcer')|
|('DB00585', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of acidreflux disorders gerd peptic ulcer disease active benign gastric ulcer and active duodenal ulcer')|
|('DB00585', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of acidreflux disorders gerd peptic ulcer disease active benign gastric ulcer and active duodenal ulcer')|
|('DB01407', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'used as a bronchodilator in the treatment of asthma patients ')|
|('DB01407', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used as a bronchodilator in the treatment of asthma patients ')|
|('DB08826', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload')|
|('DB04880', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of congestive heart failure')|
|('DB04880', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of congestive heart failure')|
|('DB00870', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used as eye drops to inhibit the miosis pupil constriction that may occur during ocular surgery')|
|('DB00611', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of moderate to severe pain')|
|('DB06772', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for treatment of patients with hormonerefractory metastatic prostate cancer previously treated with a docetaxelcontaining treatment regimen')|
|('DB06772', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'for treatment of patients with hormonerefractory metastatic prostate cancer previously treated with a docetaxelcontaining treatment regimen')|
|('DB01597', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'cilastatin is indicated in combination with imipenem with or without relebactam for the treatment of bacterial infections including respiratory skin bone gynecologic urinary tract and intraabdominal as well as septicemia and endocarditisl7526l7568')|
|('DB00465', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'ketorolac is a nonsteroidal antiinflammatory drug nsaid and has antipyretic analgesic and antiinflammatory properties a176131  it is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids l6526  clinicians may choose to initiate ketorolac to manage postoperative pain spinal and soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorders and headaches among other ailments l6520  regardless of the etiology of pain patients should use the lowest possible dose and avoid using ketorolac for an extended period of time ideally ≤ 5 daysl6526  a benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac usea176131     ')|
|('DB00465', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ketorolac is a nonsteroidal antiinflammatory drug nsaid and has antipyretic analgesic and antiinflammatory properties a176131  it is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids l6526  clinicians may choose to initiate ketorolac to manage postoperative pain spinal and soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorders and headaches among other ailments l6520  regardless of the etiology of pain patients should use the lowest possible dose and avoid using ketorolac for an extended period of time ideally ≤ 5 daysl6526  a benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac usea176131     ')|
|('DB00465', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ketorolac is a nonsteroidal antiinflammatory drug nsaid and has antipyretic analgesic and antiinflammatory properties a176131  it is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids l6526  clinicians may choose to initiate ketorolac to manage postoperative pain spinal and soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorders and headaches among other ailments l6520  regardless of the etiology of pain patients should use the lowest possible dose and avoid using ketorolac for an extended period of time ideally ≤ 5 daysl6526  a benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac usea176131     ')|
|('DB00465', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'ketorolac is a nonsteroidal antiinflammatory drug nsaid and has antipyretic analgesic and antiinflammatory properties a176131  it is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids l6526  clinicians may choose to initiate ketorolac to manage postoperative pain spinal and soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorders and headaches among other ailments l6520  regardless of the etiology of pain patients should use the lowest possible dose and avoid using ketorolac for an extended period of time ideally ≤ 5 daysl6526  a benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac usea176131     ')|
|('DB00257', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'topical preparationsclotrimazole topical cream is indicated for the topical treatment of the following dermal infections f3088 f3121tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosumcandidiasis due to candida albicanstinea versicolor due to malassezia furfurdiaper rash infected by candida albicansin some preparations clotrimazole may be combined with betamethasone dipropionate a corticosteroid f3121 oral preparationsthe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis fda label  it is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation fda label troche preparations are not indicated for the treatment of any systemic mycoses fda label')|
|('DB00257', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'topical preparationsclotrimazole topical cream is indicated for the topical treatment of the following dermal infections f3088 f3121tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosumcandidiasis due to candida albicanstinea versicolor due to malassezia furfurdiaper rash infected by candida albicansin some preparations clotrimazole may be combined with betamethasone dipropionate a corticosteroid f3121 oral preparationsthe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis fda label  it is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation fda label troche preparations are not indicated for the treatment of any systemic mycoses fda label')|
|('DB00257', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'topical preparationsclotrimazole topical cream is indicated for the topical treatment of the following dermal infections f3088 f3121tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosumcandidiasis due to candida albicanstinea versicolor due to malassezia furfurdiaper rash infected by candida albicansin some preparations clotrimazole may be combined with betamethasone dipropionate a corticosteroid f3121 oral preparationsthe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis fda label  it is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation fda label troche preparations are not indicated for the treatment of any systemic mycoses fda label')|
|('DB00257', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'topical preparationsclotrimazole topical cream is indicated for the topical treatment of the following dermal infections f3088 f3121tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosumcandidiasis due to candida albicanstinea versicolor due to malassezia furfurdiaper rash infected by candida albicansin some preparations clotrimazole may be combined with betamethasone dipropionate a corticosteroid f3121 oral preparationsthe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis fda label  it is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation fda label troche preparations are not indicated for the treatment of any systemic mycoses fda label')|
|('DB00257', 'MONDO:0005059', ['leukemia'], 'topical preparationsclotrimazole topical cream is indicated for the topical treatment of the following dermal infections f3088 f3121tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosumcandidiasis due to candida albicanstinea versicolor due to malassezia furfurdiaper rash infected by candida albicansin some preparations clotrimazole may be combined with betamethasone dipropionate a corticosteroid f3121 oral preparationsthe oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis fda label  it is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation fda label troche preparations are not indicated for the treatment of any systemic mycoses fda label')|
|('DB00678', 'MONDO:0005059', ['leukemia'], 'losartan is indicated to treat hypertension in patients older than 6 years reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritage and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertensionl7423 losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritagel7426')|
|('DB00678', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'losartan is indicated to treat hypertension in patients older than 6 years reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritage and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertensionl7423 losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritagel7426')|
|('DB00678', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'losartan is indicated to treat hypertension in patients older than 6 years reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritage and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertensionl7423 losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritagel7426')|
|('DB00678', 'MONDO:0003634', ['proteinuria'], 'losartan is indicated to treat hypertension in patients older than 6 years reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritage and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertensionl7423 losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritagel7426')|
|('DB00678', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'losartan is indicated to treat hypertension in patients older than 6 years reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritage and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertensionl7423 losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy though this benefit may not extend to patients with african heritagel7426')|
|('DB01067', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellituslabel ')|
|('DB01067', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellituslabel ')|
|('DB01000', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of bacterial infections caused by susceptible organisms')|
|('DB01282', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used to control postpartum hemorrhage and bleeding after giving birth')|
|('DB01592', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used in preventing and treating irondeficiency anemia')|
|('DB01592', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB00725', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used in conjunction with antacids or histamine h2receptor antagonists in the treatment of peptic ulcers gastric ulcers and duodenal ulcers to reduce further gastric acid secretion and delay gastric emptying')|
|('DB01218', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for treatment of severe malaria')|
|('DB01621', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the maintenance treatment of chronic nonagitated schizophrenic patients')|
|('DB01607', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of bacterial infections')|
|('DB00135', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'tyrosine is claimed to act as an effective antidepressant however results are mixed tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue however these claims have been refuted by some studies')|
|('DB00135', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tyrosine is claimed to act as an effective antidepressant however results are mixed tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue however these claims have been refuted by some studies')|
|('DB00643', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of ienterobius vermicularisi pinworm itrichuris trichiurai whipworm iascaris lumbricoidesi common roundworm iancylostoma duodenalei common hookworm inecator americanusi american hookworm in single or mixed infections')|
|('DB00643', 'MONDO:0021137', ['common []', 'not rare'], 'for the treatment of ienterobius vermicularisi pinworm itrichuris trichiurai whipworm iascaris lumbricoidesi common roundworm iancylostoma duodenalei common hookworm inecator americanusi american hookworm in single or mixed infections')|
|('DB00968', 'MONDO:0021137', ['common []', 'not rare'], 'for use in the treatment of hypertension')|
|('DB00777', 'MONDO:0021137', ['common []', 'not rare'], 'propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia')|
|('DB00777', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia')|
|('DB00128', 'MONDO:0021137', ['common []', 'not rare'], 'there is no support for the claim that aspartates are exercise performance enhancers ie ergogenic aids')|
|('DB00128', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'there is no support for the claim that aspartates are exercise performance enhancers ie ergogenic aids')|
|('DB00707', 'MONDO:0021137', ['common []', 'not rare'], 'indicated in the treatment of esophageal cancer')|
|('DB00707', 'MONDO:0007576', ['Ca lower third oesophagus', 'Ca middle third oesophagus', 'esophagus cancer', 'malignant neoplasm of distal third of esophagus', 'malignant neoplasm of lower third of oesophagus', 'malignant neoplasm of middle third of oesophagus', 'malignant neoplasm of proximal third of esophagus', 'malignant neoplasm of upper third esophagus', 'malignant tumor of abdominal esophagus', 'malignant tumor of Distal Third of esophagus', 'malignant tumor of Proximal Third of esophagus', 'malignant tumor of the middle Third of the esophagus', 'esophageal cancer'], 'indicated in the treatment of esophageal cancer')|
|('DB00589', 'MONDO:0021137', ['common []', 'not rare'], 'for the management of parkinsons disease')|
|('DB00740', 'MONDO:0021137', ['common []', 'not rare'], 'for the treatment of amyotrophic lateral sclerosis als lou gehrigs disease')|
|('DB00740', 'MONDO:0004976', ['ALS', 'Lou Gehrigs disease', 'motor neuron disease, bulbar', 'amyotrophic lateral sclerosis'], 'for the treatment of amyotrophic lateral sclerosis als lou gehrigs disease')|
|('DB06255', 'MONDO:0004976', ['ALS', 'Lou Gehrigs disease', 'motor neuron disease, bulbar', 'amyotrophic lateral sclerosis'], 'for the treatment of hypercalcemia associated with malignant disease')|
|('DB01219', 'MONDO:0004976', ['ALS', 'Lou Gehrigs disease', 'motor neuron disease, bulbar', 'amyotrophic lateral sclerosis'], 'for use along with appropriate supportive measures for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages also used preoperatively and sometimes postoperatively to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible')|
|('DB01219', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for use along with appropriate supportive measures for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages also used preoperatively and sometimes postoperatively to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible')|
|('DB00976', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of ipneumococcali infection acute sinusitis acute bacterial tonsillitis acute bronchitis and bronchiolitis lower respiratory tract infection and lobar pneumococcal pneumonia')|
|('DB00976', 'MONDO:0005961', ['sinusitis'], 'for the treatment of ipneumococcali infection acute sinusitis acute bacterial tonsillitis acute bronchitis and bronchiolitis lower respiratory tract infection and lobar pneumococcal pneumonia')|
|('DB00976', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of ipneumococcali infection acute sinusitis acute bacterial tonsillitis acute bronchitis and bronchiolitis lower respiratory tract infection and lobar pneumococcal pneumonia')|
|('DB00976', 'MONDO:0002465', ['bronchiolitis'], 'for the treatment of ipneumococcali infection acute sinusitis acute bacterial tonsillitis acute bronchitis and bronchiolitis lower respiratory tract infection and lobar pneumococcal pneumonia')|
|('DB00976', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of ipneumococcali infection acute sinusitis acute bacterial tonsillitis acute bronchitis and bronchiolitis lower respiratory tract infection and lobar pneumococcal pneumonia')|
|('DB00851', 'MONDO:0002465', ['bronchiolitis'], 'for the treatment of metastatic malignant melanoma in addition dacarbazine is also indicated for hodgkins disease as a secondaryline therapy when used in combination with other antineoplastic agents')|
|('DB00851', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for the treatment of metastatic malignant melanoma in addition dacarbazine is also indicated for hodgkins disease as a secondaryline therapy when used in combination with other antineoplastic agents')|
|('DB00874', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold bronchitis andor other breathing illnesses fda label f4510 l6079')|
|('DB00874', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold bronchitis andor other breathing illnesses fda label f4510 l6079')|
|('DB00484', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'opthalmicindicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamidetopicalindicated for the treatment of persistent nontransient facial erythema of rosacea in adults 18 years of age or olderl6535')|
|('DB00484', 'MONDO:0005041', ['glaucoma'], 'opthalmicindicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamidetopicalindicated for the treatment of persistent nontransient facial erythema of rosacea in adults 18 years of age or olderl6535')|
|('DB00484', 'MONDO:0006875', ['ocular hypertension'], 'opthalmicindicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamidetopicalindicated for the treatment of persistent nontransient facial erythema of rosacea in adults 18 years of age or olderl6535')|
|('DB00484', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'opthalmicindicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamidetopicalindicated for the treatment of persistent nontransient facial erythema of rosacea in adults 18 years of age or olderl6535')|
|('DB01247', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugsl1372 depression is a common but serious mood disorder the patient will present changes in its feelings thoughts and ability to handle everyday activities for a mood disorder to be considered as depression the symptoms should be present for at least two weeksl1375')|
|('DB01247', 'MONDO:0005371', ['episodic mood disorder', 'mood disorder'], 'isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugsl1372 depression is a common but serious mood disorder the patient will present changes in its feelings thoughts and ability to handle everyday activities for a mood disorder to be considered as depression the symptoms should be present for at least two weeksl1375')|
|('DB00486', 'MONDO:0005371', ['episodic mood disorder', 'mood disorder'], 'nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments this restriction is required because a substantial proportion of any group of patients treated with nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents')|
|('DB00486', 'MONDO:0004992', ['cancer'], 'nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments this restriction is required because a substantial proportion of any group of patients treated with nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents')|
|('DB00486', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments this restriction is required because a substantial proportion of any group of patients treated with nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents')|
|('DB00820', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used for the treatment of erectile dysfunction')|
|('DB00820', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'used for the treatment of erectile dysfunction')|
|('DB01590', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB01590', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB01590', 'MONDO:0044874', ['refractory cytopenia of childhood [NCIT:C82596]', 'RCC [NCIT:C82596]', 'refractory cytopenia of childhood'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB01590', 'MONDO:0004555', ['Angiomyolipoma of kidney', 'renal Angiomyolipoma', 'kidney angiomyolipoma'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB01590', 'MONDO:0019341', ['tuberous sclerosis [Orphanet:805]', 'Bourneville syndrome [Orphanet:805]', 'tuberous sclerosis complex'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB01590', 'MONDO:0016693', ['SEGA', 'Subependymal giant cell astrocytoma', 'subependymal giant cell astrocytoma'], 'everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer advanced hr bc in combination with exemestane after failure of treatment with letrozole or anastrozoleindicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic diseaseindicated for the treatment of adult patients with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenibindicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgeryindicated in pediatric and adult patients with tuberous sclerosis complex tsc for the treatment of subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected')|
|('DB00501', 'MONDO:0016693', ['SEGA', 'Subependymal giant cell astrocytoma', 'subependymal giant cell astrocytoma'], 'for the treatment and the management of acidreflux disorders gerd peptic ulcer disease heartburn and acid indigestion')|
|('DB00501', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment and the management of acidreflux disorders gerd peptic ulcer disease heartburn and acid indigestion')|
|('DB00370', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0001442', ['dysthymia', 'dysthymic disorder'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00370', 'MONDO:0002491', ['substance abuse'], 'this drug is indicated for the treatment of major depressive disorder and its associated symptomsfda labelmirtazapine has been used offlabel for a variety of conditions including panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes posttraumatic stress disorder ptsd sleep disorders substance abuse disorders and sexual disorders among othersa177811a177946')|
|('DB00252', 'MONDO:0002491', ['substance abuse'], 'phenytoin is indicated to treat grand mal seizures complex partial seizures and to prevent and treat seizures during or following neurosurgeryl9362 injectable phenytoin and fosphenytoin which is the phosphate ester prodrug formulation of phenytoina188571 are indicated to treat tonicclonic status epilepticus and for the prevention and treatment of seizures occurring during neurosurgeryl10740')|
|('DB00252', 'MONDO:0002125', ['Grand mal status', 'status epilepticus'], 'phenytoin is indicated to treat grand mal seizures complex partial seizures and to prevent and treat seizures during or following neurosurgeryl9362 injectable phenytoin and fosphenytoin which is the phosphate ester prodrug formulation of phenytoina188571 are indicated to treat tonicclonic status epilepticus and for the prevention and treatment of seizures occurring during neurosurgeryl10740')|
|('DB00983', 'MONDO:0002125', ['Grand mal status', 'status epilepticus'], 'for use as longterm maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a shortacting bronchodilator not indicated for asthma that can be successfully managed with occasional use of an inhaled shortacting beta2adrenergic agonist also used for the prevention of exerciseinduced bronchospasm as well as longterm treatment of bronchospasm associated with copd')|
|('DB00983', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for use as longterm maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a shortacting bronchodilator not indicated for asthma that can be successfully managed with occasional use of an inhaled shortacting beta2adrenergic agonist also used for the prevention of exerciseinduced bronchospasm as well as longterm treatment of bronchospasm associated with copd')|
|('DB00983', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use as longterm maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a shortacting bronchodilator not indicated for asthma that can be successfully managed with occasional use of an inhaled shortacting beta2adrenergic agonist also used for the prevention of exerciseinduced bronchospasm as well as longterm treatment of bronchospasm associated with copd')|
|('DB00983', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for use as longterm maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a shortacting bronchodilator not indicated for asthma that can be successfully managed with occasional use of an inhaled shortacting beta2adrenergic agonist also used for the prevention of exerciseinduced bronchospasm as well as longterm treatment of bronchospasm associated with copd')|
|('DB00983', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use as longterm maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a shortacting bronchodilator not indicated for asthma that can be successfully managed with occasional use of an inhaled shortacting beta2adrenergic agonist also used for the prevention of exerciseinduced bronchospasm as well as longterm treatment of bronchospasm associated with copd')|
|('DB06775', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the treatment of acute and chronic hyperammonaemia in patients with nacetylglutamate synthase nags deficiency this enzyme is an important component of the urea cycle to prevent build up of neurotoxic ammonium in the blood ')|
|('DB06775', 'MONDO:0009377', ['NAGS deficiency [Orphanet:927]', 'hyperammonemia due to n-acetylglutamate synthase deficiency'], 'for the treatment of acute and chronic hyperammonaemia in patients with nacetylglutamate synthase nags deficiency this enzyme is an important component of the urea cycle to prevent build up of neurotoxic ammonium in the blood ')|
|('DB06212', 'MONDO:0009377', ['NAGS deficiency [Orphanet:927]', 'hyperammonemia due to n-acetylglutamate synthase deficiency'], 'treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure siadh and cirrhosis ')|
|('DB06212', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure siadh and cirrhosis ')|
|('DB06212', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure siadh and cirrhosis ')|
|('DB01226', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for inpatients and outpatients as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation')|
|('DB08795', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for treatment of infection respiratory gi uti and meningitis due to e coli p mirabilis enterococci shigella s typhosa and other salmonella nonpenicillinaseproducing n gononhoeae h influenzae staphylococci streptococci including streptoc')|
|('DB08795', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for treatment of infection respiratory gi uti and meningitis due to e coli p mirabilis enterococci shigella s typhosa and other salmonella nonpenicillinaseproducing n gononhoeae h influenzae staphylococci streptococci including streptoc')|
|('DB00547', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB06637', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis ms ')|
|('DB06637', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis ms ')|
|('DB06637', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis ms ')|
|('DB01211', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0024330', ['acute otitis Media [NCIT:C84354]', 'infectious otitis Media [NCIT:C84354]', 'middle Ear infection [NCIT:C84354]', 'AOM [NCIT:C84354]', 'infectious otitis media'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0001039', ['chronic tonsillitis', 'Throat infection - tonsillitis', 'tonsillitis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0002186', ['acute antritis', 'acute maxillary sinusitis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0005824', ['Infection by Legionella pneumophilia', 'Legionella', 'Legionella pneumonia', 'Legionnaires disease', "legionnaires' disease"], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0005077', ['bordetella infection', 'WC - Whooping cough', 'whooping cough', 'pertussis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0005412', ['Curling Ulcer', 'Curlings ulcers', 'Stress Ulcer', 'duodenal ulcer'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0019956', ['encephalitis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0015474', ['Cryptosporidial gastroenteritis', 'Infection by Cryptosporidium', 'intestinal cryptosporidiosis', 'cryptosporidiosis'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB01211', 'MONDO:0022202', ['disseminated'], 'an alternative medication for the treatment of acute otitis media caused by ih influenzae m catarrhalis or s pneumoniaei in patients with a history of type i penicillin hypersensitivity also for the treatment of pharyngitis and tonsillitis caused by susceptible istreptococcus pyogenesi as well as respiratory tract infections including acute maxillary sinusitis acute bacterial exacerbations of chronic bronchitis mild to moderate communityacquired pneuomia legionnaires disease and pertussis other indications include treatment of uncomplicated skin or skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease and encephalitis caused by itoxoplasma gondiii in hiv infected patients in conjunction with pyrimethamine clarithromycin may also decrease the incidence of cryptosporidiosis prevent the occurence of αhemolytic viridans group streptococcal endocarditis as well as serve as a primary prevention for imycobacterium aviumi complex mac bacteremia or disseminated infections in adults adolescents and children with advanced hiv infection')|
|('DB00508', 'MONDO:0022202', ['disseminated'], 'used mainly in the management of psychoses also used to control nausea and vomiting')|
|('DB00629', 'MONDO:0022202', ['disseminated'], 'for management of high blood pressure')|
|('DB00629', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for management of high blood pressure')|
|('DB01582', 'MONDO:0022202', ['disseminated'], 'for the treatment bacterial infections causing bronchitis prostatitis and urinary tract infections')|
|('DB01582', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment bacterial infections causing bronchitis prostatitis and urinary tract infections')|
|('DB01179', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for treatment of external genital warts icondyloma acuminatumi')|
|('DB00637', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'astemizole was indicated for use in the relieving allergy symptoms particularly rhinitis and conjunctivitis it has been withdrawn from the market however due to concerns of arrhythmias')|
|('DB00637', 'MONDO:0003014', ['rhinitis'], 'astemizole was indicated for use in the relieving allergy symptoms particularly rhinitis and conjunctivitis it has been withdrawn from the market however due to concerns of arrhythmias')|
|('DB00637', 'MONDO:0003799', ['conjunctivitis'], 'astemizole was indicated for use in the relieving allergy symptoms particularly rhinitis and conjunctivitis it has been withdrawn from the market however due to concerns of arrhythmias')|
|('DB00637', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'astemizole was indicated for use in the relieving allergy symptoms particularly rhinitis and conjunctivitis it has been withdrawn from the market however due to concerns of arrhythmias')|
|('DB00354', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for prevention and treatment of nausea vomiting and dizziness associated with motion sickness and vertigo dizziness caused by other medical problems')|
|('DB00354', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for prevention and treatment of nausea vomiting and dizziness associated with motion sickness and vertigo dizziness caused by other medical problems')|
|('DB00909', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for use as adjunctive treatment of partial seizures in adults with epilepsy')|
|('DB00909', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for use as adjunctive treatment of partial seizures in adults with epilepsy')|
|('DB01060', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for the treatment of infections of the ear nose and throat the genitourinary tract the skin and skin structure and the lower respiratory tract due to susceptible only blactamasenegative strains of istreptococcusi spp a and bhemolytic strains only is pneumoniaei istaphylococcusi spp ih influenzaei ie colii ip mirabilisi or ie faecalisi also for the treatment of acute uncomplicated gonorrhea anogenital and urethral infections due to in gonorrhoeaei males and females')|
|('DB01060', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'for the treatment of infections of the ear nose and throat the genitourinary tract the skin and skin structure and the lower respiratory tract due to susceptible only blactamasenegative strains of istreptococcusi spp a and bhemolytic strains only is pneumoniaei istaphylococcusi spp ih influenzaei ie colii ip mirabilisi or ie faecalisi also for the treatment of acute uncomplicated gonorrhea anogenital and urethral infections due to in gonorrhoeaei males and females')|
|('DB00766', 'MONDO:0004277', ['chronic gonococcal infectious disease of lower genitourinary tract', 'chronic gonococcal infectious disease of upper genitourinary tract', 'gonorrhea'], 'clavulanic acid combined with other antibiotics is indicated to prevent the development of drugresistant strains of bacteria and promotes their therapeutic antibacterial effectsl7880l7904the following conditions when they produced betalactamases have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acidl7880l7904acute otitis media caused by  h influenzae and m catarrhalissinusitis due to h influenzae and m catarrhalislower respiratory tract infections due to haemophilus influenzae saureus klebsiella species and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus escherichia coli and klebsiella speciesurinary tract infections due to e coli klebsiella species of bacteria and enterobacter species of bacteria smarcescens or saureusgynecologic infections due to a variety of bacteria including pmelaninogenicus enterobacter species ecoli species klebsiella species s aureus sepidermidissepticemia due to a variety of bacteria including klebsiella species ecoli species saureus or pseudomonas speciesbone and joint infections due to saureusintraabdominal infections due to ecoli kpnemoniae or bfragilis groupa note on susceptibilityit should be noted that it is only to be administered in infections that are confirmed or highly likely to be caused by susceptible bacteria culture and susceptibility tests should be performed if possible and used in selecting whether this antibiotic is prescribed when betalactamase enzyme production is not detected during microbiological testing clavulanic acid should not be used when these tests are not available patterns of local infection and susceptibility may be used to determine the appropriateness of using clavulanic acidl7880 ticarcillin with clavulanate has shown particular efficacy in mixed infections in addition to empiric therapy before determining the susceptibility of causative organisms the ticarcillinclavulanic acid combination may prove to be an effective singleagent antibiotic therapy to treat infections where a regimen of several drugs may normally be usedl7904')|
|('DB00766', 'MONDO:0005441', ['otitis media'], 'clavulanic acid combined with other antibiotics is indicated to prevent the development of drugresistant strains of bacteria and promotes their therapeutic antibacterial effectsl7880l7904the following conditions when they produced betalactamases have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acidl7880l7904acute otitis media caused by  h influenzae and m catarrhalissinusitis due to h influenzae and m catarrhalislower respiratory tract infections due to haemophilus influenzae saureus klebsiella species and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus escherichia coli and klebsiella speciesurinary tract infections due to e coli klebsiella species of bacteria and enterobacter species of bacteria smarcescens or saureusgynecologic infections due to a variety of bacteria including pmelaninogenicus enterobacter species ecoli species klebsiella species s aureus sepidermidissepticemia due to a variety of bacteria including klebsiella species ecoli species saureus or pseudomonas speciesbone and joint infections due to saureusintraabdominal infections due to ecoli kpnemoniae or bfragilis groupa note on susceptibilityit should be noted that it is only to be administered in infections that are confirmed or highly likely to be caused by susceptible bacteria culture and susceptibility tests should be performed if possible and used in selecting whether this antibiotic is prescribed when betalactamase enzyme production is not detected during microbiological testing clavulanic acid should not be used when these tests are not available patterns of local infection and susceptibility may be used to determine the appropriateness of using clavulanic acidl7880 ticarcillin with clavulanate has shown particular efficacy in mixed infections in addition to empiric therapy before determining the susceptibility of causative organisms the ticarcillinclavulanic acid combination may prove to be an effective singleagent antibiotic therapy to treat infections where a regimen of several drugs may normally be usedl7904')|
|('DB00766', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'clavulanic acid combined with other antibiotics is indicated to prevent the development of drugresistant strains of bacteria and promotes their therapeutic antibacterial effectsl7880l7904the following conditions when they produced betalactamases have been treated with a combination of amoxicillin and clavulanic acid or ticarcillin and clavulanic acidl7880l7904acute otitis media caused by  h influenzae and m catarrhalissinusitis due to h influenzae and m catarrhalislower respiratory tract infections due to haemophilus influenzae saureus klebsiella species and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus escherichia coli and klebsiella speciesurinary tract infections due to e coli klebsiella species of bacteria and enterobacter species of bacteria smarcescens or saureusgynecologic infections due to a variety of bacteria including pmelaninogenicus enterobacter species ecoli species klebsiella species s aureus sepidermidissepticemia due to a variety of bacteria including klebsiella species ecoli species saureus or pseudomonas speciesbone and joint infections due to saureusintraabdominal infections due to ecoli kpnemoniae or bfragilis groupa note on susceptibilityit should be noted that it is only to be administered in infections that are confirmed or highly likely to be caused by susceptible bacteria culture and susceptibility tests should be performed if possible and used in selecting whether this antibiotic is prescribed when betalactamase enzyme production is not detected during microbiological testing clavulanic acid should not be used when these tests are not available patterns of local infection and susceptibility may be used to determine the appropriateness of using clavulanic acidl7880 ticarcillin with clavulanate has shown particular efficacy in mixed infections in addition to empiric therapy before determining the susceptibility of causative organisms the ticarcillinclavulanic acid combination may prove to be an effective singleagent antibiotic therapy to treat infections where a regimen of several drugs may normally be usedl7904')|
|('DB00918', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of acute migraine headache in adults')|
|('DB04786', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for treatment of human sleeping sickness onchocerciasis and other diseases caused by trypanosomes and worms')|
|('DB00156', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lthreonine makes up collagen elastin and enamel protein it aids proper fat metabolism in the liver helps the digestive and intestinal tracts function more smoothly and assists in metabolism and assimilation')|
|('DB00156', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'lthreonine makes up collagen elastin and enamel protein it aids proper fat metabolism in the liver helps the digestive and intestinal tracts function more smoothly and assists in metabolism and assimilation')|
|('DB00298', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'used in the treatment of iatrogenically induced mydriasis produced by adrenergic phenylephrine or parasympatholytic tropicamide agents used in certain eye examinations')|
|('DB00319', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'for the treatment of polymicrobial infections')|
|('DB00166', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00681', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'used to treat potentially life threatening fungal infections')|
|('DB05245', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and thirddegree burns')|
|('DB05245', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and thirddegree burns')|
|('DB00879', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'emtricitabine is indicated in combination with other medications for the treatment of hiv1 infectionsl9019l9836 treatment of hiv1 infections in pediatric patients 2535kg treatment of hiv1 infections in adult patients ≥35kg for pre exposure prophylaxis of hiv1 in adolescent and adult patients excluding those who have receptive vaginal sexl4388l9010 treatment of hiv1 infections in pediatric and adult patients ≥17kg pre exposure prophylaxis in adolescents and adults ≥35kgl9833 treatment of hiv1 in patients ≥12 years and ≥35kgl9587 treatment of hiv1 in patients weighing ≥35kgl9839l9842 treatment of hiv1 in patients weighing ≥25kgl9647l9845 and treatment of hiv1 in patients weighing ≥40kgl9848')|
|('DB01061', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of infections caused by ipseudomonas aeruginosai iescherichia colii and ihaemophilus influenzaei')|
|('DB00254', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0001195', ['Spotted fever group rickettsial disease', 'spotted fever'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0001246', ['endemic flea-borne typhus', 'Endemic Typhus fever', 'epidemic louse-borne typhus', 'Exanthematic Typhus fever', 'Flea typhus', 'Louse-borne [epidemic] typhus', 'Moscow typhus', 'Murine [endemic] typhus', 'Typhus fever', 'typhus'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0019186', ['Infection due to Coxiella burnetii', 'q fever'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0005888', ['psittacosis', 'ornithosis'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0003799', ['conjunctivitis'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB00254', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'doxycycline is indicated for the treatment of various infections by grampositive and gramnegative bacteria aerobes and anaerobes as well other types of bacteria a complete list of organisms is available in the fda label and in the indications section of this drug entry fda labelthe following are some of the major infections that may be treated with doxycycline fda labelrocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiaerespiratory tract infections caused by mycoplasma pneumoniaelymphogranuloma venereum caused by chlamydia trachomatispsittacosis ornithosis caused by chlamydia psittacitrachoma caused by chlamydia trachomatis although the infectious agent is not always eliminated as judged by immunofluorescenceinclusion conjunctivitis caused by chlamydia trachomatisuncomplicated urethral endocervical or rectal infections in adults caused by chlamydia trachomatisnongonococcal urethritis caused by ureaplasma urealyticumrelapsing fever due to borrelia recurrentisa note regarding antimicrobial resistanceit is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infectionup to 44 percent of strains of streptococcus pyogenes and 74 percent of streptococcus faecalis have been found to be resistant to tetracyclines therefore tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible fda label')|
|('DB01602', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for infections at the following sites upper and lower respiratory tract skin and soft tissue urinary tract and acute uncomplicated gonococcal urethritis when due to sensitive strains of the following organisms  grampositive streptococci including is faecalisi and is pneumoniaei and nonpenicillinaseproducing staphylococci gramnegative ih influenzaei in gonorrhoeaei ie colii ip mirabilisi isalmonellaei and ishigellaei')|
|('DB01602', 'MONDO:0020971', ['gonococcal urethritis [NCIT:C26787]', 'gc urethritis [NCIT:C26787]', 'gonococcal urethritis'], 'for infections at the following sites upper and lower respiratory tract skin and soft tissue urinary tract and acute uncomplicated gonococcal urethritis when due to sensitive strains of the following organisms  grampositive streptococci including is faecalisi and is pneumoniaei and nonpenicillinaseproducing staphylococci gramnegative ih influenzaei in gonorrhoeaei ie colii ip mirabilisi isalmonellaei and ishigellaei')|
|('DB01421', 'MONDO:0020971', ['gonococcal urethritis [NCIT:C26787]', 'gc urethritis [NCIT:C26787]', 'gonococcal urethritis'], 'for the treatment of acute and chronic intestinal amebiasis it is not effective in extraintestinal amebiasis also for the management of hepatic coma as adjunctive therapy')|
|('DB01421', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'for the treatment of acute and chronic intestinal amebiasis it is not effective in extraintestinal amebiasis also for the management of hepatic coma as adjunctive therapy')|
|('DB01421', 'MONDO:0001548', ['Hepatocerebral intoxication', 'hepatic coma'], 'for the treatment of acute and chronic intestinal amebiasis it is not effective in extraintestinal amebiasis also for the management of hepatic coma as adjunctive therapy')|
|('DB08802', 'MONDO:0001548', ['Hepatocerebral intoxication', 'hepatic coma'], 'for the topical treatment of itching associated with allergic reactions')|
|('DB08799', 'MONDO:0001548', ['Hepatocerebral intoxication', 'hepatic coma'], 'used to relieve nasal congestion and in eye drops usually in combination with naphazoline to relieve the symptoms of allergic conjunctivitis')|
|('DB06709', 'MONDO:0001548', ['Hepatocerebral intoxication', 'hepatic coma'], 'it is most commonly used for diagnosing bronchial hyperreactivity using the bronchial challenge test')|
|('DB06709', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'it is most commonly used for diagnosing bronchial hyperreactivity using the bronchial challenge test')|
|('DB00428', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of malignant neoplasms of pancreas metastatic islet cell carcinoma')|
|('DB00271', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used alone or in combination for a wide variety of diagnostic imaging methods including angiography urography cholangiography computed tomography hysterosalpingography and retrograde pyelography it can be used for imaging the gastrointestinal tract in patients allergic to barium')|
|('DB00271', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used alone or in combination for a wide variety of diagnostic imaging methods including angiography urography cholangiography computed tomography hysterosalpingography and retrograde pyelography it can be used for imaging the gastrointestinal tract in patients allergic to barium')|
|('DB01399', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorders')|
|('DB01399', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorders')|
|('DB01225', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the prophylaxis of deep vein thrombosis which may lead to pulmonary embolism and also for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin')|
|('DB01225', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for the prophylaxis of deep vein thrombosis which may lead to pulmonary embolism and also for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin')|
|('DB01225', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'for the prophylaxis of deep vein thrombosis which may lead to pulmonary embolism and also for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin')|
|('DB01225', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the prophylaxis of deep vein thrombosis which may lead to pulmonary embolism and also for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin')|
|('DB01593', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB01593', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB01593', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB00317', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'for the continued treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of either platinumbased or docetaxel chemotherapies')|
|('DB00317', 'MONDO:0004992', ['cancer'], 'for the continued treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of either platinumbased or docetaxel chemotherapies')|
|('DB01111', 'MONDO:0004992', ['cancer'], 'for the treatment of acute or chronic infections due to sensitive strains of certain gramnegative bacilli particularly pseudomonas aeruginosa')|
|('DB08822', 'MONDO:0004992', ['cancer'], 'treatment of hypertension alone or as an adjunct')|
|('DB04911', 'MONDO:0004992', ['cancer'], 'indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated grampositive microorganisms')|
|('DB01301', 'MONDO:0004992', ['cancer'], 'rolitetracycline is a broadspectrum antibiotic used in cases needing high concentrations or when oral administration is impractical')|
|('DB00639', 'MONDO:0004992', ['cancer'], 'for the local treatment of vulvovaginal candidiasis infections caused by candida')|
|('DB00639', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'for the local treatment of vulvovaginal candidiasis infections caused by candida')|
|('DB00981', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'for the treatment of glaucoma and in the treatment of severe anticholinergic toxicity')|
|('DB00981', 'MONDO:0005041', ['glaucoma'], 'for the treatment of glaucoma and in the treatment of severe anticholinergic toxicity')|
|('DB00883', 'MONDO:0005041', ['glaucoma'], 'for the prevention of angina pectoris due to coronary artery disease')|
|('DB00883', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the prevention of angina pectoris due to coronary artery disease')|
|('DB00436', 'MONDO:0005041', ['glaucoma'], 'for the treatment of high blood pressure and management of edema related to heart failure')|
|('DB00436', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for the treatment of high blood pressure and management of edema related to heart failure')|
|('DB00436', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of high blood pressure and management of edema related to heart failure')|
|('DB00863', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00863', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00863', 'MONDO:0007950', ['mast cell hyperplasia', 'mastocytosis'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00863', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00863', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00863', 'MONDO:0005412', ['Curling Ulcer', 'Curlings ulcers', 'Stress Ulcer', 'duodenal ulcer'], 'this drug is used alone or with concomitant antacids for the following conditions shortterm treatment of active duodenal ulcer treating gastric acid hypersecretion due to zollingerellison syndrome systemic mastocytosis and other conditions that may pathologically raise gastric acid levels it also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose in addition to the above ranitidine can be used for the treatment of gerd symptoms treatment of erosive esophagitis endoscopically diagnosed and the maintenance of gastric or duodenal ulcer healingl10818l10821')|
|('DB00127', 'MONDO:0005412', ['Curling Ulcer', 'Curlings ulcers', 'Stress Ulcer', 'duodenal ulcer'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00422', 'MONDO:0005412', ['Curling Ulcer', 'Curlings ulcers', 'Stress Ulcer', 'duodenal ulcer'], 'methylphenidate is indicated for the treatment of attention deficit hyperactivity disorder adhd in patients 6 years of age and older and for the treatment of narcolepsy')|
|('DB00422', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'methylphenidate is indicated for the treatment of attention deficit hyperactivity disorder adhd in patients 6 years of age and older and for the treatment of narcolepsy')|
|('DB00422', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'methylphenidate is indicated for the treatment of attention deficit hyperactivity disorder adhd in patients 6 years of age and older and for the treatment of narcolepsy')|
|('DB01253', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'used to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony ')|
|('DB08901', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'ponatinib is indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or philadelphia chromosome positive acute lymphoblastic leukemia phall that is resistant or intolerant to prior tyrosine kinase inhibitor therapy')|
|('DB08901', 'MONDO:0006115', ['blast crisis [NCIT:C9110]', 'blastic phase chronic granulocytic leukemia [NCIT:C9110]', 'blast phase CML [NCIT:C9110]', 'blast phase chronic myelocytic leukemia [NCIT:C9110]', 'blastic phase chronic myelocytic leukemia [NCIT:C9110]', 'blast phase chronic myeloid leukemia [NCIT:C9110]', 'blast phase chronic granulocytic leukemia [NCIT:C9110]', 'blast phase chronic myelogenous leukemia [NCIT:C9110]', 'blastic phase chronic myelogenous leukemia [NCIT:C9110]', 'blastic phase CML [NCIT:C9110]', 'blastic phase chronic myeloid leukemia [NCIT:C9110]', 'blast phase chronic myelogenous leukemia, bcr-abl1 positive'], 'ponatinib is indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or philadelphia chromosome positive acute lymphoblastic leukemia phall that is resistant or intolerant to prior tyrosine kinase inhibitor therapy')|
|('DB08901', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'ponatinib is indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or philadelphia chromosome positive acute lymphoblastic leukemia phall that is resistant or intolerant to prior tyrosine kinase inhibitor therapy')|
|('DB00731', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of noninsulin dependentdiabetes mellitus in conjunction with diet and exercise')|
|('DB01234', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis external10698 intramuscular and intravenous injections are indicated for a number of endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous and other conditionsl10701 oral tablets are indicated for the treatment of multiple myelomal10710 an intravitreal implant is indicated for some forms of macular edema and noninfectious posterior uveitis affecting the posterior of the eyel10719 various ophthalmic formulations are indicated for inflammatory conditions of the eyel10704l10707l10713l10716l10722l10725')|
|('DB01234', 'MONDO:0024330', ['acute otitis Media [NCIT:C84354]', 'infectious otitis Media [NCIT:C84354]', 'middle Ear infection [NCIT:C84354]', 'AOM [NCIT:C84354]', 'infectious otitis media'], 'dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis external10698 intramuscular and intravenous injections are indicated for a number of endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous and other conditionsl10701 oral tablets are indicated for the treatment of multiple myelomal10710 an intravitreal implant is indicated for some forms of macular edema and noninfectious posterior uveitis affecting the posterior of the eyel10719 various ophthalmic formulations are indicated for inflammatory conditions of the eyel10704l10707l10713l10716l10722l10725')|
|('DB01234', 'MONDO:0003005', ['macular edema', 'macular oedema', 'macular retinal oedema', 'macular retinal edema'], 'dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis external10698 intramuscular and intravenous injections are indicated for a number of endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous and other conditionsl10701 oral tablets are indicated for the treatment of multiple myelomal10710 an intravitreal implant is indicated for some forms of macular edema and noninfectious posterior uveitis affecting the posterior of the eyel10719 various ophthalmic formulations are indicated for inflammatory conditions of the eyel10704l10707l10713l10716l10722l10725')|
|('DB01234', 'MONDO:0020283', ['uveitis'], 'dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis external10698 intramuscular and intravenous injections are indicated for a number of endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous and other conditionsl10701 oral tablets are indicated for the treatment of multiple myelomal10710 an intravitreal implant is indicated for some forms of macular edema and noninfectious posterior uveitis affecting the posterior of the eyel10719 various ophthalmic formulations are indicated for inflammatory conditions of the eyel10704l10707l10713l10716l10722l10725')|
|('DB01294', 'MONDO:0020283', ['uveitis'], 'used to treat nausea heartburn indigestion upset stomach diarrhea and other temporary discomforts of the stomach and gastrointestinal tract')|
|('DB01294', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'used to treat nausea heartburn indigestion upset stomach diarrhea and other temporary discomforts of the stomach and gastrointestinal tract')|
|('DB00876', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for the management of hypertension alone or in combination with other classes of antihypertensive agents also used as a firstline agent in the treatment of diabetic nephropathy as well as a secondline agent in the treatment of congestive heart failure only in those intolerant of ace inhibitors')|
|('DB00876', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'for the management of hypertension alone or in combination with other classes of antihypertensive agents also used as a firstline agent in the treatment of diabetic nephropathy as well as a secondline agent in the treatment of congestive heart failure only in those intolerant of ace inhibitors')|
|('DB00876', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the management of hypertension alone or in combination with other classes of antihypertensive agents also used as a firstline agent in the treatment of diabetic nephropathy as well as a secondline agent in the treatment of congestive heart failure only in those intolerant of ace inhibitors')|
|('DB00698', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'nitrofurantoin is indicated to treat acute uncomplicated urinary tract infectionsl6856l6859l6862')|
|('DB00258', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia too much phosphate in the blood in patients with kidney disease')|
|('DB00258', 'MONDO:0000328', ['hyperphosphatemia'], 'calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia too much phosphate in the blood in patients with kidney disease')|
|('DB00258', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia too much phosphate in the blood in patients with kidney disease')|
|('DB00383', 'MONDO:0000328', ['hyperphosphatemia'], 'for the treatment of peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders')|
|('DB00383', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'for the treatment of peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders')|
|('DB01050', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0021137', ['common []', 'not rare'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0011827', ['Patent ductus Botalli', 'patent ductus arteriosus'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0005469', ['orthostatic hypotension [MONDO:ambiguous]', 'orthostatic hypotension'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01050', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ibuprofen is the most commonly used and prescribed nsaid it is very common over the counter medication widely used as an analgesic antiinflammatory and antipyretica39096the use of ibuprofen and its enantiomer db09213 in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis and soft tissue disordera39097due to its activity against prostaglandin and thromboxane synthesis ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labora39092as ibuprofen is a widely used medication the main therapeutic indications are patent ductus arteriosus  it is a neonatal condition wherein the ductus arteriosus blood vessel that connects the main pulmonary artery to the proximal descending aorta fails to close after birth causing severe risk of heart failure the prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin e2 is responsible for keeping the ductus arteriosus opena39100 rheumatoid and osteoarthritis  ibuprofen is very commonly used in the symptomatic treatment of inflammatory musculoskeletal and rheumatic disordersa39176 cystic fibrosis  the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungsa39177 orthostatic hypotension  ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotensiona1651 dental pain  ibuprofen is used to manage acute and chronic orofacial paina10901 minor pain  ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea it is very commonly used for the relief of acute indications such as fever and tension headachesa39092 investigational uses  efforts have been put into developing ibuprofen for the prophylaxis of alzheimers disease parkinson disease and breast cancera39092')|
|('DB01102', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to elicit acute cardiovascular responses cardiac stumulant similar to those produced by exercise in order to aid in diagnosing the presence or absence of coronary artery disease cad in patients who cannot exercise adequately')|
|('DB01102', 'MONDO:0018922', ['CAD [Orphanet:56425]', 'CAS [Orphanet:56425]', 'cold agglutinin syndrome [Orphanet:56425]', 'chronic cold agglutinin disease [Orphanet:56425]', 'cold agglutinin disease'], 'used to elicit acute cardiovascular responses cardiac stumulant similar to those produced by exercise in order to aid in diagnosing the presence or absence of coronary artery disease cad in patients who cannot exercise adequately')|
|('DB00787', 'MONDO:0018922', ['CAD [Orphanet:56425]', 'CAS [Orphanet:56425]', 'cold agglutinin syndrome [Orphanet:56425]', 'chronic cold agglutinin disease [Orphanet:56425]', 'cold agglutinin disease'], 'an acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and olderl7303 acyclovir oral tablets capsules and suspensions are indicated to treat herpes zoster genital herpes and chickenpoxl7315 an acyclovir topical ointment is indicated to treat initial genital herpes and limited nonlifethreatening mucocutaneous herpes simplex in immunocompromised patientsl7318 an acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis and shortening lesion healing time in patients 6 years and olderl7321 an acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialisl7324 an acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitisl7327')|
|('DB00787', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'an acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and olderl7303 acyclovir oral tablets capsules and suspensions are indicated to treat herpes zoster genital herpes and chickenpoxl7315 an acyclovir topical ointment is indicated to treat initial genital herpes and limited nonlifethreatening mucocutaneous herpes simplex in immunocompromised patientsl7318 an acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis and shortening lesion healing time in patients 6 years and olderl7321 an acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialisl7324 an acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitisl7327')|
|('DB00265', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'for eradication of scabies isarcoptes scabieii and for symptomatic treatment of pruritic skin')|
|('DB00265', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for eradication of scabies isarcoptes scabieii and for symptomatic treatment of pruritic skin')|
|('DB00649', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for the treatment of human immunovirus hiv infections')|
|('DB01014', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'for the treatment of mildly to moderately active ulcerative colitis')|
|('DB01014', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'for the treatment of mildly to moderately active ulcerative colitis')|
|('DB00377', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation')|
|('DB00377', 'MONDO:0004992', ['cancer'], 'for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation')|
|('DB04842', 'MONDO:0004992', ['cancer'], 'used for the treatment of schizophrenia')|
|('DB04842', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used for the treatment of schizophrenia')|
|('DB06694', 'MONDO:0004992', ['cancer'], 'it is used for treating nasal congestion and minor inflammation due to allergies or colds')|
|('DB00536', 'MONDO:0004992', ['cancer'], 'for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of eatonlambert it is not indicated for treating myasthenia gravis')|
|('DB00536', 'MONDO:0009688', ['myasthenia gravis'], 'for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of eatonlambert it is not indicated for treating myasthenia gravis')|
|('DB08868', 'MONDO:0004992', ['cancer'], 'fingolimod is a sphingosine 1phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability')|
|('DB08868', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'fingolimod is a sphingosine 1phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability')|
|('DB00545', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for the treatment of myasthenia gravis')|
|('DB00545', 'MONDO:0009688', ['myasthenia gravis'], 'for the treatment of myasthenia gravis')|
|('DB00481', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'indicated for the prevention and treatment of osteoporosis in postmenopausal women as well as prevention and treatment of corticosteroidinduced bone losslabelindicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancerlabel')|
|('DB00481', 'MONDO:0005298', ['osteoporosis'], 'indicated for the prevention and treatment of osteoporosis in postmenopausal women as well as prevention and treatment of corticosteroidinduced bone losslabelindicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancerlabel')|
|('DB00481', 'MONDO:0006256', ['invasive mammary carcinoma [NCIT:C9245]', 'infiltrating breast carcinoma [NCIT:C9245]', 'invasive breast cancer [NCIT:C9245]', 'infiltrating carcinoma of breast [NCIT:C9245]', 'invasive carcinoma of the breast [NCIT:C9245]', 'infiltrating carcinoma of the breast [NCIT:C9245]', 'infiltrating breast cancer [NCIT:C9245]', 'invasive carcinoma of breast [NCIT:C9245]', 'invasive breast carcinoma [NCIT:C9245]', 'invasive breast carcinoma'], 'indicated for the prevention and treatment of osteoporosis in postmenopausal women as well as prevention and treatment of corticosteroidinduced bone losslabelindicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancerlabel')|
|('DB00301', 'MONDO:0005298', ['osteoporosis'], 'used to treat bacterial infection by susceptible microorganisms')|
|('DB00900', 'MONDO:0005298', ['osteoporosis'], 'for use in combination with other antiretroviral agents in the treatment of hiv1 infection in adults')|
|('DB00289', 'MONDO:0005298', ['osteoporosis'], 'atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder adhd in children and adults')|
|('DB00289', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder adhd in children and adults')|
|('DB00638', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'historically used in an important medical test of renal function specifically a measure of glomerular filtration rate sometimes used to help relieve symptoms of diabetes mellitus  a condition characterised by hyperglycemia andor hyperinsulinemia')|
|('DB00638', 'MONDO:0005015', ['diabetes mellitus'], 'historically used in an important medical test of renal function specifically a measure of glomerular filtration rate sometimes used to help relieve symptoms of diabetes mellitus  a condition characterised by hyperglycemia andor hyperinsulinemia')|
|('DB00638', 'MONDO:0002909', ['hyperglycemia'], 'historically used in an important medical test of renal function specifically a measure of glomerular filtration rate sometimes used to help relieve symptoms of diabetes mellitus  a condition characterised by hyperglycemia andor hyperinsulinemia')|
|('DB00638', 'MONDO:0002177', ['hyperinsulinemia', 'hyperinsulinism'], 'historically used in an important medical test of renal function specifically a measure of glomerular filtration rate sometimes used to help relieve symptoms of diabetes mellitus  a condition characterised by hyperglycemia andor hyperinsulinemia')|
|('DB00293', 'MONDO:0002909', ['hyperglycemia'], 'for the treatment of malignant neoplasm of colon and rectum')|
|('DB00293', 'MONDO:0006517', ['malignant childhood neoplasm [NCIT:C4005]', 'malignant neoplasm [NCIT:C4005]', 'childhood cancer [NCIT:C4005]', 'childhood neoplasm, malignant [MONDO:patterns/malignant]', 'malignant pediatric neoplasm [NCIT:C4005]', 'malignant childhood tumor [NCIT:C4005]', 'malignant pediatric tumor [NCIT:C4005]', 'childhood malignant neoplasm [NCIT:C4005]', 'pediatric cancer [NCIT:C4005]', 'childhood malignant neoplasm'], 'for the treatment of malignant neoplasm of colon and rectum')|
|('DB00275', 'MONDO:0006517', ['malignant childhood neoplasm [NCIT:C4005]', 'malignant neoplasm [NCIT:C4005]', 'childhood cancer [NCIT:C4005]', 'childhood neoplasm, malignant [MONDO:patterns/malignant]', 'malignant pediatric neoplasm [NCIT:C4005]', 'malignant childhood tumor [NCIT:C4005]', 'malignant pediatric tumor [NCIT:C4005]', 'childhood malignant neoplasm [NCIT:C4005]', 'pediatric cancer [NCIT:C4005]', 'childhood malignant neoplasm'], 'olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agentsf4709f4712a173869 olmesartan is also used offlabel for the management type 2 diabetesassociated nephropathy heart failure and postmyocardial infarction particularly in patients who are unable to tolerate ace inhibitorsa178153a185912a185915 arbs such as olmesartan have been shown in a number of largescale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction stroke the progression of heart failure and hospitalizationa174124a178153a173869a185324a185327a185333a185342a185345 like other arbs olmesartan blockade of raas slows the progression of diabetic nephropathy due to its renoprotective effectsa185906a185909a185912 ')|
|('DB00275', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agentsf4709f4712a173869 olmesartan is also used offlabel for the management type 2 diabetesassociated nephropathy heart failure and postmyocardial infarction particularly in patients who are unable to tolerate ace inhibitorsa178153a185912a185915 arbs such as olmesartan have been shown in a number of largescale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction stroke the progression of heart failure and hospitalizationa174124a178153a173869a185324a185327a185333a185342a185345 like other arbs olmesartan blockade of raas slows the progression of diabetic nephropathy due to its renoprotective effectsa185906a185909a185912 ')|
|('DB00275', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agentsf4709f4712a173869 olmesartan is also used offlabel for the management type 2 diabetesassociated nephropathy heart failure and postmyocardial infarction particularly in patients who are unable to tolerate ace inhibitorsa178153a185912a185915 arbs such as olmesartan have been shown in a number of largescale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction stroke the progression of heart failure and hospitalizationa174124a178153a173869a185324a185327a185333a185342a185345 like other arbs olmesartan blockade of raas slows the progression of diabetic nephropathy due to its renoprotective effectsa185906a185909a185912 ')|
|('DB00275', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agentsf4709f4712a173869 olmesartan is also used offlabel for the management type 2 diabetesassociated nephropathy heart failure and postmyocardial infarction particularly in patients who are unable to tolerate ace inhibitorsa178153a185912a185915 arbs such as olmesartan have been shown in a number of largescale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction stroke the progression of heart failure and hospitalizationa174124a178153a173869a185324a185327a185333a185342a185345 like other arbs olmesartan blockade of raas slows the progression of diabetic nephropathy due to its renoprotective effectsa185906a185909a185912 ')|
|('DB00275', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agentsf4709f4712a173869 olmesartan is also used offlabel for the management type 2 diabetesassociated nephropathy heart failure and postmyocardial infarction particularly in patients who are unable to tolerate ace inhibitorsa178153a185912a185915 arbs such as olmesartan have been shown in a number of largescale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction stroke the progression of heart failure and hospitalizationa174124a178153a173869a185324a185327a185333a185342a185345 like other arbs olmesartan blockade of raas slows the progression of diabetic nephropathy due to its renoprotective effectsa185906a185909a185912 ')|
|('DB00617', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'used for the control of absence petit mal seizures that are refractory to treatment with other medications')|
|('DB00332', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB00332', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'inhaled ipratropium is indicated in combination with inhaled betaagonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatmenta176939asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flowl5900as a single agent ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older it does not alleviate nasal congestion nor sneezingfda labelrhinorrhea refers to recurrent or chronic watery nasal discharge this condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burdenl5903additionally ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysemafda labelthe chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness as this includes several conditions the etiology symptoms and treatments are diversel5906ipratropium has also been studied to be used for the treatment of sialorrheaa176942sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivationa176963')|
|('DB01171', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of major depressive disorder and bipolar disorder a31901')|
|('DB01171', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for the treatment of major depressive disorder and bipolar disorder a31901')|
|('DB01171', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'for the treatment of major depressive disorder and bipolar disorder a31901')|
|('DB00920', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'indicated as an addon or prophylactic oral medication in the chronic treatment of mild atopic asthmatic children also used as selfmedication for the temporary relief of itching of the eye due to allergic conjunctivitis ophthalmic')|
|('DB00790', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'for the treatment of mild to moderate essential hypertension mild to moderate congestive heart failure and to reduce the cardiovascular risk of individuals with hypertension or postmyocardial infarction and stable coronary disease ')|
|('DB00790', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of mild to moderate essential hypertension mild to moderate congestive heart failure and to reduce the cardiovascular risk of individuals with hypertension or postmyocardial infarction and stable coronary disease ')|
|('DB00790', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of mild to moderate essential hypertension mild to moderate congestive heart failure and to reduce the cardiovascular risk of individuals with hypertension or postmyocardial infarction and stable coronary disease ')|
|('DB00213', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'pantoprazole injectiontreatment of gastroesophageal reflux disease associated with a history of erosive esophagitispantoprazole for injection is indicated for shortterm treatment 710 days of patients having gastroesophageal reflux disease gerd with a history of erosive esophagitis as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayedrelease tablets safety and efficacy of pantoprazole injection as the initial treatment of patients having gerd with a history of erosive esophagitis have not been demonstrated at this timefda labelpathological hypersecretion associated with zollingerellison syndromepantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with zollingerellison syndrome or other neoplastic conditionsfda labelpantoprazole delayedrelease oral suspensionshortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerdindicated in adults and pediatric patients five years of age and above for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole may be considered safety of treatment beyond 8 weeks in pediatric patients has not been determinedf3202maintenance of healing of erosive esophagitisindicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerdf3202pathological hypersecretory conditions including zollingerellison syndromeindicated for the longterm treatment of the above conditionsf3202')|
|('DB00213', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'pantoprazole injectiontreatment of gastroesophageal reflux disease associated with a history of erosive esophagitispantoprazole for injection is indicated for shortterm treatment 710 days of patients having gastroesophageal reflux disease gerd with a history of erosive esophagitis as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayedrelease tablets safety and efficacy of pantoprazole injection as the initial treatment of patients having gerd with a history of erosive esophagitis have not been demonstrated at this timefda labelpathological hypersecretion associated with zollingerellison syndromepantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with zollingerellison syndrome or other neoplastic conditionsfda labelpantoprazole delayedrelease oral suspensionshortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerdindicated in adults and pediatric patients five years of age and above for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole may be considered safety of treatment beyond 8 weeks in pediatric patients has not been determinedf3202maintenance of healing of erosive esophagitisindicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerdf3202pathological hypersecretory conditions including zollingerellison syndromeindicated for the longterm treatment of the above conditionsf3202')|
|('DB00213', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'pantoprazole injectiontreatment of gastroesophageal reflux disease associated with a history of erosive esophagitispantoprazole for injection is indicated for shortterm treatment 710 days of patients having gastroesophageal reflux disease gerd with a history of erosive esophagitis as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayedrelease tablets safety and efficacy of pantoprazole injection as the initial treatment of patients having gerd with a history of erosive esophagitis have not been demonstrated at this timefda labelpathological hypersecretion associated with zollingerellison syndromepantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with zollingerellison syndrome or other neoplastic conditionsfda labelpantoprazole delayedrelease oral suspensionshortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerdindicated in adults and pediatric patients five years of age and above for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole may be considered safety of treatment beyond 8 weeks in pediatric patients has not been determinedf3202maintenance of healing of erosive esophagitisindicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerdf3202pathological hypersecretory conditions including zollingerellison syndromeindicated for the longterm treatment of the above conditionsf3202')|
|('DB00891', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of dermatitis herpetiformis benign mucous membrane pemphigoid and pyoderma gangrenosum')|
|('DB00891', 'MONDO:0015614', ['Dermatitis herpetiformis', 'Dermatosis herpetiformis', 'Duhrings disease', 'dermatitis herpetiformis'], 'for the treatment of dermatitis herpetiformis benign mucous membrane pemphigoid and pyoderma gangrenosum')|
|('DB00891', 'MONDO:0018746', ['benign mucous membrane pemphigoid', 'benign mucous membrane pemphigoid with ocular involvement', 'Cicatricial pemphigoid with ocular involvement', 'Ocular pemphigoid', 'ocular pemphigus', 'mucous membrane pemphigoid'], 'for the treatment of dermatitis herpetiformis benign mucous membrane pemphigoid and pyoderma gangrenosum')|
|('DB00891', 'MONDO:0018824', ['Pyoderma gangrenosum', 'pyoderma gangrenosum'], 'for the treatment of dermatitis herpetiformis benign mucous membrane pemphigoid and pyoderma gangrenosum')|
|('DB01246', 'MONDO:0018824', ['Pyoderma gangrenosum', 'pyoderma gangrenosum'], 'used to prevent and relieve allergic conditions which cause pruritus itching and urticaria some allergic skin reactions')|
|('DB01246', 'MONDO:0005492', ['urticaria'], 'used to prevent and relieve allergic conditions which cause pruritus itching and urticaria some allergic skin reactions')|
|('DB00137', 'MONDO:0005492', ['urticaria'], 'xanthophylls are taken for nutritional supplementation and also for treating dietary shortage or imbalance')|
|('DB00859', 'MONDO:0005492', ['urticaria'], 'for treatment of wilsons disease cystinuria and active rheumatoid arthritis')|
|('DB00859', 'MONDO:0010200', ['Cerebral pseudosclerosis', 'hepatolenticular degeneration', 'Westphal pseudosclerosis', 'Westphal-Strumpell syndrome', 'Wilsons disease', 'wilson disease'], 'for treatment of wilsons disease cystinuria and active rheumatoid arthritis')|
|('DB00859', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for treatment of wilsons disease cystinuria and active rheumatoid arthritis')|
|('DB00367', 'MONDO:0010200', ['Cerebral pseudosclerosis', 'hepatolenticular degeneration', 'Westphal pseudosclerosis', 'Westphal-Strumpell syndrome', 'Wilsons disease', 'wilson disease'], 'emergency contraceptionlevonorgestrel in the singleagent emergency contraceptive form is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse it is distributed by prescription for patients under 17 and over the counter for those above this agel7760 this levonorgestrelonly form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercoursea181976l7760 it has shown a lower efficacy when it is used off label within 96 hourst659longterm contraception or nonemergency contraceptionin addition to the above indication in emergency contraception levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use for example with ethinyl estradioll7766 it is used in various hormonereleasing intrauterine devices for longterm contraception ranging for a duration of 35 yearsl7778l7781l7787 product labeling for mirena specifically mentions that it is recommended in women who have had at least 1 childl7778 a subdermal implant is also available for the prevention of pregnancy for up to 5 yearsl7823hormone therapy and offlabel useslevonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosisl7805offlabel levonorgestrel may be used to treat menorrhagia endometrial hyperplasia and endometriosist659')|
|('DB00367', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'emergency contraceptionlevonorgestrel in the singleagent emergency contraceptive form is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse it is distributed by prescription for patients under 17 and over the counter for those above this agel7760 this levonorgestrelonly form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercoursea181976l7760 it has shown a lower efficacy when it is used off label within 96 hourst659longterm contraception or nonemergency contraceptionin addition to the above indication in emergency contraception levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use for example with ethinyl estradioll7766 it is used in various hormonereleasing intrauterine devices for longterm contraception ranging for a duration of 35 yearsl7778l7781l7787 product labeling for mirena specifically mentions that it is recommended in women who have had at least 1 childl7778 a subdermal implant is also available for the prevention of pregnancy for up to 5 yearsl7823hormone therapy and offlabel useslevonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosisl7805offlabel levonorgestrel may be used to treat menorrhagia endometrial hyperplasia and endometriosist659')|
|('DB00367', 'MONDO:0041161', ['hyperplasia of the endometrium [NCIT:C3013]', 'endometrial hyperplasia []', 'hyperplasia of endometrium [NCIT:C3013]', 'endometrial hyperplasia'], 'emergency contraceptionlevonorgestrel in the singleagent emergency contraceptive form is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse it is distributed by prescription for patients under 17 and over the counter for those above this agel7760 this levonorgestrelonly form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercoursea181976l7760 it has shown a lower efficacy when it is used off label within 96 hourst659longterm contraception or nonemergency contraceptionin addition to the above indication in emergency contraception levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use for example with ethinyl estradioll7766 it is used in various hormonereleasing intrauterine devices for longterm contraception ranging for a duration of 35 yearsl7778l7781l7787 product labeling for mirena specifically mentions that it is recommended in women who have had at least 1 childl7778 a subdermal implant is also available for the prevention of pregnancy for up to 5 yearsl7823hormone therapy and offlabel useslevonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosisl7805offlabel levonorgestrel may be used to treat menorrhagia endometrial hyperplasia and endometriosist659')|
|('DB00453', 'MONDO:0041161', ['hyperplasia of the endometrium [NCIT:C3013]', 'endometrial hyperplasia []', 'hyperplasia of endometrium [NCIT:C3013]', 'endometrial hyperplasia'], 'for the treatment and management of brucellosis mycoplasma infection acne vulgaris chlamydial infectionchronic bronchitis')|
|('DB00453', 'MONDO:0005683', ['Maltese fever', 'undulant fever', 'brucellosis'], 'for the treatment and management of brucellosis mycoplasma infection acne vulgaris chlamydial infectionchronic bronchitis')|
|('DB00453', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment and management of brucellosis mycoplasma infection acne vulgaris chlamydial infectionchronic bronchitis')|
|('DB01185', 'MONDO:0005683', ['Maltese fever', 'undulant fever', 'brucellosis'], 'in males used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone in females for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal')|
|('DB01185', 'MONDO:0004992', ['cancer'], 'in males used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone in females for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal')|
|('DB01212', 'MONDO:0004992', ['cancer'], 'for the treatment of the infections respiratory skin soft tissue uti ent caused by s pneumoniae h influenzae staphylococci s pyogenes group a betahemolytic streptococci e coli p mirabilis klebsiella sp coagulasenegative staph')|
|('DB00709', 'MONDO:0004992', ['cancer'], 'for the treatment of hiv infection and chronic hepatitis b hbv')|
|('DB00709', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for the treatment of hiv infection and chronic hepatitis b hbv')|
|('DB00709', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'for the treatment of hiv infection and chronic hepatitis b hbv')|
|('DB00578', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria')|
|('DB00578', 'MONDO:0001882', ['bacteriuria'], 'for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria')|
|('DB00143', 'MONDO:0001882', ['bacteriuria'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00248', 'MONDO:0001882', ['bacteriuria'], 'for the treatment of hyperprolactinemic disorders either idiopathic or due to prolactinoma prolactinsecreting adenomas may also be used to manage symptoms of parkinsonian syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease ')|
|('DB00248', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'for the treatment of hyperprolactinemic disorders either idiopathic or due to prolactinoma prolactinsecreting adenomas may also be used to manage symptoms of parkinsonian syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease ')|
|('DB01025', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'used as a paste in the mouth to treat aphthous ulcers canker sores ')|
|('DB06150', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'for use in the treatment of infections')|
|('DB00941', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'used as an adjunct with succinylcholine or suxamethonium chloride to prolong muscle relaxation and to prevent succinylcholineinduced muscle fasciculations')|
|('DB00613', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'for treatment of acute malarial attacks in nonimmune subjects')|
|('DB01216', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'indicated for the treatment of symptomatic benign prostatic hyperplasia bph in men with an enlarged prostate to improve symptoms reduce the risk of acute urinary retention and reduce the risk of the need for surgery including transurethral resection of the prostate turp and prostatectomyl10565indicated for the treatment of male pattern hair loss androgenetic alopecia hereditary alopecia or common male baldness in male patientsl6235')|
|('DB01216', 'MONDO:0005339', ['alopecia androgenetica, male pattern baldness', 'androgenetic alopecia', 'androgenetic alopecia'], 'indicated for the treatment of symptomatic benign prostatic hyperplasia bph in men with an enlarged prostate to improve symptoms reduce the risk of acute urinary retention and reduce the risk of the need for surgery including transurethral resection of the prostate turp and prostatectomyl10565indicated for the treatment of male pattern hair loss androgenetic alopecia hereditary alopecia or common male baldness in male patientsl6235')|
|('DB01216', 'MONDO:0004907', ['alopecia'], 'indicated for the treatment of symptomatic benign prostatic hyperplasia bph in men with an enlarged prostate to improve symptoms reduce the risk of acute urinary retention and reduce the risk of the need for surgery including transurethral resection of the prostate turp and prostatectomyl10565indicated for the treatment of male pattern hair loss androgenetic alopecia hereditary alopecia or common male baldness in male patientsl6235')|
|('DB01216', 'MONDO:0021137', ['common []', 'not rare'], 'indicated for the treatment of symptomatic benign prostatic hyperplasia bph in men with an enlarged prostate to improve symptoms reduce the risk of acute urinary retention and reduce the risk of the need for surgery including transurethral resection of the prostate turp and prostatectomyl10565indicated for the treatment of male pattern hair loss androgenetic alopecia hereditary alopecia or common male baldness in male patientsl6235')|
|('DB00544', 'MONDO:0021137', ['common []', 'not rare'], 'for the topical treatment of multiple actinic or solar keratoses in the 5 strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical such as with multiple lesions or difficult treatment sites fluorouracil injection is indicated in the palliative management of some types of cancer including colon esophageal gastric rectum breast biliary tract stomach head and neck cervical pancreas renal cell and carcinoid')|
|('DB00544', 'MONDO:0004992', ['cancer'], 'for the topical treatment of multiple actinic or solar keratoses in the 5 strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical such as with multiple lesions or difficult treatment sites fluorouracil injection is indicated in the palliative management of some types of cancer including colon esophageal gastric rectum breast biliary tract stomach head and neck cervical pancreas renal cell and carcinoid')|
|('DB00544', 'MONDO:0005369', ['neuroendocrine tumor G1 [MONDO:cjm]', 'NET G1 [MONDO:cjm]', 'neuroendocrine neoplasm G1 [MONDO:cjm]', 'carcinoid [NCIT:C2915]', 'carcinoid tumor [MONDO:ambiguous,NCIT:C2915]', 'carcinoid tumor'], 'for the topical treatment of multiple actinic or solar keratoses in the 5 strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical such as with multiple lesions or difficult treatment sites fluorouracil injection is indicated in the palliative management of some types of cancer including colon esophageal gastric rectum breast biliary tract stomach head and neck cervical pancreas renal cell and carcinoid')|
|('DB01252', 'MONDO:0004992', ['cancer'], 'for the treatment of type 2 diabetes')|
|('DB01252', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of type 2 diabetes')|
|('DB00313', 'MONDO:0004992', ['cancer'], 'indicated forlabel 1 use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures 2 adjunctive therapy in the management of multiple seizure types that include absence seizures 3 prophylaxis of migraine headaches4 acute management of mania associated with bipolar disorderofflabel uses include 1 maintenance therapy for bipolar disordera1779192 treatment for acute bipolar depressiona177928a177931a1779343 emergency treatment of status epilepticusa177955')|
|('DB01419', 'MONDO:0004992', ['cancer'], 'antrafenine is used as an antiinflammatory and analgesic agent for the relief of mild to moderate pain')|
|('DB01202', 'MONDO:0004992', ['cancer'], 'levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older additionally it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older and in primary generalized tonicclonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and olderl8606levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kgl8609')|
|('DB01202', 'MONDO:0009696', ['juvenile myoclonic epilepsy'], 'levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older additionally it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older and in primary generalized tonicclonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and olderl8606levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kgl8609')|
|('DB01202', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older additionally it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older and in primary generalized tonicclonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and olderl8606levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kgl8609')|
|('DB01125', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the prophylaxis and treatment of venous thrombosis and its extension the treatment of atrial fibrillation with embolization the prophylaxis and treatment of pulmonary embolism and as an adjunct in the treatment of coronary occlusion')|
|('DB01125', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the prophylaxis and treatment of venous thrombosis and its extension the treatment of atrial fibrillation with embolization the prophylaxis and treatment of pulmonary embolism and as an adjunct in the treatment of coronary occlusion')|
|('DB01125', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for the prophylaxis and treatment of venous thrombosis and its extension the treatment of atrial fibrillation with embolization the prophylaxis and treatment of pulmonary embolism and as an adjunct in the treatment of coronary occlusion')|
|('DB00442', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'for the treatment of chronic hepatitis b virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB00442', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'for the treatment of chronic hepatitis b virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB00442', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'for the treatment of chronic hepatitis b virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB00442', 'MONDO:0005103', ['well-differentiated liposarcoma [NCIT:C4250]', 'well differentiated liposarcoma of deep soft tissue [NCIT:C4250]', 'WDLS [Orphanet:99971]', 'atypical lipomatous tumor [Orphanet:99971]', 'atypical lipoma [Orphanet:99971]', 'ALT [Orphanet:99971]', 'well differentiated liposarcoma [NCIT:C4250]', 'well-differentiated liposarcoma'], 'for the treatment of chronic hepatitis b virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease')|
|('DB08913', 'MONDO:0005103', ['well-differentiated liposarcoma [NCIT:C4250]', 'well differentiated liposarcoma of deep soft tissue [NCIT:C4250]', 'WDLS [Orphanet:99971]', 'atypical lipomatous tumor [Orphanet:99971]', 'atypical lipoma [Orphanet:99971]', 'ALT [Orphanet:99971]', 'well differentiated liposarcoma [NCIT:C4250]', 'well-differentiated liposarcoma'], 'used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant')|
|('DB08913', 'MONDO:0004992', ['cancer'], 'used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant')|
|('DB08913', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant')|
|('DB01364', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'ephedrine commonly used as a stimulant appetite suppressant concentration aid decongestant and to treat hypotension associated with anaesthesia')|
|('DB01364', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'ephedrine commonly used as a stimulant appetite suppressant concentration aid decongestant and to treat hypotension associated with anaesthesia')|
|('DB00569', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'approved for 1 prophylaxis of vte for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture hip replacement and knee surgery 2 prophylaxis of vte patients undergoing abdominal surgery who are at high risk of thromboembolic complications eg patients undergoing abdominal cancer surgery 3 treatment of acute dvt and pe 4 management of ua and nstemi for the prevention of death and subsequent myocardial infarction mi and 5 management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention pci due to an increased risk of guiding catheter thrombosis ')|
|('DB00569', 'MONDO:0005315', ['fracture [NCIT:C3046]', 'fracture of bone [NCIT:C3046]', 'fracture(s) [NCIT:C3046]', 'bone fracture'], 'approved for 1 prophylaxis of vte for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture hip replacement and knee surgery 2 prophylaxis of vte patients undergoing abdominal surgery who are at high risk of thromboembolic complications eg patients undergoing abdominal cancer surgery 3 treatment of acute dvt and pe 4 management of ua and nstemi for the prevention of death and subsequent myocardial infarction mi and 5 management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention pci due to an increased risk of guiding catheter thrombosis ')|
|('DB00569', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'approved for 1 prophylaxis of vte for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture hip replacement and knee surgery 2 prophylaxis of vte patients undergoing abdominal surgery who are at high risk of thromboembolic complications eg patients undergoing abdominal cancer surgery 3 treatment of acute dvt and pe 4 management of ua and nstemi for the prevention of death and subsequent myocardial infarction mi and 5 management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention pci due to an increased risk of guiding catheter thrombosis ')|
|('DB00569', 'MONDO:0041656', ['ST segment elevation myocardial infarction []', 'acute-ST segment elevation myocardial infarction []', 'STEMI [https://www.ecgmedicaltraining.com/what-is-a-stemi/]', 'st-elevation myocardial infarction'], 'approved for 1 prophylaxis of vte for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture hip replacement and knee surgery 2 prophylaxis of vte patients undergoing abdominal surgery who are at high risk of thromboembolic complications eg patients undergoing abdominal cancer surgery 3 treatment of acute dvt and pe 4 management of ua and nstemi for the prevention of death and subsequent myocardial infarction mi and 5 management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention pci due to an increased risk of guiding catheter thrombosis ')|
|('DB00485', 'MONDO:0041656', ['ST segment elevation myocardial infarction []', 'acute-ST segment elevation myocardial infarction []', 'STEMI [https://www.ecgmedicaltraining.com/what-is-a-stemi/]', 'st-elevation myocardial infarction'], 'used to treat infections caused by penicillinaseproducing staphylococci which have demonstrated susceptibility to the drug')|
|('DB00214', 'MONDO:0041656', ['ST segment elevation myocardial infarction []', 'acute-ST segment elevation myocardial infarction []', 'STEMI [https://www.ecgmedicaltraining.com/what-is-a-stemi/]', 'st-elevation myocardial infarction'], 'torasemide is indicated for the treatment of edema associated with congestive heart failure renal or hepatic diseases from this condition it has been observed that torasemide is very effective in cases of kidney failurefda labeledema is considered when swelling is observed due to the trap of fluid in the body tissue it is mainly located in feet ankles and legs but it can also be extended to other parts such as face hands and abdomen or even the whole bodyl5251as well torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensivesfda labelhypertension is defined by the presence of high blood pressure this is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteriesl5254')|
|('DB00214', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'torasemide is indicated for the treatment of edema associated with congestive heart failure renal or hepatic diseases from this condition it has been observed that torasemide is very effective in cases of kidney failurefda labeledema is considered when swelling is observed due to the trap of fluid in the body tissue it is mainly located in feet ankles and legs but it can also be extended to other parts such as face hands and abdomen or even the whole bodyl5251as well torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensivesfda labelhypertension is defined by the presence of high blood pressure this is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteriesl5254')|
|('DB00214', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'torasemide is indicated for the treatment of edema associated with congestive heart failure renal or hepatic diseases from this condition it has been observed that torasemide is very effective in cases of kidney failurefda labeledema is considered when swelling is observed due to the trap of fluid in the body tissue it is mainly located in feet ankles and legs but it can also be extended to other parts such as face hands and abdomen or even the whole bodyl5251as well torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensivesfda labelhypertension is defined by the presence of high blood pressure this is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteriesl5254')|
|('DB00214', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'torasemide is indicated for the treatment of edema associated with congestive heart failure renal or hepatic diseases from this condition it has been observed that torasemide is very effective in cases of kidney failurefda labeledema is considered when swelling is observed due to the trap of fluid in the body tissue it is mainly located in feet ankles and legs but it can also be extended to other parts such as face hands and abdomen or even the whole bodyl5251as well torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensivesfda labelhypertension is defined by the presence of high blood pressure this is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteriesl5254')|
|('DB00214', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'torasemide is indicated for the treatment of edema associated with congestive heart failure renal or hepatic diseases from this condition it has been observed that torasemide is very effective in cases of kidney failurefda labeledema is considered when swelling is observed due to the trap of fluid in the body tissue it is mainly located in feet ankles and legs but it can also be extended to other parts such as face hands and abdomen or even the whole bodyl5251as well torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensivesfda labelhypertension is defined by the presence of high blood pressure this is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteriesl5254')|
|('DB01097', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for the management of the signs and symptoms of active rheumatoid arthritis ra to improve physical function and to slow the progression of structural damage associated with the disease has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the fda as an orphan drug for this use')|
|('DB01097', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the management of the signs and symptoms of active rheumatoid arthritis ra to improve physical function and to slow the progression of structural damage associated with the disease has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the fda as an orphan drug for this use')|
|('DB00251', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of candidiasis a yeastlike fungal infection of the vulva and vagina')|
|('DB00251', 'MONDO:0002026', ['Disseminated candidiasis', 'systemic candidiasis', 'candidiasis'], 'for the treatment of candidiasis a yeastlike fungal infection of the vulva and vagina')|
|('DB00557', 'MONDO:0002026', ['Disseminated candidiasis', 'systemic candidiasis', 'candidiasis'], 'indicated for the symptomatic relief and management of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested typically used less than 4 monthsl9677indicated for the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histaminemediated pruritusl9677indicated for the induction of sedation as a premedication preanesthetic adjunctive therapy and following general anesthesia for surgeryl9677 such asdental proceduresl9680hydroxyzine was shown to be useful in controlling nausea and vomiting excluding nausea and vomiting of pregnancyl9680')|
|('DB00557', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'indicated for the symptomatic relief and management of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested typically used less than 4 monthsl9677indicated for the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histaminemediated pruritusl9677indicated for the induction of sedation as a premedication preanesthetic adjunctive therapy and following general anesthesia for surgeryl9677 such asdental proceduresl9680hydroxyzine was shown to be useful in controlling nausea and vomiting excluding nausea and vomiting of pregnancyl9680')|
|('DB00557', 'MONDO:0005379', ['depressive neurosis', 'neurosis', 'neurotic depression', 'Neurotic depression reactive type', 'Neurotic depressive state', 'Psychoneurosis', 'reactive depression', 'neurotic disorder'], 'indicated for the symptomatic relief and management of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested typically used less than 4 monthsl9677indicated for the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histaminemediated pruritusl9677indicated for the induction of sedation as a premedication preanesthetic adjunctive therapy and following general anesthesia for surgeryl9677 such asdental proceduresl9680hydroxyzine was shown to be useful in controlling nausea and vomiting excluding nausea and vomiting of pregnancyl9680')|
|('DB00557', 'MONDO:0005492', ['urticaria'], 'indicated for the symptomatic relief and management of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested typically used less than 4 monthsl9677indicated for the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histaminemediated pruritusl9677indicated for the induction of sedation as a premedication preanesthetic adjunctive therapy and following general anesthesia for surgeryl9677 such asdental proceduresl9680hydroxyzine was shown to be useful in controlling nausea and vomiting excluding nausea and vomiting of pregnancyl9680')|
|('DB08860', 'MONDO:0005492', ['urticaria'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005015', ['diabetes mellitus'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005311', ['atherosclerosis'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0005350', ['AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1', 'abdominal aortic aneurysm'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB08860', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'pitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol tc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc it is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia hefh to reduce elevated tc ldlc and apo bf4667prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00807', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'used as a local ophthalmic anesthetic')|
|('DB00325', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for immediate reduction of blood pressure of patients in hypertensive crises reduce bleeding during surgery and for the treatment of acute congestive heart failure')|
|('DB00325', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for immediate reduction of blood pressure of patients in hypertensive crises reduce bleeding during surgery and for the treatment of acute congestive heart failure')|
|('DB01031', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'used for the shortterm treatment of insomnia however it generally has been replaced by other sedativehypnotic agents')|
|('DB01031', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used for the shortterm treatment of insomnia however it generally has been replaced by other sedativehypnotic agents')|
|('DB01031', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for the shortterm treatment of insomnia however it generally has been replaced by other sedativehypnotic agents')|
|('DB00752', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of major depressive episode without melancholia')|
|('DB00752', 'MONDO:0002444', ['melancholia'], 'for the treatment of major depressive episode without melancholia')|
|('DB06713', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'norelgestromin is used for contraception and menopausal hormonal therapy norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase  they convert sulfated steroid precursors to estrogen during pregnancy ')|
|('DB06713', 'MONDO:0004992', ['cancer'], 'norelgestromin is used for contraception and menopausal hormonal therapy norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase  they convert sulfated steroid precursors to estrogen during pregnancy ')|
|('DB08928', 'MONDO:0004992', ['cancer'], 'antiprotozoal agent effective against amoebiasis and yaws')|
|('DB08928', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'antiprotozoal agent effective against amoebiasis and yaws')|
|('DB08928', 'MONDO:0006019', ['Bouba', 'frambesia', 'frambesia tropica', 'frambosie', 'polypapilloma tropicum', 'thymosis', 'yaws'], 'antiprotozoal agent effective against amoebiasis and yaws')|
|('DB01057', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'for use in the treatment of subacute or chronic angleclosure glaucoma after iridectomy or where surgery is refused or contraindicated')|
|('DB01057', 'MONDO:0005041', ['glaucoma'], 'for use in the treatment of subacute or chronic angleclosure glaucoma after iridectomy or where surgery is refused or contraindicated')|
|('DB06802', 'MONDO:0005041', ['glaucoma'], 'for the treatment of pain and inflammation associated with cataract surgery')|
|('DB06802', 'MONDO:0005129', ['cataract'], 'for the treatment of pain and inflammation associated with cataract surgery')|
|('DB01431', 'MONDO:0005129', ['cataract'], 'allylestrenol was designed to be used for miscarriage prevention prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia')|
|('DB01431', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'allylestrenol was designed to be used for miscarriage prevention prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia')|
|('DB08899', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'enzalutamide is indicated for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel')|
|('DB08899', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'enzalutamide is indicated for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel')|
|('DB09028', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'indicated for use in smoking cessation ')|
|('DB01092', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of atrial fibrillation and flutter and heart failure')|
|('DB01092', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the treatment of atrial fibrillation and flutter and heart failure')|
|('DB01092', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the treatment of atrial fibrillation and flutter and heart failure')|
|('DB00118', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'sadenosylmethionine same is used as a drug in europe for the treatment of depression liver disorders fibromyalgia and osteoarthritis it has also been introduced into the united states market as a dietary supplement for the support of bone and joint health as well as mood and emotional well being')|
|('DB00118', 'MONDO:0005546', ['fibromyalgia'], 'sadenosylmethionine same is used as a drug in europe for the treatment of depression liver disorders fibromyalgia and osteoarthritis it has also been introduced into the united states market as a dietary supplement for the support of bone and joint health as well as mood and emotional well being')|
|('DB00118', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'sadenosylmethionine same is used as a drug in europe for the treatment of depression liver disorders fibromyalgia and osteoarthritis it has also been introduced into the united states market as a dietary supplement for the support of bone and joint health as well as mood and emotional well being')|
|('DB00118', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sadenosylmethionine same is used as a drug in europe for the treatment of depression liver disorders fibromyalgia and osteoarthritis it has also been introduced into the united states market as a dietary supplement for the support of bone and joint health as well as mood and emotional well being')|
|('DB00618', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used primarily to treat lyme disease acne and bronchitis also indicated but rarely used to treat urinary tract infections gum disease malaria and other bacterial infections such as gonorrhea and chlamydia one of its other registered uses is the treatment of hyponatremia low blood sodium concentration due to the syndrome of inappropriate antidiuretic hormone siadh where fluid restriction alone has been ineffective ')|
|('DB00618', 'MONDO:0019632', ['Bannwarth syndrome', 'Bannworths syndrome', 'Lyme borreliosis', 'lyme neuroborreliosis', 'neuroborreliosis', 'Neurological Lyme disease', 'lyme disease'], 'used primarily to treat lyme disease acne and bronchitis also indicated but rarely used to treat urinary tract infections gum disease malaria and other bacterial infections such as gonorrhea and chlamydia one of its other registered uses is the treatment of hyponatremia low blood sodium concentration due to the syndrome of inappropriate antidiuretic hormone siadh where fluid restriction alone has been ineffective ')|
|('DB00618', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'used primarily to treat lyme disease acne and bronchitis also indicated but rarely used to treat urinary tract infections gum disease malaria and other bacterial infections such as gonorrhea and chlamydia one of its other registered uses is the treatment of hyponatremia low blood sodium concentration due to the syndrome of inappropriate antidiuretic hormone siadh where fluid restriction alone has been ineffective ')|
|('DB00618', 'MONDO:0005136', ['induced malaria', 'malaria'], 'used primarily to treat lyme disease acne and bronchitis also indicated but rarely used to treat urinary tract infections gum disease malaria and other bacterial infections such as gonorrhea and chlamydia one of its other registered uses is the treatment of hyponatremia low blood sodium concentration due to the syndrome of inappropriate antidiuretic hormone siadh where fluid restriction alone has been ineffective ')|
|('DB00526', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in combination with infusional 5fulv is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients who have undergone complete resection of the primary tumor ')|
|('DB00635', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'prednisone is indicated as an antiinflammatory or immunosuppressive drug for allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious endocrine or neoplastic conditions as well as in organ transplantl10502')|
|('DB00925', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of phaeochromocytoma malignant benign prostatic hypertrophy and malignant essential hypertension')|
|('DB00925', 'MONDO:0008233', ['phaeochromocytoma', 'phaeochromocytoma'], 'for the treatment of phaeochromocytoma malignant benign prostatic hypertrophy and malignant essential hypertension')|
|('DB00925', 'MONDO:0001133', ['Accelerated essential hypertension', 'malignant Essential hypertension', 'malignant essential hypertension'], 'for the treatment of phaeochromocytoma malignant benign prostatic hypertrophy and malignant essential hypertension')|
|('DB00665', 'MONDO:0008233', ['phaeochromocytoma', 'phaeochromocytoma'], 'for use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes bone or visceral organs stage d2')|
|('DB00665', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'for use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes bone or visceral organs stage d2')|
|('DB00483', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'for use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation')|
|('DB00601', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'for the treatment of bacterial infections caused by susceptible strains of vancomycin resistant ienterococcus faeciumi istaphylococcal aureusi methicillin resistant and susceptible strains istreptococcus pneumoniaei istreptococcus pyogenesi istreptococcus agalactiaei')|
|('DB00163', 'MONDO:0004956', ['prostate carcinoma metastatic [NCIT:C8946]', 'prostate cancer metastatic [NCIT:C8946]', 'metastatic prostate carcinoma [NCIT:C8946]', 'metastatic prostate cancer [NCIT:C8946]', 'metastatic prostate carcinoma'], 'vitamin e supplementation is indicated for treatment of vitamin e deficiency which can occur in cystic fibrosis cholestasis and severe liver disease abetalipoproteinemia or simply poor dieta176104l3063')|
|('DB00163', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'vitamin e supplementation is indicated for treatment of vitamin e deficiency which can occur in cystic fibrosis cholestasis and severe liver disease abetalipoproteinemia or simply poor dieta176104l3063')|
|('DB00894', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for palliative treatment of advanced breast cancer in postmenopausal women')|
|('DB00894', 'MONDO:0004992', ['cancer'], 'for palliative treatment of advanced breast cancer in postmenopausal women')|
|('DB00104', 'MONDO:0004992', ['cancer'], 'for treatment of acromegaly and reduction of side effects from cancer chemotherapy')|
|('DB00104', 'MONDO:0019933', ['acromegaly'], 'for treatment of acromegaly and reduction of side effects from cancer chemotherapy')|
|('DB00687', 'MONDO:0004992', ['cancer'], 'fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in addisons disease it is also indicated for the treatment of saltlosing androgenital syndromel8971')|
|('DB01599', 'MONDO:0004992', ['cancer'], 'used to lower ldl and hdl cholesterol')|
|('DB00608', 'MONDO:0004992', ['cancer'], 'for the suppressive treatment and for acute attacks of malaria due to p vivax pmalariae p ovale and susceptible strains of p falciparum secondline agent in treatment of rheumatoid arthritis')|
|('DB00608', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the suppressive treatment and for acute attacks of malaria due to p vivax pmalariae p ovale and susceptible strains of p falciparum secondline agent in treatment of rheumatoid arthritis')|
|('DB00608', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the suppressive treatment and for acute attacks of malaria due to p vivax pmalariae p ovale and susceptible strains of p falciparum secondline agent in treatment of rheumatoid arthritis')|
|('DB00115', 'MONDO:0005136', ['induced malaria', 'malaria'], 'nasal spraythe cyanocobalamin nasal spray is indicated for the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy in patients with deficiency of this vitamin who have no nervous system involvement fda labelnote  calomist fda label the nasal spray form has not been evaluated for the treatment of newly diagnosed vitamin b12 deficiencyinjection forms subcutaneous intramuscularthese forms are indicated for vitamin b12 deficiencies due to various causes with or without neurologic manifestations f3736  vitamin b12 deficiency is frequently caused by malabsorption which is often associated with the following conditions l5545addisonian pernicious anemiagastrointestinal pathology dysfunction or surgery including gluten enteropathy or sprue small bowel bacterial overgrowth total or partial gastrectomyfish tapeworm infestationmalignancy of the pancreas or bowelfolic acid deficiencyoral formsvitamin b12 supplements are widely available and indicated in patients who require supplementation for various reasons  dose requirements for vitamin b12 which are higher than normal caused by pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic and renal disease can usually be achieved with oral supplementation l5545   oral products of vitamin b12 are not recommended in patients with malabsorption as these forms are primarily absorbed in the gastrointestinal tract f3739 ')|
|('DB00115', 'MONDO:0020696', ['vitamin b12 deficiency [NCIT:C131684]', 'hypocobalaminemia [NCIT:C131684]', 'cobalamin deficiency []', 'vitamin b12 deficiency'], 'nasal spraythe cyanocobalamin nasal spray is indicated for the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy in patients with deficiency of this vitamin who have no nervous system involvement fda labelnote  calomist fda label the nasal spray form has not been evaluated for the treatment of newly diagnosed vitamin b12 deficiencyinjection forms subcutaneous intramuscularthese forms are indicated for vitamin b12 deficiencies due to various causes with or without neurologic manifestations f3736  vitamin b12 deficiency is frequently caused by malabsorption which is often associated with the following conditions l5545addisonian pernicious anemiagastrointestinal pathology dysfunction or surgery including gluten enteropathy or sprue small bowel bacterial overgrowth total or partial gastrectomyfish tapeworm infestationmalignancy of the pancreas or bowelfolic acid deficiencyoral formsvitamin b12 supplements are widely available and indicated in patients who require supplementation for various reasons  dose requirements for vitamin b12 which are higher than normal caused by pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic and renal disease can usually be achieved with oral supplementation l5545   oral products of vitamin b12 are not recommended in patients with malabsorption as these forms are primarily absorbed in the gastrointestinal tract f3739 ')|
|('DB00115', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'nasal spraythe cyanocobalamin nasal spray is indicated for the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy in patients with deficiency of this vitamin who have no nervous system involvement fda labelnote  calomist fda label the nasal spray form has not been evaluated for the treatment of newly diagnosed vitamin b12 deficiencyinjection forms subcutaneous intramuscularthese forms are indicated for vitamin b12 deficiencies due to various causes with or without neurologic manifestations f3736  vitamin b12 deficiency is frequently caused by malabsorption which is often associated with the following conditions l5545addisonian pernicious anemiagastrointestinal pathology dysfunction or surgery including gluten enteropathy or sprue small bowel bacterial overgrowth total or partial gastrectomyfish tapeworm infestationmalignancy of the pancreas or bowelfolic acid deficiencyoral formsvitamin b12 supplements are widely available and indicated in patients who require supplementation for various reasons  dose requirements for vitamin b12 which are higher than normal caused by pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic and renal disease can usually be achieved with oral supplementation l5545   oral products of vitamin b12 are not recommended in patients with malabsorption as these forms are primarily absorbed in the gastrointestinal tract f3739 ')|
|('DB00115', 'MONDO:0003664', ['ANEMIA HEMOLYTIC', 'hemolytic anemia'], 'nasal spraythe cyanocobalamin nasal spray is indicated for the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy in patients with deficiency of this vitamin who have no nervous system involvement fda labelnote  calomist fda label the nasal spray form has not been evaluated for the treatment of newly diagnosed vitamin b12 deficiencyinjection forms subcutaneous intramuscularthese forms are indicated for vitamin b12 deficiencies due to various causes with or without neurologic manifestations f3736  vitamin b12 deficiency is frequently caused by malabsorption which is often associated with the following conditions l5545addisonian pernicious anemiagastrointestinal pathology dysfunction or surgery including gluten enteropathy or sprue small bowel bacterial overgrowth total or partial gastrectomyfish tapeworm infestationmalignancy of the pancreas or bowelfolic acid deficiencyoral formsvitamin b12 supplements are widely available and indicated in patients who require supplementation for various reasons  dose requirements for vitamin b12 which are higher than normal caused by pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic and renal disease can usually be achieved with oral supplementation l5545   oral products of vitamin b12 are not recommended in patients with malabsorption as these forms are primarily absorbed in the gastrointestinal tract f3739 ')|
|('DB01321', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'for the treatment of bacterial infections')|
|('DB01206', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'for the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical andor radiotherapeutic procedures also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed hodgkins disease')|
|('DB01058', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'for the treatment of infections due to all species of schistosoma')|
|('DB01058', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of infections due to all species of schistosoma')|
|('DB00176', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'indicated predominantly for the management of depression and for obsessive compulsive disorder ocd fda label has also been used in the management of bulimia nervosa a250')|
|('DB00176', 'MONDO:0008114', ['Anancastic neurosis', 'obsessive compulsive disorder', 'obsessive-compulsive disorder'], 'indicated predominantly for the management of depression and for obsessive compulsive disorder ocd fda label has also been used in the management of bulimia nervosa a250')|
|('DB00176', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated predominantly for the management of depression and for obsessive compulsive disorder ocd fda label has also been used in the management of bulimia nervosa a250')|
|('DB00176', 'MONDO:0005452', ['hyperorexia nervosa', 'bulimia nervosa'], 'indicated predominantly for the management of depression and for obsessive compulsive disorder ocd fda label has also been used in the management of bulimia nervosa a250')|
|('DB00267', 'MONDO:0005452', ['hyperorexia nervosa', 'bulimia nervosa'], 'used to treat female gynecologic and obstetric infections caused by susceptible aerobic including the gonococcus and anaerobic bacteria')|
|('DB00628', 'MONDO:0005452', ['hyperorexia nervosa', 'bulimia nervosa'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal')|
|('DB00628', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal')|
|('DB01291', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma')|
|('DB01291', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma')|
|('DB01291', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma')|
|('DB00564', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgial1335 in particular carbamazepine has shown efficacy in treating mixed seizures partial seizures with complex symptoms and generalized tonicclonic seizuresa180301l1335 carbamazepine is also indicated for the treatment of manic episodes and mixed manicdepressive episodes caused by bipolar i disorderl1335 some offlabel unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndromea180415a180421')|
|('DB00564', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgial1335 in particular carbamazepine has shown efficacy in treating mixed seizures partial seizures with complex symptoms and generalized tonicclonic seizuresa180301l1335 carbamazepine is also indicated for the treatment of manic episodes and mixed manicdepressive episodes caused by bipolar i disorderl1335 some offlabel unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndromea180415a180421')|
|('DB00564', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgial1335 in particular carbamazepine has shown efficacy in treating mixed seizures partial seizures with complex symptoms and generalized tonicclonic seizuresa180301l1335 carbamazepine is also indicated for the treatment of manic episodes and mixed manicdepressive episodes caused by bipolar i disorderl1335 some offlabel unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndromea180415a180421')|
|('DB00564', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgial1335 in particular carbamazepine has shown efficacy in treating mixed seizures partial seizures with complex symptoms and generalized tonicclonic seizuresa180301l1335 carbamazepine is also indicated for the treatment of manic episodes and mixed manicdepressive episodes caused by bipolar i disorderl1335 some offlabel unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndromea180415a180421')|
|('DB04844', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'treatment of hyperkinetic movement disorders like chorea in huntingtons disease hemiballismus senile chorea tourette syndrome and other tic disorders and tardive dyskinesia ')|
|('DB04844', 'MONDO:0001595', ['chorea', 'hereditary chorea', 'choreatic disease'], 'treatment of hyperkinetic movement disorders like chorea in huntingtons disease hemiballismus senile chorea tourette syndrome and other tic disorders and tardive dyskinesia ')|
|('DB04844', 'MONDO:0007661', ['Guinons disease', 'motor-verbal tic disorder', 'Psychogenic tics', 'Tourette syndrome', 'tourette syndrome'], 'treatment of hyperkinetic movement disorders like chorea in huntingtons disease hemiballismus senile chorea tourette syndrome and other tic disorders and tardive dyskinesia ')|
|('DB04844', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'treatment of hyperkinetic movement disorders like chorea in huntingtons disease hemiballismus senile chorea tourette syndrome and other tic disorders and tardive dyskinesia ')|
|('DB00570', 'MONDO:0007661', ['Guinons disease', 'motor-verbal tic disorder', 'Psychogenic tics', 'Tourette syndrome', 'tourette syndrome'], 'for treatment of breast cancer testicular cancer lymphomas neuroblastoma hodgkins and nonhodgkins lymphomas mycosis fungoides histiocytosis and kaposis sarcoma')|
|('DB00570', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for treatment of breast cancer testicular cancer lymphomas neuroblastoma hodgkins and nonhodgkins lymphomas mycosis fungoides histiocytosis and kaposis sarcoma')|
|('DB00570', 'MONDO:0004992', ['cancer'], 'for treatment of breast cancer testicular cancer lymphomas neuroblastoma hodgkins and nonhodgkins lymphomas mycosis fungoides histiocytosis and kaposis sarcoma')|
|('DB00570', 'MONDO:0005072', ['neuroblastoma'], 'for treatment of breast cancer testicular cancer lymphomas neuroblastoma hodgkins and nonhodgkins lymphomas mycosis fungoides histiocytosis and kaposis sarcoma')|
|('DB00570', 'MONDO:0002637', ['chronic Histiocytosis X', 'Hand Schuller Christian disease', 'histiocytosis'], 'for treatment of breast cancer testicular cancer lymphomas neuroblastoma hodgkins and nonhodgkins lymphomas mycosis fungoides histiocytosis and kaposis sarcoma')|
|('DB04845', 'MONDO:0002637', ['chronic Histiocytosis X', 'Hand Schuller Christian disease', 'histiocytosis'], 'investigated for usetreatment in breast cancer head and neck cancer melanoma lung cancer lymphoma nonhodgkins prostate cancer renal cell carcinoma and cancertumors unspecified')|
|('DB04845', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer head and neck cancer melanoma lung cancer lymphoma nonhodgkins prostate cancer renal cell carcinoma and cancertumors unspecified')|
|('DB04845', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in breast cancer head and neck cancer melanoma lung cancer lymphoma nonhodgkins prostate cancer renal cell carcinoma and cancertumors unspecified')|
|('DB04845', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in breast cancer head and neck cancer melanoma lung cancer lymphoma nonhodgkins prostate cancer renal cell carcinoma and cancertumors unspecified')|
|('DB04845', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in breast cancer head and neck cancer melanoma lung cancer lymphoma nonhodgkins prostate cancer renal cell carcinoma and cancertumors unspecified')|
|('DB01463', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive daytime fatigue lack of concentration and lethargy')|
|('DB06147', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'sulfathiazole is effective against a wide range of gram positive and gram negative pathogenic microorganisms although no longer used in humans it is used in cattle')|
|('DB00705', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of hiv1 infection in combination with appropriate antiretroviral agents when therapy is warranted')|
|('DB08903', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'bedaquiline is indicated as part of combination therapy in adults ≥ 18 years with pulmonary multidrug resistant tuberculosis mdrtb ')|
|('DB00838', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for shortterm topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroidresponsive dermatoses of the scalp')|
|('DB00977', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for treatment of moderate to severe vasomotor symptoms associated with the menopause female hypogonadism prostatic carcinomapalliative therapy of advanced disease breast cancer as an oral contraceptive and as emergency contraceptive')|
|('DB00977', 'MONDO:0002146', ['hypogonadism'], 'for treatment of moderate to severe vasomotor symptoms associated with the menopause female hypogonadism prostatic carcinomapalliative therapy of advanced disease breast cancer as an oral contraceptive and as emergency contraceptive')|
|('DB00977', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for treatment of moderate to severe vasomotor symptoms associated with the menopause female hypogonadism prostatic carcinomapalliative therapy of advanced disease breast cancer as an oral contraceptive and as emergency contraceptive')|
|('DB01613', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for the prevention of angina')|
|('DB01603', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'used to treat infections caused by susceptible grampositive bacteria particularly betalactamaseproducing organisms such as istaphylococcus aureusi that would otherwise be resistant to most penicillins')|
|('DB00199', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005828', ['Infection by Listeria monocytogenes', 'Listeria infection', 'listeriosis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005077', ['bordetella infection', 'WC - Whooping cough', 'whooping cough', 'pertussis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005504', ['corynebacterium infection', 'diphtheria'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0017767', ['ACUTE RHEUMATIC FEVER', 'RhF - Rheumatic fever', 'rheumatic fever'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0002885', ['Infection due to Corynebacterium minutissimum', 'erythrasma'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0021166', ['inflammatory disease []', 'inflammatory disorder []', 'anatomical structure inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'inflammation of anatomical structure []', 'inflammatory disease'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005976', ['syphilitic chancre', 'syphilis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0003799', ['conjunctivitis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB00199', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacterial7261 the indications for erythromycin have been summarized by body system belowrespiratory infectionsmild to moderate upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae or haemophilus influenzae when used concomitantly with appropriate doses of sulfonamides can be treated with erythromycinl7261 mild to moderate lowerrespiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated erythromycin treats listeriosis caused by listeria monocytogenes may also be treated with erythromycinl7261erythromycin is indicated to treat pertussis whooping cough caused by bordetella pertussis it is effective in eliminating the causative organism from the nasopharynx of infected individuals rendering them noninfectious clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacterial7261 respiratory tract infections due to mycoplasma pneumoniae may also be treated with erythromycinl7261  despite the fact that no controlled clinical efficacy studies have been conducted to this date in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  legionnaires’ diseasel7261 finally erythromycin is indicated to treat diphtheria and other infections due to corynebacterium diphtheriae as an adjunct to antitoxin to prevent carrier status and to eradicate the organism in existing carriersl7261 in addition to the prevention of diphtheria erythromycin can be used to prevent rheumatic fever in penicillin intolerant patientsl7261 skin infectionsmild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with erythromycin however resistant staphylococcal organisms may emergel7261 erythromycin can also be used to treat erythrasma an infectious condition caused by corynebacterium minutissimuml7261gastrointestinal infectionsintestinal amebiasis caused by entamoeba histolytica can be treated with oral erythromycin extraenteric amebiasis warrants treatment with other antimicrobial drugsl7261genital infectionsstiserythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillinl7261 syphilis caused by treponema pallidum can be treated with erythromycin  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity erythromycin can also be used in the primary stage of primary syphilisl7261 another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn pneumonia of infancy and urogenital infections occurring in pregnancy it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal urethral and endocervical infections in adults caused by chlamydia trachomatisl7261 erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered finally erythromycin is indicated to treat nongonococcal urethritis due to ureaplasma urealyticuml7261')|
|('DB04843', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for use as adjunctive therapy in the treatment of peptic ulcer it has not been shown to be effective in contributing to the healing of peptic ulcer decreasing the rate of recurrence or preventing complications')|
|('DB04843', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use as adjunctive therapy in the treatment of peptic ulcer it has not been shown to be effective in contributing to the healing of peptic ulcer decreasing the rate of recurrence or preventing complications')|
|('DB00122', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00933', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in the treatment of schizophrenia organic brain disorders alcoholism and psychoneuroses')|
|('DB00933', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used in the treatment of schizophrenia organic brain disorders alcoholism and psychoneuroses')|
|('DB00933', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'used in the treatment of schizophrenia organic brain disorders alcoholism and psychoneuroses')|
|('DB01098', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005015', ['diabetes mellitus'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005311', ['atherosclerosis'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005264', ['TIA', 'TIA - Transient ischaemic attack', 'Transient cerebral ischaemia', 'Transient cerebral ischemia', 'TRANSIENT ISCHEMIC ATTACK', 'transient ischemic attack', 'Transient ischemic attacks', 'transient ischemic attack'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0005350', ['AORTIC ANEURYSM, FAMILIAL ABDOMINAL 1', 'abdominal aortic aneurysm'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB01098', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'the fda monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia and homozygous familial hypercholesterolemiaf4649the health canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol totalc ldlc apob the totalchdlc ratio and triglycerides tg and for increasing hdlc in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate it is also indicated for the prevention of major cardiovascular events including risk of myocardial infarction nonfatal stroke and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events but with at least two conventional risk factors for cardiovascular diseasef4652prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd statinindicated conditions include diabetes mellitus clinical atherosclerosis including myocardial infarction acute coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease and claudication abdominal aortic aneurysm chronic kidney disease and severely elevated ldlc levelsa181087 a181406')|
|('DB00270', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for the management of mild to moderate essential hypertension it may be used alone or concurrently with thiazidetype diuretics')|
|('DB00997', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0005059', ['leukemia'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0004989', ['carcinoma of breast', 'Mammary carcinoma', 'breast carcinoma'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00997', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia acute myeloblastic leukemia wilms’ tumor neuroblastoma soft tissue and bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin’s disease malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer')|
|('DB00209', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and urinary frequency detrusor instability and frequency of micturition')|
|('DB00209', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and urinary frequency detrusor instability and frequency of micturition')|
|('DB00867', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment and prophylaxis of premature labour')|
|('DB01220', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'rifaximin has multiple indications by the fda for the treatment of patients ≥12 years of age with travellers diarrhea caused by noninvasive strains of escherichia coli for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age and in may 2015 it was approved for irritable bowel syndrome with diarrhea ibsd treatment in adult men and women ')|
|('DB01220', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'rifaximin has multiple indications by the fda for the treatment of patients ≥12 years of age with travellers diarrhea caused by noninvasive strains of escherichia coli for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age and in may 2015 it was approved for irritable bowel syndrome with diarrhea ibsd treatment in adult men and women ')|
|('DB01220', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'rifaximin has multiple indications by the fda for the treatment of patients ≥12 years of age with travellers diarrhea caused by noninvasive strains of escherichia coli for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age and in may 2015 it was approved for irritable bowel syndrome with diarrhea ibsd treatment in adult men and women ')|
|('DB01289', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of diabetes mellitus type 2')|
|('DB01289', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of diabetes mellitus type 2')|
|('DB04865', 'MONDO:0005015', ['diabetes mellitus'], 'used in patients who are intolerant andor resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase cml  ')|
|('DB04865', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'used in patients who are intolerant andor resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase cml  ')|
|('DB01544', 'MONDO:0005015', ['diabetes mellitus'], 'for shortterm treatment of severe insomnias that are not responsive to other hypnotics')|
|('DB00170', 'MONDO:0005015', ['diabetes mellitus'], 'the primary known function of vitamin k is to assist in the normal clotting of blood but it may also play a role in normal bone calcification')|
|('DB06714', 'MONDO:0005015', ['diabetes mellitus'], 'it is used to provide temporary symptomatic relief of nasal congestion due to colds allergies and allergic rhinitis')|
|('DB06714', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'it is used to provide temporary symptomatic relief of nasal congestion due to colds allergies and allergic rhinitis')|
|('DB00502', 'MONDO:0005015', ['diabetes mellitus'], 'haloperidol is indicated for a number of conditions including for the treatment of schizophrenia for the manifestations of psychotic disorders for the control of tics and vocal utterances of tourette’s disorder in children and adults for treatment of severe behavior problems in children of combative explosive hyperexcitability which cannot be accounted for by immediate provocation haloperidol is also indicated in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychoticsf4645')|
|('DB00502', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'haloperidol is indicated for a number of conditions including for the treatment of schizophrenia for the manifestations of psychotic disorders for the control of tics and vocal utterances of tourette’s disorder in children and adults for treatment of severe behavior problems in children of combative explosive hyperexcitability which cannot be accounted for by immediate provocation haloperidol is also indicated in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychoticsf4645')|
|('DB00502', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'haloperidol is indicated for a number of conditions including for the treatment of schizophrenia for the manifestations of psychotic disorders for the control of tics and vocal utterances of tourette’s disorder in children and adults for treatment of severe behavior problems in children of combative explosive hyperexcitability which cannot be accounted for by immediate provocation haloperidol is also indicated in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychoticsf4645')|
|('DB01089', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of hypertension')|
|('DB00719', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the relief of the symptoms of upper respiratory mucosal congestion in perennial and allergic rhinitis and for the relief of nasal congestion and eustachian tb congestion')|
|('DB00719', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the relief of the symptoms of upper respiratory mucosal congestion in perennial and allergic rhinitis and for the relief of nasal congestion and eustachian tb congestion')|
|('DB00736', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'esomeprazole is indicated for the treatment of acidreflux disorders including healing and maintenance of erosive esophagitis and symptomatic gastroesophageal reflux disease gerd peptic ulcer disease h pylori eradication prevention of gastrointestinal bleeds with nsaid use and for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome ')|
|('DB00736', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'esomeprazole is indicated for the treatment of acidreflux disorders including healing and maintenance of erosive esophagitis and symptomatic gastroesophageal reflux disease gerd peptic ulcer disease h pylori eradication prevention of gastrointestinal bleeds with nsaid use and for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome ')|
|('DB00736', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'esomeprazole is indicated for the treatment of acidreflux disorders including healing and maintenance of erosive esophagitis and symptomatic gastroesophageal reflux disease gerd peptic ulcer disease h pylori eradication prevention of gastrointestinal bleeds with nsaid use and for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome ')|
|('DB00338', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'omeprazole according to the fda label fda label is a proton pump inhibitor ppi used for the following purposes• treatment of active duodenal ulcer in adults • eradication of helicobacter pylori to reduce the risk of duodenal ulcerrecurrence in adults • treatment of active benign gastric ulcer in adults • treatment of symptomatic gastroesophageal reflux disease gerd inpatients 1 year of age and older • treatment of erosive esophagitis ee due to acidmediated gerd inpatients 1 month of age and older • maintenance of healing of ee due to acidmediated gerd in patients 1year of age and older • pathologic hypersecretory conditions in adults')|
|('DB00338', 'MONDO:0001126', ['acute gastric ulcer with haemorrhage and perforation', 'acute gastric ulcer with hemorrhage AND obstruction', 'acute gastric ulcer with hemorrhage and obstruction', 'acute gastric ulcer with hemorrhage AND perforation', 'acute gastric ulcer with hemorrhage and perforation', 'acute gastric ulcer with hemorrhage and perforation, with obstruction', 'acute gastric ulcer with hemorrhage and perforation, without mention of obstruction', 'acute gastric ulcer with hemorrhage AND with perforation but without obstruction', 'acute gastric ulcer with hemorrhage, with obstruction', 'acute gastric ulcer with hemorrhage, with perforation AND with obstruction', 'acute gastric ulcer with perforation', 'acute gastric ulcer with perforation AND obstruction', 'acute gastric ulcer with perforation, with obstruction', 'acute gastric ulcer without hemorrhage and without perforation', 'acute gastric ulcer without hemorrhage, without perforation AND without obstruction', 'acute gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction', 'bleeding acute gastric ulcer', 'chronic gastric ulcer without hemorrhage AND without perforation', 'chronic gastric ulcer without hemorrhage AND without perforation but with obstruction', 'chronic gastric ulcer without mention of hemorrhage or perforation, with obstruction', 'gastric ulcer'], 'omeprazole according to the fda label fda label is a proton pump inhibitor ppi used for the following purposes• treatment of active duodenal ulcer in adults • eradication of helicobacter pylori to reduce the risk of duodenal ulcerrecurrence in adults • treatment of active benign gastric ulcer in adults • treatment of symptomatic gastroesophageal reflux disease gerd inpatients 1 year of age and older • treatment of erosive esophagitis ee due to acidmediated gerd inpatients 1 month of age and older • maintenance of healing of ee due to acidmediated gerd in patients 1year of age and older • pathologic hypersecretory conditions in adults')|
|('DB00338', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'omeprazole according to the fda label fda label is a proton pump inhibitor ppi used for the following purposes• treatment of active duodenal ulcer in adults • eradication of helicobacter pylori to reduce the risk of duodenal ulcerrecurrence in adults • treatment of active benign gastric ulcer in adults • treatment of symptomatic gastroesophageal reflux disease gerd inpatients 1 year of age and older • treatment of erosive esophagitis ee due to acidmediated gerd inpatients 1 month of age and older • maintenance of healing of ee due to acidmediated gerd in patients 1year of age and older • pathologic hypersecretory conditions in adults')|
|('DB00093', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for use as an alternative to adrenaline as a localising agent provided that local ischaemia is not essential')|
|('DB08893', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'mirabegron is a beta3 adrenergic agonist indicated for the treatment of overactive bladder oab with symptoms of urge urinary incontinence urgency and urinary frequency')|
|('DB08893', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'mirabegron is a beta3 adrenergic agonist indicated for the treatment of overactive bladder oab with symptoms of urge urinary incontinence urgency and urinary frequency')|
|('DB06196', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'approved for use in acute attacks of hereditary angioedema hae investigated for usetreatment in angioedema liver disease and burns and burn infections')|
|('DB06196', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'approved for use in acute attacks of hereditary angioedema hae investigated for usetreatment in angioedema liver disease and burns and burn infections')|
|('DB06196', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'approved for use in acute attacks of hereditary angioedema hae investigated for usetreatment in angioedema liver disease and burns and burn infections')|
|('DB06196', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'approved for use in acute attacks of hereditary angioedema hae investigated for usetreatment in angioedema liver disease and burns and burn infections')|
|('DB00297', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'for the production of local or regional anesthesia or analgesia for surgery for oral surgery procedures for diagnostic and therapeutic procedures and for obstetrical procedures')|
|('DB00297', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for the production of local or regional anesthesia or analgesia for surgery for oral surgery procedures for diagnostic and therapeutic procedures and for obstetrical procedures')|
|('DB01366', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB01366', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB01366', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB01122', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'ambenonium is used to treat muscle weakness due to muscle disease myasthenia gravis')|
|('DB01122', 'MONDO:0009688', ['myasthenia gravis'], 'ambenonium is used to treat muscle weakness due to muscle disease myasthenia gravis')|
|('DB01260', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose')|
|('DB00239', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for treatment of dermal fungal infection')|
|('DB00555', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age partial seizuresprimary generalized tonicclonic seizuresgeneralized seizures of lennoxgastaut syndrome fda labelindicated for conversion to monotherapy in adults ≥16 years of age with partial seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aedfda label indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in adults ≥18 years of age treated for acute mood episodes with standard therapy fda label')|
|('DB00555', 'MONDO:0001866', ['bipolar I disorder'], 'indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age partial seizuresprimary generalized tonicclonic seizuresgeneralized seizures of lennoxgastaut syndrome fda labelindicated for conversion to monotherapy in adults ≥16 years of age with partial seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aedfda label indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in adults ≥18 years of age treated for acute mood episodes with standard therapy fda label')|
|('DB00956', 'MONDO:0001866', ['bipolar I disorder'], 'hydrocodone is indicated for the management of acute pain sometimes in combination with acetaminophen or ibuprofen as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants antihistamines and expectorantslabell7991')|
|('DB00956', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'hydrocodone is indicated for the management of acute pain sometimes in combination with acetaminophen or ibuprofen as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants antihistamines and expectorantslabell7991')|
|('DB00956', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'hydrocodone is indicated for the management of acute pain sometimes in combination with acetaminophen or ibuprofen as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants antihistamines and expectorantslabell7991')|
|('DB00310', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB00310', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB00310', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB00310', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB00310', 'MONDO:0002462', ['glomerulonephritis'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB00310', 'MONDO:0024327', ['chronic renal failure [NCIT:C9438]', 'CRF - chronic renal failure [NCIT:C9438]', 'Chronic renal disease [NCIT:C9438]', 'chronic kidney failure []', 'chronic renal failure disease [NCIT:C9438-modified]', 'kidney failure, chronic [MONDO:patterns/chronic]', 'chronic renal failure syndrome'], 'chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure')|
|('DB01200', 'MONDO:0002462', ['glomerulonephritis'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0009256', ['galactorrhea [MONDO:ambiguous,OMIM:230300]', 'galactorrhea'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0005804', ['hyperprolactinemia [MONDO:ambiguous]', 'hyperprolactinaemia [MESH:D006966]', 'hyperprolactinemia'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0004972', ['acinar cell adenoma', 'acinic cell adenoma', 'adenomas', 'adenoma'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0019933', ['acromegaly'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01200', 'MONDO:0019790', ['neuroleptic malignant syndrome'], 'for the treatment of galactorrhea due to hyperprolactinemia prolactindependent menstrual disorders and infertility prolactinsecreting adenomas prolactindependent male hypogonadism as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications bromocriptine has also been used offlabel to treat restless legs syndrome and neuroleptic malignant syndrome')|
|('DB01412', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'theobromine is used as a vasodilator a diuretic and heart stimulant and similar to caffeine it may be useful in management of fatigue and orthostatic hypotension')|
|('DB01412', 'MONDO:0005469', ['orthostatic hypotension [MONDO:ambiguous]', 'orthostatic hypotension'], 'theobromine is used as a vasodilator a diuretic and heart stimulant and similar to caffeine it may be useful in management of fatigue and orthostatic hypotension')|
|('DB01217', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'anastrozole is indicated as adjunct therapy in the treatment of hormone receptorpositive early breast cancer in postmenopausal women and as a firstline treatment for hormone receptorpositive or hormone receptorunknown locally advanced or metastatic breast cancer in postmenopausal womenl8863 it may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with tamoxifenl8866l8863 ')|
|('DB01217', 'MONDO:0004992', ['cancer'], 'anastrozole is indicated as adjunct therapy in the treatment of hormone receptorpositive early breast cancer in postmenopausal women and as a firstline treatment for hormone receptorpositive or hormone receptorunknown locally advanced or metastatic breast cancer in postmenopausal womenl8863 it may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with tamoxifenl8866l8863 ')|
|('DB00827', 'MONDO:0004992', ['cancer'], 'for the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms iescherichia colii iproteus mirabilisi iproteus vulgarisi iklebsiellai species including ik pneumoniaei and ienterobacteri species')|
|('DB01126', 'MONDO:0004992', ['cancer'], 'indicated for the treatment of symptomatic benign prostatic hyperplasia bph in men with an enlarged prostate gland to improve symptoms and reduce the risk of acute urinary retention and the need for bphrelated surgery alone or in combination with tamsulosinl10568')|
|('DB00568', 'MONDO:0004992', ['cancer'], 'for the treatment of vertigomenieres disease nausea and vomiting motion sickness and also useful for vestibular symptoms of other origins')|
|('DB00568', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for the treatment of vertigomenieres disease nausea and vomiting motion sickness and also useful for vestibular symptoms of other origins')|
|('DB01138', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'for the treatment of gout and gouty arthritis')|
|('DB01138', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of gout and gouty arthritis')|
|('DB08803', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of inflammation of the lining of the nose and paranasal sinuses and allergic inflammation of nasopharyngeal')|
|('DB01030', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinumbased regimens also used as a secondline therapy for treatmentsensitive small cell lung cancer as well as in combination with cisplatin for the treatment of stage ivb recurrent or persistent cervical cancer not amenable to curative treatment with surgery andor radiation therapy')|
|('DB01030', 'MONDO:0004992', ['cancer'], 'for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinumbased regimens also used as a secondline therapy for treatmentsensitive small cell lung cancer as well as in combination with cisplatin for the treatment of stage ivb recurrent or persistent cervical cancer not amenable to curative treatment with surgery andor radiation therapy')|
|('DB01030', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinumbased regimens also used as a secondline therapy for treatmentsensitive small cell lung cancer as well as in combination with cisplatin for the treatment of stage ivb recurrent or persistent cervical cancer not amenable to curative treatment with surgery andor radiation therapy')|
|('DB00829', 'MONDO:0004992', ['cancer'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0045057', ['delirium'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0006496', ['Plegias [MESH:D010243]', 'Plegia [MESH:D010243]', 'palsy'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0003757', ['Paraplegia, lower', 'paraplegia'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0006497', ['infantile cerebral palsy', 'cerebral palsy'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB00829', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'in general diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension excitation agitation fear or aggressiveness such as may occur in psychoneurosis anxiety reactions due to stress conditions and anxiety states with somatic expression f3160moreover in acute alcoholic withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor and impending acute delirium tremens f3160furthermore diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies such as inflammation of the muscle and joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and the rare stiff man syndrome f3160particular label information from the united kingdom also lists particular agespecific indications including for adults 1 the shortterm relief 24 weeks only of anxiety which is severe disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or shortterm psychosomatic organic or psychotic illness 2 cerebral palsy 3 muscle spasm 4 as an adjunct to certain types of epilepsy eg myoclonus 5 symptomatic treatment of acute alcohol withdrawal 6 as oral premedication for the nervous dental patient and 7 for premedication before surgery l5188in the same uk label information diazepam is indicated in children for 1 control of tension and irritability in cerebral spasticity in selected cases 2 as an adjunct to the control of muscle spasm in tetanus and for 3 oral premedication l5188')|
|('DB04839', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the palliative treatment of patients with advanced prostatic carcinoma')|
|('DB04839', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the palliative treatment of patients with advanced prostatic carcinoma')|
|('DB00202', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed includes intubation endoscopies and ect')|
|('DB00939', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the relief of mild to moderate pain for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis')|
|('DB00939', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the relief of mild to moderate pain for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis')|
|('DB00939', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the relief of mild to moderate pain for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis')|
|('DB00835', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of the symptoms of the common cold and allergic rhinitis such as runny nose itchy eyes watery eyes and sneezing')|
|('DB00835', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'for the treatment of the symptoms of the common cold and allergic rhinitis such as runny nose itchy eyes watery eyes and sneezing')|
|('DB00835', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of the symptoms of the common cold and allergic rhinitis such as runny nose itchy eyes watery eyes and sneezing')|
|('DB00119', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for nutritional supplementation also for treating dietary shortage or imbalance')|
|('DB00625', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for use in combination treatment of hiv infection aids')|
|('DB00625', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for use in combination treatment of hiv infection aids')|
|('DB00791', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'used for its antineoplastic properties')|
|('DB06703', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for diagnostic use only indicated for adults and children age 2 and over for contrast enhancement during cranial and spinal mri and for contrastenhanced magnetic resonance angiography cemra gadobutrol is particularly suited for the detection of very small lesions and for the visualization of tumors that do not readily take up contrast media it may be a desired agent when the exclusion or demonstration of an additional pathology may influence the choice of therapy or patient management it may also be suitable for perfusion studies in the diagnosis of stroke detection of focal cerebral ischemia and in studies of tumor perfusion ')|
|('DB06703', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for diagnostic use only indicated for adults and children age 2 and over for contrast enhancement during cranial and spinal mri and for contrastenhanced magnetic resonance angiography cemra gadobutrol is particularly suited for the detection of very small lesions and for the visualization of tumors that do not readily take up contrast media it may be a desired agent when the exclusion or demonstration of an additional pathology may influence the choice of therapy or patient management it may also be suitable for perfusion studies in the diagnosis of stroke detection of focal cerebral ischemia and in studies of tumor perfusion ')|
|('DB00779', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of urinary tract infections caused by susceptible gramnegative microorganisms including the majority of ie colii ienterobacteri species iklebsiellai species and iproteusi species')|
|('DB04573', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'used as a test to determine the general health of an unborn fetus')|
|('DB00676', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'used to kill lice and the mites responsible for the skin condition scabies')|
|('DB00676', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'used to kill lice and the mites responsible for the skin condition scabies')|
|('DB01201', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of pulmonary tuberculosis')|
|('DB01201', 'MONDO:0006052', ['pulmonary tuberculosis'], 'for the treatment of pulmonary tuberculosis')|
|('DB01156', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB01156', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB01156', 'MONDO:0000694', ['winter depression', 'seasonal affective disorder'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB01156', 'MONDO:0005015', ['diabetes mellitus'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB01156', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB01156', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'bupropion is indicated for the treatment of major depressive disorder mdd seasonal affective disorder sad and as an aid to smoking cessation when used in combination with naltrexone as the marketed product contraveⓡ bupropion is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index bmi of 30 kgm2 or greater obese or 27 kgm2 or greater overweight in the presence of at least one weightrelated comorbid condition eg hypertension type 2 diabetes mellitus or dyslipidemiabupropion is also used offlabel as a firstline treatment in patients with adhd and comorbid bipolar disorder when used as an adjunct to mood stabilizersf4624')|
|('DB00950', 'MONDO:0004985', ['bipolar depression', 'bipolar disorder manic phase', 'Manic Bipolar Affective disorder', 'Manic bipolar I disorder', 'manic depression', 'Manic Depressive disorder', 'manic disorder', 'mixed bipolar disorder', 'bipolar disorder'], 'in the united states fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months oldl4269 in canada fexofenadine carries the same indications but is approved only for patients ≥12 years oldl10779 fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years oldl10800')|
|('DB00950', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'in the united states fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months oldl4269 in canada fexofenadine carries the same indications but is approved only for patients ≥12 years oldl10779 fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years oldl10800')|
|('DB00950', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'in the united states fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months oldl4269 in canada fexofenadine carries the same indications but is approved only for patients ≥12 years oldl10779 fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years oldl10800')|
|('DB00715', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'paroxetine is indicated for the management of depression obsessivecompulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorderl3358 one form of paroxetine commercially known as brisdelle is used to manage mild to moderate vasomotor symptoms of menopausel7703 offlabel paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome ibsa1093a181754a181904')|
|('DB00715', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'paroxetine is indicated for the management of depression obsessivecompulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorderl3358 one form of paroxetine commercially known as brisdelle is used to manage mild to moderate vasomotor symptoms of menopausel7703 offlabel paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome ibsa1093a181754a181904')|
|('DB00715', 'MONDO:0001942', ['generalized anxiety disorder'], 'paroxetine is indicated for the management of depression obsessivecompulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorderl3358 one form of paroxetine commercially known as brisdelle is used to manage mild to moderate vasomotor symptoms of menopausel7703 offlabel paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome ibsa1093a181754a181904')|
|('DB00715', 'MONDO:0001780', ['premature ejaculation'], 'paroxetine is indicated for the management of depression obsessivecompulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorderl3358 one form of paroxetine commercially known as brisdelle is used to manage mild to moderate vasomotor symptoms of menopausel7703 offlabel paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome ibsa1093a181754a181904')|
|('DB00715', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'paroxetine is indicated for the management of depression obsessivecompulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorderl3358 one form of paroxetine commercially known as brisdelle is used to manage mild to moderate vasomotor symptoms of menopausel7703 offlabel paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome ibsa1093a181754a181904')|
|('DB01047', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'a topical antiinflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses')|
|('DB01119', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'used parentally to treat hypertensive emergencies also used to treat hypoglycemia secondary to insulinoma')|
|('DB01119', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'used parentally to treat hypertensive emergencies also used to treat hypoglycemia secondary to insulinoma')|
|('DB08806', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'for the treatment of disorders of the upper gastrointestinal region that are due to an excess of hydrochloric acid in the gastric juice ie duodenal ulcers benign gastric ulcers also for prophylaxis of recurrent gastric and duodenal ulcers')|
|('DB01177', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'for the treatment of acute myeloid leukemia aml in adults this includes frenchamericanbritish fab classifications m1 through m7')|
|('DB01177', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for the treatment of acute myeloid leukemia aml in adults this includes frenchamericanbritish fab classifications m1 through m7')|
|('DB00489', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutterlabel there are also oral solutions and intravenous injections indicated for patients requiring sotalol but for whom a tablet would not be appropriatelabell6373l6376')|
|('DB00489', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutterlabel there are also oral solutions and intravenous injections indicated for patients requiring sotalol but for whom a tablet would not be appropriatelabell6373l6376')|
|('DB01256', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo up to 100 cmsup2sup in total area in adults or 2 total body surface area in pediatric patients aged 9 months or older due to staphylococcus aureus methicillinsusceptible isolates only or streptococcus pyogenes')|
|('DB01256', 'MONDO:0004592', ['impetigo'], 'for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo up to 100 cmsup2sup in total area in adults or 2 total body surface area in pediatric patients aged 9 months or older due to staphylococcus aureus methicillinsusceptible isolates only or streptococcus pyogenes')|
|('DB01259', 'MONDO:0004592', ['impetigo'], 'indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 her2 protein and who have received prior therapy including an anthracycline a taxane and trastuzuma')|
|('DB01259', 'MONDO:0004992', ['cancer'], 'indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 her2 protein and who have received prior therapy including an anthracycline a taxane and trastuzuma')|
|('DB00670', 'MONDO:0004992', ['cancer'], 'for the treatment of peptic ulcer gastric ulcer and duodenal ulcer')|
|('DB00670', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of peptic ulcer gastric ulcer and duodenal ulcer')|
|('DB00670', 'MONDO:0005412', ['Curling Ulcer', 'Curlings ulcers', 'Stress Ulcer', 'duodenal ulcer'], 'for the treatment of peptic ulcer gastric ulcer and duodenal ulcer')|
|('DB00217', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the treatment of hypertension')|
|('DB00727', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'nitroglycerin is indicated for various purposesl4894 it is indicated to prevent and treat angina or chest pain due to cardiovascular disease as well as to treat perioperative hypertension or induce intraoperative hypotensionl4429l7099 it is also indicated to treat acute heart failure in patients with myocardial infarctionl7099 in the ointment form nitroglycerin is indicated to treat pain caused by anal fissuresl7096 the transdermal form is applied directly to the skin to prevent acute anginal attacksl7141 the intravenous form is used offlabel in emergency settings and is commonly used to treat acute coronary spasm caused by cocaine hypertensive emergencies as well as acute congestive heart failure exacerbationst628 some other offlabel uses of nitroglycerin include management of variceal hemorrhagea180280 management of esophageal spasticitya180283 and induction of uterine relaxationa180277')|
|('DB00727', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'nitroglycerin is indicated for various purposesl4894 it is indicated to prevent and treat angina or chest pain due to cardiovascular disease as well as to treat perioperative hypertension or induce intraoperative hypotensionl4429l7099 it is also indicated to treat acute heart failure in patients with myocardial infarctionl7099 in the ointment form nitroglycerin is indicated to treat pain caused by anal fissuresl7096 the transdermal form is applied directly to the skin to prevent acute anginal attacksl7141 the intravenous form is used offlabel in emergency settings and is commonly used to treat acute coronary spasm caused by cocaine hypertensive emergencies as well as acute congestive heart failure exacerbationst628 some other offlabel uses of nitroglycerin include management of variceal hemorrhagea180280 management of esophageal spasticitya180283 and induction of uterine relaxationa180277')|
|('DB00727', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'nitroglycerin is indicated for various purposesl4894 it is indicated to prevent and treat angina or chest pain due to cardiovascular disease as well as to treat perioperative hypertension or induce intraoperative hypotensionl4429l7099 it is also indicated to treat acute heart failure in patients with myocardial infarctionl7099 in the ointment form nitroglycerin is indicated to treat pain caused by anal fissuresl7096 the transdermal form is applied directly to the skin to prevent acute anginal attacksl7141 the intravenous form is used offlabel in emergency settings and is commonly used to treat acute coronary spasm caused by cocaine hypertensive emergencies as well as acute congestive heart failure exacerbationst628 some other offlabel uses of nitroglycerin include management of variceal hemorrhagea180280 management of esophageal spasticitya180283 and induction of uterine relaxationa180277')|
|('DB00528', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of hypertension management of angina pectoris and raynauds syndrome')|
|('DB00528', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'for the treatment of hypertension management of angina pectoris and raynauds syndrome')|
|('DB01424', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'formerly widely used as an antipyretic and analgesic in rheumatism neuritis and common colds currently used to measure total body water')|
|('DB01424', 'MONDO:0002122', ['peripheral neuritis', 'neuritis'], 'formerly widely used as an antipyretic and analgesic in rheumatism neuritis and common colds currently used to measure total body water')|
|('DB01424', 'MONDO:0021137', ['common []', 'not rare'], 'formerly widely used as an antipyretic and analgesic in rheumatism neuritis and common colds currently used to measure total body water')|
|('DB00856', 'MONDO:0021137', ['common []', 'not rare'], 'used along with rest and physical therapy to treat injuries and other painful muscular conditions investigated for use in trigeminal neuralgia tic douloureux a neuropathic disorder characterized by severe facial pain was investigated as a modulator of histamine release')|
|('DB00856', 'MONDO:0021667', ['neuralgia []', 'neuralgia'], 'used along with rest and physical therapy to treat injuries and other painful muscular conditions investigated for use in trigeminal neuralgia tic douloureux a neuropathic disorder characterized by severe facial pain was investigated as a modulator of histamine release')|
|('DB06716', 'MONDO:0021667', ['neuralgia []', 'neuralgia'], 'for monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy ')|
|('DB00375', 'MONDO:0021667', ['neuralgia []', 'neuralgia'], 'colestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and lowdensity lipoprotein cholesterol ldlc in patients with primary hypercholesterolemia a condition that features elevated ldlc who do not respond adequately to diet fda label l6115 f4555therapy with lipidaltering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia fda label l6115 f4555 treatment should begin and continue with dietary therapy fda label l6115 f4555 in general a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol fda label f4555 shorter periods may be considered in patients with severe elevations of ldlc or with definite coronary heart disease fda label f4555although colestipol is effective in all types of hypercholesterolemia some regional prescribing information note in particular that it is medically most appropriate in patients with fredricksons type ii hyperlipoproteinemia l6115 nevertheless in patients with combined hypercholesterolemia and hypertriglyceridemia although colestipol may be helpful in reducing elevated cholesterol it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern f4567')|
|('DB00375', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'colestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and lowdensity lipoprotein cholesterol ldlc in patients with primary hypercholesterolemia a condition that features elevated ldlc who do not respond adequately to diet fda label l6115 f4555therapy with lipidaltering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia fda label l6115 f4555 treatment should begin and continue with dietary therapy fda label l6115 f4555 in general a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol fda label f4555 shorter periods may be considered in patients with severe elevations of ldlc or with definite coronary heart disease fda label f4555although colestipol is effective in all types of hypercholesterolemia some regional prescribing information note in particular that it is medically most appropriate in patients with fredricksons type ii hyperlipoproteinemia l6115 nevertheless in patients with combined hypercholesterolemia and hypertriglyceridemia although colestipol may be helpful in reducing elevated cholesterol it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern f4567')|
|('DB00375', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'colestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and lowdensity lipoprotein cholesterol ldlc in patients with primary hypercholesterolemia a condition that features elevated ldlc who do not respond adequately to diet fda label l6115 f4555therapy with lipidaltering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia fda label l6115 f4555 treatment should begin and continue with dietary therapy fda label l6115 f4555 in general a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol fda label f4555 shorter periods may be considered in patients with severe elevations of ldlc or with definite coronary heart disease fda label f4555although colestipol is effective in all types of hypercholesterolemia some regional prescribing information note in particular that it is medically most appropriate in patients with fredricksons type ii hyperlipoproteinemia l6115 nevertheless in patients with combined hypercholesterolemia and hypertriglyceridemia although colestipol may be helpful in reducing elevated cholesterol it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern f4567')|
|('DB00375', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'colestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and lowdensity lipoprotein cholesterol ldlc in patients with primary hypercholesterolemia a condition that features elevated ldlc who do not respond adequately to diet fda label l6115 f4555therapy with lipidaltering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia fda label l6115 f4555 treatment should begin and continue with dietary therapy fda label l6115 f4555 in general a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol fda label f4555 shorter periods may be considered in patients with severe elevations of ldlc or with definite coronary heart disease fda label f4555although colestipol is effective in all types of hypercholesterolemia some regional prescribing information note in particular that it is medically most appropriate in patients with fredricksons type ii hyperlipoproteinemia l6115 nevertheless in patients with combined hypercholesterolemia and hypertriglyceridemia although colestipol may be helpful in reducing elevated cholesterol it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern f4567')|
|('DB00236', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'for the treatment of polycythaemia vera and refractory chronic myeloid leukaemia')|
|('DB00236', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'for the treatment of polycythaemia vera and refractory chronic myeloid leukaemia')|
|('DB01227', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'for the treatment and management of opiate dependence it is sometimes used to treat severe pain in terminal patients')|
|('DB01227', 'MONDO:0005530', ['Opioid type dependence', 'opiate dependence'], 'for the treatment and management of opiate dependence it is sometimes used to treat severe pain in terminal patients')|
|('DB01501', 'MONDO:0005530', ['Opioid type dependence', 'opiate dependence'], 'motofenr is a combination of atropine an anticholinergic drug and difenoxin an antidiarrheal drug it has been used in many countries for many years as a second line opioidagonist antidiarrheal which exists an intermediate between loperamide and paragoric 2diarrhea which is a result of cyclic or diarrhea predominant inflammatory bowel syndrome may not be treated effectively with difenoxin diphenoxylate or loperamide as such diarrhea and cramping which does not respond to noncentrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine in patients with acute ulcerative colitis as induction of toxic megacolon is possible and thus use of motofenr is cautioned  motofenr has been assigned pregnancy category c by the fda and is to be used only when the potential benefits outweigh the potential risk to the fetus the safety of use during lactation is unknown and thus not recommended ')|
|('DB01501', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'motofenr is a combination of atropine an anticholinergic drug and difenoxin an antidiarrheal drug it has been used in many countries for many years as a second line opioidagonist antidiarrheal which exists an intermediate between loperamide and paragoric 2diarrhea which is a result of cyclic or diarrhea predominant inflammatory bowel syndrome may not be treated effectively with difenoxin diphenoxylate or loperamide as such diarrhea and cramping which does not respond to noncentrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine in patients with acute ulcerative colitis as induction of toxic megacolon is possible and thus use of motofenr is cautioned  motofenr has been assigned pregnancy category c by the fda and is to be used only when the potential benefits outweigh the potential risk to the fetus the safety of use during lactation is unknown and thus not recommended ')|
|('DB01501', 'MONDO:0005292', ['colitis'], 'motofenr is a combination of atropine an anticholinergic drug and difenoxin an antidiarrheal drug it has been used in many countries for many years as a second line opioidagonist antidiarrheal which exists an intermediate between loperamide and paragoric 2diarrhea which is a result of cyclic or diarrhea predominant inflammatory bowel syndrome may not be treated effectively with difenoxin diphenoxylate or loperamide as such diarrhea and cramping which does not respond to noncentrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine in patients with acute ulcerative colitis as induction of toxic megacolon is possible and thus use of motofenr is cautioned  motofenr has been assigned pregnancy category c by the fda and is to be used only when the potential benefits outweigh the potential risk to the fetus the safety of use during lactation is unknown and thus not recommended ')|
|('DB01501', 'MONDO:0002105', ['toxic megacolon'], 'motofenr is a combination of atropine an anticholinergic drug and difenoxin an antidiarrheal drug it has been used in many countries for many years as a second line opioidagonist antidiarrheal which exists an intermediate between loperamide and paragoric 2diarrhea which is a result of cyclic or diarrhea predominant inflammatory bowel syndrome may not be treated effectively with difenoxin diphenoxylate or loperamide as such diarrhea and cramping which does not respond to noncentrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine in patients with acute ulcerative colitis as induction of toxic megacolon is possible and thus use of motofenr is cautioned  motofenr has been assigned pregnancy category c by the fda and is to be used only when the potential benefits outweigh the potential risk to the fetus the safety of use during lactation is unknown and thus not recommended ')|
|('DB01188', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement due to itrichophyton rubrumi')|
|('DB05271', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for usetreatment in neurologic disorders and parkinsons disease as well as moderatetosevere primary restless legs syndrome')|
|('DB01136', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'carvedilol is indicated to treat mild to severe heart failure left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40 or hypertensionl7889l7892')|
|('DB01136', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'carvedilol is indicated to treat mild to severe heart failure left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40 or hypertensionl7889l7892')|
|('DB00397', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of nasal congestion control of urinary incontinence priapism and obesity')|
|('DB00397', 'MONDO:0004745', ['Mentulagra', 'priapism'], 'for the treatment of nasal congestion control of urinary incontinence priapism and obesity')|
|('DB00805', 'MONDO:0004745', ['Mentulagra', 'priapism'], 'for the treatment of depression')|
|('DB01254', 'MONDO:0004745', ['Mentulagra', 'priapism'], 'for the treatment of adults with chronic accelerated or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy also indicated for the treatment of adults with philadelphia chromosomepositive acute lymphoblastic leukemia with resistance or intolerance to prior therapy')|
|('DB01254', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of adults with chronic accelerated or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy also indicated for the treatment of adults with philadelphia chromosomepositive acute lymphoblastic leukemia with resistance or intolerance to prior therapy')|
|('DB00460', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to agerelated macular degeneration pathologic myopia or presumed ocular histoplasmosis syndrome verteporfin can also be used to destroy tumors')|
|('DB00460', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to agerelated macular degeneration pathologic myopia or presumed ocular histoplasmosis syndrome verteporfin can also be used to destroy tumors')|
|('DB00460', 'MONDO:0001384', ['near vision', 'near-sightedness', 'short-sightedness', 'myopia'], 'for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to agerelated macular degeneration pathologic myopia or presumed ocular histoplasmosis syndrome verteporfin can also be used to destroy tumors')|
|('DB00460', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to agerelated macular degeneration pathologic myopia or presumed ocular histoplasmosis syndrome verteporfin can also be used to destroy tumors')|
|('DB01330', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for prophylaxis and treatment of bacterial infections')|
|('DB00775', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for treatment in combination with heparin of acute coronary syndrome including patients who are to be managed medically and those undergoing ptca or atherectomy')|
|('DB00775', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'for treatment in combination with heparin of acute coronary syndrome including patients who are to be managed medically and those undergoing ptca or atherectomy')|
|('DB00513', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'for use in the treatment of excessive postoperative bleeding')|
|('DB00221', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'for the treatment of asthma wheezing and chronic asthmatic bronchitis')|
|('DB00221', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of asthma wheezing and chronic asthmatic bronchitis')|
|('DB00221', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'for the treatment of asthma wheezing and chronic asthmatic bronchitis')|
|('DB06718', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'stanozolol is a synthetic anabolic steroid with therapeutic uses in treating c1inhibitor deficient hereditary angioedema c1inhibitor is a protease that inhibits the complement system part of the innate immune system a biochemical chain of reactions which assists the body in removing pathogens from the body stanozolol may help control attacks of hereditary angioedema  stanozolol can be administered orally or intramuscularly ')|
|('DB06718', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'stanozolol is a synthetic anabolic steroid with therapeutic uses in treating c1inhibitor deficient hereditary angioedema c1inhibitor is a protease that inhibits the complement system part of the innate immune system a biochemical chain of reactions which assists the body in removing pathogens from the body stanozolol may help control attacks of hereditary angioedema  stanozolol can be administered orally or intramuscularly ')|
|('DB06718', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'stanozolol is a synthetic anabolic steroid with therapeutic uses in treating c1inhibitor deficient hereditary angioedema c1inhibitor is a protease that inhibits the complement system part of the innate immune system a biochemical chain of reactions which assists the body in removing pathogens from the body stanozolol may help control attacks of hereditary angioedema  stanozolol can be administered orally or intramuscularly ')|
|('DB06718', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'stanozolol is a synthetic anabolic steroid with therapeutic uses in treating c1inhibitor deficient hereditary angioedema c1inhibitor is a protease that inhibits the complement system part of the innate immune system a biochemical chain of reactions which assists the body in removing pathogens from the body stanozolol may help control attacks of hereditary angioedema  stanozolol can be administered orally or intramuscularly ')|
|('DB01019', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of acute postoperative and postpartum nonobstructive functional urinary retention and for neurogenic atony of the urinary bladder with retention')|
|('DB06207', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'treatment for symptomatic relief of benign prostatic hyperplasia ')|
|('DB06207', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'treatment for symptomatic relief of benign prostatic hyperplasia ')|
|('DB00323', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as an adjunct to levodopacarbidopa therapy for the symptomatic treatment of parkinsons disease this drug is generally reserved for patients with parkinsonian syndrome receiving levodopacarbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies')|
|('DB01326', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of serious infections caused by susceptible strains of  microorganisms')|
|('DB01090', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to produce controlled hypotension during surgical procedures and in hypertensive crises')|
|('DB01090', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'used to produce controlled hypotension during surgical procedures and in hypertensive crises')|
|('DB00577', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'valacyclovir is a nucleoside analog dna polymerase inhibitor indicated for fda label adults• cold sores herpes labialis• genital herpes• treatment of genital herpes lesions in immunocompetent patients initial or recurrent episode• suppression of genital herpes lesions in immunocompetent or hivinfected patients• reduction of viral transmission• herpes zosterpediatric patients • cold sores herpes labialis• chickenpox limitations of use fda labelthe efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients')|
|('DB00577', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'valacyclovir is a nucleoside analog dna polymerase inhibitor indicated for fda label adults• cold sores herpes labialis• genital herpes• treatment of genital herpes lesions in immunocompetent patients initial or recurrent episode• suppression of genital herpes lesions in immunocompetent or hivinfected patients• reduction of viral transmission• herpes zosterpediatric patients • cold sores herpes labialis• chickenpox limitations of use fda labelthe efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients')|
|('DB00577', 'MONDO:0005770', ['Genital herpes simplex', 'Herpes Genitalis', 'venereal herpes', 'Virus-Genital Herpes', 'genital herpes'], 'valacyclovir is a nucleoside analog dna polymerase inhibitor indicated for fda label adults• cold sores herpes labialis• genital herpes• treatment of genital herpes lesions in immunocompetent patients initial or recurrent episode• suppression of genital herpes lesions in immunocompetent or hivinfected patients• reduction of viral transmission• herpes zosterpediatric patients • cold sores herpes labialis• chickenpox limitations of use fda labelthe efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients')|
|('DB00577', 'MONDO:0005700', ['varicella', 'chickenpox'], 'valacyclovir is a nucleoside analog dna polymerase inhibitor indicated for fda label adults• cold sores herpes labialis• genital herpes• treatment of genital herpes lesions in immunocompetent patients initial or recurrent episode• suppression of genital herpes lesions in immunocompetent or hivinfected patients• reduction of viral transmission• herpes zosterpediatric patients • cold sores herpes labialis• chickenpox limitations of use fda labelthe efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients')|
|('DB00599', 'MONDO:0005700', ['varicella', 'chickenpox'], 'for use as the sole anesthetic agent for brief 15 minute procedures for induction of anesthesia prior to administration of other anesthetic agents to supplement regional anesthesia to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation for the control of convulsive states during or following inhalation anesthesia or local anesthesia in neurosurgical patients with increased intracranial pressure and for narcoanalysis and narcosynthesis in psychiatric disorders')|
|('DB00599', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'for use as the sole anesthetic agent for brief 15 minute procedures for induction of anesthesia prior to administration of other anesthetic agents to supplement regional anesthesia to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation for the control of convulsive states during or following inhalation anesthesia or local anesthesia in neurosurgical patients with increased intracranial pressure and for narcoanalysis and narcosynthesis in psychiatric disorders')|
|('DB01011', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'used as a diagnostic drug for testing hypothalamicpituitary acth function occasionally used in cushings syndrome')|
|('DB00855', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp')|
|('DB00855', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp')|
|('DB01427', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'used in the treatment of congestive heart failure')|
|('DB01427', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'used in the treatment of congestive heart failure')|
|('DB06605', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation prophylaxis of deep vein thrombosisdvt leading to pulmonary embolismpe in patients after a hip or knee replacement surgery and treatment of dvt and pe to reduce the risk of recurrencelabela177565a6897')|
|('DB06605', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation prophylaxis of deep vein thrombosisdvt leading to pulmonary embolismpe in patients after a hip or knee replacement surgery and treatment of dvt and pe to reduce the risk of recurrencelabela177565a6897')|
|('DB06605', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation prophylaxis of deep vein thrombosisdvt leading to pulmonary embolismpe in patients after a hip or knee replacement surgery and treatment of dvt and pe to reduce the risk of recurrencelabela177565a6897')|
|('DB06590', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms')|
|('DB00241', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'indicated for the management of the symptom complex of tension or muscle contraction headache when other nonopioid analgesics and alternative treatments are inadequate in various combinations with acetaminophen aspirin caffeine and codeine l10370')|
|('DB00147', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'pyridoxal is one of the natural forms available of vitamin b6 therefore it is used for nutritional supplementation and for treating dietary shortage or imbalances')|
|('DB01303', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'used to treat the symptoms of asthma bronchitis copd and emphysema')|
|('DB01303', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used to treat the symptoms of asthma bronchitis copd and emphysema')|
|('DB01303', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used to treat the symptoms of asthma bronchitis copd and emphysema')|
|('DB00203', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0005362', ['erectile dysfunction', 'Sexual impotence', 'erectile dysfunction'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0005149', ['pulmonary hypertension'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0003900', ['connective tissue disorder', 'disorder of connective tissue', 'connective tissue disease'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0017147', ['primary pulmonary arterial hypertension [Orphanet:275766]', 'IPAH [Orphanet:275766]', 'idiopathic pulmonary arterial hypertension'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00203', 'MONDO:0021140', ['inborn []', 'congenital'], 'sildenafil is a phosphodiesterase5 pde5 inhibitor that is predominantly employed for two primary indications1 the treatment of erectile dysfunction a175582 l5611 f3853 f3856 f3886 and2 treatment of pulmonary hypertension wherea the us fda specifically indicates sildenafil for the treatment of pulmonary arterial hypertension pah who group i in adults to improve exercise ability and delay clinical worsening f3850 the delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy f3850 studies establishing effectiveness were shortterm 12 to 16 weeks and included predominately patients with new york heart association nyha functional class iiiii symptoms and idiopathic etiology 71 or associated with connective tissue disease ctd 25 f3850b the canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension pph or pulmonary hypertension secondary to connective tissue disease ctd in adult patients with who functional class ii or iii who have not responded to conventional therapy f3859 in addition improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy f3859 andc the ema product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii to improve exercise capacity f3883 efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease f3883 the ema label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension f3883 efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease f3883')|
|('DB00337', 'MONDO:0021140', ['inborn []', 'congenital'], 'for treatment of mild to moderate atopic dermatitis')|
|('DB00337', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for treatment of mild to moderate atopic dermatitis')|
|('DB00572', 'MONDO:0021140', ['inborn []', 'congenital'], 'for the treatment of poisoning by susceptible organophosphorous nerve agents having anticholinesterase activity cholinesterase inhibitors as well as organophosphorous or carbamate insecticides')|
|('DB00572', 'MONDO:0029000', ['poisoning'], 'for the treatment of poisoning by susceptible organophosphorous nerve agents having anticholinesterase activity cholinesterase inhibitors as well as organophosphorous or carbamate insecticides')|
|('DB06708', 'MONDO:0029000', ['poisoning'], 'lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB06708', 'MONDO:0005136', ['induced malaria', 'malaria'], 'lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB06708', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB00864', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use after allogenic organ transplant to reduce the activity of the patients immune system and so the risk of organ rejection it was given fda approval in 1994 for use in liver transplantation since then this indication has expanded to kidney heart small bowel pancreas lung trachea skin cornea and limb transplants it has also been used in a topical preparation in the treatment of severe atopic dermatitis')|
|('DB00864', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for use after allogenic organ transplant to reduce the activity of the patients immune system and so the risk of organ rejection it was given fda approval in 1994 for use in liver transplantation since then this indication has expanded to kidney heart small bowel pancreas lung trachea skin cornea and limb transplants it has also been used in a topical preparation in the treatment of severe atopic dermatitis')|
|('DB01413', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of pneumonia moderate to severe caused by istreptococcus pneumoniaei including cases associated with concurrent bacteremia ipseudomonas aeruginosai iklebsiella pneumoniaei or ienterobacteri species also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections including pyelonephritis caused by iescherichia colii or iklebsiella pneumoniaei when the infection is severe or caused by iescherichia colii iklebsiella pneumoniaei or iproteus mirabilisi when the infection is mild to moderate including cases associated with concurrent bacteremia with these microorganisms also for the treatment of uncomplicated skin and skin structure infections caused by istaphylococcus aureusi methicillinsusceptible strains only or istreptococcus pyogenesi and complicated intraabdominal infections used in combination with metronidazole caused by iescherichia colii viridans group streptococci ipseudomonas aeruginosai iklebsiella pneumoniaei ienterobacteri species or ibacteroides fragilisi')|
|('DB01413', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of pneumonia moderate to severe caused by istreptococcus pneumoniaei including cases associated with concurrent bacteremia ipseudomonas aeruginosai iklebsiella pneumoniaei or ienterobacteri species also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections including pyelonephritis caused by iescherichia colii or iklebsiella pneumoniaei when the infection is severe or caused by iescherichia colii iklebsiella pneumoniaei or iproteus mirabilisi when the infection is mild to moderate including cases associated with concurrent bacteremia with these microorganisms also for the treatment of uncomplicated skin and skin structure infections caused by istaphylococcus aureusi methicillinsusceptible strains only or istreptococcus pyogenesi and complicated intraabdominal infections used in combination with metronidazole caused by iescherichia colii viridans group streptococci ipseudomonas aeruginosai iklebsiella pneumoniaei ienterobacteri species or ibacteroides fragilisi')|
|('DB01413', 'MONDO:0006939', ['pyelonephritis'], 'for the treatment of pneumonia moderate to severe caused by istreptococcus pneumoniaei including cases associated with concurrent bacteremia ipseudomonas aeruginosai iklebsiella pneumoniaei or ienterobacteri species also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections including pyelonephritis caused by iescherichia colii or iklebsiella pneumoniaei when the infection is severe or caused by iescherichia colii iklebsiella pneumoniaei or iproteus mirabilisi when the infection is mild to moderate including cases associated with concurrent bacteremia with these microorganisms also for the treatment of uncomplicated skin and skin structure infections caused by istaphylococcus aureusi methicillinsusceptible strains only or istreptococcus pyogenesi and complicated intraabdominal infections used in combination with metronidazole caused by iescherichia colii viridans group streptococci ipseudomonas aeruginosai iklebsiella pneumoniaei ienterobacteri species or ibacteroides fragilisi')|
|('DB00350', 'MONDO:0006939', ['pyelonephritis'], 'for the treatment of severe hypertension and in the topical treatment regrowth of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia')|
|('DB00350', 'MONDO:0004907', ['alopecia'], 'for the treatment of severe hypertension and in the topical treatment regrowth of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia')|
|('DB00511', 'MONDO:0004907', ['alopecia'], 'used for fast digitalization in congestive heart failure')|
|('DB00511', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'used for fast digitalization in congestive heart failure')|
|('DB01149', 'MONDO:0004907', ['alopecia'], 'for the treatment of depression')|
|('DB00189', 'MONDO:0004907', ['alopecia'], 'used for shortterm hypnotic therapy in the management of insomnia for periods of up to one week in duration however this medication generally has been replaced by other sedativehypnotic agents')|
|('DB00189', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used for shortterm hypnotic therapy in the management of insomnia for periods of up to one week in duration however this medication generally has been replaced by other sedativehypnotic agents')|
|('DB00189', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for shortterm hypnotic therapy in the management of insomnia for periods of up to one week in duration however this medication generally has been replaced by other sedativehypnotic agents')|
|('DB00861', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for symptomatic treatment of mild to moderate pain accompanied by inflammation eg musculoskeletal trauma postdental extraction postepisiotomy osteoarthritis and rheumatoid arthritis')|
|('DB00861', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for symptomatic treatment of mild to moderate pain accompanied by inflammation eg musculoskeletal trauma postdental extraction postepisiotomy osteoarthritis and rheumatoid arthritis')|
|('DB00861', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for symptomatic treatment of mild to moderate pain accompanied by inflammation eg musculoskeletal trauma postdental extraction postepisiotomy osteoarthritis and rheumatoid arthritis')|
|('DB06144', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used in the treatment of schizophrenia')|
|('DB06144', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used in the treatment of schizophrenia')|
|('DB01091', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the topical treatment of the following dermatologic infections tinea pityriasis versicolor due to im furfuri interdigital tinea pedis athletersquos foot tinea corporis ringworm and tinea cruris jock itch due to ie floccosumi it mentagrophytesi it rubrumi and it tonsuransi')|
|('DB01091', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'for the topical treatment of the following dermatologic infections tinea pityriasis versicolor due to im furfuri interdigital tinea pedis athletersquos foot tinea corporis ringworm and tinea cruris jock itch due to ie floccosumi it mentagrophytesi it rubrumi and it tonsuransi')|
|('DB01091', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for the topical treatment of the following dermatologic infections tinea pityriasis versicolor due to im furfuri interdigital tinea pedis athletersquos foot tinea corporis ringworm and tinea cruris jock itch due to ie floccosumi it mentagrophytesi it rubrumi and it tonsuransi')|
|('DB00279', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0021140', ['inborn []', 'congenital'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0015595', ['pale [Orphanet:163921]', 'posttransplant acute limbic encephalitis'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0005397', ['goitre', 'goiter'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00279', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'liothyronine is officially approved for the following indications replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomyfda labelin general terms exogenous liothyronine is used to replace insufficient hormonal production and restore t3 plasma levelst457the lack of liothyronine can be presented as a pale and puffy face coarse  brittle hair dry skin croaky voice and constipation as well as irregular periods drowsiness and lethargyt457liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodinesufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditisfda label')|
|('DB00763', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'in the united states methimazole is indicated for the treatment of hyperthyroidism in patients with graves disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options methimazole is also indicated for the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapyl8336in canada methimazole carries the above indications and is also indicated for the medical treatment of hyperthyroidism regardless of other available treatment optionsl8339')|
|('DB00763', 'MONDO:0005364', ['exophthalmic goiter', 'Graves disease', 'Graves disease', 'graves disease'], 'in the united states methimazole is indicated for the treatment of hyperthyroidism in patients with graves disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options methimazole is also indicated for the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapyl8336in canada methimazole carries the above indications and is also indicated for the medical treatment of hyperthyroidism regardless of other available treatment optionsl8339')|
|('DB00763', 'MONDO:0005397', ['goitre', 'goiter'], 'in the united states methimazole is indicated for the treatment of hyperthyroidism in patients with graves disease or toxic multinodular goiter for whom thyroidectomy or radioactive iodine therapy are not appropriate treatment options methimazole is also indicated for the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapyl8336in canada methimazole carries the above indications and is also indicated for the medical treatment of hyperthyroidism regardless of other available treatment optionsl8339')|
|('DB00772', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'for patients infected with pediculus humanus capitis head lice and their ova of the scalp hair')|
|('DB08823', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'spinosad is indicated for the topical treatment of head lice in children four years old and over and in adults')|
|('DB00844', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'for the relief of moderate to severe pain')|
|('DB01624', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'used in the management of acute psychoses such as mania or schizophrenia however the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments haloperidol clotiapine etc should be cautioned since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted zuclopenthixol acetate is not intended for longterm use')|
|('DB01624', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used in the management of acute psychoses such as mania or schizophrenia however the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments haloperidol clotiapine etc should be cautioned since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted zuclopenthixol acetate is not intended for longterm use')|
|('DB00890', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for use in the treatment of atrophic vaginitis and kraurosis vulvae')|
|('DB00890', 'MONDO:0001410', ['atrophic vaginitis', 'Senile vaginitis', 'postmenopausal atrophic vaginitis'], 'for use in the treatment of atrophic vaginitis and kraurosis vulvae')|
|('DB01511', 'MONDO:0001410', ['atrophic vaginitis', 'Senile vaginitis', 'postmenopausal atrophic vaginitis'], 'mainly used as an antianxiety agent studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants however after 4 weeks antidepressants showed superior antianxiety effects wikipedia antianxiety effects also appear to be weaker in elderly patients 1effectiveness has also been observed in the treatment of alcohol withdrawal delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal 3')|
|('DB01511', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mainly used as an antianxiety agent studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants however after 4 weeks antidepressants showed superior antianxiety effects wikipedia antianxiety effects also appear to be weaker in elderly patients 1effectiveness has also been observed in the treatment of alcohol withdrawal delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal 3')|
|('DB01511', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'mainly used as an antianxiety agent studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants however after 4 weeks antidepressants showed superior antianxiety effects wikipedia antianxiety effects also appear to be weaker in elderly patients 1effectiveness has also been observed in the treatment of alcohol withdrawal delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal 3')|
|('DB00229', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'for treatment of severe infections caused by susceptible bacteria')|
|('DB01606', 'MONDO:0005433', ['alcohol withdrawal syndrome []', 'alcohol withdrawal'], 'tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action treating susceptible infections as with any other antibiotic tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drugtazobactampiperacillinwhen combined with piperacillin it is used to treat a variety of infections including those caused by aerobic and facultative grampositive and gramnegative bacteria in addition to grampositive and gramnegative anaerobes some examples of infections treated with piperacillintazobactam include cellulitis diabetic foot infections appendicitis and postpartum endometritis infectionsl4417 certain gramnegative bacilli infections with betalactamase producing organisms cannot be treated with piperacillintazobactam due to a gene mutation conferring antibiotic resistancea179266tazobactamceftolozanetazobactamceftolozane combined with metronidazole is used to treat complicated urinary tract infections uti and complicated intraabdominal infections as well as ventilatorassociated bacterial pneumonia and hospitalacquired bacterial pneumoniafda label this combination increases efficacy against infections with gramnegative bacillia7657')|
|('DB01606', 'MONDO:0005230', ['cellulitis'], 'tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action treating susceptible infections as with any other antibiotic tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drugtazobactampiperacillinwhen combined with piperacillin it is used to treat a variety of infections including those caused by aerobic and facultative grampositive and gramnegative bacteria in addition to grampositive and gramnegative anaerobes some examples of infections treated with piperacillintazobactam include cellulitis diabetic foot infections appendicitis and postpartum endometritis infectionsl4417 certain gramnegative bacilli infections with betalactamase producing organisms cannot be treated with piperacillintazobactam due to a gene mutation conferring antibiotic resistancea179266tazobactamceftolozanetazobactamceftolozane combined with metronidazole is used to treat complicated urinary tract infections uti and complicated intraabdominal infections as well as ventilatorassociated bacterial pneumonia and hospitalacquired bacterial pneumoniafda label this combination increases efficacy against infections with gramnegative bacillia7657')|
|('DB01606', 'MONDO:0005649', ['acute appendicitis', 'acute appendicitis with generalized peritonitis', 'acute appendicitis with peritoneal abscess', 'appendicitis'], 'tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action treating susceptible infections as with any other antibiotic tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drugtazobactampiperacillinwhen combined with piperacillin it is used to treat a variety of infections including those caused by aerobic and facultative grampositive and gramnegative bacteria in addition to grampositive and gramnegative anaerobes some examples of infections treated with piperacillintazobactam include cellulitis diabetic foot infections appendicitis and postpartum endometritis infectionsl4417 certain gramnegative bacilli infections with betalactamase producing organisms cannot be treated with piperacillintazobactam due to a gene mutation conferring antibiotic resistancea179266tazobactamceftolozanetazobactamceftolozane combined with metronidazole is used to treat complicated urinary tract infections uti and complicated intraabdominal infections as well as ventilatorassociated bacterial pneumonia and hospitalacquired bacterial pneumoniafda label this combination increases efficacy against infections with gramnegative bacillia7657')|
|('DB01606', 'MONDO:0005247', ['infection, urinary tract [NCIT:C50791]', 'urinary tract infectious disease [NCIT:C50791]', 'tract, infection Of urinary [NCIT:C50791]', 'UTI [NCIT:C50791]', 'urinary tract infection [MONDO:ambiguous]', 'urinary tract infection'], 'tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action treating susceptible infections as with any other antibiotic tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drugtazobactampiperacillinwhen combined with piperacillin it is used to treat a variety of infections including those caused by aerobic and facultative grampositive and gramnegative bacteria in addition to grampositive and gramnegative anaerobes some examples of infections treated with piperacillintazobactam include cellulitis diabetic foot infections appendicitis and postpartum endometritis infectionsl4417 certain gramnegative bacilli infections with betalactamase producing organisms cannot be treated with piperacillintazobactam due to a gene mutation conferring antibiotic resistancea179266tazobactamceftolozanetazobactamceftolozane combined with metronidazole is used to treat complicated urinary tract infections uti and complicated intraabdominal infections as well as ventilatorassociated bacterial pneumonia and hospitalacquired bacterial pneumoniafda label this combination increases efficacy against infections with gramnegative bacillia7657')|
|('DB01606', 'MONDO:0004652', ['gram-negative pneumonia', 'Pneumonia due to other gram-negative bacteria', 'bacterial pneumonia'], 'tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action treating susceptible infections as with any other antibiotic tazobactam should only be used for infections that are either proven or strongly suspected to be susceptible to the tazobactam containing drugtazobactampiperacillinwhen combined with piperacillin it is used to treat a variety of infections including those caused by aerobic and facultative grampositive and gramnegative bacteria in addition to grampositive and gramnegative anaerobes some examples of infections treated with piperacillintazobactam include cellulitis diabetic foot infections appendicitis and postpartum endometritis infectionsl4417 certain gramnegative bacilli infections with betalactamase producing organisms cannot be treated with piperacillintazobactam due to a gene mutation conferring antibiotic resistancea179266tazobactamceftolozanetazobactamceftolozane combined with metronidazole is used to treat complicated urinary tract infections uti and complicated intraabdominal infections as well as ventilatorassociated bacterial pneumonia and hospitalacquired bacterial pneumoniafda label this combination increases efficacy against infections with gramnegative bacillia7657')|
|('DB00283', 'MONDO:0004652', ['gram-negative pneumonia', 'Pneumonia due to other gram-negative bacteria', 'bacterial pneumonia'], 'for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and acrimation also for the management of mild uncomplicated allergic skin manifestations of urticaria and angioedema used as selfmedication for temporary relief of symptoms associated with the common cold')|
|('DB00283', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and acrimation also for the management of mild uncomplicated allergic skin manifestations of urticaria and angioedema used as selfmedication for temporary relief of symptoms associated with the common cold')|
|('DB00283', 'MONDO:0005492', ['urticaria'], 'for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and acrimation also for the management of mild uncomplicated allergic skin manifestations of urticaria and angioedema used as selfmedication for temporary relief of symptoms associated with the common cold')|
|('DB00283', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and acrimation also for the management of mild uncomplicated allergic skin manifestations of urticaria and angioedema used as selfmedication for temporary relief of symptoms associated with the common cold')|
|('DB00283', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and acrimation also for the management of mild uncomplicated allergic skin manifestations of urticaria and angioedema used as selfmedication for temporary relief of symptoms associated with the common cold')|
|('DB00206', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'foe the treatment of hypertension')|
|('DB00512', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'a variety of dosage forms for example oral injections etc exist for the treatment of serious or severe infections caused by susceptible strains of methicillinresistant betalactamresistant staphylococci fda labeladditionally a unique fda approved oral liquid treatment is also available and indicated for the treatment of clostridium difficile associated diarrhea and enterocolitis caused by staphylococcus aureus including methicillinresistant strains l1196')|
|('DB00512', 'MONDO:0009172', ['enterocolitis [MONDO:ambiguous,OMIM:226150]', 'enterocolitis'], 'a variety of dosage forms for example oral injections etc exist for the treatment of serious or severe infections caused by susceptible strains of methicillinresistant betalactamresistant staphylococci fda labeladditionally a unique fda approved oral liquid treatment is also available and indicated for the treatment of clostridium difficile associated diarrhea and enterocolitis caused by staphylococcus aureus including methicillinresistant strains l1196')|
|('DB01423', 'MONDO:0009172', ['enterocolitis [MONDO:ambiguous,OMIM:226150]', 'enterocolitis'], 'strepronin is a mucolytic expectorant drug')|
|('DB00347', 'MONDO:0009172', ['enterocolitis [MONDO:ambiguous,OMIM:226150]', 'enterocolitis'], 'used in the control of absence petit mal seizures that are refractory to treatment with other medications')|
|('DB01764', 'MONDO:0009172', ['enterocolitis [MONDO:ambiguous,OMIM:226150]', 'enterocolitis'], 'for the treatment of bacterial infections usually in combination with quinupristin')|
|('DB00403', 'MONDO:0009172', ['enterocolitis [MONDO:ambiguous,OMIM:226150]', 'enterocolitis'], 'caerulein is used in the treatment of paralytic ileus and as diagnostic aid in pancreatic malfunction')|
|('DB00403', 'MONDO:0004568', ['paralytic ileus'], 'caerulein is used in the treatment of paralytic ileus and as diagnostic aid in pancreatic malfunction')|
|('DB01232', 'MONDO:0004568', ['paralytic ileus'], 'for the treatment of hiv1 with advanced immunodeficiency together with antiretroviral nucleoside analogues')|
|('DB00743', 'MONDO:0004568', ['paralytic ileus'], 'gadobenate dimeglumine is an mri contrast agent used primarily for mr imaging of the liver it can also be used for mri of the heart as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier the brain spine or other associated tissues')|
|('DB00743', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'gadobenate dimeglumine is an mri contrast agent used primarily for mr imaging of the liver it can also be used for mri of the heart as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier the brain spine or other associated tissues')|
|('DB00468', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of malaria and leg cramps')|
|('DB00468', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of malaria and leg cramps')|
|('DB08804', 'MONDO:0005136', ['induced malaria', 'malaria'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB08804', 'MONDO:0004989', ['carcinoma of breast', 'Mammary carcinoma', 'breast carcinoma'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB08804', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB08804', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for the treatment of refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure and turners syndrome it is also indicated in the prophylaxis of hereditary angioedema')|
|('DB01401', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis this medication is also used to treat fever in adults')|
|('DB00224', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'indinavir is an antiretroviral drug for the treatment of hiv infection')|
|('DB00224', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'indinavir is an antiretroviral drug for the treatment of hiv infection')|
|('DB00244', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'mesalazine is indicated for the induction of remission in patients with active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis fda label l5101 prescribing information for mesalazine in the uk also indicates the medication for the maintenance of remission of crohns ileocolitis l5101')|
|('DB00244', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'mesalazine is indicated for the induction of remission in patients with active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis fda label l5101 prescribing information for mesalazine in the uk also indicates the medication for the maintenance of remission of crohns ileocolitis l5101')|
|('DB04794', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'used for the treatment of various topical fungal infections including athletes foot tinea pedis')|
|('DB04794', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'used for the treatment of various topical fungal infections including athletes foot tinea pedis')|
|('DB01099', 'MONDO:0005984', ['Athletes foot', 'Dermatophytosis of foot', 'tinea pedis'], 'for the treatment in combination with amphotericin b of serious infections caused by susceptible strains of candida septicemia endocarditis and urinary system infections andor cryptococcus meningitis and pulmonary infections')|
|('DB01099', 'MONDO:0005025', ['endocarditis'], 'for the treatment in combination with amphotericin b of serious infections caused by susceptible strains of candida septicemia endocarditis and urinary system infections andor cryptococcus meningitis and pulmonary infections')|
|('DB01099', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the treatment in combination with amphotericin b of serious infections caused by susceptible strains of candida septicemia endocarditis and urinary system infections andor cryptococcus meningitis and pulmonary infections')|
|('DB00518', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm itaenia soliumi and for the treatment of cystic hydatid disease of the liver lung and peritoneum caused by the larval form of the dog tapeworm iechinococcus granulosusi')|
|('DB00518', 'MONDO:0015484', ['intestinal taenia solium infection', 'neurocysticercosis', 'Pork tapeworm infection', 'Tapeworm infection: intestinal taenia solum', 'Tapeworm infection: pork', 'tenia solium infectious disease', 'cysticercosis'], 'for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm itaenia soliumi and for the treatment of cystic hydatid disease of the liver lung and peritoneum caused by the larval form of the dog tapeworm iechinococcus granulosusi')|
|('DB00850', 'MONDO:0015484', ['intestinal taenia solium infection', 'neurocysticercosis', 'Pork tapeworm infection', 'Tapeworm infection: intestinal taenia solum', 'Tapeworm infection: pork', 'tenia solium infectious disease', 'cysticercosis'], 'for use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults')|
|('DB01151', 'MONDO:0015484', ['intestinal taenia solium infection', 'neurocysticercosis', 'Pork tapeworm infection', 'Tapeworm infection: intestinal taenia solum', 'Tapeworm infection: pork', 'tenia solium infectious disease', 'cysticercosis'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0012048', ['clinical depression', 'unipolar depression', 'endogenous depression'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01151', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'for relief of symptoms in various depressive syndromes especially endogenous depression it has also been used to manage chronic peripheral neuropathic pain as a second line agent for the management of anxiety disorders eg panic disorder generalized anxiety disorder and as a second or third line agent in the adhd management ')|
|('DB01362', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'iohexol ia used in myelography arthrography nephroangiography arteriography and other radiographic procedures')|
|('DB00612', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'bisoprolol is indicated for the treatment of mild to moderate hypertensionl7219 it may be used offlabel to treat heart failure atrial fibrillation and angina pectorisa180460a180463')|
|('DB00612', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'bisoprolol is indicated for the treatment of mild to moderate hypertensionl7219 it may be used offlabel to treat heart failure atrial fibrillation and angina pectorisa180460a180463')|
|('DB00178', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'for the management of mild to severe hypertension may be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction fda label to reduce the rate of death myocardial infarction and stroke in individuals at high risk of cardiovascular events may be used to slow the progression of renal disease in individuals with hypertension diabetes mellitus and microalubinuria or overt nephropathy t116 ')|
|('DB00178', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the management of mild to severe hypertension may be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction fda label to reduce the rate of death myocardial infarction and stroke in individuals at high risk of cardiovascular events may be used to slow the progression of renal disease in individuals with hypertension diabetes mellitus and microalubinuria or overt nephropathy t116 ')|
|('DB00178', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the management of mild to severe hypertension may be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction fda label to reduce the rate of death myocardial infarction and stroke in individuals at high risk of cardiovascular events may be used to slow the progression of renal disease in individuals with hypertension diabetes mellitus and microalubinuria or overt nephropathy t116 ')|
|('DB00178', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the management of mild to severe hypertension may be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction fda label to reduce the rate of death myocardial infarction and stroke in individuals at high risk of cardiovascular events may be used to slow the progression of renal disease in individuals with hypertension diabetes mellitus and microalubinuria or overt nephropathy t116 ')|
|('DB00178', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'for the management of mild to severe hypertension may be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction fda label to reduce the rate of death myocardial infarction and stroke in individuals at high risk of cardiovascular events may be used to slow the progression of renal disease in individuals with hypertension diabetes mellitus and microalubinuria or overt nephropathy t116 ')|
|('DB00603', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'medroxyprogesterone acetate mpa oral tablets are indicated to treat secondary amenorrhea reduce the incidence of endometrial hyperplasia in postmenopausal women and to treat abnormal uterine bleeding due to hormonal imbalance not organic pathologyl8657 oral tablets containing mpa and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms vulvar atrophy and vaginal atrophyl8660 subcutaneous mpa is indicated to prevent pregnancy and manage pain associated with endometriosisl8663 intramuscular mpa is indicated to prevent pregnancyl8666 and at higher concentrations for palliative treatment of endometrial or renal carcinomal8669')|
|('DB00603', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'medroxyprogesterone acetate mpa oral tablets are indicated to treat secondary amenorrhea reduce the incidence of endometrial hyperplasia in postmenopausal women and to treat abnormal uterine bleeding due to hormonal imbalance not organic pathologyl8657 oral tablets containing mpa and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms vulvar atrophy and vaginal atrophyl8660 subcutaneous mpa is indicated to prevent pregnancy and manage pain associated with endometriosisl8663 intramuscular mpa is indicated to prevent pregnancyl8666 and at higher concentrations for palliative treatment of endometrial or renal carcinomal8669')|
|('DB00603', 'MONDO:0041161', ['hyperplasia of the endometrium [NCIT:C3013]', 'endometrial hyperplasia []', 'hyperplasia of endometrium [NCIT:C3013]', 'endometrial hyperplasia'], 'medroxyprogesterone acetate mpa oral tablets are indicated to treat secondary amenorrhea reduce the incidence of endometrial hyperplasia in postmenopausal women and to treat abnormal uterine bleeding due to hormonal imbalance not organic pathologyl8657 oral tablets containing mpa and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms vulvar atrophy and vaginal atrophyl8660 subcutaneous mpa is indicated to prevent pregnancy and manage pain associated with endometriosisl8663 intramuscular mpa is indicated to prevent pregnancyl8666 and at higher concentrations for palliative treatment of endometrial or renal carcinomal8669')|
|('DB00603', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'medroxyprogesterone acetate mpa oral tablets are indicated to treat secondary amenorrhea reduce the incidence of endometrial hyperplasia in postmenopausal women and to treat abnormal uterine bleeding due to hormonal imbalance not organic pathologyl8657 oral tablets containing mpa and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms vulvar atrophy and vaginal atrophyl8660 subcutaneous mpa is indicated to prevent pregnancy and manage pain associated with endometriosisl8663 intramuscular mpa is indicated to prevent pregnancyl8666 and at higher concentrations for palliative treatment of endometrial or renal carcinomal8669')|
|('DB02300', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'for the treatment of moderate plaque psoriasis in adults')|
|('DB02300', 'MONDO:0005083', ['psoriasis'], 'for the treatment of moderate plaque psoriasis in adults')|
|('DB06594', 'MONDO:0005083', ['psoriasis'], 'agomelatine is indicated to treat major depressive episodes in adults')|
|('DB01425', 'MONDO:0005083', ['psoriasis'], 'alizapride is used in the treatment of nausea and vomiting including postoperative nausea and vomiting ')|
|('DB00919', 'MONDO:0005083', ['psoriasis'], 'for use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of ineisseria gonorrhoeaei')|
|('DB00919', 'MONDO:0005297', ['Non-Gonococcal Urethritis', 'Nongonococcal urethritis', 'urethritis'], 'for use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of ineisseria gonorrhoeaei')|
|('DB00919', 'MONDO:0005538', ['proctitis'], 'for use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of ineisseria gonorrhoeaei')|
|('DB00919', 'MONDO:0002345', ['cervicitis'], 'for use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of ineisseria gonorrhoeaei')|
|('DB00753', 'MONDO:0005538', ['proctitis'], 'for induction and maintenance of general anesthesia')|
|('DB00636', 'MONDO:0005538', ['proctitis'], 'for primary dysbetalipoproteinemia type iii hyperlipidemia that does not respond adequately to diet this helps control high cholesterol and high triglyceride levels ')|
|('DB00991', 'MONDO:0005538', ['proctitis'], 'used to relieve the inflammation swelling stiffness and joint pain associated with rheumatoid arthritis and osteoarthritis')|
|('DB00991', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used to relieve the inflammation swelling stiffness and joint pain associated with rheumatoid arthritis and osteoarthritis')|
|('DB00991', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used to relieve the inflammation swelling stiffness and joint pain associated with rheumatoid arthritis and osteoarthritis')|
|('DB06267', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in erectile dysfunction and hypertension')|
|('DB01002', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the production of local or regional anesthesia for surgery and obstetrics and for postoperative pain management')|
|('DB00718', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'indicated for the treatment of chronic hepatitis b in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease this is based on histological virological biochemical and serological responses in adult patients with hbeag and hbeag chronic hepatitis b with compensated liver function and in adult patients with clinical evidence of lamivudineresistant hepatitis b virus with either compensated or decompensated liver function')|
|('DB00718', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'indicated for the treatment of chronic hepatitis b in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease this is based on histological virological biochemical and serological responses in adult patients with hbeag and hbeag chronic hepatitis b with compensated liver function and in adult patients with clinical evidence of lamivudineresistant hepatitis b virus with either compensated or decompensated liver function')|
|('DB00718', 'MONDO:0005103', ['well-differentiated liposarcoma [NCIT:C4250]', 'well differentiated liposarcoma of deep soft tissue [NCIT:C4250]', 'WDLS [Orphanet:99971]', 'atypical lipomatous tumor [Orphanet:99971]', 'atypical lipoma [Orphanet:99971]', 'ALT [Orphanet:99971]', 'well differentiated liposarcoma [NCIT:C4250]', 'well-differentiated liposarcoma'], 'indicated for the treatment of chronic hepatitis b in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease this is based on histological virological biochemical and serological responses in adult patients with hbeag and hbeag chronic hepatitis b with compensated liver function and in adult patients with clinical evidence of lamivudineresistant hepatitis b virus with either compensated or decompensated liver function')|
|('DB00718', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'indicated for the treatment of chronic hepatitis b in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases alt or ast or histologically active disease this is based on histological virological biochemical and serological responses in adult patients with hbeag and hbeag chronic hepatitis b with compensated liver function and in adult patients with clinical evidence of lamivudineresistant hepatitis b virus with either compensated or decompensated liver function')|
|('DB00415', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'for treatment of infection respiratory gi uti and meningitis due to e coli p mirabilis enterococci shigella s typhosa and other salmonella nonpenicillinaseproducing n gononhoeae h influenzae staphylococci streptococci including streptoc')|
|('DB00415', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for treatment of infection respiratory gi uti and meningitis due to e coli p mirabilis enterococci shigella s typhosa and other salmonella nonpenicillinaseproducing n gononhoeae h influenzae staphylococci streptococci including streptoc')|
|('DB01167', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised patients pulmonary and extrapulmonary blastomycosis histoplasmosis aspergillosis and onychomycosis')|
|('DB01167', 'MONDO:0018312', ['histoplasmosis'], 'for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised patients pulmonary and extrapulmonary blastomycosis histoplasmosis aspergillosis and onychomycosis')|
|('DB01187', 'MONDO:0018312', ['histoplasmosis'], 'iophendylate is used as a contrast agent to locate spinal tumors')|
|('DB09017', 'MONDO:0018312', ['histoplasmosis'], 'brotizolam is indicated for 24 weeks in the treatment of severe or debilitating insomnia ')|
|('DB09017', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'brotizolam is indicated for 24 weeks in the treatment of severe or debilitating insomnia ')|
|('DB00462', 'MONDO:0018312', ['histoplasmosis'], 'used as adjunctive therapy for the treatment of peptic ulcer also used to treat nausea and vomiting due to motion sickness')|
|('DB00462', 'MONDO:0008015', ['Travel Sickness', 'motion sickness'], 'used as adjunctive therapy for the treatment of peptic ulcer also used to treat nausea and vomiting due to motion sickness')|
|('DB08909', 'MONDO:0018312', ['histoplasmosis'], 'glycerol phenylbutyrate is a nitrogenbinding agent for the chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders ucds who cannot be managed by dietary protein restriction andor amino acid supplementation alone ')|
|('DB00417', 'MONDO:0018312', ['histoplasmosis'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00417', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00417', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00417', 'MONDO:0006669', ['Bacteria endocarditis (disease) []', 'bacterial endocarditis [MONDO:ambiguous]', 'Bacteria caused endocarditis (disease) [MONDO:patterns/specific_infectious_disease_by_agent]', 'bacterial endocarditis'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00417', 'MONDO:0021140', ['inborn []', 'congenital'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00417', 'MONDO:0005267', ['heart disease'], 'indicated for the treatment of mild to moderately severe infections due to penicillin g\xadsensitive microorganisms with the use of bacteriological studies including sensitivity tests and clinical responselabel phenoxymethylpenicillin may be used for the treatment of  mild to moderate infections of the upper respiratory tract scarlet fever and mild erysipelas caused by streptococcus without bacteremia mild to moderately severe infections of the respiratory tract caused by pneumococcus mild infections of the skin and soft tissues caused by penicillin gsensitive staphylococcus mild to moderately severe infections of the oropharynx caused by fusospirochetosis including vincent’s gingivitis and pharyngitis usually respond to oral penicillin therapyofflabelindicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tractlabel')|
|('DB00944', 'MONDO:0005267', ['heart disease'], 'for the topical treatment of chronic openangle glaucoma')|
|('DB00944', 'MONDO:0005041', ['glaucoma'], 'for the topical treatment of chronic openangle glaucoma')|
|('DB01116', 'MONDO:0005267', ['heart disease'], 'for the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies')|
|('DB01348', 'MONDO:0005267', ['heart disease'], 'spirapril is an ace inhibitor class drug used to treat hypertension')|
|('DB06697', 'MONDO:0005267', ['heart disease'], 'artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB06697', 'MONDO:0005136', ['induced malaria', 'malaria'], 'artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB06697', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'artemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by iplasmodium falciparumi including malaria acquired in chloroquineresistant areas may also be used to treat uncomplicated malaria when the iplasmodiumi species has not been identified indicated for use in adults and children greater than 5 kg ')|
|('DB01620', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'pheniramine is commonly used in overthecounter products to treat seasonal allergies or cold and flu symptomsl7649l7652')|
|('DB01620', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'pheniramine is commonly used in overthecounter products to treat seasonal allergies or cold and flu symptomsl7649l7652')|
|('DB01620', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'pheniramine is commonly used in overthecounter products to treat seasonal allergies or cold and flu symptomsl7649l7652')|
|('DB00001', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of heparininduced thrombocytopenia')|
|('DB00001', 'MONDO:0002049', ['thrombocytopenia'], 'for the treatment of heparininduced thrombocytopenia')|
|('DB00002', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'cetuximab used in combination with irinotecan is indicated for the treatment of egfrexpressing metastatic colorectal carcinoma in patients who are refractory to irinotecanbased chemotherapy cetuximab administered as a single agent is indicated for the treatment of egfrexpressing metastatic colorectal carcinoma in patients who are intolerant to irinotecanbased chemotherapy')|
|('DB00002', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'cetuximab used in combination with irinotecan is indicated for the treatment of egfrexpressing metastatic colorectal carcinoma in patients who are refractory to irinotecanbased chemotherapy cetuximab administered as a single agent is indicated for the treatment of egfrexpressing metastatic colorectal carcinoma in patients who are intolerant to irinotecanbased chemotherapy')|
|('DB00003', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'used as adjunct therapy in the treatment of cystic fibrosis ')|
|('DB00003', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'used as adjunct therapy in the treatment of cystic fibrosis ')|
|('DB00004', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for treatment of cutaneous tcell lymphoma')|
|('DB00004', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for treatment of cutaneous tcell lymphoma')|
|('DB00005', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more diseasemodifying antirheumatic drugs etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis ')|
|('DB00005', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more diseasemodifying antirheumatic drugs etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis ')|
|('DB00005', 'MONDO:0005083', ['psoriasis'], 'etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more diseasemodifying antirheumatic drugs etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis ')|
|('DB00005', 'MONDO:0011849', ['arthritis psoriatica', 'arthropathic psoriasis', 'psoriatic arthritis'], 'etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more diseasemodifying antirheumatic drugs etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis ')|
|('DB00005', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more diseasemodifying antirheumatic drugs etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis ')|
|('DB00006', 'MONDO:0011849', ['arthritis psoriatica', 'arthropathic psoriasis', 'psoriatic arthritis'], 'for treatment of heparininduced thrombocytopenia and for the prevention of thrombosis bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention pci in patients at moderate to high risk acute coronary syndromes due to unstable angina or nonst segment elevation in whom a pci is planned')|
|('DB00006', 'MONDO:0002049', ['thrombocytopenia'], 'for treatment of heparininduced thrombocytopenia and for the prevention of thrombosis bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention pci in patients at moderate to high risk acute coronary syndromes due to unstable angina or nonst segment elevation in whom a pci is planned')|
|('DB00006', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'for treatment of heparininduced thrombocytopenia and for the prevention of thrombosis bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention pci in patients at moderate to high risk acute coronary syndromes due to unstable angina or nonst segment elevation in whom a pci is planned')|
|('DB00007', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'for treatment of prostate cancer endometriosis uterine fibroids and premature puberty')|
|('DB00007', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for treatment of prostate cancer endometriosis uterine fibroids and premature puberty')|
|('DB00008', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'peginterferon alfa2a is indicated for the treatment of hcv in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease fda label may be used as a monotherapy in patients with contraindications to or significant intolerance to other antiviral therapiespeginterferon alfa2a is also indicated as a monotherapy for adult patients with hbeag positive and hbeag negative chronic hepatitis b infection who havecompensated liver disease and evidence of viral replication and liver inflammation fda label')|
|('DB00008', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'peginterferon alfa2a is indicated for the treatment of hcv in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease fda label may be used as a monotherapy in patients with contraindications to or significant intolerance to other antiviral therapiespeginterferon alfa2a is also indicated as a monotherapy for adult patients with hbeag positive and hbeag negative chronic hepatitis b infection who havecompensated liver disease and evidence of viral replication and liver inflammation fda label')|
|('DB00008', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'peginterferon alfa2a is indicated for the treatment of hcv in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease fda label may be used as a monotherapy in patients with contraindications to or significant intolerance to other antiviral therapiespeginterferon alfa2a is also indicated as a monotherapy for adult patients with hbeag positive and hbeag negative chronic hepatitis b infection who havecompensated liver disease and evidence of viral replication and liver inflammation fda label')|
|('DB00009', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'for management of acute myocardial infarction acute ischemic strok and for lysis of acute pulmonary emboli')|
|('DB00009', 'MONDO:0004781', ['acute myocardial infarction'], 'for management of acute myocardial infarction acute ischemic strok and for lysis of acute pulmonary emboli')|
|('DB00010', 'MONDO:0004781', ['acute myocardial infarction'], 'for the treatment of dwarfism prevention of hivinduced weight loss')|
|('DB00011', 'MONDO:0004781', ['acute myocardial infarction'], 'for treatment of venereal or genital warts caused by the human papiloma virus')|
|('DB00011', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'for treatment of venereal or genital warts caused by the human papiloma virus')|
|('DB00012', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'for the treatment of anemia from renal transplants or certain hiv treatment')|
|('DB00012', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the treatment of anemia from renal transplants or certain hiv treatment')|
|('DB00013', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'urokinase can be used for the treatment of pulminary embolism coronary artery thrombosis iv catheter clearance and venous and arterial blood clots')|
|('DB00013', 'MONDO:0006716', ['Coronary artery thrombosis', 'coronary thrombosis'], 'urokinase can be used for the treatment of pulminary embolism coronary artery thrombosis iv catheter clearance and venous and arterial blood clots')|
|('DB00015', 'MONDO:0006716', ['Coronary artery thrombosis', 'coronary thrombosis'], 'for lysis of acute pulmonary emboli intracoronary emboli and management of myocardial infarction')|
|('DB00015', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for lysis of acute pulmonary emboli intracoronary emboli and management of myocardial infarction')|
|('DB00016', 'MONDO:0006716', ['Coronary artery thrombosis', 'coronary thrombosis'], 'indicated in adult and paediatric patients for the  treatment of anemia due to chronic kidney disease ckd in patients on dialysis and not on dialysis treatment of anemia due to zidovudine in patients with hivinfection  treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy and upon initiation there is a minimum of two additional months of planned chemotherapy reduction of allogeneic rbc transfusions in patients undergoing elective noncardiac nonvascular surgery')|
|('DB00016', 'MONDO:0002280', ['anaemia', 'anemia'], 'indicated in adult and paediatric patients for the  treatment of anemia due to chronic kidney disease ckd in patients on dialysis and not on dialysis treatment of anemia due to zidovudine in patients with hivinfection  treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy and upon initiation there is a minimum of two additional months of planned chemotherapy reduction of allogeneic rbc transfusions in patients undergoing elective noncardiac nonvascular surgery')|
|('DB00016', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated in adult and paediatric patients for the  treatment of anemia due to chronic kidney disease ckd in patients on dialysis and not on dialysis treatment of anemia due to zidovudine in patients with hivinfection  treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy and upon initiation there is a minimum of two additional months of planned chemotherapy reduction of allogeneic rbc transfusions in patients undergoing elective noncardiac nonvascular surgery')|
|('DB00017', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in the treatment of symptomatic pagets disease for patients unresponsive to alternate treatments or intolerant to such treatments in addition it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified it can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves also for the treatment of postmenopausal osteoporosis in women more than 5 years postmenopause  ')|
|('DB00017', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used in the treatment of symptomatic pagets disease for patients unresponsive to alternate treatments or intolerant to such treatments in addition it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified it can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves also for the treatment of postmenopausal osteoporosis in women more than 5 years postmenopause  ')|
|('DB00017', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'used in the treatment of symptomatic pagets disease for patients unresponsive to alternate treatments or intolerant to such treatments in addition it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified it can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves also for the treatment of postmenopausal osteoporosis in women more than 5 years postmenopause  ')|
|('DB00018', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'for the intralesional treatment of refractory or recurring external condylomata acuminata')|
|('DB00019', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'pegfilgrastim is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with non\xad myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenial9746it is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation hematopoietic subsyndrome of acute radiation syndromel9746')|
|('DB00020', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'for the treatment of cancer and bone marrow transplant')|
|('DB00020', 'MONDO:0004992', ['cancer'], 'for the treatment of cancer and bone marrow transplant')|
|('DB00022', 'MONDO:0004992', ['cancer'], 'peginterferon alfa2b is indicated for the treatment of hcv in combination with db00811 and a ns34a protease inhibitor for genotype 1 or without a ns34a protease inhibitor for genotypes 26 fda label may be used as a monotherapy in patients with contraindications to or significant intolerance to other antiviral therapies')|
|('DB00023', 'MONDO:0004992', ['cancer'], 'indicated as a component of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia all fda label')|
|('DB00023', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'indicated as a component of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia all fda label')|
|('DB00024', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for detection of residueal or recurrent thyroid cancer')|
|('DB00024', 'MONDO:0004992', ['cancer'], 'for detection of residueal or recurrent thyroid cancer')|
|('DB00025', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB00025', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB00025', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB00025', 'MONDO:0002241', ['FXIIID [MONDO:cjm]', 'factor xiii deficiency'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB00026', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'for the treatment of adult rheumatoid arthritis and treatment of neonatalonset multisystem inflammatory disease nomid ')|
|('DB00026', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of adult rheumatoid arthritis and treatment of neonatalonset multisystem inflammatory disease nomid ')|
|('DB00027', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for treatment of skin lesions surface wounds and eye infections')|
|('DB00028', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ivig is used in the treatment of immunodeficiencies as well as autoimmune and inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillainbarré syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott–aldrich syndrome and inflammatory skin diseases')|
|('DB00028', 'MONDO:0008558', ['Autoimmune thrombocytopenic purpura', 'idiopathic thrombocytopenic purpura', 'Immune thrombocytopenic purpura', 'primary thrombocytopenic purpura', 'autoimmune thrombocytopenic purpura'], 'ivig is used in the treatment of immunodeficiencies as well as autoimmune and inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillainbarré syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott–aldrich syndrome and inflammatory skin diseases')|
|('DB00028', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'ivig is used in the treatment of immunodeficiencies as well as autoimmune and inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillainbarré syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott–aldrich syndrome and inflammatory skin diseases')|
|('DB00028', 'MONDO:0001824', ['polyneuropathy'], 'ivig is used in the treatment of immunodeficiencies as well as autoimmune and inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillainbarré syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott–aldrich syndrome and inflammatory skin diseases')|
|('DB00028', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'ivig is used in the treatment of immunodeficiencies as well as autoimmune and inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillainbarré syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott–aldrich syndrome and inflammatory skin diseases')|
|('DB00029', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for lysis of acute pulmonary emboli intracoronary emboli and management of myocardial infarction')|
|('DB00029', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for lysis of acute pulmonary emboli intracoronary emboli and management of myocardial infarction')|
|('DB00030', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus')|
|('DB00030', 'MONDO:0005015', ['diabetes mellitus'], 'human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus')|
|('DB00031', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for treatment of myocardial infarction and lysis of intracoronary emboli')|
|('DB00031', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for treatment of myocardial infarction and lysis of intracoronary emboli')|
|('DB00032', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of female infertility')|
|('DB00032', 'MONDO:0021124', ['female reproductive system infertility disorder [MONDO:design_pattern,MONDO:patterns/location]', 'female reproductive system infertility [MONDO:patterns/location]', 'infertility disorder of female reproductive system [MONDO:design_pattern]', 'female infertility [MESH:D007247]', 'female infertility'], 'for the treatment of female infertility')|
|('DB00033', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'interferon gamma1b is used for the treatment of chronic granulomatous disease and osteopetrosis')|
|('DB00033', 'MONDO:0018305', ['Bridges-Good syndrome', 'CGD', 'Congenital dysphagocytosis', 'Quie syndrome', 'chronic granulomatous disease'], 'interferon gamma1b is used for the treatment of chronic granulomatous disease and osteopetrosis')|
|('DB00033', 'MONDO:0017198', ['Albers-Schonberg disease', 'marble bone', 'osteopetrosis'], 'interferon gamma1b is used for the treatment of chronic granulomatous disease and osteopetrosis')|
|('DB00034', 'MONDO:0018305', ['Bridges-Good syndrome', 'CGD', 'Congenital dysphagocytosis', 'Quie syndrome', 'chronic granulomatous disease'], 'for the treatment of chronic hepatitis c hairy cell leukemia aidsrelated kaposis sarcoma and chronic myelogenous leukemia also for the treatment of oral warts arising from hiv infection')|
|('DB00034', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'for the treatment of chronic hepatitis c hairy cell leukemia aidsrelated kaposis sarcoma and chronic myelogenous leukemia also for the treatment of oral warts arising from hiv infection')|
|('DB00034', 'MONDO:0018935', ['hairy cell leukemia'], 'for the treatment of chronic hepatitis c hairy cell leukemia aidsrelated kaposis sarcoma and chronic myelogenous leukemia also for the treatment of oral warts arising from hiv infection')|
|('DB00034', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for the treatment of chronic hepatitis c hairy cell leukemia aidsrelated kaposis sarcoma and chronic myelogenous leukemia also for the treatment of oral warts arising from hiv infection')|
|('DB00034', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for the treatment of chronic hepatitis c hairy cell leukemia aidsrelated kaposis sarcoma and chronic myelogenous leukemia also for the treatment of oral warts arising from hiv infection')|
|('DB00036', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for treatment of hemorrhagic complications in hemophilia a and b')|
|('DB00038', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenialabel')|
|('DB00039', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for treatment of oral mucositis associated with chemotherapy and radiation therapy')|
|('DB00040', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemial7634l7637l7640l7643l8519')|
|('DB00041', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for treatment of adults with metastatic renal cell carcinoma')|
|('DB00042', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia')|
|('DB00042', 'MONDO:0000481', ['spasmodic torticollis', 'cervical dystonia'], 'for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia')|
|('DB00043', 'MONDO:0000481', ['spasmodic torticollis', 'cervical dystonia'], 'this drug is an antiige antibody indicated for1 moderate to severe persistent asthma in patients 6 years of age and olderwith a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids fda label2 chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite h1 antihistamine treatment fda label')|
|('DB00043', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'this drug is an antiige antibody indicated for1 moderate to severe persistent asthma in patients 6 years of age and olderwith a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids fda label2 chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite h1 antihistamine treatment fda label')|
|('DB00043', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'this drug is an antiige antibody indicated for1 moderate to severe persistent asthma in patients 6 years of age and olderwith a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids fda label2 chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite h1 antihistamine treatment fda label')|
|('DB00044', 'MONDO:0044212', ['idiopathic urticaria, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic idiopathic urticaria []', 'chronic idiopathic urticaria'], 'for treatment of infertility in women with hypothalamic or pituitary insufficiency hypogonadotropic hypogonadism and profound lh deficiency lh 12 international units iul')|
|('DB00044', 'MONDO:0005152', ['pituitary hormone deficiency', 'Pituitary insufficiency', 'hypopituitarism'], 'for treatment of infertility in women with hypothalamic or pituitary insufficiency hypogonadotropic hypogonadism and profound lh deficiency lh 12 international units iul')|
|('DB00044', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'for treatment of infertility in women with hypothalamic or pituitary insufficiency hypogonadotropic hypogonadism and profound lh deficiency lh 12 international units iul')|
|('DB00045', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'for prophylactic treatment of lyme disease')|
|('DB00045', 'MONDO:0019632', ['Bannwarth syndrome', 'Bannworths syndrome', 'Lyme borreliosis', 'lyme neuroborreliosis', 'neuroborreliosis', 'Neurological Lyme disease', 'lyme disease'], 'for prophylactic treatment of lyme disease')|
|('DB00046', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'insulin lispro is indicated to improve glycemic control in adults and children with diabetes mellitus ')|
|('DB00046', 'MONDO:0005015', ['diabetes mellitus'], 'insulin lispro is indicated to improve glycemic control in adults and children with diabetes mellitus ')|
|('DB00047', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus')|
|('DB00047', 'MONDO:0005147', ['IDDM', 'insulin-dependent diabetes mellitus', 'type I diabetes mellitus', 'type 1 diabetes mellitus'], 'insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus')|
|('DB00047', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus')|
|('DB00048', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used to promote debridement of necrotic tissue in the treatment of severe burns and dermal ulcers including decubitus ulcers')|
|('DB00049', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for treatment of hyperuricemia reduces elevated plasma uric acid levels from chemotherapy')|
|('DB00051', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0003937', ['spondylitis'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0005292', ['colitis'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00051', 'MONDO:0005083', ['psoriasis'], 'the following are conditions for which adalimumab has been indicated f2118 fda label l4805 a40001 a40002 l4806 rheumatoid arthritis moderate to severejuvenile idiopathic arthritis moderately to severely activepsoriatic arthritis activeankylosing spondylitis activecrohn’s disease moderately to severely activeulcerative colitis moderately to severely activeplaque psoriasis moderate to severe chronicnoninfectious intermediate posterior and panuveitishidradenitis suppurativa moderate to severepyoderma gangrenosum offlabel')|
|('DB00052', 'MONDO:0005083', ['psoriasis'], 'for treatment of dwarfism acromegaly and prevention of hivinduced weight loss')|
|('DB00053', 'MONDO:0005083', ['psoriasis'], 'for the treatment of gauchers disease deficiency in glucocerebrosidase')|
|('DB00054', 'MONDO:0005083', ['psoriasis'], 'abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours abciximab is intended for use with aspirin and heparin and has been studied only in that setting')|
|('DB00054', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours abciximab is intended for use with aspirin and heparin and has been studied only in that setting')|
|('DB00054', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours abciximab is intended for use with aspirin and heparin and has been studied only in that setting')|
|('DB00055', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for reduction of mortality in patients with severe sepsis')|
|('DB00056', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of patients with cd33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy indicated for the treatment of patients aged 2 years and older with cd33positive aml who have experienced a relapse or who have not responded to initial treatment refractory ')|
|('DB00056', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'indicated for the treatment of patients with cd33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy indicated for the treatment of patients aged 2 years and older with cd33positive aml who have experienced a relapse or who have not responded to initial treatment refractory ')|
|('DB00057', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for diagnosis of extrahepatic malignant cancers')|
|('DB00058', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for chronic augmentation and maintenance therapy in individuals with alpha1proteinase inhibitor a1pi deficiency and clinical evidence of emphysema')|
|('DB00059', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for treatment of acute lymphoblastic leukemia')|
|('DB00059', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for treatment of acute lymphoblastic leukemia')|
|('DB00060', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'for treatment of relapsingremitting multiple sclerosis also for condyloma acuminatum')|
|('DB00060', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for treatment of relapsingremitting multiple sclerosis also for condyloma acuminatum')|
|('DB00061', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for treatment of adenosine deaminase deficiency')|
|('DB00061', 'MONDO:0007064', ['ADA', 'adenosine deaminase deficiency'], 'for treatment of adenosine deaminase deficiency')|
|('DB00062', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'albuminex solution is indicated for adults and children for hypovolemia ascites hypoalbuminemia including from burns acute nephrosis acute respiratory distress syndrome and cardipulmonary bypass f229')|
|('DB00063', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for treatment of myocardial infarction and acute coronary syndrome')|
|('DB00063', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for treatment of myocardial infarction and acute coronary syndrome')|
|('DB00063', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'for treatment of myocardial infarction and acute coronary syndrome')|
|('DB00065', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00065', 'MONDO:0005292', ['colitis'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00065', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00065', 'MONDO:0003937', ['spondylitis'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00065', 'MONDO:0011849', ['arthritis psoriatica', 'arthropathic psoriasis', 'psoriatic arthritis'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00065', 'MONDO:0005083', ['psoriasis'], ' indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ≥ 6 years of age patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn’s disease  indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult or pediatric ≥ 6 years of age patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy  indicated for in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis  indicated for reducing signs and symptoms in patients with active ankylosing spondylitis  indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis  indicated for the treatment of adult patients with chronic severe ie extensive andor disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate')|
|('DB00066', 'MONDO:0005083', ['psoriasis'], 'in women having been diagnosed with primary ovarian failure it is used in combination with human chorionic gonadotropin hcg to assist in ovulation and fertility in men with hypogonadotrophic hypogonadism it is used to induce spermatogenesis follitropin may also be used to cause the ovary to produce several follicles which can then be harvested for use in gamete intrafallopian transfer gift or in vitro fertilization ivf')|
|('DB00066', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'in women having been diagnosed with primary ovarian failure it is used in combination with human chorionic gonadotropin hcg to assist in ovulation and fertility in men with hypogonadotrophic hypogonadism it is used to induce spermatogenesis follitropin may also be used to cause the ovary to produce several follicles which can then be harvested for use in gamete intrafallopian transfer gift or in vitro fertilization ivf')|
|('DB00066', 'MONDO:0002146', ['hypogonadism'], 'in women having been diagnosed with primary ovarian failure it is used in combination with human chorionic gonadotropin hcg to assist in ovulation and fertility in men with hypogonadotrophic hypogonadism it is used to induce spermatogenesis follitropin may also be used to cause the ovary to produce several follicles which can then be harvested for use in gamete intrafallopian transfer gift or in vitro fertilization ivf')|
|('DB00066', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'in women having been diagnosed with primary ovarian failure it is used in combination with human chorionic gonadotropin hcg to assist in ovulation and fertility in men with hypogonadotrophic hypogonadism it is used to induce spermatogenesis follitropin may also be used to cause the ovary to produce several follicles which can then be harvested for use in gamete intrafallopian transfer gift or in vitro fertilization ivf')|
|('DB00067', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of enuresis polyuria diabetes insipidus polydipsia and oesophageal varices with bleeding')|
|('DB00067', 'MONDO:0024290', ['enuresis [NCIT:C34588]', 'enuresis'], 'for the treatment of enuresis polyuria diabetes insipidus polydipsia and oesophageal varices with bleeding')|
|('DB00067', 'MONDO:0004782', ['diabetes insipidus'], 'for the treatment of enuresis polyuria diabetes insipidus polydipsia and oesophageal varices with bleeding')|
|('DB00068', 'MONDO:0004782', ['diabetes insipidus'], 'interferon beta1b is a drug used for the treatment of relapsingremitting multiple sclerosis it has been shown to slow the advance of the disease as well as to decrease the frequency of attacks')|
|('DB00068', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'interferon beta1b is a drug used for the treatment of relapsingremitting multiple sclerosis it has been shown to slow the advance of the disease as well as to decrease the frequency of attacks')|
|('DB00068', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'interferon beta1b is a drug used for the treatment of relapsingremitting multiple sclerosis it has been shown to slow the advance of the disease as well as to decrease the frequency of attacks')|
|('DB00069', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00069', 'MONDO:0018935', ['hairy cell leukemia'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00069', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00070', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for increase of absorption and distribution of other injected drugs and for rehydration')|
|('DB00071', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for the treatment of type i and ii diabetes mellitus')|
|('DB00071', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of type i and ii diabetes mellitus')|
|('DB00072', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'indicated for treatment of early stage her2positive breast cancer or metastatic breast cancer that substantially overexpress her2 the intravenous powder for solution ogivri is approved in canada for early breast cancer metastatic breast cancer and gastric cancer provided these cancers overexpress her2l6214')|
|('DB00072', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'indicated for treatment of early stage her2positive breast cancer or metastatic breast cancer that substantially overexpress her2 the intravenous powder for solution ogivri is approved in canada for early breast cancer metastatic breast cancer and gastric cancer provided these cancers overexpress her2l6214')|
|('DB00072', 'MONDO:0004992', ['cancer'], 'indicated for treatment of early stage her2positive breast cancer or metastatic breast cancer that substantially overexpress her2 the intravenous powder for solution ogivri is approved in canada for early breast cancer metastatic breast cancer and gastric cancer provided these cancers overexpress her2l6214')|
|('DB00072', 'MONDO:0001056', ['Ca body - stomach', 'ca greater curvature of stomach', 'Ca lesser curvature - stomach', 'gastric cancer', 'gastric neoplasm', 'malignant neoplasm of body of stomach', 'malignant neoplasm of lesser curve of stomach', 'malignant tumor of body of stomach', 'malignant tumor of greater curve of stomach', 'malignant tumor of lesser curve of stomach', 'gastric cancer'], 'indicated for treatment of early stage her2positive breast cancer or metastatic breast cancer that substantially overexpress her2 the intravenous powder for solution ogivri is approved in canada for early breast cancer metastatic breast cancer and gastric cancer provided these cancers overexpress her2l6214')|
|('DB00073', 'MONDO:0001056', ['Ca body - stomach', 'ca greater curvature of stomach', 'Ca lesser curvature - stomach', 'gastric cancer', 'gastric neoplasm', 'malignant neoplasm of body of stomach', 'malignant neoplasm of lesser curve of stomach', 'malignant tumor of body of stomach', 'malignant tumor of greater curve of stomach', 'malignant tumor of lesser curve of stomach', 'gastric cancer'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00073', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00073', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00073', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00073', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00073', 'MONDO:0012105', ['Necrotizing respiratory granulomatosis', 'Wegener granulomatosis, formerly', 'granulomatosis with polyangiitis'], 'rituximab is indicated in the following conditions fda labelnon–hodgkin’s lymphoma nhlchronic lymphocytic leukemia cllrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ragranulomatosis with polyangiitis gpa wegener’s granulomatosis and microscopic polyangiitis mpamoderate to severe pemphigus vulgaris pv in adult patientsthe biosimilar approved in november 2018 truxima is indicated for the treatment of adult patients with cd20positive bcell nonhodgkin’s lymphoma nhl to be used as a single agent or in combination with chemotherapy l4808in september 2019 the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis gpa in addition to microscopic polyangiitis mpa in children of at least 2 years of age l8920')|
|('DB00074', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for prophylactic treatment of kidney transplant rejection')|
|('DB00075', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for treatment of organ transplant recipients prevention of organ rejection')|
|('DB00076', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for treatment of digitoxin overdose or digitalis glycoside toxicity')|
|('DB00078', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for treatment of nonhodgkins lymphoma')|
|('DB00078', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for treatment of nonhodgkins lymphoma')|
|('DB00080', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for the treatment of complicated skin and skin structure infections caused by susceptible strains of grampositive microorganisms')|
|('DB00081', 'MONDO:0019124', ['microscopic polyarteritis [Orphanet:727]', 'Micropolyangiitis [Orphanet:727]', 'MPA [Orphanet:727]', 'microscopic polyangiitis'], 'for treatment of nonhodgkins lymphoma cd20 positive follicular')|
|('DB00081', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for treatment of nonhodgkins lymphoma cd20 positive follicular')|
|('DB00082', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly')|
|('DB00082', 'MONDO:0019933', ['acromegaly'], 'pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly')|
|('DB00083', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia including benign essential blepharospasm or vii nerve disorders in patients 12 years of age and above also used cosmetically to temporarily improve the appearance of moderatetosevere frown lines between the eyebrows glabellar lines as well as for the treatment of excessive underarm sweating')|
|('DB00083', 'MONDO:0000481', ['spasmodic torticollis', 'cervical dystonia'], 'for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia including benign essential blepharospasm or vii nerve disorders in patients 12 years of age and above also used cosmetically to temporarily improve the appearance of moderatetosevere frown lines between the eyebrows glabellar lines as well as for the treatment of excessive underarm sweating')|
|('DB00083', 'MONDO:0003432', ['strabismus'], 'for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia including benign essential blepharospasm or vii nerve disorders in patients 12 years of age and above also used cosmetically to temporarily improve the appearance of moderatetosevere frown lines between the eyebrows glabellar lines as well as for the treatment of excessive underarm sweating')|
|('DB00083', 'MONDO:0011728', ['blepharospasm'], 'for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia including benign essential blepharospasm or vii nerve disorders in patients 12 years of age and above also used cosmetically to temporarily improve the appearance of moderatetosevere frown lines between the eyebrows glabellar lines as well as for the treatment of excessive underarm sweating')|
|('DB00085', 'MONDO:0011728', ['blepharospasm'], 'the use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy this therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis chronic pancreatitis or any other medically defined pancreatic disease that might require ita32721 a32736 pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas once established pancreatic insufficiency results in malnutrition weight loss and steatorrheaa32723')|
|('DB00085', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'the use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy this therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis chronic pancreatitis or any other medically defined pancreatic disease that might require ita32721 a32736 pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas once established pancreatic insufficiency results in malnutrition weight loss and steatorrheaa32723')|
|('DB00085', 'MONDO:0004982', ['pancreatitis'], 'the use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy this therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis chronic pancreatitis or any other medically defined pancreatic disease that might require ita32721 a32736 pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas once established pancreatic insufficiency results in malnutrition weight loss and steatorrheaa32723')|
|('DB00086', 'MONDO:0004982', ['pancreatitis'], 'for the treatment of acute evolving transmural myocardial infarction pulmonary embolism deep vein thrombosis arterial thrombosis or emolism and occlusion of arteriovenous cannulae')|
|('DB00086', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of acute evolving transmural myocardial infarction pulmonary embolism deep vein thrombosis arterial thrombosis or emolism and occlusion of arteriovenous cannulae')|
|('DB00087', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'alemtuzumab campath is a monoclonal antibody therapy used for treatment of bcell chronic lymphocytic leukemia')|
|('DB00088', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of gauchers disease deficiency in glucocerebrosidase')|
|('DB00089', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for diagnosis of prostate cancer and detection of intrapelvic metastases')|
|('DB00089', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for diagnosis of prostate cancer and detection of intrapelvic metastases')|
|('DB00090', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of mucopolysaccharidosis')|
|('DB00090', 'MONDO:0019249', ['mucopolysaccharidosis'], 'for the treatment of mucopolysaccharidosis')|
|('DB00092', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'as an immunosuppressive drug alefacept can be used for treatment of moderate to severe chronic plaque psoriasis')|
|('DB00092', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'as an immunosuppressive drug alefacept can be used for treatment of moderate to severe chronic plaque psoriasis')|
|('DB00092', 'MONDO:0005083', ['psoriasis'], 'as an immunosuppressive drug alefacept can be used for treatment of moderate to severe chronic plaque psoriasis')|
|('DB00094', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for treatment of female infertility')|
|('DB00094', 'MONDO:0021124', ['female reproductive system infertility disorder [MONDO:design_pattern,MONDO:patterns/location]', 'female reproductive system infertility [MONDO:patterns/location]', 'infertility disorder of female reproductive system [MONDO:design_pattern]', 'female infertility [MESH:D007247]', 'female infertility'], 'for treatment of female infertility')|
|('DB00095', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for phototherapy or systemic therapy')|
|('DB00095', 'MONDO:0005083', ['psoriasis'], 'for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for phototherapy or systemic therapy')|
|('DB00097', 'MONDO:0005083', ['psoriasis'], 'for the treatment of female infertility')|
|('DB00097', 'MONDO:0021124', ['female reproductive system infertility disorder [MONDO:design_pattern,MONDO:patterns/location]', 'female reproductive system infertility [MONDO:patterns/location]', 'infertility disorder of female reproductive system [MONDO:design_pattern]', 'female infertility [MESH:D007247]', 'female infertility'], 'for the treatment of female infertility')|
|('DB00098', 'MONDO:0005083', ['psoriasis'], 'for prevention of renal transplant rejection')|
|('DB00099', 'MONDO:0005083', ['psoriasis'], 'this drug is a leucocyte growth factor fda label indicated todecrease the incidence of infection‚ as manifested by febrile neutropenia‚in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever fda label reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia aml fda labelreduce the duration of neutropenia and neutropeniarelated clinical sequelae‚ eg‚ febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt fda labelmobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis fda labelreduce the incidence and duration of sequelae of severe neutropenia eg‚ fever‚ infections‚ oropharyngeal ulcers in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia fda labelneupogen is approved for treatment of patients with radiationinduced myelosuppression following a radiologicalnuclear incident l3739')|
|('DB00099', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'this drug is a leucocyte growth factor fda label indicated todecrease the incidence of infection‚ as manifested by febrile neutropenia‚in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever fda label reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia aml fda labelreduce the duration of neutropenia and neutropeniarelated clinical sequelae‚ eg‚ febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt fda labelmobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis fda labelreduce the incidence and duration of sequelae of severe neutropenia eg‚ fever‚ infections‚ oropharyngeal ulcers in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia fda labelneupogen is approved for treatment of patients with radiationinduced myelosuppression following a radiologicalnuclear incident l3739')|
|('DB00099', 'MONDO:0001475', ['neutropenia'], 'this drug is a leucocyte growth factor fda label indicated todecrease the incidence of infection‚ as manifested by febrile neutropenia‚in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever fda label reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia aml fda labelreduce the duration of neutropenia and neutropeniarelated clinical sequelae‚ eg‚ febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt fda labelmobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis fda labelreduce the incidence and duration of sequelae of severe neutropenia eg‚ fever‚ infections‚ oropharyngeal ulcers in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia fda labelneupogen is approved for treatment of patients with radiationinduced myelosuppression following a radiologicalnuclear incident l3739')|
|('DB00099', 'MONDO:0021140', ['inborn []', 'congenital'], 'this drug is a leucocyte growth factor fda label indicated todecrease the incidence of infection‚ as manifested by febrile neutropenia‚in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever fda label reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia aml fda labelreduce the duration of neutropenia and neutropeniarelated clinical sequelae‚ eg‚ febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt fda labelmobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis fda labelreduce the incidence and duration of sequelae of severe neutropenia eg‚ fever‚ infections‚ oropharyngeal ulcers in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia fda labelneupogen is approved for treatment of patients with radiationinduced myelosuppression following a radiologicalnuclear incident l3739')|
|('DB00100', 'MONDO:0021140', ['inborn []', 'congenital'], 'for treatment of hemophilia christmas disease')|
|('DB00100', 'MONDO:0018660', ['hemophilia'], 'for treatment of hemophilia christmas disease')|
|('DB00102', 'MONDO:0018660', ['hemophilia'], 'for topical treatment of skin ulcers from diabetes')|
|('DB00103', 'MONDO:0018660', ['hemophilia'], 'for treatment of fabrys disease alphagalactosidase a deficiency')|
|('DB00103', 'MONDO:0010526', ['alpha galactosidase deficiency', 'Alpha-galactosidase A deficiency', 'Angiokeratoma Corporis Diffusum', 'deficiency of melibiase', 'Fabrys disease', 'fabry disease'], 'for treatment of fabrys disease alphagalactosidase a deficiency')|
|('DB00105', 'MONDO:0010526', ['alpha galactosidase deficiency', 'Alpha-galactosidase A deficiency', 'Angiokeratoma Corporis Diffusum', 'deficiency of melibiase', 'Fabrys disease', 'fabry disease'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00105', 'MONDO:0018935', ['hairy cell leukemia'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00105', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for the treatment of hairy cell leukemia malignant melanoma and aidsrelated kaposis sarcoma')|
|('DB00106', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for palliative treatment of advanced prostate cancer')|
|('DB00106', 'MONDO:0004992', ['cancer'], 'for palliative treatment of advanced prostate cancer')|
|('DB00107', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'used for labor induction augmentation of labor postpartum abbreviation of third stage of labor postpartum control of uterine bleeding termination of pregnancy and for the evaluation of fetal respiratory capability oxytocin cannot be used for elective induction of labor there must be a clear medical requirement ')|
|('DB00108', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for treatment of multiple sclerosis')|
|('DB00108', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for treatment of multiple sclerosis')|
|('DB00109', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of hiv1aids')|
|('DB00110', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for prophylaxis of respiratory diseases casued by respiratory syncytial virus')|
|('DB00111', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection')|
|('DB00112', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'as part of combination therapy for metastatic colorectal cancer and her2negative metastatic breast cancer')|
|('DB00112', 'MONDO:0004992', ['cancer'], 'as part of combination therapy for metastatic colorectal cancer and her2negative metastatic breast cancer')|
|('DB00113', 'MONDO:0004992', ['cancer'], 'for imaging colorectal tumors')|
|('DB00114', 'MONDO:0004992', ['cancer'], 'for nutritional supplementation and for treating dietary shortage or imbalance')|
|('DB00142', 'MONDO:0004992', ['cancer'], 'considered to be natures brain food by improving mental capacities helps speed the healing of ulcers gives a lift from fatigue helps control alcoholism schizophrenia and the craving for sugar')|
|('DB00142', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'considered to be natures brain food by improving mental capacities helps speed the healing of ulcers gives a lift from fatigue helps control alcoholism schizophrenia and the craving for sugar')|
|('DB00142', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'considered to be natures brain food by improving mental capacities helps speed the healing of ulcers gives a lift from fatigue helps control alcoholism schizophrenia and the craving for sugar')|
|('DB00157', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'some evidence suggests that nadh might be useful in treating parkinsons disease chronic fatigue syndrome alzheimers disease and cardiovascular disease')|
|('DB00157', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'some evidence suggests that nadh might be useful in treating parkinsons disease chronic fatigue syndrome alzheimers disease and cardiovascular disease')|
|('DB00197', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'for the treatment of type ii diabetes mellitus it is used alone or in combination with a sulfonylurea metformin or insulin as an adjunct to diet and exercise')|
|('DB00197', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of type ii diabetes mellitus it is used alone or in combination with a sulfonylurea metformin or insulin as an adjunct to diet and exercise')|
|('DB00269', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'used to treat symptoms of menopause deficiencies in ovary function including underdevelopment of female sexual characteristics and some types of infertility and in rare cases prostate cancer chlorotrianisene may also be used to prevent breast engorgement following childbirth')|
|('DB00269', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used to treat symptoms of menopause deficiencies in ovary function including underdevelopment of female sexual characteristics and some types of infertility and in rare cases prostate cancer chlorotrianisene may also be used to prevent breast engorgement following childbirth')|
|('DB00311', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for use in the treatment of duodenal ulcers as a diuretic and in the treatment of glaucoma and may also be useful in the treatment of seizures associated with epilepsy')|
|('DB00311', 'MONDO:0005041', ['glaucoma'], 'for use in the treatment of duodenal ulcers as a diuretic and in the treatment of glaucoma and may also be useful in the treatment of seizures associated with epilepsy')|
|('DB00311', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for use in the treatment of duodenal ulcers as a diuretic and in the treatment of glaucoma and may also be useful in the treatment of seizures associated with epilepsy')|
|('DB00342', 'MONDO:0005041', ['glaucoma'], 'for the treatment of allergic rhinitis hay fever and allergic skin disorders')|
|('DB00342', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of allergic rhinitis hay fever and allergic skin disorders')|
|('DB00365', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for treatment of adults with mild to moderate infections caused by susceptible strains of ihaemophilus influenzaei istreptococcus pneumoniaei or imoraxella catarrhalisi')|
|('DB00372', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment or relief of nausea and vomiting')|
|('DB00382', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the palliative treatment of mild to moderate dementia of the alzheimers type')|
|('DB00414', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'used in the management of diabetes mellitus type 2 adultonset')|
|('DB00414', 'MONDO:0005015', ['diabetes mellitus'], 'used in the management of diabetes mellitus type 2 adultonset')|
|('DB00416', 'MONDO:0005015', ['diabetes mellitus'], 'for use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy')|
|('DB00439', 'MONDO:0005015', ['diabetes mellitus'], 'used as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia fredrickson types iia and iib when the response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures alone has been inadequate')|
|('DB00439', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia fredrickson types iia and iib when the response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures alone has been inadequate')|
|('DB00447', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to treat upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis and tonsillitis skin absceses urinary tract infections and pyelonephritis caused by ie colii is pyogenesi is aureusi is saprphyticusi is penumoniaei ih influenzaei and im catarrhalisi')|
|('DB00447', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'used to treat upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis and tonsillitis skin absceses urinary tract infections and pyelonephritis caused by ie colii is pyogenesi is aureusi is saprphyticusi is penumoniaei ih influenzaei and im catarrhalisi')|
|('DB00447', 'MONDO:0005961', ['sinusitis'], 'used to treat upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis and tonsillitis skin absceses urinary tract infections and pyelonephritis caused by ie colii is pyogenesi is aureusi is saprphyticusi is penumoniaei ih influenzaei and im catarrhalisi')|
|('DB00447', 'MONDO:0001039', ['chronic tonsillitis', 'Throat infection - tonsillitis', 'tonsillitis'], 'used to treat upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis and tonsillitis skin absceses urinary tract infections and pyelonephritis caused by ie colii is pyogenesi is aureusi is saprphyticusi is penumoniaei ih influenzaei and im catarrhalisi')|
|('DB00447', 'MONDO:0006939', ['pyelonephritis'], 'used to treat upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis and tonsillitis skin absceses urinary tract infections and pyelonephritis caused by ie colii is pyogenesi is aureusi is saprphyticusi is penumoniaei ih influenzaei and im catarrhalisi')|
|('DB00463', 'MONDO:0006939', ['pyelonephritis'], 'metharbital is used for the treatment of epilepsy')|
|('DB00463', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'metharbital is used for the treatment of epilepsy')|
|('DB00466', 'MONDO:0006939', ['pyelonephritis'], 'used internally for relieving respiratory distress also for use as an antidote in poisoning by cns depressants especially barbiturates')|
|('DB00505', 'MONDO:0006939', ['pyelonephritis'], 'used as an adjunct in the treatment of peptic ulcer disease and in acquired nystagmus')|
|('DB00505', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'used as an adjunct in the treatment of peptic ulcer disease and in acquired nystagmus')|
|('DB00522', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'indicated as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy')|
|('DB00522', 'MONDO:0001684', ['Exocrine pancreatic insufficiency', 'exocrine pancreatic insufficiency'], 'indicated as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy')|
|('DB00532', 'MONDO:0001684', ['Exocrine pancreatic insufficiency', 'exocrine pancreatic insufficiency'], 'for the treatment of refractory partial epilepsy')|
|('DB00532', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the treatment of refractory partial epilepsy')|
|('DB00533', 'MONDO:0001684', ['Exocrine pancreatic insufficiency', 'exocrine pancreatic insufficiency'], 'for the treatment of osteoarthritis rheumatoid arthritis acute pain in adults and primary dysmenorrhea as well as acute treatment of migraine attacks with or without auras')|
|('DB00533', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of osteoarthritis rheumatoid arthritis acute pain in adults and primary dysmenorrhea as well as acute treatment of migraine attacks with or without auras')|
|('DB00533', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of osteoarthritis rheumatoid arthritis acute pain in adults and primary dysmenorrhea as well as acute treatment of migraine attacks with or without auras')|
|('DB00574', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the management of exogenous obesity as a shortterm a few weeks adjunct in a regimen of weight reduction based on caloric restriction')|
|('DB00580', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of osteoarthritis and dysmenorrhoea')|
|('DB00580', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of osteoarthritis and dysmenorrhoea')|
|('DB00702', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used for continuous ambulatory peritoneal dialysis capd of diabetic patients or automated peritoneal dialysis apd for the management of endstage renal disease')|
|('DB00767', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used to prevent and treat nausea and vomiting associated with anesthesia and surgery administered intramuscularly or intravenously')|
|('DB00785', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of hypertension')|
|('DB00840', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used to relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases keratoconjunctivitis sicca recurrent corneal erosions decreased corneal sensitivity exposure and neuroparalytic keratitis and as a lubricant for artificial eyes')|
|('DB00840', 'MONDO:0004768', ['keratoconjunctivitis'], 'used to relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases keratoconjunctivitis sicca recurrent corneal erosions decreased corneal sensitivity exposure and neuroparalytic keratitis and as a lubricant for artificial eyes')|
|('DB00840', 'MONDO:0003085', ['keratitis'], 'used to relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases keratoconjunctivitis sicca recurrent corneal erosions decreased corneal sensitivity exposure and neuroparalytic keratitis and as a lubricant for artificial eyes')|
|('DB00848', 'MONDO:0003085', ['keratitis'], 'for adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes stage c colon cancer also used to treat malignant melanoma and headneck cancer')|
|('DB00848', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes stage c colon cancer also used to treat malignant melanoma and headneck cancer')|
|('DB00848', 'MONDO:0004992', ['cancer'], 'for adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes stage c colon cancer also used to treat malignant melanoma and headneck cancer')|
|('DB14596', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'a number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of postoperative inflammation and pain following ocular surgery fda label ')|
|('DB00886', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for the treatment of hypertension')|
|('DB00893', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible also used to replenish body iron stores in nondialysis dependentchronic kidney disease nddckd patients receiving or not receiving erythropoietin and in hemodialysis dependent hddckd and peritoneal dialysis dependent pddckd  chronic kidney disease patients receiving an erythropoietin')|
|('DB00893', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible also used to replenish body iron stores in nondialysis dependentchronic kidney disease nddckd patients receiving or not receiving erythropoietin and in hemodialysis dependent hddckd and peritoneal dialysis dependent pddckd  chronic kidney disease patients receiving an erythropoietin')|
|('DB00893', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible also used to replenish body iron stores in nondialysis dependentchronic kidney disease nddckd patients receiving or not receiving erythropoietin and in hemodialysis dependent hddckd and peritoneal dialysis dependent pddckd  chronic kidney disease patients receiving an erythropoietin')|
|('DB00901', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation it is used in the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00901', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation it is used in the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00901', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation it is used in the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00901', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation it is used in the treatment of asthma and chronic obstructive pulmonary disease copd')|
|('DB00926', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of severe psoriasis in adults')|
|('DB00930', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use alone or in combination with an hmgcoa reductase inhibitor as adjunctive therapy to diet and exercise for the reduction of elevated ldl cholesterol in patients with primary hypercholesterolemia fredrickson type iia')|
|('DB00965', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use as a radioopaque medium for hysterosalpingography and lymphography and as an antineoplastic agent when part of the iodine is 131i it is also used in followup imaging for chemoembolization')|
|('DB01038', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients')|
|('DB01079', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'tegaserod is a serotonin4 5ht4 receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation ibsc f4223 f4229 the safety and effectiveness of tegaserod in men with ibsc have not been established f4223 f4229')|
|('DB01079', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'tegaserod is a serotonin4 5ht4 receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation ibsc f4223 f4229 the safety and effectiveness of tegaserod in men with ibsc have not been established f4223 f4229')|
|('DB01109', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension prevention of postoperative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery in cardiology it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina andor nonq wave myocardial infarctions ie nonst elevated acute coronary artery syndrome who are on platelet glycoprotein iibiiia receptor inhibitors additionally it is used to prevent clotting during dialysis and surgical procedures maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values')|
|('DB01109', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension prevention of postoperative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery in cardiology it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina andor nonq wave myocardial infarctions ie nonst elevated acute coronary artery syndrome who are on platelet glycoprotein iibiiia receptor inhibitors additionally it is used to prevent clotting during dialysis and surgical procedures maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values')|
|('DB01109', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension prevention of postoperative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery in cardiology it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina andor nonq wave myocardial infarctions ie nonst elevated acute coronary artery syndrome who are on platelet glycoprotein iibiiia receptor inhibitors additionally it is used to prevent clotting during dialysis and surgical procedures maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values')|
|('DB01109', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension prevention of postoperative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery in cardiology it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina andor nonq wave myocardial infarctions ie nonst elevated acute coronary artery syndrome who are on platelet glycoprotein iibiiia receptor inhibitors additionally it is used to prevent clotting during dialysis and surgical procedures maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values')|
|('DB01134', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'examined for treatment of adrenocortical insufficiency especially in multiple sclerosis congenital cerebral palsy polyarteritis nodosa and rheumatoid arthritis currently only approved in treating cats and dogs for the treatment of addisons disease')|
|('DB01134', 'MONDO:0000004', ['Adrenal Cortical Insufficiency', 'Corticoadrenal insufficiency', 'adrenocortical insufficiency'], 'examined for treatment of adrenocortical insufficiency especially in multiple sclerosis congenital cerebral palsy polyarteritis nodosa and rheumatoid arthritis currently only approved in treating cats and dogs for the treatment of addisons disease')|
|('DB01134', 'MONDO:0021140', ['inborn []', 'congenital'], 'examined for treatment of adrenocortical insufficiency especially in multiple sclerosis congenital cerebral palsy polyarteritis nodosa and rheumatoid arthritis currently only approved in treating cats and dogs for the treatment of addisons disease')|
|('DB01134', 'MONDO:0006496', ['Plegias [MESH:D010243]', 'Plegia [MESH:D010243]', 'palsy'], 'examined for treatment of adrenocortical insufficiency especially in multiple sclerosis congenital cerebral palsy polyarteritis nodosa and rheumatoid arthritis currently only approved in treating cats and dogs for the treatment of addisons disease')|
|('DB01134', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'examined for treatment of adrenocortical insufficiency especially in multiple sclerosis congenital cerebral palsy polyarteritis nodosa and rheumatoid arthritis currently only approved in treating cats and dogs for the treatment of addisons disease')|
|('DB01152', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in the topical treatment of vulvovaginal candidiasis')|
|('DB01152', 'MONDO:0006014', ['Candidal vulvovaginitis', 'Candidal: cervix', 'Candidiasis of vulva and vagina', 'Monilial vulvovaginitis', 'Vulvovaginal Candidiasis', 'vulvovaginal candidiasis'], 'used in the topical treatment of vulvovaginal candidiasis')|
|('DB01163', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in the treatment of urinary tract infections caused by some strains of e coli and klebsiella and enterobacter species used mainly against gram negative organisms')|
|('DB01230', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for treatment of attention deficit hyperactivity disorder adhd')|
|('DB01230', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'for treatment of attention deficit hyperactivity disorder adhd')|
|('DB01257', 'MONDO:0007743', ['attention deficit hyperactivity disorder [NCIT:C97160]', 'attention deficit/hyperactivity disorder [NCIT:C97160]', 'attention deficit-hyperactivity disorder [MONDO:Lexical,OMIM:143465]', 'attention deficit-hyperactivity disorder'], 'eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria pnh to reduce hemolysis atypical hemolytic uremic syndrome to inhibit complementmediated thrombotic microangiopathyl6919a2246 and neuromyelitis optica spectrum disorder nmosdl6916')|
|('DB01257', 'MONDO:0018641', ['paroxysmal nocturnal hemoglobinuria'], 'eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria pnh to reduce hemolysis atypical hemolytic uremic syndrome to inhibit complementmediated thrombotic microangiopathyl6919a2246 and neuromyelitis optica spectrum disorder nmosdl6916')|
|('DB01257', 'MONDO:0019100', ['Devics disease', 'Devics syndrome', 'neuromyelitis optica'], 'eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria pnh to reduce hemolysis atypical hemolytic uremic syndrome to inhibit complementmediated thrombotic microangiopathyl6919a2246 and neuromyelitis optica spectrum disorder nmosdl6916')|
|('DB01266', 'MONDO:0019100', ['Devics disease', 'Devics syndrome', 'neuromyelitis optica'], 'for the topical treatment of external genital and perianal warts condylomata acuminata in immunocompetent patients 18 years and older')|
|('DB01269', 'MONDO:0019100', ['Devics disease', 'Devics syndrome', 'neuromyelitis optica'], 'for the treatment of egfrexpressing metastatic colorectal carcinoma that is refractory to fluoropyrimidine oxaliplatin and irinotecan containing chemotherapy regimens')|
|('DB01269', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of egfrexpressing metastatic colorectal carcinoma that is refractory to fluoropyrimidine oxaliplatin and irinotecan containing chemotherapy regimens')|
|('DB01270', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'for the treatment of patients with macular edema after retinal vein occlusion agerelated macular degeneration wet and diabetic macular edema')|
|('DB01270', 'MONDO:0003005', ['macular edema', 'macular oedema', 'macular retinal oedema', 'macular retinal edema'], 'for the treatment of patients with macular edema after retinal vein occlusion agerelated macular degeneration wet and diabetic macular edema')|
|('DB01270', 'MONDO:0006951', ['Occlusion, of retinal vein', 'Retinal vein occlusion', 'retinal vein occlusion'], 'for the treatment of patients with macular edema after retinal vein occlusion agerelated macular degeneration wet and diabetic macular edema')|
|('DB01270', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'for the treatment of patients with macular edema after retinal vein occlusion agerelated macular degeneration wet and diabetic macular edema')|
|('DB01270', 'MONDO:0004728', ['diabetic macular edema'], 'for the treatment of patients with macular edema after retinal vein occlusion agerelated macular degeneration wet and diabetic macular edema')|
|('DB01271', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'for the treatment of hunter syndrome in adults and children ages 5 and older')|
|('DB01271', 'MONDO:0010674', ['deficiency of iduronate-2-sulphatase', 'Hunter syndrome', 'Hunters syndrome', 'MPS II - Hunter syndrome', 'Mucopolysaccharidosis, MPS-II', 'mucopolysaccharidosis type 2'], 'for the treatment of hunter syndrome in adults and children ages 5 and older')|
|('DB01272', 'MONDO:0010674', ['deficiency of iduronate-2-sulphatase', 'Hunter syndrome', 'Hunters syndrome', 'MPS II - Hunter syndrome', 'Mucopolysaccharidosis, MPS-II', 'mucopolysaccharidosis type 2'], 'for the treatment of pompe disease gaa deficiency in infants and pediatric patients')|
|('DB01276', 'MONDO:0010674', ['deficiency of iduronate-2-sulphatase', 'Hunter syndrome', 'Hunters syndrome', 'MPS II - Hunter syndrome', 'Mucopolysaccharidosis, MPS-II', 'mucopolysaccharidosis type 2'], 'exenatide is indicated for improving glycemic control in adults with type 2 diabetes mellitus along with diet and exerciselabel')|
|('DB01276', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'exenatide is indicated for improving glycemic control in adults with type 2 diabetes mellitus along with diet and exerciselabel')|
|('DB01277', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the longterm treatment of growth failure in pediatric patients with primary igfd or with gh gene deletion who have developed neutralizing antibodies to gh a2322 it is not indicated to treat secondary igfd resulting from gh deficiency malnutrition hypothyroidism or other causes it is not a substitute for gh therapy')|
|('DB01277', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for the longterm treatment of growth failure in pediatric patients with primary igfd or with gh gene deletion who have developed neutralizing antibodies to gh a2322 it is not indicated to treat secondary igfd resulting from gh deficiency malnutrition hypothyroidism or other causes it is not a substitute for gh therapy')|
|('DB01278', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy')|
|('DB01278', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy')|
|('DB01279', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of adults and children with mucopolysaccharidosis vi')|
|('DB01279', 'MONDO:0019249', ['mucopolysaccharidosis'], 'for the treatment of adults and children with mucopolysaccharidosis vi')|
|('DB01281', 'MONDO:0019249', ['mucopolysaccharidosis'], 'for the management of the signs and symptoms of moderatetosevere active rheumatoid arthritis inducing major clinical response slowing the progression of structural damage and improving physical function in adult patients it is indicated both as a monotherapy and for use in combination with a continued regimen of dmards not including tnf antagonists also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children')|
|('DB01281', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the management of the signs and symptoms of moderatetosevere active rheumatoid arthritis inducing major clinical response slowing the progression of structural damage and improving physical function in adult patients it is indicated both as a monotherapy and for use in combination with a continued regimen of dmards not including tnf antagonists also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children')|
|('DB01281', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'for the management of the signs and symptoms of moderatetosevere active rheumatoid arthritis inducing major clinical response slowing the progression of structural damage and improving physical function in adult patients it is indicated both as a monotherapy and for use in combination with a continued regimen of dmards not including tnf antagonists also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children')|
|('DB01284', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency')|
|('DB01284', 'MONDO:0000004', ['Adrenal Cortical Insufficiency', 'Corticoadrenal insufficiency', 'adrenocortical insufficiency'], 'for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency')|
|('DB01285', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency')|
|('DB01285', 'MONDO:0000004', ['Adrenal Cortical Insufficiency', 'Corticoadrenal insufficiency', 'adrenocortical insufficiency'], 'for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency')|
|('DB01306', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus')|
|('DB01306', 'MONDO:0005015', ['diabetes mellitus'], 'insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus')|
|('DB01307', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus')|
|('DB01307', 'MONDO:0005015', ['diabetes mellitus'], 'insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus')|
|('DB01309', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus')|
|('DB01309', 'MONDO:0005015', ['diabetes mellitus'], 'insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus')|
|('DB01344', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'used to treat abnormally high potassium levels')|
|('DB01345', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions ')|
|('DB01363', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'ephedra is indicated for the temporary relief of shortness of breath tightness of chest and wheezing due to bronchial asthma  for the temporary relief of bronchial asthma in overthecounter formulations ')|
|('DB01373', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'calcium plays a vital role in the anatomy physiology and biochemistry of organisms and of the cell particularly in signal transduction pathways it is vital in cell signaling muscular contractions bone health and signalling cascades')|
|('DB01381', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'appears to be effective in alleviating agerelated memory impairment in some elderly people with mild to moderate agerelated memory or cognitive impairment improving cognitive function in healthy young to middleaged people improving symptoms of alzheimers vascular or mixed dementia improving damage to the visual field in patients with normal tension glaucoma decreasing the number of painful attacks in patients with raynauds syndrome and may improve symptoms of vertigo and dizziness in some patients ')|
|('DB01381', 'MONDO:0006837', ['Normal tension glaucoma', 'low tension glaucoma'], 'appears to be effective in alleviating agerelated memory impairment in some elderly people with mild to moderate agerelated memory or cognitive impairment improving cognitive function in healthy young to middleaged people improving symptoms of alzheimers vascular or mixed dementia improving damage to the visual field in patients with normal tension glaucoma decreasing the number of painful attacks in patients with raynauds syndrome and may improve symptoms of vertigo and dizziness in some patients ')|
|('DB01381', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'appears to be effective in alleviating agerelated memory impairment in some elderly people with mild to moderate agerelated memory or cognitive impairment improving cognitive function in healthy young to middleaged people improving symptoms of alzheimers vascular or mixed dementia improving damage to the visual field in patients with normal tension glaucoma decreasing the number of painful attacks in patients with raynauds syndrome and may improve symptoms of vertigo and dizziness in some patients ')|
|('DB01388', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'for the treatment of angina and high blood pressure')|
|('DB01388', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'for the treatment of angina and high blood pressure')|
|('DB01405', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'for the treatment of lower respiratory tract infections genital and urinary infections like prostatitis and skin infections')|
|('DB01405', 'MONDO:0005280', ['prostatitis'], 'for the treatment of lower respiratory tract infections genital and urinary infections like prostatitis and skin infections')|
|('DB01432', 'MONDO:0005280', ['prostatitis'], 'indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia elevated low density lipoprotein ldl cholesterol who do not respond adequately to diet also for the relief of pruritus associated with partial biliary obstruction')|
|('DB01434', 'MONDO:0005280', ['prostatitis'], 'the claim that supplemental 19norandrostenedione has anabolic effects is unsubstantiated')|
|('DB01434', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the claim that supplemental 19norandrostenedione has anabolic effects is unsubstantiated')|
|('DB01442', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mmda is a recreational drug it has no current medical uses and is a schedule i controlled substance in the usa at present')|
|('DB01444', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dimethylthiambutene is an opioid analgesic previously used in moderate pain relief')|
|('DB01454', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'clinical trials are now testing the therapeutic potential of mdma for posttraumatic stress disorder ptsd and anxiety associated with terminal cancer mdma is one of the four most widely used illicit drugs in the us')|
|('DB01454', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'clinical trials are now testing the therapeutic potential of mdma for posttraumatic stress disorder ptsd and anxiety associated with terminal cancer mdma is one of the four most widely used illicit drugs in the us')|
|('DB01459', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'a narcotic analgesic once used for the treatment of severe chronic pain a14383 ')|
|('DB01486', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used to decrease appetite')|
|('DB01488', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'some people use this compound as a psychedelic inducing agent')|
|('DB01497', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'etorphine is only available for its use in veterinary this main usage is related to the immobilization of large mammals')|
|('DB01520', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'because of its high affinity for the phencyclidine binding site on the nmda receptor the 3h radiolabelled form of tenocyclidine is widely used in research into nmda receptors')|
|('DB01535', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'carfentanil is similar but more potent to the opioid analgesic fentanyl it is used as a tranquilizer for large animals')|
|('DB01546', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'developed in the 1960s for use as an antidepressant before market withdrawal in 1962 ')|
|('DB01548', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'diprenorphine is indicated to reverse the effects of powerful opioids including etorphine and carfentanil often used for tranquilizing large animals this drug is not approved for use in humans')|
|('DB01549', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'rolicyclidine has anesthetic properties and can induce a sedative effect ')|
|('DB01549', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'rolicyclidine has anesthetic properties and can induce a sedative effect ')|
|('DB01556', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as an appetite suppressant')|
|('DB01563', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'mainly used as a hypnotic in the treatment of insomnia however it is only effective as a hypnotic for shortterm use may be used as a routine sedative preoperatively to decrease anxiety and cause sedation andor sleep with respiration depression or cough reflex ')|
|('DB01563', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'mainly used as a hypnotic in the treatment of insomnia however it is only effective as a hypnotic for shortterm use may be used as a routine sedative preoperatively to decrease anxiety and cause sedation andor sleep with respiration depression or cough reflex ')|
|('DB01563', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'mainly used as a hypnotic in the treatment of insomnia however it is only effective as a hypnotic for shortterm use may be used as a routine sedative preoperatively to decrease anxiety and cause sedation andor sleep with respiration depression or cough reflex ')|
|('DB01564', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'an anabolic steroid which can theoretically aid in restauration and buildup of certain tissues especially muscle it is similar to synthetic testosterone and is still in early investigation it was also investigated for use as a treatment for metastatic breast cancer')|
|('DB01564', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'an anabolic steroid which can theoretically aid in restauration and buildup of certain tissues especially muscle it is similar to synthetic testosterone and is still in early investigation it was also investigated for use as a treatment for metastatic breast cancer')|
|('DB01564', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'an anabolic steroid which can theoretically aid in restauration and buildup of certain tissues especially muscle it is similar to synthetic testosterone and is still in early investigation it was also investigated for use as a treatment for metastatic breast cancer')|
|('DB01565', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'dihydromorphine is an opioid analgesic used for moderate to severe pain relief')|
|('DB01569', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'no approved indications studied experimentally as a treatment for nonpituitary growth retardationa14416')|
|('DB01574', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'when used in medicine it physically binds to acids and toxic substances in the stomach and digestive tract for that reason it has often been used in antidiarrheal medications attapulgite is an adsorbent ')|
|('DB01574', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'when used in medicine it physically binds to acids and toxic substances in the stomach and digestive tract for that reason it has often been used in antidiarrheal medications attapulgite is an adsorbent ')|
|('DB01575', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used for upset stomach and diarrhea a traditional medicine used in china south america and africa kaolin is also used to treat aidsrelated diarrhea kaolin based bandages are also under investigation ')|
|('DB01584', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of hypothyroidism deficiency in the production of thyroid hormone')|
|('DB01584', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for the treatment of hypothyroidism deficiency in the production of thyroid hormone')|
|('DB01638', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'used as a nonstimulant laxative via an oral suspension or enema')|
|('DB01645', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'currently genistein is being studied in clinical trials as a treatment for prostate cancer  ')|
|('DB01645', 'MONDO:0004992', ['cancer'], 'currently genistein is being studied in clinical trials as a treatment for prostate cancer  ')|
|('DB01669', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for the treatment of bacterial infections')|
|('DB01685', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'indicated for the treatment of gout and hyperurcemia in japan')|
|('DB01685', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'indicated for the treatment of gout and hyperurcemia in japan')|
|('DB01708', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0005298', ['osteoporosis'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0007931', ['polymorphic vitelline macular degeneration [Orphanet:1243]', 'BMD [Orphanet:1243]', 'macular degeneration, polymorphic vitelline [https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'macular dystrophy, vitelliform, type 2 [MONDORULE:1,OMIM:153700]', 'vitelliform macular dystrophy, early-onset [https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'Best disease [Orphanet:1243,https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'juvenile-onset vitelliform macular dystrophy [Orphanet:1243,https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'vitelliform macular dystrophy, juvenile-onset [https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'BVMD [GARD:0000182,Orphanet:1243]', 'Best macular dystrophy [Orphanet:1243,https://rarediseases.org/rare-diseases/best-vitelliform-macular-dystrophy/]', 'early-onset vitelliform macular dystrophy [Orphanet:1243]', 'vitelliform macular dystrophy type 2 [GARD:0000182,Orphanet:1243]', 'BEST1 retinopathy [GARD:0010301]', 'vitelliform macular dystrophy 2'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0005451', ['eating disorder'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01708', 'MONDO:0005351', ['anorexia nervosa'], 'dhea is taken as a supplement for a variety of unsubstantiated indications the following indications have shown promise and are backed up by some scientific evidence schizophrenia dhea may be more effective in women than men improving the appearance of older people’s skin taking dhea by mouth seems to increase skin thickness and moisture and decrease facial “age spots” in elderly men and women improving ability to achieve an erection in men with sexual dysfunction additionally dhea has shown promise in improving symptoms of lupus sle taking dhea by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed dhea may also help sle symptoms such as muscle ache and mouth ulcers dhea also seems to strengthen bones in sle patients being treated with highdose steroids corticosteroidsdhea also shows promise in the treatment of osteoporosis taking dhea by mouth daily seems to improve bone mineral density bmd in older women and men with osteoporosis or osteopenia preosteoporosis dhea may also increase bmd in young women with the eating disorder called anorexia nervosa dhea is often prescribed in india for the induction of ovulation to improve chances of pregnancy')|
|('DB01783', 'MONDO:0005351', ['anorexia nervosa'], 'studied for the treatment of many uses such as treatment of testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy it has also been investigated for its hypolipidemic effects and as cholesterol lowering agent')|
|('DB01783', 'MONDO:0008541', ['testicular Torsion', 'Torsion of testicle', 'Torsion of testis', 'spermatic cord torsion'], 'studied for the treatment of many uses such as treatment of testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy it has also been investigated for its hypolipidemic effects and as cholesterol lowering agent')|
|('DB01783', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'studied for the treatment of many uses such as treatment of testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy it has also been investigated for its hypolipidemic effects and as cholesterol lowering agent')|
|('DB01783', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'studied for the treatment of many uses such as treatment of testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy it has also been investigated for its hypolipidemic effects and as cholesterol lowering agent')|
|('DB01783', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'studied for the treatment of many uses such as treatment of testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy it has also been investigated for its hypolipidemic effects and as cholesterol lowering agent')|
|('DB01873', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in colorectal cancer lung cancer breast cancer solid tumors and prostate cancer')|
|('DB01873', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer lung cancer breast cancer solid tumors and prostate cancer')|
|('DB01873', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in colorectal cancer lung cancer breast cancer solid tumors and prostate cancer')|
|('DB01914', 'MONDO:0004992', ['cancer'], 'glucose pharmaceutical formulations oral tablets injections are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation it is also used for metabolic disorders such as hypoglycemial787')|
|('DB01956', 'MONDO:0004992', ['cancer'], 'the use of diet supplements containing taurine is indicated for the nutritional support of infants and young pediatric patients requiring total parenteral nutrition via central or peripheral routes the usage of diet supplements containing taurine prevents nitrogen and weight loss or to treat negative nitrogen balance in pediatric patients where the alimentary tract cannot be done through oral gastrostomy or jejunostomy administration there is impaired gastrointestinal absorption or protein requirements are substantially increasedfda label')|
|('DB02132', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in neuropathy diabetic')|
|('DB02342', 'MONDO:0004992', ['cancer'], 'for the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis')|
|('DB02342', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis')|
|('DB02342', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis')|
|('DB02383', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for the pharmacological control of certain diabetic complications')|
|('DB02659', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'oral cholic acid is indicated for treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including zellweger spectrum disorders in patients who exhibit manifestations of liver disease steatorrhea or complications from decreased fat soluble vitamin absorption ')|
|('DB02659', 'MONDO:0019234', ['peroxisome biogenesis disorders, Zellweger syndrome spectrum [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'Zellweger syndrome spectrum [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'peroxisome biogenesis disorder spectrum [Orphanet:79189]', 'Zellweger spectrum disorder [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'Zellweger spectrum [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'PBD-ZSD [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'PBD, ZSS [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'ZSD [MONDO:cjm,https://ghr.nlm.nih.gov/condition/zellweger-spectrum-disorder]', 'peroxisome biogenesis disorder'], 'oral cholic acid is indicated for treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including zellweger spectrum disorders in patients who exhibit manifestations of liver disease steatorrhea or complications from decreased fat soluble vitamin absorption ')|
|('DB02659', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'oral cholic acid is indicated for treatment of bile acid synthesis disorders due to single enzyme defects and as adjunctive treatment of peroxisomal disorders including zellweger spectrum disorders in patients who exhibit manifestations of liver disease steatorrhea or complications from decreased fat soluble vitamin absorption ')|
|('DB02709', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'being investigated for the treatment of herpes labialis infections cold sores')|
|('DB02709', 'MONDO:0043653', ['cold Sore [MESH:D006560,NCIT:C34695]', 'herpes labialis []', 'herpes labialis'], 'being investigated for the treatment of herpes labialis infections cold sores')|
|('DB02709', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'being investigated for the treatment of herpes labialis infections cold sores')|
|('DB03010', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in ovarian cancer lung cancer brain cancer breast cancer and gastric cancer')|
|('DB03010', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer lung cancer brain cancer breast cancer and gastric cancer')|
|('DB03010', 'MONDO:0001056', ['Ca body - stomach', 'ca greater curvature of stomach', 'Ca lesser curvature - stomach', 'gastric cancer', 'gastric neoplasm', 'malignant neoplasm of body of stomach', 'malignant neoplasm of lesser curve of stomach', 'malignant tumor of body of stomach', 'malignant tumor of greater curve of stomach', 'malignant tumor of lesser curve of stomach', 'gastric cancer'], 'investigated for usetreatment in ovarian cancer lung cancer brain cancer breast cancer and gastric cancer')|
|('DB03088', 'MONDO:0004992', ['cancer'], 'there is currently no clinically approved andor marketed medicine that relies upon pidolic acid as an active ingredient for any formal therapeutic indicationalthough pidolic acid may be sold in a variety of nonprescription overthecounter dietary supplement products for cognitive or memory enhancement there are many studies that suggest that such products or such supplementation do not elicit any kind of cognitive benefit to users a32981 a32982 in fact the general suggestion for any such pidolic acid product is to exercise caution in their recommendation as much more research is necessary a32981pidolic acid and sodium pidolic acid are however used to some extent in skin and hair conditioning agents owing to their humectant characteristics f53')|
|('DB03128', 'MONDO:0004992', ['cancer'], 'used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery in penetrating keratoplasty iridectomy and other anterior segment surgery where rapid miosis may be required')|
|('DB03128', 'MONDO:0005129', ['cataract'], 'used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery in penetrating keratoplasty iridectomy and other anterior segment surgery where rapid miosis may be required')|
|('DB03209', 'MONDO:0005129', ['cataract'], 'oteracil is used as an adjunct to antineoplastic therapy when used within the product teysuno oteracil is indicated for the treatment of adults with advanced gastric stomach cancer when given in combination with cisplatin')|
|('DB03348', 'MONDO:0005129', ['cataract'], 'under investigation for the treatment of alzheimers disease')|
|('DB03404', 'MONDO:0005129', ['cataract'], 'used in the management of porphyria attacks particularly in acute intermittent porphyria')|
|('DB03404', 'MONDO:0037939', ['porphyria []', 'porphyria'], 'used in the management of porphyria attacks particularly in acute intermittent porphyria')|
|('DB03424', 'MONDO:0037939', ['porphyria []', 'porphyria'], 'an adjuvant therapy used  for acute and chronic myelonous leukemia lung cancer and nasopharyngeal cancer it is also used to treat hypercholesterolaemia')|
|('DB03424', 'MONDO:0005059', ['leukemia'], 'an adjuvant therapy used  for acute and chronic myelonous leukemia lung cancer and nasopharyngeal cancer it is also used to treat hypercholesterolaemia')|
|('DB03424', 'MONDO:0004992', ['cancer'], 'an adjuvant therapy used  for acute and chronic myelonous leukemia lung cancer and nasopharyngeal cancer it is also used to treat hypercholesterolaemia')|
|('DB03496', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in esophageal cancer leukemia lymphoid lung cancer liver cancer and lymphoma unspecified')|
|('DB03496', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in esophageal cancer leukemia lymphoid lung cancer liver cancer and lymphoma unspecified')|
|('DB03516', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of cancer in combination with 5fluorouracil')|
|('DB03516', 'MONDO:0004992', ['cancer'], 'for the treatment of cancer in combination with 5fluorouracil')|
|('DB03619', 'MONDO:0004992', ['cancer'], 'for improvement in appearance of moderate to severe fullness associated with submental fat in adults ')|
|('DB03754', 'MONDO:0004992', ['cancer'], 'for the prevention and correction of metabolic acidosis')|
|('DB03754', 'MONDO:0000440', ['metabolic acidosis'], 'for the prevention and correction of metabolic acidosis')|
|('DB03756', 'MONDO:0004992', ['cancer'], 'used as a highdocosahexaenoic acid dha oral supplement ')|
|('DB03766', 'MONDO:0004992', ['cancer'], 'propanoic acid and various direct sodium or calcium salt formulations of the acid are currently most commonly approved and indicated by organizations like the fda and ema for use as an antibacterial food additive preservative in animal feed and food for human consumption l2715 l2716similarly although the use of propanoic acid or any of its direct sodium or calcium salt formulations as excipient ingredients in pharmaceuticals is not necessarily a major role for the compound today sodium propionate was used in some vaginal cream preparations indicated for cervicitis cervical tears andor postcauterization postcryosurgery and postconization of the cervix t193 in such products the sodium propionate was primarily used to elicit a preservative bacteriostatic l2710 f50 effect while other active ingredients combined in the formulation like urea benzalkonium chloride inositol and methionine and cystine amino acids facilitated debridement enhanced medication spread epithelialization promotion and wound healing respectively l2710 a32973nevertheless a great variety of propionic acid derivatives exist as separate pharmaceuticals each with their own unique therapeutic categories pharmacodynamics and pharmacokinetics')|
|('DB03766', 'MONDO:0002345', ['cervicitis'], 'propanoic acid and various direct sodium or calcium salt formulations of the acid are currently most commonly approved and indicated by organizations like the fda and ema for use as an antibacterial food additive preservative in animal feed and food for human consumption l2715 l2716similarly although the use of propanoic acid or any of its direct sodium or calcium salt formulations as excipient ingredients in pharmaceuticals is not necessarily a major role for the compound today sodium propionate was used in some vaginal cream preparations indicated for cervicitis cervical tears andor postcauterization postcryosurgery and postconization of the cervix t193 in such products the sodium propionate was primarily used to elicit a preservative bacteriostatic l2710 f50 effect while other active ingredients combined in the formulation like urea benzalkonium chloride inositol and methionine and cystine amino acids facilitated debridement enhanced medication spread epithelialization promotion and wound healing respectively l2710 a32973nevertheless a great variety of propionic acid derivatives exist as separate pharmaceuticals each with their own unique therapeutic categories pharmacodynamics and pharmacokinetics')|
|('DB03766', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'propanoic acid and various direct sodium or calcium salt formulations of the acid are currently most commonly approved and indicated by organizations like the fda and ema for use as an antibacterial food additive preservative in animal feed and food for human consumption l2715 l2716similarly although the use of propanoic acid or any of its direct sodium or calcium salt formulations as excipient ingredients in pharmaceuticals is not necessarily a major role for the compound today sodium propionate was used in some vaginal cream preparations indicated for cervicitis cervical tears andor postcauterization postcryosurgery and postconization of the cervix t193 in such products the sodium propionate was primarily used to elicit a preservative bacteriostatic l2710 f50 effect while other active ingredients combined in the formulation like urea benzalkonium chloride inositol and methionine and cystine amino acids facilitated debridement enhanced medication spread epithelialization promotion and wound healing respectively l2710 a32973nevertheless a great variety of propionic acid derivatives exist as separate pharmaceuticals each with their own unique therapeutic categories pharmacodynamics and pharmacokinetics')|
|('DB03783', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'used principally as an analgesic')|
|('DB03843', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'use for drying skin before or after surgical removal of warts or where dryness is required ')|
|('DB03849', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in chronic obstructive pulmonary disease copd')|
|('DB03904', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'ulli10 hydrate skinlili15 accelerate fibrin degradationlili2030 are antipruritic break down keratin decrease the thickness of the stratum corneum and are used in scaling conditions such as ichthysosislili40 are proteolytic and may be used to dissolve and peel dystrophic nailsliulbrpatient self care 2010br')|
|('DB03925', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in chronic obstructive pulmonary disease copd')|
|('DB04209', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'effective local treatment as vaginal tablets for infections such as fluor vaginalis bacterial vaginosis aerobic vaginitis vulvovaginal candidiasis and trichomoniasis used as a topical antimicrobial agent ')|
|('DB04209', 'MONDO:0005316', ['bacterial vaginosis'], 'effective local treatment as vaginal tablets for infections such as fluor vaginalis bacterial vaginosis aerobic vaginitis vulvovaginal candidiasis and trichomoniasis used as a topical antimicrobial agent ')|
|('DB04209', 'MONDO:0002234', ['vaginitis'], 'effective local treatment as vaginal tablets for infections such as fluor vaginalis bacterial vaginosis aerobic vaginitis vulvovaginal candidiasis and trichomoniasis used as a topical antimicrobial agent ')|
|('DB04209', 'MONDO:0002026', ['Disseminated candidiasis', 'systemic candidiasis', 'candidiasis'], 'effective local treatment as vaginal tablets for infections such as fluor vaginalis bacterial vaginosis aerobic vaginitis vulvovaginal candidiasis and trichomoniasis used as a topical antimicrobial agent ')|
|('DB04209', 'MONDO:0002154', ['trichomoniasis'], 'effective local treatment as vaginal tablets for infections such as fluor vaginalis bacterial vaginosis aerobic vaginitis vulvovaginal candidiasis and trichomoniasis used as a topical antimicrobial agent ')|
|('DB04335', 'MONDO:0002154', ['trichomoniasis'], 'the primary popular claim made for inosine that it enhances exercise and athletic performance is refuted by the available research data there is some preliminary evidence that inosine may have some neurorestorative antiinflammatory immunomodulatory and cardioprotective effects')|
|('DB04339', 'MONDO:0002154', ['trichomoniasis'], 'used to help relieve the symptoms of chronic obstructive pulmonary disorder copd and bronchiectasis')|
|('DB04339', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'used to help relieve the symptoms of chronic obstructive pulmonary disorder copd and bronchiectasis')|
|('DB04339', 'MONDO:0004822', ['Polynesian bronchiectasis', 'bronchiectasis'], 'used to help relieve the symptoms of chronic obstructive pulmonary disorder copd and bronchiectasis')|
|('DB04398', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use as an alkalinizing agent')|
|('DB04468', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the potential treatment of menstrualcycle related mastalgia fibrocystic breast disease breast disease gynecomastia and keloid scarring')|
|('DB04468', 'MONDO:0005348', ['keloid'], 'for the potential treatment of menstrualcycle related mastalgia fibrocystic breast disease breast disease gynecomastia and keloid scarring')|
|('DB04576', 'MONDO:0005348', ['keloid'], 'fleroxacin is a broadspectrum antimicrobial fluoroquinolone')|
|('DB04626', 'MONDO:0005348', ['keloid'], 'for the treatment of bacterial infections in animals')|
|('DB04690', 'MONDO:0005348', ['keloid'], 'investigated for the treatment of cancer')|
|('DB04690', 'MONDO:0004992', ['cancer'], 'investigated for the treatment of cancer')|
|('DB04725', 'MONDO:0005348', ['keloid'], 'for the management of osteoarthritis')|
|('DB04725', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the management of osteoarthritis')|
|('DB04743', 'MONDO:0005348', ['keloid'], 'for the treatment of acute pain the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old')|
|('DB04743', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of acute pain the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old')|
|('DB04796', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in prostate cancer psoriasis and hyperparathyroidism')|
|('DB04796', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer psoriasis and hyperparathyroidism')|
|('DB04796', 'MONDO:0001741', ['hyperparathyroidism'], 'investigated for usetreatment in prostate cancer psoriasis and hyperparathyroidism')|
|('DB04815', 'MONDO:0004992', ['cancer'], 'used as a topical antifungal treatment')|
|('DB04817', 'MONDO:0004992', ['cancer'], 'used in the past as a powerful painkiller and fever reducer')|
|('DB04818', 'MONDO:0004992', ['cancer'], 'for the treatment of depression originally intended to treat tuberculosis')|
|('DB04818', 'MONDO:0018076', ['tuberculosis'], 'for the treatment of depression originally intended to treat tuberculosis')|
|('DB04824', 'MONDO:0004992', ['cancer'], 'used for over a century as a laxative')|
|('DB04828', 'MONDO:0004992', ['cancer'], 'zomepirac was indicated for the management of mild to severe pain')|
|('DB04831', 'MONDO:0004992', ['cancer'], 'for the treatment of hypertension')|
|('DB04832', 'MONDO:0004992', ['cancer'], 'for the treatment of depression')|
|('DB04833', 'MONDO:0004992', ['cancer'], 'for the treatment of insomnia and as a sedative and muscle relaxant')|
|('DB04833', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of insomnia and as a sedative and muscle relaxant')|
|('DB04834', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'used in anaesthesia to aid and enable endotracheal intubation')|
|('DB04836', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of depression')|
|('DB04846', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'celiprolol is indicated for the management of mild to moderate hypertension and effortinduced angina pectoris ')|
|('DB04847', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'in clinical development for the treatment of anemia of chronic inflammatory disease')|
|('DB04847', 'MONDO:0002280', ['anaemia', 'anemia'], 'in clinical development for the treatment of anemia of chronic inflammatory disease')|
|('DB04848', 'MONDO:0002280', ['anaemia', 'anemia'], 'intended for the treatment of urinary incontinence')|
|('DB04849', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the treatment of liver cancer advanced nonsmall cell lung cancer nsclc advanced colorectal cancer crc and other solid tumors')|
|('DB04849', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'for the treatment of liver cancer advanced nonsmall cell lung cancer nsclc advanced colorectal cancer crc and other solid tumors')|
|('DB04849', 'MONDO:0004992', ['cancer'], 'for the treatment of liver cancer advanced nonsmall cell lung cancer nsclc advanced colorectal cancer crc and other solid tumors')|
|('DB04850', 'MONDO:0004992', ['cancer'], 'for the treatment of grampositive infections including multiresistant strains')|
|('DB04851', 'MONDO:0004992', ['cancer'], 'administered intravenously biricodar dicitrate is to be used in combination with cancer chemotherapy agents')|
|('DB04852', 'MONDO:0004992', ['cancer'], 'for the treatment of atherosclerosis')|
|('DB04852', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment of atherosclerosis')|
|('DB04853', 'MONDO:0004992', ['cancer'], 'for cardiac pharmacologic stress spect imaging which is used to diagnose coronary artery disease')|
|('DB04853', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for cardiac pharmacologic stress spect imaging which is used to diagnose coronary artery disease')|
|('DB04854', 'MONDO:0004992', ['cancer'], 'for the treatment of hyperuricemia in patients with gout')|
|('DB04854', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for the treatment of hyperuricemia in patients with gout')|
|('DB04856', 'MONDO:0004992', ['cancer'], 'for the treatment of irritable bowel syndrome ibs and gastroesophageal reflux disease gerd')|
|('DB04856', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of irritable bowel syndrome ibs and gastroesophageal reflux disease gerd')|
|('DB04856', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of irritable bowel syndrome ibs and gastroesophageal reflux disease gerd')|
|('DB04857', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of parkinsons disease')|
|('DB04858', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of head and neck cancer')|
|('DB04858', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'for the treatment of head and neck cancer')|
|('DB04859', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'for the treatment of dementia in subjects with alzheimer’s disease')|
|('DB04859', 'MONDO:0001627', ['dementia'], 'for the treatment of dementia in subjects with alzheimer’s disease')|
|('DB04860', 'MONDO:0001627', ['dementia'], 'for the treatment of hepatitis c')|
|('DB04860', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'for the treatment of hepatitis c')|
|('DB04862', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'for the treatment of hepatitis c virus hcv infection')|
|('DB04863', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'for the treatment of unstable angina')|
|('DB04863', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'for the treatment of unstable angina')|
|('DB04864', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in alzheimers disease')|
|('DB04866', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'for the treatment of scleroderma cancer and restenosis')|
|('DB04866', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the treatment of scleroderma cancer and restenosis')|
|('DB04867', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the treatment of pancreatic cancer and appetite disorders')|
|('DB04869', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the treatment of migraine headaches')|
|('DB04870', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the treatment of obesity')|
|('DB04871', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'for the treatment of obesity as an adjunct to a reducedcalorie diet and increased physical activity')|
|('DB04872', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'potential therapy for schizophrenia depression and visceral pain')|
|('DB04872', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'potential therapy for schizophrenia depression and visceral pain')|
|('DB04873', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of atrial fibrillation and irritable bowel syndrome ibs')|
|('DB04873', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'for the treatment of atrial fibrillation and irritable bowel syndrome ibs')|
|('DB04873', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of atrial fibrillation and irritable bowel syndrome ibs')|
|('DB04874', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of patients with solid tumors')|
|('DB04875', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of rheumatoid arthritis ra')|
|('DB04875', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of rheumatoid arthritis ra')|
|('DB04879', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in combination with first and secondline chemotherapy for the treatment of metastatic colorectal cancer and nonsmall cell lung cancer nsclc')|
|('DB04879', 'MONDO:0004992', ['cancer'], 'used in combination with first and secondline chemotherapy for the treatment of metastatic colorectal cancer and nonsmall cell lung cancer nsclc')|
|('DB04881', 'MONDO:0004992', ['cancer'], 'for the treatment of solid tumors')|
|('DB04882', 'MONDO:0004992', ['cancer'], 'clinical studies with edotecarin have shown activity in subjects with colorectal cancer esophageal cancer and other solid tumors')|
|('DB04882', 'MONDO:0005575', ['colorectal cancer'], 'clinical studies with edotecarin have shown activity in subjects with colorectal cancer esophageal cancer and other solid tumors')|
|('DB04883', 'MONDO:0004992', ['cancer'], 'for the treatment of congestive heart failure and hypertension')|
|('DB04883', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of congestive heart failure and hypertension')|
|('DB04884', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of premature ejaculation')|
|('DB04884', 'MONDO:0001780', ['premature ejaculation'], 'for the treatment of premature ejaculation')|
|('DB04885', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of symptoms associated with irritable bowel syndrome')|
|('DB04885', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of symptoms associated with irritable bowel syndrome')|
|('DB04886', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for use in combination treatment of hiv infection aids')|
|('DB04886', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for use in combination treatment of hiv infection aids')|
|('DB04887', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'for the treatment of hiv1 infection in combination with other antiretroviral agents')|
|('DB04888', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'bifeprunox is being evaluated for the treatment of schizophrenia psychosis and parkinsons disease')|
|('DB04888', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'bifeprunox is being evaluated for the treatment of schizophrenia psychosis and parkinsons disease')|
|('DB04889', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of pain')|
|('DB04891', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for topical treatment of psoriasis and psoriatic disorders')|
|('DB04891', 'MONDO:0005083', ['psoriasis'], 'for topical treatment of psoriasis and psoriatic disorders')|
|('DB04892', 'MONDO:0005083', ['psoriasis'], 'for the treatment of alzheimers disease ad')|
|('DB04893', 'MONDO:0005083', ['psoriasis'], 'for the treatment of solid tumors')|
|('DB04895', 'MONDO:0005083', ['psoriasis'], 'for the treatment of neovascular wet agerelated macular degeneration')|
|('DB04895', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'for the treatment of neovascular wet agerelated macular degeneration')|
|('DB04897', 'MONDO:0005083', ['psoriasis'], 'intended for the prevention of respiratory distress syndrome rds in premature infants at high risk for rds ')|
|('DB04899', 'MONDO:0005083', ['psoriasis'], 'for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity')|
|('DB04899', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity')|
|('DB04900', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis b vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization')|
|('DB04900', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis b vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization')|
|('DB04900', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis b vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization')|
|('DB04901', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in lymphoma nonhodgkins psoriasis and psoriatic disorders bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB04901', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in lymphoma nonhodgkins psoriasis and psoriatic disorders bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB04901', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in lymphoma nonhodgkins psoriasis and psoriatic disorders bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB04901', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in lymphoma nonhodgkins psoriasis and psoriatic disorders bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB04903', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the potential treatment of panic and anxiety disorders')|
|('DB04903', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the potential treatment of panic and anxiety disorders')|
|('DB04904', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'intended for the treatment of cervical dysplasia associated with the human papillomavirus hpv')|
|('DB04905', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'intended for the treatment of various forms of cancer')|
|('DB04905', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04907', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'intended for the treatment of brain cancer')|
|('DB04907', 'MONDO:0001657', ['adult brain tumor', 'adult malignant brain neoplasm', 'brain neoplasm', 'brain neoplasm, adult', 'BT - Brain tumour', 'malignant brain tumour', 'malignant primary brain neoplasm', 'malignant primary brain tumor', 'malignant tumor of adult brain', 'malignant tumor of Brain', 'neoplasm of brain', 'primary brain neoplasm', 'primary brain tumor', 'primary malignant neoplasm of brain', 'tumor of the Brain', 'brain cancer'], 'intended for the treatment of brain cancer')|
|('DB04908', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of hypoactive sexual desire disorder hsdd in premenopausal women ')|
|('DB04908', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'for the treatment of hypoactive sexual desire disorder hsdd in premenopausal women ')|
|('DB04909', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'investigated for usetreatment in infectious and parasitic disease unspecified')|
|('DB04910', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'investigated for usetreatment in infectious and parasitic disease unspecified and pediatric indications')|
|('DB04912', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'investigated for usetreatment in liver disease metabolic disease and pediatric indications')|
|('DB04914', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'intended for the treatment of various forms of cancer')|
|('DB04914', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04915', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'intended for the treatment of various forms of cancer')|
|('DB04915', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04917', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'for the treatment of constipationpredominant irritable bowel syndrome ibsc')|
|('DB04917', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of constipationpredominant irritable bowel syndrome ibsc')|
|('DB04918', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of serious bacterial infections in hospitalised patients')|
|('DB04919', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'alfimeprase is being evaluated as a potential treatment for acute ischemic stroke catheter occlusion co and acute peripheral arterial occlusion pao')|
|('DB04919', 'MONDO:0020673', ['arterial occlusion [NCIT:C35318]', 'arterial obstruction [NCIT:C35318]', 'arterial occlusion'], 'alfimeprase is being evaluated as a potential treatment for acute ischemic stroke catheter occlusion co and acute peripheral arterial occlusion pao')|
|('DB04921', 'MONDO:0020673', ['arterial occlusion [NCIT:C35318]', 'arterial obstruction [NCIT:C35318]', 'arterial occlusion'], 'for the treatment of multiple sclerosis ms')|
|('DB04921', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for the treatment of multiple sclerosis ms')|
|('DB04923', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in blood blood forming organ disorders unspecified and hemorrhage')|
|('DB04924', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous')|
|('DB04925', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in cerebral ischemia and strokes')|
|('DB04926', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in alzheimers disease hearing loss and pain acute or chronic')|
|('DB04928', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in menstrual disorders')|
|('DB04929', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in heart disease and myocardial infarction')|
|('DB04929', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in heart disease and myocardial infarction')|
|('DB04931', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'afamelanotide is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria eppl9086')|
|('DB04931', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'afamelanotide is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria eppl9086')|
|('DB04932', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'indicated for the treatment of severe hepatic venoocclusive disease vod also known as sinusoidal obstruction syndrome sos with renal or pulmonary dysfunction following hematopoietic stemcell transplantation hsctlabel')|
|('DB04933', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'investigated for usetreatment in sepsis and septicemia')|
|('DB04934', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'investigated for usetreatment in atherosclerosis bacterial infection and peripheral vascular disease')|
|('DB04934', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in atherosclerosis bacterial infection and peripheral vascular disease')|
|('DB04936', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'intended for use as a therapeutic adjunct in the treatment of type ii diabetes')|
|('DB04941', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'for the symptomatic treatment of noninfectious diarrhea in adult patients with hivaids who are taking antiretroviral therapy')|
|('DB04943', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'investigated for usetreatment in eye disordersinfections and transplant rejection')|
|('DB04944', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'investigated for usetreatment in cardiac reperfusion injury cardiovascular disorders and coronary artery disease')|
|('DB04944', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in cardiac reperfusion injury cardiovascular disorders and coronary artery disease')|
|('DB04944', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in cardiac reperfusion injury cardiovascular disorders and coronary artery disease')|
|('DB04945', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in blood blood forming organ disorders unspecified and hemorrhage')|
|('DB04947', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in attention deficithyperactivity disorder adhd parkinsons disease and pediatric indications')|
|('DB04949', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of inflammation during cardiac surgery')|
|('DB04950', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of various forms of cancer')|
|('DB04950', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB04951', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of idiopathic pulmonary fibrosis ipf')|
|('DB04951', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'for the treatment of idiopathic pulmonary fibrosis ipf')|
|('DB04952', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'for the treatment of bacterial infections')|
|('DB04954', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB04954', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB04955', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in asthma lung injury and surgical adhesions')|
|('DB04956', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in sepsis and septicemia')|
|('DB04957', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB04957', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB04958', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in leukemia lymphoid lymphoma nonhodgkins and systemic lupus erythematosus')|
|('DB04958', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in leukemia lymphoid lymphoma nonhodgkins and systemic lupus erythematosus')|
|('DB04959', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'investigated for usetreatment in anal dysplasia cervical dysplasiacancer genital warts hiv infection infectious and parasitic disease unspecified pediatric indications warts and viral infection')|
|('DB04959', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in anal dysplasia cervical dysplasiacancer genital warts hiv infection infectious and parasitic disease unspecified pediatric indications warts and viral infection')|
|('DB04959', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in anal dysplasia cervical dysplasiacancer genital warts hiv infection infectious and parasitic disease unspecified pediatric indications warts and viral infection')|
|('DB04960', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in colorectal cancer leukemia myeloid pancreatic cancer and solid tumors')|
|('DB04960', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer leukemia myeloid pancreatic cancer and solid tumors')|
|('DB04961', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia myeloid')|
|('DB04962', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lymphoma nonhodgkins')|
|('DB04963', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 1')|
|('DB04964', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer')|
|('DB04968', 'MONDO:0004992', ['cancer'], 'intended for the acute treatment of social phobia')|
|('DB04968', 'MONDO:0001247', ['social phobia'], 'intended for the acute treatment of social phobia')|
|('DB04969', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04970', 'MONDO:0004992', ['cancer'], 'intended for the treatment of anxiety disorders')|
|('DB04970', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'intended for the treatment of anxiety disorders')|
|('DB04971', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of diabetes mellitus type 1 and 2')|
|('DB04971', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of diabetes mellitus type 1 and 2')|
|('DB04972', 'MONDO:0005015', ['diabetes mellitus'], 'intended for the treatment of various forms of cancer')|
|('DB04972', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04973', 'MONDO:0005015', ['diabetes mellitus'], 'intended for the treatment of various forms of cancer')|
|('DB04973', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04974', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in bone marrow transplant and graft versus host disease')|
|('DB04974', 'MONDO:0013730', ['graft VS host disease [NCIT:C3063]', 'graft-versus-host disease [MESH:D006086,NCIT:C3063]', 'runt disease [MESH:D006086,NCIT:C3063]', 'GVH [Orphanet:39812]', 'graft VS. host disease [NCIT:C3063]', 'GVHD [NCIT:C3063]', 'graft versus host disease [MESH:D006086]', 'graft-versus-host-disease [NCIT:C3063]', 'graft versus host disease'], 'investigated for usetreatment in bone marrow transplant and graft versus host disease')|
|('DB04975', 'MONDO:0005015', ['diabetes mellitus'], 'for the treatment of various forms of cancer')|
|('DB04975', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB04976', 'MONDO:0005015', ['diabetes mellitus'], 'intended for the treatment of pain and possibly various forms of cancer')|
|('DB04976', 'MONDO:0004992', ['cancer'], 'intended for the treatment of pain and possibly various forms of cancer')|
|('DB04977', 'MONDO:0005015', ['diabetes mellitus'], 'intended for the treatment of various forms of cancer')|
|('DB04977', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04978', 'MONDO:0005015', ['diabetes mellitus'], 'intended for the treatment of carcinoma of the oesophagus')|
|('DB04978', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'intended for the treatment of carcinoma of the oesophagus')|
|('DB04980', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'intended for the treatment of benign prostatic hyperplasia and prostrate disorders')|
|('DB04980', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'intended for the treatment of benign prostatic hyperplasia and prostrate disorders')|
|('DB04981', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'intended for the treatment of various forms of cancer')|
|('DB04981', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04982', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'for the treatment of epilepsy')|
|('DB04982', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'for the treatment of epilepsy')|
|('DB04983', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'for use as an inhaled treatment for cystic fibrosis')|
|('DB04985', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'for the treatment of late stage hormone refractory prostate cancer hrpc for which no effective therapy currently exists')|
|('DB04985', 'MONDO:0004992', ['cancer'], 'for the treatment of late stage hormone refractory prostate cancer hrpc for which no effective therapy currently exists')|
|('DB04986', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB04987', 'MONDO:0004992', ['cancer'], 'for the potential treatment of cystic fibrosis and bacterial infections')|
|('DB04987', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the potential treatment of cystic fibrosis and bacterial infections')|
|('DB04988', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'intended for the treatment of various forms of cancer')|
|('DB04988', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB04989', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the production of immunity to isalmonella typhii the cause of typhoid fever')|
|('DB04989', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'for the production of immunity to isalmonella typhii the cause of typhoid fever')|
|('DB04991', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'for treatment in patients with diabetes who have clinically significant proteinuria')|
|('DB04991', 'MONDO:0003634', ['proteinuria'], 'for treatment in patients with diabetes who have clinically significant proteinuria')|
|('DB04992', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'for the treatment of various forms of cancer')|
|('DB04992', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB04995', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'investigated for usetreatment in pain acute or chronic')|
|('DB04996', 'MONDO:0005619', ['Typhoid', 'typhoid fever'], 'investigated for usetreatment in lung cancer prostate cancer and solid tumors')|
|('DB04996', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer prostate cancer and solid tumors')|
|('DB04997', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in asthma and multiple sclerosis')|
|('DB04997', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in asthma and multiple sclerosis')|
|('DB04998', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified kidney cancer leukemia myeloid and pancreatic cancer')|
|('DB04999', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in liver cancer')|
|('DB05000', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05001', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 1 and 2')|
|('DB05003', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in melanoma multiple myeloma ovarian cancer pancreatic cancer and solid tumors')|
|('DB05003', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in melanoma multiple myeloma ovarian cancer pancreatic cancer and solid tumors')|
|('DB05004', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in metabolic disease and obesity')|
|('DB05006', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer and prostate cancer')|
|('DB05006', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in breast cancer and prostate cancer')|
|('DB05009', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiovascular disorders and inflammatory disorders unspecified')|
|('DB05010', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd memory loss and schizophrenia and schizoaffective disorders')|
|('DB05010', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd memory loss and schizophrenia and schizoaffective disorders')|
|('DB05011', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cardiovascular disorders and kidney disease')|
|('DB05011', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in cardiovascular disorders and kidney disease')|
|('DB05012', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of chronic cancer pain')|
|('DB05014', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cancertumors unspecified lung cancer and solid tumors')|
|('DB05014', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified lung cancer and solid tumors')|
|('DB05015', 'MONDO:0004992', ['cancer'], 'belinostat is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl with manageable safety profile it is a potential alternative therapy for patients who did not experience adequate response to firstline drugs for ptcl it can be used in patients with baseline thrombocytopenia a19161 ')|
|('DB05015', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'belinostat is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl with manageable safety profile it is a potential alternative therapy for patients who did not experience adequate response to firstline drugs for ptcl it can be used in patients with baseline thrombocytopenia a19161 ')|
|('DB05015', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'belinostat is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl with manageable safety profile it is a potential alternative therapy for patients who did not experience adequate response to firstline drugs for ptcl it can be used in patients with baseline thrombocytopenia a19161 ')|
|('DB05015', 'MONDO:0002049', ['thrombocytopenia'], 'belinostat is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl with manageable safety profile it is a potential alternative therapy for patients who did not experience adequate response to firstline drugs for ptcl it can be used in patients with baseline thrombocytopenia a19161 ')|
|('DB05016', 'MONDO:0002049', ['thrombocytopenia'], 'ataluren is approved for use by the european medicines agency to treat duchenne muscular dystrophy in patients aged 5 years and older who are able to walk more specifically ataluren is used in the small group of patients whose disease is caused by a specific genetic defect called a ‘nonsense mutation’ in the dystrophin gene')|
|('DB05016', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'ataluren is approved for use by the european medicines agency to treat duchenne muscular dystrophy in patients aged 5 years and older who are able to walk more specifically ataluren is used in the small group of patients whose disease is caused by a specific genetic defect called a ‘nonsense mutation’ in the dystrophin gene')|
|('DB05017', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'investigated for usetreatment in crohns disease psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05017', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in crohns disease psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05018', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'migalastat is an alphagalactosidase a alphagal a pharmacological chaperone indicated for the longterm treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of fabry disease alphagalactosidase a deficiency and an amenable galactosidase alpha gene gla mutationvariant based upon in vitro assay data fda label f1107 this indication is approved by the us fda under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide kic gl3 substrate fda label continued approval by the us fda for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials fda label')|
|('DB05018', 'MONDO:0010526', ['alpha galactosidase deficiency', 'Alpha-galactosidase A deficiency', 'Angiokeratoma Corporis Diffusum', 'deficiency of melibiase', 'Fabrys disease', 'fabry disease'], 'migalastat is an alphagalactosidase a alphagal a pharmacological chaperone indicated for the longterm treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of fabry disease alphagalactosidase a deficiency and an amenable galactosidase alpha gene gla mutationvariant based upon in vitro assay data fda label f1107 this indication is approved by the us fda under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide kic gl3 substrate fda label continued approval by the us fda for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials fda label')|
|('DB05018', 'MONDO:0015408', ['diffuse lymphangiomatosis [Orphanet:141209]', 'disseminated lymphatic malformation [Orphanet:141209]', 'diffuse lymphangioma [Orphanet:141209]', 'generalized lymphatic anomaly [Orphanet:141209]', 'disseminated lymphangioma [Orphanet:141209]', 'Gla [Orphanet:141209]', 'disseminated lymphangiomatosis [Orphanet:141209]', 'diffuse lymphatic malformation'], 'migalastat is an alphagalactosidase a alphagal a pharmacological chaperone indicated for the longterm treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of fabry disease alphagalactosidase a deficiency and an amenable galactosidase alpha gene gla mutationvariant based upon in vitro assay data fda label f1107 this indication is approved by the us fda under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide kic gl3 substrate fda label continued approval by the us fda for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials fda label')|
|('DB05019', 'MONDO:0015408', ['diffuse lymphangiomatosis [Orphanet:141209]', 'disseminated lymphatic malformation [Orphanet:141209]', 'diffuse lymphangioma [Orphanet:141209]', 'generalized lymphatic anomaly [Orphanet:141209]', 'disseminated lymphangioma [Orphanet:141209]', 'Gla [Orphanet:141209]', 'disseminated lymphangiomatosis [Orphanet:141209]', 'diffuse lymphatic malformation'], 'investigated for usetreatment in viral infection')|
|('DB05020', 'MONDO:0015408', ['diffuse lymphangiomatosis [Orphanet:141209]', 'disseminated lymphatic malformation [Orphanet:141209]', 'diffuse lymphangioma [Orphanet:141209]', 'generalized lymphatic anomaly [Orphanet:141209]', 'disseminated lymphangioma [Orphanet:141209]', 'Gla [Orphanet:141209]', 'disseminated lymphangiomatosis [Orphanet:141209]', 'diffuse lymphatic malformation'], 'investigated for usetreatment in hepatitis viral b')|
|('DB05021', 'MONDO:0015408', ['diffuse lymphangiomatosis [Orphanet:141209]', 'disseminated lymphatic malformation [Orphanet:141209]', 'diffuse lymphangioma [Orphanet:141209]', 'generalized lymphatic anomaly [Orphanet:141209]', 'disseminated lymphangioma [Orphanet:141209]', 'Gla [Orphanet:141209]', 'disseminated lymphangiomatosis [Orphanet:141209]', 'diffuse lymphatic malformation'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05022', 'MONDO:0015408', ['diffuse lymphangiomatosis [Orphanet:141209]', 'disseminated lymphatic malformation [Orphanet:141209]', 'diffuse lymphangioma [Orphanet:141209]', 'generalized lymphatic anomaly [Orphanet:141209]', 'disseminated lymphangioma [Orphanet:141209]', 'Gla [Orphanet:141209]', 'disseminated lymphangiomatosis [Orphanet:141209]', 'diffuse lymphatic malformation'], 'investigated for usetreatment in breast cancer ovarian cancer and prostate cancer')|
|('DB05022', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer ovarian cancer and prostate cancer')|
|('DB05022', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in breast cancer ovarian cancer and prostate cancer')|
|('DB05023', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB05024', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in kidney disease and psoriasis and psoriatic disorders')|
|('DB05024', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in kidney disease and psoriasis and psoriatic disorders')|
|('DB05025', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als diabetes mellitus type 2 neurologic disorders and neuropathy diabetic')|
|('DB05025', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als diabetes mellitus type 2 neurologic disorders and neuropathy diabetic')|
|('DB05025', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in amyotrophic lateral sclerosis als diabetes mellitus type 2 neurologic disorders and neuropathy diabetic')|
|('DB05027', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05027', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05029', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cystic fibrosis and eye disordersinfections')|
|('DB05032', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in allergic reaction allergic rhinitis and cataracts')|
|('DB05032', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in allergic reaction allergic rhinitis and cataracts')|
|('DB05033', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in breast cancer')|
|('DB05033', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05034', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in congestive heart failure')|
|('DB05034', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure')|
|('DB05035', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in hyperlipidemia metabolic disease and obesity')|
|('DB05035', 'MONDO:0005066', ['metabolic disease', 'metabolic disease'], 'investigated for usetreatment in hyperlipidemia metabolic disease and obesity')|
|('DB05036', 'MONDO:0005066', ['metabolic disease', 'metabolic disease'], 'investigated for usetreatment in leukemia lymphoid and solid tumors')|
|('DB05038', 'MONDO:0005066', ['metabolic disease', 'metabolic disease'], 'investigated for usetreatment in traumatic brain injuries')|
|('DB05040', 'MONDO:0005066', ['metabolic disease', 'metabolic disease'], 'investigated for usetreatment in viral infection')|
|('DB05042', 'MONDO:0005066', ['metabolic disease', 'metabolic disease'], 'investigated for usetreatment in neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05042', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05043', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05043', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05044', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05045', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in obesity')|
|('DB05046', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05047', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'april 18 2007 cortex pharmaceuticals submitted two large data packages to the fda regarding cx717 one data set went to the fdas division of neurology drug products for the treatment of alzheimers disease while the other went to the division of psychiatry products where the company intends to file a second cx717 ind for the treatment of adhd on 18 april 2007 cortex pharmaeuticals submitted data to the fda for the treatment of alzheimers disease as well as adhd the data shows that histopathological changes seen in animal studies were an artifact of postmortem fixation methods and not a change that occurred in the living animals as a result of the drug')|
|('DB05047', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'april 18 2007 cortex pharmaceuticals submitted two large data packages to the fda regarding cx717 one data set went to the fdas division of neurology drug products for the treatment of alzheimers disease while the other went to the division of psychiatry products where the company intends to file a second cx717 ind for the treatment of adhd on 18 april 2007 cortex pharmaeuticals submitted data to the fda for the treatment of alzheimers disease as well as adhd the data shows that histopathological changes seen in animal studies were an artifact of postmortem fixation methods and not a change that occurred in the living animals as a result of the drug')|
|('DB05048', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05049', 'MONDO:0005302', ['ADHD', 'attention deficit disorder', 'hyperkinetic disorder', 'attention deficit hyperactivity disorder'], 'investigated for usetreatment in constipation gastroesophageal reflux disease gerd gastrointestinal diseases and disorders miscellaneous and irritable bowel syndrome ibs')|
|('DB05049', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in constipation gastroesophageal reflux disease gerd gastrointestinal diseases and disorders miscellaneous and irritable bowel syndrome ibs')|
|('DB05049', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in constipation gastroesophageal reflux disease gerd gastrointestinal diseases and disorders miscellaneous and irritable bowel syndrome ibs')|
|('DB05050', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05051', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in breast cancer')|
|('DB05051', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05052', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in hormone replacement therapy menopause and menopause')|
|('DB05053', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05054', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in acne atopic dermatitis pediatric indications and psoriasis and psoriatic disorders')|
|('DB05054', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'investigated for usetreatment in acne atopic dermatitis pediatric indications and psoriasis and psoriatic disorders')|
|('DB05054', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in acne atopic dermatitis pediatric indications and psoriasis and psoriatic disorders')|
|('DB05055', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in bipolar disorders and manic disorders')|
|('DB05056', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in crohns disease hepatitis unspecified and liver disease')|
|('DB05056', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in crohns disease hepatitis unspecified and liver disease')|
|('DB05057', 'MONDO:0005083', ['psoriasis'], 'fro the treatment of chronic bronchitis in adults')|
|('DB05057', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'fro the treatment of chronic bronchitis in adults')|
|('DB05059', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in kidney disease')|
|('DB05060', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05061', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in cardiovascular disorders and hyperlipidemia')|
|('DB05061', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in cardiovascular disorders and hyperlipidemia')|
|('DB05063', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in hepatitis viral c and parkinsons disease')|
|('DB05064', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in diabetes mellitus type 2 and diabetes prevention')|
|('DB05068', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in diabetic foot ulcers and wounds')|
|('DB05069', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in macular degeneration')|
|('DB05070', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'investigated for usetreatment in anxiety disorders gastroesophageal reflux disease gerd and migraine and cluster headaches')|
|('DB05070', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in anxiety disorders gastroesophageal reflux disease gerd and migraine and cluster headaches')|
|('DB05071', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in diarrhea and infectious and parasitic disease unspecified')|
|('DB05072', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in anxiety disorders irritable bowel syndrome ibs and urinary incontinence')|
|('DB05073', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in diabetes mellitus type 2 and neurologic disorders')|
|('DB05075', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in macular degeneration')|
|('DB05076', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in macular degeneration')|
|('DB05077', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in obesity')|
|('DB05078', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in asthma')|
|('DB05079', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in insomnia')|
|('DB05080', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in adverse effects drug hyperlipidemia and obesity')|
|('DB05081', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in psoriasis and psoriatic disorders and skin infectionsdisorders')|
|('DB05082', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in growth hormone deficienciesabnormalities')|
|('DB05084', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in postmenopausal osteoporosis to reduce vertebral andor nonvertebral fractures')|
|('DB05084', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in postmenopausal osteoporosis to reduce vertebral andor nonvertebral fractures')|
|('DB05085', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders')|
|('DB05087', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in pediatric indications and seizure disorders')|
|('DB05088', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in liver disease and pulmonary fibrosis')|
|('DB05088', 'MONDO:0002771', ['Fibrosis of lung', 'pulmonary fibrosis'], 'investigated for usetreatment in liver disease and pulmonary fibrosis')|
|('DB05089', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in prostate cancer')|
|('DB05089', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB05090', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als and parkinsons disease')|
|('DB05090', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als and parkinsons disease')|
|('DB05091', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'vasopressin regulates renal water resorption through the v2 receptor inhibition of vasopressin’s effects on v2 receptors enhances water excretion and increases urinary output m0002 is a vasopressin 2 antagonis it is an electrolytesparing aquaretic and causes much lower levels of salt excretion ')|
|('DB05092', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in multiple sclerosis')|
|('DB05093', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in cardiovascular disorders and strokes')|
|('DB05095', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in depression')|
|('DB05096', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in psychosis and schizophrenia and schizoaffective disorders')|
|('DB05096', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in psychosis and schizophrenia and schizoaffective disorders')|
|('DB05097', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'labetuzumab is a humanized monoclonal antibody used to treat cancer retrieved from httpenwikipediaorgwikilabetuzumab')|
|('DB05097', 'MONDO:0004992', ['cancer'], 'labetuzumab is a humanized monoclonal antibody used to treat cancer retrieved from httpenwikipediaorgwikilabetuzumab')|
|('DB05098', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lipodystrophy and obesity')|
|('DB05099', 'MONDO:0004992', ['cancer'], 'ancrod is indicated for the treatment of deep vein thrombosis dvt central retinal branch vein thrombosis pripaism pulmonary hypertension of embolic origin embolism after insertion of prosthetic cardiac valves rethrombosis after thrombolytic therapy rethrombosis after vascular surgery and prevention of dvt after repair of a fractured neck of a femur')|
|('DB05099', 'MONDO:0005149', ['pulmonary hypertension'], 'ancrod is indicated for the treatment of deep vein thrombosis dvt central retinal branch vein thrombosis pripaism pulmonary hypertension of embolic origin embolism after insertion of prosthetic cardiac valves rethrombosis after thrombolytic therapy rethrombosis after vascular surgery and prevention of dvt after repair of a fractured neck of a femur')|
|('DB05100', 'MONDO:0005149', ['pulmonary hypertension'], 'investigated for usetreatment in brain cancer lung cancer and prostate cancer')|
|('DB05100', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer lung cancer and prostate cancer')|
|('DB05100', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in brain cancer lung cancer and prostate cancer')|
|('DB05101', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cervical dysplasiacancer colorectal cancer gastric cancer and lung cancer')|
|('DB05101', 'MONDO:0005575', ['colorectal cancer'], 'investigated for usetreatment in cervical dysplasiacancer colorectal cancer gastric cancer and lung cancer')|
|('DB05101', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in cervical dysplasiacancer colorectal cancer gastric cancer and lung cancer')|
|('DB05102', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in viral infection')|
|('DB05103', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in liver cancer lung cancer melanoma and leukemia lymphoid')|
|('DB05103', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in liver cancer lung cancer melanoma and leukemia lymphoid')|
|('DB05104', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in irritable bowel syndrome ibs')|
|('DB05105', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in upper respiratory infection')|
|('DB05106', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in multiple sclerosis')|
|('DB05107', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in cystic fibrosis hiv infection hepatitis viral b and malaria')|
|('DB05107', 'MONDO:0005136', ['induced malaria', 'malaria'], 'investigated for usetreatment in cystic fibrosis hiv infection hepatitis viral b and malaria')|
|('DB05108', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in hepatitis viral b')|
|('DB05110', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in hiv infection')|
|('DB05111', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in crohns disease and psoriasis and psoriatic disorders')|
|('DB05111', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in crohns disease and psoriasis and psoriatic disorders')|
|('DB05112', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in solid tumors')|
|('DB05113', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in colorectal cancer')|
|('DB05113', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer')|
|('DB05114', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in hepatitis viral c and hepatocellular carcinoma')|
|('DB05114', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'investigated for usetreatment in hepatitis viral c and hepatocellular carcinoma')|
|('DB05115', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in diabetes mellitus type 1 and 2')|
|('DB05116', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in colorectal cancer')|
|('DB05116', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer')|
|('DB05117', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05118', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in depression')|
|('DB05119', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in atherosclerosis and cardiovascular disorders')|
|('DB05120', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in diabetes mellitus type 1 and 2')|
|('DB05121', 'MONDO:0005083', ['psoriasis'], 'intended for the treatment of various forms of cancer')|
|('DB05121', 'MONDO:0004992', ['cancer'], 'intended for the treatment of various forms of cancer')|
|('DB05122', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05122', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05123', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in atherosclerosis cardiovascular disorders and hyperlipidemia')|
|('DB05123', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in atherosclerosis cardiovascular disorders and hyperlipidemia')|
|('DB05124', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cardiac surgery and coronary artery disease')|
|('DB05124', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cardiac surgery and coronary artery disease')|
|('DB05125', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in multiple sclerosis and rheumatoid arthritis')|
|('DB05125', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in multiple sclerosis and rheumatoid arthritis')|
|('DB05126', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05126', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05127', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05128', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in fungal infections')|
|('DB05129', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in lymphoma nonhodgkins')|
|('DB05130', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB05131', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cardiac surgery and venous thromboembolism')|
|('DB05131', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cardiac surgery and venous thromboembolism')|
|('DB05132', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in depression')|
|('DB05133', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in alzheimers disease and inflammatory disorders unspecified')|
|('DB05134', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in leukemia myeloid and solid tumors')|
|('DB05135', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in burns and burn infections')|
|('DB05135', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in burns and burn infections')|
|('DB05136', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in breast cancer cancertumors unspecified hiv infection hepatitis viral c and solid tumors')|
|('DB05136', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer cancertumors unspecified hiv infection hepatitis viral c and solid tumors')|
|('DB05137', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in addictions')|
|('DB05138', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in macular degeneration')|
|('DB05139', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in nephropathy')|
|('DB05140', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05141', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05142', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in anxiety disorders and depression')|
|('DB05143', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05144', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in malaria')|
|('DB05145', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 1 and 2')|
|('DB05146', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05147', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05148', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer')|
|('DB05149', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05150', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease')|
|('DB05151', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05152', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease and schizophrenia and schizoaffective disorders')|
|('DB05152', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease and schizophrenia and schizoaffective disorders')|
|('DB05154', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrugresistant mdr extensively drugresistant xdr and treatmentintolerant forms of pulmonary tuberculosis tbl8048it is important to note that the following conditions are not approved indications for pretomanid therapy according to the fdal8048drugsensitive ds tuberculosis latent tuberculosis caused by mtuberculosis extrapulmonary tuberculosis caused by mtuberculosis and multidrugresistant tb that is not treatmentintolerant or nonresponsive to conventional tb therapy')|
|('DB05154', 'MONDO:0006052', ['pulmonary tuberculosis'], 'pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrugresistant mdr extensively drugresistant xdr and treatmentintolerant forms of pulmonary tuberculosis tbl8048it is important to note that the following conditions are not approved indications for pretomanid therapy according to the fdal8048drugsensitive ds tuberculosis latent tuberculosis caused by mtuberculosis extrapulmonary tuberculosis caused by mtuberculosis and multidrugresistant tb that is not treatmentintolerant or nonresponsive to conventional tb therapy')|
|('DB05154', 'MONDO:0018076', ['tuberculosis'], 'pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrugresistant mdr extensively drugresistant xdr and treatmentintolerant forms of pulmonary tuberculosis tbl8048it is important to note that the following conditions are not approved indications for pretomanid therapy according to the fdal8048drugsensitive ds tuberculosis latent tuberculosis caused by mtuberculosis extrapulmonary tuberculosis caused by mtuberculosis and multidrugresistant tb that is not treatmentintolerant or nonresponsive to conventional tb therapy')|
|('DB05154', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrugresistant mdr extensively drugresistant xdr and treatmentintolerant forms of pulmonary tuberculosis tbl8048it is important to note that the following conditions are not approved indications for pretomanid therapy according to the fdal8048drugsensitive ds tuberculosis latent tuberculosis caused by mtuberculosis extrapulmonary tuberculosis caused by mtuberculosis and multidrugresistant tb that is not treatmentintolerant or nonresponsive to conventional tb therapy')|
|('DB05155', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05156', 'MONDO:0000368', ['extrapulmonary tuberculosis'], 'investigated for usetreatment in acne actinic keratosis cancertumors unspecified keratoses and skin infectionsdisorders')|
|('DB05156', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'investigated for usetreatment in acne actinic keratosis cancertumors unspecified keratoses and skin infectionsdisorders')|
|('DB05157', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'investigated for usetreatment in cardiovascular disorders inflammatory bowel disease inflammatory disorders unspecified psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05157', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in cardiovascular disorders inflammatory bowel disease inflammatory disorders unspecified psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05158', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05159', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'investigated for usetreatment in multiple sclerosis and neurologic disorders')|
|('DB05160', 'MONDO:0005173', ['actinic (Solar) Keratosis', 'Senile hyperkeratosis', 'SK - Solar keratosis', 'Solar keratosis', 'actinic keratosis'], 'investigated for usetreatment in benign prostatic hyperplasia cancertumors unspecified prostate cancer prostate disorders and solid tumors')|
|('DB05160', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in benign prostatic hyperplasia cancertumors unspecified prostate cancer prostate disorders and solid tumors')|
|('DB05161', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB05163', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in infertility')|
|('DB05164', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia myeloid')|
|('DB05165', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05166', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05167', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral b')|
|('DB05168', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05169', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified leukemia myeloid and solid tumors')|
|('DB05170', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05171', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease')|
|('DB05172', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05173', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05174', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in skin infectionsdisorders')|
|('DB05177', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in myocardial infarction')|
|('DB05178', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in parkinsons disease')|
|('DB05179', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in parkinsons disease')|
|('DB05180', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd dementia neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05180', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd dementia neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05180', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd dementia neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05181', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in viral infection')|
|('DB05182', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in kidney cancer and melanoma')|
|('DB05182', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in kidney cancer and melanoma')|
|('DB05182', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in kidney cancer and melanoma')|
|('DB05183', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB05184', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia lymphoid and leukemia myeloid')|
|('DB05185', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in neurologic disorders')|
|('DB05186', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bacterial infection infectious and parasitic disease unspecified and tuberculosis')|
|('DB05186', 'MONDO:0018076', ['tuberculosis'], 'investigated for usetreatment in bacterial infection infectious and parasitic disease unspecified and tuberculosis')|
|('DB05187', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in atherosclerosis and diabetes mellitus type 2')|
|('DB05187', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in atherosclerosis and diabetes mellitus type 2')|
|('DB05188', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in metabolic disease and obesity')|
|('DB05189', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05190', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in solid tumors')|
|('DB05191', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB05192', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05194', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05194', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05195', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05195', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05196', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in affective disorders bipolar disorders and psychosis')|
|('DB05197', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in gastroenteritis and ulcers')|
|('DB05197', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in gastroenteritis and ulcers')|
|('DB05198', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'advanced solid tumors')|
|('DB05199', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'irritable bowel syndrome ibs and other gastrointestinal disorders')|
|('DB05200', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'pompe disease also known as glycogen storage disease type ii or acid maltase deficiency is a relatively rare neuromuscular and lysosomal storage disorder caused by inherited genetic mutations in a key enzyme called αglucosidase gaa')|
|('DB05200', 'MONDO:0009290', ['acid maltase deficiency', 'deficiency of glucoamylase', 'deficiency of maltase', 'Generalized glycogenosis', 'glycogen storage disease type II', 'Glycogen storage disease, type II', 'Glycogenosis, type 2', 'Lysosomal alpha-1,4-glucosidase deficiency', 'Pompes disease', 'glycogen storage disease ii'], 'pompe disease also known as glycogen storage disease type ii or acid maltase deficiency is a relatively rare neuromuscular and lysosomal storage disorder caused by inherited genetic mutations in a key enzyme called αglucosidase gaa')|
|('DB05200', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'pompe disease also known as glycogen storage disease type ii or acid maltase deficiency is a relatively rare neuromuscular and lysosomal storage disorder caused by inherited genetic mutations in a key enzyme called αglucosidase gaa')|
|('DB05200', 'MONDO:0021152', ['inherited'], 'pompe disease also known as glycogen storage disease type ii or acid maltase deficiency is a relatively rare neuromuscular and lysosomal storage disorder caused by inherited genetic mutations in a key enzyme called αglucosidase gaa')|
|('DB05201', 'MONDO:0021152', ['inherited'], 'obesity related disorders such as cardiovascular disease and type ii diabetes')|
|('DB05202', 'MONDO:0021152', ['inherited'], 'platelet aggregation thrombosis and acute coronary syndromes')|
|('DB05203', 'MONDO:0021152', ['inherited'], 'investigated for usetreatment in hypertension')|
|('DB05204', 'MONDO:0021152', ['inherited'], 'cancer')|
|('DB05205', 'MONDO:0021152', ['inherited'], 'anxiety disorders idepression i')|
|('DB05207', 'MONDO:0021152', ['inherited'], 'central nervous system  neuropathic pain ')|
|('DB05209', 'MONDO:0021152', ['inherited'], 'investigated for usetreatment in thrombocytopenia')|
|('DB05210', 'MONDO:0021152', ['inherited'], 'for the treatment of various forms of cancer')|
|('DB05210', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB05211', 'MONDO:0021152', ['inherited'], 'for the treatment of inflammatory disease')|
|('DB05211', 'MONDO:0021166', ['inflammatory disease []', 'inflammatory disorder []', 'anatomical structure inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'inflammation of anatomical structure []', 'inflammatory disease'], 'for the treatment of inflammatory disease')|
|('DB05212', 'MONDO:0021152', ['inherited'], 'for the treatment of rheumatoid arthritis and type 2 diabetes')|
|('DB05212', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of rheumatoid arthritis and type 2 diabetes')|
|('DB05212', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'for the treatment of rheumatoid arthritis and type 2 diabetes')|
|('DB05214', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of pain')|
|('DB05217', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'intended for the treatment of solid tumors and lymphomas')|
|('DB05218', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'intended for the treatment of autoimmune diseases such as rheumatoid arthritis psoriasis and crohns disease')|
|('DB05218', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'intended for the treatment of autoimmune diseases such as rheumatoid arthritis psoriasis and crohns disease')|
|('DB05219', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older')|
|('DB05219', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older')|
|('DB05220', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of various forms of cancer')|
|('DB05220', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB05222', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of infections caused by multidrug resistant empseudomonas aeruginosaem')|
|('DB05223', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of various forms of cancer')|
|('DB05223', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB05224', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the treatment of bacterial infections caused by susceptible microorganisms istaphylococcus aureusi including methicillinresistant is aureusi mrsa and istreptococcus pyogenesi')|
|('DB05224', 'MONDO:0100073', ['MRSA []', 'methicillin-resistant staphylococcus aureus infectious disease'], 'for the treatment of bacterial infections caused by susceptible microorganisms istaphylococcus aureusi including methicillinresistant is aureusi mrsa and istreptococcus pyogenesi')|
|('DB05225', 'MONDO:0100073', ['MRSA []', 'methicillin-resistant staphylococcus aureus infectious disease'], 'for the treatment of asthma and cardiovascular disease')|
|('DB05225', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of asthma and cardiovascular disease')|
|('DB05225', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'for the treatment of asthma and cardiovascular disease')|
|('DB05226', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of respiratory syncytial virus infections')|
|('DB05227', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment and prophylaxis of arterial thrombosis')|
|('DB05228', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of hiv1 infection in combination with appropriate antiretroviral agents when therapy is warranted')|
|('DB05229', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of pulmonary hypertension')|
|('DB05229', 'MONDO:0005149', ['pulmonary hypertension'], 'for the treatment of pulmonary hypertension')|
|('DB05230', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels')|
|('DB05230', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels')|
|('DB05232', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence')|
|('DB05233', 'MONDO:0005311', ['atherosclerosis'], 'for use as a female contraceptive')|
|('DB05234', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment and prevention of osteoporosis')|
|('DB05234', 'MONDO:0005298', ['osteoporosis'], 'for the treatment and prevention of osteoporosis')|
|('DB05235', 'MONDO:0005311', ['atherosclerosis'], 'for use in treatment of hypothyroidism')|
|('DB05235', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'for use in treatment of hypothyroidism')|
|('DB05236', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment of stroke')|
|('DB05236', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the treatment of stroke')|
|('DB05237', 'MONDO:0005311', ['atherosclerosis'], 'investigated for usetreatment in immunodeficiency and infectious and parasitic disease unspecified')|
|('DB05239', 'MONDO:0005311', ['atherosclerosis'], 'for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation cobimetinib is used in combination with vemurafenib a braf inhibitor')|
|('DB05239', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation cobimetinib is used in combination with vemurafenib a braf inhibitor')|
|('DB05241', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for the treatment of various forms of cancer')|
|('DB05241', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB05242', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'investigated for usetreatment in hepatitis viral b')|
|('DB05243', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for the treatment of various forms of cancer')|
|('DB05243', 'MONDO:0004992', ['cancer'], 'for the treatment of various forms of cancer')|
|('DB05244', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'for treatment of nonhodgkins lymphoma bone metastases pagets disease and osteoporosis')|
|('DB05244', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for treatment of nonhodgkins lymphoma bone metastases pagets disease and osteoporosis')|
|('DB05244', 'MONDO:0005298', ['osteoporosis'], 'for treatment of nonhodgkins lymphoma bone metastases pagets disease and osteoporosis')|
|('DB05249', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'bcell nonhodgkins lymphoma')|
|('DB05252', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'chronic angina and coronary artery disease \t')|
|('DB05252', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'chronic angina and coronary artery disease \t')|
|('DB05253', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of uterine fibroids and endometriosis')|
|('DB05253', 'MONDO:0005133', ['endometriosis'], 'for the treatment of uterine fibroids and endometriosis')|
|('DB05254', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'fibrinolysin assists with the healing of minor burns superficial wounds ulcers surgical wounds and superficial hematomas')|
|('DB05254', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'fibrinolysin assists with the healing of minor burns superficial wounds ulcers surgical wounds and superficial hematomas')|
|('DB05255', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'postmenopausal women with osteoporosis')|
|('DB05255', 'MONDO:0005298', ['osteoporosis'], 'postmenopausal women with osteoporosis')|
|('DB05257', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05258', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in hepatitis viral c leukemia lymphoid leukemia myeloid leukemia unspecified and melanoma')|
|('DB05258', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in hepatitis viral c leukemia lymphoid leukemia myeloid leukemia unspecified and melanoma')|
|('DB05258', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in hepatitis viral c leukemia lymphoid leukemia myeloid leukemia unspecified and melanoma')|
|('DB05259', 'MONDO:0005059', ['leukemia'], 'for reduction of the frequency of relapses in patients with relapsingremitting multiple sclerosis')|
|('DB05259', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for reduction of the frequency of relapses in patients with relapsingremitting multiple sclerosis')|
|('DB05262', 'MONDO:0005059', ['leukemia'], 'intended for the treatment of congestive heart failure and hyperuricemia')|
|('DB05262', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'intended for the treatment of congestive heart failure and hyperuricemia')|
|('DB05263', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'alzheimers disease')|
|('DB05264', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'atopic dermatitis')|
|('DB05268', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'various eye diseases')|
|('DB05273', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'investigated for usetreatment in bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB05273', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB05273', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB05273', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in bone metastases multiple myeloma prostate cancer and rheumatoid arthritis')|
|('DB05276', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral b liver transplant surgery and pediatric indications')|
|('DB05282', 'MONDO:0004992', ['cancer'], 'bladder cancer')|
|('DB05285', 'MONDO:0004992', ['cancer'], 'lung cancermelanoma\t')|
|('DB05288', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in glaucoma and macular degeneration')|
|('DB05288', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in glaucoma and macular degeneration')|
|('DB05289', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease and prostate cancer')|
|('DB05289', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in alzheimers disease and prostate cancer')|
|('DB05290', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiovascular disorders and neuropathy diabetic')|
|('DB05292', 'MONDO:0004992', ['cancer'], 'ovarian cancer')|
|('DB05293', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer')|
|('DB05295', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in osteoporosis')|
|('DB05296', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer breast cancer cervical dysplasiacancer prostate cancer cancertumors unspecified coronary artery disease macular degeneration and peripheral vascular disease')|
|('DB05296', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in brain cancer breast cancer cervical dysplasiacancer prostate cancer cancertumors unspecified coronary artery disease macular degeneration and peripheral vascular disease')|
|('DB05296', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in brain cancer breast cancer cervical dysplasiacancer prostate cancer cancertumors unspecified coronary artery disease macular degeneration and peripheral vascular disease')|
|('DB05296', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in brain cancer breast cancer cervical dysplasiacancer prostate cancer cancertumors unspecified coronary artery disease macular degeneration and peripheral vascular disease')|
|('DB05297', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer and skin cancer')|
|('DB05297', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer and skin cancer')|
|('DB05297', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'investigated for usetreatment in breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer and skin cancer')|
|('DB05298', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05298', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05299', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer and solid tumors')|
|('DB05300', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in addictions osteoarthritis and pain acute or chronic')|
|('DB05300', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in addictions osteoarthritis and pain acute or chronic')|
|('DB05301', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in depression and huntingtons disease')|
|('DB05303', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in inflammatory disorders unspecified knee replacement orthopedic surgery and pain acute or chronic')|
|('DB05304', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in gall bladder cancer and renal cell carcinoma')|
|('DB05304', 'MONDO:0022578', ['childhood bladder carcinoma [GARD:0009305,NCIT:C118816]', 'childhood bladder cancer [GARD:0009305,NCIT:C118816]', 'bladder cancer [NCIT:C118816]', 'childhood bladder carcinoma'], 'investigated for usetreatment in gall bladder cancer and renal cell carcinoma')|
|('DB05304', 'MONDO:0005549', ['adenocarcinoma of kidney [NCIT:C9385]', 'kidney adenocarcinoma [NCIT:C9385]', 'renal cell carcinoma [NCIT:C9385]', 'RCC [NCIT:C9385]', 'adenocarcinoma of the kidney [NCIT:C9385]', 'carcinoma, renal cell, malignant [NCIT:C9385]', 'renal cell carcinoma, stage unspecified [NCIT:C9385]', 'renal cell adenocarcinoma [NCIT:C9385]', 'renal cell cancer [NCIT:C9385]', 'renal cell adenocarcinoma'], 'investigated for usetreatment in gall bladder cancer and renal cell carcinoma')|
|('DB05305', 'MONDO:0022578', ['childhood bladder carcinoma [GARD:0009305,NCIT:C118816]', 'childhood bladder cancer [GARD:0009305,NCIT:C118816]', 'bladder cancer [NCIT:C118816]', 'childhood bladder carcinoma'], 'investigated for usetreatment in brain cancer')|
|('DB05305', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB05306', 'MONDO:0022578', ['childhood bladder carcinoma [GARD:0009305,NCIT:C118816]', 'childhood bladder cancer [GARD:0009305,NCIT:C118816]', 'bladder cancer [NCIT:C118816]', 'childhood bladder carcinoma'], 'investigated for usetreatment in angina coronary artery disease and heart disease')|
|('DB05306', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in angina coronary artery disease and heart disease')|
|('DB05306', 'MONDO:0005267', ['heart disease'], 'investigated for usetreatment in angina coronary artery disease and heart disease')|
|('DB05308', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in breast cancer colorectal cancer gall bladder cancer and pancreatic cancer')|
|('DB05308', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer colorectal cancer gall bladder cancer and pancreatic cancer')|
|('DB05308', 'MONDO:0022578', ['childhood bladder carcinoma [GARD:0009305,NCIT:C118816]', 'childhood bladder cancer [GARD:0009305,NCIT:C118816]', 'bladder cancer [NCIT:C118816]', 'childhood bladder carcinoma'], 'investigated for usetreatment in breast cancer colorectal cancer gall bladder cancer and pancreatic cancer')|
|('DB05309', 'MONDO:0022578', ['childhood bladder carcinoma [GARD:0009305,NCIT:C118816]', 'childhood bladder cancer [GARD:0009305,NCIT:C118816]', 'bladder cancer [NCIT:C118816]', 'childhood bladder carcinoma'], 'investigated for usetreatment in bone fractures diabetic foot ulcers and wounds')|
|('DB05309', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in bone fractures diabetic foot ulcers and wounds')|
|('DB05310', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in endometriosis')|
|('DB05311', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'indicated for the symptomatic treatment of acute attacks of hereditary angioedema hae in patients 12 years of age and older fda label')|
|('DB05311', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'indicated for the symptomatic treatment of acute attacks of hereditary angioedema hae in patients 12 years of age and older fda label')|
|('DB05312', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in autoimmune diseases and rheumatoid arthritis')|
|('DB05312', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in autoimmune diseases and rheumatoid arthritis')|
|('DB05313', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in hemorrhage and transfusion')|
|('DB05315', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in coronary artery disease')|
|('DB05316', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in neurologic disorders parkinsons disease psychosis schizophrenia and schizoaffective disorders and sleep disorders')|
|('DB05316', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in neurologic disorders parkinsons disease psychosis schizophrenia and schizoaffective disorders and sleep disorders')|
|('DB05317', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05319', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in bladder cancer and head and neck cancer')|
|('DB05319', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer and head and neck cancer')|
|('DB05319', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'investigated for usetreatment in bladder cancer and head and neck cancer')|
|('DB05320', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in immunosuppressive and transplant rejection')|
|('DB05321', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hyperuricemia')|
|('DB05322', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer brain cancer breast cancer esophageal cancer head and neck cancer lung cancer oral cavity cancer ovarian cancer and prostate cancer')|
|('DB05322', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in bladder cancer brain cancer breast cancer esophageal cancer head and neck cancer lung cancer oral cavity cancer ovarian cancer and prostate cancer')|
|('DB05322', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in bladder cancer brain cancer breast cancer esophageal cancer head and neck cancer lung cancer oral cavity cancer ovarian cancer and prostate cancer')|
|('DB05325', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer head and neck cancer and lung cancer')|
|('DB05325', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in breast cancer head and neck cancer and lung cancer')|
|('DB05325', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in breast cancer head and neck cancer and lung cancer')|
|('DB05326', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous')|
|('DB05327', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in neuropathy diabetic')|
|('DB05328', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in hiv infection')|
|('DB05329', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in melanoma')|
|('DB05330', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in cystic fibrosis and pancreatic disorders')|
|('DB05332', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'treatment of chronic immune thrombocytopenic purpura ')|
|('DB05332', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'treatment of chronic immune thrombocytopenic purpura ')|
|('DB05333', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in attention deficithyperactivity disorder adhd neurologic disorders and tourettes syndrome')|
|('DB05336', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in anthrax exposure bacterial infection crohns disease and graft versus host disease')|
|('DB05336', 'MONDO:0013730', ['graft VS host disease [NCIT:C3063]', 'graft-versus-host disease [MESH:D006086,NCIT:C3063]', 'runt disease [MESH:D006086,NCIT:C3063]', 'GVH [Orphanet:39812]', 'graft VS. host disease [NCIT:C3063]', 'GVHD [NCIT:C3063]', 'graft versus host disease [MESH:D006086]', 'graft-versus-host-disease [NCIT:C3063]', 'graft versus host disease'], 'investigated for usetreatment in anthrax exposure bacterial infection crohns disease and graft versus host disease')|
|('DB05337', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in brain cancer')|
|('DB05337', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB05339', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in anxiety disorders depression insomnia and neurologic disorders')|
|('DB05339', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'investigated for usetreatment in anxiety disorders depression insomnia and neurologic disorders')|
|('DB05340', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'investigated for usetreatment in inflammatory bowel disease and ulcerative colitis')|
|('DB05340', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in inflammatory bowel disease and ulcerative colitis')|
|('DB05343', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in cerebral ischemia')|
|('DB05344', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in eye disordersinfections macular degeneration and retinal disorders unspecified')|
|('DB05344', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in eye disordersinfections macular degeneration and retinal disorders unspecified')|
|('DB05345', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in insomnia')|
|('DB05346', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in osteoarthritis and pain acute or chronic')|
|('DB05351', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'dexlansoprazole is indicated for healing all grades of erosive esophagitis ee maintaining and healing of ee and relief of heartburn and treating heartburn associated with symptomatic nonerosive gastroesophageal reflux disease gerd ')|
|('DB05351', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'dexlansoprazole is indicated for healing all grades of erosive esophagitis ee maintaining and healing of ee and relief of heartburn and treating heartburn associated with symptomatic nonerosive gastroesophageal reflux disease gerd ')|
|('DB05351', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'dexlansoprazole is indicated for healing all grades of erosive esophagitis ee maintaining and healing of ee and relief of heartburn and treating heartburn associated with symptomatic nonerosive gastroesophageal reflux disease gerd ')|
|('DB05352', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in amyloidosis')|
|('DB05353', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in liver cancer')|
|('DB05353', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in liver cancer')|
|('DB05361', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in cardiovascular disorders thrombosis and venous thromboembolism')|
|('DB05361', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in cardiovascular disorders thrombosis and venous thromboembolism')|
|('DB05362', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in thrombosis and venous thromboembolism')|
|('DB05362', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in thrombosis and venous thromboembolism')|
|('DB05363', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in bipolar disorders')|
|('DB05364', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05367', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in cardiovascular disorders hypertension and pulmonary hypertension')|
|('DB05367', 'MONDO:0005149', ['pulmonary hypertension'], 'investigated for usetreatment in cardiovascular disorders hypertension and pulmonary hypertension')|
|('DB05368', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in allergic reaction')|
|('DB05369', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05371', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in huntingtons disease and schizophrenia and schizoaffective disorders')|
|('DB05371', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in huntingtons disease and schizophrenia and schizoaffective disorders')|
|('DB05372', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in obesity')|
|('DB05374', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in brain cancer')|
|('DB05374', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB05377', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in fungal infections')|
|('DB05380', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in multiple myeloma')|
|('DB05380', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in multiple myeloma')|
|('DB05382', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in breast disorders unspecified and pain acute or chronic')|
|('DB05383', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in diabetic kidney disease')|
|('DB05383', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in diabetic kidney disease')|
|('DB05384', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in contraception and hiv prevention')|
|('DB05385', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in hiv prevention prevention of stdis and vaginal infection')|
|('DB05385', 'MONDO:0023557', ['vaginal infection [NCIT:C84353]', 'infective vaginitis'], 'investigated for usetreatment in hiv prevention prevention of stdis and vaginal infection')|
|('DB05386', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in adverse effects chemotherapy and bone marrow transplant')|
|('DB05387', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer and psoriasis and psoriatic disorders')|
|('DB05387', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer and psoriasis and psoriatic disorders')|
|('DB05387', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer and psoriasis and psoriatic disorders')|
|('DB05387', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer and psoriasis and psoriatic disorders')|
|('DB05390', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in lung cancer')|
|('DB05390', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer')|
|('DB05391', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in neuropathy diabetic and peripheral vascular disease')|
|('DB05391', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in neuropathy diabetic and peripheral vascular disease')|
|('DB05393', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB05393', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB05393', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB05394', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer and neurologic disorders')|
|('DB05395', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in depression irritable bowel syndrome ibs and obesity')|
|('DB05395', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in depression irritable bowel syndrome ibs and obesity')|
|('DB05396', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05398', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in contraception hiv infection and prevention of stdis')|
|('DB05398', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in contraception hiv infection and prevention of stdis')|
|('DB05399', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in atherosclerosis coronary artery disease diabetes mellitus type 2 and instent restenosis')|
|('DB05399', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in atherosclerosis coronary artery disease diabetes mellitus type 2 and instent restenosis')|
|('DB05400', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in genital herpes hiv infection hepatitis viral b influenza malaria melanoma and viral infection')|
|('DB05400', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'investigated for usetreatment in genital herpes hiv infection hepatitis viral b influenza malaria melanoma and viral infection')|
|('DB05400', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in genital herpes hiv infection hepatitis viral b influenza malaria melanoma and viral infection')|
|('DB05400', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in genital herpes hiv infection hepatitis viral b influenza malaria melanoma and viral infection')|
|('DB05403', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in asthma and parkinsons disease')|
|('DB05404', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in gastroesophageal reflux disease gerd')|
|('DB05404', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in gastroesophageal reflux disease gerd')|
|('DB05405', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in hepatitis viral b')|
|('DB05406', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in prostate cancer and solid tumors')|
|('DB05406', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer and solid tumors')|
|('DB05407', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in congestive heart failure hypertension and pulmonary hypertension')|
|('DB05407', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure hypertension and pulmonary hypertension')|
|('DB05407', 'MONDO:0005149', ['pulmonary hypertension'], 'investigated for usetreatment in congestive heart failure hypertension and pulmonary hypertension')|
|('DB05408', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in hepatitis viral c liver disease and transplantation organ or tissue')|
|('DB05408', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in hepatitis viral c liver disease and transplantation organ or tissue')|
|('DB05409', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05410', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05410', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05411', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05412', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in pain acute or chronic and rheumatoid arthritis')|
|('DB05412', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in pain acute or chronic and rheumatoid arthritis')|
|('DB05413', 'MONDO:0005154', ['disorder of liver', 'hepatic disorder', 'liver disease'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB05413', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB05413', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB05414', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in breast cancer')|
|('DB05414', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05415', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in crohns disease inflammatory bowel disease kidney cancer leukemia lymphoid and prostate cancer')|
|('DB05415', 'MONDO:0002367', ['malignant neoplasm of kidney except pelvis', 'malignant tumour of kidney', 'renal cancer', 'kidney cancer'], 'investigated for usetreatment in crohns disease inflammatory bowel disease kidney cancer leukemia lymphoid and prostate cancer')|
|('DB05415', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in crohns disease inflammatory bowel disease kidney cancer leukemia lymphoid and prostate cancer')|
|('DB05416', 'MONDO:0002367', ['malignant neoplasm of kidney except pelvis', 'malignant tumour of kidney', 'renal cancer', 'kidney cancer'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05417', 'MONDO:0002367', ['malignant neoplasm of kidney except pelvis', 'malignant tumour of kidney', 'renal cancer', 'kidney cancer'], 'investigated for usetreatment in tobacco dependence')|
|('DB05418', 'MONDO:0002367', ['malignant neoplasm of kidney except pelvis', 'malignant tumour of kidney', 'renal cancer', 'kidney cancer'], 'investigated for usetreatment in adverse effects chemotherapy anxiety disorders depression and gastrointestinal diseases and disorders miscellaneous')|
|('DB05418', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in adverse effects chemotherapy anxiety disorders depression and gastrointestinal diseases and disorders miscellaneous')|
|('DB05419', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in sleep disorders smoking cessation and substance abuse')|
|('DB05419', 'MONDO:0002491', ['substance abuse'], 'investigated for usetreatment in sleep disorders smoking cessation and substance abuse')|
|('DB05420', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in bladder cancer lymphoma unspecified multiple myeloma pagets disease and prostate cancer')|
|('DB05420', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bladder cancer lymphoma unspecified multiple myeloma pagets disease and prostate cancer')|
|('DB05420', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in bladder cancer lymphoma unspecified multiple myeloma pagets disease and prostate cancer')|
|('DB05420', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in bladder cancer lymphoma unspecified multiple myeloma pagets disease and prostate cancer')|
|('DB05421', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in asthma depression and irritable bowel syndrome ibs')|
|('DB05421', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in asthma depression and irritable bowel syndrome ibs')|
|('DB05422', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in bulimia depression and obsessivecompulsive disorders')|
|('DB05423', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in depression')|
|('DB05424', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in breast cancer and lung cancer')|
|('DB05424', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer and lung cancer')|
|('DB05424', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in breast cancer and lung cancer')|
|('DB05426', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in adverse effects chemotherapy cancertumors unspecified diabetic foot ulcers lung cancer solid tumors and ulcers')|
|('DB05426', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in adverse effects chemotherapy cancertumors unspecified diabetic foot ulcers lung cancer solid tumors and ulcers')|
|('DB05426', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in adverse effects chemotherapy cancertumors unspecified diabetic foot ulcers lung cancer solid tumors and ulcers')|
|('DB05427', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in melanoma')|
|('DB05428', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in brain cancer cancertumors unspecified lung cancer and lymphoma nonhodgkins')|
|('DB05428', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer cancertumors unspecified lung cancer and lymphoma nonhodgkins')|
|('DB05428', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in brain cancer cancertumors unspecified lung cancer and lymphoma nonhodgkins')|
|('DB05429', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in allergic rhinitis')|
|('DB05429', 'MONDO:0003014', ['rhinitis'], 'investigated for usetreatment in allergic rhinitis')|
|('DB05430', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05430', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05431', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05431', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05432', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in addictions dementia parkinsons disease schizophrenia and schizoaffective disorders and strokes')|
|('DB05432', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in addictions dementia parkinsons disease schizophrenia and schizoaffective disorders and strokes')|
|('DB05433', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in congestive heart failure and diabetes mellitus type 2')|
|('DB05433', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure and diabetes mellitus type 2')|
|('DB05433', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in congestive heart failure and diabetes mellitus type 2')|
|('DB05434', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in lymphoma unspecified melanoma and solid tumors')|
|('DB05437', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in colorectal cancer and solid tumors')|
|('DB05437', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer and solid tumors')|
|('DB05438', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia lymphoid')|
|('DB05439', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB05440', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in asthma atopic dermatitis and pediatric atopic dermatitis indications')|
|('DB05440', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'investigated for usetreatment in asthma atopic dermatitis and pediatric atopic dermatitis indications')|
|('DB05440', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in asthma atopic dermatitis and pediatric atopic dermatitis indications')|
|('DB05441', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in asthma and atopic dermatitis')|
|('DB05441', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'investigated for usetreatment in asthma and atopic dermatitis')|
|('DB05442', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in asthma and crohns disease')|
|('DB05443', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in pain acute or chronic and rheumatoid arthritis trials are also being conducted for relieving burn pain and dermal itch')|
|('DB05443', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in pain acute or chronic and rheumatoid arthritis trials are also being conducted for relieving burn pain and dermal itch')|
|('DB05443', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in pain acute or chronic and rheumatoid arthritis trials are also being conducted for relieving burn pain and dermal itch')|
|('DB05444', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in atherosclerosis and vascular diseases as a cardioprotective agent its use has also been suggested for the prevention of early restenosis following vascular surgery or balloon angioplasty')|
|('DB05444', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in atherosclerosis and vascular diseases as a cardioprotective agent its use has also been suggested for the prevention of early restenosis following vascular surgery or balloon angioplasty')|
|('DB05445', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in tobacco dependence')|
|('DB05446', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in autoimmune diseases strokes and thrombosis')|
|('DB05447', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in adverse effects chemotherapy and adverse effects drug')|
|('DB05448', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in cancertumors unspecified gastric cancer and pancreatic cancer')|
|('DB05448', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified gastric cancer and pancreatic cancer')|
|('DB05449', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hyperlipidemia and cancertumors unspecifiedmonotherapy is recommended for people with marginally high ldlcholesterol or who cannot be prescribed statins due to drug interactions and safety concerns combination therapy is recommended if statin therapy alone is either insufficient to achieve the guidelines set by the ncep or there is concern over side effects as statin doses can be lowered in combination treatment without losing efficacy')|
|('DB05449', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in hyperlipidemia and cancertumors unspecifiedmonotherapy is recommended for people with marginally high ldlcholesterol or who cannot be prescribed statins due to drug interactions and safety concerns combination therapy is recommended if statin therapy alone is either insufficient to achieve the guidelines set by the ncep or there is concern over side effects as statin doses can be lowered in combination treatment without losing efficacy')|
|('DB05450', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in alzheimers disease parkinsons disease and other neurodegenerative diseases')|
|('DB05451', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in cancertumors unspecified crohns disease inflammatory bowel disease osteoarthritis and ulcerative colitis')|
|('DB05451', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in cancertumors unspecified crohns disease inflammatory bowel disease osteoarthritis and ulcerative colitis')|
|('DB05451', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in cancertumors unspecified crohns disease inflammatory bowel disease osteoarthritis and ulcerative colitis')|
|('DB05452', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in anorexia and other conditions causing harmful weight loss the manufacturer suggests it could be relevant for treatment of weight loss and the associated symptoms ie lack of energy decrease in appetite physical wasting vulnerability to toxicity and sometimes reduced life expectancy in patients with eating disorders patients with advanced cancer patients with aids and patients experiencing loss of appetite due to aging acute illness or pregnancy')|
|('DB05452', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in anorexia and other conditions causing harmful weight loss the manufacturer suggests it could be relevant for treatment of weight loss and the associated symptoms ie lack of energy decrease in appetite physical wasting vulnerability to toxicity and sometimes reduced life expectancy in patients with eating disorders patients with advanced cancer patients with aids and patients experiencing loss of appetite due to aging acute illness or pregnancy')|
|('DB05454', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in alzheimers disease and parkinsons disease')|
|('DB05455', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in cardiovascular disorders in the treatment of syndrome of inappropriate secretion of antidiuretic hormone siadh and in hyponatremia ')|
|('DB05455', 'MONDO:0006802', ['syndrome of Inappropriate Antidiuretic Hormone Secretion', 'syndrome of inappropriate secretion of ADH', 'syndrome of inappropriate secretion of antidiuretic hormone', 'syndrome of inappropriate vasopressin secretion', 'inappropriate adh syndrome'], 'investigated for usetreatment in cardiovascular disorders in the treatment of syndrome of inappropriate secretion of antidiuretic hormone siadh and in hyponatremia ')|
|('DB05456', 'MONDO:0006802', ['syndrome of Inappropriate Antidiuretic Hormone Secretion', 'syndrome of inappropriate secretion of ADH', 'syndrome of inappropriate secretion of antidiuretic hormone', 'syndrome of inappropriate vasopressin secretion', 'inappropriate adh syndrome'], 'investigated for usetreatment in atherosclerosis coronary artery disease and vascular diseases')|
|('DB05456', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in atherosclerosis coronary artery disease and vascular diseases')|
|('DB05457', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in gastric cancer')|
|('DB05457', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in gastric cancer')|
|('DB05458', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd and schizophrenia and schizoaffective disorders')|
|('DB05458', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease attention deficithyperactivity disorder adhd and schizophrenia and schizoaffective disorders')|
|('DB05459', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in autoimmune diseases crohns disease multiple sclerosis psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05459', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in autoimmune diseases crohns disease multiple sclerosis psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05459', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in autoimmune diseases crohns disease multiple sclerosis psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05460', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in myelodysplastic syndrome')|
|('DB05461', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in peripheral vascular disease and raynauds disease')|
|('DB05461', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease and raynauds disease')|
|('DB05461', 'MONDO:0008364', ['Raynauds disease', 'Raynauds syndrome', 'raynaud disease'], 'investigated for usetreatment in peripheral vascular disease and raynauds disease')|
|('DB05462', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05462', 'MONDO:0001657', ['adult brain tumor', 'adult malignant brain neoplasm', 'brain neoplasm', 'brain neoplasm, adult', 'BT - Brain tumour', 'malignant brain tumour', 'malignant primary brain neoplasm', 'malignant primary brain tumor', 'malignant tumor of adult brain', 'malignant tumor of Brain', 'neoplasm of brain', 'primary brain neoplasm', 'primary brain tumor', 'primary malignant neoplasm of brain', 'tumor of the Brain', 'brain cancer'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05462', 'MONDO:0021042', ['glioma [NCIT:C3059]', 'neoplasm of the neuroglia [NCIT:C3059]', 'tumor of the neuroglia [NCIT:C3059]', 'neuroglial neoplasm [NCIT:C3059]', 'glial neoplasm [NCIT:C3059]', 'neuroglial tumor [NCIT:C3059]', 'glial tumor [NCIT:C3059]', 'tumor of neuroglia [NCIT:C3059]', 'neoplasm of neuroglia [NCIT:C3059]', 'glioma'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05462', 'MONDO:0018177', ['adult glioblastoma multiforme', 'GBM', 'grade IV adult Astrocytic tumor', 'primary glioblastoma multiforme', 'spongioblastoma multiforme', 'glioblastoma'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05462', 'MONDO:0019781', ['astrocytoma [NCIT:C60781,https://github.com/NCI-Thesaurus/thesaurus-obo-edition/issues/23]', 'astrocytoma (excluding glioblastoma)'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05462', 'MONDO:0016681', ['Glioblastoma with sarcomatous component', 'gliosarcoma'], 'investigated for usetreatment in various forms of brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligoastrocytoma  gliosarcoma')|
|('DB05463', 'MONDO:0019781', ['astrocytoma [NCIT:C60781,https://github.com/NCI-Thesaurus/thesaurus-obo-edition/issues/23]', 'astrocytoma (excluding glioblastoma)'], 'investigated for usetreatment in colorectal cancer hepatitis viral b and lymphoma nonhodgkinsiss 1018 is currently being investigated in combination with hbsag vaccine as a prophylactic treatment for to prevent hepatitis b in adults it has also been investigated in combination with rituximab for treatment of bcell or nonhodgkins lymphoma')|
|('DB05463', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer hepatitis viral b and lymphoma nonhodgkinsiss 1018 is currently being investigated in combination with hbsag vaccine as a prophylactic treatment for to prevent hepatitis b in adults it has also been investigated in combination with rituximab for treatment of bcell or nonhodgkins lymphoma')|
|('DB05463', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in colorectal cancer hepatitis viral b and lymphoma nonhodgkinsiss 1018 is currently being investigated in combination with hbsag vaccine as a prophylactic treatment for to prevent hepatitis b in adults it has also been investigated in combination with rituximab for treatment of bcell or nonhodgkins lymphoma')|
|('DB05463', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in colorectal cancer hepatitis viral b and lymphoma nonhodgkinsiss 1018 is currently being investigated in combination with hbsag vaccine as a prophylactic treatment for to prevent hepatitis b in adults it has also been investigated in combination with rituximab for treatment of bcell or nonhodgkins lymphoma')|
|('DB05463', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in colorectal cancer hepatitis viral b and lymphoma nonhodgkinsiss 1018 is currently being investigated in combination with hbsag vaccine as a prophylactic treatment for to prevent hepatitis b in adults it has also been investigated in combination with rituximab for treatment of bcell or nonhodgkins lymphoma')|
|('DB05464', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05465', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in leukemia myeloid')|
|('DB05466', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in depression and anxiety')|
|('DB05466', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in depression and anxiety')|
|('DB05467', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in emphysema')|
|('DB05468', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in asthma')|
|('DB05469', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in urinary incontinence')|
|('DB05470', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in coronary artery disease inflammatory disorders unspecified and rheumatoid arthritis')|
|('DB05470', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in coronary artery disease inflammatory disorders unspecified and rheumatoid arthritis')|
|('DB05471', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in autoimmune diseases cancertumors unspecified lymphoma nonhodgkins and lymphoma unspecified')|
|('DB05471', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in autoimmune diseases cancertumors unspecified lymphoma nonhodgkins and lymphoma unspecified')|
|('DB05472', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05473', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in saliva and salivary gland dysfunction sialorrhea')|
|('DB05474', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in inflammatory disorders such as rheumatoid arthritis inflammatory bowel disease and psoriasis')|
|('DB05474', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in inflammatory disorders such as rheumatoid arthritis inflammatory bowel disease and psoriasis')|
|('DB05474', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in inflammatory disorders such as rheumatoid arthritis inflammatory bowel disease and psoriasis')|
|('DB05475', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in hepatitis viral c infectious and parasitic disease unspecified and tuberculosis')|
|('DB05475', 'MONDO:0018076', ['tuberculosis'], 'investigated for usetreatment in hepatitis viral c infectious and parasitic disease unspecified and tuberculosis')|
|('DB05476', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors')|
|('DB05477', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified and ovarian cancer')|
|('DB05477', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in cancertumors unspecified and ovarian cancer')|
|('DB05478', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for use as a prodrug for hepsera in treating hepatitis viral b')|
|('DB05478', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for use as a prodrug for hepsera in treating hepatitis viral b')|
|('DB05479', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in candidiasis and vaginitis')|
|('DB05479', 'MONDO:0002234', ['vaginitis'], 'investigated for usetreatment in candidiasis and vaginitis')|
|('DB05480', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in adverse effects chemotherapy anemia and chemotherapy')|
|('DB05480', 'MONDO:0002280', ['anaemia', 'anemia'], 'investigated for usetreatment in adverse effects chemotherapy anemia and chemotherapy')|
|('DB05481', 'MONDO:0002280', ['anaemia', 'anemia'], 'investigated for usetreatment in alpha 1 antitrypsin deficiency atopic dermatitis and chronic obstructive pulmonary disease copd')|
|('DB05481', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in alpha 1 antitrypsin deficiency atopic dermatitis and chronic obstructive pulmonary disease copd')|
|('DB05481', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in alpha 1 antitrypsin deficiency atopic dermatitis and chronic obstructive pulmonary disease copd')|
|('DB05482', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in colorectal cancer')|
|('DB05482', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer')|
|('DB05483', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in acne herpes labialis infections cold sores and venereal disease')|
|('DB05483', 'MONDO:0043653', ['cold Sore [MESH:D006560,NCIT:C34695]', 'herpes labialis []', 'herpes labialis'], 'investigated for usetreatment in acne herpes labialis infections cold sores and venereal disease')|
|('DB05484', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in autoimmune diseases and inflammatory disorders unspecified')|
|('DB05485', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in breast cancer cancertumors unspecified melanoma ovarian cancer and solid tumors')|
|('DB05485', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer cancertumors unspecified melanoma ovarian cancer and solid tumors')|
|('DB05485', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in breast cancer cancertumors unspecified melanoma ovarian cancer and solid tumors')|
|('DB05487', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in brain cancer and breast cancer')|
|('DB05487', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer and breast cancer')|
|('DB05487', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in brain cancer and breast cancer')|
|('DB05488', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in infectious and parasitic disease unspecified')|
|('DB05489', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer')|
|('DB05490', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05491', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer and cancertumors unspecified')|
|('DB05492', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in neuropathy diabetic and pain acute or chronic')|
|('DB05493', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in benign prostatic hyperplasia')|
|('DB05494', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia unspecified and melanoma')|
|('DB05494', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in leukemia unspecified and melanoma')|
|('DB05495', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in osteoarthritis')|
|('DB05496', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 1 pediatric indications and psoriasis and psoriatic disorders')|
|('DB05496', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in diabetes mellitus type 1 pediatric indications and psoriasis and psoriatic disorders')|
|('DB05498', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in urinary incontinence')|
|('DB05499', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in neuropathy diabetic')|
|('DB05500', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in cancertumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma and pancreatic cancer')|
|('DB05500', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in cancertumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma and pancreatic cancer')|
|('DB05501', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in hiv infection')|
|('DB05502', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in leukemia myeloid')|
|('DB05505', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05505', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05506', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05507', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in inflammatory disorders unspecified and psoriasis and psoriatic disorders')|
|('DB05507', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in inflammatory disorders unspecified and psoriasis and psoriatic disorders')|
|('DB05509', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in premature ejaculation')|
|('DB05511', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in cancertumors unspecified eye disordersinfections psoriasis and psoriatic disorders and rheumatoid arthritiscanfite biopharma has reported that by targeting the adenosine a3receptor cf101 may also be used to treat crohns disease a serious gastrointestinal disorder')|
|('DB05511', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in cancertumors unspecified eye disordersinfections psoriasis and psoriatic disorders and rheumatoid arthritiscanfite biopharma has reported that by targeting the adenosine a3receptor cf101 may also be used to treat crohns disease a serious gastrointestinal disorder')|
|('DB05511', 'MONDO:0004335', ['alimentary system disease', 'digestive system disorder', 'Gastroenteropathy', 'gastrointestinal disease', 'gastrointestinal disorder', 'GIT disease', 'digestive system disease'], 'investigated for usetreatment in cancertumors unspecified eye disordersinfections psoriasis and psoriatic disorders and rheumatoid arthritiscanfite biopharma has reported that by targeting the adenosine a3receptor cf101 may also be used to treat crohns disease a serious gastrointestinal disorder')|
|('DB05512', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05512', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05512', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05513', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in cancertumors unspecified multiple myeloma and rheumatoid arthritis')|
|('DB05513', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in cancertumors unspecified multiple myeloma and rheumatoid arthritis')|
|('DB05513', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in cancertumors unspecified multiple myeloma and rheumatoid arthritis')|
|('DB05514', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in cystic fibrosis')|
|('DB05516', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in autoimmune diseases and skin infectionsdisorders')|
|('DB05518', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05519', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB05519', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in arrhythmia and atrial fibrillation')|
|('DB05520', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in alzheimers disease')|
|('DB05524', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB05524', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB05524', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB05525', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05525', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB05528', 'MONDO:0004992', ['cancer'], 'used in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipidlowering medications')|
|('DB05528', 'MONDO:0018328', ['HoFH [Orphanet:391665]', 'homozygous familial hypercholesterolemia'], 'used in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipidlowering medications')|
|('DB05530', 'MONDO:0018328', ['HoFH [Orphanet:391665]', 'homozygous familial hypercholesterolemia'], 'investigated for usetreatment in hepatitis viral c and viral infection')|
|('DB05530', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in hepatitis viral c and viral infection')|
|('DB05531', 'MONDO:0018328', ['HoFH [Orphanet:391665]', 'homozygous familial hypercholesterolemia'], 'investigated for usetreatment in actinic keratosis breast cancer liver cancer melanoma psoriasis and psoriatic disorders and solid tumors')|
|('DB05531', 'MONDO:0006566', ['keratosis'], 'investigated for usetreatment in actinic keratosis breast cancer liver cancer melanoma psoriasis and psoriatic disorders and solid tumors')|
|('DB05531', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in actinic keratosis breast cancer liver cancer melanoma psoriasis and psoriatic disorders and solid tumors')|
|('DB05531', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in actinic keratosis breast cancer liver cancer melanoma psoriasis and psoriatic disorders and solid tumors')|
|('DB05532', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in hiv infection')|
|('DB05533', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in neuropathy diabetic')|
|('DB05540', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in brain cancer and cancertumors unspecified')|
|('DB05540', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer and cancertumors unspecified')|
|('DB05541', 'MONDO:0004992', ['cancer'], 'used as adjunctive therapy for partialonset seizures in patients 16 years of age or older')|
|('DB05542', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB05542', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB05542', 'MONDO:0006769', ['gastric atonia', 'Gastroparalysis', 'Gastroparesis syndrome', 'gastroparesis'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB05545', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in osteoarthritis and rheumatoid arthritis')|
|('DB05545', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in osteoarthritis and rheumatoid arthritis')|
|('DB05549', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in brain cancer cardiovascular disorders and myocardial infarction')|
|('DB05549', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer cardiovascular disorders and myocardial infarction')|
|('DB05549', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in brain cancer cardiovascular disorders and myocardial infarction')|
|('DB05550', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lymphoma unspecified')|
|('DB05552', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in angioedema and myocardial infarction')|
|('DB05552', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in angioedema and myocardial infarction')|
|('DB05553', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiac surgery coronary artery disease thrombosis and transfusion')|
|('DB05553', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in cardiac surgery coronary artery disease thrombosis and transfusion')|
|('DB05555', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in asthma')|
|('DB05559', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in atopic dermatitis inflammatory disorders unspecified and skin infectionsdisorders')|
|('DB05559', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in atopic dermatitis inflammatory disorders unspecified and skin infectionsdisorders')|
|('DB05560', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in myocardial infarction')|
|('DB05562', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in anxiety disorders and depression')|
|('DB05565', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in alzheimers disease')|
|('DB05575', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in solid tumors')|
|('DB05578', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for use in advanced gastric or gastroesophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine or platinumcontaining chemotherapy')|
|('DB05578', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'for use in advanced gastric or gastroesophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine or platinumcontaining chemotherapy')|
|('DB05580', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'investigated for usetreatment in lymphoma unspecified and rheumatoid arthritis')|
|('DB05580', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in lymphoma unspecified and rheumatoid arthritis')|
|('DB05584', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'investigated for usetreatment in spinal cord injuries')|
|('DB05585', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'investigated for usetreatment in brain cancer lung cancer melanoma and solid tumors')|
|('DB05585', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer lung cancer melanoma and solid tumors')|
|('DB05586', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05586', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease neurologic disorders and schizophrenia and schizoaffective disorders')|
|('DB05590', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in asthma and labor and delivery')|
|('DB05592', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in breast cancer')|
|('DB05592', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05594', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in gastric cancer')|
|('DB05594', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in gastric cancer')|
|('DB05595', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in ovarian cancer')|
|('DB05595', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer')|
|('DB05596', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease and memory loss')|
|('DB05599', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in coronary artery disease and peripheral vascular disease')|
|('DB05599', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in coronary artery disease and peripheral vascular disease')|
|('DB05606', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in leukemia lymphoid')|
|('DB05607', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in chronic obstructive pulmonary disease copd and pulmonary hypertension')|
|('DB05607', 'MONDO:0005149', ['pulmonary hypertension'], 'investigated for usetreatment in chronic obstructive pulmonary disease copd and pulmonary hypertension')|
|('DB05608', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in breast cancer leukemia unspecified lung cancer and solid tumors')|
|('DB05608', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer leukemia unspecified lung cancer and solid tumors')|
|('DB05611', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in crohns disease and psoriasis and psoriatic disorders')|
|('DB05611', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in crohns disease and psoriasis and psoriatic disorders')|
|('DB05616', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in inflammatory disorders unspecified psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05616', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in inflammatory disorders unspecified psoriasis and psoriatic disorders and rheumatoid arthritis')|
|('DB05620', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05624', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in benign prostatic hyperplasia endometriosis and prostate cancer')|
|('DB05624', 'MONDO:0005133', ['endometriosis'], 'investigated for usetreatment in benign prostatic hyperplasia endometriosis and prostate cancer')|
|('DB05624', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in benign prostatic hyperplasia endometriosis and prostate cancer')|
|('DB05625', 'MONDO:0005133', ['endometriosis'], 'investigated for usetreatment in cancertumors unspecified lung cancer and sarcoma')|
|('DB05625', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified lung cancer and sarcoma')|
|('DB05625', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'investigated for usetreatment in cancertumors unspecified lung cancer and sarcoma')|
|('DB05626', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in gastric cancer lung cancer and multiple myeloma')|
|('DB05631', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiovascular disorders and diabetes mellitus type 1 and 2')|
|('DB05631', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cardiovascular disorders and diabetes mellitus type 1 and 2')|
|('DB05633', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in neurologic disorders')|
|('DB05638', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in infectious and parasitic disease unspecified and viral infection')|
|('DB05638', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in infectious and parasitic disease unspecified and viral infection')|
|('DB05642', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in alzheimers disease depression diarrhea gastrointestinal diseases and disorders miscellaneous and irritable bowel syndrome ibs')|
|('DB05642', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in alzheimers disease depression diarrhea gastrointestinal diseases and disorders miscellaneous and irritable bowel syndrome ibs')|
|('DB05644', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in hiv infection')|
|('DB05645', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in autoimmune diseases diabetes mellitus type 1 and gastrointestinal diseases and disorders miscellaneous')|
|('DB05645', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in autoimmune diseases diabetes mellitus type 1 and gastrointestinal diseases and disorders miscellaneous')|
|('DB05649', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in strokes')|
|('DB05650', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cataracts eye disordersinfections glaucoma and macular degeneration')|
|('DB05650', 'MONDO:0005041', ['glaucoma'], 'investigated for usetreatment in cataracts eye disordersinfections glaucoma and macular degeneration')|
|('DB05650', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in cataracts eye disordersinfections glaucoma and macular degeneration')|
|('DB05652', 'MONDO:0005041', ['glaucoma'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB05653', 'MONDO:0005041', ['glaucoma'], 'investigated for usetreatment in adverse effects chemotherapy and blood blood forming organ disorders unspecified')|
|('DB05656', 'MONDO:0005041', ['glaucoma'], 'investigated for usetreatment in lymphoma nonhodgkins')|
|('DB05659', 'MONDO:0005041', ['glaucoma'], 'investigated for usetreatment in bacterial infection bronchitis otitis media and pediatric indications')|
|('DB05659', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in bacterial infection bronchitis otitis media and pediatric indications')|
|('DB05660', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in hearing loss')|
|('DB05662', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in eye disordersinfections')|
|('DB05667', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05668', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in cancertumors unspecified lymphoma unspecified and sarcoma')|
|('DB05668', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'investigated for usetreatment in cancertumors unspecified lymphoma unspecified and sarcoma')|
|('DB05670', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in adverse effects chemotherapy')|
|('DB05671', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in periodontal disease')|
|('DB05675', 'MONDO:0005441', ['otitis media'], 'investigated for usetreatment in cardiovascular disorders and thrombosis')|
|('DB05676', 'MONDO:0005441', ['otitis media'], 'apremilast is indicated for the treating of active psoriatic arthritis in adults for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment  in addition apremilast is now indicated for the treatment of oral ulcers associated with behcets disease in adultsl7501')|
|('DB05676', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'apremilast is indicated for the treating of active psoriatic arthritis in adults for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment  in addition apremilast is now indicated for the treatment of oral ulcers associated with behcets disease in adultsl7501')|
|('DB05678', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05679', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ustekinumab is indicated for the management of moderate to severe plaque psoriasis in adolescent over 12 years of age and adult patients who are candidates for phototherapy or systemic therapyl9383l9386it is indicated for the management of active psoriatic arthritis in adults alone or in combination with methotrexatel9383it is indicated for the management of moderately to severely active crohn’s disease in adults who were clinically unresponsive or intolerant to immunomodulator or corticosteroid therapy but never failed a tutor necrosis factor tnf blocker or treatment with one or more tnf blockersl9383it is indicated for the management of moderately to severely active ulcerative colitis in adultsl9386')|
|('DB05679', 'MONDO:0005083', ['psoriasis'], 'ustekinumab is indicated for the management of moderate to severe plaque psoriasis in adolescent over 12 years of age and adult patients who are candidates for phototherapy or systemic therapyl9383l9386it is indicated for the management of active psoriatic arthritis in adults alone or in combination with methotrexatel9383it is indicated for the management of moderately to severely active crohn’s disease in adults who were clinically unresponsive or intolerant to immunomodulator or corticosteroid therapy but never failed a tutor necrosis factor tnf blocker or treatment with one or more tnf blockersl9383it is indicated for the management of moderately to severely active ulcerative colitis in adultsl9386')|
|('DB05679', 'MONDO:0005292', ['colitis'], 'ustekinumab is indicated for the management of moderate to severe plaque psoriasis in adolescent over 12 years of age and adult patients who are candidates for phototherapy or systemic therapyl9383l9386it is indicated for the management of active psoriatic arthritis in adults alone or in combination with methotrexatel9383it is indicated for the management of moderately to severely active crohn’s disease in adults who were clinically unresponsive or intolerant to immunomodulator or corticosteroid therapy but never failed a tutor necrosis factor tnf blocker or treatment with one or more tnf blockersl9383it is indicated for the management of moderately to severely active ulcerative colitis in adultsl9386')|
|('DB05680', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in actinic keratosis and skin infectionsdisorders')|
|('DB05680', 'MONDO:0006566', ['keratosis'], 'investigated for usetreatment in actinic keratosis and skin infectionsdisorders')|
|('DB05683', 'MONDO:0006566', ['keratosis'], 'investigated for usetreatment in cardiac ischemia')|
|('DB05685', 'MONDO:0006566', ['keratosis'], 'investigated for usetreatment in cardiac reperfusion injury and myocardial infarction')|
|('DB05685', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in cardiac reperfusion injury and myocardial infarction')|
|('DB05685', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in cardiac reperfusion injury and myocardial infarction')|
|('DB05686', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in cervical dysplasiacancer genital warts and skin cancer')|
|('DB05686', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in cervical dysplasiacancer genital warts and skin cancer')|
|('DB05686', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'investigated for usetreatment in cervical dysplasiacancer genital warts and skin cancer')|
|('DB05687', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders')|
|('DB05688', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in periodontal disease and rheumatoid arthritis')|
|('DB05688', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in periodontal disease and rheumatoid arthritis')|
|('DB05695', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in osteoporosis')|
|('DB05698', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in pancreatic cancer')|
|('DB05698', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer')|
|('DB05705', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05705', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05706', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in breast cancer and cancertumors unspecified')|
|('DB05706', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer and cancertumors unspecified')|
|('DB05708', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease and schizophrenia and schizoaffective disorders')|
|('DB05708', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease and schizophrenia and schizoaffective disorders')|
|('DB05710', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in anesthesia unspecified')|
|('DB05712', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in thrombosis')|
|('DB05713', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in thrombosis and venous thromboembolism')|
|('DB05713', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in thrombosis and venous thromboembolism')|
|('DB05714', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in thrombosis')|
|('DB05718', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in adverse effects chemotherapy and neutropenics')|
|('DB05719', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in melanoma')|
|('DB05721', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in insomnia')|
|('DB05722', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in lymphoma unspecified macular degeneration prostate cancer and solid tumors')|
|('DB05722', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lymphoma unspecified macular degeneration prostate cancer and solid tumors')|
|('DB05723', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in addictions and alcohol dependence')|
|('DB05723', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'investigated for usetreatment in addictions and alcohol dependence')|
|('DB05724', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05730', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05730', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05732', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in osteoporosis')|
|('DB05735', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bacterial infection skin infectionsdisorders and staph bacterial infections')|
|('DB05736', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in osteoporosis')|
|('DB05737', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in atherosclerosis and coronary artery disease')|
|('DB05737', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in atherosclerosis and coronary artery disease')|
|('DB05738', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05738', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05739', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hypertension')|
|('DB05740', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in multiple sclerosis neurologic disorders and pain acute or chronic')|
|('DB05741', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in leukemia lymphoid')|
|('DB05742', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB05744', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05744', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05746', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in glaucoma and ocular hypertension')|
|('DB05746', 'MONDO:0006875', ['ocular hypertension'], 'investigated for usetreatment in glaucoma and ocular hypertension')|
|('DB05747', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cervical dysplasiacancer and viral infection')|
|('DB05747', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in cervical dysplasiacancer and viral infection')|
|('DB05749', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in menstrual disorders')|
|('DB05750', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease obesity and schizophrenia and schizoaffective disorders')|
|('DB05750', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease obesity and schizophrenia and schizoaffective disorders')|
|('DB05751', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in allergic reaction and asthma')|
|('DB05751', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in allergic reaction and asthma')|
|('DB05752', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in chronic obstructive pulmonary disease copd')|
|('DB05753', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in sleep disorders')|
|('DB05754', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in hepatitis viral c leukemia myeloid and lymphoma nonhodgkins')|
|('DB05754', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in hepatitis viral c leukemia myeloid and lymphoma nonhodgkins')|
|('DB05754', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in hepatitis viral c leukemia myeloid and lymphoma nonhodgkins')|
|('DB05755', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05755', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'investigated for usetreatment in atopic dermatitis')|
|('DB05756', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in candidiasis fungal infections and saliva and salivary gland dysfunction')|
|('DB05757', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in ocular hypertension')|
|('DB05758', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB05765', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in actinic keratosis')|
|('DB05765', 'MONDO:0006566', ['keratosis'], 'investigated for usetreatment in actinic keratosis')|
|('DB05766', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders')|
|('DB05767', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05767', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05768', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05768', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05769', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05771', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB05772', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05772', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05773', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'used in her2positive metastatic breast cancer patients who have already used taxane andor trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment')|
|('DB05773', 'MONDO:0004992', ['cancer'], 'used in her2positive metastatic breast cancer patients who have already used taxane andor trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment')|
|('DB05773', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'used in her2positive metastatic breast cancer patients who have already used taxane andor trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment')|
|('DB05775', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05776', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05777', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in blood preservative blood blood forming organ disorders unspecified sepsis and septicemia and thrombosis')|
|('DB05778', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in skin infectionsdisorders')|
|('DB05779', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05780', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05785', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05786', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indications prostate cancer and sarcoma')|
|('DB05786', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indications prostate cancer and sarcoma')|
|('DB05786', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'investigated for usetreatment in brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indications prostate cancer and sarcoma')|
|('DB05787', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in colorectal cancer melanoma prostate cancer psoriasis and psoriatic disorders rheumatoid arthritis and solid tumors')|
|('DB05787', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer melanoma prostate cancer psoriasis and psoriatic disorders rheumatoid arthritis and solid tumors')|
|('DB05787', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in colorectal cancer melanoma prostate cancer psoriasis and psoriatic disorders rheumatoid arthritis and solid tumors')|
|('DB05789', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in cervical dysplasiacancer')|
|('DB05790', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in asthma and inflammatory bowel disease')|
|('DB05790', 'MONDO:0005265', ['inflammatory bowel disease'], 'investigated for usetreatment in asthma and inflammatory bowel disease')|
|('DB05791', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in cardiac surgery hemorrhage and ileus')|
|('DB05791', 'MONDO:0004567', ['Ileus of intestine', 'ileus'], 'investigated for usetreatment in cardiac surgery hemorrhage and ileus')|
|('DB05792', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in cancertumors unspecified immunosuppressive and prostate cancer')|
|('DB05792', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in cancertumors unspecified immunosuppressive and prostate cancer')|
|('DB05793', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections hiv infection and pediatric indications')|
|('DB05793', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections hiv infection and pediatric indications')|
|('DB05793', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections hiv infection and pediatric indications')|
|('DB05794', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in cardiovascular disorders congestive heart failure infertility peripheral vascular disease and scleroderma')|
|('DB05794', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in cardiovascular disorders congestive heart failure infertility peripheral vascular disease and scleroderma')|
|('DB05794', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in cardiovascular disorders congestive heart failure infertility peripheral vascular disease and scleroderma')|
|('DB05794', 'MONDO:0019340', ['dermatosclerosis', 'scleroderma'], 'investigated for usetreatment in cardiovascular disorders congestive heart failure infertility peripheral vascular disease and scleroderma')|
|('DB05795', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in depression')|
|('DB05796', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in congestive heart failure and hypertension')|
|('DB05796', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure and hypertension')|
|('DB05797', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in allergic reaction')|
|('DB05798', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in solid tumors')|
|('DB05799', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in sepsis and septicemia')|
|('DB05800', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in blood blood forming organ disorders unspecified lymphoma unspecified and multiple myeloma')|
|('DB05800', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in blood blood forming organ disorders unspecified lymphoma unspecified and multiple myeloma')|
|('DB05801', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma and solid tumors')|
|('DB05801', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma and solid tumors')|
|('DB05801', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'investigated for usetreatment in breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma and solid tumors')|
|('DB05801', 'MONDO:0044873', ['myelodysplastic syndrome [NCIT:C68744]', 'childhood MDS [NCIT:C68744]', 'childhood myelodysplastic syndrome [NCIT:C68744]', 'childhood myelodysplastic syndrome'], 'investigated for usetreatment in breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma and solid tumors')|
|('DB05803', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05804', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in asthma and burns and burn infections')|
|('DB05804', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in asthma and burns and burn infections')|
|('DB05805', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in addictions attention deficithyperactivity disorder adhd and depression')|
|('DB05806', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in brain cancer lung cancer and melanoma')|
|('DB05806', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer lung cancer and melanoma')|
|('DB05806', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in brain cancer lung cancer and melanoma')|
|('DB05807', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB05808', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatocellular carcinoma liver cancer melanoma and multiple myeloma')|
|('DB05808', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'investigated for usetreatment in hepatocellular carcinoma liver cancer melanoma and multiple myeloma')|
|('DB05809', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cervical dysplasiacancer')|
|('DB05810', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in myocardial infarction')|
|('DB05811', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in genital herpes')|
|('DB05814', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in erectile dysfunction and parkinsons disease')|
|('DB05815', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB05817', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer cancertumors unspecified colorectal cancer leukemia lymphoid leukemia myeloid lung cancer myelodysplastic syndrome pediatric indications and solid tumors')|
|('DB05817', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'investigated for usetreatment in brain cancer cancertumors unspecified colorectal cancer leukemia lymphoid leukemia myeloid lung cancer myelodysplastic syndrome pediatric indications and solid tumors')|
|('DB05817', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in brain cancer cancertumors unspecified colorectal cancer leukemia lymphoid leukemia myeloid lung cancer myelodysplastic syndrome pediatric indications and solid tumors')|
|('DB05818', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in breast cancer colorectal cancer and lung cancer')|
|('DB05818', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer colorectal cancer and lung cancer')|
|('DB05819', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in diabetes mellitus type 1 and pediatric indications')|
|('DB05820', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in strokes and traumatic brain injuries')|
|('DB05821', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bipolar disorders epilepsy and migraine and cluster headaches')|
|('DB05824', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in migraine and cluster headaches neuropathy diabetic and pain acute or chronic')|
|('DB05825', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in arthritis and arthritic pain and inflammatory bowel disease')|
|('DB05825', 'MONDO:0005265', ['inflammatory bowel disease'], 'investigated for usetreatment in arthritis and arthritic pain and inflammatory bowel disease')|
|('DB05826', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in infertility')|
|('DB05827', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB05828', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in psychosis and schizophrenia and schizoaffective disorders')|
|('DB05828', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in psychosis and schizophrenia and schizoaffective disorders')|
|('DB05829', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for usetreatment in osteoporosis')|
|('DB05830', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in contraception and male hormonal deficienciesabnormalities')|
|('DB05831', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05832', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease')|
|('DB05834', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in adverse effects chemotherapy and head and neck cancer')|
|('DB05834', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'investigated for usetreatment in adverse effects chemotherapy and head and neck cancer')|
|('DB05835', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in anemia sickle cell and cancertumors unspecified')|
|('DB05836', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in genital herpes')|
|('DB05837', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in solid tumors')|
|('DB05838', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in nocturia frequent nighttime urination and urinary incontinence')|
|('DB05839', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cytomegalovirus cmv retinitis hiv infection influenza and pneumonia')|
|('DB05839', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'investigated for usetreatment in cytomegalovirus cmv retinitis hiv infection influenza and pneumonia')|
|('DB05839', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for usetreatment in cytomegalovirus cmv retinitis hiv infection influenza and pneumonia')|
|('DB05840', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'investigated for usetreatment in transplant rejection')|
|('DB05841', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'investigated for usetreatment in asthma')|
|('DB05842', 'MONDO:0000878', ['CMV retinitis', 'cytomegalovirus retinitis'], 'investigated for usetreatment in breast cancer and solid tumors')|
|('DB05842', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer and solid tumors')|
|('DB05843', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiovascular disorders and hypertension')|
|('DB05845', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in skin cancer and skin infectionsdisorders')|
|('DB05846', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease neurologic disorders parkinsons disease and retinal disorders unspecified')|
|('DB05848', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in autoimmune diseases and inflammatory disorders unspecified')|
|('DB05849', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05849', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma and chronic obstructive pulmonary disease copd')|
|('DB05851', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in adverse effects chemotherapy and renal cell carcinoma')|
|('DB05851', 'MONDO:0005549', ['adenocarcinoma of kidney [NCIT:C9385]', 'kidney adenocarcinoma [NCIT:C9385]', 'renal cell carcinoma [NCIT:C9385]', 'RCC [NCIT:C9385]', 'adenocarcinoma of the kidney [NCIT:C9385]', 'carcinoma, renal cell, malignant [NCIT:C9385]', 'renal cell carcinoma, stage unspecified [NCIT:C9385]', 'renal cell adenocarcinoma [NCIT:C9385]', 'renal cell cancer [NCIT:C9385]', 'renal cell adenocarcinoma'], 'investigated for usetreatment in adverse effects chemotherapy and renal cell carcinoma')|
|('DB05852', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in liver disease')|
|('DB05854', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB05855', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05855', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB05856', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in metabolic disease')|
|('DB05858', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in acne')|
|('DB05859', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in liver cancer')|
|('DB05859', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in liver cancer')|
|('DB05860', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05861', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in prostate cancer')|
|('DB05861', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB05863', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in autoimmune diseases')|
|('DB05864', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in lymphoma nonhodgkins and solid tumors')|
|('DB05865', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in diabetic retinopathy scar tissue and vitreous hemorrhage')|
|('DB05866', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in hyperlipidemia')|
|('DB05867', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in breast cancer')|
|('DB05867', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05868', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05869', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in burns and burn infections cardiac surgery inflammatory disorders unspecified ischemic reperfusion injury and sepsis and septicemia')|
|('DB05869', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in burns and burn infections cardiac surgery inflammatory disorders unspecified ischemic reperfusion injury and sepsis and septicemia')|
|('DB05869', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in burns and burn infections cardiac surgery inflammatory disorders unspecified ischemic reperfusion injury and sepsis and septicemia')|
|('DB05870', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in colorectal cancer pancreatic cancer and solid tumors')|
|('DB05870', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer pancreatic cancer and solid tumors')|
|('DB05871', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB05873', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in infectious and parasitic disease unspecified and viral infection')|
|('DB05873', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in infectious and parasitic disease unspecified and viral infection')|
|('DB05874', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05874', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als')|
|('DB05875', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in acute respiratory distress syndrome ards and viral infection')|
|('DB05875', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in acute respiratory distress syndrome ards and viral infection')|
|('DB05879', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05879', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB05880', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in solid tumors')|
|('DB05881', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in alzheimers disease and neurologic disorders')|
|('DB05882', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in osteoporosis')|
|('DB05883', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in chronic renal failure and parathyroid disorders')|
|('DB05883', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in chronic renal failure and parathyroid disorders')|
|('DB05884', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05885', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in epilepsy')|
|('DB05886', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in solid tumors')|
|('DB05887', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in transplant rejection')|
|('DB05888', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'investigated for usetreatment in alzheimers disease depression memory loss and neurologic disorders')|
|('DB05889', 'MONDO:0001106', ['renal failure', 'kidney failure'], 'indicated as monotherapy for the treatment of adults with relapsed or refractory cd22positive b cell precursor acute lymphoblastic leukaemia all ')|
|('DB05889', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'indicated as monotherapy for the treatment of adults with relapsed or refractory cd22positive b cell precursor acute lymphoblastic leukaemia all ')|
|('DB05890', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05892', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05894', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in obesity')|
|('DB05895', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in solid tumors')|
|('DB05896', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in macular degeneration')|
|('DB05897', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05898', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in alzheimers disease and gene therapy')|
|('DB05899', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05903', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in solid tumors')|
|('DB05904', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05905', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'investigated for usetreatment in constipation gastrointestinal diseases and disorders miscellaneous gastroparesis and irritable bowel syndrome ibs')|
|('DB05905', 'MONDO:0006769', ['gastric atonia', 'Gastroparalysis', 'Gastroparesis syndrome', 'gastroparesis'], 'investigated for usetreatment in constipation gastrointestinal diseases and disorders miscellaneous gastroparesis and irritable bowel syndrome ibs')|
|('DB05905', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in constipation gastrointestinal diseases and disorders miscellaneous gastroparesis and irritable bowel syndrome ibs')|
|('DB05906', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in hiv infection')|
|('DB05911', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in atherosclerosis')|
|('DB05912', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in multiple sclerosis')|
|('DB05913', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in solid tumors')|
|('DB05915', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in muscular dystrophy')|
|('DB05916', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05918', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in macular degeneration')|
|('DB05919', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in urinary incontinence')|
|('DB05920', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in brain cancer')|
|('DB05920', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB05924', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in parkinsons disease')|
|('DB05928', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in multiple myeloma and solid tumors')|
|('DB05928', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in multiple myeloma and solid tumors')|
|('DB05929', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer and prostate cancer')|
|('DB05929', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer and prostate cancer')|
|('DB05929', 'MONDO:0005072', ['neuroblastoma'], 'investigated for usetreatment in breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer and prostate cancer')|
|('DB05929', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer and prostate cancer')|
|('DB05930', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in thrombocytopenia')|
|('DB05931', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and macular degeneration')|
|('DB05931', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in cancertumors unspecified and macular degeneration')|
|('DB05932', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors')|
|('DB05934', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in adverse effects chemotherapy blood blood forming organ disorders unspecified cancertumors unspecified neutropenics and vascular diseases')|
|('DB05936', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in asthma')|
|('DB05938', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease')|
|('DB05939', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in atherosclerosis')|
|('DB05941', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB05942', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral c')|
|('DB05943', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in sepsis and septicemia')|
|('DB05944', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05945', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in anthrax exposure and bacterial infection')|
|('DB05950', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pain acute or chronic')|
|('DB05956', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease neurologic disorders pain acute or chronic and parkinsons disease')|
|('DB05959', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05961', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB05964', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in depression')|
|('DB05966', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer')|
|('DB05967', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and liver cancer')|
|('DB05967', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'investigated for usetreatment in cancertumors unspecified and liver cancer')|
|('DB05968', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB05969', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma and solid tumors')|
|('DB05969', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in cancertumors unspecified leukemia unspecified lymphoma unspecified multiple myeloma and solid tumors')|
|('DB05971', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in solid tumors')|
|('DB05973', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous inflammatory bowel disease and ulcerative colitis')|
|('DB05973', 'MONDO:0005265', ['inflammatory bowel disease'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous inflammatory bowel disease and ulcerative colitis')|
|('DB05973', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous inflammatory bowel disease and ulcerative colitis')|
|('DB05974', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in cancertumors unspecified hemorrhage hypoxia respiratory failure and strokes')|
|('DB05974', 'MONDO:0021113', ['acute and chronic respiratory failure', 'acute respiratory Failure', 'acute-on-chronic respiratory failure', 'chronic respiratory failure', 'respiratory insufficiency/failure', 'respiratory failure'], 'investigated for usetreatment in cancertumors unspecified hemorrhage hypoxia respiratory failure and strokes')|
|('DB05983', 'MONDO:0021113', ['acute and chronic respiratory failure', 'acute respiratory Failure', 'acute-on-chronic respiratory failure', 'chronic respiratory failure', 'respiratory insufficiency/failure', 'respiratory failure'], 'investigated for usetreatment in lymphoma unspecified multiple myeloma and solid tumors')|
|('DB05983', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in lymphoma unspecified multiple myeloma and solid tumors')|
|('DB05984', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in melanoma')|
|('DB05990', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid udca in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca ')|
|('DB05990', 'MONDO:0005388', ['biliary liver cirrhosis', 'cholestatic cirrhosis', 'chronic nonsuppurative destructive cholangitis', 'primary biliary cholangitis'], 'indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid udca in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca ')|
|('DB05992', 'MONDO:0005388', ['biliary liver cirrhosis', 'cholestatic cirrhosis', 'chronic nonsuppurative destructive cholangitis', 'primary biliary cholangitis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB05993', 'MONDO:0005388', ['biliary liver cirrhosis', 'cholestatic cirrhosis', 'chronic nonsuppurative destructive cholangitis', 'primary biliary cholangitis'], 'investigated for usetreatment in alzheimers disease obesity and schizophrenia and schizoaffective disorders')|
|('DB05993', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in alzheimers disease obesity and schizophrenia and schizoaffective disorders')|
|('DB05996', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in melanoma')|
|('DB06005', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cardiovascular disorders and coronary artery disease')|
|('DB06005', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in cardiovascular disorders and coronary artery disease')|
|('DB06011', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06013', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in solid tumors')|
|('DB06014', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'eteplirsen is indicated for treatment of certain individuals with duchenne muscular dystrophy dmd  its use is limited to those with a confirmed mutation of the dmd gene which would benefit from exon 51 skipping  based on clinical studies showing increased dystrophin production in skeletal muscle in some patients given this drug the above indication was approved under accelerated approval   further confirmatory trials are required to demonstrate clinical benefit of eteplirsen')|
|('DB06014', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'eteplirsen is indicated for treatment of certain individuals with duchenne muscular dystrophy dmd  its use is limited to those with a confirmed mutation of the dmd gene which would benefit from exon 51 skipping  based on clinical studies showing increased dystrophin production in skeletal muscle in some patients given this drug the above indication was approved under accelerated approval   further confirmatory trials are required to demonstrate clinical benefit of eteplirsen')|
|('DB06016', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar idisorder')|
|('DB06016', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar idisorder')|
|('DB06021', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06022', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in adverse effects chemotherapy and neutropenics')|
|('DB06039', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in hiv infection')|
|('DB06040', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06042', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06043', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'olaratumab is indicated in combination with doxorubicin for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma sts with a histologic subtype for which an anthracyclinecontaining regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery')|
|('DB06043', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'olaratumab is indicated in combination with doxorubicin for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma sts with a histologic subtype for which an anthracyclinecontaining regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery')|
|('DB06045', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in traumatic brain injuries')|
|('DB06049', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in leukemia myeloid and multiple myeloma')|
|('DB06049', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in leukemia myeloid and multiple myeloma')|
|('DB06050', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in atrial fibrillation and thrombosis')|
|('DB06058', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in hepatitis viral c')|
|('DB06061', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06063', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in acromegaly and cancertumors unspecified')|
|('DB06064', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in ischemic reperfusion injury')|
|('DB06064', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in ischemic reperfusion injury')|
|('DB06069', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in solid tumors')|
|('DB06070', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06071', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06073', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in alzheimers disease')|
|('DB06075', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB06077', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'lumateperone is approved for the treatment of schizophrenia in adultsl10860')|
|('DB06077', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'lumateperone is approved for the treatment of schizophrenia in adultsl10860')|
|('DB06080', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for usetreatment in leukemia myeloid myelodysplastic syndrome and solid tumors')|
|('DB06081', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06081', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06081', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06081', 'MONDO:0002049', ['thrombocytopenia'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06081', 'MONDO:0002280', ['anaemia', 'anemia'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06081', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura attp in conjunction with plasma exchange and immunosuppression in patients 18 years or oldera174634 l5302attp is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia hemolytic anemia and organ ischemia it is caused by the production of autoantibodies against adamts13 which is the protein in charge of cleaving the vonwilebrand factor the lack of this process produces the generation of ultra large von wilebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complicationsa174649previously capacizumab was under review for the prevention of thrombosis in highrisk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawna174634')|
|('DB06082', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06083', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB06087', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in bacterial infection')|
|('DB06089', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in epilepsy')|
|('DB06090', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in neurologic disorders')|
|('DB06091', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in solid tumors')|
|('DB06093', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in neurologic disorders')|
|('DB06094', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06096', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in migraine and cluster headaches')|
|('DB06097', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in cancertumors unspecified and solid tumors')|
|('DB06098', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in solid tumors')|
|('DB06101', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06103', 'MONDO:0005542', ['acute coronary syndrome [NCIT:C53652]', 'acute coronary syndrome'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and viral infection')|
|('DB06103', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and viral infection')|
|('DB06103', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in autoimmune diseases psoriasis and psoriatic disorders and viral infection')|
|('DB06106', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in dementia')|
|('DB06109', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders')|
|('DB06111', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06112', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in asthma cystic fibrosis and hiv infection')|
|('DB06112', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in asthma cystic fibrosis and hiv infection')|
|('DB06112', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in asthma cystic fibrosis and hiv infection')|
|('DB06116', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB06116', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in ulcerative colitis')|
|('DB06117', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in parathyroid disorders')|
|('DB06119', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'cenobamate is indicated for the treatment of partial onset seizures in adultsl10653')|
|('DB06124', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in muscular dystrophy')|
|('DB06127', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06129', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in cancertumors unspecified and lung cancer')|
|('DB06129', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in cancertumors unspecified and lung cancer')|
|('DB06130', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in lymphoma nonhodgkins')|
|('DB06133', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in acne and alopecia')|
|('DB06133', 'MONDO:0004907', ['alopecia'], 'investigated for usetreatment in acne and alopecia')|
|('DB06134', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in solid tumors')|
|('DB06137', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06138', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06140', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in neurologic disorders')|
|('DB06145', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'macrolide antibiotic for treatment of various infections')|
|('DB06149', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment of bacterial infections caused by susceptible microorganisms')|
|('DB06152', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'nylidrin is mainly indicated in conditions like arteriosclerosis cerebrovascular disease peripheral vascular disease raynauds disease thromboangitis obliterans and thrombophlebitis l2285 it may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor however the drug is not approved for premature labora32531')|
|('DB06152', 'MONDO:0002277', ['Arteriosclerosis', 'Arteriosclerotic vascular disease', 'arteriosclerosis disorder'], 'nylidrin is mainly indicated in conditions like arteriosclerosis cerebrovascular disease peripheral vascular disease raynauds disease thromboangitis obliterans and thrombophlebitis l2285 it may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor however the drug is not approved for premature labora32531')|
|('DB06152', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'nylidrin is mainly indicated in conditions like arteriosclerosis cerebrovascular disease peripheral vascular disease raynauds disease thromboangitis obliterans and thrombophlebitis l2285 it may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor however the drug is not approved for premature labora32531')|
|('DB06152', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'nylidrin is mainly indicated in conditions like arteriosclerosis cerebrovascular disease peripheral vascular disease raynauds disease thromboangitis obliterans and thrombophlebitis l2285 it may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor however the drug is not approved for premature labora32531')|
|('DB06153', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'indicated for the prophylactic management of migraines l2292 ')|
|('DB06154', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'used for the treatment of angina pectoris l2393')|
|('DB06156', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'investigated for usetreatment in alzheimers disease parkinsons disease and obesity')|
|('DB06157', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'investigated for usetreatment in heart disease')|
|('DB06159', 'MONDO:0002800', ['Phlebitis and thrombophlebitis of superficial vessels of lower extremities', 'Superficial thrombophlebitis of leg', 'Thrombophlebitis of a superficial leg vein', 'Thrombophlebitis of superficial veins of lower extremity', 'thrombophlebitis'], 'investigated for usetreatment in pancreatic cancer leukemia unspecified melanoma ovarian cancer and cancertumors unspecified')|
|('DB06159', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer leukemia unspecified melanoma ovarian cancer and cancertumors unspecified')|
|('DB06159', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in pancreatic cancer leukemia unspecified melanoma ovarian cancer and cancertumors unspecified')|
|('DB06160', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in bacterial infection')|
|('DB06161', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in crohns disease congenital anomaly unspecified cardiovascular disorders pediatric indications and burns and burn infections')|
|('DB06161', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in crohns disease congenital anomaly unspecified cardiovascular disorders pediatric indications and burns and burn infections')|
|('DB06162', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'investigated for usetreatment in asthma and leukemia lymphoid')|
|('DB06162', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in asthma and leukemia lymphoid')|
|('DB06163', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in pancreatic cancer solid tumors gastric cancer lung cancer and colorectal cancer')|
|('DB06163', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer solid tumors gastric cancer lung cancer and colorectal cancer')|
|('DB06163', 'MONDO:0005575', ['colorectal cancer'], 'investigated for usetreatment in pancreatic cancer solid tumors gastric cancer lung cancer and colorectal cancer')|
|('DB06166', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06166', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06166', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06168', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'used in patients 4 years of age and older to treat familial cold autoinflammatory syndrome fcas and mucklewells syndrome mws which are both part of the cryopyrinassociated periodic syndromes caps as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis sjia ')|
|('DB06168', 'MONDO:0018768', ['familial cold autoinflammatory syndrome'], 'used in patients 4 years of age and older to treat familial cold autoinflammatory syndrome fcas and mucklewells syndrome mws which are both part of the cryopyrinassociated periodic syndromes caps as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis sjia ')|
|('DB06168', 'MONDO:0018737', ['caps [Orphanet:464343]', 'catastrophic APS [Orphanet:464343]', 'catastrophic antiphospholipid syndrome'], 'used in patients 4 years of age and older to treat familial cold autoinflammatory syndrome fcas and mucklewells syndrome mws which are both part of the cryopyrinassociated periodic syndromes caps as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis sjia ')|
|('DB06168', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'used in patients 4 years of age and older to treat familial cold autoinflammatory syndrome fcas and mucklewells syndrome mws which are both part of the cryopyrinassociated periodic syndromes caps as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis sjia ')|
|('DB06169', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors')|
|('DB06171', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in brain cancer')|
|('DB06171', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer')|
|('DB06174', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid cancertumors unspecified and multiple myeloma')|
|('DB06174', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid cancertumors unspecified and multiple myeloma')|
|('DB06176', 'MONDO:0005059', ['leukemia'], 'for the treatment of cutaneous tcell lymphoma ctcl orand peripheral tcell lymphoma ptcl in patients who have received at least one prior systemic therapy these indications are based on response rate clinical benefit such as improvement in overall survival has not been demonstrated ')|
|('DB06176', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'for the treatment of cutaneous tcell lymphoma ctcl orand peripheral tcell lymphoma ptcl in patients who have received at least one prior systemic therapy these indications are based on response rate clinical benefit such as improvement in overall survival has not been demonstrated ')|
|('DB06176', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of cutaneous tcell lymphoma ctcl orand peripheral tcell lymphoma ptcl in patients who have received at least one prior systemic therapy these indications are based on response rate clinical benefit such as improvement in overall survival has not been demonstrated ')|
|('DB06177', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'investigated for usetreatment in pancreatic cancer solid tumors breast cancer colorectal cancer brain cancer lung cancer ovarian cancer and sarcoma')|
|('DB06177', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer solid tumors breast cancer colorectal cancer brain cancer lung cancer ovarian cancer and sarcoma')|
|('DB06177', 'MONDO:0005089', ['connective and soft tissue neoplasm', 'tumor of soft tissue and skeleton', 'sarcoma'], 'investigated for usetreatment in pancreatic cancer solid tumors breast cancer colorectal cancer brain cancer lung cancer ovarian cancer and sarcoma')|
|('DB06178', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors lung cancer leukemia unspecified and leukemia lymphoid')|
|('DB06178', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in solid tumors lung cancer leukemia unspecified and leukemia lymphoid')|
|('DB06179', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cancertumors unspecified solid tumors multiple myeloma and liver cancer')|
|('DB06179', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cancertumors unspecified solid tumors multiple myeloma and liver cancer')|
|('DB06179', 'MONDO:0018531', ['liver and intrahepatic biliary tract cancer [NCIT:C7927]', 'cancer of liver and intrahepatic biliary tract [NCIT:C7927]', 'liver and intrahepatic bile duct cancer [NCIT:C7927]', 'liver/hepatobiliary cancer [NCIT:C7927]', 'hepatic cancer [NCIT:C7927]', 'cancer of the liver [NCIT:C7927]', 'liver carcinoma [MONDO:cjm]', 'liver and intrahepatic bile duct carcinoma [NCIT:C7927]', 'liver and intrahepatic biliary tract carcinoma [NCIT:C7927]', 'liver cancer [NCIT:C7927]', 'cancer of the liver and intrahepatic biliary tract [NCIT:C7927]', 'carcinoma of liver and IBT [Orphanet:424936]', 'primary liver carcinoma [NCIT:C7927]', 'cancer of liver [NCIT:C7927]', 'carcinoma of liver [MONDO:patterns/carcinoma]', 'carcinoma of liver and intrahepatic biliary tract'], 'investigated for usetreatment in blood blood forming organ disorders unspecified cancertumors unspecified solid tumors multiple myeloma and liver cancer')|
|('DB06180', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in solid tumors and melanoma')|
|('DB06180', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in solid tumors and melanoma')|
|('DB06181', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in renal cell carcinoma solid tumors and lung cancer')|
|('DB06181', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in renal cell carcinoma solid tumors and lung cancer')|
|('DB06182', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid lung cancer melanoma and pancreatic cancer')|
|('DB06182', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid lung cancer melanoma and pancreatic cancer')|
|('DB06182', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid lung cancer melanoma and pancreatic cancer')|
|('DB06184', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in cancertumors unspecified and leukemia myeloid')|
|('DB06184', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in cancertumors unspecified and leukemia myeloid')|
|('DB06185', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06186', 'MONDO:0005059', ['leukemia'], 'ipilimumab is approved for different conditions such as treatment of unresectable or metastatic melanoma in patients 12 years and older  adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomyfda labelin combination with nivolumab ipilimumab is approved for treatment of patients with intermediate or poor risk previously untreated advanced renal cell carcinoma treatment of 12 years and older patients with msihdmmr metastatic colorectal cancer with progression after treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB06186', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'ipilimumab is approved for different conditions such as treatment of unresectable or metastatic melanoma in patients 12 years and older  adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomyfda labelin combination with nivolumab ipilimumab is approved for treatment of patients with intermediate or poor risk previously untreated advanced renal cell carcinoma treatment of 12 years and older patients with msihdmmr metastatic colorectal cancer with progression after treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB06186', 'MONDO:0005012', ['cutaneous melanoma', 'malignant ear melanoma', 'malignant lip melanoma', 'malignant lower limb melanoma', 'malignant melanoma of ear and/or external auricular canal', 'malignant melanoma of skin of lower limb', 'malignant melanoma of skin of trunk except scrotum', 'malignant melanoma of skin of upper limb', 'malignant neck melanoma', 'malignant scalp melanoma', 'malignant trunk melanoma', 'malignant upper limb melanoma', 'cutaneous melanoma'], 'ipilimumab is approved for different conditions such as treatment of unresectable or metastatic melanoma in patients 12 years and older  adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomyfda labelin combination with nivolumab ipilimumab is approved for treatment of patients with intermediate or poor risk previously untreated advanced renal cell carcinoma treatment of 12 years and older patients with msihdmmr metastatic colorectal cancer with progression after treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB06186', 'MONDO:0004992', ['cancer'], 'ipilimumab is approved for different conditions such as treatment of unresectable or metastatic melanoma in patients 12 years and older  adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomyfda labelin combination with nivolumab ipilimumab is approved for treatment of patients with intermediate or poor risk previously untreated advanced renal cell carcinoma treatment of 12 years and older patients with msihdmmr metastatic colorectal cancer with progression after treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB06187', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral b')|
|('DB06188', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer lung cancer solid tumors renal cell carcinoma pediatric indications ovarian cancer and head and neck cancer')|
|('DB06188', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in breast cancer lung cancer solid tumors renal cell carcinoma pediatric indications ovarian cancer and head and neck cancer')|
|('DB06188', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'investigated for usetreatment in breast cancer lung cancer solid tumors renal cell carcinoma pediatric indications ovarian cancer and head and neck cancer')|
|('DB06190', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in diabetes mellitus type 2 irritable bowel syndrome ibs and urinary incontinence')|
|('DB06191', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in leukemia myeloid and myelodysplastic syndrome')|
|('DB06192', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in head and neck cancer brain cancer pediatric indications pancreatic cancer lung cancer and colorectal cancer')|
|('DB06192', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in head and neck cancer brain cancer pediatric indications pancreatic cancer lung cancer and colorectal cancer')|
|('DB06192', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in head and neck cancer brain cancer pediatric indications pancreatic cancer lung cancer and colorectal cancer')|
|('DB06192', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in head and neck cancer brain cancer pediatric indications pancreatic cancer lung cancer and colorectal cancer')|
|('DB06192', 'MONDO:0005575', ['colorectal cancer'], 'investigated for usetreatment in head and neck cancer brain cancer pediatric indications pancreatic cancer lung cancer and colorectal cancer')|
|('DB06193', 'MONDO:0008903', ['lung cancer'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0021137', ['common []', 'not rare'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0005059', ['leukemia'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06193', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'currently in phase iii investigation for treatment of relapsed or refractory aggressive nonhodgkins lymphoma in patients who have failed two prior lines of therapy presently no standard therapy exists for patients with relapsed or refractory nhl 2 after first line therapy has been initiated most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracyclineinduced congestive heart failure chf pixantrone is an attractive alternative as a second line agent due to its lack of cardiac toxicity 2 the phase iii trial pixr is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large bcell lymphoma the most common type of nhlprevious study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients in myocardial strips which are doxorubicin naive pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed and once absorbed exhibits redox inactivity 3 pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia diffuse large bcell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas and general metastatic cancers     ')|
|('DB06194', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in benign prostatic hyperplasia urinary incontinence prostate disorders and infertility')|
|('DB06195', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in breast cancer lung cancer lymphoma unspecified multiple myeloma leukemia lymphoid and cancertumors unspecified')|
|('DB06195', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer lung cancer lymphoma unspecified multiple myeloma leukemia lymphoid and cancertumors unspecified')|
|('DB06195', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in breast cancer lung cancer lymphoma unspecified multiple myeloma leukemia lymphoid and cancertumors unspecified')|
|('DB06197', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in asthma psoriasis and psoriatic disorders atopic dermatitis inflammatory disorders unspecified and chronic obstructive pulmonary disease copd')|
|('DB06197', 'MONDO:0005083', ['psoriasis'], 'investigated for usetreatment in asthma psoriasis and psoriatic disorders atopic dermatitis inflammatory disorders unspecified and chronic obstructive pulmonary disease copd')|
|('DB06197', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'investigated for usetreatment in asthma psoriasis and psoriatic disorders atopic dermatitis inflammatory disorders unspecified and chronic obstructive pulmonary disease copd')|
|('DB06197', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma psoriasis and psoriatic disorders atopic dermatitis inflammatory disorders unspecified and chronic obstructive pulmonary disease copd')|
|('DB06198', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in hiv infection')|
|('DB06199', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in prostate cancer and cancertumors unspecified')|
|('DB06199', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer and cancertumors unspecified')|
|('DB06200', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in arrhythmia atrial fibrillation and angina')|
|('DB06200', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in arrhythmia atrial fibrillation and angina')|
|('DB06202', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures as well as address other postmenopausal conditions including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy vva')|
|('DB06202', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures as well as address other postmenopausal conditions including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy vva')|
|('DB06202', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures as well as address other postmenopausal conditions including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy vva')|
|('DB06205', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'indicated as an adjuvant to increase the absorption and dispersion of other injected drugs for hypodermoclysis and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents')|
|('DB06206', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery')|
|('DB06211', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'doripenem is indicated in the treatment of complicated intraabdominal infections and complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria ')|
|('DB06211', 'MONDO:0006939', ['pyelonephritis'], 'doripenem is indicated in the treatment of complicated intraabdominal infections and complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria ')|
|('DB06215', 'MONDO:0006939', ['pyelonephritis'], 'this drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron orwho have chronic kidney disease ckd fda label')|
|('DB06215', 'MONDO:0001356', ['iron deficiency anemia'], 'this drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron orwho have chronic kidney disease ckd fda label')|
|('DB06215', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'this drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron orwho have chronic kidney disease ckd fda label')|
|('DB06217', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for nonsurgery patients that lasts for less than 7 days of duration and postcardiac surgery patients with atrial fibrillation lasting less than 3 days of duration')|
|('DB06217', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for nonsurgery patients that lasts for less than 7 days of duration and postcardiac surgery patients with atrial fibrillation lasting less than 3 days of duration')|
|('DB06219', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections absssi caused by susceptible isolates of the following grampositive microorganisms staphylococcus aureus including methicillinsusceptible and methicillinresistant strains streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius streptococcus constellatus and enterococcus faecalis vancomycin susceptible strains fda label f2356dalbavancin is not active against gramnegative bacteria therefore combination therapy may be clinically indicated if the absssi is polymicrobial and includes a suspected or documented gramnegative pathogen f2356to reduce the development of drugresistant bacteria and maintain the effectiveness of dalbavancin and other antibacterial drugs dalbavancin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria fda label f2356 when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy fda label f2356 in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy fda label f2356   ')|
|('DB06224', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in crohns disease and ulcerative colitis')|
|('DB06224', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in crohns disease and ulcerative colitis')|
|('DB06225', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in asthma')|
|('DB06226', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'investigated for usetreatment in prostate cancer and breast cancer')|
|('DB06226', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer and breast cancer')|
|('DB06226', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in prostate cancer and breast cancer')|
|('DB06229', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders')|
|('DB06230', 'MONDO:0004992', ['cancer'], 'indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level drl without physical withdrawal symptoms and who do not require immediate detoxification l1024indicated for the complete or partial reversal of opioid drug effects including respiratory depression  induced by either natural or synthetic opioids  or in the management of known or suspected opioid overdose fda label')|
|('DB06230', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level drl without physical withdrawal symptoms and who do not require immediate detoxification l1024indicated for the complete or partial reversal of opioid drug effects including respiratory depression  induced by either natural or synthetic opioids  or in the management of known or suspected opioid overdose fda label')|
|('DB06231', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'investigated for usetreatment in heart disease and myocardial infarction')|
|('DB06231', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in heart disease and myocardial infarction')|
|('DB06233', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'investigated for usetreatment in solid tumors sarcoma cancertumors unspecified endometrial cancer prostate cancer and bone metastases')|
|('DB06233', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors sarcoma cancertumors unspecified endometrial cancer prostate cancer and bone metastases')|
|('DB06234', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in viral infection transplantation organ or tissue cytomegalovirus cmv retinitis and retinal disorders unspecified')|
|('DB06234', 'MONDO:0002708', ['retinitis'], 'investigated for usetreatment in viral infection transplantation organ or tissue cytomegalovirus cmv retinitis and retinal disorders unspecified')|
|('DB06235', 'MONDO:0002708', ['retinitis'], 'investigated for usetreatment in solid tumors lung cancer ovarian cancer and prostate cancer')|
|('DB06235', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors lung cancer ovarian cancer and prostate cancer')|
|('DB06235', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in solid tumors lung cancer ovarian cancer and prostate cancer')|
|('DB06236', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral b and hiv infection')|
|('DB06236', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in hepatitis viral b and hiv infection')|
|('DB06239', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cervical dysplasiacancer viral infection and vulvar dysplasia and carcinoma')|
|('DB06239', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in cervical dysplasiacancer viral infection and vulvar dysplasia and carcinoma')|
|('DB06239', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'investigated for usetreatment in cervical dysplasiacancer viral infection and vulvar dysplasia and carcinoma')|
|('DB06240', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in ovarian cancer lung cancer and breast cancer')|
|('DB06240', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer lung cancer and breast cancer')|
|('DB06240', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'investigated for usetreatment in ovarian cancer lung cancer and breast cancer')|
|('DB06241', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06241', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06243', 'MONDO:0004992', ['cancer'], 'eflornithine is indicated in the treatment of facial hirsutism excessive hair growth')|
|('DB06244', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in coronary artery disease peripheral vascular disease periodontal disease bone fractures enterorelated fistulae and diabetic foot ulcers')|
|('DB06244', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in coronary artery disease peripheral vascular disease periodontal disease bone fractures enterorelated fistulae and diabetic foot ulcers')|
|('DB06244', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in coronary artery disease peripheral vascular disease periodontal disease bone fractures enterorelated fistulae and diabetic foot ulcers')|
|('DB06245', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in myocardial infarction')|
|('DB06246', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in adenomatous polyposis coli lung cancer prostate cancer colon polyps barretts esophagus disease and pediatric indications')|
|('DB06246', 'MONDO:0000147', ['multiple polyps [NCIT:C4089]', 'polyposis [NCIT:C4089]', 'polyposis'], 'investigated for usetreatment in adenomatous polyposis coli lung cancer prostate cancer colon polyps barretts esophagus disease and pediatric indications')|
|('DB06246', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in adenomatous polyposis coli lung cancer prostate cancer colon polyps barretts esophagus disease and pediatric indications')|
|('DB06246', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in adenomatous polyposis coli lung cancer prostate cancer colon polyps barretts esophagus disease and pediatric indications')|
|('DB06247', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in alzheimers disease memory loss autism neurologic disorders dementia schizophrenia and schizoaffective disorders attention deficithyperactivity disorder adhd and sleep disorders')|
|('DB06247', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in alzheimers disease memory loss autism neurologic disorders dementia schizophrenia and schizoaffective disorders attention deficithyperactivity disorder adhd and sleep disorders')|
|('DB06248', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in asthma chronic obstructive pulmonary disease copd cystic fibrosis and rheumatoid arthritis')|
|('DB06248', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in asthma chronic obstructive pulmonary disease copd cystic fibrosis and rheumatoid arthritis')|
|('DB06248', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in asthma chronic obstructive pulmonary disease copd cystic fibrosis and rheumatoid arthritis')|
|('DB06248', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in asthma chronic obstructive pulmonary disease copd cystic fibrosis and rheumatoid arthritis')|
|('DB06249', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'investigated for usetreatment in breast cancer osteoporosis and endometrial cancer')|
|('DB06249', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer osteoporosis and endometrial cancer')|
|('DB06249', 'MONDO:0011962', ['endometrial Ca', 'endometrial neoplasm', 'malignant endometrial neoplasm', 'malignant neoplasm of endometrium', 'neoplasm of endometrium', 'primary malignant neoplasm of endometrium', 'tumor of Endometrium', 'endometrial cancer'], 'investigated for usetreatment in breast cancer osteoporosis and endometrial cancer')|
|('DB06250', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in psoriasis and psoriatic disorders hyperlipidemia metabolic disease cancertumors unspecified and obesity')|
|('DB06250', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in psoriasis and psoriatic disorders hyperlipidemia metabolic disease cancertumors unspecified and obesity')|
|('DB06251', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in inflammatory bowel disease')|
|('DB06253', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in diabetes mellitus type 2 neuropathy diabetic and vascular diseases')|
|('DB06256', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in myocardial infarction red blood cell disorders anemia kidney transplant surgery transplant rejection liver transplant surgery and ischemic reperfusion injury')|
|('DB06256', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'investigated for usetreatment in myocardial infarction red blood cell disorders anemia kidney transplant surgery transplant rejection liver transplant surgery and ischemic reperfusion injury')|
|('DB06257', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in adverse effects chemotherapy hyperlipidemia autoimmune diseases and hepatitis viral b')|
|('DB06257', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in adverse effects chemotherapy hyperlipidemia autoimmune diseases and hepatitis viral b')|
|('DB06258', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'investigated for usetreatment in neuropathy diabetic and wounds')|
|('DB06261', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'hexaminolevulinate is indicated for use in the cystoscopic detection of nonmuscle invasive papillary cancer of the bladder among patients suspected or known to have lesions on the basis of a prior cystoscopy ')|
|('DB06261', 'MONDO:0004992', ['cancer'], 'hexaminolevulinate is indicated for use in the cystoscopic detection of nonmuscle invasive papillary cancer of the bladder among patients suspected or known to have lesions on the basis of a prior cystoscopy ')|
|('DB06263', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer a4138')|
|('DB06264', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in neurologic disorders spinal cord injuries muscle spasm back pain and multiple sclerosis')|
|('DB06264', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in neurologic disorders spinal cord injuries muscle spasm back pain and multiple sclerosis')|
|('DB06266', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in benign prostatic hyperplasia prostate disorders and cancertumors unspecified')|
|('DB06270', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hyperlipidemia')|
|('DB06271', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis including intermittent claudication peripheral arterial occlusive disease and postmyocardial infarction also investigated in the treatment of diabetic kidney disease and diabetic neuropathy new antiinflammatory properties have also extended its use in venous disease')|
|('DB06271', 'MONDO:0005295', ['Charcots syndrome', 'Intermittent claudication', 'intermittent vascular claudication'], 'sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis including intermittent claudication peripheral arterial occlusive disease and postmyocardial infarction also investigated in the treatment of diabetic kidney disease and diabetic neuropathy new antiinflammatory properties have also extended its use in venous disease')|
|('DB06271', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis including intermittent claudication peripheral arterial occlusive disease and postmyocardial infarction also investigated in the treatment of diabetic kidney disease and diabetic neuropathy new antiinflammatory properties have also extended its use in venous disease')|
|('DB06271', 'MONDO:0005016', ['diabetic nephropathy [NCIT:C84417]', 'diabetic kidney disease [NCIT:C84417]', 'diabetic nephropathy'], 'sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis including intermittent claudication peripheral arterial occlusive disease and postmyocardial infarction also investigated in the treatment of diabetic kidney disease and diabetic neuropathy new antiinflammatory properties have also extended its use in venous disease')|
|('DB06271', 'MONDO:0006626', ['diabetic neuropathy'], 'sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis including intermittent claudication peripheral arterial occlusive disease and postmyocardial infarction also investigated in the treatment of diabetic kidney disease and diabetic neuropathy new antiinflammatory properties have also extended its use in venous disease')|
|('DB06273', 'MONDO:0006626', ['diabetic neuropathy'], 'indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra who have had an inadequate response to one or more diseasemodifying antirheumatic drugs dmards it is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis pjia and active systemic juvenile idiopathic arthritis sjia in patients 2 years of age and older')|
|('DB06273', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra who have had an inadequate response to one or more diseasemodifying antirheumatic drugs dmards it is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis pjia and active systemic juvenile idiopathic arthritis sjia in patients 2 years of age and older')|
|('DB06273', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra who have had an inadequate response to one or more diseasemodifying antirheumatic drugs dmards it is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis pjia and active systemic juvenile idiopathic arthritis sjia in patients 2 years of age and older')|
|('DB06276', 'MONDO:0011429', ['acute juvenile rheumatoid arthritis', 'juvenile chronic polyarthritis', 'juvenile idiopathic arthritis', 'monarticular juvenile rheumatoid arthritis', 'pauciarticular juvenile arthritis', 'Pauciarticular onset juvenile chronic arthritis', 'Stills disease', 'systemic juvenile rheumatoid arthritis', 'juvenile idiopathic arthritis'], 'investigated for usetreatment in pancreatic cancer lung cancer ovarian cancer and osteoarthritis')|
|('DB06276', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer lung cancer ovarian cancer and osteoarthritis')|
|('DB06276', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'investigated for usetreatment in pancreatic cancer lung cancer ovarian cancer and osteoarthritis')|
|('DB06280', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in anemia sickle cell and asthma')|
|('DB06280', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in anemia sickle cell and asthma')|
|('DB06281', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in peripheral vascular disease and hyperlipidemia')|
|('DB06281', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease and hyperlipidemia')|
|('DB06281', 'MONDO:0021187', ['hyperlipidemia [MESH:D006949]', 'hyperlipidemia'], 'investigated for usetreatment in peripheral vascular disease and hyperlipidemia')|
|('DB06282', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticarial7694 it is also used over the counter for a variety of mild allergy symptomsa181748')|
|('DB06282', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticarial7694 it is also used over the counter for a variety of mild allergy symptomsa181748')|
|('DB06285', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture')|
|('DB06285', 'MONDO:0005298', ['osteoporosis'], 'for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture')|
|('DB06285', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture')|
|('DB06285', 'MONDO:0005315', ['fracture [NCIT:C3046]', 'fracture of bone [NCIT:C3046]', 'fracture(s) [NCIT:C3046]', 'bone fracture'], 'for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture')|
|('DB06293', 'MONDO:0005298', ['osteoporosis'], 'investigated for usetreatment in thrombosis coronary artery disease and vascular diseases')|
|('DB06293', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in thrombosis coronary artery disease and vascular diseases')|
|('DB06294', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in thrombosis')|
|('DB06295', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in seborrhea fungal infections skin infectionsdisorders and onychomycosis')|
|('DB06297', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'investigated for usetreatment in rheumatoid arthritis inflammatory disorders unspecified and autoimmune diseases')|
|('DB06297', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis inflammatory disorders unspecified and autoimmune diseases')|
|('DB06299', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in liver disease')|
|('DB06302', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06303', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB06304', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors')|
|('DB06305', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors')|
|('DB06306', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06307', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06309', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06310', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in viral infection and pediatric indications')|
|('DB06311', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in atherosclerosis')|
|('DB06313', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06314', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors and cancertumors unspecified')|
|('DB06317', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies')|
|('DB06318', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in leukemia myeloid')|
|('DB06321', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in autoimmune diseases')|
|('DB06322', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in solid tumors')|
|('DB06323', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in scar tissue')|
|('DB06324', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in lymphoma unspecified and lymphoma nonhodgkins')|
|('DB06324', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in lymphoma unspecified and lymphoma nonhodgkins')|
|('DB06325', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in macular degeneration and eye disordersinfections')|
|('DB06326', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous and autoimmune diseases such as celiac disease')|
|('DB06328', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06331', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in solid tumors')|
|('DB06333', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in obesity and diabetes mellitus type 2')|
|('DB06333', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in obesity and diabetes mellitus type 2')|
|('DB06334', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06336', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in diarrhea and adverse effects chemotherapy')|
|('DB06342', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in lymphoma nonhodgkins')|
|('DB06343', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in solid tumors')|
|('DB06345', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in hypertension')|
|('DB06346', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in inflammatory disorders unspecified')|
|('DB06347', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in solid tumors leukemia myeloid myelodysplastic syndrome and cancertumors unspecified')|
|('DB06350', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cardiovascular disorders and myocardial infarction')|
|('DB06350', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in cardiovascular disorders and myocardial infarction')|
|('DB06354', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in pain acute or chronic and migraine and cluster headaches')|
|('DB06355', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in cardiac ischemia and cardiovascular disorders')|
|('DB06356', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in solid tumors and cancertumors unspecified')|
|('DB06358', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in bacterial infection skin infectionsdisorders obesity liver disease kidney disease and pneumonia')|
|('DB06358', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for usetreatment in bacterial infection skin infectionsdisorders obesity liver disease kidney disease and pneumonia')|
|('DB06360', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in leukemia lymphoid multiple myeloma and lymphoma unspecified')|
|('DB06360', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in leukemia lymphoid multiple myeloma and lymphoma unspecified')|
|('DB06360', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in leukemia lymphoid multiple myeloma and lymphoma unspecified')|
|('DB06361', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in prostate cancer')|
|('DB06361', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB06362', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in cancertumors unspecified liver cancer gastric cancer and leukemia unspecified')|
|('DB06362', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified liver cancer gastric cancer and leukemia unspecified')|
|('DB06362', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in cancertumors unspecified liver cancer gastric cancer and leukemia unspecified')|
|('DB06364', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in solid tumors')|
|('DB06365', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in solid tumors cutaneous tcell lymphoma myelodysplastic syndrome and leukemia lymphoid')|
|('DB06365', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'investigated for usetreatment in solid tumors cutaneous tcell lymphoma myelodysplastic syndrome and leukemia lymphoid')|
|('DB06366', 'MONDO:0005059', ['leukemia'], 'pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2positive metastatic breast cancer who have not received prior antiher2 therapy or chemotherapy for metastatic disease')|
|('DB06366', 'MONDO:0004992', ['cancer'], 'pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2positive metastatic breast cancer who have not received prior antiher2 therapy or chemotherapy for metastatic disease')|
|('DB06366', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2positive metastatic breast cancer who have not received prior antiher2 therapy or chemotherapy for metastatic disease')|
|('DB06367', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in osteoporosis and bone metastases')|
|('DB06368', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral b')|
|('DB06370', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer')|
|('DB06371', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in psoriasis and psoriatic disorders transplant rejection graft versus host disease lymphoma unspecified and leukemia unspecified')|
|('DB06371', 'MONDO:0013730', ['graft VS host disease [NCIT:C3063]', 'graft-versus-host disease [MESH:D006086,NCIT:C3063]', 'runt disease [MESH:D006086,NCIT:C3063]', 'GVH [Orphanet:39812]', 'graft VS. host disease [NCIT:C3063]', 'GVHD [NCIT:C3063]', 'graft versus host disease [MESH:D006086]', 'graft-versus-host-disease [NCIT:C3063]', 'graft versus host disease'], 'investigated for usetreatment in psoriasis and psoriatic disorders transplant rejection graft versus host disease lymphoma unspecified and leukemia unspecified')|
|('DB06371', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in psoriasis and psoriatic disorders transplant rejection graft versus host disease lymphoma unspecified and leukemia unspecified')|
|('DB06372', 'MONDO:0005059', ['leukemia'], 'rilonacept is currently used in the treatment of cryopyrinassociated periodic syndrome in may 2012 an advisory panel for the fda voted 110 against the use of rilonacept for the treatment of gout ')|
|('DB06372', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'rilonacept is currently used in the treatment of cryopyrinassociated periodic syndrome in may 2012 an advisory panel for the fda voted 110 against the use of rilonacept for the treatment of gout ')|
|('DB06374', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in menopause and female hormonal deficienciesabnormalities')|
|('DB06376', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in skin infectionsdisorders')|
|('DB06379', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in myocardial infarction heart disease and asthma')|
|('DB06379', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in myocardial infarction heart disease and asthma')|
|('DB06393', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in amyotrophic lateral sclerosis als and alzheimers disease')|
|('DB06393', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amyotrophic lateral sclerosis als and alzheimers disease')|
|('DB06394', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in amputation limb and peripheral vascular disease')|
|('DB06394', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in amputation limb and peripheral vascular disease')|
|('DB06395', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in fungal infections bacterial infection skin infectionsdisorders and onychomycosis')|
|('DB06397', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in cerebrovascular disease unspecified')|
|('DB06399', 'MONDO:0018155', ['adult-onset primary lateral sclerosis', 'primary lateral sclerosis', 'lateral sclerosis'], 'investigated for usetreatment in autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06399', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06399', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06399', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06399', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma nonhodgkins and leukemia lymphoid')|
|('DB06400', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer and brain cancer')|
|('DB06400', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer and brain cancer')|
|('DB06400', 'MONDO:0005549', ['adenocarcinoma of kidney [NCIT:C9385]', 'kidney adenocarcinoma [NCIT:C9385]', 'renal cell carcinoma [NCIT:C9385]', 'RCC [NCIT:C9385]', 'adenocarcinoma of the kidney [NCIT:C9385]', 'carcinoma, renal cell, malignant [NCIT:C9385]', 'renal cell carcinoma, stage unspecified [NCIT:C9385]', 'renal cell adenocarcinoma [NCIT:C9385]', 'renal cell cancer [NCIT:C9385]', 'renal cell adenocarcinoma'], 'investigated for usetreatment in kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer and brain cancer')|
|('DB06400', 'MONDO:0001657', ['adult brain tumor', 'adult malignant brain neoplasm', 'brain neoplasm', 'brain neoplasm, adult', 'BT - Brain tumour', 'malignant brain tumour', 'malignant primary brain neoplasm', 'malignant primary brain tumor', 'malignant tumor of adult brain', 'malignant tumor of Brain', 'neoplasm of brain', 'primary brain neoplasm', 'primary brain tumor', 'primary malignant neoplasm of brain', 'tumor of the Brain', 'brain cancer'], 'investigated for usetreatment in kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer and brain cancer')|
|('DB06401', 'MONDO:0004992', ['cancer'], 'indicated for following conditions alone or in combination with conjugated estrogens in women with a uterus treatment of moderate to severe vasomotor symptoms associated with menopause prevention of postmenopausal osteoporosis')|
|('DB06401', 'MONDO:0008159', ['postmenopausal osteoporosis'], 'indicated for following conditions alone or in combination with conjugated estrogens in women with a uterus treatment of moderate to severe vasomotor symptoms associated with menopause prevention of postmenopausal osteoporosis')|
|('DB06403', 'MONDO:0004992', ['cancer'], 'ambrisentan is indicated for treatment of idiopathic ‘primary’ pulmonary arterial hypertension ipah and pulmonary arterial hypertension pah associated with connective tissue disease in patients with who functional class ii or iii symptoms in the united states of america ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening pah and to improve exercise ability')|
|('DB06403', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'ambrisentan is indicated for treatment of idiopathic ‘primary’ pulmonary arterial hypertension ipah and pulmonary arterial hypertension pah associated with connective tissue disease in patients with who functional class ii or iii symptoms in the united states of america ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening pah and to improve exercise ability')|
|('DB06403', 'MONDO:0003900', ['connective tissue disorder', 'disorder of connective tissue', 'connective tissue disease'], 'ambrisentan is indicated for treatment of idiopathic ‘primary’ pulmonary arterial hypertension ipah and pulmonary arterial hypertension pah associated with connective tissue disease in patients with who functional class ii or iii symptoms in the united states of america ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening pah and to improve exercise ability')|
|('DB06404', 'MONDO:0003900', ['connective tissue disorder', 'disorder of connective tissue', 'connective tissue disease'], 'for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema hae')|
|('DB06404', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema hae')|
|('DB06404', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema hae')|
|('DB06405', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in amyloidosis')|
|('DB06406', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'investigated for usetreatment in thrombosis venous thromboembolism strokes heart disease and atrial fibrillation')|
|('DB06406', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in thrombosis venous thromboembolism strokes heart disease and atrial fibrillation')|
|('DB06406', 'MONDO:0005267', ['heart disease'], 'investigated for usetreatment in thrombosis venous thromboembolism strokes heart disease and atrial fibrillation')|
|('DB06406', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'investigated for usetreatment in thrombosis venous thromboembolism strokes heart disease and atrial fibrillation')|
|('DB06408', 'MONDO:0005267', ['heart disease'], 'investigated for usetreatment in hepatitis viral c')|
|('DB06409', 'MONDO:0005267', ['heart disease'], 'investigated for usetreatment in pain acute or chronic')|
|('DB06410', 'MONDO:0005267', ['heart disease'], 'doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis as well as for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease ')|
|('DB06410', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis as well as for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease ')|
|('DB06410', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis as well as for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease ')|
|('DB06412', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'indicated in the treatment of anemias caused by deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond oxymetholone should not replace other supportive measures such as transfusion correction of iron folic acid vitamin b12 or pyridoxine deficiency antibacterial therapy and the appropriate use of corticosteroids ')|
|('DB06412', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'indicated in the treatment of anemias caused by deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond oxymetholone should not replace other supportive measures such as transfusion correction of iron folic acid vitamin b12 or pyridoxine deficiency antibacterial therapy and the appropriate use of corticosteroids ')|
|('DB06412', 'MONDO:0002280', ['anaemia', 'anemia'], 'indicated in the treatment of anemias caused by deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond oxymetholone should not replace other supportive measures such as transfusion correction of iron folic acid vitamin b12 or pyridoxine deficiency antibacterial therapy and the appropriate use of corticosteroids ')|
|('DB06412', 'MONDO:0015909', ['aplastic anemia'], 'indicated in the treatment of anemias caused by deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond oxymetholone should not replace other supportive measures such as transfusion correction of iron folic acid vitamin b12 or pyridoxine deficiency antibacterial therapy and the appropriate use of corticosteroids ')|
|('DB06413', 'MONDO:0015909', ['aplastic anemia'], 'investigated for usetreatment in sleep disorders obstructive sleep apnea schizophrenia and schizoaffective disorders depression and bipolar disorders')|
|('DB06415', 'MONDO:0015909', ['aplastic anemia'], 'calfactant is indicated for prophylaxis therapy to prevent respiratory distress syndrome rds in premature infants 29 weeks of gestational age with low lung surfactant and at high risk for rds calfactant therapy is also indicated for the treatment of respiratory distress syndrome in infants 72 hours or less of age with rds confirmed by clinical and radiologic findings and requiring endotracheal intubation')|
|('DB06419', 'MONDO:0015909', ['aplastic anemia'], 'investigated for usetreatment in bacterial infection pediatric indications and pneumonia')|
|('DB06419', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for usetreatment in bacterial infection pediatric indications and pneumonia')|
|('DB06420', 'MONDO:0015909', ['aplastic anemia'], 'investigated for usetreatment in breast cancer and leukemia unspecified')|
|('DB06420', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer and leukemia unspecified')|
|('DB06420', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in breast cancer and leukemia unspecified')|
|('DB06421', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in colorectal cancer and inflammatory bowel disease')|
|('DB06421', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer and inflammatory bowel disease')|
|('DB06421', 'MONDO:0005265', ['inflammatory bowel disease'], 'investigated for usetreatment in colorectal cancer and inflammatory bowel disease')|
|('DB06422', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB06422', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB06422', 'MONDO:0006769', ['gastric atonia', 'Gastroparalysis', 'Gastroparesis syndrome', 'gastroparesis'], 'investigated for usetreatment in gastroesophageal reflux disease gerd and gastroparesis')|
|('DB06423', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in cancertumors unspecified macular degeneration and diabetic retinopathy')|
|('DB06423', 'MONDO:0005266', ['Retinal abnormality - diabetes-related', 'diabetic retinopathy'], 'investigated for usetreatment in cancertumors unspecified macular degeneration and diabetic retinopathy')|
|('DB06429', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders irritable bowel syndrome ibs and chronic obstructive pulmonary disease copd')|
|('DB06429', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders irritable bowel syndrome ibs and chronic obstructive pulmonary disease copd')|
|('DB06429', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders irritable bowel syndrome ibs and chronic obstructive pulmonary disease copd')|
|('DB06431', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in bacterial infection')|
|('DB06433', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'investigated for usetreatment in colorectal cancer lung cancer leukemia unspecified and gastric cancer')|
|('DB06433', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer lung cancer leukemia unspecified and gastric cancer')|
|('DB06433', 'MONDO:0001056', ['Ca body - stomach', 'ca greater curvature of stomach', 'Ca lesser curvature - stomach', 'gastric cancer', 'gastric neoplasm', 'malignant neoplasm of body of stomach', 'malignant neoplasm of lesser curve of stomach', 'malignant tumor of body of stomach', 'malignant tumor of greater curve of stomach', 'malignant tumor of lesser curve of stomach', 'gastric cancer'], 'investigated for usetreatment in colorectal cancer lung cancer leukemia unspecified and gastric cancer')|
|('DB06434', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in bone marrow transplant ulcers and inflammatory bowel disease')|
|('DB06434', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in bone marrow transplant ulcers and inflammatory bowel disease')|
|('DB06434', 'MONDO:0005265', ['inflammatory bowel disease'], 'investigated for usetreatment in bone marrow transplant ulcers and inflammatory bowel disease')|
|('DB06435', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in gastrointestinal diseases and disorders miscellaneous')|
|('DB06436', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB06436', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB06436', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in colorectal cancer and lung cancer')|
|('DB06437', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in sepsis and septicemia and pneumonia')|
|('DB06437', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for usetreatment in sepsis and septicemia and pneumonia')|
|('DB06440', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in fungal infections aspergillosis candidiasis and onychomycosis')|
|('DB06440', 'MONDO:0005657', ['Infection due to Aspergillus', 'aspergillosis'], 'investigated for usetreatment in fungal infections aspergillosis candidiasis and onychomycosis')|
|('DB06441', 'MONDO:0005657', ['Infection due to Aspergillus', 'aspergillosis'], 'for use as an adjunct to percutaneous coronary intervention pci for reducing the risk of periprocedural myocardial infarction mi repeat coronary revascularization and stent thrombosis st in patients in who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iibiiia inhibitor')|
|('DB06441', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for use as an adjunct to percutaneous coronary intervention pci for reducing the risk of periprocedural myocardial infarction mi repeat coronary revascularization and stent thrombosis st in patients in who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iibiiia inhibitor')|
|('DB06442', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB06442', 'MONDO:0005385', ['vascular tissue disease', 'vascular disease'], 'investigated for usetreatment in peripheral vascular disease')|
|('DB06444', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in traumatic brain injuries and neurologic disorders')|
|('DB06445', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'investigated for usetreatment in renal cell carcinoma pancreatic cancer melanoma and lung cancer')|
|('DB06445', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in renal cell carcinoma pancreatic cancer melanoma and lung cancer')|
|('DB06445', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in renal cell carcinoma pancreatic cancer melanoma and lung cancer')|
|('DB06446', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in migraine and cluster headaches')|
|('DB06447', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in sepsis and septicemia')|
|('DB06448', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in solid tumors leukemia unspecified and lung cancer')|
|('DB06448', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in solid tumors leukemia unspecified and lung cancer')|
|('DB06449', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in inflammatory disorders unspecified crohns disease and rheumatoid arthritis')|
|('DB06449', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in inflammatory disorders unspecified crohns disease and rheumatoid arthritis')|
|('DB06451', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in lung cancer')|
|('DB06451', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer')|
|('DB06453', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB06453', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB06453', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in breast cancer lung cancer and ovarian cancer')|
|('DB06454', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in schizophrenia and schizoaffective disorders and parkinsons disease')|
|('DB06455', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in colorectal cancer prostate cancer schizophrenia and schizoaffective disorders psychosis depression and lung cancer')|
|('DB06455', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in colorectal cancer prostate cancer schizophrenia and schizoaffective disorders psychosis depression and lung cancer')|
|('DB06457', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in allergic rhinitis')|
|('DB06457', 'MONDO:0003014', ['rhinitis'], 'investigated for usetreatment in allergic rhinitis')|
|('DB06458', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in epilepsy huntingtons disease and parkinsons disease')|
|('DB06460', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in congestive heart failure chronic obstructive pulmonary disease copd and benign prostatic hyperplasia')|
|('DB06460', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure chronic obstructive pulmonary disease copd and benign prostatic hyperplasia')|
|('DB06460', 'MONDO:0010811', ['benign prostatic hyperplasia'], 'investigated for usetreatment in congestive heart failure chronic obstructive pulmonary disease copd and benign prostatic hyperplasia')|
|('DB06461', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in ovarian cancer lung cancer and macular degeneration')|
|('DB06461', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in ovarian cancer lung cancer and macular degeneration')|
|('DB06461', 'MONDO:0003004', ['Macular degeneration of retina', 'macular degeneration'], 'investigated for usetreatment in ovarian cancer lung cancer and macular degeneration')|
|('DB06462', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer and melanoma')|
|('DB06462', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in lung cancer and melanoma')|
|('DB06463', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in psoriasis and psoriatic disorders')|
|('DB06464', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06464', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06465', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in dementia alzheimers disease schizophrenia and schizoaffective disorders and memory loss')|
|('DB06467', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid and solid tumors')|
|('DB06467', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in lymphoma nonhodgkins leukemia lymphoid and solid tumors')|
|('DB06468', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in cardiac surgery')|
|('DB06469', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in pancreatic cancer prostate cancer and leukemia myeloid')|
|('DB06469', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pancreatic cancer prostate cancer and leukemia myeloid')|
|('DB06470', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in strokes')|
|('DB06471', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in congestive heart failure')|
|('DB06471', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure')|
|('DB06472', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in angina')|
|('DB06474', 'MONDO:0005059', ['leukemia'], 'investigated for usetreatment in cancertumors unspecified colorectal cancer and lung cancer')|
|('DB06474', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified colorectal cancer and lung cancer')|
|('DB06474', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in cancertumors unspecified colorectal cancer and lung cancer')|
|('DB06475', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in thrombocytopenia systemic lupus erythematosus transplant rejection blood blood forming organ disorders unspecified and multiple sclerosis')|
|('DB06475', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in thrombocytopenia systemic lupus erythematosus transplant rejection blood blood forming organ disorders unspecified and multiple sclerosis')|
|('DB06475', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'investigated for usetreatment in thrombocytopenia systemic lupus erythematosus transplant rejection blood blood forming organ disorders unspecified and multiple sclerosis')|
|('DB06477', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in parkinsons disease')|
|('DB06478', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in head and neck cancer')|
|('DB06478', 'MONDO:0021310', ['cancer of the neck [NCIT:C4940]', 'malignant neck tumor [NCIT:C4940]', 'malignant neoplasm of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant tumor of the neck [NCIT:C4940]', 'cancer of neck [MONDO:patterns/cancer,NCIT:C4940]', 'malignant neck neoplasm [MONDO:patterns/cancer,NCIT:C4940]', 'neck cancer [MONDO:patterns/location,NCIT:C4940]', 'malignant neoplasm of the neck [NCIT:C4940]', 'malignant tumor of neck'], 'investigated for usetreatment in head and neck cancer')|
|('DB06479', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in alzheimers disease')|
|('DB06480', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'prucalopride is indicated for the treatment of chronic idiopathic constipation cic in adultsl4882cic is one of the most common chronic functional gastrointestinal disorders worldwide the diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the followingstraining during more than 25 of the bowel movementslumpy or hard stools in 25 of the bowel movementssensation of incomplete evacuation in more than 25 of all bowel movementssensation of anorectal blockage or obstruction in more than 25 of the bowel movementsmanual maneuvers required in more than 25 of the bowel movementsfewer than 3 bowel movements per weekl4883')|
|('DB06480', 'MONDO:0021137', ['common []', 'not rare'], 'prucalopride is indicated for the treatment of chronic idiopathic constipation cic in adultsl4882cic is one of the most common chronic functional gastrointestinal disorders worldwide the diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the followingstraining during more than 25 of the bowel movementslumpy or hard stools in 25 of the bowel movementssensation of incomplete evacuation in more than 25 of all bowel movementssensation of anorectal blockage or obstruction in more than 25 of the bowel movementsmanual maneuvers required in more than 25 of the bowel movementsfewer than 3 bowel movements per weekl4883')|
|('DB06480', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'prucalopride is indicated for the treatment of chronic idiopathic constipation cic in adultsl4882cic is one of the most common chronic functional gastrointestinal disorders worldwide the diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the followingstraining during more than 25 of the bowel movementslumpy or hard stools in 25 of the bowel movementssensation of incomplete evacuation in more than 25 of all bowel movementssensation of anorectal blockage or obstruction in more than 25 of the bowel movementsmanual maneuvers required in more than 25 of the bowel movementsfewer than 3 bowel movements per weekl4883')|
|('DB06480', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'prucalopride is indicated for the treatment of chronic idiopathic constipation cic in adultsl4882cic is one of the most common chronic functional gastrointestinal disorders worldwide the diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the followingstraining during more than 25 of the bowel movementslumpy or hard stools in 25 of the bowel movementssensation of incomplete evacuation in more than 25 of all bowel movementssensation of anorectal blockage or obstruction in more than 25 of the bowel movementsmanual maneuvers required in more than 25 of the bowel movementsfewer than 3 bowel movements per weekl4883')|
|('DB06481', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'investigated for usetreatment in immunosuppressive and transplant rejection')|
|('DB06482', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'investigated for usetreatment in pain acute or chronic')|
|('DB06485', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06486', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'investigated for usetreatment in brain cancer lymphoma nonhodgkins and lung cancer')|
|('DB06486', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer lymphoma nonhodgkins and lung cancer')|
|('DB06486', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in brain cancer lymphoma nonhodgkins and lung cancer')|
|('DB06489', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in parkinsons disease')|
|('DB06492', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in transplant rejection kidney disease and rheumatoid arthritis')|
|('DB06492', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in transplant rejection kidney disease and rheumatoid arthritis')|
|('DB06492', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'investigated for usetreatment in transplant rejection kidney disease and rheumatoid arthritis')|
|('DB06493', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in adverse effects chemotherapy')|
|('DB06494', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in endometriosis and uterine fibroids')|
|('DB06495', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in psoriasis and psoriatic disorders and crohns disease')|
|('DB06496', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in hiv prevention')|
|('DB06497', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in hiv infection')|
|('DB06498', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in lung cancer')|
|('DB06498', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer')|
|('DB06499', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in hepatitis viral c')|
|('DB06503', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in coronary artery disease')|
|('DB06504', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in alzheimers disease and dementia')|
|('DB06504', 'MONDO:0001627', ['dementia'], 'investigated for usetreatment in alzheimers disease and dementia')|
|('DB06506', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in strokes cerebral ischemia and depression')|
|('DB06506', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in strokes cerebral ischemia and depression')|
|('DB06508', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in asthma and allergic rhinitis')|
|('DB06508', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in asthma and allergic rhinitis')|
|('DB06510', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06511', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in osteoporosis and bone metastases')|
|('DB06512', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in anxiety disorders')|
|('DB06515', 'MONDO:0005299', ['cerebral ischemia', 'Ischaemic encephalopathy', 'Ischemic encephalopathy', 'brain ischemia'], 'investigated for usetreatment in interstitial cystitis and urinary incontinence')|
|('DB06515', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in interstitial cystitis and urinary incontinence')|
|('DB06518', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06518', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06519', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06521', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06523', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in hepatitis viral c')|
|('DB06525', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in alzheimers disease')|
|('DB06527', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in strokes and alzheimers disease')|
|('DB06529', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in anxiety disorders')|
|('DB06530', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in genital herpes')|
|('DB06532', 'MONDO:0006032', ['cystitis'], 'investigated for usetreatment in pneumonia trypanosomiasis malaria hiv infection and infectious and parasitic disease unspecified')|
|('DB06532', 'MONDO:0000940', ['trypanosomiasis'], 'investigated for usetreatment in pneumonia trypanosomiasis malaria hiv infection and infectious and parasitic disease unspecified')|
|('DB06532', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in pneumonia trypanosomiasis malaria hiv infection and infectious and parasitic disease unspecified')|
|('DB06533', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06534', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in thrombocytopenia')|
|('DB06535', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in parkinsons disease')|
|('DB06536', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in diabetes mellitus type 2')|
|('DB06538', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in anxiety disorders and depression')|
|('DB06543', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in eye disordersinfections cancertumors unspecified and asthma')|
|('DB06543', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in eye disordersinfections cancertumors unspecified and asthma')|
|('DB06545', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in graft versus host disease')|
|('DB06548', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in multiple myeloma breast cancer osteoporosis and lung cancer')|
|('DB06548', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in multiple myeloma breast cancer osteoporosis and lung cancer')|
|('DB06548', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in multiple myeloma breast cancer osteoporosis and lung cancer')|
|('DB06548', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in multiple myeloma breast cancer osteoporosis and lung cancer')|
|('DB06549', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in brain cancer and pediatric indications')|
|('DB06550', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cancertumors unspecified and head and neck cancer')|
|('DB06550', 'MONDO:0005627', ['head and neck neoplasm', 'head and neck tumours', 'head/neck neoplasm', 'tumor of head and neck', 'head and neck cancer'], 'investigated for usetreatment in cancertumors unspecified and head and neck cancer')|
|('DB06552', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in thrombosis deep vein angina coronary artery disease and colorectal cancer')|
|('DB06552', 'MONDO:0005575', ['colorectal cancer'], 'investigated for usetreatment in thrombosis deep vein angina coronary artery disease and colorectal cancer')|
|('DB06554', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in sleep disorders and insomnia')|
|('DB06554', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'investigated for usetreatment in sleep disorders and insomnia')|
|('DB06555', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in anxiety disorders')|
|('DB06556', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in cardiac surgery peripheral vascular disease and kidney disease')|
|('DB06556', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in cardiac surgery peripheral vascular disease and kidney disease')|
|('DB06556', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in cardiac surgery peripheral vascular disease and kidney disease')|
|('DB06557', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in glaucoma and cataracts')|
|('DB06558', 'MONDO:0005294', ['arterial occlusive disease', 'peripheral vascular disease'], 'investigated for usetreatment in congestive heart failure liver disease and heart disease')|
|('DB06558', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in congestive heart failure liver disease and heart disease')|
|('DB06558', 'MONDO:0005267', ['heart disease'], 'investigated for usetreatment in congestive heart failure liver disease and heart disease')|
|('DB06559', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in fungal infections')|
|('DB06560', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in asthma')|
|('DB06562', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in adverse effects chemotherapy reproductive health and infertility')|
|('DB06568', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in hiv infection')|
|('DB06569', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in obesity')|
|('DB06573', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'investigated for usetreatment in lung cancer and prostate cancer')|
|('DB06573', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in lung cancer and prostate cancer')|
|('DB06573', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in lung cancer and prostate cancer')|
|('DB06575', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in herpes zoster infections and viral infection')|
|('DB06575', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in herpes zoster infections and viral infection')|
|('DB06576', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06576', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06578', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in migraine and cluster headaches')|
|('DB06579', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in insomnia and sleep disorders')|
|('DB06580', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hepatitis viral c')|
|('DB06581', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in hiv infection')|
|('DB06582', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in irritable bowel syndrome ibs')|
|('DB06584', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in breast cancer renal cell carcinoma prostate cancer and lung cancer')|
|('DB06584', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in breast cancer renal cell carcinoma prostate cancer and lung cancer')|
|('DB06584', 'MONDO:0008903', ['lung cancer'], 'investigated for usetreatment in breast cancer renal cell carcinoma prostate cancer and lung cancer')|
|('DB06585', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in parkinsons disease and neurologic disorders')|
|('DB06586', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in obesity')|
|('DB06587', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in gastroparesis and irritable bowel syndrome ibs')|
|('DB06587', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in gastroparesis and irritable bowel syndrome ibs')|
|('DB06588', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06592', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in melanoma and hepatocellular carcinoma')|
|('DB06592', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'investigated for usetreatment in melanoma and hepatocellular carcinoma')|
|('DB06595', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'investigated for usetreatment in adult patients with highrisk acute myeloid leukemia aml who are flt3 mutationpositive agressive systemic mastocytosis asm systemic mastocytosis with associated hematological neoplasm smahn or mast cell leukemia mcl ')|
|('DB06595', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'investigated for usetreatment in adult patients with highrisk acute myeloid leukemia aml who are flt3 mutationpositive agressive systemic mastocytosis asm systemic mastocytosis with associated hematological neoplasm smahn or mast cell leukemia mcl ')|
|('DB06595', 'MONDO:0016586', ['SMCD - systemic mast cell disease', 'systemic tissue mast cell disease', 'systemic mastocytosis'], 'investigated for usetreatment in adult patients with highrisk acute myeloid leukemia aml who are flt3 mutationpositive agressive systemic mastocytosis asm systemic mastocytosis with associated hematological neoplasm smahn or mast cell leukemia mcl ')|
|('DB06595', 'MONDO:0044881', ['malignant hematopoietic neoplasm [NCIT:C27134]', 'hematopoietic neoplasms including Lymphomas [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm [NCIT:C27134]', 'hematological tumor [NCIT:C27134]', 'hematopoietic cancer [NCIT:C27134]', 'hematological neoplasm [NCIT:C27134]', 'hematologic neoplasm [NCIT:C27134]', 'hematopoietic malignancy, NOS [NCIT:C27134]', 'HEMOLYMPHORETICULAR tumor, malignant [NCIT:C27134]', 'hematopoietic, Including myeloma [NCIT:C27134]', 'hematopoietic neoplasm [NCIT:C27134]', 'hematologic cancer [NCIT:C27134]', 'hematologic malignancy [NCIT:C27134]', 'hematopoietic and lymphoid neoplasms [NCIT:C27134]', 'hematopoietic tumor [NCIT:C27134]', 'malignant hematologic neoplasm [NCIT:C27134]', 'hematopoietic cell tumor [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm'], 'investigated for usetreatment in adult patients with highrisk acute myeloid leukemia aml who are flt3 mutationpositive agressive systemic mastocytosis asm systemic mastocytosis with associated hematological neoplasm smahn or mast cell leukemia mcl ')|
|('DB06595', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in adult patients with highrisk acute myeloid leukemia aml who are flt3 mutationpositive agressive systemic mastocytosis asm systemic mastocytosis with associated hematological neoplasm smahn or mast cell leukemia mcl ')|
|('DB06597', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in endometriosis')|
|('DB06598', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in solid tumors')|
|('DB06599', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in cancertumors unspecified')|
|('DB06600', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in bacterial infection and pneumonia')|
|('DB06600', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for usetreatment in bacterial infection and pneumonia')|
|('DB06602', 'MONDO:0020334', ['mast cell leukemia'], 'indicated for the addon maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype')|
|('DB06603', 'MONDO:0020334', ['mast cell leukemia'], 'panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent this indication is approved by accelerated approval based on progression free survival as of february 23 2015 ')|
|('DB06604', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in hypertension')|
|('DB06606', 'MONDO:0020334', ['mast cell leukemia'], 'investigated for usetreatment in diabetes mellitus type 1')|
|('DB06607', 'MONDO:0020334', ['mast cell leukemia'], 'for use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible fda label')|
|('DB06608', 'MONDO:0020334', ['mast cell leukemia'], 'tafenoquine is used for the treatment and prevention of relapse of vivax malaria in patients 16 years and older tafenoquine is not indicated to treat acute vivax malariaa35671 malaria is a disease that remains to occur in many tropical countries vivax malaria caused by plasmodium vivax is known to be less virulent and seldom causes death however it causes a substantive illnessrelated burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months this dormant form produces ongoing relapsesa35671')|
|('DB06608', 'MONDO:0005921', ['Malaria by Plasmodium vivax', 'Vivax Malaria', 'plasmodium vivax malaria'], 'tafenoquine is used for the treatment and prevention of relapse of vivax malaria in patients 16 years and older tafenoquine is not indicated to treat acute vivax malariaa35671 malaria is a disease that remains to occur in many tropical countries vivax malaria caused by plasmodium vivax is known to be less virulent and seldom causes death however it causes a substantive illnessrelated burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months this dormant form produces ongoing relapsesa35671')|
|('DB06608', 'MONDO:0005136', ['induced malaria', 'malaria'], 'tafenoquine is used for the treatment and prevention of relapse of vivax malaria in patients 16 years and older tafenoquine is not indicated to treat acute vivax malariaa35671 malaria is a disease that remains to occur in many tropical countries vivax malaria caused by plasmodium vivax is known to be less virulent and seldom causes death however it causes a substantive illnessrelated burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months this dormant form produces ongoing relapsesa35671')|
|('DB06608', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tafenoquine is used for the treatment and prevention of relapse of vivax malaria in patients 16 years and older tafenoquine is not indicated to treat acute vivax malariaa35671 malaria is a disease that remains to occur in many tropical countries vivax malaria caused by plasmodium vivax is known to be less virulent and seldom causes death however it causes a substantive illnessrelated burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months this dormant form produces ongoing relapsesa35671')|
|('DB06609', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in atrial fibrillation cardiovascular disorders thrombosis and venous thromboembolism')|
|('DB06609', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'investigated for usetreatment in atrial fibrillation cardiovascular disorders thrombosis and venous thromboembolism')|
|('DB06610', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in bacterial infection and rosacea')|
|('DB06610', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'investigated for usetreatment in bacterial infection and rosacea')|
|('DB06611', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06611', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in rheumatoid arthritis')|
|('DB06612', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'mepolizumab is indicated for addon maintenance treatment of severe eosinophilic asthma as identified by blood eosinophils greater than or equal to 150 cellsμl at initiation of treatment or blood eosinophils greater than or equal to 300 cellsμl in the past 12 months in patients aged 12 years and older mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history')|
|('DB06612', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'mepolizumab is indicated for addon maintenance treatment of severe eosinophilic asthma as identified by blood eosinophils greater than or equal to 150 cellsμl at initiation of treatment or blood eosinophils greater than or equal to 300 cellsμl in the past 12 months in patients aged 12 years and older mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history')|
|('DB06612', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mepolizumab is indicated for addon maintenance treatment of severe eosinophilic asthma as identified by blood eosinophils greater than or equal to 150 cellsμl at initiation of treatment or blood eosinophils greater than or equal to 300 cellsμl in the past 12 months in patients aged 12 years and older mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history')|
|('DB06618', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in strokes and depression')|
|('DB06619', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06619', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06619', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in hiv infection and acquired immune deficiency syndrome aids and aidsrelated infections')|
|('DB06620', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in parkinsons disease and neurologic disorders')|
|('DB06622', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in alzheimers disease')|
|('DB06624', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in obesity')|
|('DB06625', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in parkinsons disease')|
|('DB06626', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'used in kidney cell cancer and investigated for usetreatment in pancreatic and thyroid cancer')|
|('DB06626', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'used in kidney cell cancer and investigated for usetreatment in pancreatic and thyroid cancer')|
|('DB06629', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in prostate cancer')|
|('DB06629', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in prostate cancer')|
|('DB06630', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in hyperlipidemia')|
|('DB06633', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in eye disordersinfections')|
|('DB06634', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in urinary incontinence and adverse effects chemotherapy')|
|('DB06635', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in thrombosis')|
|('DB06636', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'indicated in the treatment of invasive aspergillosis and invasive mucormycosis')|
|('DB06636', 'MONDO:0000240', ['invasive aspergillosis'], 'indicated in the treatment of invasive aspergillosis and invasive mucormycosis')|
|('DB06638', 'MONDO:0000240', ['invasive aspergillosis'], 'investigated for usetreatment in leukemia lymphoid')|
|('DB06640', 'MONDO:0000240', ['invasive aspergillosis'], 'investigated for usetreatment in male hormonal deficienciesabnormalities')|
|('DB06641', 'MONDO:0000240', ['invasive aspergillosis'], 'investigated for usetreatment in solid tumors multiple myeloma leukemia unspecified lung cancer and brain cancer')|
|('DB06641', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'investigated for usetreatment in solid tumors multiple myeloma leukemia unspecified lung cancer and brain cancer')|
|('DB06641', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors multiple myeloma leukemia unspecified lung cancer and brain cancer')|
|('DB06641', 'MONDO:0001657', ['adult brain tumor', 'adult malignant brain neoplasm', 'brain neoplasm', 'brain neoplasm, adult', 'BT - Brain tumour', 'malignant brain tumour', 'malignant primary brain neoplasm', 'malignant primary brain tumor', 'malignant tumor of adult brain', 'malignant tumor of Brain', 'neoplasm of brain', 'primary brain neoplasm', 'primary brain tumor', 'primary malignant neoplasm of brain', 'tumor of the Brain', 'brain cancer'], 'investigated for usetreatment in solid tumors multiple myeloma leukemia unspecified lung cancer and brain cancer')|
|('DB06642', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in macular degeneration and diabetic retinopathy')|
|('DB06642', 'MONDO:0005266', ['Retinal abnormality - diabetes-related', 'diabetic retinopathy'], 'investigated for usetreatment in macular degeneration and diabetic retinopathy')|
|('DB06643', 'MONDO:0004992', ['cancer'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06643', 'MONDO:0005298', ['osteoporosis'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06643', 'MONDO:0005315', ['fracture [NCIT:C3046]', 'fracture of bone [NCIT:C3046]', 'fracture(s) [NCIT:C3046]', 'bone fracture'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06643', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06643', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06643', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture it reduces the incidence of vertebral nonvertebral and hip fractures prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer it can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass xgeva is indicated for the prevention of skeletalrelated events in patients with bone metastases from solid tumors')|
|('DB06645', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in cachexia and anorexia')|
|('DB06647', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'investigated for usetreatment in solid tumors renal cell carcinoma melanoma pancreatic cancer lung cancer and ovarian cancer')|
|('DB06647', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'investigated for usetreatment in solid tumors renal cell carcinoma melanoma pancreatic cancer lung cancer and ovarian cancer')|
|('DB06647', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in solid tumors renal cell carcinoma melanoma pancreatic cancer lung cancer and ovarian cancer')|
|('DB06647', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'investigated for usetreatment in solid tumors renal cell carcinoma melanoma pancreatic cancer lung cancer and ovarian cancer')|
|('DB06649', 'MONDO:0004992', ['cancer'], 'investigated for usetreatment in pain acute or chronic')|
|('DB06650', 'MONDO:0004992', ['cancer'], 'ofatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia cll refractory to fludarabine and alemtuzumab')|
|('DB06650', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'ofatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia cll refractory to fludarabine and alemtuzumab')|
|('DB06651', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'investigated for usetreatment in diabetes mellitus type 1 autoimmune diseases and diabetes mellitus type 2')|
|('DB06651', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in diabetes mellitus type 1 autoimmune diseases and diabetes mellitus type 2')|
|('DB06652', 'MONDO:0005015', ['diabetes mellitus'], 'investigated for usetreatment in hiv infection and viral infection')|
|('DB06652', 'MONDO:0005108', ['Viral disease', 'Viral Infection', 'virus infection', 'viral infectious disease'], 'investigated for usetreatment in hiv infection and viral infection')|
|('DB06654', 'MONDO:0005015', ['diabetes mellitus'], 'safinamide is indicated as an addon treatment to levodopa with or without other medicines for parkinson’s disease')|
|('DB06655', 'MONDO:0005015', ['diabetes mellitus'], 'liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellituslabell6718 it is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular diseaselabel')|
|('DB06655', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellituslabell6718 it is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular diseaselabel')|
|('DB06656', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'investigated for usetreatment in solid tumors and cancertumors unspecified')|
|('DB06657', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'investigated for usetreatment in epilepsy')|
|('DB06659', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'investigated for usetreatment in macular degeneration')|
|('DB06660', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'investigated for usetreatment in depression and anxiety disorders')|
|('DB06660', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in depression and anxiety disorders')|
|('DB06662', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in kidney disease and systemic lupus erythematosus')|
|('DB06662', 'MONDO:0007915', ['disseminated lupus erythematosus', 'Lupus Erythematosus, systemic', 'SLE - Lupus Erythematosus, systemic', 'systemic lupus erythematosus'], 'investigated for usetreatment in kidney disease and systemic lupus erythematosus')|
|('DB06666', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in hyponatremia and congestive heart failure')|
|('DB06666', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'investigated for usetreatment in hyponatremia and congestive heart failure')|
|('DB06669', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in irritable bowel syndrome ibs and diarrhea')|
|('DB06670', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in osteoporosis a19388')|
|('DB06673', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'investigated for usetreatment in sleep disorders and insomnia')|
|('DB06673', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'investigated for usetreatment in sleep disorders and insomnia')|
|('DB06674', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used in adults i as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis ra ii alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis psa iii as a single agent in patients with active ankylosing spondylitis as and iv as a single agent in patients with moderate to severe ulcerative colitis uc who require chronic steroids or have experienced intolerance or only a partial response to previous medications')|
|('DB06674', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used in adults i as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis ra ii alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis psa iii as a single agent in patients with active ankylosing spondylitis as and iv as a single agent in patients with moderate to severe ulcerative colitis uc who require chronic steroids or have experienced intolerance or only a partial response to previous medications')|
|('DB06674', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'used in adults i as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis ra ii alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis psa iii as a single agent in patients with active ankylosing spondylitis as and iv as a single agent in patients with moderate to severe ulcerative colitis uc who require chronic steroids or have experienced intolerance or only a partial response to previous medications')|
|('DB06674', 'MONDO:0003937', ['spondylitis'], 'used in adults i as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis ra ii alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis psa iii as a single agent in patients with active ankylosing spondylitis as and iv as a single agent in patients with moderate to severe ulcerative colitis uc who require chronic steroids or have experienced intolerance or only a partial response to previous medications')|
|('DB06674', 'MONDO:0005292', ['colitis'], 'used in adults i as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis ra ii alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis psa iii as a single agent in patients with active ankylosing spondylitis as and iv as a single agent in patients with moderate to severe ulcerative colitis uc who require chronic steroids or have experienced intolerance or only a partial response to previous medications')|
|('DB06677', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in strokes')|
|('DB06678', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in insomnia and sleep disorders')|
|('DB06679', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in myocardial infarction and thrombosis')|
|('DB06680', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in uterine fibroids')|
|('DB06681', 'MONDO:0005292', ['colitis'], 'for prophylaxis of organ rejection it is also used concomitantly with basiliximumab for induction therapy mycophenolate and corticosteriods in kidney transplant recepients that are seropositive for the epsteinbarr virus ')|
|('DB06682', 'MONDO:0005292', ['colitis'], 'investigated for usetreatment in pain acute or chronic inflammatory disorders unspecified osteoarthritis and arthritis and arthritic pain')|
|('DB06682', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in pain acute or chronic inflammatory disorders unspecified osteoarthritis and arthritis and arthritic pain')|
|('DB06683', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in hepatitis viral b')|
|('DB06685', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'investigated for usetreatment in multiple sclerosis')|
|('DB06688', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'sipuleucelt is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant hormone refractory prostate cancer ')|
|('DB06688', 'MONDO:0004992', ['cancer'], 'sipuleucelt is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant hormone refractory prostate cancer ')|
|('DB06692', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion')|
|('DB06693', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'not used therapeutically due to its many side effects ')|
|('DB06719', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'buserelin may be used in the treatment of hormoneresponsive cancers such as prostate cancer or breast cancer estrogendependent conditions such as endometriosis or uterine fibroids and in assisted reproduction')|
|('DB06719', 'MONDO:0004992', ['cancer'], 'buserelin may be used in the treatment of hormoneresponsive cancers such as prostate cancer or breast cancer estrogendependent conditions such as endometriosis or uterine fibroids and in assisted reproduction')|
|('DB06719', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'buserelin may be used in the treatment of hormoneresponsive cancers such as prostate cancer or breast cancer estrogendependent conditions such as endometriosis or uterine fibroids and in assisted reproduction')|
|('DB06720', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'velaglucerase alfa is a hydrolytic lysosomal glucocerebrosidespecific enzyme indicated for longterm enzyme replacement therapy for pediatric and adult patients with type 1 gaucher disease')|
|('DB06724', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for relief of heartburn and acid indigestion may also be used as a nutritional supplement or to treat hypocalcemia ')|
|('DB06736', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis rheumatoid arthritis and ankylosing spondylitis ')|
|('DB06736', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis rheumatoid arthritis and ankylosing spondylitis ')|
|('DB06736', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis rheumatoid arthritis and ankylosing spondylitis ')|
|('DB06736', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis rheumatoid arthritis and ankylosing spondylitis ')|
|('DB06742', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ambroxol is indicated for secretolytic therapy in bronchoplmonary diseaes with abnormal mucus secretion and transport it allows the mucus to be more easily cleared and ease a patients breathing')|
|('DB06752', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'chymopapain is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelographya32687 a disc herniation occurs when the outer portion of the spinal disc breaks down and the inner portion nucleus pulposus leaks out pressing surrounding nerves and leading to irradiating painl2496 the chemonucleolysis is a nonsurgical treatment that involves the injection of an enzyme to dissolve the nucleus pulposusl2482')|
|('DB06754', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for the prophylaxis of postoperative deep venous thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing elective hip replacement surgery fda label')|
|('DB06754', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'indicated for the prophylaxis of postoperative deep venous thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing elective hip replacement surgery fda label')|
|('DB06755', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'betacarotene is fda approved to be used as a nutrient supplement and to be even added in infant formula as a source of vitamin al2191 it is also approved to be used as a color additive for food productsl2192 drugs with the label of only as a color additivel2193 and cosmeticsl2194it is used commonly for the reduction of photosensitivity in patients with erythropoietic protoporphyria and other photosensitivity diseasesa32485')|
|('DB06755', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'betacarotene is fda approved to be used as a nutrient supplement and to be even added in infant formula as a source of vitamin al2191 it is also approved to be used as a color additive for food productsl2192 drugs with the label of only as a color additivel2193 and cosmeticsl2194it is used commonly for the reduction of photosensitivity in patients with erythropoietic protoporphyria and other photosensitivity diseasesa32485')|
|('DB06756', 'MONDO:0008319', ['erythropoietic protoporphyria [NCIT:C84698]', 'protoporphyria, erythropoietic [MONDO:Lexical,OMIM:177000]', 'protoporphyria, erythropoietic'], 'betaine is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are deficiencies or defects in 1 cystathionine betasynthase cbs 2 510methylenetetrahydrofolate reductase mthfr 3 cobalamin cofactor metabolism cbl ')|
|('DB06756', 'MONDO:0004737', ['CBS deficiency', 'cystathionine beta synthase deficiency', 'cystathionine synthase deficiency', 'homocystinuria'], 'betaine is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are deficiencies or defects in 1 cystathionine betasynthase cbs 2 510methylenetetrahydrofolate reductase mthfr 3 cobalamin cofactor metabolism cbl ')|
|('DB06757', 'MONDO:0004737', ['CBS deficiency', 'cystathionine beta synthase deficiency', 'cystathionine synthase deficiency', 'homocystinuria'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms')|
|('DB06759', 'MONDO:0004737', ['CBS deficiency', 'cystathionine beta synthase deficiency', 'cystathionine synthase deficiency', 'homocystinuria'], 'indicated for the local treatment of cytomegalovirus cmv retinitis in patients with acquired immunodeficiency syndrome aids when other therapy has been ineffective or is considered unsuitable fda label l1428')|
|('DB06759', 'MONDO:0002708', ['retinitis'], 'indicated for the local treatment of cytomegalovirus cmv retinitis in patients with acquired immunodeficiency syndrome aids when other therapy has been ineffective or is considered unsuitable fda label l1428')|
|('DB06759', 'MONDO:0017769', ['acquired immunodeficiency'], 'indicated for the local treatment of cytomegalovirus cmv retinitis in patients with acquired immunodeficiency syndrome aids when other therapy has been ineffective or is considered unsuitable fda label l1428')|
|('DB06759', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the local treatment of cytomegalovirus cmv retinitis in patients with acquired immunodeficiency syndrome aids when other therapy has been ineffective or is considered unsuitable fda label l1428')|
|('DB06760', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of congenital sucroseisomaltase deficiency csid')|
|('DB06760', 'MONDO:0021140', ['inborn []', 'congenital'], 'for the treatment of congenital sucroseisomaltase deficiency csid')|
|('DB06761', 'MONDO:0021140', ['inborn []', 'congenital'], 'beractant is indicated for prevention and treatment of respiratory distress syndrome rds in premature infants')|
|('DB06764', 'MONDO:0021140', ['inborn []', 'congenital'], 'for temporary relief of discomfort and redness of the eye due to minor eye irritations')|
|('DB06767', 'MONDO:0021140', ['inborn []', 'congenital'], '1 expectorant in cough syrups2 the ammonium ion nh4 in the body plays an important role in the maintenance of acidbase balance the kidney uses ammonium nh4 in place of sodium na to combine with fixed anions in maintaining acidbase balance especially as a homeostatic compensatory mechanism in metabolic acidosisthe therapeutic effects of ammonium chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver thereby liberating hydrogen h and chloride cl– ions into the extracellular fluidammonium chloride injection usp after dilution in isotonic sodium chloride injection may be indicated in the treatment of patients with 1 hypochloremic states and 2 metabolic alkalosis')|
|('DB06767', 'MONDO:0044688', ['ion [Orphanet:499096]', 'isolated optic neuritis'], '1 expectorant in cough syrups2 the ammonium ion nh4 in the body plays an important role in the maintenance of acidbase balance the kidney uses ammonium nh4 in place of sodium na to combine with fixed anions in maintaining acidbase balance especially as a homeostatic compensatory mechanism in metabolic acidosisthe therapeutic effects of ammonium chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver thereby liberating hydrogen h and chloride cl– ions into the extracellular fluidammonium chloride injection usp after dilution in isotonic sodium chloride injection may be indicated in the treatment of patients with 1 hypochloremic states and 2 metabolic alkalosis')|
|('DB06769', 'MONDO:0044688', ['ion [Orphanet:499096]', 'isolated optic neuritis'], 'bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia cll and indolent bcell nonhodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen')|
|('DB06769', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia cll and indolent bcell nonhodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen')|
|('DB06769', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia cll and indolent bcell nonhodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen')|
|('DB06769', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia cll and indolent bcell nonhodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen')|
|('DB06773', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'human calcitonin is indicated for the treatment of pagets disease in the cases where the use of salmon calcitonin may provoke the generation of hightiter of antibodiesa32100 pagets disease is a metabolic bone disorder characterized by focal areas of increased and disorganized bone turnover coupled with an increased bone formation the majority of the cases are asymptomatic but some clinical manifestations include pain bone deformity and some complications such as pathological fractures and deafnessa32105 the increased activity in bone is associated with a rise in serum level of alkaline phosphatase and the increased urinary excretion of hydroxyproline which is a product of bone breakdowna32099')|
|('DB06773', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'human calcitonin is indicated for the treatment of pagets disease in the cases where the use of salmon calcitonin may provoke the generation of hightiter of antibodiesa32100 pagets disease is a metabolic bone disorder characterized by focal areas of increased and disorganized bone turnover coupled with an increased bone formation the majority of the cases are asymptomatic but some clinical manifestations include pain bone deformity and some complications such as pathological fractures and deafnessa32105 the increased activity in bone is associated with a rise in serum level of alkaline phosphatase and the increased urinary excretion of hydroxyproline which is a product of bone breakdowna32099')|
|('DB06774', 'MONDO:0002648', ['mammary Paget disease', 'Paget cell neoplasm', 'Pagets disease', 'Pagets disease of the breast', 'mammary paget disease'], 'the capsaicin 8 patch is indicated in the treatment of neuropathic pain associated with postherpetic neuralgia there are multiple topical capsaicin formulations available including creams and solutions indicated for temporary analgesia in muscle and join pain as well as neuropathic pain ')|
|('DB06774', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'the capsaicin 8 patch is indicated in the treatment of neuropathic pain associated with postherpetic neuralgia there are multiple topical capsaicin formulations available including creams and solutions indicated for temporary analgesia in muscle and join pain as well as neuropathic pain ')|
|('DB06774', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'the capsaicin 8 patch is indicated in the treatment of neuropathic pain associated with postherpetic neuralgia there are multiple topical capsaicin formulations available including creams and solutions indicated for temporary analgesia in muscle and join pain as well as neuropathic pain ')|
|('DB06778', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'elemental use in copper deficiency l1823copper and copper containing compounds are broadly used in medical practice metallic copper is used already for many years in dental fillings and in copper intrauterine devices iud for reversible contraception ointments containing copper which release copper ions that are absorbed by the skin in the management of cramps disturbances of renal function peripheral venous hypostatic circulatory disturbances rheumatic disease and swelling associated with trauma there are also cosmetic facial creams containing copper as their main active ingredient l1828')|
|('DB06778', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'elemental use in copper deficiency l1823copper and copper containing compounds are broadly used in medical practice metallic copper is used already for many years in dental fillings and in copper intrauterine devices iud for reversible contraception ointments containing copper which release copper ions that are absorbed by the skin in the management of cramps disturbances of renal function peripheral venous hypostatic circulatory disturbances rheumatic disease and swelling associated with trauma there are also cosmetic facial creams containing copper as their main active ingredient l1828')|
|('DB06779', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06779', 'MONDO:0004992', ['cancer'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06779', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06779', 'MONDO:0005275', ['lung disease'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06779', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06779', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'dalteparin is used as a prophylaxis for deepvein thrombosis and pulmonary embolisms in patients undergoing general surgery eg abdominal gynecologic urologic and in patients with acute medical conditions eg cancer bed rest heart failure severe lung disease it is also used in patients who have severely restricted mobility which poses a risk for thromboembolic complications dalteparin is also used concomitantly with aspirin andor other therapy eg nitrates βadrenergic blockers clopidogrel platelet glycoprotein gp iibiiiareceptor inhibitors to reduce the risk of acute cardiac ischemic events the patients who undergo this treatment combination have unstable angina or nonstsegment elevationnonqwave myocardial infarction ie nonstsegment elevation acute coronary syndromesit is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency')|
|('DB06783', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'indicated for treatment of patients with known or suspected internal contamination with radioactive cesium andor radioactive or nonradioactive thallium to increase their rates of elimination ')|
|('DB06784', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkins disease lymphoma and bronchogenic carcinoma positive gallium ga67 uptake in the absence of prior symptoms warrants followup as an indication of a potential disease state gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions')|
|('DB06784', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkins disease lymphoma and bronchogenic carcinoma positive gallium ga67 uptake in the absence of prior symptoms warrants followup as an indication of a potential disease state gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions')|
|('DB06784', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkins disease lymphoma and bronchogenic carcinoma positive gallium ga67 uptake in the absence of prior symptoms warrants followup as an indication of a potential disease state gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions')|
|('DB06785', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'for the inhibition of premature lh surges in women undergoing controlled ovarian hyperstimulation')|
|('DB06786', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'indicated for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses ')|
|('DB06787', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'the world health organization classifies hexocyclium as a drug for functional gastrointestinal disorders l876 like other antimuscarinic agents hexocyclium was likely used to treat peptic ulcers or diarrhea')|
|('DB06788', 'MONDO:0002806', ['BC - Bronchogenic carcinoma', 'bronchogenic carcinoma'], 'as the product supprelin la fda histrelin is indicated for the treatment of children with central precocious puberty cpp as the product vantas fda histrelin is indicated for the palliative treatment of advanced prostate cancer ')|
|('DB06788', 'MONDO:0019165', ['precocious puberty, central [OMIMPS:176400]', 'CPP [Orphanet:759]', 'gonadotropin-dependent precocious puberty []', 'gonadotropin-dependant precocious puberty [Orphanet:759]', 'central precocious puberty'], 'as the product supprelin la fda histrelin is indicated for the treatment of children with central precocious puberty cpp as the product vantas fda histrelin is indicated for the palliative treatment of advanced prostate cancer ')|
|('DB06788', 'MONDO:0004992', ['cancer'], 'as the product supprelin la fda histrelin is indicated for the treatment of children with central precocious puberty cpp as the product vantas fda histrelin is indicated for the palliative treatment of advanced prostate cancer ')|
|('DB06789', 'MONDO:0019165', ['precocious puberty, central [OMIMPS:176400]', 'CPP [Orphanet:759]', 'gonadotropin-dependent precocious puberty []', 'gonadotropin-dependant precocious puberty [Orphanet:759]', 'central precocious puberty'], 'hydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth 1 ')|
|('DB06791', 'MONDO:0019165', ['precocious puberty, central [OMIMPS:176400]', 'CPP [Orphanet:759]', 'gonadotropin-dependent precocious puberty []', 'gonadotropin-dependant precocious puberty [Orphanet:759]', 'central precocious puberty'], 'lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly 2')|
|('DB06791', 'MONDO:0019933', ['acromegaly'], 'lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly 2')|
|('DB06792', 'MONDO:0019933', ['acromegaly'], 'used to reduce serum phosphate in patients with end stage renal disease esrd')|
|('DB06792', 'MONDO:0004375', ['end stage renal disease', 'end stage renal failure'], 'used to reduce serum phosphate in patients with end stage renal disease esrd')|
|('DB06793', 'MONDO:0004375', ['end stage renal disease', 'end stage renal failure'], 'levopropoxyphene was used as an antitussive an antitussive is a medication often recommended for the treatment of cough and associated respiratory tract disordersa32160 its enantiomer dextropropoxyphene presents an analgesic effecta32161')|
|('DB06794', 'MONDO:0004375', ['end stage renal disease', 'end stage renal failure'], 'indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB06794', 'MONDO:0019085', ['Spring catarrh [Orphanet:70476]', 'vernal keratoconjunctivitis'], 'indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB06794', 'MONDO:0003799', ['conjunctivitis'], 'indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis')|
|('DB06796', 'MONDO:0003799', ['conjunctivitis'], 'indicated for use as an organspecific paramagnetic contrast agent developed for imaging of the hepatobiliary system and detecting lesions in liver and pancreas')|
|('DB06799', 'MONDO:0003799', ['conjunctivitis'], 'for prophylactic or suppressive treatment of frequently recurring urinary tract infections when longterm therapy is considered necessary  this drug is not used to treat  infection and should only be used after appropriate eradication of infection with antimicrobial agents')|
|('DB06812', 'MONDO:0003799', ['conjunctivitis'], 'for topical application in the treatment and prevention of infection in wounds')|
|('DB06815', 'MONDO:0003799', ['conjunctivitis'], 'indicated for the treatment of dandruff and seborrheic dermatitis a27133 ')|
|('DB06815', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'indicated for the treatment of dandruff and seborrheic dermatitis a27133 ')|
|('DB06816', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'pyrvinium was once used in the treatment of pinworm infestations t39')|
|('DB06819', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in carbamylphosphate cps ornithine transcarbamylase otc or argininosuccinic acid synthetase it is indicated in all neonatal onset efficiency presenting within the first 28 days of life also indicated in patients with lateonset presenting after the first month of life with a history of hyperammonemic encephalopathy  ')|
|('DB06820', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'sulconazole solution 10 is indicated for the treatment of tinea cruris and tinea corporis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum and microsporum canis and for the treatment of tinea versicolor effectiveness has not been proven in tinea pedis athlete’s foot')|
|('DB06820', 'MONDO:0005982', ['Tinea caused disease or disorder [MONDO:patterns/specific_infectious_disease_by_agent]', 'Tinea disease or disorder []', 'Tinea infectious disease []', 'Tinea infection [NCIT:C112181]', 'Tinea [NCIT:C112181]', 'tinea infection'], 'sulconazole solution 10 is indicated for the treatment of tinea cruris and tinea corporis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum and microsporum canis and for the treatment of tinea versicolor effectiveness has not been proven in tinea pedis athlete’s foot')|
|('DB06820', 'MONDO:0001461', ['Dermatophytosis of the body', 'dermatophytosis of the body', 'Dermatophytosis of the trunk', 'tinea corporis'], 'sulconazole solution 10 is indicated for the treatment of tinea cruris and tinea corporis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum and microsporum canis and for the treatment of tinea versicolor effectiveness has not been proven in tinea pedis athlete’s foot')|
|('DB06820', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sulconazole solution 10 is indicated for the treatment of tinea cruris and tinea corporis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum and microsporum canis and for the treatment of tinea versicolor effectiveness has not been proven in tinea pedis athlete’s foot')|
|('DB06822', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism it is also used for the treatment of deep vein thrombosis andor pulmonary embolism it is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis')|
|('DB06822', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism it is also used for the treatment of deep vein thrombosis andor pulmonary embolism it is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis')|
|('DB06823', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mgday and who have failed treatment with nonpharmacological measures of increased fluid intake decreased sodium and protein intake and urine alkalinization')|
|('DB06823', 'MONDO:0024647', ['urolithiasis []', 'calculus []', 'urinary stones [NCIT:C114688]', 'kidney stone []', 'urolithiasis'], 'tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mgday and who have failed treatment with nonpharmacological measures of increased fluid intake decreased sodium and protein intake and urine alkalinization')|
|('DB06823', 'MONDO:0009067', ['cystinuria'], 'tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mgday and who have failed treatment with nonpharmacological measures of increased fluid intake decreased sodium and protein intake and urine alkalinization')|
|('DB06824', 'MONDO:0009067', ['cystinuria'], 'trientine is a copper chelator used in the treatment of wilsons disease as an alternative to dpenicillamine it tends to be used in patients who are experiencing serious adverse effects from penicillamine therapy or intolerance of penicillamine ')|
|('DB06824', 'MONDO:0010200', ['Cerebral pseudosclerosis', 'hepatolenticular degeneration', 'Westphal pseudosclerosis', 'Westphal-Strumpell syndrome', 'Wilsons disease', 'wilson disease'], 'trientine is a copper chelator used in the treatment of wilsons disease as an alternative to dpenicillamine it tends to be used in patients who are experiencing serious adverse effects from penicillamine therapy or intolerance of penicillamine ')|
|('DB06825', 'MONDO:0010200', ['Cerebral pseudosclerosis', 'hepatolenticular degeneration', 'Westphal pseudosclerosis', 'Westphal-Strumpell syndrome', 'Wilsons disease', 'wilson disease'], 'triptorelin is indicated for the palliative treatment of advanced prostate cancer')|
|('DB06825', 'MONDO:0004992', ['cancer'], 'triptorelin is indicated for the palliative treatment of advanced prostate cancer')|
|('DB06826', 'MONDO:0010200', ['Cerebral pseudosclerosis', 'hepatolenticular degeneration', 'Westphal pseudosclerosis', 'Westphal-Strumpell syndrome', 'Wilsons disease', 'wilson disease'], 'for the lowering of intraocular pressure in patients with openangle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive failed to achieve target iop determined after multiple measurements over time to another intraocular pressure lowering medication')|
|('DB06826', 'MONDO:0005041', ['glaucoma'], 'for the lowering of intraocular pressure in patients with openangle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive failed to achieve target iop determined after multiple measurements over time to another intraocular pressure lowering medication')|
|('DB06826', 'MONDO:0006875', ['ocular hypertension'], 'for the lowering of intraocular pressure in patients with openangle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive failed to achieve target iop determined after multiple measurements over time to another intraocular pressure lowering medication')|
|('DB07615', 'MONDO:0006875', ['ocular hypertension'], 'for the treatment of bronchial asthma keloid and hypertrophic scar and allergic disorders such as asthma allergic rhinitis and atopic dermatitis')|
|('DB07615', 'MONDO:0005348', ['keloid'], 'for the treatment of bronchial asthma keloid and hypertrophic scar and allergic disorders such as asthma allergic rhinitis and atopic dermatitis')|
|('DB07615', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'for the treatment of bronchial asthma keloid and hypertrophic scar and allergic disorders such as asthma allergic rhinitis and atopic dermatitis')|
|('DB07615', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'for the treatment of bronchial asthma keloid and hypertrophic scar and allergic disorders such as asthma allergic rhinitis and atopic dermatitis')|
|('DB08142', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in leukemia unspecified lymphoma unspecified myelodysplastic syndrome and solid tumors')|
|('DB08439', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'used for short term perioperative pain control')|
|('DB08502', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB08502', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB08502', 'MONDO:0005109', ['HIV infection', 'hiv infectious disease'], 'investigated for usetreatment in acquired immune deficiency syndrome aids and aidsrelated infections and hiv infection')|
|('DB08687', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'investigated for usetreatment in anemia and kidney disease')|
|('DB08687', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'investigated for usetreatment in anemia and kidney disease')|
|('DB08805', 'MONDO:0012268', ['acquired Immune deficiency', 'AIDS', 'aids'], 'potential in the treatment and the management of acidreflux disorders gerd peptic ulcer disease heartburn and acid indigestion')|
|('DB08805', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'potential in the treatment and the management of acidreflux disorders gerd peptic ulcer disease heartburn and acid indigestion')|
|('DB08813', 'MONDO:0004247', ['acute peptic ulcer with hemorrhage', 'acute peptic ulcer with hemorrhage and perforation', 'acute peptic ulcer without hemorrhage AND without perforation', 'acute peptic ulcer without hemorrhage and without perforation', 'peptic ulcer disease'], 'nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery treatment of deep vein thrombosis prevention of clotting during hemodialysis and treatment of unstable angina and nonq wave myocardial infarction')|
|('DB08813', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery treatment of deep vein thrombosis prevention of clotting during hemodialysis and treatment of unstable angina and nonq wave myocardial infarction')|
|('DB08813', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery treatment of deep vein thrombosis prevention of clotting during hemodialysis and treatment of unstable angina and nonq wave myocardial infarction')|
|('DB08814', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'triflusal is indicated as prophylaxis of thromboembolic disordersl1185 it has been registered in spain and in other countries of europe south america and south korea for the prevention of stroke and myocardial infarctiont93')|
|('DB08814', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'triflusal is indicated as prophylaxis of thromboembolic disordersl1185 it has been registered in spain and in other countries of europe south america and south korea for the prevention of stroke and myocardial infarctiont93')|
|('DB08814', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'triflusal is indicated as prophylaxis of thromboembolic disordersl1185 it has been registered in spain and in other countries of europe south america and south korea for the prevention of stroke and myocardial infarctiont93')|
|('DB08818', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'used to treat knee pain in patients with joint inflammation osteoarthritis it is usually used in patients who have not responded to other treatments such as acetaminophen exercise or physical therapy hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body may be used in ophthalmology to assist in the extraction of cataracts the implantation of intraocular lenses corneal transplants glaucoma filtration retinal attachment and in the treatment of dry eyes finally hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis')|
|('DB08818', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'used to treat knee pain in patients with joint inflammation osteoarthritis it is usually used in patients who have not responded to other treatments such as acetaminophen exercise or physical therapy hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body may be used in ophthalmology to assist in the extraction of cataracts the implantation of intraocular lenses corneal transplants glaucoma filtration retinal attachment and in the treatment of dry eyes finally hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis')|
|('DB08818', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'used to treat knee pain in patients with joint inflammation osteoarthritis it is usually used in patients who have not responded to other treatments such as acetaminophen exercise or physical therapy hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body may be used in ophthalmology to assist in the extraction of cataracts the implantation of intraocular lenses corneal transplants glaucoma filtration retinal attachment and in the treatment of dry eyes finally hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis')|
|('DB08818', 'MONDO:0005041', ['glaucoma'], 'used to treat knee pain in patients with joint inflammation osteoarthritis it is usually used in patients who have not responded to other treatments such as acetaminophen exercise or physical therapy hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body may be used in ophthalmology to assist in the extraction of cataracts the implantation of intraocular lenses corneal transplants glaucoma filtration retinal attachment and in the treatment of dry eyes finally hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis')|
|('DB08818', 'MONDO:0018301', ['interstitial cystitis'], 'used to treat knee pain in patients with joint inflammation osteoarthritis it is usually used in patients who have not responded to other treatments such as acetaminophen exercise or physical therapy hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body may be used in ophthalmology to assist in the extraction of cataracts the implantation of intraocular lenses corneal transplants glaucoma filtration retinal attachment and in the treatment of dry eyes finally hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis')|
|('DB08830', 'MONDO:0005041', ['glaucoma'], 'there is no approved indication for dehydroascorbic acid but it has potential therapeutic use in patients with certain viruses and ischemic stroke')|
|('DB08830', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'there is no approved indication for dehydroascorbic acid but it has potential therapeutic use in patients with certain viruses and ischemic stroke')|
|('DB08831', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'as of july 2013 there is no approved therapeutic indication for 2deoxyglucose 2deoxyglucose may have several potential indications as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors as an antiviral treatment in herpes simplex patients and as an antiepileptic in temporal lobe epilepsy patients')|
|('DB08831', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'as of july 2013 there is no approved therapeutic indication for 2deoxyglucose 2deoxyglucose may have several potential indications as an adjunct to chemotherapy and radiotherapy in the treatment of solid tumors as an antiviral treatment in herpes simplex patients and as an antiepileptic in temporal lobe epilepsy patients')|
|('DB08833', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'taurochenodeoxycholic acid is likely indicated as a choleretic and cholagogue it is also being investigated for its role in inflammation and cancer therapy')|
|('DB08833', 'MONDO:0004992', ['cancer'], 'taurochenodeoxycholic acid is likely indicated as a choleretic and cholagogue it is also being investigated for its role in inflammation and cancer therapy')|
|('DB08836', 'MONDO:0004992', ['cancer'], 'temocapril is an ace inhibitor primarily indicated in the treatment of hypertension and congestive heart failure diabetic nephropathy and improvement of prognosis for coronary artery diseases including acute myocardial infarction ')|
|('DB08836', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'temocapril is an ace inhibitor primarily indicated in the treatment of hypertension and congestive heart failure diabetic nephropathy and improvement of prognosis for coronary artery diseases including acute myocardial infarction ')|
|('DB08836', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'temocapril is an ace inhibitor primarily indicated in the treatment of hypertension and congestive heart failure diabetic nephropathy and improvement of prognosis for coronary artery diseases including acute myocardial infarction ')|
|('DB08836', 'MONDO:0004781', ['acute myocardial infarction'], 'temocapril is an ace inhibitor primarily indicated in the treatment of hypertension and congestive heart failure diabetic nephropathy and improvement of prognosis for coronary artery diseases including acute myocardial infarction ')|
|('DB08837', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'tetraethylammonium is an experimental drug with no approved indication')|
|('DB08838', 'MONDO:0005240', ['impaired renal function disease', 'nephropathy', 'kidney disease'], 'agmatine is being studied experimentally for several indications such as cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma and neuropathic pain and psychiatric conditions depression anxiety schizophrenia and cognition as an investigational drug agamatine is being studied in a nonblinded prospective case study in the united states looking at patients who have been diagnosed with small fiber peripheral neuropathy')|
|('DB08838', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'agmatine is being studied experimentally for several indications such as cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma and neuropathic pain and psychiatric conditions depression anxiety schizophrenia and cognition as an investigational drug agamatine is being studied in a nonblinded prospective case study in the united states looking at patients who have been diagnosed with small fiber peripheral neuropathy')|
|('DB08838', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'agmatine is being studied experimentally for several indications such as cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma and neuropathic pain and psychiatric conditions depression anxiety schizophrenia and cognition as an investigational drug agamatine is being studied in a nonblinded prospective case study in the united states looking at patients who have been diagnosed with small fiber peripheral neuropathy')|
|('DB08838', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'agmatine is being studied experimentally for several indications such as cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma and neuropathic pain and psychiatric conditions depression anxiety schizophrenia and cognition as an investigational drug agamatine is being studied in a nonblinded prospective case study in the united states looking at patients who have been diagnosed with small fiber peripheral neuropathy')|
|('DB08838', 'MONDO:0005244', ['peripheral neuropathy', 'peripheral neuropathy'], 'agmatine is being studied experimentally for several indications such as cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma and neuropathic pain and psychiatric conditions depression anxiety schizophrenia and cognition as an investigational drug agamatine is being studied in a nonblinded prospective case study in the united states looking at patients who have been diagnosed with small fiber peripheral neuropathy')|
|('DB08840', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'nmethylnicotinamide is an experimental drug with no approved indication')|
|('DB08844', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'at present august 2013 there is no approved indication for uric acid  the potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke')|
|('DB08845', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'ααketoglutarate is not approved for any indication in the world but is an investigational drug in the united states the potential indications for αketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss ')|
|('DB08845', 'MONDO:0011628', ['GLYCINEMIA, KETOTIC', 'ketotic glycinemia', 'KETOTIC HYPERGLYCINEMIA', 'ketotic II glycinemia', 'propionic aciduria', 'propionyl-CoA carboxylase deficiency', 'propionic acidemia'], 'ααketoglutarate is not approved for any indication in the world but is an investigational drug in the united states the potential indications for αketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss ')|
|('DB08846', 'MONDO:0011628', ['GLYCINEMIA, KETOTIC', 'ketotic glycinemia', 'KETOTIC HYPERGLYCINEMIA', 'ketotic II glycinemia', 'propionic aciduria', 'propionyl-CoA carboxylase deficiency', 'propionic acidemia'], 'ellagic acid is being investigated for use in follicular lymphoma brain injury in intrauterine growth restricted babies obese adolescents and solar lentigines')|
|('DB08846', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'ellagic acid is being investigated for use in follicular lymphoma brain injury in intrauterine growth restricted babies obese adolescents and solar lentigines')|
|('DB08846', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'ellagic acid is being investigated for use in follicular lymphoma brain injury in intrauterine growth restricted babies obese adolescents and solar lentigines')|
|('DB08848', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'there is no approved indication for guvacine')|
|('DB08862', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for use as a diagnostic aid for evaluation of gallbladder disorders  it is also used in conjunction with secretin in pancreatic insufficiency l1634')|
|('DB08867', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'as the product ella available in canada and the us ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours 5 days after unprotected intercourse or a known or suspected contraceptive failure as the product fibristal available in canada ulipristal is indicated for treatment of the signs and symptoms of uterine fibroids in adult women')|
|('DB08869', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'tesamorelin acetate is a synthetic analogue of human hypothalamic growth hormone releasing factor hgrf indicated to induce and maintain a reduction of excess abdominal fat in hivinfected patients with lipodystrophy ')|
|('DB08869', 'MONDO:0006573', ['lipodystrophy'], 'tesamorelin acetate is a synthetic analogue of human hypothalamic growth hormone releasing factor hgrf indicated to induce and maintain a reduction of excess abdominal fat in hivinfected patients with lipodystrophy ')|
|('DB08870', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'seattle genetics announced fda approval of adcetris® brentuximab vedotin in combination with chemotherapy for adults with previously untreated stage iii or iv classical hodgkin lymphoma in march 2018  l1737 l1739hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates fda label l1737systemic anaplastic large cell lymphoma after failure of at least one prior multiagent chemotherapy regimen fda label')|
|('DB08870', 'MONDO:0009348', ['classic Hodgkin disease [Orphanet:391]', "classical Hodgkin's lymphoma [NCIT:C7164]", 'classical Hodgkin lymphoma [NCIT:C7164]', 'classic hodgkin lymphoma'], 'seattle genetics announced fda approval of adcetris® brentuximab vedotin in combination with chemotherapy for adults with previously untreated stage iii or iv classical hodgkin lymphoma in march 2018  l1737 l1739hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates fda label l1737systemic anaplastic large cell lymphoma after failure of at least one prior multiagent chemotherapy regimen fda label')|
|('DB08870', 'MONDO:0009359', ['MARCH', 'multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome'], 'seattle genetics announced fda approval of adcetris® brentuximab vedotin in combination with chemotherapy for adults with previously untreated stage iii or iv classical hodgkin lymphoma in march 2018  l1737 l1739hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates fda label l1737systemic anaplastic large cell lymphoma after failure of at least one prior multiagent chemotherapy regimen fda label')|
|('DB08870', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'seattle genetics announced fda approval of adcetris® brentuximab vedotin in combination with chemotherapy for adults with previously untreated stage iii or iv classical hodgkin lymphoma in march 2018  l1737 l1739hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates fda label l1737systemic anaplastic large cell lymphoma after failure of at least one prior multiagent chemotherapy regimen fda label')|
|('DB08870', 'MONDO:0020325', ['anaplastic large cell lymphoma'], 'seattle genetics announced fda approval of adcetris® brentuximab vedotin in combination with chemotherapy for adults with previously untreated stage iii or iv classical hodgkin lymphoma in march 2018  l1737 l1739hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not asct candidates fda label l1737systemic anaplastic large cell lymphoma after failure of at least one prior multiagent chemotherapy regimen fda label')|
|('DB08872', 'MONDO:0020325', ['anaplastic large cell lymphoma'], 'for the treatment of adult restless legs syndrome rls and postherpetic neuralgia phn')|
|('DB08872', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'for the treatment of adult restless legs syndrome rls and postherpetic neuralgia phn')|
|('DB08875', 'MONDO:0041052', ['postherpetic neuralgia []', 'postherpetic neuralgia'], 'for the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma rcc who have received prior antiangiogenic therapy')|
|('DB08875', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'for the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma rcc who have received prior antiangiogenic therapy')|
|('DB08875', 'MONDO:0044874', ['refractory cytopenia of childhood [NCIT:C82596]', 'RCC [NCIT:C82596]', 'refractory cytopenia of childhood'], 'for the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma rcc who have received prior antiangiogenic therapy')|
|('DB08876', 'MONDO:0044874', ['refractory cytopenia of childhood [NCIT:C82596]', 'RCC [NCIT:C82596]', 'refractory cytopenia of childhood'], 'for the treatment of adult type 1 gaucher disease ')|
|('DB08876', 'MONDO:0018150', ['acid beta-glucosidase deficiency', 'Gaucher disease', 'glocucerebrosidase deficiency', 'glucosylceramide beta-glucosidase deficiency', 'kerasin thesaurismosis', 'gaucher disease'], 'for the treatment of adult type 1 gaucher disease ')|
|('DB08878', 'MONDO:0044874', ['refractory cytopenia of childhood [NCIT:C82596]', 'RCC [NCIT:C82596]', 'refractory cytopenia of childhood'], 'prior to its withdrawal aminopterin was initially used in the treatment of childhood leukemia specifically to induce remissions later aminopterin was used offlabel in the united states to treat psoriasis yielding dramatic lesion clearing aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index aminopterin as well as methotrexate has also been explored for use as an abortifacient however their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome ')|
|('DB08878', 'MONDO:0004355', ['childhood leukemia'], 'prior to its withdrawal aminopterin was initially used in the treatment of childhood leukemia specifically to induce remissions later aminopterin was used offlabel in the united states to treat psoriasis yielding dramatic lesion clearing aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index aminopterin as well as methotrexate has also been explored for use as an abortifacient however their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome ')|
|('DB08878', 'MONDO:0005083', ['psoriasis'], 'prior to its withdrawal aminopterin was initially used in the treatment of childhood leukemia specifically to induce remissions later aminopterin was used offlabel in the united states to treat psoriasis yielding dramatic lesion clearing aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index aminopterin as well as methotrexate has also been explored for use as an abortifacient however their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome ')|
|('DB08878', 'MONDO:0004992', ['cancer'], 'prior to its withdrawal aminopterin was initially used in the treatment of childhood leukemia specifically to induce remissions later aminopterin was used offlabel in the united states to treat psoriasis yielding dramatic lesion clearing aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index aminopterin as well as methotrexate has also been explored for use as an abortifacient however their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome ')|
|('DB08878', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'prior to its withdrawal aminopterin was initially used in the treatment of childhood leukemia specifically to induce remissions later aminopterin was used offlabel in the united states to treat psoriasis yielding dramatic lesion clearing aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index aminopterin as well as methotrexate has also been explored for use as an abortifacient however their association with severe congenital malformations and teratogenic effects have become known as fetal aminopterin syndrome ')|
|('DB08879', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'adjunct treatment for autoantibodypositive active systemic lupus erythematosus sle the intravenous injectable form is the only fda approved treatment for pediatric patients with sle')|
|('DB08879', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'adjunct treatment for autoantibodypositive active systemic lupus erythematosus sle the intravenous injectable form is the only fda approved treatment for pediatric patients with sle')|
|('DB08880', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'used in the treatment of relapsing forms of multiple sclerosis ms')|
|('DB08880', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'used in the treatment of relapsing forms of multiple sclerosis ms')|
|('DB08883', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'used in patients over 12 years old for the treatment of partialonset seizures that may or may not occur with generalized seizures')|
|('DB08885', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'the opthalmic agent is used for the treatment of neovascular wet agerelated mascular degeneration amd and macular edema following central retinal vein occulsion crvo the systemic injection known as zivaflibercept in combination with 5fluorouracil leucovorin irinotecanfolfiri is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin ')|
|('DB08885', 'MONDO:0003005', ['macular edema', 'macular oedema', 'macular retinal oedema', 'macular retinal edema'], 'the opthalmic agent is used for the treatment of neovascular wet agerelated mascular degeneration amd and macular edema following central retinal vein occulsion crvo the systemic injection known as zivaflibercept in combination with 5fluorouracil leucovorin irinotecanfolfiri is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin ')|
|('DB08885', 'MONDO:0004992', ['cancer'], 'the opthalmic agent is used for the treatment of neovascular wet agerelated mascular degeneration amd and macular edema following central retinal vein occulsion crvo the systemic injection known as zivaflibercept in combination with 5fluorouracil leucovorin irinotecanfolfiri is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin ')|
|('DB08886', 'MONDO:0004992', ['cancer'], 'asparaginase erwinia chrysanthemi is for the treatment of patients with acute lymphoblastic leukemia all that have developed a hypersensitivity to e coliderivied asparaginase l149 it is a component of a multiagent chemotherpeutic regimen l149 for the treatment of the aforementioned disease and is considered second or third line treatment in european and american protocols a7464 ')|
|('DB08886', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'asparaginase erwinia chrysanthemi is for the treatment of patients with acute lymphoblastic leukemia all that have developed a hypersensitivity to e coliderivied asparaginase l149 it is a component of a multiagent chemotherpeutic regimen l149 for the treatment of the aforementioned disease and is considered second or third line treatment in european and american protocols a7464 ')|
|('DB08888', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion ')|
|('DB08891', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis autism spectrum disorder and social withdrawal in fragile x syndrome')|
|('DB08891', 'MONDO:0005260', ['autism', 'autistic disorder of childhood onset', 'childhood autism', 'infantile autism', 'Kanners syndrome', 'autism'], 'investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis autism spectrum disorder and social withdrawal in fragile x syndrome')|
|('DB08892', 'MONDO:0005260', ['autism', 'autistic disorder of childhood onset', 'childhood autism', 'infantile autism', 'Kanners syndrome', 'autism'], 'investigated for the treatment of spasticity in multiple sclerosis acute back spasms and gerd ')|
|('DB08892', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'investigated for the treatment of spasticity in multiple sclerosis acute back spasms and gerd ')|
|('DB08894', 'MONDO:0005260', ['autism', 'autistic disorder of childhood onset', 'childhood autism', 'infantile autism', 'Kanners syndrome', 'autism'], 'peginesatide is used for the treatment of anemia due to chronic kidney disease ckd in adult patients on dialysis ')|
|('DB08894', 'MONDO:0002280', ['anaemia', 'anemia'], 'peginesatide is used for the treatment of anemia due to chronic kidney disease ckd in adult patients on dialysis ')|
|('DB08894', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'peginesatide is used for the treatment of anemia due to chronic kidney disease ckd in adult patients on dialysis ')|
|('DB08895', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0045042', ['localized'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08895', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy it may also be used as an adjunct to methotrexate therapy or other nonbiologic diseasemodifying antirheumatic drugs dmards when methotrexate alone is not sufficient  tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections and as a treatment for psoriasis ulcerative colitis and ankylosing spondylitis it is not to be initiated in patients with a history of chronic or recurrent infections or in the presence of active infection even if localized due to reports of serious and sometimes fatal infections commonly pneumonia herpes zoster and urinary tract infections use of tofacitinib is also discouraged in those who have been or are likely to be exposed to tb an increased likelihood of exposure may be encountered by traveling to certain areas in addition tofacitinib is not to be used in patients with severe hepatic impairment or low hemoglobin less than 9gdl cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation and in the elderly who are more susceptible to infection   ')|
|('DB08898', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'used in patients on methotrexate treatment who have kidney dysfunction and are experiencing an abnormally high plasma concentration of methotrexate  1 micromole per liter')|
|('DB08900', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'treatment of short bowel syndrome sbs malabsorption associated with the removal of the intestine in adults patients who are dependent on parenteral support ')|
|('DB08900', 'MONDO:0015183', ['acquired short bowel syndrome', 'short gut syndrome', 'short bowel syndrome'], 'treatment of short bowel syndrome sbs malabsorption associated with the removal of the intestine in adults patients who are dependent on parenteral support ')|
|('DB08900', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'treatment of short bowel syndrome sbs malabsorption associated with the removal of the intestine in adults patients who are dependent on parenteral support ')|
|('DB08902', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate ')|
|('DB08902', 'MONDO:0016595', ['pulmonary anthrax', 'respiratory anthrax', 'wool-sorters disease', 'woolsorters disease', 'inhalational anthrax'], 'raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate ')|
|('DB08904', 'MONDO:0016595', ['pulmonary anthrax', 'respiratory anthrax', 'wool-sorters disease', 'woolsorters disease', 'inhalational anthrax'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08904', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08904', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08904', 'MONDO:0003937', ['spondylitis'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08904', 'MONDO:0005083', ['psoriasis'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08904', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'certolizumab pegol has been approved for several different conditions listed below symptomatic management of chrons disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy treatment of adult patients with moderate to severely active rheumatoid arthritis treatment of adult patients with active psoriatic arthritis treatment of adult patients with active ankylosing spondylitis treatment of adult patients with moderatetosevere plaque psoriasis that are candidates for systemic therapy or phototherapyfda label treatment of adult patients with active nonradiographic axial spondyloarthritis with objective signs of inflammationl5819in canada certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment including major clinical response and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritisl5825inflammation is a biological response against a potential threat this response can be normal but in certain conditions the immune system can attack the bodys normal cells or tissues which causes an abnormal inflammationl5840 tnfalpha has been identified as a key regulator of the inflammatory response the signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death survival differentiation proliferation and migrationa176660 ')|
|('DB08908', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used in multiple sclerosis patients with relapsing forms')|
|('DB08915', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'investigated for use in patients with type ii diabetes to reduce their risks of cardiovascular mortality and morbidity')|
|('DB08917', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have nondialysis dependent chronic kidney disease ')|
|('DB08917', 'MONDO:0001356', ['iron deficiency anemia'], 'ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have nondialysis dependent chronic kidney disease ')|
|('DB08917', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have nondialysis dependent chronic kidney disease ')|
|('DB08922', 'MONDO:0001356', ['iron deficiency anemia'], 'for the treatment of schizophrenia and acute cases of bipolar mania')|
|('DB08922', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of schizophrenia and acute cases of bipolar mania')|
|('DB08925', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used to relieve excessive sleepiness and inattention in elderly patients')|
|('DB08931', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'riociguat is indicated for the treatment of adults with persistentrecurrent chronic thromboembolic pulmonary hypertension cteph who group 4 after surgical treatment or inoperable cteph to improve exercise capacity and who functional classriociguat is indicated for the treatment of adults with pulmonary arterial hypertension pah who group 1 to improve exercise capacity who functional class and to delay clinical worsening efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids studies establishing effectiveness included predominately patients with who functional class ii–iii and etiologies of idiopathic or heritable pah 61 or pah associated with connective tissue diseases 25')|
|('DB08931', 'MONDO:0013024', ['CTEPH [Orphanet:70591]', 'chronic thromboembolic pulmonary hypertension'], 'riociguat is indicated for the treatment of adults with persistentrecurrent chronic thromboembolic pulmonary hypertension cteph who group 4 after surgical treatment or inoperable cteph to improve exercise capacity and who functional classriociguat is indicated for the treatment of adults with pulmonary arterial hypertension pah who group 1 to improve exercise capacity who functional class and to delay clinical worsening efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids studies establishing effectiveness included predominately patients with who functional class ii–iii and etiologies of idiopathic or heritable pah 61 or pah associated with connective tissue diseases 25')|
|('DB08931', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'riociguat is indicated for the treatment of adults with persistentrecurrent chronic thromboembolic pulmonary hypertension cteph who group 4 after surgical treatment or inoperable cteph to improve exercise capacity and who functional classriociguat is indicated for the treatment of adults with pulmonary arterial hypertension pah who group 1 to improve exercise capacity who functional class and to delay clinical worsening efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids studies establishing effectiveness included predominately patients with who functional class ii–iii and etiologies of idiopathic or heritable pah 61 or pah associated with connective tissue diseases 25')|
|('DB08935', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia')|
|('DB08949', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'indicated as a dietary supplement for the source of niacin has been investigated for potential beneficial effects on serum lipids in europe inositol hexanicotinate is indicated as a patented drug known as hexopal which is therapeutically indicated for the symptomatic relief of severe intermittent claudication and raynaud’s phenomenon ')|
|('DB08964', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'indicated for the softening and dilatation of the cervix uteri prior to transcervical intrauterine operative procedures in the first trimester of pregnancy or facilitating therapeutic termination of pregnancy in patients in the second trimester of gestation')|
|('DB09001', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'created for the treatment for epilepsy with the intent of creating an antiepileptic with less sedative properties than phenobarbital ')|
|('DB09005', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'no approved indications batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously')|
|('DB09005', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'no approved indications batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously')|
|('DB09011', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'has been used in the management of epilepsy and epilepsy related behavioural disorders  it was used for generalised tonicclonic seizures and was not effective for absence seizuresmore recently focus has shifted to the use of beclamide in behavioural disorders in mentally handicapped epileptic patients it has been found to decrease anxiety antisocial and demanding behaviours and impulsivity mood stabilizing effects were also noted 2additionally due to its effects on monoamines beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes 2')|
|('DB09011', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'has been used in the management of epilepsy and epilepsy related behavioural disorders  it was used for generalised tonicclonic seizures and was not effective for absence seizuresmore recently focus has shifted to the use of beclamide in behavioural disorders in mentally handicapped epileptic patients it has been found to decrease anxiety antisocial and demanding behaviours and impulsivity mood stabilizing effects were also noted 2additionally due to its effects on monoamines beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes 2')|
|('DB09011', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'has been used in the management of epilepsy and epilepsy related behavioural disorders  it was used for generalised tonicclonic seizures and was not effective for absence seizuresmore recently focus has shifted to the use of beclamide in behavioural disorders in mentally handicapped epileptic patients it has been found to decrease anxiety antisocial and demanding behaviours and impulsivity mood stabilizing effects were also noted 2additionally due to its effects on monoamines beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes 2')|
|('DB09012', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'indicated for capillary and parenchymal hemorrhage trauma tonsillectomy during surgery intestinal bleeding and thrombocytopenic purpura')|
|('DB09012', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated for capillary and parenchymal hemorrhage trauma tonsillectomy during surgery intestinal bleeding and thrombocytopenic purpura')|
|('DB09012', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'indicated for capillary and parenchymal hemorrhage trauma tonsillectomy during surgery intestinal bleeding and thrombocytopenic purpura')|
|('DB09013', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'used in the management of open angle glaucoma pmid 12480285 ')|
|('DB09013', 'MONDO:0005338', ['glaucoma simplex', 'open angle glaucoma', 'pigmentary glaucoma', 'Wide-angle glaucoma', 'open-angle glaucoma'], 'used in the management of open angle glaucoma pmid 12480285 ')|
|('DB09026', 'MONDO:0005338', ['glaucoma simplex', 'open angle glaucoma', 'pigmentary glaucoma', 'Wide-angle glaucoma', 'open-angle glaucoma'], 'for the treatment of hypertension to lower blood pressure')|
|('DB09027', 'MONDO:0005338', ['glaucoma simplex', 'open angle glaucoma', 'pigmentary glaucoma', 'Wide-angle glaucoma', 'open-angle glaucoma'], 'when used in combination with the antiviral medication sofosbuvir as the commercially available product harvoni ledipasvir is indicated for the treatment of hcv genotypes 1 4 5 and 6 with or without ribavirin depending on the level of liver damage or cirrhosis fda label its use has also proven successful in the treatment of hcv in patients coinfected with hiv a19627')|
|('DB09027', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'when used in combination with the antiviral medication sofosbuvir as the commercially available product harvoni ledipasvir is indicated for the treatment of hcv genotypes 1 4 5 and 6 with or without ribavirin depending on the level of liver damage or cirrhosis fda label its use has also proven successful in the treatment of hcv in patients coinfected with hiv a19627')|
|('DB09027', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'when used in combination with the antiviral medication sofosbuvir as the commercially available product harvoni ledipasvir is indicated for the treatment of hcv genotypes 1 4 5 and 6 with or without ribavirin depending on the level of liver damage or cirrhosis fda label its use has also proven successful in the treatment of hcv in patients coinfected with hiv a19627')|
|('DB09029', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy ')|
|('DB09029', 'MONDO:0005083', ['psoriasis'], 'for the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy ')|
|('DB09030', 'MONDO:0005083', ['psoriasis'], 'vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or peripheral arterial disease pad it is usually coadministered with acetylsalicylic acid asa andor clopidogrel and should therefore be administered as an addition to these medications as it has not been studied alone ')|
|('DB09030', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or peripheral arterial disease pad it is usually coadministered with acetylsalicylic acid asa andor clopidogrel and should therefore be administered as an addition to these medications as it has not been studied alone ')|
|('DB09030', 'MONDO:0005386', ['peripheral arterial disease'], 'vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or peripheral arterial disease pad it is usually coadministered with acetylsalicylic acid asa andor clopidogrel and should therefore be administered as an addition to these medications as it has not been studied alone ')|
|('DB09030', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or peripheral arterial disease pad it is usually coadministered with acetylsalicylic acid asa andor clopidogrel and should therefore be administered as an addition to these medications as it has not been studied alone ')|
|('DB09031', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of mucosal caused by leishmania braziliensis cutaneous caused by l braziliensis l guyanensis and l panamensis and visceral leishmaniasis caused by l donovani in comparing leishmania drug susceptibility it has been found that l donovani is the most susceptible to miltefosine while l major is the least susceptible  offlabel use includes treatment of freeliving amebae fla infections unlabeled use cdc 2013 ')|
|('DB09031', 'MONDO:0005445', ['Infection by visceral leishmaniasis', 'Kala-Azar', 'visceral leishmaniasis'], 'for the treatment of mucosal caused by leishmania braziliensis cutaneous caused by l braziliensis l guyanensis and l panamensis and visceral leishmaniasis caused by l donovani in comparing leishmania drug susceptibility it has been found that l donovani is the most susceptible to miltefosine while l major is the least susceptible  offlabel use includes treatment of freeliving amebae fla infections unlabeled use cdc 2013 ')|
|('DB09033', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'vedolizumab is indicated for adult patients with moderately to severely active uc or cd who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids ')|
|('DB09034', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset andor sleep maintenance')|
|('DB09034', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset andor sleep maintenance')|
|('DB09035', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0004992', ['cancer'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0005549', ['adenocarcinoma of kidney [NCIT:C9385]', 'kidney adenocarcinoma [NCIT:C9385]', 'renal cell carcinoma [NCIT:C9385]', 'RCC [NCIT:C9385]', 'adenocarcinoma of the kidney [NCIT:C9385]', 'carcinoma, renal cell, malignant [NCIT:C9385]', 'renal cell carcinoma, stage unspecified [NCIT:C9385]', 'renal cell adenocarcinoma [NCIT:C9385]', 'renal cell cancer [NCIT:C9385]', 'renal cell adenocarcinoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0004952', ['HL', 'Hodgkin disease', 'Hodgkin lymphoma', 'Hodgkins sarcoma', 'Hodgkins lymphoma', 'stage I Subdiaphragmatic Hodgkin Lymphoma', 'stage II Subdiaphragmatic Hodgkin Lymphoma', 'hodgkins lymphoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0044907', ['Metastatic squamous cell carcinoma [NCIT:C4104]', 'metastatic squamous cell carcinoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09035', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'nivolumab is indicated as a single agent for the treatment of braf v600 wildtype unresectable or metastatic melanoma braf v600 mutationpositive unresectable or metastatic melanoma metastatic nonsmall cell lung cancer and progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on diseasespecific fda therapy advanced renal cell carcinoma with prior antiangiogenic therapy classical hodgkin lymphoma in adults that has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinumbased therapy locally advanced or metastatic urothelial carcinoma with disease progression during or after platinumcontaining chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecan hepatocellular carcinoma previously treated with sorafenibfda labelin combination with ipilimumab nivolumab is indicated for the treatment of unresectable or metastatic melanoma melanoma with lymph node involvement or metastatic disease that has gone through complete resection intermediate or poor risk previously untreated advanced renal cell carcinoma microsatellite instabilityhigh msih or mismatch repair deficient dmmr metastatic colorectal cancer in patients 12 years or older that progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanfda label')|
|('DB09036', 'MONDO:0004992', ['cancer'], 'siltuximab is indicated for the treatment of patients with multicentric castlemans disease mcd who are human immunodeficiency virus hiv negative and human herpesvirus8 hhv8 negative siltuximab did not bind to virally produced il6 in a nonclinical study and was therefore not studied in patients with mcd who are hiv or hhv8 positive')|
|('DB09036', 'MONDO:0019754', ['MCD', 'multicentric giant lymph node hyperplasia', 'plasmablastic multicentric Castleman disease', 'PMCD', 'multicentric castleman disease'], 'siltuximab is indicated for the treatment of patients with multicentric castlemans disease mcd who are human immunodeficiency virus hiv negative and human herpesvirus8 hhv8 negative siltuximab did not bind to virally produced il6 in a nonclinical study and was therefore not studied in patients with mcd who are hiv or hhv8 positive')|
|('DB09037', 'MONDO:0019754', ['MCD', 'multicentric giant lymph node hyperplasia', 'plasmablastic multicentric Castleman disease', 'PMCD', 'multicentric castleman disease'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0004992', ['cancer'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0004952', ['HL', 'Hodgkin disease', 'Hodgkin lymphoma', 'Hodgkins sarcoma', 'Hodgkins lymphoma', 'stage I Subdiaphragmatic Hodgkin Lymphoma', 'stage II Subdiaphragmatic Hodgkin Lymphoma', 'hodgkins lymphoma'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0005575', ['colorectal cancer'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09037', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'pembrolizumab is indicated for the treatment ofpatients with unresectable or metastatic melanomafda label as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors have high pdl1 expression tumor proportion score tps ≥50 as determined by an fdaapproved test with no egfr or alk genomic tumor aberrationsf137as a single therapy pembrolizumab is indicated for firstline treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl1 tps ≥1 as determined by an fdaapproved test with disease progression on or after platinumcontaining chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to treatmentf137 the following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pdl1 cps  1 as determined by an fdaapproved testl2955in combination with pemetrexed and carboplatin is indicated for the firstline treatment of patients with metastatic nonsquamous nonsmall cell lung cancerf137patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapyf137treatment of adults and pediatric patients with refractory classical hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapyf137treatment of adult and pediatric patients with refractory primary mediastinal large bcell lymphoma or who have relapsed after 2 or more prior lines of therapyf137treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatincontaining chemotherapyf137patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinumcontaining chemotherapyf137treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabilityhigh or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine oxaliplatin and irinotecanf137patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express pdl1 cps 1 as determined by an fdaapproved test with disease progression on or after two or more prior lines of therapy including fluoropyrimidine and platinumcontaining chemotherapy and if appropriate her2neutargeted therapyf137')|
|('DB09038', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes')|
|('DB09038', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes')|
|('DB09039', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'eliglustat is indicated for the longterm treatment of type 1 gaucher disease in adult patients who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fdacleared testlabel')|
|('DB09040', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'indicated in the treatment of fungal infection of the nail known as onychomycosis')|
|('DB09041', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'indicated for the treatment of onychomycosis a fungal infection of the toenails due to itrichophyton rubrumi or itrichophyton mentagrophytesi ')|
|('DB09042', 'MONDO:0003219', ['adenocarcinoma of Cardioesophageal junction', 'gastroesophageal junction adenocarcinoma'], 'tedizolid phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections absssi caused by susceptible isolates of the following grampositive microorganisms staphylococcus aureus including methicillinresistant mrsa and methicillinsusceptible mssa isolates streptococcus pyogenes streptococcus agalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius and streptococcus constellatus and enterococcus faecalis')|
|('DB09042', 'MONDO:0100073', ['MRSA []', 'methicillin-resistant staphylococcus aureus infectious disease'], 'tedizolid phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections absssi caused by susceptible isolates of the following grampositive microorganisms staphylococcus aureus including methicillinresistant mrsa and methicillinsusceptible mssa isolates streptococcus pyogenes streptococcus agalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius and streptococcus constellatus and enterococcus faecalis')|
|('DB09043', 'MONDO:0100073', ['MRSA []', 'methicillin-resistant staphylococcus aureus infectious disease'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus')|
|('DB09043', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus')|
|('DB09045', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus')|
|('DB09046', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy')|
|('DB09046', 'MONDO:0021140', ['inborn []', 'congenital'], 'metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy')|
|('DB09046', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy')|
|('DB09046', 'MONDO:0006573', ['lipodystrophy'], 'metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy')|
|('DB09047', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'finafloxacin is indicated for the treatment of acute otitis externa aoe with or without an otowick caused by susceptible strains of ipseudomonas aeruginosai and istaphylococcus aureusi in patients age 1 year and older ')|
|('DB09047', 'MONDO:0001051', ['acute bacterial inflammation of external ear', 'acute otitis externa, diffuse', 'acute swimmers ear', 'acute swimmers ear', 'Tank ear', 'acute otitis externa'], 'finafloxacin is indicated for the treatment of acute otitis externa aoe with or without an otowick caused by susceptible strains of ipseudomonas aeruginosai and istaphylococcus aureusi in patients age 1 year and older ')|
|('DB09048', 'MONDO:0001051', ['acute bacterial inflammation of external ear', 'acute otitis externa, diffuse', 'acute swimmers ear', 'acute swimmers ear', 'Tank ear', 'acute otitis externa'], 'netupitant is an antiemitic drug approved by the fda in october 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy')|
|('DB09048', 'MONDO:0004992', ['cancer'], 'netupitant is an antiemitic drug approved by the fda in october 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy')|
|('DB09049', 'MONDO:0004992', ['cancer'], 'indicated for the treatment of opioidinduced constipation oic in adult patients with chronic noncancer pain')|
|('DB09050', 'MONDO:0004992', ['cancer'], 'this drug is administered in combination with tazobactam for the treatment of complicated intraabdominal infections in combination with metronidazole and complicated urinary tract infectionsa179425 which may include pyelonephritis ceftolozanetazobactam is also indicated in the treatment of bacterial ventilatorassociated pneumonia and bacterial hospitalacquired pneumoniafda label')|
|('DB09050', 'MONDO:0006939', ['pyelonephritis'], 'this drug is administered in combination with tazobactam for the treatment of complicated intraabdominal infections in combination with metronidazole and complicated urinary tract infectionsa179425 which may include pyelonephritis ceftolozanetazobactam is also indicated in the treatment of bacterial ventilatorassociated pneumonia and bacterial hospitalacquired pneumoniafda label')|
|('DB09050', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'this drug is administered in combination with tazobactam for the treatment of complicated intraabdominal infections in combination with metronidazole and complicated urinary tract infectionsa179425 which may include pyelonephritis ceftolozanetazobactam is also indicated in the treatment of bacterial ventilatorassociated pneumonia and bacterial hospitalacquired pneumoniafda label')|
|('DB09051', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'vimizim is a hydrolytic lysosomal glycosaminoglycan gagspecific enzyme indicated for patients with mucopolysaccharidosis type iva mps iva morquio a syndrome ')|
|('DB09051', 'MONDO:0019249', ['mucopolysaccharidosis'], 'vimizim is a hydrolytic lysosomal glycosaminoglycan gagspecific enzyme indicated for patients with mucopolysaccharidosis type iva mps iva morquio a syndrome ')|
|('DB09052', 'MONDO:0019249', ['mucopolysaccharidosis'], 'indicated for the treatment of philadelphia chromosomenegative relapsed or refractory bcell precursor acute lymphoblastic leukemia all')|
|('DB09052', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'indicated for the treatment of philadelphia chromosomenegative relapsed or refractory bcell precursor acute lymphoblastic leukemia all')|
|('DB09053', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0018876', ['mantle cell lymphoma'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0004992', ['cancer'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0005059', ['leukemia'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0005190', ['primary macroglobulinemia', 'macroglobulinemia'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09053', 'MONDO:0000432', ['lymphoplasmacytic lymphoma'], 'ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapyfda label mantle cell lymphoma mcl is a bcell nonhodgkin lymphoma that develops in the outer edge of a lymph node mcl is usually diagnosed at late stages and it is easily spread into bone marrow spleen liver and gastrointestinal tractl1929ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll who have at least one prior therapyfda label cll is a type of cancer caused by an overproduction of lymphocytes by the bone marrow some of the symptoms include swollen lymph nodes and tirednessl1931ibrutinib is indicated for the treatment of chronic lymphocytic leukemia cll with 17p deletionfda label cll with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the tp53 gene the remaining allele is mainly inactivated and thus this type of leukemia is unresponsive to p53dependent treatmentsa32305ibrutinib is indicated for the treatment of patients with waldenstroms macroglobulinemia wmfda label wm also called lymphoplasmacytic lymphoma is a type of nonhodgkin lymphoma in which the cancer cells make large amounts of macroglobulin the macroglobulin is a monoclonal protein that corresponds to the type of igm antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous systeml1934')|
|('DB09054', 'MONDO:0004992', ['cancer'], 'idelalisib is indicated in the treatment of chronic lymphocytic leukemia cll relapsed follicular bcell nonhodgkin lymphoma fl and relapsed small lymphocytic lymphoma sll for the treatment of relapsed cll it is currently indicated as a secondline agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities while in the treatment of fl and sll it is intended to be used in patients who have received at least two prior systemic therapies')|
|('DB09054', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'idelalisib is indicated in the treatment of chronic lymphocytic leukemia cll relapsed follicular bcell nonhodgkin lymphoma fl and relapsed small lymphocytic lymphoma sll for the treatment of relapsed cll it is currently indicated as a secondline agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities while in the treatment of fl and sll it is intended to be used in patients who have received at least two prior systemic therapies')|
|('DB09054', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'idelalisib is indicated in the treatment of chronic lymphocytic leukemia cll relapsed follicular bcell nonhodgkin lymphoma fl and relapsed small lymphocytic lymphoma sll for the treatment of relapsed cll it is currently indicated as a secondline agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities while in the treatment of fl and sll it is intended to be used in patients who have received at least two prior systemic therapies')|
|('DB09055', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'used in the treatment of hyperlipidemias abnormally elevated levels of any or all lipids andor lipoproteins in the blood')|
|('DB09055', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'used in the treatment of hyperlipidemias abnormally elevated levels of any or all lipids andor lipoproteins in the blood')|
|('DB09057', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs')|
|('DB09057', 'MONDO:0016595', ['pulmonary anthrax', 'respiratory anthrax', 'wool-sorters disease', 'woolsorters disease', 'inhalational anthrax'], 'anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs')|
|('DB09059', 'MONDO:0016595', ['pulmonary anthrax', 'respiratory anthrax', 'wool-sorters disease', 'woolsorters disease', 'inhalational anthrax'], 'atosiban is indicated for use in delaying imminent preterm birth in pregnant adult women with  regular uterine contractions of at least 30 s duration at a rate of at least 4 per 30 min a cervical dilation of 13cm 03cm for nulliparas and effacement of  at least 50 a gestational age of 2433 weeks a normal fetal heart rate')|
|('DB09060', 'MONDO:0016595', ['pulmonary anthrax', 'respiratory anthrax', 'wool-sorters disease', 'woolsorters disease', 'inhalational anthrax'], 'avycaz ceftazidimeavibactam in combination with metronidazole is indicated for the treatment of complicated intraabdominal infections caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae proteus mirabilis providencia stuartii enterobacter cloacae klebsiella oxytoca and pseudomonas aeruginosa in patients 18 years or olderavycaz is also indicated for the treatment of complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae citrobacter koseri enterobacter aerogenes enterobacter cloacae citrobacter freundii proteus spp and pseudomonas aeruginosa in patients 18 years or older')|
|('DB09060', 'MONDO:0006939', ['pyelonephritis'], 'avycaz ceftazidimeavibactam in combination with metronidazole is indicated for the treatment of complicated intraabdominal infections caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae proteus mirabilis providencia stuartii enterobacter cloacae klebsiella oxytoca and pseudomonas aeruginosa in patients 18 years or olderavycaz is also indicated for the treatment of complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae citrobacter koseri enterobacter aerogenes enterobacter cloacae citrobacter freundii proteus spp and pseudomonas aeruginosa in patients 18 years or older')|
|('DB09061', 'MONDO:0006939', ['pyelonephritis'], 'when used in combination with delta9tetrahydrocannabinol as the product sativex cannabidiol was given a standard marketing authorization ie a notice of compliance noc by health canada for the following indications 1 as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis ms who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy l886due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence sativex was also given a notice of compliance with conditions nocc by health canada for the following indications 1 as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis 2 as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain l886')|
|('DB09061', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'when used in combination with delta9tetrahydrocannabinol as the product sativex cannabidiol was given a standard marketing authorization ie a notice of compliance noc by health canada for the following indications 1 as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis ms who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy l886due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence sativex was also given a notice of compliance with conditions nocc by health canada for the following indications 1 as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis 2 as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain l886')|
|('DB09063', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response an improvement in survival or diseaserelated symptoms has not been established continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials')|
|('DB09063', 'MONDO:0004992', ['cancer'], 'ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response an improvement in survival or diseaserelated symptoms has not been established continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials')|
|('DB09063', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response an improvement in survival or diseaserelated symptoms has not been established continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials')|
|('DB09065', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'cobicistat is a cyp3a inhibitor indicated to increase systemic exposure of atazanavir or darunavir once daily dosing regimen in combination with other antiretroviral agents in the treatment of hiv1 infection it is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily fosamprenavir saquinavir or tipranavir due to lack of exposure data the use of cobicistat is not recommended with darunavir 600 mg twice daily fosamprenavir saquinavir or tipranavir complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications')|
|('DB09066', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'controlled ovarian stimulation l2273 in cases of women who are undergoing fertility treatment to stimulate the development of more than one mature egg simultaneously in the ovaries in combination with a gonadotrophinreleasing hormone gnrh antagonist a type of medicine also used in fertility treatmentsl2270')|
|('DB09067', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'corticorelin is indicated for use in differentiating pituitary and ectopic production of acth in patients with acthdependent cushings syndrome')|
|('DB09067', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'corticorelin is indicated for use in differentiating pituitary and ectopic production of acth in patients with acthdependent cushings syndrome')|
|('DB09067', 'MONDO:0003009', ['Cushing syndrome', 'Cushings syndrome', 'hyperaldosteronism', 'hyperaldosteronism'], 'corticorelin is indicated for use in differentiating pituitary and ectopic production of acth in patients with acthdependent cushings syndrome')|
|('DB09068', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'vortioxetine is indicated for the treatment of major depressive disorder mdd')|
|('DB09068', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'vortioxetine is indicated for the treatment of major depressive disorder mdd')|
|('DB09069', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'trimetazidine is indicated for use in angina pectoris')|
|('DB09070', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for the relief of postmenopausal symptoms and for the prevention of osteoporosis l1724')|
|('DB09070', 'MONDO:0005298', ['osteoporosis'], 'for the relief of postmenopausal symptoms and for the prevention of osteoporosis l1724')|
|('DB09071', 'MONDO:0005298', ['osteoporosis'], 'tasimelteon is indicated for the treatment of non24hour sleepwake disorder n24hswd')|
|('DB09072', 'MONDO:0005298', ['osteoporosis'], 'for the treatment of cataplexy and excessive daytime sleepiness eds associated with narcolepsy')|
|('DB09072', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'for the treatment of cataplexy and excessive daytime sleepiness eds associated with narcolepsy')|
|('DB09073', 'MONDO:0005298', ['osteoporosis'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0004992', ['cancer'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0005051', ['Lobular carcinoma', 'Lobular carcinoma of breast', 'Lobular carcinoma of the breast', 'invasive lobular breast carcinoma'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0021165', ["Paget's cell neoplasm [NCIT:C7073]", "Paget's disease [NCIT:C7073]", 'Paget cell neoplasm [NCIT:C7073]', 'Paget disease [NCIT:C7073]', 'paget disease'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09073', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'palbociclib is indicated in combination with letrozole as initial endocrinebased therapy for the treatment of human epidermal growth factor receptor type 2 her2negative and hormone receptorhrpositive tumors in adult patients with advancedmetastatic breast cancer it is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapya176783in the official labeling the use of palbociclib should be accompanied with either an aromatase inhibition no restricted to letrozole as initial endocrinebased therapy in postmenopausal women or in manfda labelthe breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue this growth can spread into other parts of the body which is called metastasis according to the location of the cancer cells it can be categorized in ductal carcinoma and lobular carcinoma however other types of breast cancer include inflammatory breast cancer paget disease of the breast triple negative breast cancer nonhodgkin lymphoma and soft tissue sarcomal5870 in males breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinomal5873')|
|('DB09074', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'olaparib is a poly adpribose polymerase parp inhibitor indicated for the treatment ofi ovarian cancer in which the medication is intended for a the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy or b for the treatment of adult patients with deleterious or suspected deleterious germline brcamutated gbrcam advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda labelii breast cancer in which the medication is intended for use in patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 her2negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant adjuvant or metastatic setting patients with hormone receptor hrpositive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda label')|
|('DB09074', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'olaparib is a poly adpribose polymerase parp inhibitor indicated for the treatment ofi ovarian cancer in which the medication is intended for a the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy or b for the treatment of adult patients with deleterious or suspected deleterious germline brcamutated gbrcam advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda labelii breast cancer in which the medication is intended for use in patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 her2negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant adjuvant or metastatic setting patients with hormone receptor hrpositive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda label')|
|('DB09074', 'MONDO:0015686', ['serous surface papillary carcinoma [Orphanet:168829]', 'PPC [NCIT:C40022,Orphanet:168829]', 'Extra-ovarian primary peritoneal carcinoma [Orphanet:168829]', 'primary peritoneal serous carcinoma [Orphanet:168829]', 'EOPPC [Orphanet:168829]', 'primary peritoneal carcinoma [MONDO:ambiguous,NCIT:C40022]', 'primary peritoneal cancer [NCIT:C40022]', 'primary peritoneal carcinoma'], 'olaparib is a poly adpribose polymerase parp inhibitor indicated for the treatment ofi ovarian cancer in which the medication is intended for a the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy or b for the treatment of adult patients with deleterious or suspected deleterious germline brcamutated gbrcam advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda labelii breast cancer in which the medication is intended for use in patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 her2negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant adjuvant or metastatic setting patients with hormone receptor hrpositive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda label')|
|('DB09074', 'MONDO:0004992', ['cancer'], 'olaparib is a poly adpribose polymerase parp inhibitor indicated for the treatment ofi ovarian cancer in which the medication is intended for a the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy or b for the treatment of adult patients with deleterious or suspected deleterious germline brcamutated gbrcam advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda labelii breast cancer in which the medication is intended for use in patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 her2negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant adjuvant or metastatic setting patients with hormone receptor hrpositive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda label')|
|('DB09074', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'olaparib is a poly adpribose polymerase parp inhibitor indicated for the treatment ofi ovarian cancer in which the medication is intended for a the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy or b for the treatment of adult patients with deleterious or suspected deleterious germline brcamutated gbrcam advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda labelii breast cancer in which the medication is intended for use in patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 her2negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant adjuvant or metastatic setting patients with hormone receptor hrpositive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment fda label select patients for therapy based on an fdaapproved companion diagnostic for olaparib fda label')|
|('DB09075', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'edoxaban is indicated for reducing the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf however it should not be used in patients with creatinine clearance crcl  95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg it is also indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 510 days of initial therapy with a parenteral anticoagulant')|
|('DB09075', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'edoxaban is indicated for reducing the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf however it should not be used in patients with creatinine clearance crcl  95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg it is also indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 510 days of initial therapy with a parenteral anticoagulant')|
|('DB09075', 'MONDO:0004981', ['A-fib', 'atrial fibrillation'], 'edoxaban is indicated for reducing the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf however it should not be used in patients with creatinine clearance crcl  95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg it is also indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 510 days of initial therapy with a parenteral anticoagulant')|
|('DB09075', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'edoxaban is indicated for reducing the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf however it should not be used in patients with creatinine clearance crcl  95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg it is also indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 510 days of initial therapy with a parenteral anticoagulant')|
|('DB09076', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd')|
|('DB09076', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd')|
|('DB09077', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'dinutuximab is indicated in combination with granulocytemacrophage colonystimulating factor gmcsf interleukin2 il2 and 13cisretinoic acid ra for the treatment of pediatric patients with highrisk neuroblastoma who achieve at least a partial response to prior firstline multiagent multimodality therapy despite a high clinical response seen after firstline treatment the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse')|
|('DB09077', 'MONDO:0005072', ['neuroblastoma'], 'dinutuximab is indicated in combination with granulocytemacrophage colonystimulating factor gmcsf interleukin2 il2 and 13cisretinoic acid ra for the treatment of pediatric patients with highrisk neuroblastoma who achieve at least a partial response to prior firstline multiagent multimodality therapy despite a high clinical response seen after firstline treatment the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse')|
|('DB09078', 'MONDO:0005072', ['neuroblastoma'], 'lenvatinib is indicated for the treatment of following conditions treatment of locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer treatment of advanced renal cell carcinoma rcc in combination with everolimus following one prior antiangiogenic therapy firstline treatment of unresectable hepatocellular carcinoma hcc')|
|('DB09078', 'MONDO:0015447', ['thyroid gland well differentiated carcinoma [NCIT:C7153]', 'differentiated thyroid cancer [NCIT:C7153]', 'thyroid gland differentiated carcinoma [NCIT:C7153]', 'papillary or follicular thyroid carcinoma [Orphanet:146]', 'differentiated thyroid gland carcinoma [NCIT:C7153]', 'well differentiated thyroid gland carcinoma [NCIT:C7153]', 'well-differentiated thyroid carcinoma [Orphanet:146]', 'differentiated thyroid carcinoma [NCIT:C7153]', 'differentiated thyroid gland cancer [NCIT:C7153]', 'well differentiated thyroid carcinoma [NCIT:C7153]', 'well-differentiated thyroid cancer [NCIT:C7153]', 'differentiated thyroid carcinoma'], 'lenvatinib is indicated for the treatment of following conditions treatment of locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer treatment of advanced renal cell carcinoma rcc in combination with everolimus following one prior antiangiogenic therapy firstline treatment of unresectable hepatocellular carcinoma hcc')|
|('DB09078', 'MONDO:0044874', ['refractory cytopenia of childhood [NCIT:C82596]', 'RCC [NCIT:C82596]', 'refractory cytopenia of childhood'], 'lenvatinib is indicated for the treatment of following conditions treatment of locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer treatment of advanced renal cell carcinoma rcc in combination with everolimus following one prior antiangiogenic therapy firstline treatment of unresectable hepatocellular carcinoma hcc')|
|('DB09078', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'lenvatinib is indicated for the treatment of following conditions treatment of locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer treatment of advanced renal cell carcinoma rcc in combination with everolimus following one prior antiangiogenic therapy firstline treatment of unresectable hepatocellular carcinoma hcc')|
|('DB09079', 'MONDO:0007256', ['Hepatoma', 'hepatocellular carcinoma'], 'in the us nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis ipfl8453 and to slow declining pulmonary function in patients with systemic sclerosisassociated interstitial lung diseasel8462 in the eu nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic locally advanced or locally recurrent nonsmall cell lung cancer of adenocarcinoma histology who have already tried firstline therapyl8459')|
|('DB09079', 'MONDO:0008345', ['cryptogenic fibrosing alveolitis', 'FIBROCYSTIC PULMONARY DYSPLASIA', 'IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL', 'idiopathic pulmonary fibrosis'], 'in the us nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis ipfl8453 and to slow declining pulmonary function in patients with systemic sclerosisassociated interstitial lung diseasel8462 in the eu nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic locally advanced or locally recurrent nonsmall cell lung cancer of adenocarcinoma histology who have already tried firstline therapyl8459')|
|('DB09079', 'MONDO:0004992', ['cancer'], 'in the us nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis ipfl8453 and to slow declining pulmonary function in patients with systemic sclerosisassociated interstitial lung diseasel8462 in the eu nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic locally advanced or locally recurrent nonsmall cell lung cancer of adenocarcinoma histology who have already tried firstline therapyl8459')|
|('DB09079', 'MONDO:0004970', ['adenocarcinomas', 'adenocarcinoma'], 'in the us nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis ipfl8453 and to slow declining pulmonary function in patients with systemic sclerosisassociated interstitial lung diseasel8462 in the eu nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic locally advanced or locally recurrent nonsmall cell lung cancer of adenocarcinoma histology who have already tried firstline therapyl8459')|
|('DB09080', 'MONDO:0004970', ['adenocarcinomas', 'adenocarcinoma'], 'olodaterol is indicated for use in chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema it is not indicated for the treatment of acute exacerbations of copd or for the treatment of asthma')|
|('DB09080', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'olodaterol is indicated for use in chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema it is not indicated for the treatment of acute exacerbations of copd or for the treatment of asthma')|
|('DB09080', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'olodaterol is indicated for use in chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema it is not indicated for the treatment of acute exacerbations of copd or for the treatment of asthma')|
|('DB09080', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'olodaterol is indicated for use in chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema it is not indicated for the treatment of acute exacerbations of copd or for the treatment of asthma')|
|('DB09081', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'idebenone is indicated for use by the european medicines agency ema for the treatment of visual impairment in adolescent and adult patients withleber’s hereditary optic neuropathy lhon it is not currently approved for use by either the food and drug administration usa or health canada l885')|
|('DB09081', 'MONDO:0001941', ['vision impairment', 'vision loss', 'visual impairment', 'blindness (disorder)'], 'idebenone is indicated for use by the european medicines agency ema for the treatment of visual impairment in adolescent and adult patients withleber’s hereditary optic neuropathy lhon it is not currently approved for use by either the food and drug administration usa or health canada l885')|
|('DB09081', 'MONDO:0020249', ['hereditary optic neuropathy'], 'idebenone is indicated for use by the european medicines agency ema for the treatment of visual impairment in adolescent and adult patients withleber’s hereditary optic neuropathy lhon it is not currently approved for use by either the food and drug administration usa or health canada l885')|
|('DB09082', 'MONDO:0020249', ['hereditary optic neuropathy'], 'vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta approved by the fda in 2013 use of breo ellipta is indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with copd including chronic bronchitis and emphysema it is also indicated for oncedaily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease')|
|('DB09082', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta approved by the fda in 2013 use of breo ellipta is indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with copd including chronic bronchitis and emphysema it is also indicated for oncedaily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease')|
|('DB09082', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta approved by the fda in 2013 use of breo ellipta is indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with copd including chronic bronchitis and emphysema it is also indicated for oncedaily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease')|
|('DB09082', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta approved by the fda in 2013 use of breo ellipta is indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with copd including chronic bronchitis and emphysema it is also indicated for oncedaily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease')|
|('DB09083', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'ivabradine is indicated by the fda to reduce the risk of hospitalization for worsening heart failure in adult patients with stable symptomatic chronic heart failure with left ventricular ejection fraction ≤35 who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to betablocker use it is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or morefda label')|
|('DB09083', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'ivabradine is indicated by the fda to reduce the risk of hospitalization for worsening heart failure in adult patients with stable symptomatic chronic heart failure with left ventricular ejection fraction ≤35 who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to betablocker use it is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or morefda label')|
|('DB09083', 'MONDO:0005254', ['symptomatic heart failure'], 'ivabradine is indicated by the fda to reduce the risk of hospitalization for worsening heart failure in adult patients with stable symptomatic chronic heart failure with left ventricular ejection fraction ≤35 who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to betablocker use it is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or morefda label')|
|('DB09083', 'MONDO:0005021', ['primary dilated cardiomyopathy', 'dilated cardiomyopathy'], 'ivabradine is indicated by the fda to reduce the risk of hospitalization for worsening heart failure in adult patients with stable symptomatic chronic heart failure with left ventricular ejection fraction ≤35 who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to betablocker use it is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or morefda label')|
|('DB09084', 'MONDO:0005021', ['primary dilated cardiomyopathy', 'dilated cardiomyopathy'], 'available predominantly as a liquid mouthwash oromucosal spray or topical cream benzydamine is most frequently employed as a locally acting analgesic and antiinflammatory treatment for the relief of painful inflammatory conditions when formulated as a mouthwash or spray benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a nasogastric tube inflammatory conditions like pharyngitis aphthous ulcers and oral ulceration due to radiation therapy dentistry operations and procedures or more general conditions like sore throat sore tongue sore gums mouth ulcers or discomfort caused by dentures l1121 when used as a topical cream benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscoloskeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains strains bruises sore muscles stiff joints or even the aftereffects of fractures  l1123')|
|('DB09084', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'available predominantly as a liquid mouthwash oromucosal spray or topical cream benzydamine is most frequently employed as a locally acting analgesic and antiinflammatory treatment for the relief of painful inflammatory conditions when formulated as a mouthwash or spray benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a nasogastric tube inflammatory conditions like pharyngitis aphthous ulcers and oral ulceration due to radiation therapy dentistry operations and procedures or more general conditions like sore throat sore tongue sore gums mouth ulcers or discomfort caused by dentures l1121 when used as a topical cream benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscoloskeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains strains bruises sore muscles stiff joints or even the aftereffects of fractures  l1123')|
|('DB09084', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'available predominantly as a liquid mouthwash oromucosal spray or topical cream benzydamine is most frequently employed as a locally acting analgesic and antiinflammatory treatment for the relief of painful inflammatory conditions when formulated as a mouthwash or spray benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a nasogastric tube inflammatory conditions like pharyngitis aphthous ulcers and oral ulceration due to radiation therapy dentistry operations and procedures or more general conditions like sore throat sore tongue sore gums mouth ulcers or discomfort caused by dentures l1121 when used as a topical cream benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscoloskeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains strains bruises sore muscles stiff joints or even the aftereffects of fractures  l1123')|
|('DB09084', 'MONDO:0002471', ['bursitis'], 'available predominantly as a liquid mouthwash oromucosal spray or topical cream benzydamine is most frequently employed as a locally acting analgesic and antiinflammatory treatment for the relief of painful inflammatory conditions when formulated as a mouthwash or spray benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a nasogastric tube inflammatory conditions like pharyngitis aphthous ulcers and oral ulceration due to radiation therapy dentistry operations and procedures or more general conditions like sore throat sore tongue sore gums mouth ulcers or discomfort caused by dentures l1121 when used as a topical cream benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscoloskeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains strains bruises sore muscles stiff joints or even the aftereffects of fractures  l1123')|
|('DB09085', 'MONDO:0002471', ['bursitis'], 'ophthalmic tetracaine is indicated for the for procedures requiring a rapid and short acting topical ophthalmic anestheticthe combination lidocaine and tetracaine patch is indicated for local dermal analgesia for superficial dermatological procedures and superficial venous access  the combination lidocaine and tetracaine cream is intended to provide topical local analgesia for superficial dermatological procedures')|
|('DB09085', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'ophthalmic tetracaine is indicated for the for procedures requiring a rapid and short acting topical ophthalmic anestheticthe combination lidocaine and tetracaine patch is indicated for local dermal analgesia for superficial dermatological procedures and superficial venous access  the combination lidocaine and tetracaine cream is intended to provide topical local analgesia for superficial dermatological procedures')|
|('DB09086', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'eugenol is not currently available in any fdaapproved drug products there are a number of unapproved otc products that advertise it for the use of toothache  eugenol is is also commonly used in combination with zinc oxide in dental procedures for the cementation of temporary prostheses and the temporary restoration of teeth and cavities')|
|('DB09087', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'potassium alum is considered safe by the fda and its use is in homepathic or otc products due to its presence in several different drugs the main indications for the use of potassium alum areconstipationl1071cosmetic or drug astringent helping the shrinkage of tissues and the dry of secretionsl1072oral health care drugl1072part of formulation in cleansing products skincare products mosturizers face powders and deodorantsl1073antiperspirantl1074antifungall1074')|
|('DB09087', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'potassium alum is considered safe by the fda and its use is in homepathic or otc products due to its presence in several different drugs the main indications for the use of potassium alum areconstipationl1071cosmetic or drug astringent helping the shrinkage of tissues and the dry of secretionsl1072oral health care drugl1072part of formulation in cleansing products skincare products mosturizers face powders and deodorantsl1073antiperspirantl1074antifungall1074')|
|('DB09088', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'the most common indication for the usage of amylocaine was spinal anesthesia a32277')|
|('DB09088', 'MONDO:0021137', ['common []', 'not rare'], 'the most common indication for the usage of amylocaine was spinal anesthesia a32277')|
|('DB09089', 'MONDO:0021137', ['common []', 'not rare'], 'indicated for symptomatic treatment of irritable bowel syndrome ibs and treatment of postoperative paralytic ileus following abdominal surgery ')|
|('DB09089', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'indicated for symptomatic treatment of irritable bowel syndrome ibs and treatment of postoperative paralytic ileus following abdominal surgery ')|
|('DB09089', 'MONDO:0004567', ['Ileus of intestine', 'ileus'], 'indicated for symptomatic treatment of irritable bowel syndrome ibs and treatment of postoperative paralytic ileus following abdominal surgery ')|
|('DB09090', 'MONDO:0004567', ['Ileus of intestine', 'ileus'], 'pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome ibs and functional disorders of the biliary tract')|
|('DB09090', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome ibs and functional disorders of the biliary tract')|
|('DB09091', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol it is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditionsl1077 it is also the substance used for the screening of contact allergies to class a steroidsa31435')|
|('DB09091', 'MONDO:0003014', ['rhinitis'], 'tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol it is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditionsl1077 it is also the substance used for the screening of contact allergies to class a steroidsa31435')|
|('DB09091', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol it is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditionsl1077 it is also the substance used for the screening of contact allergies to class a steroidsa31435')|
|('DB09091', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol it is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditionsl1077 it is also the substance used for the screening of contact allergies to class a steroidsa31435')|
|('DB09091', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol it is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditionsl1077 it is also the substance used for the screening of contact allergies to class a steroidsa31435')|
|('DB09092', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'xanthinol is primarily used in diet supplements to increase the brain metabolism of glucose and obtain atp xanthinol is also used as an agent to reduced cholesterol as it is a vasodilatorl1080 its action allows having an elevated rate of blood flow in the brain which helps improve memory function concentration and awarenessl1079 thus due to his actions xanthinol is indicated to improve cerebrovascular and peripheral vascular disorders as well as hyperlipidaemiasl1081')|
|('DB09093', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used in the manufacuring of medicated animal feeds fda label')|
|('DB09094', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], '25 podophyllin in benzoin tincture is indicated for the removal of soft genital venereal warts condylomata acuminata')|
|('DB09095', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema seborrheic eczema lichen planus and psoriasis all these disorders present as a common characteristic the occurrence of symptoms as itching swelling redness and scalingl1083')|
|('DB09095', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema seborrheic eczema lichen planus and psoriasis all these disorders present as a common characteristic the occurrence of symptoms as itching swelling redness and scalingl1083')|
|('DB09095', 'MONDO:0005083', ['psoriasis'], 'difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema seborrheic eczema lichen planus and psoriasis all these disorders present as a common characteristic the occurrence of symptoms as itching swelling redness and scalingl1083')|
|('DB09095', 'MONDO:0021137', ['common []', 'not rare'], 'difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema seborrheic eczema lichen planus and psoriasis all these disorders present as a common characteristic the occurrence of symptoms as itching swelling redness and scalingl1083')|
|('DB09096', 'MONDO:0021137', ['common []', 'not rare'], 'benzoyl peroxide is indicated for the treatment of mild to moderate acne vulgaris and rosacea combined with other agents it may be used in the treatment of more severe acne')|
|('DB09096', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'benzoyl peroxide is indicated for the treatment of mild to moderate acne vulgaris and rosacea combined with other agents it may be used in the treatment of more severe acne')|
|('DB09097', 'MONDO:0006604', ['Acne roscea', 'Acne, erythematosa', 'rosacea'], 'indicated for the treatment of hyperprolactinemia idiopathic or originating from a prolactinsecreting pituitary microadenoma or macroadenoma')|
|('DB09097', 'MONDO:0005804', ['hyperprolactinemia [MONDO:ambiguous]', 'hyperprolactinaemia [MESH:D006966]', 'hyperprolactinemia'], 'indicated for the treatment of hyperprolactinemia idiopathic or originating from a prolactinsecreting pituitary microadenoma or macroadenoma')|
|('DB09097', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'indicated for the treatment of hyperprolactinemia idiopathic or originating from a prolactinsecreting pituitary microadenoma or macroadenoma')|
|('DB09098', 'MONDO:0021156', ['hypophysis [NCIT:C12399]', 'gland, pituitary [NCIT:C12399]', 'pituitary gland inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'pituitary gland [NCIT:C12399]', 'hypophysis cerebri [NCIT:C12399]', 'pituitary [NCIT:C12399]', 'nervous system, pituitary [NCIT:C12399]', 'hypophysitides [MESH:D000072659]', 'inflammation of pituitary gland []', 'hypophysitis'], 'somatrem is a recombinant human growth hormone indicated for a treatment of paediatric patients with growth failure due to growth hormone deficiency ghd b treatment of paediatric patients with growth failure due to idiopathic short stature iss  c treatment of paediatric patients with growth failure due to turner syndrome ts d treatment of paediatric patients with growth failure due to chronic kidney disease ckd up to the time of renal transplantation e treatment of adults with childhoodonset ghd or f treatment of adults with adultonset ghd fda label')|
|('DB09098', 'MONDO:0019499', ['Bonnevie-Ullrich syndrome', 'Gonadal dysgenesis - Turner', 'Karyotype 45, X', 'Monosomy X', 'monosomy X syndrome', 'XO syndrome', 'turner syndrome'], 'somatrem is a recombinant human growth hormone indicated for a treatment of paediatric patients with growth failure due to growth hormone deficiency ghd b treatment of paediatric patients with growth failure due to idiopathic short stature iss  c treatment of paediatric patients with growth failure due to turner syndrome ts d treatment of paediatric patients with growth failure due to chronic kidney disease ckd up to the time of renal transplantation e treatment of adults with childhoodonset ghd or f treatment of adults with adultonset ghd fda label')|
|('DB09098', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'somatrem is a recombinant human growth hormone indicated for a treatment of paediatric patients with growth failure due to growth hormone deficiency ghd b treatment of paediatric patients with growth failure due to idiopathic short stature iss  c treatment of paediatric patients with growth failure due to turner syndrome ts d treatment of paediatric patients with growth failure due to chronic kidney disease ckd up to the time of renal transplantation e treatment of adults with childhoodonset ghd or f treatment of adults with adultonset ghd fda label')|
|('DB09099', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the symptomatic treatment of acute bleeding from esophageal varices other treatment options for longterm management of the condition may be considered if necessary once initial control has been established')|
|('DB09099', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'for the symptomatic treatment of acute bleeding from esophageal varices other treatment options for longterm management of the condition may be considered if necessary once initial control has been established')|
|('DB09099', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the symptomatic treatment of acute bleeding from esophageal varices other treatment options for longterm management of the condition may be considered if necessary once initial control has been established')|
|('DB09100', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'replacement or supplemental therapy in hypothyroidism tsh suppression in thyroid cancer nodules goiters and enlargement in chronic thyroiditis diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism')|
|('DB09100', 'MONDO:0005420', ['Thyroid deficiency', 'Thyroid insufficiency', 'hypothyroidism'], 'replacement or supplemental therapy in hypothyroidism tsh suppression in thyroid cancer nodules goiters and enlargement in chronic thyroiditis diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism')|
|('DB09100', 'MONDO:0002108', ['malignant neoplasm of thyroid gland', 'malignant tumour of thyroid gland', 'neoplasm of thyroid gland', 'Thyroid gland neoplasm', 'thyroid neoplasm', 'thyroid cancer'], 'replacement or supplemental therapy in hypothyroidism tsh suppression in thyroid cancer nodules goiters and enlargement in chronic thyroiditis diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism')|
|('DB09100', 'MONDO:0004126', ['thyroiditis'], 'replacement or supplemental therapy in hypothyroidism tsh suppression in thyroid cancer nodules goiters and enlargement in chronic thyroiditis diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism')|
|('DB09100', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'replacement or supplemental therapy in hypothyroidism tsh suppression in thyroid cancer nodules goiters and enlargement in chronic thyroiditis diagnostic agent to differentiate suspected hyperthyroidism from euthyroidism')|
|('DB09101', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'elvitegravir in combination with an hiv protease inhibitor coadministered with ritonavir and with other antiretroviral drugs is indicated for the treatment of hiv1 infection in antiretroviral treatmentexperienced adults')|
|('DB09102', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'indicated for use with sofosbuvir with or without ribavirin for the treatment of chronic hcv genotype 1ab or 3 infection the dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes resistance reduced susceptibility to daclatasvir was associated with the polymorphisms at ns5a amino acid positions m28 q30 l31 and y93 in genotypes 1a 1b and 3a patients ns5a resistance testing is recommended for hcv genotype 1ainfected patients with cirrhosis prior to the initiaition of the treatment as the risk of resistance development is higher in genotype 1a patients ')|
|('DB09102', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for use with sofosbuvir with or without ribavirin for the treatment of chronic hcv genotype 1ab or 3 infection the dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes resistance reduced susceptibility to daclatasvir was associated with the polymorphisms at ns5a amino acid positions m28 q30 l31 and y93 in genotypes 1a 1b and 3a patients ns5a resistance testing is recommended for hcv genotype 1ainfected patients with cirrhosis prior to the initiaition of the treatment as the risk of resistance development is higher in genotype 1a patients ')|
|('DB09103', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'ancestim in combination with filgrastim is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisationl1090 the use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment it is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy the harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapiesl1089')|
|('DB09103', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ancestim in combination with filgrastim is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisationl1090 the use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment it is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy the harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapiesl1089')|
|('DB09104', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'magnesium hydroxide can be used as an antacid or a laxative depending on the administered doseas an antacid it is used for the temporary relief of heartburn upset stomach sour stomach or acid indigestionas a laxative it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours')|
|('DB09105', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for the treatment of patients with perinatalinfantile and juvenile onset hypophosphatasia hpp ')|
|('DB09106', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'an intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma surgery or other issues')|
|('DB09106', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'an intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma surgery or other issues')|
|('DB09107', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the treatment of patients with anaemia associated with chronic kidney disease not a substitute for rbc transfusion if immediate correction of anemia is required')|
|('DB09107', 'MONDO:0002280', ['anaemia', 'anemia'], 'for the treatment of patients with anaemia associated with chronic kidney disease not a substitute for rbc transfusion if immediate correction of anemia is required')|
|('DB09107', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the treatment of patients with anaemia associated with chronic kidney disease not a substitute for rbc transfusion if immediate correction of anemia is required')|
|('DB09108', 'MONDO:0002280', ['anaemia', 'anemia'], 'indicated for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia a congenital factor viii deficiency fda label')|
|('DB09108', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'indicated for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia a congenital factor viii deficiency fda label')|
|('DB09109', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia al1105 the treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative managementl1106 hemophilia a is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor viii this disease is manifested as excessive spontaneous or traumadriven bleeding the coagulation factor viii is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the x chromosomea31505')|
|('DB09109', 'MONDO:0018660', ['hemophilia'], 'turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia al1105 the treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative managementl1106 hemophilia a is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor viii this disease is manifested as excessive spontaneous or traumadriven bleeding the coagulation factor viii is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the x chromosomea31505')|
|('DB09109', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia al1105 the treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative managementl1106 hemophilia a is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor viii this disease is manifested as excessive spontaneous or traumadriven bleeding the coagulation factor viii is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the x chromosomea31505')|
|('DB09109', 'MONDO:0021140', ['inborn []', 'congenital'], 'turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia al1105 the treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative managementl1106 hemophilia a is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor viii this disease is manifested as excessive spontaneous or traumadriven bleeding the coagulation factor viii is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the x chromosomea31505')|
|('DB09110', 'MONDO:0021140', ['inborn []', 'congenital'], 'mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitisa18572')|
|('DB09111', 'MONDO:0021140', ['inborn []', 'congenital'], 'the primary intended use of pentastarch is as a substitute for older colloids such as albumin or hetastarch for use in plasma volume expansion ')|
|('DB09112', 'MONDO:0021140', ['inborn []', 'congenital'], 'for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be lifethreatening fda label')|
|('DB09112', 'MONDO:0029000', ['poisoning'], 'for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be lifethreatening fda label')|
|('DB09113', 'MONDO:0029000', ['poisoning'], 'poractant alfa is indicated for the treatment of respiratory distress syndrome rds in premature infants')|
|('DB09114', 'MONDO:0029000', ['poisoning'], 'colfosceril palmitate is indicated for the treatment of respiratory distress syndrome rds in premature infants the official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing rds or in infants with birth weight greater than 1350 grams with pulmonary immaturity or as rescue treatment of infants that already developed rdsl1109 the central feature of rds is a surfactant deficiency due to lung immaturity this lung condition is more frequently presented due to risk factors like prematurity delayed lung maturation caused by maternal diabetes or male gender or surfactant dysfuntion due to perinatal asphyxia pulmonary infection or delivery without labort70')|
|('DB09114', 'MONDO:0002929', ['primary atelectasis of newborn', 'primary atelectasis, in perinatal period', 'pulmonary immaturity'], 'colfosceril palmitate is indicated for the treatment of respiratory distress syndrome rds in premature infants the official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing rds or in infants with birth weight greater than 1350 grams with pulmonary immaturity or as rescue treatment of infants that already developed rdsl1109 the central feature of rds is a surfactant deficiency due to lung immaturity this lung condition is more frequently presented due to risk factors like prematurity delayed lung maturation caused by maternal diabetes or male gender or surfactant dysfuntion due to perinatal asphyxia pulmonary infection or delivery without labort70')|
|('DB09115', 'MONDO:0002929', ['primary atelectasis of newborn', 'primary atelectasis, in perinatal period', 'pulmonary immaturity'], 'used in the treatment of amoebiasis')|
|('DB09115', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'used in the treatment of amoebiasis')|
|('DB09116', 'MONDO:0002929', ['primary atelectasis of newborn', 'primary atelectasis, in perinatal period', 'pulmonary immaturity'], 'calcium carbimide has not been approved by the fda but the intended indication is for the treatment of alcoholismt74 this medication was marketed in canada united kingdom and europe under the trade name of temposil for the sole use of alcoholism treatmentl1114')|
|('DB09116', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'calcium carbimide has not been approved by the fda but the intended indication is for the treatment of alcoholismt74 this medication was marketed in canada united kingdom and europe under the trade name of temposil for the sole use of alcoholism treatmentl1114')|
|('DB09116', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'calcium carbimide has not been approved by the fda but the intended indication is for the treatment of alcoholismt74 this medication was marketed in canada united kingdom and europe under the trade name of temposil for the sole use of alcoholism treatmentl1114')|
|('DB09117', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'paraldehyde was used historically as a sedative and hypnotic a19735 it has been used in the treatment of seizures as an anticonvulsant a19736')|
|('DB09117', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'paraldehyde was used historically as a sedative and hypnotic a19735 it has been used in the treatment of seizures as an anticonvulsant a19736')|
|('DB09118', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonicclonic seizures in patients with severe myoclonic epilepsy in infancy smei dravet’s syndrome whose seizures are not adequately controlled with clobazam and valproate')|
|('DB09118', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonicclonic seizures in patients with severe myoclonic epilepsy in infancy smei dravet’s syndrome whose seizures are not adequately controlled with clobazam and valproate')|
|('DB09119', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partialonset seizures that are not adequately controlled with conventional therapy in epileptic patients ')|
|('DB09120', 'MONDO:0005027', ['epilepsy syndrome', 'epileptic syndrome', 'epilepsy'], 'indicated to be used in conjunction with oral cox2 inhibitors or nsaids for the relief of severe pain in adult patients with osteoarthritis of the knee not controlled with oral cox2 inhibitors or nsaids alone for a duration of no more than three months ')|
|('DB09120', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'indicated to be used in conjunction with oral cox2 inhibitors or nsaids for the relief of severe pain in adult patients with osteoarthritis of the knee not controlled with oral cox2 inhibitors or nsaids alone for a duration of no more than three months ')|
|('DB09121', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'aurothioglucose is indicated for the adjunctive treatment of early active adult and juvenile type rheumatoid arthritis that is not adequately controlled by other antiinflammatory agents and conservative measures like salicylate glucocorticoids etc l1925 l1937 in chronic advanced cases of rheumatoid arthritis such gold therapy is not demonstrated to be as valuable l1937antirheumatic measures such as salicylate and other antiinflammatory drugs both steroidal and non steroidal may be continued after initiation of gold therapy l1937 after improvement commences these measures may be discontinued slowly as symptoms permit l1937')|
|('DB09121', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'aurothioglucose is indicated for the adjunctive treatment of early active adult and juvenile type rheumatoid arthritis that is not adequately controlled by other antiinflammatory agents and conservative measures like salicylate glucocorticoids etc l1925 l1937 in chronic advanced cases of rheumatoid arthritis such gold therapy is not demonstrated to be as valuable l1937antirheumatic measures such as salicylate and other antiinflammatory drugs both steroidal and non steroidal may be continued after initiation of gold therapy l1937 after improvement commences these measures may be discontinued slowly as symptoms permit l1937')|
|('DB09121', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'aurothioglucose is indicated for the adjunctive treatment of early active adult and juvenile type rheumatoid arthritis that is not adequately controlled by other antiinflammatory agents and conservative measures like salicylate glucocorticoids etc l1925 l1937 in chronic advanced cases of rheumatoid arthritis such gold therapy is not demonstrated to be as valuable l1937antirheumatic measures such as salicylate and other antiinflammatory drugs both steroidal and non steroidal may be continued after initiation of gold therapy l1937 after improvement commences these measures may be discontinued slowly as symptoms permit l1937')|
|('DB09122', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for the treatment of patients with relapsing forms of multiple sclerosis')|
|('DB09122', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for the treatment of patients with relapsing forms of multiple sclerosis')|
|('DB09123', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol ')|
|('DB09123', 'MONDO:0005133', ['endometriosis'], 'indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol ')|
|('DB09124', 'MONDO:0005133', ['endometriosis'], 'medrogestone is indicated as adjunct to treat endometial shedding in menopausal women to treat secondary amenorrhea to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent woment76')|
|('DB09125', 'MONDO:0005133', ['endometriosis'], 'for the management of renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis and uric acid lithiasis with or without calcium stones')|
|('DB09125', 'MONDO:0001909', ['renal tubular acidosis'], 'for the management of renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis and uric acid lithiasis with or without calcium stones')|
|('DB09125', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'for the management of renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis and uric acid lithiasis with or without calcium stones')|
|('DB09126', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'for the treatment of prepubertal cryptorchidism not due to anatomical obstruction for the treatment of selected cases of hypogonadotropic hypogonadism hypogonadism secondary to a pituitary deficiency in males and for the induction of ovulation and pregnancy in the anovulatory infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins')|
|('DB09126', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'for the treatment of prepubertal cryptorchidism not due to anatomical obstruction for the treatment of selected cases of hypogonadotropic hypogonadism hypogonadism secondary to a pituitary deficiency in males and for the induction of ovulation and pregnancy in the anovulatory infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins')|
|('DB09126', 'MONDO:0002775', ['anovulation'], 'for the treatment of prepubertal cryptorchidism not due to anatomical obstruction for the treatment of selected cases of hypogonadotropic hypogonadism hypogonadism secondary to a pituitary deficiency in males and for the induction of ovulation and pregnancy in the anovulatory infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins')|
|('DB09126', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'for the treatment of prepubertal cryptorchidism not due to anatomical obstruction for the treatment of selected cases of hypogonadotropic hypogonadism hypogonadism secondary to a pituitary deficiency in males and for the induction of ovulation and pregnancy in the anovulatory infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins')|
|('DB09128', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'as an adjunctive treatment of major depressive disorder mdd and for treatment of schizophrenia ')|
|('DB09128', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'as an adjunctive treatment of major depressive disorder mdd and for treatment of schizophrenia ')|
|('DB09128', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'as an adjunctive treatment of major depressive disorder mdd and for treatment of schizophrenia ')|
|('DB09129', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for use as a supplement to intravenous solutions given for total parenteral nutrition tpn')|
|('DB09130', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices fda label l801')|
|('DB09131', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for use as a supplement to intravenous solutions given for total parenteral nutrition tpn')|
|('DB09132', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'gadoteric acid is indicated for intravenous use with magnetic resonance imaging mri in brain intracranial spine and associated tissues in adult and pediatric patients 2 years of age and older to detect and visualize areas with disruption of the blood brain barrier bbb andor abnormal vascularity')|
|('DB09133', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'conray is indicated for use in excretory urography cerebral angiography peripheral arteriography venography arthrography direct cholangiography endoscopic retrograde cholangiopancreatography contrast enhancement of computed tomographic brain images cranial computerized angiotomography intravenous digital subtraction angiography and arterial digital subtraction angiographyconray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver pancreas kidneys abdominal aorta mediastinum abdominal cavity and retroperitoneal space')|
|('DB09134', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body intravenous excretory urography intravenous digital subtraction angiography and venography optiray 350 is indicated in children for angiocardiographyoptiray 320 is indicated in adults for angiography throughout the cardiovascular system the uses include cerebral coronary peripheral visceral and renal arteriography venography aortography and left ventriculography optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urographyoptiray 320 is indicated in children for angiocardiography contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urographyoptiray 300 is indicated for cerebral angiography and peripheral arteriography optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body venography and intravenous excretory urographyoptiray 240 is indicated for cerebral angiography and venography optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography')|
|('DB09135', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'when administered  intraarterially ioxilan is indicated for the following diagnostic tests cerebral arteriography 300 mgiml  coronary arteriography and left ventriculography 350 mgiml visceral angiography350 mgiml aortography350 mgiml and peripheral arteriography350 mgimlwhen administered intravenously ioxilan is indicated for excretory urography and contrast enhanced computed tomographic cect imaging of the head and body 300 and 350 mgiml')|
|('DB09136', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'isosulfan blue is a synthetic visual lymphatic imaging agent isosulfan blue upon subcutaneous administration delineates the lymphatic vessels draining the region of injection it is an adjunct to lymphography in primary and secondary lymphedema of the extremities chyluria chylous ascites or chylothorax lymph node involvement by primary or secondary neoplasm lymph node response to therapeutic modalities ')|
|('DB09136', 'MONDO:0008829', ['chylous ascites'], 'isosulfan blue is a synthetic visual lymphatic imaging agent isosulfan blue upon subcutaneous administration delineates the lymphatic vessels draining the region of injection it is an adjunct to lymphography in primary and secondary lymphedema of the extremities chyluria chylous ascites or chylothorax lymph node involvement by primary or secondary neoplasm lymph node response to therapeutic modalities ')|
|('DB09136', 'MONDO:0024882', ['secondary tumor [NCIT:C36255]', 'secondary neoplasm [NCIT:C36255]', 'secondary neoplasm'], 'isosulfan blue is a synthetic visual lymphatic imaging agent isosulfan blue upon subcutaneous administration delineates the lymphatic vessels draining the region of injection it is an adjunct to lymphography in primary and secondary lymphedema of the extremities chyluria chylous ascites or chylothorax lymph node involvement by primary or secondary neoplasm lymph node response to therapeutic modalities ')|
|('DB09137', 'MONDO:0024882', ['secondary tumor [NCIT:C36255]', 'secondary neoplasm [NCIT:C36255]', 'secondary neoplasm'], 'technetium tc 99m mebrofenin is indicated as a hepatobiliary imaging agent')|
|('DB09138', 'MONDO:0024882', ['secondary tumor [NCIT:C36255]', 'secondary neoplasm [NCIT:C36255]', 'secondary neoplasm'], 'technetium tc 99m medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis')|
|('DB09139', 'MONDO:0024882', ['secondary tumor [NCIT:C36255]', 'secondary neoplasm [NCIT:C36255]', 'secondary neoplasm'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0020771', ['SCAN [MONDO:cjm]', 'spinocerebellar ataxia, autosomal recessive, with axonal neuropathy'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0005246', ['osteomyelitis'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0005315', ['fracture [NCIT:C3046]', 'fracture of bone [NCIT:C3046]', 'fracture(s) [NCIT:C3046]', 'bone fracture'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0005298', ['osteoporosis'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09139', 'MONDO:0021137', ['common []', 'not rare'], 'technetium tc99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis when administered intravenously it is able to generate a clear image of the bones which allows the physician to diagnose any bone probleml1141 it is important to point out that this drug has to be manipulated only under the service of a nuclear specialistl1140 the approved indications for a bone scan are 1 visualization of tumor metastasis in bone 2 osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis and 7 prosthetic joint evaluation from all the major indications the detection of a metastatic disease is the most common because it presents a 95 of sensitivity and lesion detection can be done 6 months earlier than with xray studiesl1139')|
|('DB09140', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'oxygen therapy in clinical settings is used across diverse specialties including various types of anoxia hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses trauma poisonings and drug overdoses oxygen therapy tries to achieve hyperoxia l745 to reduce the extent of hypoxiainduced tissue damage and malfunction ')|
|('DB09140', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'oxygen therapy in clinical settings is used across diverse specialties including various types of anoxia hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses trauma poisonings and drug overdoses oxygen therapy tries to achieve hyperoxia l745 to reduce the extent of hypoxiainduced tissue damage and malfunction ')|
|('DB09141', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'protamine sulfate is indicated for counteracting or reversing the anticoagulant effect of heparin as necessary f3559 f3562 l5371 l5443 such reversal may for example be required often before surgery after renal hemodialysis post open heart surgery whenever excessive bleeding results from heparin use andor for the treatment of heparin overdosage among other similar or related circumstances f3559 f3562 l5371 l5443')|
|('DB09142', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'as the product kinevac fda sincalide is used for the following indications 1 to stimulate gallbladder contraction as may be assessed by various methods of diagnostic imaging or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol bile salts phospholipids and crystals 2 to stimulate pancreatic secretion especially in conjunction with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity composition and cytology 3 to accelerate the transit of a barium meal through the small bowel thereby decreasing the time and extent of radiation associated with fluoroscopy and xray examination of the intestinal tract')|
|('DB09143', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'sonidegib is approved for use in the us and eu for treatment of adults with locally advanced basal cell carcinoma bcc that has recurred post surgery or radiation therapy  it is also approved for adult patients with bcc who are not eligible for surgery or radiation therapy 2')|
|('DB09143', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sonidegib is approved for use in the us and eu for treatment of adults with locally advanced basal cell carcinoma bcc that has recurred post surgery or radiation therapy  it is also approved for adult patients with bcc who are not eligible for surgery or radiation therapy 2')|
|('DB09144', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'marketed as the product xuriden fda uridine triacetate is indicated for the treatment of hereditary orotic aciduriamarketed as the product vistogard fda uridine triacetate is indicated for the emergency treatment of adult and pediatric patients in the following situations following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or who exhibit earlyonset severe or lifethreatening toxicity affecting the cardiac or central nervous system andor earlyonset unusually severe adverse reactions eg gastrointestinal toxicity andor neutropenia within 96 hours following the end of fluorouracil or capecitabine administration ')|
|('DB09144', 'MONDO:0001475', ['neutropenia'], 'marketed as the product xuriden fda uridine triacetate is indicated for the treatment of hereditary orotic aciduriamarketed as the product vistogard fda uridine triacetate is indicated for the emergency treatment of adult and pediatric patients in the following situations following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or who exhibit earlyonset severe or lifethreatening toxicity affecting the cardiac or central nervous system andor earlyonset unusually severe adverse reactions eg gastrointestinal toxicity andor neutropenia within 96 hours following the end of fluorouracil or capecitabine administration ')|
|('DB09145', 'MONDO:0001475', ['neutropenia'], 'for diluting or dissolving drugs for intravenous intramuscular or subcutaneous injection according to instructions of the manufacturer of the drug to be administered fda label')|
|('DB09146', 'MONDO:0001475', ['neutropenia'], 'iron sucrose is elemental iron as an injection it replenishes body iron stores in patients with iron deficiency')|
|('DB09147', 'MONDO:0001475', ['neutropenia'], 'ferric pyrophosphate is intended to be indicated for the treatment of iron loss or iron deficiency as a formulation with a milder gastrointestinal effectl1423 l1433 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB09147', 'MONDO:0002875', ['ectoparasitism', 'parasitic ectoparasitic infectious disease'], 'ferric pyrophosphate is intended to be indicated for the treatment of iron loss or iron deficiency as a formulation with a milder gastrointestinal effectl1423 l1433 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB09147', 'MONDO:0002049', ['thrombocytopenia'], 'ferric pyrophosphate is intended to be indicated for the treatment of iron loss or iron deficiency as a formulation with a milder gastrointestinal effectl1423 l1433 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB09148', 'MONDO:0002049', ['thrombocytopenia'], 'florbetaben is a radioactive diagnostic agent indicated for positron emission tomography pet imaging of the brain to estimate βamyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for alzheimer’s disease ad and other causes of cognitive decline')|
|('DB09149', 'MONDO:0002049', ['thrombocytopenia'], 'florbetapir 18f is indicated for positron emission tomography pet imaging of the brain to estimate βamyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for alzheimers disease ad and other causes of cognitive decline')|
|('DB09151', 'MONDO:0002049', ['thrombocytopenia'], 'flutemetamol f18 is indicated for positron emission tomography pet imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for alzheimers disease ad or other causes of cognitive decline ')|
|('DB09152', 'MONDO:0002049', ['thrombocytopenia'], 'liquid nitrogen is used mainly as a cryogenic agent for the treatment of various benign and malignant skin lesions ')|
|('DB09153', 'MONDO:0002049', ['thrombocytopenia'], 'this intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration also designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives ')|
|('DB09154', 'MONDO:0002049', ['thrombocytopenia'], 'used as an anticoagulant during plasmophoresis as well as a neutralizing agent in the treatment of upset stomach and acidic urine fda label l788 l789')|
|('DB09155', 'MONDO:0002049', ['thrombocytopenia'], 'for use in patients who are not getting enough oxygen into their blood due to blockages in the lungs from pathological conditions or injuries suggested potential benefit in upper airway obstruction in severe asthma and in exacerbations of copdcold helium may be used in place of carbon monoxide during laparoscopic surgeries as it lowers the risk of developing respiratory acidosis in selected patients ')|
|('DB09155', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for use in patients who are not getting enough oxygen into their blood due to blockages in the lungs from pathological conditions or injuries suggested potential benefit in upper airway obstruction in severe asthma and in exacerbations of copdcold helium may be used in place of carbon monoxide during laparoscopic surgeries as it lowers the risk of developing respiratory acidosis in selected patients ')|
|('DB09156', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'iopromide as the product iovist is indicated for use as an xray contrast agent in the following proceduresintraarterial digital subtraction angiography iadsa 150 mg iml cerebral arteriography and peripheral arteriography 300 mg iml coronary arteriography and left ventriculography visceral angiography and aortography 370 mg iml peripheral venography 240 mg iml excretory urography 300 mg imlcontrast computed tomography ct imaging of head and body 300 mg iml and 370 mg iml ')|
|('DB09157', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'carbon dioxide is commonly used as an insufflation gas for minimal invasive surgery laparoscopy endoscopy and arthroscopy to enlarge and stabilize body cavities to provide better visibility of the surgical area it has been used also in cryotherapy and as respiratory stimulant before and after anesthesia  it could be used also in expansion of blood vessels if required to increase carbon dioxide level after rapid breathing and to stimulate breathing after a period of nonbreathing ')|
|('DB09157', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'carbon dioxide is commonly used as an insufflation gas for minimal invasive surgery laparoscopy endoscopy and arthroscopy to enlarge and stabilize body cavities to provide better visibility of the surgical area it has been used also in cryotherapy and as respiratory stimulant before and after anesthesia  it could be used also in expansion of blood vessels if required to increase carbon dioxide level after rapid breathing and to stimulate breathing after a period of nonbreathing ')|
|('DB09158', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'trypan blue is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures facilitating removal of the tissue ')|
|('DB09160', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'technetium99m tetrofosmin is indicated for the diagnosis of heart abnormalities by exercise myocardial scintigraphy the exercise myocardial scintigraphy is an established method for the diagnosis of the severity of coronary artery diseasea31592 this method allows distinguishing regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium following rest and stress conditionsl1147 the use of technetium99m tetrofosmin is mainly used to assess myocardial perfusion in ischemia and infarctionl1146')|
|('DB09161', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'technetium tc 99m sestamibi is indicated for 1 detecting coronary artery disease by localizing myocardial ischemia reversible defects and infarction nonreversible defects and 2 evaluating myocardial function and developing information for use in patient management decisions')|
|('DB09161', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'technetium tc 99m sestamibi is indicated for 1 detecting coronary artery disease by localizing myocardial ischemia reversible defects and infarction nonreversible defects and 2 evaluating myocardial function and developing information for use in patient management decisions')|
|('DB09161', 'MONDO:0024644', ['IHD [NCIT:C50625]', 'myocardium ischemic disease [MONDO:design_pattern,MONDO:patterns/location]', 'ischemic disease of myocardium [MONDO:design_pattern]', 'ischemic heart disease [MESH:D017202]', 'myocardial ischemia'], 'technetium tc 99m sestamibi is indicated for 1 detecting coronary artery disease by localizing myocardial ischemia reversible defects and infarction nonreversible defects and 2 evaluating myocardial function and developing information for use in patient management decisions')|
|('DB09163', 'MONDO:0024644', ['IHD [NCIT:C50625]', 'myocardium ischemic disease [MONDO:design_pattern,MONDO:patterns/location]', 'ischemic disease of myocardium [MONDO:design_pattern]', 'ischemic heart disease [MESH:D017202]', 'myocardial ischemia'], 'technetium tc99m exametazime scintigraphy with or without methylene blue stabilization may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease')|
|('DB09163', 'MONDO:0005265', ['inflammatory bowel disease'], 'technetium tc99m exametazime scintigraphy with or without methylene blue stabilization may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease')|
|('DB09164', 'MONDO:0024644', ['IHD [NCIT:C50625]', 'myocardium ischemic disease [MONDO:design_pattern,MONDO:patterns/location]', 'ischemic disease of myocardium [MONDO:design_pattern]', 'ischemic heart disease [MESH:D017202]', 'myocardial ischemia'], 'technetium tc99m disofenin is indicated as a hepatobiliary imaging agent hepatolite is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain fever jaundice right upper quadrant tenderness and mass or rebound tenderness but not limited to these signs and symptoms')|
|('DB09164', 'MONDO:0043994', ['acute cholecystitis [MESH:D041881,NCIT:C35152]', 'acute cholecystitis'], 'technetium tc99m disofenin is indicated as a hepatobiliary imaging agent hepatolite is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain fever jaundice right upper quadrant tenderness and mass or rebound tenderness but not limited to these signs and symptoms')|
|('DB09165', 'MONDO:0043994', ['acute cholecystitis [MESH:D041881,NCIT:C35152]', 'acute cholecystitis'], 'for use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction fda label may also be used to image gated blood pools and detect gastrointetinal bleeding')|
|('DB09165', 'MONDO:0004781', ['acute myocardial infarction'], 'for use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction fda label may also be used to image gated blood pools and detect gastrointetinal bleeding')|
|('DB09166', 'MONDO:0004781', ['acute myocardial infarction'], 'indicated for the treatment of generalized anxiety disorder with depression panic disorder and insomnia')|
|('DB09166', 'MONDO:0001942', ['generalized anxiety disorder'], 'indicated for the treatment of generalized anxiety disorder with depression panic disorder and insomnia')|
|('DB09166', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'indicated for the treatment of generalized anxiety disorder with depression panic disorder and insomnia')|
|('DB09166', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'indicated for the treatment of generalized anxiety disorder with depression panic disorder and insomnia')|
|('DB09167', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'indicated in the treatment of symptoms of depressive illness especially where an antianxiety effect is required')|
|('DB09173', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'butyrfentanyl was investigated as a potential opioid analgesic but is no longer used for this purposea182060 it is more often being used as a recreational druga182060')|
|('DB09183', 'MONDO:0005383', ['panic anxiety syndrome', 'panic disorder'], 'dasabuvir in combination with db09296 db09297 and db00503 as viekira pak is indicated for the treatment of patients with hcv genotype 1a with db00811 or genotype 1b without db00811 including those with compensated cirrhosis fda label')|
|('DB09183', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'dasabuvir in combination with db09296 db09297 and db00503 as viekira pak is indicated for the treatment of patients with hcv genotype 1a with db00811 or genotype 1b without db00811 including those with compensated cirrhosis fda label')|
|('DB09185', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of clinical depression')|
|('DB09185', 'MONDO:0012048', ['clinical depression', 'unipolar depression', 'endogenous depression'], 'indicated for the treatment of clinical depression')|
|('DB09194', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'etoperidone has been studied for the treatment of depressiont47 tremors in parkinson extrapyramidal symptomsl1041 and male impotencel1042 it is not certain if it was ever approved and marketed but its current status is withdrawn')|
|('DB09195', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'in 2016 lorpiprazole was classified in the chemical structurerelated druglike criteria of global approved drugs as an antipsychotic and anxiolyticl1167 an antipsychotic is a medication used to treat a state of delusion hallucination paranoia or disordered thought on the other hand an anxiolytic is a medication used for the treatment of severe chronic or debilitating anxiety the anxiety state can be defined as an unpleasant state of tension apprehension or uneasinesst77')|
|('DB09195', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'in 2016 lorpiprazole was classified in the chemical structurerelated druglike criteria of global approved drugs as an antipsychotic and anxiolyticl1167 an antipsychotic is a medication used to treat a state of delusion hallucination paranoia or disordered thought on the other hand an anxiolytic is a medication used for the treatment of severe chronic or debilitating anxiety the anxiety state can be defined as an unpleasant state of tension apprehension or uneasinesst77')|
|('DB09195', 'MONDO:0005618', ['anxiety', 'anxiety state', 'anxiety disorder'], 'in 2016 lorpiprazole was classified in the chemical structurerelated druglike criteria of global approved drugs as an antipsychotic and anxiolyticl1167 an antipsychotic is a medication used to treat a state of delusion hallucination paranoia or disordered thought on the other hand an anxiolytic is a medication used for the treatment of severe chronic or debilitating anxiety the anxiety state can be defined as an unpleasant state of tension apprehension or uneasinesst77')|
|('DB09195', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'in 2016 lorpiprazole was classified in the chemical structurerelated druglike criteria of global approved drugs as an antipsychotic and anxiolyticl1167 an antipsychotic is a medication used to treat a state of delusion hallucination paranoia or disordered thought on the other hand an anxiolytic is a medication used for the treatment of severe chronic or debilitating anxiety the anxiety state can be defined as an unpleasant state of tension apprehension or uneasinesst77')|
|('DB09197', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of anxiety neuroses')|
|('DB09197', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for the treatment of anxiety neuroses')|
|('DB09198', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'lobeglitazone was approved by the ministry of food and drug safety south korea in 2013 and is being monitored by postmarketing surveillance until 2019 lobeglitazone is not approved for use by either the food and drug administration usa health canada or by the european medicines agency for use in the management of diabetes')|
|('DB09204', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'artinolol was introduced to be used as an antihypertensive agent since 1986t88 it has been studied for other functions like tremor control for patients with parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart ratel1168')|
|('DB09204', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'artinolol was introduced to be used as an antihypertensive agent since 1986t88 it has been studied for other functions like tremor control for patients with parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart ratel1168')|
|('DB09204', 'MONDO:0005180', ['paralysis agitans', 'Parkinson disease', 'parkinson disease'], 'artinolol was introduced to be used as an antihypertensive agent since 1986t88 it has been studied for other functions like tremor control for patients with parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart ratel1168')|
|('DB09205', 'MONDO:0005180', ['paralysis agitans', 'Parkinson disease', 'parkinson disease'], 'by the who moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhaget91 the cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolusa31644 on the other hand the fda classified moxisylyte for the reversal of phenylephrineinduced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angleclosure glaucomal1172  closedangle glaucoma is caused by the contact between the iris and the trabecular meshwork this contact will damage the aqueous outflow by the meshwork thus increasing eye pressure and producing the symptoms of glaucomaa31645 mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closedangle glaucomathis risk is explained by the generation of a pupillary block which is the contact between the pupillary margins and the lens thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradientl1173 moxisylyte is also approved in france as the first drug for the treatment of impotencea31647')|
|('DB09205', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'by the who moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhaget91 the cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolusa31644 on the other hand the fda classified moxisylyte for the reversal of phenylephrineinduced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angleclosure glaucomal1172  closedangle glaucoma is caused by the contact between the iris and the trabecular meshwork this contact will damage the aqueous outflow by the meshwork thus increasing eye pressure and producing the symptoms of glaucomaa31645 mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closedangle glaucomathis risk is explained by the generation of a pupillary block which is the contact between the pupillary margins and the lens thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradientl1173 moxisylyte is also approved in france as the first drug for the treatment of impotencea31647')|
|('DB09205', 'MONDO:0005041', ['glaucoma'], 'by the who moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhaget91 the cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolusa31644 on the other hand the fda classified moxisylyte for the reversal of phenylephrineinduced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angleclosure glaucomal1172  closedangle glaucoma is caused by the contact between the iris and the trabecular meshwork this contact will damage the aqueous outflow by the meshwork thus increasing eye pressure and producing the symptoms of glaucomaa31645 mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closedangle glaucomathis risk is explained by the generation of a pupillary block which is the contact between the pupillary margins and the lens thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradientl1173 moxisylyte is also approved in france as the first drug for the treatment of impotencea31647')|
|('DB09208', 'MONDO:0005041', ['glaucoma'], 'for the treatment of chronic gout in adult patients refractory to conventional therapy')|
|('DB09209', 'MONDO:0005041', ['glaucoma'], 'pholcodine is indicated as a cough suppressant for the temporary relief of nonproductive dry cough it is stated to present a required label indication of temporary relief of dry coughl1200 cough is the respiratory movement that occurs after an irritation signal is transmitted to the central nervous system and further stimulates the medulla oblongata this stimulation causes a motor output that is sent through motoneurons to the respiratory muscles a nonproductive cough is a type of cough characterized by the absence of sputum and it has a large inspiration that will cause continuous coughing')|
|('DB09209', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'pholcodine is indicated as a cough suppressant for the temporary relief of nonproductive dry cough it is stated to present a required label indication of temporary relief of dry coughl1200 cough is the respiratory movement that occurs after an irritation signal is transmitted to the central nervous system and further stimulates the medulla oblongata this stimulation causes a motor output that is sent through motoneurons to the respiratory muscles a nonproductive cough is a type of cough characterized by the absence of sputum and it has a large inspiration that will cause continuous coughing')|
|('DB09210', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated in adult patients suffering from myoclonus of cortical origin irrespective of aetiology and should be used in combination with other antimyoclonic therapies l1125')|
|('DB09211', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'limaprost is used for the improvement of various ischemic symptoms such as ulcer pain and feeling of coldness associated with thromboangiitis obliterans as well as improvement of subjective symptoms pain and numbness of lower legs and gait ability associated with acquired lumbar spinal canal stenosis in patients with bilateral intermittent claudication showing normal slr test result')|
|('DB09211', 'MONDO:0008889', ['Buergers disease', 'Presenile gangrene', 'Thromboangiitis obliterans', 'thromboangiitis obliterans'], 'limaprost is used for the improvement of various ischemic symptoms such as ulcer pain and feeling of coldness associated with thromboangiitis obliterans as well as improvement of subjective symptoms pain and numbness of lower legs and gait ability associated with acquired lumbar spinal canal stenosis in patients with bilateral intermittent claudication showing normal slr test result')|
|('DB09211', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'limaprost is used for the improvement of various ischemic symptoms such as ulcer pain and feeling of coldness associated with thromboangiitis obliterans as well as improvement of subjective symptoms pain and numbness of lower legs and gait ability associated with acquired lumbar spinal canal stenosis in patients with bilateral intermittent claudication showing normal slr test result')|
|('DB09212', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'loxoprofen is nonsteroidal antiinflammatory medication nsaid indicated for pain and inflammation related to musculoskeletal and joint disordersl1226 in addition to its effects on pain it is an antipyretic and antiinflammatory medicationl1227')|
|('DB09213', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'for more information refer to ibuprofen')|
|('DB09214', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'for shortterm treatment of mild to moderate pain including dysmenorrhoea musculoskeletal pain and toothache l1302 ')|
|('DB09215', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'droxicam is an nsaid previously used for the treatment of inflammation and rheumatoid arthritis l1119')|
|('DB09215', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'droxicam is an nsaid previously used for the treatment of inflammation and rheumatoid arthritis l1119')|
|('DB09216', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'in the information for tolfenamic acid it is stated that this drug being an nsaid is effective in treating the pain associated with the acute attack of migraines in adultsl1293')|
|('DB09217', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'used for the treatment of pain inflammation and fever in horses and dogs')|
|('DB09218', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'indicated for use in the management of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation')|
|('DB09219', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'for use in the treatment of constipation in the absence of bowel obstruction and for surgical preparation of the colon l926')|
|('DB09220', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes ')|
|('DB09221', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'peptic ulcer disease dyspepsia l1308')|
|('DB09221', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'peptic ulcer disease dyspepsia l1308')|
|('DB09222', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency including afibrinogenemia and hypofibrinogenemia')|
|('DB09222', 'MONDO:0021140', ['inborn []', 'congenital'], 'for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency including afibrinogenemia and hypofibrinogenemia')|
|('DB09223', 'MONDO:0021140', ['inborn []', 'congenital'], 'used for the treatment of schizophrenia l1097')|
|('DB09223', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'used for the treatment of schizophrenia l1097')|
|('DB09224', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of schizophrenia sleep disorders agitation and mentally confused states l1317 l1319 l1322  ')|
|('DB09225', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'zotepine like other atypical antipsychotics is considered as the firstline treatment in newly diagnosed schizophrenia it is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible zotepine as an atypical antipsychotic is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlledt108 it is important to consider that the indications stated above are related to atypical antipsychotics that zotepine is not currently fda canada or ema approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychoticsa31857schizophrenia is a chronic and severe mental disorder that affects how a person thinks feels and behaves it is usually marked for a loose reality perspective delineated by hallucinations delusions and thought and movement disordersl1320')|
|('DB09226', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'investigated for the treatment of schizophrenia and schizoaffective disorder')|
|('DB09226', 'MONDO:0005487', ['schizoaffective disorder'], 'investigated for the treatment of schizophrenia and schizoaffective disorder')|
|('DB09227', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'indicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina')|
|('DB09228', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of acute attacks of hereditary angioedema hae due to c1 esterase inhibitor deficiency in adults')|
|('DB09228', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'for the treatment of acute attacks of hereditary angioedema hae due to c1 esterase inhibitor deficiency in adults')|
|('DB09229', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'aranidipine has been used for many years to treat angina pectoris and hypertensiona31895')|
|('DB09230', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for the treatment of hypertension')|
|('DB09231', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'benidipine is a potent and longlasting drug indicated for the treatment of cardiovascular diseases such as hypertension renoparenchymal hypertension and angina pectorisa31950')|
|('DB09232', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'cilnidipine is indicated for the management of hypertension for endorgan protectionl1436 it is reported to be useful in elderly patients and in those with diabetes and albuminuria cilnidipine has been increasingly used in patients with chronic kidney disease hypertension is the term used to describe the presence of high blood pressure the blood pressure is generated by the force of the blood pumped from the heart against the blood vessels thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessell1438')|
|('DB09232', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'cilnidipine is indicated for the management of hypertension for endorgan protectionl1436 it is reported to be useful in elderly patients and in those with diabetes and albuminuria cilnidipine has been increasingly used in patients with chronic kidney disease hypertension is the term used to describe the presence of high blood pressure the blood pressure is generated by the force of the blood pumped from the heart against the blood vessels thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessell1438')|
|('DB09232', 'MONDO:0005044', ['High blood pressure', 'HTN', 'hyperpiesia', 'vascular hypertensive disorder', 'hypertensive disorder'], 'cilnidipine is indicated for the management of hypertension for endorgan protectionl1436 it is reported to be useful in elderly patients and in those with diabetes and albuminuria cilnidipine has been increasingly used in patients with chronic kidney disease hypertension is the term used to describe the presence of high blood pressure the blood pressure is generated by the force of the blood pumped from the heart against the blood vessels thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessell1438')|
|('DB09232', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'cilnidipine is indicated for the management of hypertension for endorgan protectionl1436 it is reported to be useful in elderly patients and in those with diabetes and albuminuria cilnidipine has been increasingly used in patients with chronic kidney disease hypertension is the term used to describe the presence of high blood pressure the blood pressure is generated by the force of the blood pumped from the heart against the blood vessels thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessell1438')|
|('DB09235', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of hypertension')|
|('DB09236', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents including βadrenoceptor antagonists diuretics and aceinhibitors l1126')|
|('DB09237', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'levamlodipine is indicated alone or in combination to treat hypertension in adults and childrenl10833')|
|('DB09238', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the treatment of hypertension')|
|('DB09241', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia other clinical applications of methylene blue include improvement of hypotension associated with various clinical states an antiseptic in urinary tract infections treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome and treatment of ifofosamide induced neurotoxicity')|
|('DB09241', 'MONDO:0018740', ['acquired methemoglobinemia [MONDO:patterns/acquired,Orphanet:464453]', 'drug induced methemoglobinemia [NCIT:C101045]', 'drug-induced methemoglobinemia'], 'indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia other clinical applications of methylene blue include improvement of hypotension associated with various clinical states an antiseptic in urinary tract infections treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome and treatment of ifofosamide induced neurotoxicity')|
|('DB09241', 'MONDO:0005468', ['hypotension (disease) [https://github.com/monarch-initiative/mondo/issues/1030]', 'hypotension [MONDO:ambiguous]', 'hypotensive disorder'], 'indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia other clinical applications of methylene blue include improvement of hypotension associated with various clinical states an antiseptic in urinary tract infections treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome and treatment of ifofosamide induced neurotoxicity')|
|('DB09241', 'MONDO:0004694', ['Hepatopulmonary syndrome', 'hepatopulmonary syndrome'], 'indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia other clinical applications of methylene blue include improvement of hypotension associated with various clinical states an antiseptic in urinary tract infections treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome and treatment of ifofosamide induced neurotoxicity')|
|('DB09242', 'MONDO:0004694', ['Hepatopulmonary syndrome', 'hepatopulmonary syndrome'], 'for the treatment of mild to moderate essential or primary hypertension l1025 effective as most firstline antihypertensives when used as monotherapy a27137')|
|('DB09242', 'MONDO:0001134', ['idiopathic hypertension', 'primary hypertension', 'essential hypertension'], 'for the treatment of mild to moderate essential or primary hypertension l1025 effective as most firstline antihypertensives when used as monotherapy a27137')|
|('DB09243', 'MONDO:0001134', ['idiopathic hypertension', 'primary hypertension', 'essential hypertension'], 'was used for the treatment of hypertension a19790')|
|('DB09244', 'MONDO:0001134', ['idiopathic hypertension', 'primary hypertension', 'essential hypertension'], 'for the treatment of major depressionit is being studied in the treatment of fibromyalgia pain syndrome one study determined that the effect of pirlindole on sensorimotor performance while driving a motor vehicle shows many similarities to that of placebo the drug appears to stimulate the central nervous system rather than exhibit a sedative effect like many antidepressants  because of its selective reversible inhibition of monoamine oxidase maoa and short halflife unpleasant cheese effects are avoided this refers to the effects of consuming tyraminerich foods such as cheese while medicated with monoamine oxidase inhibitors leading to severe headaches and hypertension l1395  of the available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome l1394 ')|
|('DB09244', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of major depressionit is being studied in the treatment of fibromyalgia pain syndrome one study determined that the effect of pirlindole on sensorimotor performance while driving a motor vehicle shows many similarities to that of placebo the drug appears to stimulate the central nervous system rather than exhibit a sedative effect like many antidepressants  because of its selective reversible inhibition of monoamine oxidase maoa and short halflife unpleasant cheese effects are avoided this refers to the effects of consuming tyraminerich foods such as cheese while medicated with monoamine oxidase inhibitors leading to severe headaches and hypertension l1395  of the available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome l1394 ')|
|('DB09245', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of major depressive disorder ')|
|('DB09245', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'for the treatment of major depressive disorder ')|
|('DB09246', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of depression')|
|('DB09247', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of depression')|
|('DB09248', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of depression')|
|('DB09249', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of depression')|
|('DB09250', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of depression schizophrenia and angina pectoris')|
|('DB09250', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of depression schizophrenia and angina pectoris')|
|('DB09251', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of depression')|
|('DB09252', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of depression')|
|('DB09253', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of depression')|
|('DB09254', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'for the treatment of depression')|
|('DB09255', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration it is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15 of the blood mass if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection dextran is also used for the prevention of profound postoperative venous thrombosisl1455dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritationsl1461')|
|('DB09255', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration it is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15 of the blood mass if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection dextran is also used for the prevention of profound postoperative venous thrombosisl1455dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritationsl1461')|
|('DB09255', 'MONDO:0000948', ['Conjunctival xerosis', 'xerophthalmia'], 'dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration it is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15 of the blood mass if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection dextran is also used for the prevention of profound postoperative venous thrombosisl1455dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritationsl1461')|
|('DB09256', 'MONDO:0000948', ['Conjunctival xerosis', 'xerophthalmia'], 'indicated for the treatment of cancer usually in combination with other biochemically modulating drugsindicated in adults for the treatment of advanced gastric cancer when given in combination with db00515 l933 indicated for the firstline treatment of metastatic colorectal cancer with db03419 and calcium folinate l934 ')|
|('DB09256', 'MONDO:0004992', ['cancer'], 'indicated for the treatment of cancer usually in combination with other biochemically modulating drugsindicated in adults for the treatment of advanced gastric cancer when given in combination with db00515 l933 indicated for the firstline treatment of metastatic colorectal cancer with db03419 and calcium folinate l934 ')|
|('DB09257', 'MONDO:0004992', ['cancer'], 'gimeracil is used as an adjunct to antineoplastic therapy when used within the product teysuno gimeracil is indicated for the treatment of adults with advanced gastric stomach cancer when given in combination with cisplatin')|
|('DB09258', 'MONDO:0004992', ['cancer'], 'bemiparin is indicated in the following cases to prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism in the prevention of the thromboembolic disease in nonsurgical patients prevention of clotting in the extracorporeal circuit during hemodialysis to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism secondary prevention of venous thromboembolism recurrence in patients with deep vein thrombosis transient prevention and treatment of deep vein thrombosis dvt l1463')|
|('DB09258', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'bemiparin is indicated in the following cases to prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism in the prevention of the thromboembolic disease in nonsurgical patients prevention of clotting in the extracorporeal circuit during hemodialysis to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism secondary prevention of venous thromboembolism recurrence in patients with deep vein thrombosis transient prevention and treatment of deep vein thrombosis dvt l1463')|
|('DB09259', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'by the fda reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients it is also indicated for the longterm treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patientsl1469')|
|('DB09259', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'by the fda reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients it is also indicated for the longterm treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patientsl1469')|
|('DB09260', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09260', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09260', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09261', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09261', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09261', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'used in the prevention and treatment of venous thromboembolism deep vein thrombosis and pulmonary embolism and in the treatment of myocardial infarction')|
|('DB09262', 'MONDO:0005279', ['pulmonary artery embolism', 'pulmonary embolus', 'pulmonary embolism'], 'used in the treatment of overactive bladder fda label')|
|('DB09262', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'used in the treatment of overactive bladder fda label')|
|('DB09263', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for the treatment of hyperkalemia')|
|('DB09264', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for use in patients treated with dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgeryurgent procedures and in lifethreatening or uncontrolled bleeding')|
|('DB09265', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'for use as an antihyperglycemic agent in the treatment of t2dm fda label')|
|('DB09266', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management fda labelindicated with or without scintigraphic imaging for guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity breast cancer or melanoma fda label ')|
|('DB09266', 'MONDO:0004992', ['cancer'], 'indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management fda labelindicated with or without scintigraphic imaging for guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity breast cancer or melanoma fda label ')|
|('DB09266', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management fda labelindicated with or without scintigraphic imaging for guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity breast cancer or melanoma fda label ')|
|('DB09267', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'strontium ranelate is therapeutically indicated for the treatment of severe osteoperosis in a postmenopasual women and b adult men who are at high risk of fractures for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to for example contraindications or intolerance l1127in postmenopausal women strontium ranelate can also reduce the risk of vertebral and hip fractures l1127')|
|('DB09267', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'strontium ranelate is therapeutically indicated for the treatment of severe osteoperosis in a postmenopasual women and b adult men who are at high risk of fractures for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to for example contraindications or intolerance l1127in postmenopausal women strontium ranelate can also reduce the risk of vertebral and hip fractures l1127')|
|('DB09267', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'strontium ranelate is therapeutically indicated for the treatment of severe osteoperosis in a postmenopasual women and b adult men who are at high risk of fractures for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to for example contraindications or intolerance l1127in postmenopausal women strontium ranelate can also reduce the risk of vertebral and hip fractures l1127')|
|('DB09268', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for cleansing of the colon as a preparation for colonoscopy in adults fda label')|
|('DB09269', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle')|
|('DB09269', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for use as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle')|
|('DB09270', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'the diet supplements containing ubidecarenone are indicated as stated in the product label to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension in the product ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like parkinson fibromyalgia migraine periodontal disease and diabetes based on preclinical studiesl1064 it is important to highlight that these products are not fda approved and it is recommended to use under discretion')|
|('DB09270', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'the diet supplements containing ubidecarenone are indicated as stated in the product label to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension in the product ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like parkinson fibromyalgia migraine periodontal disease and diabetes based on preclinical studiesl1064 it is important to highlight that these products are not fda approved and it is recommended to use under discretion')|
|('DB09272', 'MONDO:0005009', ['Cardiac Failure Congestive', 'CHF', 'Congestive heart disease', 'Weak heart', 'congestive heart failure'], 'for the treatment of irritable bowel syndrome with diarrhea ibsd')|
|('DB09272', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of irritable bowel syndrome with diarrhea ibsd')|
|('DB09273', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'indicated for the treatment of chronic obstructive pulmonary disease copd bronchial asthma and pulmonary disease with spastic bronchial component')|
|('DB09273', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated for the treatment of chronic obstructive pulmonary disease copd bronchial asthma and pulmonary disease with spastic bronchial component')|
|('DB09274', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of severe malaria caused by plasmodium falciparum in adults and children l891')|
|('DB09275', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for the treatment of peptic ulcer and gastrooesophageal reflux disease gordtreatment of inflammatory and erosiveulcerous diseases of gastric and duodenal mucosa  gastritis ulcer disease of the stomach and duodenum functional nonulcerous dyspepsia erosive duodenitis postoperative inflammatory and erosive changes – anastomositis peptic ulcer of anastomosis')|
|('DB09275', 'MONDO:0004966', ['acute gastric mucosal erosion', 'Erosive Gastritis', 'Erosive gastropathy', 'gastritis'], 'for the treatment of peptic ulcer and gastrooesophageal reflux disease gordtreatment of inflammatory and erosiveulcerous diseases of gastric and duodenal mucosa  gastritis ulcer disease of the stomach and duodenum functional nonulcerous dyspepsia erosive duodenitis postoperative inflammatory and erosive changes – anastomositis peptic ulcer of anastomosis')|
|('DB09275', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for the treatment of peptic ulcer and gastrooesophageal reflux disease gordtreatment of inflammatory and erosiveulcerous diseases of gastric and duodenal mucosa  gastritis ulcer disease of the stomach and duodenum functional nonulcerous dyspepsia erosive duodenitis postoperative inflammatory and erosive changes – anastomositis peptic ulcer of anastomosis')|
|('DB09275', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'for the treatment of peptic ulcer and gastrooesophageal reflux disease gordtreatment of inflammatory and erosiveulcerous diseases of gastric and duodenal mucosa  gastritis ulcer disease of the stomach and duodenum functional nonulcerous dyspepsia erosive duodenitis postoperative inflammatory and erosive changes – anastomositis peptic ulcer of anastomosis')|
|('DB09276', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'a diseasemodifying antirheumatic drug dmard indicated for the symptomatic treatment of arthritis ')|
|('DB09276', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'a diseasemodifying antirheumatic drug dmard indicated for the symptomatic treatment of arthritis ')|
|('DB09277', 'MONDO:0004627', ['Hemorrhagic duodenitis', 'duodenitis'], 'choline c11 is indicated for its use in positron emission tomography pet imaging in patients with suspected prostate cancer recurrence and noninformative bone scintigraphy computerized tomography or magnetic resonance imagingfda label a32037')|
|('DB09277', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'choline c11 is indicated for its use in positron emission tomography pet imaging in patients with suspected prostate cancer recurrence and noninformative bone scintigraphy computerized tomography or magnetic resonance imagingfda label a32037')|
|('DB09278', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used as a antidote to treat poisonings following excessive oral ingestion of certain medications or poisons ')|
|('DB09279', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used for the treatment of hypertension and heart failure a20319')|
|('DB09279', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'used for the treatment of hypertension and heart failure a20319')|
|('DB09280', 'MONDO:0005252', ['cardiac failure [NCIT:C50577]', 'cardiac insufficiency [NCIT:C50577]', 'heart failure [https://en.wikipedia.org/wiki/Heart_failure]', 'failure, heart [NCIT:C50577]', 'insufficiency, Cardiac [NCIT:C50577]', 'heart failure'], 'when given in combination with db08820 as the fixed dose combination product orkambi lumacaftor is indicated for the treatment of cystic fibrosis cf in patients age 6 years and older who are homozygous for the f508del mutation in the cftr gene fda label')|
|('DB09280', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'when given in combination with db08820 as the fixed dose combination product orkambi lumacaftor is indicated for the treatment of cystic fibrosis cf in patients age 6 years and older who are homozygous for the f508del mutation in the cftr gene fda label')|
|('DB09281', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'for the treatment of peptic ulcersrelieving indigestion and heartburn')|
|('DB09281', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'for the treatment of peptic ulcersrelieving indigestion and heartburn')|
|('DB09282', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'the indications for use of molsidomine include ischemic heart disease angina chronic heart failure and pulmonary hypertension l1370 l1371')|
|('DB09282', 'MONDO:0024644', ['IHD [NCIT:C50625]', 'myocardium ischemic disease [MONDO:design_pattern,MONDO:patterns/location]', 'ischemic disease of myocardium [MONDO:design_pattern]', 'ischemic heart disease [MESH:D017202]', 'myocardial ischemia'], 'the indications for use of molsidomine include ischemic heart disease angina chronic heart failure and pulmonary hypertension l1370 l1371')|
|('DB09282', 'MONDO:0005149', ['pulmonary hypertension'], 'the indications for use of molsidomine include ischemic heart disease angina chronic heart failure and pulmonary hypertension l1370 l1371')|
|('DB09283', 'MONDO:0005149', ['pulmonary hypertension'], 'used in the treatment of chronic stable angina a19770')|
|('DB09284', 'MONDO:0005149', ['pulmonary hypertension'], 'imolamine is indicated for the treatment of angina pectoris the hydrochloride form is used as a local anesthetict83')|
|('DB09285', 'MONDO:0005149', ['pulmonary hypertension'], 'morniflumate is indicated for the treatment of inflammatory conditions affecting the airways ent system urogenital tract and bone and joint systems in adults in italy morniflumate is also indicated for the treatment of pain associated with ear nose throat ent and gastrointestinal inflammatory conditions in children  morniflumate is a well established nsaid that has been in use for over three decades in italy particularly for the treatment of upper respiratory tract infections in children france belgium austria switzerland spain and portugal it has a generally favorable tolerability profile')|
|('DB09285', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'morniflumate is indicated for the treatment of inflammatory conditions affecting the airways ent system urogenital tract and bone and joint systems in adults in italy morniflumate is also indicated for the treatment of pain associated with ear nose throat ent and gastrointestinal inflammatory conditions in children  morniflumate is a well established nsaid that has been in use for over three decades in italy particularly for the treatment of upper respiratory tract infections in children france belgium austria switzerland spain and portugal it has a generally favorable tolerability profile')|
|('DB09286', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'treatment of chronic psychoses and states of aggressiveness of various origins l1515')|
|('DB09287', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used to treat and prevent constipation')|
|('DB09288', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'propacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapyl1511')|
|('DB09288', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'propacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapyl1511')|
|('DB09289', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'used primarily in the treatment of major depressive disorder and anxiety a31969 it is currently being studied for fibromyalgia pain treatment l1426')|
|('DB09289', 'MONDO:0005263', ['major depressive disorder [NCIT:C35094]', 'major depression [NCIT:C35094]', 'unipolar depression'], 'used primarily in the treatment of major depressive disorder and anxiety a31969 it is currently being studied for fibromyalgia pain treatment l1426')|
|('DB09289', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used primarily in the treatment of major depressive disorder and anxiety a31969 it is currently being studied for fibromyalgia pain treatment l1426')|
|('DB09289', 'MONDO:0005546', ['fibromyalgia'], 'used primarily in the treatment of major depressive disorder and anxiety a31969 it is currently being studied for fibromyalgia pain treatment l1426')|
|('DB09290', 'MONDO:0005546', ['fibromyalgia'], 'for the treatment of nausea and vomiting and diarrheapredominant irritable bowel syndrome in males')|
|('DB09290', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'for the treatment of nausea and vomiting and diarrheapredominant irritable bowel syndrome in males')|
|('DB09291', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'this drug is indicated in adults in combination with other antiemetics for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy')|
|('DB09292', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure nyha class iiiv and reduced ejection fraction  it is usually administered in conjunction with other heart failure therapies in place of an ace inhibitor or other arb')|
|('DB09293', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'therapeutic solutions of sodium iodide131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine  palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine  it is also indicated for use in performance of the radioactive iodide rai uptake test to evaluate thyroid function')|
|('DB09293', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'therapeutic solutions of sodium iodide131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine  palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine  it is also indicated for use in performance of the radioactive iodide rai uptake test to evaluate thyroid function')|
|('DB09295', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'talnifumate is a phthalidyl ester of nifumic acid which has potent analgesic and antiinflammatory effects and is widely used to treat inflammatory disorders such as rheumatoid arthritis and osteoarthritis l1409 and has also been studied for the management of cystic fibrosis l1403')|
|('DB09295', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'talnifumate is a phthalidyl ester of nifumic acid which has potent analgesic and antiinflammatory effects and is widely used to treat inflammatory disorders such as rheumatoid arthritis and osteoarthritis l1409 and has also been studied for the management of cystic fibrosis l1403')|
|('DB09295', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'talnifumate is a phthalidyl ester of nifumic acid which has potent analgesic and antiinflammatory effects and is widely used to treat inflammatory disorders such as rheumatoid arthritis and osteoarthritis l1409 and has also been studied for the management of cystic fibrosis l1403')|
|('DB09295', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'talnifumate is a phthalidyl ester of nifumic acid which has potent analgesic and antiinflammatory effects and is widely used to treat inflammatory disorders such as rheumatoid arthritis and osteoarthritis l1409 and has also been studied for the management of cystic fibrosis l1403')|
|('DB09295', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'talnifumate is a phthalidyl ester of nifumic acid which has potent analgesic and antiinflammatory effects and is widely used to treat inflammatory disorders such as rheumatoid arthritis and osteoarthritis l1409 and has also been studied for the management of cystic fibrosis l1403')|
|('DB09296', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'when used in combination with db09297 and db00503 as the fixed dose product technivie ombitasvir is indicated in combination with db00811 for the treatment of patients with genotype 4 chronic hepatitis c virus hcv infection without cirrhosis l866when used in combination with db09297 db00503 and db09183 as the fixed dose product viekira pak ombitasvir is indicated for the treatment of hcv genotype 1b and when combined with db00811 for the treatment of hcv genotype 1a fda label')|
|('DB09296', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'when used in combination with db09297 and db00503 as the fixed dose product technivie ombitasvir is indicated in combination with db00811 for the treatment of patients with genotype 4 chronic hepatitis c virus hcv infection without cirrhosis l866when used in combination with db09297 db00503 and db09183 as the fixed dose product viekira pak ombitasvir is indicated for the treatment of hcv genotype 1b and when combined with db00811 for the treatment of hcv genotype 1a fda label')|
|('DB09296', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'when used in combination with db09297 and db00503 as the fixed dose product technivie ombitasvir is indicated in combination with db00811 for the treatment of patients with genotype 4 chronic hepatitis c virus hcv infection without cirrhosis l866when used in combination with db09297 db00503 and db09183 as the fixed dose product viekira pak ombitasvir is indicated for the treatment of hcv genotype 1b and when combined with db00811 for the treatment of hcv genotype 1a fda label')|
|('DB09297', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'when used within the fixeddose combination product with db09296 db09183 and db00503 as the fdaapproved product viekira pak paritaprevir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis and when combined with db00811 for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosiswhen used within the fixeddose combination product with db09296 and db00503 as the fda and health canadaapproved product technivie paritaprevir is indicated in combination with db00811 for the treatment of patients with genotype 4 chronic hepatitis c virus hcv infection without cirrhosis or with compensated cirrhosiswhen used within the fixeddose combination product with db09296 db09183 and db00503 as the health canadaapproved commercially available product holkira pak paritaprevir is indicated for the treatment of hcv genotype 1b with or without cirrhosis and when combined with db00811 for the treatment of hcv genotype 1a with or without cirrhosis')|
|('DB09297', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'when used within the fixeddose combination product with db09296 db09183 and db00503 as the fdaapproved product viekira pak paritaprevir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis and when combined with db00811 for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosiswhen used within the fixeddose combination product with db09296 and db00503 as the fda and health canadaapproved product technivie paritaprevir is indicated in combination with db00811 for the treatment of patients with genotype 4 chronic hepatitis c virus hcv infection without cirrhosis or with compensated cirrhosiswhen used within the fixeddose combination product with db09296 db09183 and db00503 as the health canadaapproved commercially available product holkira pak paritaprevir is indicated for the treatment of hcv genotype 1b with or without cirrhosis and when combined with db00811 for the treatment of hcv genotype 1a with or without cirrhosis')|
|('DB09298', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'currently being tested as a treatment of severe intoxications with hepatotoxic substances such as death cap amanita phalloides poisoning')|
|('DB09298', 'MONDO:0029000', ['poisoning'], 'currently being tested as a treatment of severe intoxications with hepatotoxic substances such as death cap amanita phalloides poisoning')|
|('DB09299', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'tenofovir alafenamide is indicated for the treatment of chronic hepatitis b in adult patients with compensated liver diseasel6241in combination with emtricitabine and other antiretrovirals it is indicated for the treatment of hiv1 infection in adolescent and adult patients with a weight higher than 35 kgl4388 this combination is also indicated to prevent hiv1 infections in high risk adolescent and adult patients excluding patients at risk from receptive vaginal sexl4388l9010 when combined with antiretrovirals other than protease inhibitors that require a cyp3a inhibitor it can be used to treat pediatric patients weighing 2535 kgl4388in the combination product with emtricitabine and bictegravir tenofovir alafenamide is considered as a complete regimen for the treatment of hiv1 infection in treatmentnaive patients or in patients virologically suppressed for at least 3 months with no history of treatment failurel6277 additionally the combination product including elvitegravir cobicistat emtricitabine and tenofovir alafenamide and the combination product including emtricitabine rilpivirine and tenofovir alafenamide can be used in the treatment of hiv1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failurel6280the combination product including darunavir cobicistat emtricitabine and tenofovir alafenamide is indicated for the treatment of hiv1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovirl6283')|
|('DB09299', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'tenofovir alafenamide is indicated for the treatment of chronic hepatitis b in adult patients with compensated liver diseasel6241in combination with emtricitabine and other antiretrovirals it is indicated for the treatment of hiv1 infection in adolescent and adult patients with a weight higher than 35 kgl4388 this combination is also indicated to prevent hiv1 infections in high risk adolescent and adult patients excluding patients at risk from receptive vaginal sexl4388l9010 when combined with antiretrovirals other than protease inhibitors that require a cyp3a inhibitor it can be used to treat pediatric patients weighing 2535 kgl4388in the combination product with emtricitabine and bictegravir tenofovir alafenamide is considered as a complete regimen for the treatment of hiv1 infection in treatmentnaive patients or in patients virologically suppressed for at least 3 months with no history of treatment failurel6277 additionally the combination product including elvitegravir cobicistat emtricitabine and tenofovir alafenamide and the combination product including emtricitabine rilpivirine and tenofovir alafenamide can be used in the treatment of hiv1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failurel6280the combination product including darunavir cobicistat emtricitabine and tenofovir alafenamide is indicated for the treatment of hiv1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovirl6283')|
|('DB09299', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tenofovir alafenamide is indicated for the treatment of chronic hepatitis b in adult patients with compensated liver diseasel6241in combination with emtricitabine and other antiretrovirals it is indicated for the treatment of hiv1 infection in adolescent and adult patients with a weight higher than 35 kgl4388 this combination is also indicated to prevent hiv1 infections in high risk adolescent and adult patients excluding patients at risk from receptive vaginal sexl4388l9010 when combined with antiretrovirals other than protease inhibitors that require a cyp3a inhibitor it can be used to treat pediatric patients weighing 2535 kgl4388in the combination product with emtricitabine and bictegravir tenofovir alafenamide is considered as a complete regimen for the treatment of hiv1 infection in treatmentnaive patients or in patients virologically suppressed for at least 3 months with no history of treatment failurel6277 additionally the combination product including elvitegravir cobicistat emtricitabine and tenofovir alafenamide and the combination product including emtricitabine rilpivirine and tenofovir alafenamide can be used in the treatment of hiv1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failurel6280the combination product including darunavir cobicistat emtricitabine and tenofovir alafenamide is indicated for the treatment of hiv1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovirl6283')|
|('DB09300', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to treat abdmoninal cramping and pain fda label')|
|('DB09301', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'chondroitin sulfate used with glucosamine is indicated to alleviate pain and inflammation from primary osteoarthritisl1527 this supplement is reported to improve joint function and slow disease progressionl1528 osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues mainly cartilage degradation subchondral bone sclerosis and inflammation of synovial membranea32066studies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplementsa32065')|
|('DB09301', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'chondroitin sulfate used with glucosamine is indicated to alleviate pain and inflammation from primary osteoarthritisl1527 this supplement is reported to improve joint function and slow disease progressionl1528 osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues mainly cartilage degradation subchondral bone sclerosis and inflammation of synovial membranea32066studies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplementsa32065')|
|('DB09302', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity that is indicated fori use in reducing the risk of myocardial infarction stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease f4591 andorii use as an adjunct to diet or use alone or in combination with other lipidlowering therapies statins ezetimibe for example for the treatment of adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia to reduce lowdensity lipoprotein cholesterol ldlc levels in the body f4591')|
|('DB09302', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity that is indicated fori use in reducing the risk of myocardial infarction stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease f4591 andorii use as an adjunct to diet or use alone or in combination with other lipidlowering therapies statins ezetimibe for example for the treatment of adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia to reduce lowdensity lipoprotein cholesterol ldlc levels in the body f4591')|
|('DB09302', 'MONDO:0006805', ['Angina at rest', 'Anginal chest pain at rest', 'Impending infarction', 'Preinfarction angina', 'Unstable angina', 'Worsening angina', 'intermediate coronary syndrome'], 'alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity that is indicated fori use in reducing the risk of myocardial infarction stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease f4591 andorii use as an adjunct to diet or use alone or in combination with other lipidlowering therapies statins ezetimibe for example for the treatment of adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia to reduce lowdensity lipoprotein cholesterol ldlc levels in the body f4591')|
|('DB09302', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity that is indicated fori use in reducing the risk of myocardial infarction stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease f4591 andorii use as an adjunct to diet or use alone or in combination with other lipidlowering therapies statins ezetimibe for example for the treatment of adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia to reduce lowdensity lipoprotein cholesterol ldlc levels in the body f4591')|
|('DB09303', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'for the treatment of heterozygoushomozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional ldlcholesterol lowering ')|
|('DB09303', 'MONDO:0005439', ['familial hyperbetalipoproteinaemia', 'familial hypercholesteremia', 'Fredrickson type IIa hyperlipoproteinemia', 'Fredrickson type IIa lipidaemia', 'hyperbetalipoproteinemia', 'type II hyperlipidemia', 'familial hypercholesterolemia'], 'for the treatment of heterozygoushomozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional ldlcholesterol lowering ')|
|('DB09304', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'for the treatment of depression a19792')|
|('DB09305', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'investigated for the treatment of depression')|
|('DB09306', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'investigated for the treatment of depression')|
|('DB09307', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'investigated for the treatment of depression')|
|('DB09308', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'investigated for the treatment of communityacquired pneumonia cap')|
|('DB09308', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'investigated for the treatment of communityacquired pneumonia cap')|
|('DB09310', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for routine prophylaxis of bleeding in patients with congenital factor xiii asubunit deficiency')|
|('DB09310', 'MONDO:0021140', ['inborn []', 'congenital'], 'for routine prophylaxis of bleeding in patients with congenital factor xiii asubunit deficiency')|
|('DB09311', 'MONDO:0021140', ['inborn []', 'congenital'], 'polycarbophil is used to treat constipation and to help maintain regular bowel movements')|
|('DB09312', 'MONDO:0021140', ['inborn []', 'congenital'], 'for prevention of renal transplant rejection and for the treatment of aplastic anemia')|
|('DB09312', 'MONDO:0015909', ['aplastic anemia'], 'for prevention of renal transplant rejection and for the treatment of aplastic anemia')|
|('DB09313', 'MONDO:0021140', ['inborn []', 'congenital'], 'this medicinal product is for diagnostic use only in adults and children as a lowosmolality medium l1883 a7924 ')|
|('DB09314', 'MONDO:0021140', ['inborn []', 'congenital'], 'sodium pertechnetate tc99m injection is indicated for use in adults for imaging in the following tissues thyroid salivary gland  urinary bladder for detection of vesicoureteral reflux and nasolacrimal drainage system dacryoscintigraphy it is indicated for use in children for imaging the following tissues thyroid and urinary bladder ')|
|('DB09314', 'MONDO:0006007', ['vesico-ureteral reflux', 'vesicoureteral reflux'], 'sodium pertechnetate tc99m injection is indicated for use in adults for imaging in the following tissues thyroid salivary gland  urinary bladder for detection of vesicoureteral reflux and nasolacrimal drainage system dacryoscintigraphy it is indicated for use in children for imaging the following tissues thyroid and urinary bladder ')|
|('DB09315', 'MONDO:0006007', ['vesico-ureteral reflux', 'vesicoureteral reflux'], 'inhalation of xenon xe 133 gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs it may also be applied to assessment of cerebral flow ')|
|('DB09316', 'MONDO:0006007', ['vesico-ureteral reflux', 'vesicoureteral reflux'], 'for use as a diagnostic radiopharmaceuticalit is indicated to help diagnose heart disease eg coronary artery disease heart attack it is also used for the diagnosis of parathyroid problems ')|
|('DB09316', 'MONDO:0005267', ['heart disease'], 'for use as a diagnostic radiopharmaceuticalit is indicated to help diagnose heart disease eg coronary artery disease heart attack it is also used for the diagnosis of parathyroid problems ')|
|('DB09316', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for use as a diagnostic radiopharmaceuticalit is indicated to help diagnose heart disease eg coronary artery disease heart attack it is also used for the diagnosis of parathyroid problems ')|
|('DB09317', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of moderate to severe vasomotor symptoms due to menopause and for treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause')|
|('DB09318', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe vaginal dryness pain with intercourse and symptoms of vulvar and vaginal atrophy due to menopause')|
|('DB09319', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter and enterococci also indicated in the treatment of prostatitis due to susceptible strains escherichia coli enterococcus s faecalis proteus mirabilis enterobacter sp')|
|('DB09319', 'MONDO:0001882', ['bacteriuria'], 'for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter and enterococci also indicated in the treatment of prostatitis due to susceptible strains escherichia coli enterococcus s faecalis proteus mirabilis enterobacter sp')|
|('DB09319', 'MONDO:0005280', ['prostatitis'], 'for the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter and enterococci also indicated in the treatment of prostatitis due to susceptible strains escherichia coli enterococcus s faecalis proteus mirabilis enterobacter sp')|
|('DB09320', 'MONDO:0005280', ['prostatitis'], 'for the treatment of a number of bacterial infections such as syphilis anthrax mouth infections pneumonia and diphtheria ')|
|('DB09320', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for the treatment of a number of bacterial infections such as syphilis anthrax mouth infections pneumonia and diphtheria ')|
|('DB09320', 'MONDO:0005504', ['corynebacterium infection', 'diphtheria'], 'for the treatment of a number of bacterial infections such as syphilis anthrax mouth infections pneumonia and diphtheria ')|
|('DB09321', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'for adjunctive treatment of diaper dermatitis also it can be used to treat minor skin irritations eg cuts burns and scrapes poison ivyzinc oxide can be used in ointments creams and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light')|
|('DB09321', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for adjunctive treatment of diaper dermatitis also it can be used to treat minor skin irritations eg cuts burns and scrapes poison ivyzinc oxide can be used in ointments creams and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light')|
|('DB09321', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for adjunctive treatment of diaper dermatitis also it can be used to treat minor skin irritations eg cuts burns and scrapes poison ivyzinc oxide can be used in ointments creams and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light')|
|('DB09321', 'MONDO:0005326', ['sunburn'], 'for adjunctive treatment of diaper dermatitis also it can be used to treat minor skin irritations eg cuts burns and scrapes poison ivyzinc oxide can be used in ointments creams and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light')|
|('DB09322', 'MONDO:0005326', ['sunburn'], 'this medication is a mineral used to treat or prevent low levels of zinc alone and together with oral rehydration therapy ort it is also used as a topical astringent zinc sulfate injection usp is indicated for use as a supplement to intravenous solutions given for tpn ')|
|('DB09324', 'MONDO:0005326', ['sunburn'], 'sulbactam is currently available in combination products with ampicillin within this formulation it is indicated  for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed belowskin and skin structure infections caused by betalactamase producing strains of staphylococcus aureus escherichia coli klebsiella spp including k pneumoniae proteus mirabilis bacteroides fragilis enterobacter spp and acinetobacter calcoaceticusintraabdominal infections caused by betalactamase producing strains of escherichia coli klebsiella spp including k pneumoniae bacteroides spp including b fragilis and enterobacter sppgynecological infections caused by betalactamase producing strains of escherichia coli and bacteroides spp including b fragilis')|
|('DB09325', 'MONDO:0005326', ['sunburn'], 'sodium fluoride in the oral or topical form is indicated for the prevention and control of dental caries and for the maintenance of dental healtha181652l7670  fluoride supplements in the form of tablets and other formulas may be prescribed to prevent tooth decay in highrisk children aged 6 months to 16 years old whose drinking water source contains low fluoride concentrationsl7691')|
|('DB09325', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'sodium fluoride in the oral or topical form is indicated for the prevention and control of dental caries and for the maintenance of dental healtha181652l7670  fluoride supplements in the form of tablets and other formulas may be prescribed to prevent tooth decay in highrisk children aged 6 months to 16 years old whose drinking water source contains low fluoride concentrationsl7691')|
|('DB09326', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'for diagnostic positron emission tomography pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease')|
|('DB09326', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'for diagnostic positron emission tomography pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease')|
|('DB09327', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'tegafururacil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinatel934 colorectal cancer is the third most diagnosed cancer and 30 of the cases can present the metastatic statea32077')|
|('DB09327', 'MONDO:0004992', ['cancer'], 'tegafururacil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinatel934 colorectal cancer is the third most diagnosed cancer and 30 of the cases can present the metastatic statea32077')|
|('DB09327', 'MONDO:0005575', ['colorectal cancer'], 'tegafururacil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinatel934 colorectal cancer is the third most diagnosed cancer and 30 of the cases can present the metastatic statea32077')|
|('DB09327', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tegafururacil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinatel934 colorectal cancer is the third most diagnosed cancer and 30 of the cases can present the metastatic statea32077')|
|('DB09328', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'adhd in children  hypertriglyceridemia l1502 l1503')|
|('DB09328', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'adhd in children  hypertriglyceridemia l1502 l1503')|
|('DB09329', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'for the management of hemophilia a congenital factor viii deficiency fda label a32064this medication is a human antihemophilic factor indicated in adolescent and adult patients 12 years and older with hemophilia a congenital factor viii deficiency it is also used for ondemand treatment and control of bleeding and routine prophylaxis of bleeding episodes it is not indicated for the treatment of von willebrand disease fda label')|
|('DB09329', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'for the management of hemophilia a congenital factor viii deficiency fda label a32064this medication is a human antihemophilic factor indicated in adolescent and adult patients 12 years and older with hemophilia a congenital factor viii deficiency it is also used for ondemand treatment and control of bleeding and routine prophylaxis of bleeding episodes it is not indicated for the treatment of von willebrand disease fda label')|
|('DB09329', 'MONDO:0021140', ['inborn []', 'congenital'], 'for the management of hemophilia a congenital factor viii deficiency fda label a32064this medication is a human antihemophilic factor indicated in adolescent and adult patients 12 years and older with hemophilia a congenital factor viii deficiency it is also used for ondemand treatment and control of bleeding and routine prophylaxis of bleeding episodes it is not indicated for the treatment of von willebrand disease fda label')|
|('DB09329', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'for the management of hemophilia a congenital factor viii deficiency fda label a32064this medication is a human antihemophilic factor indicated in adolescent and adult patients 12 years and older with hemophilia a congenital factor viii deficiency it is also used for ondemand treatment and control of bleeding and routine prophylaxis of bleeding episodes it is not indicated for the treatment of von willebrand disease fda label')|
|('DB09330', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor egfr t790m mutationpositive nonsmall cell lung cancer nsclc as detected by an fda approved test who have progressed on or after egfrtki therapy')|
|('DB09330', 'MONDO:0004992', ['cancer'], 'osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor egfr t790m mutationpositive nonsmall cell lung cancer nsclc as detected by an fda approved test who have progressed on or after egfrtki therapy')|
|('DB09331', 'MONDO:0004992', ['cancer'], 'for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy a proteasome inhibitor pi and an immunomodulatory agent or who are doublerefractory to a pi and an immunomodulatory agent this indication was approved by accelerated approval based on response rate')|
|('DB09332', 'MONDO:0024307', ['prothrombin deficiency'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09332', 'MONDO:0002243', ['Hemorrhagic diathesis', 'Hemorrhagic disease', 'hemorrhagic disease'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09332', 'MONDO:0006874', ['Cholestatic Jaundice', 'Cholestatic jaundice syndrome', 'Obstructive hyperbilirubinemia', 'Obstructive jaundice', 'obstructive jaundice'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09332', 'MONDO:0005292', ['colitis'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09332', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09332', 'MONDO:0013361', ['hypoprothrombinemia', 'congenital prothrombin deficiency'], 'anticoagulantinduced prothrombin deficiency caused by coumadin or indanedione derivativesprophylaxis and therapy of hemorrhagic disease of the newborn hypoprothrombinemia due to antibacterial therapyhypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k for example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis of the pancreas and regional enteritis other druginduced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism l1545 l1546')|
|('DB09333', 'MONDO:0013361', ['hypoprothrombinemia', 'congenital prothrombin deficiency'], 'iopodic acid is available as a cholecystographic agent this denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal xrayl1587 a32087 an abdominal xray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity it is commonly used to evaluate the stomach liver intestines and spleenl1589iopodic acid has also been indicated for the treatment of hyperthyroidism such as graves diseasea32085 a32086 hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body overactive thyroid when the overactivity involves the entire thyroid gland it is known as graves diseasel1590')|
|('DB09333', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'iopodic acid is available as a cholecystographic agent this denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal xrayl1587 a32087 an abdominal xray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity it is commonly used to evaluate the stomach liver intestines and spleenl1589iopodic acid has also been indicated for the treatment of hyperthyroidism such as graves diseasea32085 a32086 hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body overactive thyroid when the overactivity involves the entire thyroid gland it is known as graves diseasel1590')|
|('DB09333', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'iopodic acid is available as a cholecystographic agent this denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal xrayl1587 a32087 an abdominal xray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity it is commonly used to evaluate the stomach liver intestines and spleenl1589iopodic acid has also been indicated for the treatment of hyperthyroidism such as graves diseasea32085 a32086 hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body overactive thyroid when the overactivity involves the entire thyroid gland it is known as graves diseasel1590')|
|('DB09336', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'tc99m nm is one of the technetiumlabeled antibodies and it is indicated for the detection of smallcell lung cancerl1146 the small cell lung cancer is a syndrome characterized by the abnormal and uncontrolled cell growth and it is characterized by a shorter doubling time higher growth fraction and earlier development of metastasesl1651')|
|('DB09337', 'MONDO:0004425', ['overactive thyroid', 'hyperthyroidism'], 'for use as a source of clean air fda label')|
|('DB09337', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'for use as a source of clean air fda label')|
|('DB09338', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'elevated blood pressure edema l1577 l1585')|
|('DB09340', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'for use in cholecystography xray diagnosisimaging of gallstones')|
|('DB09340', 'MONDO:0005346', ['gallstones'], 'for use in cholecystography xray diagnosisimaging of gallstones')|
|('DB09341', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'glucose pharmaceutical formulations oral tablets injections are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation it is also used in metabolic disorders such as hypoglycemia')|
|('DB09342', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'propoxycaine is a local anesthetic medication  it was used beginning in the 1950s during dental procedures l1591  it has been combined with procaine to accelerate its onset of action and provide longerlasting anesthetic effect l1592it was produced for use when amide local anesthetics were contraindicated due to allergy or when several amide anesthetics were unsuccessful l1592')|
|('DB09342', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'propoxycaine is a local anesthetic medication  it was used beginning in the 1950s during dental procedures l1591  it has been combined with procaine to accelerate its onset of action and provide longerlasting anesthetic effect l1592it was produced for use when amide local anesthetics were contraindicated due to allergy or when several amide anesthetics were unsuccessful l1592')|
|('DB09343', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tipiracil in combination with trifluridine is indicated for the treatment of refractory mestastatic colorectal cancer patients who keep progressing despite of treatment with standard chemotherapy and biologicsa31256')|
|('DB09343', 'MONDO:0005575', ['colorectal cancer'], 'tipiracil in combination with trifluridine is indicated for the treatment of refractory mestastatic colorectal cancer patients who keep progressing despite of treatment with standard chemotherapy and biologicsa31256')|
|('DB09344', 'MONDO:0005575', ['colorectal cancer'], 'invert sugar presents a large variety of uses it can be used therapeutically for parenteral hyperalimentationt127 or to be used as an excipient with a known effectl1691 invert sugar is also approved for its use in food products as a humectant crystallization modifier and liquid and nutritive sweetenert128')|
|('DB09344', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'invert sugar presents a large variety of uses it can be used therapeutically for parenteral hyperalimentationt127 or to be used as an excipient with a known effectl1691 invert sugar is also approved for its use in food products as a humectant crystallization modifier and liquid and nutritive sweetenert128')|
|('DB09344', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'invert sugar presents a large variety of uses it can be used therapeutically for parenteral hyperalimentationt127 or to be used as an excipient with a known effectl1691 invert sugar is also approved for its use in food products as a humectant crystallization modifier and liquid and nutritive sweetenert128')|
|('DB09345', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'it is indicated for  temporary relief of pain and pruritus from minor lip and skin irritations as well as for temporary relief from pain burning itching and discomfort associated with hemorrhoids and other anorectalanogenital disorders ')|
|('DB09346', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'for use as a contrast medium l1597')|
|('DB09347', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'acetrizoic acid indication was to be used as a contrast agent for xray some information indicates its nephrotropic property as one of the characteristics for the utilization of acetrizoic acida32135 the xray imaging depends on the difference in tissue density which is provided by an xray attenuation between the area of interest and the surrounding tissue the use of contrast agents will provoke a contrast enhancement or opacification and it will improve the differentiation of pathological processes from normal tissuet125')|
|('DB09348', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'propiolactone was used for vaccines tissue grafts surgical instruments and enzymes as a sterilant of blood plasma water milk and nutrient broth as a vaporphase disinfectant in enclosed spaces its sporicidal action is used against vegetative bacteria pathologic fungi and virusesl1717 it is no longer used in medical procedures or in fooda32144')|
|('DB09349', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'intrinsic factor is not currently available in any fda or health canada approved products however it is currently in the marketed but unapproved product hematogen in combination with cyanocobalamin synthetic vitamin b12 ferrous  fumarate and ascorbic acid for the treatment of anemias responsive to oral iron therapy ')|
|('DB09350', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'for the treatment of head pubic crab and body lice')|
|('DB09351', 'MONDO:0021125', ['disease qualifier []', 'modifier [NCIT:C41009]', 'qualifier [NCIT:C41009]', 'disease characteristic'], 'used in the treatment of openangle glaucoma and ocular hypertension fda label')|
|('DB09351', 'MONDO:0005041', ['glaucoma'], 'used in the treatment of openangle glaucoma and ocular hypertension fda label')|
|('DB09351', 'MONDO:0006875', ['ocular hypertension'], 'used in the treatment of openangle glaucoma and ocular hypertension fda label')|
|('DB09352', 'MONDO:0006875', ['ocular hypertension'], 'mydriatic agent eye pupil dilatation for diagnosis of ophthalmic nerve lesions')|
|('DB09353', 'MONDO:0006875', ['ocular hypertension'], 'topically it is indicated for dandruff acne hayfever common cold scaly and red skin patches seborrheic dermatitispoison ivy and sumac infections ')|
|('DB09353', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'topically it is indicated for dandruff acne hayfever common cold scaly and red skin patches seborrheic dermatitispoison ivy and sumac infections ')|
|('DB09353', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'topically it is indicated for dandruff acne hayfever common cold scaly and red skin patches seborrheic dermatitispoison ivy and sumac infections ')|
|('DB09357', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'injection prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus intestinal atony causing abdominal distention postoperative or postpartum retention of flatus or postoperative delay in resumption of intestinal motility paralytic ileustopical this medication is used as a moisturizer to treat or prevent dry rough scaly itchy skin and minor skin irritations eg diaper rash skin burns from radiation therapy ')|
|('DB09357', 'MONDO:0004568', ['paralytic ileus'], 'injection prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus intestinal atony causing abdominal distention postoperative or postpartum retention of flatus or postoperative delay in resumption of intestinal motility paralytic ileustopical this medication is used as a moisturizer to treat or prevent dry rough scaly itchy skin and minor skin irritations eg diaper rash skin burns from radiation therapy ')|
|('DB09357', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'injection prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus intestinal atony causing abdominal distention postoperative or postpartum retention of flatus or postoperative delay in resumption of intestinal motility paralytic ileustopical this medication is used as a moisturizer to treat or prevent dry rough scaly itchy skin and minor skin irritations eg diaper rash skin burns from radiation therapy ')|
|('DB09363', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'rauwolfia alkaloids are indicated in the treatment of hypertension l1614 rauwolfia alkaloids have been used for relief of symptoms in agitated psychotic states such as schizophrenia however use as antipsychotics and sedatives have been replaced with the use of more effective safer agents l1614')|
|('DB09372', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09372', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09372', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09372', 'MONDO:0005326', ['sunburn'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09372', 'MONDO:0002769', ['discharge - leukorrhea', 'Leukorrhea of vagina', 'leukorrhea'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09372', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tannic acid is indicated for cold sores fever blisters diaper rash minor burn or sunburn and prickly heatvaginally tannic acid is used as a douche for leukorrhea it has been also indicated for sore throat inflamed tonsils spongy or receding gums and acute dermatitis')|
|('DB09374', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for determining cardiac output hepatic function and liver blood flowfor ophthalmic angiography')|
|('DB09375', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'no therapeutic indications ')|
|('DB09376', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as a surfactant antistatic agent and biocide in cosmetic products a19426')|
|('DB09379', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sutilain was indicated in the form of an ointment as a biochemical debridement of second and thirddegree burns incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseasest169')|
|('DB09379', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'sutilain was indicated in the form of an ointment as a biochemical debridement of second and thirddegree burns incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseasest169')|
|('DB09381', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the bodyit is also indicated for the treatment of symptoms of breast cancer in both men and women in men it can be used for the treatment of advanced prostate cancerit is also indicated for the treatment of menopausal symptoms  ')|
|('DB09381', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the bodyit is also indicated for the treatment of symptoms of breast cancer in both men and women in men it can be used for the treatment of advanced prostate cancerit is also indicated for the treatment of menopausal symptoms  ')|
|('DB09381', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the bodyit is also indicated for the treatment of symptoms of breast cancer in both men and women in men it can be used for the treatment of advanced prostate cancerit is also indicated for the treatment of menopausal symptoms  ')|
|('DB09381', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'esterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the bodyit is also indicated for the treatment of symptoms of breast cancer in both men and women in men it can be used for the treatment of advanced prostate cancerit is also indicated for the treatment of menopausal symptoms  ')|
|('DB09389', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception')|
|('DB09394', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'phosphoric acid is used in dentistry and orthodontics as an etching solution to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed')|
|('DB09395', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'injection usp 40 meq is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions sodium acetate and other bicarbonate precursors are alkalinising agents and can be used to correct metabolic acidosis or for alkalinisation of the urine')|
|('DB09395', 'MONDO:0000440', ['metabolic acidosis'], 'injection usp 40 meq is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions sodium acetate and other bicarbonate precursors are alkalinising agents and can be used to correct metabolic acidosis or for alkalinisation of the urine')|
|('DB09397', 'MONDO:0000440', ['metabolic acidosis'], 'technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma and evaluation of peritoneovenous leveen shunt patency it is indicated in both adult and pediatric patients for imaging areas of functioning reticuloendothelial cells in the liver spleen and bone marrow and studies of esophageal transit and gastroesophageal reflux and detection of pulmonary aspiration of gastric contents')|
|('DB09397', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma and evaluation of peritoneovenous leveen shunt patency it is indicated in both adult and pediatric patients for imaging areas of functioning reticuloendothelial cells in the liver spleen and bone marrow and studies of esophageal transit and gastroesophageal reflux and detection of pulmonary aspiration of gastric contents')|
|('DB09397', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma and evaluation of peritoneovenous leveen shunt patency it is indicated in both adult and pediatric patients for imaging areas of functioning reticuloendothelial cells in the liver spleen and bone marrow and studies of esophageal transit and gastroesophageal reflux and detection of pulmonary aspiration of gastric contents')|
|('DB09397', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], 'technetium 99m sulfur colloid is indicated as a diagnostic agent in adults for the following tests localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma and evaluation of peritoneovenous leveen shunt patency it is indicated in both adult and pediatric patients for imaging areas of functioning reticuloendothelial cells in the liver spleen and bone marrow and studies of esophageal transit and gastroesophageal reflux and detection of pulmonary aspiration of gastric contents')|
|('DB09398', 'MONDO:0007186', ['Acid reflux', 'Gastresophageal reflux', 'Gastro-esophageal reflux', 'Gastroesophageal reflux', 'Gastroesophageal reflux disease', 'GERD', 'GERD - Gastro-esophageal reflux disease', 'gastroesophageal reflux disease'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09398', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09398', 'MONDO:0005246', ['osteomyelitis'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09398', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09398', 'MONDO:0005043', ['hyperplasia [NCIT:C3113]', 'hyperplastic [NCIT:C3113]', 'hyperplasia'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09398', 'MONDO:0016370', ['Marchiafava Bignami disease [GARD:0006971]', 'metabolic bone disease [NCIT:C97045]', 'metabolic bone disorder [NCIT:C97045]', 'marchiafava-bignami disease'], '18f is used as a bone imaging agent to define areas of altered osteogenic activity  it has been indicated for back pain  and otherwise unexplained bone pain child abuse abnormal radiographic or laboratory findings osteomyelitis trauma inflammatory and degenerative arthritis avascular necrosis osteonecrosis of the mandible condylar hyperplasia and metabolic bone disease are also among the indications for fluoride imaging ')|
|('DB09401', 'MONDO:0016370', ['Marchiafava Bignami disease [GARD:0006971]', 'metabolic bone disease [NCIT:C97045]', 'metabolic bone disorder [NCIT:C97045]', 'marchiafava-bignami disease'], 'indicated for the prevention and treatment of angina pectoris due to coronary artery disease the onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episodelabel')|
|('DB09401', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'indicated for the prevention and treatment of angina pectoris due to coronary artery disease the onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episodelabel')|
|('DB09407', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'magnesium chloride  is used in several medical and topical skin related applications magnesium chloride usp anhydrous uses as electrolyte replenisher pharmaceutic necessity for hemodialysis and peritoneal dialysis fluids')|
|('DB09409', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'used as magnesium salfcontaining laxatives to prevent constipation it can bring synergistic effect to restore normal bowel function when using in combination with aluminum salts that induce bowel retention t28 magnesium acetate tetrahydrate is used as a source of water and electrolytes when combined with dextrose and other salts to form intravenous infusions this injection can be used for patients with carbohydrate or magnesium deficiency insulin hypoglycemia constipation or hypertension during pregnancy')|
|('DB09409', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as magnesium salfcontaining laxatives to prevent constipation it can bring synergistic effect to restore normal bowel function when using in combination with aluminum salts that induce bowel retention t28 magnesium acetate tetrahydrate is used as a source of water and electrolytes when combined with dextrose and other salts to form intravenous infusions this injection can be used for patients with carbohydrate or magnesium deficiency insulin hypoglycemia constipation or hypertension during pregnancy')|
|('DB09409', 'MONDO:0006844', ['magnesium deficiency'], 'used as magnesium salfcontaining laxatives to prevent constipation it can bring synergistic effect to restore normal bowel function when using in combination with aluminum salts that induce bowel retention t28 magnesium acetate tetrahydrate is used as a source of water and electrolytes when combined with dextrose and other salts to form intravenous infusions this injection can be used for patients with carbohydrate or magnesium deficiency insulin hypoglycemia constipation or hypertension during pregnancy')|
|('DB09409', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'used as magnesium salfcontaining laxatives to prevent constipation it can bring synergistic effect to restore normal bowel function when using in combination with aluminum salts that induce bowel retention t28 magnesium acetate tetrahydrate is used as a source of water and electrolytes when combined with dextrose and other salts to form intravenous infusions this injection can be used for patients with carbohydrate or magnesium deficiency insulin hypoglycemia constipation or hypertension during pregnancy')|
|('DB09413', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'used in buffers determination of ph pharmaceutical production urinary acidifier paper processing baking powder and food nutrient solutions yeast foods special liquid fertilizers sonar systems and other electronic applications used as a nutritional supplement in foods a nonlinear optical material for laser use and in wastewater treatment ')|
|('DB09414', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'dipotassium phosphate is used in imitation dairy creamers dry powder beverages mineral supplements and starter cultures as an additive it is used in nondairy creamers to prevent coagulation dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria')|
|('DB09418', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'no current fda or emaapproved therapeutic indications')|
|('DB09419', 'MONDO:0004946', ['Hypoglycaemia', 'hypoglycemia'], 'the predominant everyday nutritional usage of xylose is as a parent sugar alcohol from which another sugar alcohol  xylitol can be derived from and used as an extremely common food additive or sweetener to be used in place of regular sugars as a lower calorie alternative l2428 l2429 a32661alternatively xylose was also involved in a procedure known as a dxylose absorption test that used to be employed to evaluate how well an individual was capable of absorbing a simple sugar like dxylose from the intestines l2432 by measuring the amount of dxylose in urine and blood samples after an individual ingested a certain amount of the simple sugar dissolved in some water the test sought to determine if nutrients were being properly absorbed in the patients gastrointestinal tract l2432')|
|('DB09419', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'the predominant everyday nutritional usage of xylose is as a parent sugar alcohol from which another sugar alcohol  xylitol can be derived from and used as an extremely common food additive or sweetener to be used in place of regular sugars as a lower calorie alternative l2428 l2429 a32661alternatively xylose was also involved in a procedure known as a dxylose absorption test that used to be employed to evaluate how well an individual was capable of absorbing a simple sugar like dxylose from the intestines l2432 by measuring the amount of dxylose in urine and blood samples after an individual ingested a certain amount of the simple sugar dissolved in some water the test sought to determine if nutrients were being properly absorbed in the patients gastrointestinal tract l2432')|
|('DB09419', 'MONDO:0021137', ['common []', 'not rare'], 'the predominant everyday nutritional usage of xylose is as a parent sugar alcohol from which another sugar alcohol  xylitol can be derived from and used as an extremely common food additive or sweetener to be used in place of regular sugars as a lower calorie alternative l2428 l2429 a32661alternatively xylose was also involved in a procedure known as a dxylose absorption test that used to be employed to evaluate how well an individual was capable of absorbing a simple sugar like dxylose from the intestines l2432 by measuring the amount of dxylose in urine and blood samples after an individual ingested a certain amount of the simple sugar dissolved in some water the test sought to determine if nutrients were being properly absorbed in the patients gastrointestinal tract l2432')|
|('DB09420', 'MONDO:0021137', ['common []', 'not rare'], 'administration of sodium iodide i 123 capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function andor morphology')|
|('DB09422', 'MONDO:0021137', ['common []', 'not rare'], 'indicated for parenteral nutrition as a source of calories and essential fatty acids when oral or enteral nutrition is not possible insufficient or contraindicated ')|
|('DB09425', 'MONDO:0021137', ['common []', 'not rare'], 'pentetate indium disodium in 111 is recommended for use in radionuclide cisternography')|
|('DB09446', 'MONDO:0021137', ['common []', 'not rare'], 'no approved therapeutic indications')|
|('DB09449', 'MONDO:0021137', ['common []', 'not rare'], 'used to treat constipation or to clean the bowel before a colonoscopy fda label')|
|('DB09459', 'MONDO:0021137', ['common []', 'not rare'], 'tartaric acid is primarily indicated in conditions like antiscorbutic antiseptic')|
|('DB09460', 'MONDO:0021137', ['common []', 'not rare'], 'used topically for dermatitides mouthwash vaginal douche veterinary use as emergency emeticoccasionally for dermatitides topically as a lotion medication vet in solution to cleanse skin in eczema to soften scabs of ringworm')|
|('DB09460', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'used topically for dermatitides mouthwash vaginal douche veterinary use as emergency emeticoccasionally for dermatitides topically as a lotion medication vet in solution to cleanse skin in eczema to soften scabs of ringworm')|
|('DB09462', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'it is used as a solvent emollient pharmaceutical agent and sweetening agent')|
|('DB09472', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for bowel cleansing prior to colonoscopy or barium enema xray examination')|
|('DB09473', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indium in 111 oxyquinoline is indicated for radiolabeling autologous leukocytes')|
|('DB09477', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical')|
|('DB09479', 'MONDO:0008380', ['neuroblastoma of Retina', 'RB', 'RB - Retinoblastoma', 'retinoblastoma'], 'rubidium rb 82 chloride injection is indicated for positron emission tomography pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease')|
|('DB09479', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'rubidium rb 82 chloride injection is indicated for positron emission tomography pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease')|
|('DB09481', 'MONDO:0008380', ['neuroblastoma of Retina', 'RB', 'RB - Retinoblastoma', 'retinoblastoma'], 'used as an over the counter antacid l593')|
|('DB09484', 'MONDO:0008380', ['neuroblastoma of Retina', 'RB', 'RB - Retinoblastoma', 'retinoblastoma'], 'sodium monofluorophosphate is indicated for the treatment of cavities')|
|('DB09488', 'MONDO:0008380', ['neuroblastoma of Retina', 'RB', 'RB - Retinoblastoma', 'retinoblastoma'], 'for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing rhinorrhea pruritus lacrimation and nasal congestion')|
|('DB09488', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing rhinorrhea pruritus lacrimation and nasal congestion')|
|('DB09490', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'indium in111 chloride is indicated for radio labeling of monoclonal antibodies in preparations used for in vivo diagnostic imaging procedures indiclor is also indicated for radiolabeling zevalin in preparations used for radio immunotherapy procedure')|
|('DB09493', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'indicated for blood pool imaging including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding fda label ')|
|('DB09494', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'no therapeutic indications in medicinal products indicated to be used as an indirect additive in food contact substances or an ingredient in commercial or cosmetic products ')|
|('DB09495', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'sun protection factor added in the sunscreen products for its wide spectrum ultraviolet absorption properties ')|
|('DB09496', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'as an active ingredient in sunscreens and lip balms used for protection against damaging effects of sun rays ')|
|('DB09498', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'strontium89 chloride injection is indicated as a paliative for the relief of bone pain in patients with skeletal metastases it is impotant to confirm the presence of bone metastases prior the beginning of therapya31264')|
|('DB09499', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'indicated for sequential intravenous use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be lifethreatening')|
|('DB09499', 'MONDO:0029000', ['poisoning'], 'indicated for sequential intravenous use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be lifethreatening')|
|('DB09502', 'MONDO:0029000', ['poisoning'], 'the uptake of 18ffdg by tissues is a marker for the tissue uptake of glucose which in turn is closely correlated with certain types of tissue metabolismfludeoxyglucose f 18 injection is indicated in positron emission tomography pet imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities or in patients with an existing diagnoses of cancer ')|
|('DB09502', 'MONDO:0004992', ['cancer'], 'the uptake of 18ffdg by tissues is a marker for the tissue uptake of glucose which in turn is closely correlated with certain types of tissue metabolismfludeoxyglucose f 18 injection is indicated in positron emission tomography pet imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities or in patients with an existing diagnoses of cancer ')|
|('DB09510', 'MONDO:0029000', ['poisoning'], 'urea13c is indicated for use in the qualitative detection of urease associated with helicobacter pylori in the human stomach and as an aid in the initial diagnosis and posttreatment monitoring of helicobacter pylori infection in adult patients the test may be used for monitoring treatment if used at least four 4 weeks following completion of therapy for these purposes the system utilizes an infrared spectrophotometer for the measurement of the ratio of 13co2 to 12co2 in breath samples')|
|('DB09511', 'MONDO:0029000', ['poisoning'], 'indicated to prevent recurrence of malignant pleural effusions in symptomatic patients during thoracoscopy or open thoracotomy')|
|('DB09512', 'MONDO:0029000', ['poisoning'], '1 to relieve pain and discomfort caused by excess gas in the intestine and stomach in cases such as flatulence and post operative gaseous distention2 it could be used also prior to an endoscopy to eliminate foam gas and air from the gastrointestinal tract to reduce gas shadow which will result in better visualization  ')|
|('DB09512', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], '1 to relieve pain and discomfort caused by excess gas in the intestine and stomach in cases such as flatulence and post operative gaseous distention2 it could be used also prior to an endoscopy to eliminate foam gas and air from the gastrointestinal tract to reduce gas shadow which will result in better visualization  ')|
|('DB09513', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], '14curea is intended for use in the detection of gastric urease as an aid in the diagnosis of helicobacter pylori h pylori infection in the human stomach the test utilizes a liquid scintillation counter for the measurement of 14co2 in breath samples')|
|('DB09516', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'mequinol is currently primarily available only as an active ingredient in combination products combined with tretinoin that are indicated for the treatment of solar lentigines and related hyperpigmented lesions resulting from chronic sun exposure fda label')|
|('DB09517', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'used to replete the total body content of iron during iron deficiency anemia in patients age 6 years and older with chronic kidney disease receiving hemodialysis and receiving supplemental epoetin therapy')|
|('DB09517', 'MONDO:0001356', ['iron deficiency anemia'], 'used to replete the total body content of iron during iron deficiency anemia in patients age 6 years and older with chronic kidney disease receiving hemodialysis and receiving supplemental epoetin therapy')|
|('DB09517', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'used to replete the total body content of iron during iron deficiency anemia in patients age 6 years and older with chronic kidney disease receiving hemodialysis and receiving supplemental epoetin therapy')|
|('DB09526', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'hydroquinone is used as an otc topical lightening agent for disorders of hyperpigmentation including melasma postinflammatory hyperpigmention sunspots and freckles ')|
|('DB09532', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for the stimulation of pancreatic secretions including bicarbonate to aid in the diagnosis of pancreatic exocrine dysfunction fda label gastrin secretion to aid in the diagnosis of gastrinoma fda label pancreatic secretions to facilitate the identification of the ampulla of vater and accessory papilla during endoscopic retrograde cholangiopancreatography ercp fda label')|
|('DB09534', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'applied topically to filter out uva rays')|
|('DB09535', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'in the us octocrylene has been evaluated by the fda and is considered safe for use up to 10 in the formula similarly the eu allows its use up to 10 in a formula while health canada allows a maximum use level of 12 ')|
|('DB09535', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'in the us octocrylene has been evaluated by the fda and is considered safe for use up to 10 in the formula similarly the eu allows its use up to 10 in a formula while health canada allows a maximum use level of 12 ')|
|('DB09536', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'titanium dioxide is used in most sunscreens to block uva and uvb rays similar to zinc oxide')|
|('DB09537', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'antispetic and germicidal agent it is indicated for use as a patient preoperative skin preparation for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection')|
|('DB09537', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'antispetic and germicidal agent it is indicated for use as a patient preoperative skin preparation for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection')|
|('DB09537', 'MONDO:0021201', ['skin infection [NCIT:C35025]', 'skin infection'], 'antispetic and germicidal agent it is indicated for use as a patient preoperative skin preparation for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection')|
|('DB09539', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'omega3acid ethyl esters capsules usp are indicated as an adjunct to diet to reduce triglyceride tg levels in adult patients with severe ≥500 mgdl hypertriglyceridemia htgfda labela176687')|
|('DB09539', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'omega3acid ethyl esters capsules usp are indicated as an adjunct to diet to reduce triglyceride tg levels in adult patients with severe ≥500 mgdl hypertriglyceridemia htgfda labela176687')|
|('DB09543', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbagosciatica and rheumatic conditions local analgesics for human and veterinary medicine')|
|('DB09546', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'for use in the diagnostic imaging of adrenergically inervated tissues for the purposes of detecting metastatic pheochromocytoma or neuroblastoma fda label also used to assess the sympathetic inervation of the myocardium via determination of the heart to mediastinum ratio of radioactivity in patients with new york heart association class ii or iii heart failure')|
|('DB09546', 'MONDO:0005072', ['neuroblastoma'], 'for use in the diagnostic imaging of adrenergically inervated tissues for the purposes of detecting metastatic pheochromocytoma or neuroblastoma fda label also used to assess the sympathetic inervation of the myocardium via determination of the heart to mediastinum ratio of radioactivity in patients with new york heart association class ii or iii heart failure')|
|('DB09552', 'MONDO:0005072', ['neuroblastoma'], 'used as a monocationic surfactant and detergent to help penetration of active ingredients through cellular debris for its antibacterial action')|
|('DB09555', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma and dermographism')|
|('DB09555', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma and dermographism')|
|('DB09555', 'MONDO:0005492', ['urticaria'], 'dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma and dermographism')|
|('DB09555', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma and dermographism')|
|('DB09555', 'MONDO:0007448', ['dermatographic urticaria', 'dermographism', 'familial dermatographia'], 'dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis due to inhalant allergens and foods mild uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma and dermographism')|
|('DB09559', 'MONDO:0010481', ['angioneurotic edema', 'Angioneurotic oedema', 'giant urticaria', 'Quinckes edema', 'angioedema'], 'necitumumab is approved for use in combination with cisplatin and gemcitabine as a firstline treatment for metastatic squamous nonsmall cell lung cancer nsclc it is not indicated for treatment of nonsquamous nsclc ')|
|('DB09559', 'MONDO:0004992', ['cancer'], 'necitumumab is approved for use in combination with cisplatin and gemcitabine as a firstline treatment for metastatic squamous nonsmall cell lung cancer nsclc it is not indicated for treatment of nonsquamous nsclc ')|
|('DB09559', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'necitumumab is approved for use in combination with cisplatin and gemcitabine as a firstline treatment for metastatic squamous nonsmall cell lung cancer nsclc it is not indicated for treatment of nonsquamous nsclc ')|
|('DB09561', 'MONDO:0004992', ['cancer'], 'sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition fda label it is used in combination with amino acids dextrose lipid emulsions and other electrolytes')|
|('DB09563', 'MONDO:0004992', ['cancer'], 'choline c 11 injection is indicated for  positron emission tomography pet imaging of patients with suspected prostate cancer recurrence and noninformative bone scintigraphy computerized tomography ct    or magnetic resonance imaging mri  in these patients 11 ccholine pet  imaging may  help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation suspected prostate recurrence is based upon elevated blood prostate specific antigen psa levels following initial therapy  in clinical studies imag   es w  ere produced with petct coregistration ')|
|('DB09563', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'choline c 11 injection is indicated for  positron emission tomography pet imaging of patients with suspected prostate cancer recurrence and noninformative bone scintigraphy computerized tomography ct    or magnetic resonance imaging mri  in these patients 11 ccholine pet  imaging may  help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation suspected prostate recurrence is based upon elevated blood prostate specific antigen psa levels following initial therapy  in clinical studies imag   es w  ere produced with petct coregistration ')|
|('DB09564', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus')|
|('DB09564', 'MONDO:0005015', ['diabetes mellitus'], 'insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus')|
|('DB09567', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for use in adults as a source of calories and fatty acids in total parenteral nutrition fda label sometimes used as an additive in cosmetic products')|
|('DB09568', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'om3ca is indicated as an adjunct to diet to reduce triglycerides levels in adults patients with severe hypertriglyceridemia 500 mgdl the patients involved in this treatment should be laced with an appropriate lipidlowering dietl2387hypertriglyceridemia is defined as an elevated plasma triglyceride concentration it is usually correlated to other secondary conditions such as poor diet alcohol use obesity metabolic syndrome and type 2 diabetesa32630')|
|('DB09570', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy ')|
|('DB09571', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'used overthecounter for nasal congestion')|
|('DB10276', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'rotarix is indicated for prevention of rotavirus gastroenteritis caused by g1 g3 g4 and g9 types in infants aged 624 weeks fda labelrotateq is indicated for the prevention of rotavirus gastroenteritis caused by g1 g2 g3 g4 and g9 types in infants aged 632 weeks l1116')|
|('DB10276', 'MONDO:0024491', ['well differentiated []', 'low grade []', 'G1 [NCIT:C28077]', 'grade I [NCIT:C28077]', 'grade 1 [NCIT:C28077]', 'tumor grade 1, general grading system'], 'rotarix is indicated for prevention of rotavirus gastroenteritis caused by g1 g3 g4 and g9 types in infants aged 624 weeks fda labelrotateq is indicated for the prevention of rotavirus gastroenteritis caused by g1 g2 g3 g4 and g9 types in infants aged 632 weeks l1116')|
|('DB10276', 'MONDO:0024494', ['G4 [NCIT:C28082]', 'undifferentiated []', 'grade IV [NCIT:C28082]', 'grade 4 [NCIT:C28082]', 'tumor grade 4, general grading system'], 'rotarix is indicated for prevention of rotavirus gastroenteritis caused by g1 g3 g4 and g9 types in infants aged 624 weeks fda labelrotateq is indicated for the prevention of rotavirus gastroenteritis caused by g1 g2 g3 g4 and g9 types in infants aged 632 weeks l1116')|
|('DB10276', 'MONDO:0024493', ['poorly differentiated []', 'grade 3 [NCIT:C28079]', 'grade III [NCIT:C28079]', 'G3 [NCIT:C28079]', 'tumor grade 3, general grading system'], 'rotarix is indicated for prevention of rotavirus gastroenteritis caused by g1 g3 g4 and g9 types in infants aged 624 weeks fda labelrotateq is indicated for the prevention of rotavirus gastroenteritis caused by g1 g2 g3 g4 and g9 types in infants aged 632 weeks l1116')|
|('DB10318', 'MONDO:0024493', ['poorly differentiated []', 'grade 3 [NCIT:C28079]', 'grade III [NCIT:C28079]', 'G3 [NCIT:C28079]', 'tumor grade 3, general grading system'], 'zostavax vaccine is indicated for the prevention of herpes zoster shingles in immunocompetent adults aged 50 years and oldervarivax vaccine is indicated for active immunization for the prevention of varicella in individuals 12 months of age and older')|
|('DB10318', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'zostavax vaccine is indicated for the prevention of herpes zoster shingles in immunocompetent adults aged 50 years and oldervarivax vaccine is indicated for active immunization for the prevention of varicella in individuals 12 months of age and older')|
|('DB10318', 'MONDO:0005700', ['varicella', 'chickenpox'], 'zostavax vaccine is indicated for the prevention of herpes zoster shingles in immunocompetent adults aged 50 years and oldervarivax vaccine is indicated for active immunization for the prevention of varicella in individuals 12 months of age and older')|
|('DB10400', 'MONDO:0005700', ['varicella', 'chickenpox'], 'dermatophagoides farinae extract  is  an  allergen  extract  indicated  as  immunotherapy  for  house   dust   mite   hdminduced   allergic   rhinitis   with   or   without   conjunctivitis   confirmed   by   in   vitro testing   for   ige   antibodies   to   dermatophagoidesfarinae  house dust  mites  or  skin  testing  to  licensed  house  dust  mite  allergen  extracts odactra is approved for use in adults 18 through 65 years of age')|
|('DB10400', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'dermatophagoides farinae extract  is  an  allergen  extract  indicated  as  immunotherapy  for  house   dust   mite   hdminduced   allergic   rhinitis   with   or   without   conjunctivitis   confirmed   by   in   vitro testing   for   ige   antibodies   to   dermatophagoidesfarinae  house dust  mites  or  skin  testing  to  licensed  house  dust  mite  allergen  extracts odactra is approved for use in adults 18 through 65 years of age')|
|('DB10400', 'MONDO:0003799', ['conjunctivitis'], 'dermatophagoides farinae extract  is  an  allergen  extract  indicated  as  immunotherapy  for  house   dust   mite   hdminduced   allergic   rhinitis   with   or   without   conjunctivitis   confirmed   by   in   vitro testing   for   ige   antibodies   to   dermatophagoidesfarinae  house dust  mites  or  skin  testing  to  licensed  house  dust  mite  allergen  extracts odactra is approved for use in adults 18 through 65 years of age')|
|('DB10401', 'MONDO:0003799', ['conjunctivitis'], 'dermatophagoides pteronyssinus is an allergen extract indicated as immunotherapy for house dust mite hdminduced allergic rhinitis with or without conjunctivitis confirmed by in vitro testing for ige antibodies to dermatophagoides pteronyssinus house dust mites or skin testing to licensed house dust mite allergen extracts dermatophagoides pteronyssinus is approved for use in adults 18 through 65 years of age ')|
|('DB10401', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'dermatophagoides pteronyssinus is an allergen extract indicated as immunotherapy for house dust mite hdminduced allergic rhinitis with or without conjunctivitis confirmed by in vitro testing for ige antibodies to dermatophagoides pteronyssinus house dust mites or skin testing to licensed house dust mite allergen extracts dermatophagoides pteronyssinus is approved for use in adults 18 through 65 years of age ')|
|('DB10552', 'MONDO:0003799', ['conjunctivitis'], 'for the treatment of pneumococcal pneumonia due to susceptible strains and group a betahemolytic streptococcal infections of the upper respiratory tract')|
|('DB10770', 'MONDO:0003799', ['conjunctivitis'], 'this device is indicated for use for the treatment of fullthickness  diabetic foot ulcers greater than six weeks duration which extends through the dermis but without tendon muscle joint capsule or bone exposure this drug should be used in conjunction with standard wound care regimens and in patients with an adequate blood supply to the involved foot l2418')|
|('DB10770', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'this device is indicated for use for the treatment of fullthickness  diabetic foot ulcers greater than six weeks duration which extends through the dermis but without tendon muscle joint capsule or bone exposure this drug should be used in conjunction with standard wound care regimens and in patients with an adequate blood supply to the involved foot l2418')|
|('DB10770', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'this device is indicated for use for the treatment of fullthickness  diabetic foot ulcers greater than six weeks duration which extends through the dermis but without tendon muscle joint capsule or bone exposure this drug should be used in conjunction with standard wound care regimens and in patients with an adequate blood supply to the involved foot l2418')|
|('DB10771', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for the management of wounds including partial and full thickness wounds pressure ulcers venous ulcers diabetic ulcers chronic vascular ulcers tunneledundermined wounds surgical wounds donor sitesgraft postmoh’s dermatological surgery postlaser surgery podiatric wound dehiscence trauma wounds abrasions lacerations seconddegree burns and skin tears and draining wounds l2500gintuit allogeneic cultured keratinocytes and fibroblasts in bovine collagen is an allogeneic cellularized scaffold product indicated for topical nonsubmerged application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults it uses bovine collagen as a matrix to support the growth of keratinocytes and fibroblasts in wound healing l2450 other products using bovine type 1 collagen include primatrix integra orcel and matriderm l2490orcel is a bilayered cellular matrix in which normal human allogeneic skin cells both epidermal keratinocytes and dermal fibroblasts are cultured in two separate layers into a type i bovine collagen sponge indicated in venous leg ulcers and diabetic foot type i bovine collagen acts as a matrix for the growth and proliferation of fibroblasts and keratinocytes offering structure and support l2427in the laboratory bovine collagen type i purified protein standard is used as a control for sdspage western blot elisa immunoprecipitation and for other immunological assays l2488')|
|('DB10771', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for the management of wounds including partial and full thickness wounds pressure ulcers venous ulcers diabetic ulcers chronic vascular ulcers tunneledundermined wounds surgical wounds donor sitesgraft postmoh’s dermatological surgery postlaser surgery podiatric wound dehiscence trauma wounds abrasions lacerations seconddegree burns and skin tears and draining wounds l2500gintuit allogeneic cultured keratinocytes and fibroblasts in bovine collagen is an allogeneic cellularized scaffold product indicated for topical nonsubmerged application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults it uses bovine collagen as a matrix to support the growth of keratinocytes and fibroblasts in wound healing l2450 other products using bovine type 1 collagen include primatrix integra orcel and matriderm l2490orcel is a bilayered cellular matrix in which normal human allogeneic skin cells both epidermal keratinocytes and dermal fibroblasts are cultured in two separate layers into a type i bovine collagen sponge indicated in venous leg ulcers and diabetic foot type i bovine collagen acts as a matrix for the growth and proliferation of fibroblasts and keratinocytes offering structure and support l2427in the laboratory bovine collagen type i purified protein standard is used as a control for sdspage western blot elisa immunoprecipitation and for other immunological assays l2488')|
|('DB10772', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for chronic leg ulcers and diabetic foot l2439  orcel is indicated for use with standard therapeutic compression for the treatment of noninfected partial and fullthickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy orcel is also for use with standard diabetic foot ulcer care for the treatment of fullthickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy and which extend through the dermis but without tendon muscle capsule or bone involvement l2459')|
|('DB10772', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'for chronic leg ulcers and diabetic foot l2439  orcel is indicated for use with standard therapeutic compression for the treatment of noninfected partial and fullthickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy orcel is also for use with standard diabetic foot ulcer care for the treatment of fullthickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy and which extend through the dermis but without tendon muscle capsule or bone involvement l2459')|
|('DB10772', 'MONDO:0000945', ['peripheral venous insufficiency', 'venous insufficiency'], 'for chronic leg ulcers and diabetic foot l2439  orcel is indicated for use with standard therapeutic compression for the treatment of noninfected partial and fullthickness skin ulcers due to venous insufficiency of greater than 1 month in duration and which have not effectively responded to conventional ulcer therapy orcel is also for use with standard diabetic foot ulcer care for the treatment of fullthickness neuropathic diabetic foot ulcers of greater than 3 weeks in duration which have not effectively responded to conventional ulcer therapy and which extend through the dermis but without tendon muscle capsule or bone involvement l2459')|
|('DB10804', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ cis of the urinary bladder and for the prophylaxis of primary or recurrent stage ta andor t1 papillary tumors following transurethral resection tur ')|
|('DB10804', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ cis of the urinary bladder and for the prophylaxis of primary or recurrent stage ta andor t1 papillary tumors following transurethral resection tur ')|
|('DB10805', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'yellow fever vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories1 persons living in or traveling to endemic areas while the actual risk for contracting yellow fever during travel is probably low variability of itineraries behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone2 persons travelling internationally through countries with yellow fever some countries require an individual to have a valid international certificate of vaccination or prophylaxis icvp if the individual has been in countries either known or thought to harbor yellow fever virus the certificate becomes valid 10 days after vaccination with yellow fever vaccine3 laboratory personnel laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols')|
|('DB10805', 'MONDO:0020502', ['jungle yellow fever', 'Sylvatic yellow fever', 'urban yellow fever', 'Yellow fever, sylvan', 'yellow fever'], 'yellow fever vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories1 persons living in or traveling to endemic areas while the actual risk for contracting yellow fever during travel is probably low variability of itineraries behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone2 persons travelling internationally through countries with yellow fever some countries require an individual to have a valid international certificate of vaccination or prophylaxis icvp if the individual has been in countries either known or thought to harbor yellow fever virus the certificate becomes valid 10 days after vaccination with yellow fever vaccine3 laboratory personnel laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols')|
|('DB10805', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'yellow fever vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories1 persons living in or traveling to endemic areas while the actual risk for contracting yellow fever during travel is probably low variability of itineraries behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone2 persons travelling internationally through countries with yellow fever some countries require an individual to have a valid international certificate of vaccination or prophylaxis icvp if the individual has been in countries either known or thought to harbor yellow fever virus the certificate becomes valid 10 days after vaccination with yellow fever vaccine3 laboratory personnel laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols')|
|('DB10989', 'MONDO:0020502', ['jungle yellow fever', 'Sylvatic yellow fever', 'urban yellow fever', 'Yellow fever, sylvan', 'yellow fever'], 'hepatitis a vaccine is indicated for active immunization against disease caused by hepatitis a virus hav it is approved for use in persons 12 months of age and older primary immunization should be administered at least 2 weeks prior to expected exposure to havhavrix® will not prevent hepatitis infection caused by other agents such as hepatitis b virus hepatitis c virus hepatitis e virus or other pathogens known to infect the liverin areas of low to intermediate prevalence of hepatitis a immunization with havrix® is particularly recommended in subjects who are or will be at increased risk of infection such as travelers persons traveling to areas where the prevalence of hepatitis a is high these areas include africa asia the mediterranean basin the middle east central and south america armed forces armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of hav infection active immunization is indicated for these individuals persons for whom hepatitis a is an occupational hazard these include employees in daycare centres nursing medical and paramedical personnel in hospitals and institutions especially gastroenterology and pediatric units sewage workers and food handlers among others persons for whom there is an increased risk of transmission of hepatitis a eg homosexuals persons with multiple sexual partners abusers of injectable drugs hemophiliac patients contacts of infected persons since virus shedding of infected persons may occur for a prolonged period active immunization of close contacts is recommended specific population groups known to have higher incidence of hepatitis a eg north american indians inuits recognized communitywide hav epidemics subjects with chronic liver disease or who are at risk of developing chronic liver disease eg hepatitis b hb and hepatitis c hc chronic carriers and alcohol abusers')|
|('DB10989', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'hepatitis a vaccine is indicated for active immunization against disease caused by hepatitis a virus hav it is approved for use in persons 12 months of age and older primary immunization should be administered at least 2 weeks prior to expected exposure to havhavrix® will not prevent hepatitis infection caused by other agents such as hepatitis b virus hepatitis c virus hepatitis e virus or other pathogens known to infect the liverin areas of low to intermediate prevalence of hepatitis a immunization with havrix® is particularly recommended in subjects who are or will be at increased risk of infection such as travelers persons traveling to areas where the prevalence of hepatitis a is high these areas include africa asia the mediterranean basin the middle east central and south america armed forces armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of hav infection active immunization is indicated for these individuals persons for whom hepatitis a is an occupational hazard these include employees in daycare centres nursing medical and paramedical personnel in hospitals and institutions especially gastroenterology and pediatric units sewage workers and food handlers among others persons for whom there is an increased risk of transmission of hepatitis a eg homosexuals persons with multiple sexual partners abusers of injectable drugs hemophiliac patients contacts of infected persons since virus shedding of infected persons may occur for a prolonged period active immunization of close contacts is recommended specific population groups known to have higher incidence of hepatitis a eg north american indians inuits recognized communitywide hav epidemics subjects with chronic liver disease or who are at risk of developing chronic liver disease eg hepatitis b hb and hepatitis c hc chronic carriers and alcohol abusers')|
|('DB10990', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by haemophilus influenzae type b ')|
|('DB10997', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'cellular repair strategy for patients with symptomatic cartilage defects of the femoral condyle medial lateral or trochlea caused by trauma or patients who were previously unresponsive to available surgical procedures ')|
|('DB10997', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'cellular repair strategy for patients with symptomatic cartilage defects of the femoral condyle medial lateral or trochlea caused by trauma or patients who were previously unresponsive to available surgical procedures ')|
|('DB11051', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults fda label')|
|('DB11054', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited acquired or result from myeloablative treatment fda label ')|
|('DB11054', 'MONDO:0021152', ['inherited'], 'indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited acquired or result from myeloablative treatment fda label ')|
|('DB11056', 'MONDO:0021152', ['inherited'], 'stannous chloride is a component of technetium99m agents indicated for imaging of the skeleton for areas of altered osteogenesis or in the detection of  infarcted heart tissue fda label')|
|('DB11057', 'MONDO:0021152', ['inherited'], 'mineral oil is not considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indication it is typically present in topical formulations as an emollient and occlusive agent t182')|
|('DB11057', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'mineral oil is not considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indication it is typically present in topical formulations as an emollient and occlusive agent t182')|
|('DB11058', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use as an over the counter skin protectant fda label commonly used to treat diaper rash and chapped lips fda label l858')|
|('DB11058', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'for use as an over the counter skin protectant fda label commonly used to treat diaper rash and chapped lips fda label l858')|
|('DB11059', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'indicated for the symptomatic relief of burning irritation and discomfort of the eyes due to dryness or exposure to wind or sun')|
|('DB11060', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'for use as a lubricant to prevent further irritation or to relieve dryness of the eyes l2828')|
|('DB11061', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'when in complex with iodine indicated for inducing antisepsis for prevention of infection in minor cuts scrapes and burns ')|
|('DB11062', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'ingredient in sunscreens for protection against damage effects of sun light provides protection from sunburns aging and skin cancer ')|
|('DB11062', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'ingredient in sunscreens for protection against damage effects of sun light provides protection from sunburns aging and skin cancer ')|
|('DB11063', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'it is used as a solubilizer antimicrobial preservative and disinfectant l1853')|
|('DB11064', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'as ingredient in many sunscreen for protection against sunburn skin aging and skin cancer ')|
|('DB11064', 'MONDO:0005326', ['sunburn'], 'as ingredient in many sunscreen for protection against sunburn skin aging and skin cancer ')|
|('DB11064', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'as ingredient in many sunscreen for protection against sunburn skin aging and skin cancer ')|
|('DB11065', 'MONDO:0005326', ['sunburn'], 'please refer to db00085')|
|('DB11066', 'MONDO:0005326', ['sunburn'], 'please refer to db00085')|
|('DB11068', 'MONDO:0005326', ['sunburn'], 'indicated for use as a nutritional supplement ')|
|('DB11071', 'MONDO:0005326', ['sunburn'], 'pain and fever l2468')|
|('DB11073', 'MONDO:0005326', ['sunburn'], 'typically employed as the cetylpyridinium chloride salt this compound is commonly used as an active ingredient in various overthecounter mouthwashes toothpastes lozenges and mouth sprays where it is generally indicated for antiseptic actions gingivitis and plaque prevention as well as action or prevention against some other oropharyngeal bacterial infections a24813 l2754 l2755')|
|('DB11073', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'typically employed as the cetylpyridinium chloride salt this compound is commonly used as an active ingredient in various overthecounter mouthwashes toothpastes lozenges and mouth sprays where it is generally indicated for antiseptic actions gingivitis and plaque prevention as well as action or prevention against some other oropharyngeal bacterial infections a24813 l2754 l2755')|
|('DB11074', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'dimethicone is a colorless liquid with both cosmetic and therapeutic uses it is used in topical creams and ointments to help distribute the active ingredients dimethicone is used as an antifoaming agent a hair and skin conditioner and in the treatment of head lice and as an antibloatingantiflatulence agent l1765 l1772')|
|('DB11075', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'protectant ophthalmic l1805tears artificial l1805lubricant ophthalmic l1805diagnostic aid contact lens procedures gonioscopy l1805')|
|('DB11077', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'peg400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye andfor protection against further irritation and desiccation l1795 l1796 l1797')|
|('DB11079', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the temporary relief of aches and pains of muscles and joints associated with backache lumbago strains bruises sprains and arthritic or rheumatic pain pain of tendons and ligaments l1791')|
|('DB11081', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], ' indicated for the control of minor hemorrhage during dental restorative procedures indicated to reduce underarm perspiration')|
|('DB11082', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'relieving itching irritation redness dryness scaling and flaking of the skin caused by psoriasis seborrhea or eczema ')|
|('DB11082', 'MONDO:0005083', ['psoriasis'], 'relieving itching irritation redness dryness scaling and flaking of the skin caused by psoriasis seborrhea or eczema ')|
|('DB11082', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'relieving itching irritation redness dryness scaling and flaking of the skin caused by psoriasis seborrhea or eczema ')|
|('DB11085', 'MONDO:0005083', ['psoriasis'], 'contemporary therapeutic uses for resorcinol primarily revolve around the use of the phenol derivative as an active ingredient in topical antiseptics l2745 l2744 l2727 f61 or as topical antibacterial skin treatment products for conditions like acne seborrheic dermatitis eczema and others l2746 l2745 l2744 l2727 f61')|
|('DB11085', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'contemporary therapeutic uses for resorcinol primarily revolve around the use of the phenol derivative as an active ingredient in topical antiseptics l2745 l2744 l2727 f61 or as topical antibacterial skin treatment products for conditions like acne seborrheic dermatitis eczema and others l2746 l2745 l2744 l2727 f61')|
|('DB11085', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'contemporary therapeutic uses for resorcinol primarily revolve around the use of the phenol derivative as an active ingredient in topical antiseptics l2745 l2744 l2727 f61 or as topical antibacterial skin treatment products for conditions like acne seborrheic dermatitis eczema and others l2746 l2745 l2744 l2727 f61')|
|('DB11086', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for topical use in overthecounter skin products for the treatment of skin dryness and reduction of striae gravidarum stretch marks ')|
|('DB11089', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the treatment of constipation associated with dry hard stools or opioid induced constipationa176984 though recently pressure has been building to end the use of docusate over concerns of efficacya176972a176987l5912')|
|('DB11090', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'for the relief of tooth sensitivity and is also used as a pesticide insecticide as a food additive and a rodenticide l1751 l1754 l1757')|
|('DB11091', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated to be used as a disinfectant and sterilizer ')|
|('DB11092', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for use to relieve dental hypersensitivity increase enamel production prevent gingivitis and cavities and control periodontal infections ')|
|('DB11092', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'indicated for use to relieve dental hypersensitivity increase enamel production prevent gingivitis and cavities and control periodontal infections ')|
|('DB11093', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'for use as an over the counter calcium supplement')|
|('DB11094', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'vitamin d is indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia fda label')|
|('DB11094', 'MONDO:0001220', ['hypoparathyroidism'], 'vitamin d is indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia fda label')|
|('DB11094', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'vitamin d is indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia fda label')|
|('DB11095', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery ')|
|('DB11096', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'meradimate is used as an active ingredient in sunscreens or as a sunblock factor in different products it fits under the category of broadspectrum absorbent agent these characteristics are important to consider due to the fact that this kind of ingredients can either absorb or reflect uv radiation it is also important to know the type of rays that cover uva rays are the responsible of causing sun damage and reaching deeper layers of the skin while uvb can only cause sunburn in the outer layer of the skin when an agent is of broad spectrum this means that this agent is capable of acting in both uva and uvb raysl2749')|
|('DB11096', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'meradimate is used as an active ingredient in sunscreens or as a sunblock factor in different products it fits under the category of broadspectrum absorbent agent these characteristics are important to consider due to the fact that this kind of ingredients can either absorb or reflect uv radiation it is also important to know the type of rays that cover uva rays are the responsible of causing sun damage and reaching deeper layers of the skin while uvb can only cause sunburn in the outer layer of the skin when an agent is of broad spectrum this means that this agent is capable of acting in both uva and uvb raysl2749')|
|('DB11096', 'MONDO:0005326', ['sunburn'], 'meradimate is used as an active ingredient in sunscreens or as a sunblock factor in different products it fits under the category of broadspectrum absorbent agent these characteristics are important to consider due to the fact that this kind of ingredients can either absorb or reflect uv radiation it is also important to know the type of rays that cover uva rays are the responsible of causing sun damage and reaching deeper layers of the skin while uvb can only cause sunburn in the outer layer of the skin when an agent is of broad spectrum this means that this agent is capable of acting in both uva and uvb raysl2749')|
|('DB11097', 'MONDO:0005326', ['sunburn'], 'indications include the treatment of patients needing a high fibre regime perhaps for a the relief of constipation including constipation in pregnancy and the maintenance of regularity b the management of bowel function in patients with colostomy ileostomy hemorrhoids anal fissure chronic diarrhea with diverticular disease irritable bowel syndrome and ulcerative colitis l1865')|
|('DB11097', 'MONDO:0002519', ['anal disease', 'anal fissure', 'anal fissure and fistula', 'anal ulcer', 'fissure in ano', 'Nontraumatic tear of anus', 'Solitary anal ulcer', 'Ulcer of anus', 'anus disease'], 'indications include the treatment of patients needing a high fibre regime perhaps for a the relief of constipation including constipation in pregnancy and the maintenance of regularity b the management of bowel function in patients with colostomy ileostomy hemorrhoids anal fissure chronic diarrhea with diverticular disease irritable bowel syndrome and ulcerative colitis l1865')|
|('DB11097', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'indications include the treatment of patients needing a high fibre regime perhaps for a the relief of constipation including constipation in pregnancy and the maintenance of regularity b the management of bowel function in patients with colostomy ileostomy hemorrhoids anal fissure chronic diarrhea with diverticular disease irritable bowel syndrome and ulcerative colitis l1865')|
|('DB11098', 'MONDO:0005101', ['Left-sided ulcerative colitis', 'ulcerative colitis'], 'potassium bicarbonate is used as an antacid electrolyte replenisher and potassium supplement it can also be used as an excipient in drug formulationsl1837 an antacid is a medication used to neutralize gastric acid in a short timeframe after ingestion and the effect is soon overcome by mealstimulated acid secretiona32214')|
|('DB11098', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'potassium bicarbonate is used as an antacid electrolyte replenisher and potassium supplement it can also be used as an excipient in drug formulationsl1837 an antacid is a medication used to neutralize gastric acid in a short timeframe after ingestion and the effect is soon overcome by mealstimulated acid secretiona32214')|
|('DB11100', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'allantoin is commonly applied in a variety of topical vehicles or applications such as cosmetic creams toothpastes mouthwashes shampoos lipsticks antiacne products and lotions a32213 for the purpose of moisturizing skin enhancing the smoothness of skin stimulating the healing of wounds and soothing irritated skin a32213 fda label')|
|('DB11102', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'nacetyltyrosine is indicated in combination with several other amino acids and dextrose as a peripherally administered source of nitrogen for nutritional support in patients with adequate stores of body fat in whom for short periods oral administration cannot be tolerated is undesirable or inadequate fda labelit is also indicated with other amino acids 510 dextrose and fat emulsion  for parenteral nutrition to preserve protein and reduce catabolism in stress conditions where oral administration is inadequate fda labelwhen administered with other amino acids and concentrated dextrose it is indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract by the oral gastrostomy or jejestomy routes cannot or should not be used or in patients in which gastrointestinal absorption of protein is impaired metabolic requirements for protein are substantially increased or morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown fda label')|
|('DB11104', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'echocardiography sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border ultrasonography of the liver sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions')|
|('DB11105', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'when used as an active ingredient in products like antibacterial antiseptic or disinfectant soaps topical sanitizers or cleaning agents benzalkonium is primarily implemented in its salt form benzalkonium chloride where it may often be the only active ingredient present and indicated for the primary purpose of topical washing to decrease bacteria on skin l1806conversely when implemented as an excipient ingredient in a variety of multidose aqueous nose eye or ear products benzalkonium chloride is being used as the antimicrobial preservative of choice to facilitate effective bactericidal and fungicidal actions to help minimize the growth of unwanted organisms in the multidose containers fda label ')|
|('DB11107', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for the treatment of constipation ')|
|('DB11110', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'magnesium citrate has been used in bowel preparations prior to a colonoscopy as a cathartic agentt215 it is also used in overthecounter products to relieve occasional constipationl2841magnesium citrate can be one of the forms used for the administration of dietary supplementsl2842')|
|('DB11110', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'magnesium citrate has been used in bowel preparations prior to a colonoscopy as a cathartic agentt215 it is also used in overthecounter products to relieve occasional constipationl2841magnesium citrate can be one of the forms used for the administration of dietary supplementsl2842')|
|('DB11112', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as a skin protectant and to relieve dryness and irritation of the skin l2586 l2581 helps prevent and treat diaper dermatitis l2579')|
|('DB11112', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'used as a skin protectant and to relieve dryness and irritation of the skin l2586 l2581 helps prevent and treat diaper dermatitis l2579')|
|('DB11113', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for overthecounter use as a laxative for oral use and as a soothing agent for topical use on skin and hair ')|
|('DB11114', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'as an active agent eucalyptus oil has been indicated for relief of the symptoms of catarrhal colds andor the relief of the symptoms of minor muscular sprains and cramps l1857')|
|('DB11114', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'as an active agent eucalyptus oil has been indicated for relief of the symptoms of catarrhal colds andor the relief of the symptoms of minor muscular sprains and cramps l1857')|
|('DB11115', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated to be used as an uvbabsorbing molecule in sunscreen formulations ')|
|('DB11117', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of fungal infections as a salt form no therapeutic indications on its own')|
|('DB11118', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], ' indicated for use as a smelling salt to treat or prevent fainting  when radiolabelled indicated for diagnostic pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease fda label')|
|('DB11118', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], ' indicated for use as a smelling salt to treat or prevent fainting  when radiolabelled indicated for diagnostic pet imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease fda label')|
|('DB11119', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn l2065 ')|
|('DB11120', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'turpentine has been used experimentally in a bath for the treatment of disseminated sclerosis and sexual dysfunction it also has been studied for its antibacterial activity and inhibition of osteoclast activity turpentine is utilized in experimental models of inflammation to induce a systemic inflammatory immune response in animals')|
|('DB11120', 'MONDO:0022202', ['disseminated'], 'turpentine has been used experimentally in a bath for the treatment of disseminated sclerosis and sexual dysfunction it also has been studied for its antibacterial activity and inhibition of osteoclast activity turpentine is utilized in experimental models of inflammation to induce a systemic inflammatory immune response in animals')|
|('DB11121', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the predominant medical applications for which chloroxylenol is formally indicated for therapeutic use is as an application to the skin for use in cuts bites stings abrasions and for use as antiseptic hand cleaner l1992')|
|('DB11123', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for overthecounter use as a disinfectant agent in the sodium hypochlorite form ')|
|('DB11124', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for temporary relief of mild symptoms of intermittent asthma')|
|('DB11125', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated as an antiseptic agent no therapeutic indications for clinical use ')|
|('DB11126', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'oral calcium salts are used as dietary supplemental therapy for person who may not get enough calcium in their regular diet calcium gluconate is used as a cardioprotective agent in high blood potassium calcium gluconate is the antidote for magnesium sulfate toxicity')|
|('DB11127', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'selenium injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn administration of selenious acid in tpn formulas helps to maintain plasma selenium levels and also to maintain endogenous stores to prevent deficiency l1922selenium compounds such as selenium sulfide are used topically in antidandruff shampoos and in cases of seborrhea l1916  for the purpose of brevity selenite will the focus of discussion and more information about selenium can be obtained at db11135')|
|('DB11127', 'MONDO:0006608', ['seborrhea', 'Seborrhoeic dermatitis', 'Seborrhoeic eczema', 'SKIN SEBORRHEIC', 'seborrheic dermatitis'], 'selenium injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn administration of selenious acid in tpn formulas helps to maintain plasma selenium levels and also to maintain endogenous stores to prevent deficiency l1922selenium compounds such as selenium sulfide are used topically in antidandruff shampoos and in cases of seborrhea l1916  for the purpose of brevity selenite will the focus of discussion and more information about selenium can be obtained at db11135')|
|('DB11127', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'selenium injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn administration of selenious acid in tpn formulas helps to maintain plasma selenium levels and also to maintain endogenous stores to prevent deficiency l1922selenium compounds such as selenium sulfide are used topically in antidandruff shampoos and in cases of seborrhea l1916  for the purpose of brevity selenite will the focus of discussion and more information about selenium can be obtained at db11135')|
|('DB11129', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated as a dental bleaching agent indicated as an oral wound healing agent in oral mucosal injuriesindicated as an aid in the removal of hardened ear wax')|
|('DB11130', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'opium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain opium and its alkaloidderivatives can also be used as tranquilizers antitussives and in the treatment of diarrheat138 the direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine as well as the use of a tincture of opium for severe diarrhea can be seen in medical practicet139illegal use of opium has been registered to be for both recreational and medicinal purposesa32182')|
|('DB11130', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'opium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain opium and its alkaloidderivatives can also be used as tranquilizers antitussives and in the treatment of diarrheat138 the direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine as well as the use of a tincture of opium for severe diarrhea can be seen in medical practicet139illegal use of opium has been registered to be for both recreational and medicinal purposesa32182')|
|('DB11131', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the temporary relief of minor aches and pains of muscles and joints associated with simple backache arthritis strains and sprains ')|
|('DB11131', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for the temporary relief of minor aches and pains of muscles and joints associated with simple backache arthritis strains and sprains ')|
|('DB11133', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'provided as daily supplements aa preparation of omega3acid ethyl esters is licensed in uk for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia ')|
|('DB11133', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'provided as daily supplements aa preparation of omega3acid ethyl esters is licensed in uk for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia ')|
|('DB11134', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'no fda or emaapproved therapeutic indications ')|
|('DB11135', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the supplementation of total parenteral nutrition to prevent hyposelenemia fda label')|
|('DB11136', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB11141', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'manganese gluconate is currently only available in combination products it is indicated for the prophylactic or nutritional supplementation of db06757 fda label')|
|('DB11143', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'the primary medical indications for cresols in general include being used as bactericides pesticides and disinfectants l2020 certain isomers of cresol like mcresol may be used as inactive ingredients for the purpose of serving as a preservative in some pharmaceuticals l2020 conversely many other active pharmaceuticals are also derivatives of various cresol isomer precursors or intermediates l2049')|
|('DB11145', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'oxyquinoline is used as a biocidal component of several over the counter products these products are marketed for the purposes of inhibiting abnormal biological growth in the vagina and restoring natural ph ')|
|('DB11148', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'butamben was indicated for the treatment of chronic pain due to its longduration effecta32663 it is also indicated as a surface anesthetic for skin a mucous membrane and for the relief of pain and pruritus associated with anorectal disordersl2445')|
|('DB11150', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], ' barium sulfate is a radiographic contrast agent indicated for use in computed tomography ct of the abdomen to delineate the gastrointestinal gi tract in adult and pediatric patients fda label')|
|('DB11151', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'used to destroy or kill the nail matrix matrixectomies l1968')|
|('DB11153', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'medically the microscopic examination of potassium hydroxide koh preparations is utilized in the diagnosis of fungal hyphae or trichomonads l1950samples from hair skin or nail tissue are obtained by scraping with a scalpel cottontipped applicator and are inoculated directly onto the koh solution l1950in addition to the above potassium hydroxide is used as a softener for nail grooves l1949')|
|('DB11155', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'triclocarban tcc or 344trichlorocarbanilide is an antibacterial agent used in bar and liquid soaps and body washes l2685')|
|('DB11156', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'for the treatment of enterobiasis including roundworm ascariasis pinworm enterobius and hookworm strongyloides and hookworm ancylostoma in the pyrantel pamoate form l1893pyrantel is available in various formulations for humans dogs and cats as the pamoate us pharmacopeia nomenclature or embonate european pharmacopoeia nomenclature salt which contains 347 pyrantel base combined with pamoic acid l1893 l1900 a32283pyrantel pamoate embonate ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs adult toxocara canis toxascaris leonina ancylostoma tubaeforme an braziliense uncinaria stenocephala cats adult toxocara cati toxa leonina an caninum an braziliense u stenocephala horses and ponies adult and immature parascaris equorum adult strongylus vulgaris s edentatus s equinus cyathostomes triodontophorus spp cyathostomum spp cylicodontophorus spp cylicocyclus spp cylicostephanus spp poteriostomum spp oxyuris equi anoplocephala perfoliata swine adult ascaris suum oesophagostomum dentatum and humans adult a lumbricoides enterobius vermicularis an duodenale necator americanus l1900')|
|('DB11156', 'MONDO:0005746', ['Oxyuris vermicularis infection', 'Threadworm infection', 'enterobiasis'], 'for the treatment of enterobiasis including roundworm ascariasis pinworm enterobius and hookworm strongyloides and hookworm ancylostoma in the pyrantel pamoate form l1893pyrantel is available in various formulations for humans dogs and cats as the pamoate us pharmacopeia nomenclature or embonate european pharmacopoeia nomenclature salt which contains 347 pyrantel base combined with pamoic acid l1893 l1900 a32283pyrantel pamoate embonate ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs adult toxocara canis toxascaris leonina ancylostoma tubaeforme an braziliense uncinaria stenocephala cats adult toxocara cati toxa leonina an caninum an braziliense u stenocephala horses and ponies adult and immature parascaris equorum adult strongylus vulgaris s edentatus s equinus cyathostomes triodontophorus spp cyathostomum spp cylicodontophorus spp cylicocyclus spp cylicostephanus spp poteriostomum spp oxyuris equi anoplocephala perfoliata swine adult ascaris suum oesophagostomum dentatum and humans adult a lumbricoides enterobius vermicularis an duodenale necator americanus l1900')|
|('DB11156', 'MONDO:0005654', ['Ascariasis - roundworm', 'ascariasis'], 'for the treatment of enterobiasis including roundworm ascariasis pinworm enterobius and hookworm strongyloides and hookworm ancylostoma in the pyrantel pamoate form l1893pyrantel is available in various formulations for humans dogs and cats as the pamoate us pharmacopeia nomenclature or embonate european pharmacopoeia nomenclature salt which contains 347 pyrantel base combined with pamoic acid l1893 l1900 a32283pyrantel pamoate embonate ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs adult toxocara canis toxascaris leonina ancylostoma tubaeforme an braziliense uncinaria stenocephala cats adult toxocara cati toxa leonina an caninum an braziliense u stenocephala horses and ponies adult and immature parascaris equorum adult strongylus vulgaris s edentatus s equinus cyathostomes triodontophorus spp cyathostomum spp cylicodontophorus spp cylicocyclus spp cylicostephanus spp poteriostomum spp oxyuris equi anoplocephala perfoliata swine adult ascaris suum oesophagostomum dentatum and humans adult a lumbricoides enterobius vermicularis an duodenale necator americanus l1900')|
|('DB11157', 'MONDO:0005654', ['Ascariasis - roundworm', 'ascariasis'], 'stable plaque psoriasis of the skin and scalp l1933it is also used topically in the management of psoriasis dermatoses and alopecia areata anthralin is also used in biomedical research due to its effect on egfr autophosphorylation l1936')|
|('DB11157', 'MONDO:0005083', ['psoriasis'], 'stable plaque psoriasis of the skin and scalp l1933it is also used topically in the management of psoriasis dermatoses and alopecia areata anthralin is also used in biomedical research due to its effect on egfr autophosphorylation l1936')|
|('DB11157', 'MONDO:0005340', ['Circumscribed alopecia', 'alopecia areata'], 'stable plaque psoriasis of the skin and scalp l1933it is also used topically in the management of psoriasis dermatoses and alopecia areata anthralin is also used in biomedical research due to its effect on egfr autophosphorylation l1936')|
|('DB11158', 'MONDO:0005340', ['Circumscribed alopecia', 'alopecia areata'], 'pectin is used in food as a gelling agent and stabilizer as a medical drug it has obtained a great interest in its potential use as a source of dietary fiber lipid cholesterol serum glucose and insulin level lowering effect gastric emptying delaya32327 some recent studies have researched the possibility of using pectin for the formation of nanoparticles as a delivery vehicle of drugsa32331')|
|('DB11158', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'pectin is used in food as a gelling agent and stabilizer as a medical drug it has obtained a great interest in its potential use as a source of dietary fiber lipid cholesterol serum glucose and insulin level lowering effect gastric emptying delaya32327 some recent studies have researched the possibility of using pectin for the formation of nanoparticles as a delivery vehicle of drugsa32331')|
|('DB11160', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the primary therapeutic use for which phenyltoloxamine is currently indicated is as an adjuvant therapy in various combination products containing an analgesics either narcotic or nonnarcotic where it is expected to potentiate the pain relieving antitussive etc effects of the analgesic component of the productin that regard some of these aforementioned combination products are typically indicated for the temporary relief of minor aches and pains like headache muscular aches backaches minor arthritis pain common cold toothaches menstrual cramps etc l2499 or perhaps for the treatment of exhausting or nonproductive cough associated with cold or with upper respiratory allergic condition that does not respond to nonnarcotic antitussives l2495')|
|('DB11160', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'the primary therapeutic use for which phenyltoloxamine is currently indicated is as an adjuvant therapy in various combination products containing an analgesics either narcotic or nonnarcotic where it is expected to potentiate the pain relieving antitussive etc effects of the analgesic component of the productin that regard some of these aforementioned combination products are typically indicated for the temporary relief of minor aches and pains like headache muscular aches backaches minor arthritis pain common cold toothaches menstrual cramps etc l2499 or perhaps for the treatment of exhausting or nonproductive cough associated with cold or with upper respiratory allergic condition that does not respond to nonnarcotic antitussives l2495')|
|('DB11161', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated as a lubricant in overthecounter ophthalmic solutions to temporarily relieve redness burning and irritation of the eyes')|
|('DB11164', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'bicisate as a complex with technetium tc99m is used in single photon emission computerized tomography spect as an adjunct to conventional ct or mri in the localization of stroke in patients whom the presence of a stroke has already been diagnosed it is not indicated to assess the functional viability of brain tissue or to distinguish between a stroke and other brain lesionsl2034a stroke is defined as a condition in which the blood stops flowing to any part of the brain causing a damage to brain cells the potential effect of a stroke depends on the part of the brain that was affected by it as well as the extension of the damagel2069')|
|('DB11164', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'bicisate as a complex with technetium tc99m is used in single photon emission computerized tomography spect as an adjunct to conventional ct or mri in the localization of stroke in patients whom the presence of a stroke has already been diagnosed it is not indicated to assess the functional viability of brain tissue or to distinguish between a stroke and other brain lesionsl2034a stroke is defined as a condition in which the blood stops flowing to any part of the brain causing a damage to brain cells the potential effect of a stroke depends on the part of the brain that was affected by it as well as the extension of the damagel2069')|
|('DB11164', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'bicisate as a complex with technetium tc99m is used in single photon emission computerized tomography spect as an adjunct to conventional ct or mri in the localization of stroke in patients whom the presence of a stroke has already been diagnosed it is not indicated to assess the functional viability of brain tissue or to distinguish between a stroke and other brain lesionsl2034a stroke is defined as a condition in which the blood stops flowing to any part of the brain causing a damage to brain cells the potential effect of a stroke depends on the part of the brain that was affected by it as well as the extension of the damagel2069')|
|('DB11166', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'antithrombin alfa is a recombinant antithrombin it is indicated for the prevention of perioperative and peripartum thromboembolic events in patients with hereditary deficiency of antithrombin ')|
|('DB11168', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'no approved therapeutic indications ')|
|('DB11171', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'ferric sulfate was first used in dermatology as part of the monsels solution this solution is an antihemorrhagic agent used in skin and mucosal biopsies the use of ferric sulfate in dermatology is under review as ferric sulfate is corrosive and injurious and it can cause degenerative changes that are not observed with other alternatives like collagena32357ferric sulfate is also used as a coagulative and hemostatic agent it is a mechanic hemostatic agent used directly on the damaged tissuea32355in dentistry ferric sulfate is used as a pulpotomy medicament to control pulpal bleeding as an antibacterial agent and as a hemostatic reagent for restorative dentistry for postextraction hemorrhage and for periradicular and endodontic surgerya32356')|
|('DB11171', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ferric sulfate was first used in dermatology as part of the monsels solution this solution is an antihemorrhagic agent used in skin and mucosal biopsies the use of ferric sulfate in dermatology is under review as ferric sulfate is corrosive and injurious and it can cause degenerative changes that are not observed with other alternatives like collagena32357ferric sulfate is also used as a coagulative and hemostatic agent it is a mechanic hemostatic agent used directly on the damaged tissuea32355in dentistry ferric sulfate is used as a pulpotomy medicament to control pulpal bleeding as an antibacterial agent and as a hemostatic reagent for restorative dentistry for postextraction hemorrhage and for periradicular and endodontic surgerya32356')|
|('DB11180', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tetrofosmin is indicated to be used as a complex with technetium tc99m for scintigraphic imaging of the myocardium following separate administrations under exercise andor resting conditions it helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardiuml2001this complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery diseasel2001this complex is indicated for the assessment of left ventricular function in patients evaluated for heart diseasel2001')|
|('DB11181', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated as an overdoserescuing agent in combination with hydrocodone antitussive fda labelindicated for the induction of mydriasis in ophthalmic solutions ')|
|('DB11182', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected and as an aid in the diagnosis of keratoconjunctivitis sicca keratitis abrasions or corrosions as well as the detection of foreign bodies')|
|('DB11182', 'MONDO:0004768', ['keratoconjunctivitis'], 'indicated as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected and as an aid in the diagnosis of keratoconjunctivitis sicca keratitis abrasions or corrosions as well as the detection of foreign bodies')|
|('DB11182', 'MONDO:0003085', ['keratitis'], 'indicated as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected and as an aid in the diagnosis of keratoconjunctivitis sicca keratitis abrasions or corrosions as well as the detection of foreign bodies')|
|('DB11185', 'MONDO:0003085', ['keratitis'], 'sunscreening agents are used to prevent sunburn actinic keratosis and premature skin aging and to reduce the incidence of skin cancer l2664')|
|('DB11185', 'MONDO:0005326', ['sunburn'], 'sunscreening agents are used to prevent sunburn actinic keratosis and premature skin aging and to reduce the incidence of skin cancer l2664')|
|('DB11185', 'MONDO:0006566', ['keratosis'], 'sunscreening agents are used to prevent sunburn actinic keratosis and premature skin aging and to reduce the incidence of skin cancer l2664')|
|('DB11185', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'sunscreening agents are used to prevent sunburn actinic keratosis and premature skin aging and to reduce the incidence of skin cancer l2664')|
|('DB11186', 'MONDO:0002898', ['CA - skin cancer', 'malignant neoplasm of skin', 'melanoma and Non-melanoma skin cancer', 'skin cancer'], 'indicated as a cough suppressant to relieve cough caused by the common cold flu bronchitis and sinusitis a32160 ')|
|('DB11186', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'indicated as a cough suppressant to relieve cough caused by the common cold flu bronchitis and sinusitis a32160 ')|
|('DB11186', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'indicated as a cough suppressant to relieve cough caused by the common cold flu bronchitis and sinusitis a32160 ')|
|('DB11186', 'MONDO:0005961', ['sinusitis'], 'indicated as a cough suppressant to relieve cough caused by the common cold flu bronchitis and sinusitis a32160 ')|
|('DB11193', 'MONDO:0005961', ['sinusitis'], 'no fdaapproved therapeutic indications ')|
|('DB11195', 'MONDO:0005961', ['sinusitis'], 'indicated for use as a sugar substitute and oral hygiene active ingredient ')|
|('DB11198', 'MONDO:0005961', ['sinusitis'], 'indicated for the overthecounter use forthe symptomatic relief of minor spasms of the gastrointestinal tract flatulence and abdominal pain especially in patients with irritable bowel syndromethe temporary relief of itching associated with insect bites eczema minor burn sunburn minor skin irritations minor cuts scrapes atopic dermatitis and other skin disordersthe temporary symptomatic relief of mild joint and muscle pain as a local topical analgesicthe temporary relief of tensiontype headache')|
|('DB11198', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the overthecounter use forthe symptomatic relief of minor spasms of the gastrointestinal tract flatulence and abdominal pain especially in patients with irritable bowel syndromethe temporary relief of itching associated with insect bites eczema minor burn sunburn minor skin irritations minor cuts scrapes atopic dermatitis and other skin disordersthe temporary symptomatic relief of mild joint and muscle pain as a local topical analgesicthe temporary relief of tensiontype headache')|
|('DB11198', 'MONDO:0043519', ['Burn [NCIT:C34441]', 'burn [MESH:D002056]', 'Burn(s) [NCIT:C34441]', 'burn'], 'indicated for the overthecounter use forthe symptomatic relief of minor spasms of the gastrointestinal tract flatulence and abdominal pain especially in patients with irritable bowel syndromethe temporary relief of itching associated with insect bites eczema minor burn sunburn minor skin irritations minor cuts scrapes atopic dermatitis and other skin disordersthe temporary symptomatic relief of mild joint and muscle pain as a local topical analgesicthe temporary relief of tensiontype headache')|
|('DB11198', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'indicated for the overthecounter use forthe symptomatic relief of minor spasms of the gastrointestinal tract flatulence and abdominal pain especially in patients with irritable bowel syndromethe temporary relief of itching associated with insect bites eczema minor burn sunburn minor skin irritations minor cuts scrapes atopic dermatitis and other skin disordersthe temporary symptomatic relief of mild joint and muscle pain as a local topical analgesicthe temporary relief of tensiontype headache')|
|('DB11200', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'aluminumbased antiperspirant preparations intended for the reduction of normal underarm perspiration and indicated for use in hyperhidrosis l2708')|
|('DB11201', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'for the temporary relief of pain associated with rheumatism arthritis neuralgia sprains and strains of joints and muscles lumbago and fibrositis f91')|
|('DB11201', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'for the temporary relief of pain associated with rheumatism arthritis neuralgia sprains and strains of joints and muscles lumbago and fibrositis f91')|
|('DB11202', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'nalkyl c12c14 dimethyl ethylbenzyl ammonium chloride is added to products to function as a cleaning agent or as antimicrobial agents in disinfecting cleaning products l2855')|
|('DB11204', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'panthenol containing a racemic mixture of dexpanthenol and levopanthenol is not currently available in any fdaapproved products and therefore does not have an indicationplease see db09357 for fdaapproved uses of the dextrorotatory form of panthenol ')|
|('DB11206', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated as an active sunscreen agent ')|
|('DB11207', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated as an active sunscreen agent ')|
|('DB11217', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for overthecounter use for epidermal hyperpigmentation in various skin conditions such as melasma freckles and senile lentigines ')|
|('DB11218', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for topical use to help protect against infection in minor cuts scrapes and burns no fdaapproved therapeutic indications')|
|('DB11219', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for use as an active sunscreen agent ')|
|('DB11221', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for use as an active sunscreen agent ')|
|('DB11222', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'indicated for mild antisepsis of skin cuts and abrasions ')|
|('DB11226', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ethylhexyl methoxycrylene is employed as a photostabilizing agent in various sunscreen products l2847')|
|('DB11228', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'solutions containing methyl cellulose are used as substitute for tears or saliva if the natural production of these fluids is disturbed it is also used or constipation diverticulosis hemorrhoids and irritable bowel syndrome used in the manufacture of capsules in nutritional supplements its edible and nontoxic properties provide a vegetarian alternative to the use of gelatin')|
|('DB11228', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'solutions containing methyl cellulose are used as substitute for tears or saliva if the natural production of these fluids is disturbed it is also used or constipation diverticulosis hemorrhoids and irritable bowel syndrome used in the manufacture of capsules in nutritional supplements its edible and nontoxic properties provide a vegetarian alternative to the use of gelatin')|
|('DB11230', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'magnesium aluminum silicate is used as an over the counter antacid for the selftreatment of heartburn sour stomach or acid indigestion fda label')|
|('DB11235', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms fda label it is typically a part of combination over the counter products')|
|('DB11235', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms fda label it is typically a part of combination over the counter products')|
|('DB11239', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'solutions containing 5 to 10 aluminum sulfate have been used as local applications to ulcers and to arrest foul discharges from mucous surfaces aluminum sulfate is also used in the preparation of aluminum acetate ear drops l2149  it is often purchased over the counter and is available in solid stick or powder form for minor cuts and abrasions after shaving l2157 l2164 aluminum sulfate is also used as an adjuvant in vaccines l2158')|
|('DB11239', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'solutions containing 5 to 10 aluminum sulfate have been used as local applications to ulcers and to arrest foul discharges from mucous surfaces aluminum sulfate is also used in the preparation of aluminum acetate ear drops l2149  it is often purchased over the counter and is available in solid stick or powder form for minor cuts and abrasions after shaving l2157 l2164 aluminum sulfate is also used as an adjuvant in vaccines l2158')|
|('DB11242', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11242', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11242', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11242', 'MONDO:0005298', ['osteoporosis'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11242', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11242', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'gelatin is used for weight loss and for treating osteoarthritis rheumatoid arthritis and brittle bones osteoporosis some people also use it for strengthening bones joints and fingernails gelatin is also used for improving hair condition and to shorten the recovery after exercise and sportsrelated injury l2113 gelatin is used in preparations of foods cosmetics and medicine l2113plasma volume expander in hypovolaemic shock l2115 haemostatic l2115gelatinbased hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation in addition these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties manufacturing technologies such as ultraviolet stereolithography and twophoton polymerization can be used to prepare structures containing photosensitive gelatinbased hydrogels l2111')|
|('DB11248', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'zinc gluconate is mainly indicated in conditions like zinc deficiency and can also be administered in adjunctive therapy as an alternative drug of choice in diarrhea l2088')|
|('DB11251', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tocopherol can be used as a dietary supplement for patients with a deficit of vitamin e this is mainly prescribed in the alpha forma32443 vitamin e deficiency is rare and it is primarily found in premature babies of very low birth weight patients with fat malabsorption or patients with abetalipoproteinemial2120tocopherol due to its antioxidant properties is studied for its use in prevention or treatment in different complex diseases such as cancera32436 atherosclerosis cardiovascular diseasesa32442 and agerelated macular degenerationa32444')|
|('DB11251', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'tocopherol can be used as a dietary supplement for patients with a deficit of vitamin e this is mainly prescribed in the alpha forma32443 vitamin e deficiency is rare and it is primarily found in premature babies of very low birth weight patients with fat malabsorption or patients with abetalipoproteinemial2120tocopherol due to its antioxidant properties is studied for its use in prevention or treatment in different complex diseases such as cancera32436 atherosclerosis cardiovascular diseasesa32442 and agerelated macular degenerationa32444')|
|('DB11251', 'MONDO:0005311', ['atherosclerosis'], 'tocopherol can be used as a dietary supplement for patients with a deficit of vitamin e this is mainly prescribed in the alpha forma32443 vitamin e deficiency is rare and it is primarily found in premature babies of very low birth weight patients with fat malabsorption or patients with abetalipoproteinemial2120tocopherol due to its antioxidant properties is studied for its use in prevention or treatment in different complex diseases such as cancera32436 atherosclerosis cardiovascular diseasesa32442 and agerelated macular degenerationa32444')|
|('DB11254', 'MONDO:0005311', ['atherosclerosis'], 'hexylresorcinol is predominantly employed as the active ingredient in lotions sprays or lozenges indicated as a a topical antiseptic to help prevent skin infection in minor cuts scrapes or burns or b as an antiseptic and local anesthetic for the relief of a sore throat and its associated pain l2734 l2735in addition hexylresorcinol is used as an active ingredient in various commercial cosmetic skincare products as an antiaging cream l2736 while other studies have looked into whether or not the compound could be used effectively as an antiinflammatory agent or even as an anticancer therapy l2736')|
|('DB11254', 'MONDO:0021201', ['skin infection [NCIT:C35025]', 'skin infection'], 'hexylresorcinol is predominantly employed as the active ingredient in lotions sprays or lozenges indicated as a a topical antiseptic to help prevent skin infection in minor cuts scrapes or burns or b as an antiseptic and local anesthetic for the relief of a sore throat and its associated pain l2734 l2735in addition hexylresorcinol is used as an active ingredient in various commercial cosmetic skincare products as an antiaging cream l2736 while other studies have looked into whether or not the compound could be used effectively as an antiinflammatory agent or even as an anticancer therapy l2736')|
|('DB11256', 'MONDO:0021201', ['skin infection [NCIT:C35025]', 'skin infection'], 'for the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product being studied for use as a treatment for cardiovascular diseases a19273 and adjunct therapy for patients undergoing antidepressant pharmacotherapy a19271 a19272')|
|('DB11262', 'MONDO:0021201', ['skin infection [NCIT:C35025]', 'skin infection'], 'indicated for use as a sunscreen agent in cosmetic products ')|
|('DB11264', 'MONDO:0021201', ['skin infection [NCIT:C35025]', 'skin infection'], 'calcium glycerophosphate is found in otc dental products such as toothpastes for the prevention of dental caries as otc products these do not have an official indicationin prescription products it is indicated as a db01373 or phosphate donor for replacement or supplementation in patients with insufficient db01373 or phosphate')|
|('DB11264', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'calcium glycerophosphate is found in otc dental products such as toothpastes for the prevention of dental caries as otc products these do not have an official indicationin prescription products it is indicated as a db01373 or phosphate donor for replacement or supplementation in patients with insufficient db01373 or phosphate')|
|('DB11265', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'indicated for the symptomatic relief of digestive disturbances such as feelings of fullness slow digestion and flatulence f114 ')|
|('DB11269', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'indicated for use as a sunscreen agent ')|
|('DB11271', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'polysilicone15 is used as an uvfilter in cosmetic sunscreen products as well as in other cosmetic products like shampoos conditioners hairsprays etc where it can confer photostability to the products l2799 f89')|
|('DB11271', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'polysilicone15 is used as an uvfilter in cosmetic sunscreen products as well as in other cosmetic products like shampoos conditioners hairsprays etc where it can confer photostability to the products l2799 f89')|
|('DB11273', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'to know more about the approved indications please visit db01049')|
|('DB11274', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'alphadihydroergocryptine has been studied for the early treatment of parkinson diseasea32980 as well as for its use in migraine prophylaxisa32983 treatment of low blood pressure and peripheral vascular disorder to know more about the ergoloid mesylate mixture and its uses please visit db01049')|
|('DB11275', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'please refer to db01049 and to know more about the isomer please refer to db11274')|
|('DB11278', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as an antitussive and decongestant l2834')|
|('DB11282', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'diethyltoluamide or deet is an active ingredient that is predominantly indicated for as an insect repellant used to repel biting pests like mosquitoes and ticks l2774 products containing deet currently are available to the public in a variety of liquids lotions sprays and impregnated materials like towelettes or rollons l2774')|
|('DB11283', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dldimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication')|
|('DB11284', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dldimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications')|
|('DB11294', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated to detect delayedtype hypersensitivity to coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis  use in 1864 year old patients  a positive result occurs if 48h after administration  if the diameter of the induration is 5mm ')|
|('DB11294', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'indicated to detect delayedtype hypersensitivity to coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis  use in 1864 year old patients  a positive result occurs if 48h after administration  if the diameter of the induration is 5mm ')|
|('DB11296', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'commonly used in cosmetic products for the skin and hair a19503')|
|('DB11300', 'MONDO:0005271', ['allergic disease', 'hypersensitivity', 'hypersensitivity reaction type I disease', 'allergic disease'], 'bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques like suture ligature or cautery is ineffective or impractical fda label additionally topical bovine thrombin can also be used in combination with an absorbable gelatin sponge usp fda label')|
|('DB11300', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques like suture ligature or cautery is ineffective or impractical fda label additionally topical bovine thrombin can also be used in combination with an absorbable gelatin sponge usp fda label')|
|('DB11304', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'antimicrobial agent used as a preservative in cosmetics l2618 l2619 l2625')|
|('DB11311', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin k antagonist therapy prothrombin is administered as part of a cocktail containing several coagulation factors')|
|('DB11312', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'protein c concentrate is indicated for pediatric and adult patients with severe congenital protein c deficiency for the prevention and treatment of venous thrombosis and purpura fulminans')|
|('DB11312', 'MONDO:0000809', ['purpura gangrenosa', 'purpura fulminans'], 'protein c concentrate is indicated for pediatric and adult patients with severe congenital protein c deficiency for the prevention and treatment of venous thrombosis and purpura fulminans')|
|('DB11321', 'MONDO:0000809', ['purpura gangrenosa', 'purpura fulminans'], 'cod liver oil is predominantly manufactured marketed and used by the population at large as a general nutraceutical dietary supplement a27154 a33159 l2872historically cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin d deficiency and condition of rickets associated with it a33159 over time this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful allpurpose dietary supplementhowever since cod liver oil is a composite of several other nutritional compounds including the omega3 fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha as well as vitamin a and vitamin d a33159 l2872 l2871 the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiencyregardless because it does contain a combination of a number of important and healthy nutritional compounds cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds such as the potential use of cod liver oil supplements in postheart attack patients for secondary prophylaxis associated with the use of omega3 fatty acids a33165')|
|('DB11321', 'MONDO:0005520', ['active rickets', 'vitamin D hydroxylation-deficient rickets', 'vitamin D-dependent rickets', 'rickets'], 'cod liver oil is predominantly manufactured marketed and used by the population at large as a general nutraceutical dietary supplement a27154 a33159 l2872historically cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin d deficiency and condition of rickets associated with it a33159 over time this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful allpurpose dietary supplementhowever since cod liver oil is a composite of several other nutritional compounds including the omega3 fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha as well as vitamin a and vitamin d a33159 l2872 l2871 the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiencyregardless because it does contain a combination of a number of important and healthy nutritional compounds cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds such as the potential use of cod liver oil supplements in postheart attack patients for secondary prophylaxis associated with the use of omega3 fatty acids a33165')|
|('DB11321', 'MONDO:0021137', ['common []', 'not rare'], 'cod liver oil is predominantly manufactured marketed and used by the population at large as a general nutraceutical dietary supplement a27154 a33159 l2872historically cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin d deficiency and condition of rickets associated with it a33159 over time this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful allpurpose dietary supplementhowever since cod liver oil is a composite of several other nutritional compounds including the omega3 fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha as well as vitamin a and vitamin d a33159 l2872 l2871 the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiencyregardless because it does contain a combination of a number of important and healthy nutritional compounds cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds such as the potential use of cod liver oil supplements in postheart attack patients for secondary prophylaxis associated with the use of omega3 fatty acids a33165')|
|('DB11321', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'cod liver oil is predominantly manufactured marketed and used by the population at large as a general nutraceutical dietary supplement a27154 a33159 l2872historically cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin d deficiency and condition of rickets associated with it a33159 over time this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful allpurpose dietary supplementhowever since cod liver oil is a composite of several other nutritional compounds including the omega3 fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha as well as vitamin a and vitamin d a33159 l2872 l2871 the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiencyregardless because it does contain a combination of a number of important and healthy nutritional compounds cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds such as the potential use of cod liver oil supplements in postheart attack patients for secondary prophylaxis associated with the use of omega3 fatty acids a33165')|
|('DB11321', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'cod liver oil is predominantly manufactured marketed and used by the population at large as a general nutraceutical dietary supplement a27154 a33159 l2872historically cod liver oil was often given to children because the vitamin d content in the oil had been shown to prevent or treat vitamin d deficiency and condition of rickets associated with it a33159 over time this common use in children growing up may have conferred upon cod liver oil its identity as a healthy and useful allpurpose dietary supplementhowever since cod liver oil is a composite of several other nutritional compounds including the omega3 fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha as well as vitamin a and vitamin d a33159 l2872 l2871 the presence in varying amounts of all of these compounds at once makes it difficult to recommend or use cod liver oil as an appropriate supplement to confer any one particular health effect or for any one particular nutritional deficiencyregardless because it does contain a combination of a number of important and healthy nutritional compounds cod liver oil has sometimes been recommended in the literature for conferring the health effects of some of these compounds such as the potential use of cod liver oil supplements in postheart attack patients for secondary prophylaxis associated with the use of omega3 fatty acids a33165')|
|('DB11323', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'this drug is only recommended for topical usages for the relief of muscular and rheumatic pain in human and animals l2687')|
|('DB11324', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], ' nonivamide is used as a topical analgesic and is also used as a flavoring ingredient l2641 a32884 l2642 ')|
|('DB11326', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'no fda or emaapproved therapeutic indications on its own')|
|('DB11327', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'scalp dandruff l2610')|
|('DB11328', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sotradecol sodium tetradecyl sulfate injection is indicated in the treatment of small uncomplicated varicose veins of the legs showing simple dilation with competent valves l2030sodium tetradecyl sulfate has been designated as an orphan drug by the fda for the treatment of gastrointestinal bleeding due to esophageal varices l2041')|
|('DB11328', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'sotradecol sodium tetradecyl sulfate injection is indicated in the treatment of small uncomplicated varicose veins of the legs showing simple dilation with competent valves l2030sodium tetradecyl sulfate has been designated as an orphan drug by the fda for the treatment of gastrointestinal bleeding due to esophageal varices l2041')|
|('DB11330', 'MONDO:0001221', ['Bleeding esophageal varices', 'Bleeding oesophageal varices', 'esophageal varices', 'esophageal varices in disease classified elsewhere, with bleeding', 'esophageal varices with bleeding', 'esophageal varices with bleeding in disease EC', 'esophageal varices without bleeding', 'esophageal varices without mention of bleeding', 'esophageal varices'], 'factor ix complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia b patients it is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin k antagonist vka eg warfarin therapy in adult patients with acute major bleeding or who require rapid reversal of therapy ')|
|('DB11330', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'factor ix complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia b patients it is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin k antagonist vka eg warfarin therapy in adult patients with acute major bleeding or who require rapid reversal of therapy ')|
|('DB11331', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'palmitoyloleoylphosphatidylglycerol was a component of surfaxin which was indicated for the prevention of respiratory distress syndrome in premature infants')|
|('DB11332', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'infant respiratory distress syndrome l2502 l2506 l2507 l2511')|
|('DB11333', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'indicated to reduce viscosity in the blood before transfusions ')|
|('DB11338', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'clove oil is primarily indicated in conditions like colic flatulence and toothache l2849')|
|('DB11345', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'indicated for the temporary symptomatic relief of minor aches and pains of muscles and joints in topical analgesics ')|
|('DB11348', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'for use as an over the counter calcium and phosphate supplement antacid or a source of calcium and phosphate in toothpaste fda label l851')|
|('DB11358', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'evening primrose oil is used as part of overthecounter dietary supplementsl1113it is also used for the treatment of systemic inflammatory diseases and for womens health conditions such as cyclical mastalgia these indications do not have sufficient evidence of their effectiveness it was used for the treatment of atopic dermatitis in the united kingdom but it is currently withdrawn due to lack of evidence of effectivenessa33131')|
|('DB11358', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'evening primrose oil is used as part of overthecounter dietary supplementsl1113it is also used for the treatment of systemic inflammatory diseases and for womens health conditions such as cyclical mastalgia these indications do not have sufficient evidence of their effectiveness it was used for the treatment of atopic dermatitis in the united kingdom but it is currently withdrawn due to lack of evidence of effectivenessa33131')|
|('DB11359', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'it is used medicinally as an expectorant antiseptic and local anesthetic guaiacol is used in traditional dental pulp sedation and has the property of inducing cell proliferation guaiacol is a potent scavenger of reactive oxygen radicals and its radical scavenging activity may be associated with its effect on cell proliferation ')|
|('DB11359', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'it is used medicinally as an expectorant antiseptic and local anesthetic guaiacol is used in traditional dental pulp sedation and has the property of inducing cell proliferation guaiacol is a potent scavenger of reactive oxygen radicals and its radical scavenging activity may be associated with its effect on cell proliferation ')|
|('DB11361', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'betula pendula tar oil is used in overthecounter products for the treatment of wounds ulcers bedsores and shallow inflammatory processes such as thrombophlebitis and erysipelas it is only used externally in overthecounter dermatologic combinations with db11113l2863 ')|
|('DB11361', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'betula pendula tar oil is used in overthecounter products for the treatment of wounds ulcers bedsores and shallow inflammatory processes such as thrombophlebitis and erysipelas it is only used externally in overthecounter dermatologic combinations with db11113l2863 ')|
|('DB11361', 'MONDO:0001266', ['erysipelas'], 'betula pendula tar oil is used in overthecounter products for the treatment of wounds ulcers bedsores and shallow inflammatory processes such as thrombophlebitis and erysipelas it is only used externally in overthecounter dermatologic combinations with db11113l2863 ')|
|('DB11362', 'MONDO:0001266', ['erysipelas'], 'selexipag is indicated for the treatment of pulmonary arterial hypertension pah to delay disease progression and reduce risk of hospitalization')|
|('DB11362', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'selexipag is indicated for the treatment of pulmonary arterial hypertension pah to delay disease progression and reduce risk of hospitalization')|
|('DB11363', 'MONDO:0015924', ['PAH [Orphanet:182090]', 'pulmonary arterial hypertension'], 'alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials')|
|('DB11363', 'MONDO:0004992', ['cancer'], 'alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc who have progressed on or are intolerant to crizotinib this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials')|
|('DB11364', 'MONDO:0004992', ['cancer'], 'for use as immunostimulant therapy for treatment of cellmediated immunosuppression with respiratory or urinary infections l929')|
|('DB11365', 'MONDO:0004992', ['cancer'], 'for the over the counter treatment of constipationfda labell771')|
|('DB11366', 'MONDO:0004992', ['cancer'], 'roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions as well roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia ')|
|('DB11366', 'MONDO:0010643', ['Stem cell leukaemia', 'Stem cell Leukemia', 'acute leukemia'], 'roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions as well roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia ')|
|('DB11367', 'MONDO:0004992', ['cancer'], 'was used for the treatment of bacterial infections')|
|('DB11386', 'MONDO:0004992', ['cancer'], 'no approved therapeutic indications on its own ')|
|('DB11431', 'MONDO:0004992', ['cancer'], 'moxidectin is indicated for the treatment of river blindness also called onchocerciasis in patients aged 12 years and older river blindness is caused by a parasitic worm onchocerca volvulus and it is manifested as severe itching disfiguring skin conditions and visual impairment caused by the worms larvael2971 the transmission of onchocerca volvulus is performed person to person by black flies that breed in fastflowing rivers in subsaharan africa yemen and south and central america the larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestationsl2971')|
|('DB11431', 'MONDO:0017137', ['Infection by Onchocerca volvulus', 'Onchocerca volvulus infection', 'volvulosis', 'onchocerciasis'], 'moxidectin is indicated for the treatment of river blindness also called onchocerciasis in patients aged 12 years and older river blindness is caused by a parasitic worm onchocerca volvulus and it is manifested as severe itching disfiguring skin conditions and visual impairment caused by the worms larvael2971 the transmission of onchocerca volvulus is performed person to person by black flies that breed in fastflowing rivers in subsaharan africa yemen and south and central america the larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestationsl2971')|
|('DB11431', 'MONDO:0004570', ['familial intestinal malrotation', 'Twist of intestine, bowel, or colon', 'Volvulus', 'volvulus of midgut', 'intestinal volvulus'], 'moxidectin is indicated for the treatment of river blindness also called onchocerciasis in patients aged 12 years and older river blindness is caused by a parasitic worm onchocerca volvulus and it is manifested as severe itching disfiguring skin conditions and visual impairment caused by the worms larvael2971 the transmission of onchocerca volvulus is performed person to person by black flies that breed in fastflowing rivers in subsaharan africa yemen and south and central america the larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestationsl2971')|
|('DB11431', 'MONDO:0001941', ['vision impairment', 'vision loss', 'visual impairment', 'blindness (disorder)'], 'moxidectin is indicated for the treatment of river blindness also called onchocerciasis in patients aged 12 years and older river blindness is caused by a parasitic worm onchocerca volvulus and it is manifested as severe itching disfiguring skin conditions and visual impairment caused by the worms larvael2971 the transmission of onchocerca volvulus is performed person to person by black flies that breed in fastflowing rivers in subsaharan africa yemen and south and central america the larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestationsl2971')|
|('DB11431', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'moxidectin is indicated for the treatment of river blindness also called onchocerciasis in patients aged 12 years and older river blindness is caused by a parasitic worm onchocerca volvulus and it is manifested as severe itching disfiguring skin conditions and visual impairment caused by the worms larvael2971 the transmission of onchocerca volvulus is performed person to person by black flies that breed in fastflowing rivers in subsaharan africa yemen and south and central america the larvae released by the adult parasite invade skin and eyes where they can produce the severe disease manifestationsl2971')|
|('DB11481', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs')|
|('DB11482', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'balsam of peru is found in diverse cosmetics and perfumes as well as a flavoring agent in cough syrups lozenges chewing gum and candiesf117as a medical agent balsam of peru is used in the local treatment of burns and wounds as an antiseptica27160 it is also used as an expectorant heart stimulant to increase blood pressure and as a parasiticidet221')|
|('DB11490', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to reverse opioid overdose')|
|('DB11556', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used as a large animal sedative primarily in horses')|
|('DB11558', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used for the removal of ascarids toxocara canis and toxascaris leonina and hookworms ancylostoma caninum and uncinaria stenocephala and as an aid in removing tapeworms taenia pisiformis dipylidium caninum and echinococcus granulosus from dogs and cats')|
|('DB11558', 'MONDO:0018408', ['echinococcus granulosus', 'Echinococcus granulosus infection', 'Echinococcus granulosus infection of lung', 'Echinococcus granulosus infection of thyroid', 'echinococcus granulosus infectious disease', 'Echinococcus granulosus infectious disease of liver', 'echinococcus granulosus infectious disease of liver', 'echinococcus granulosus infectious disease of thyroid', 'Liver echinococcus granulosus', 'lung echinococcus granulosus', 'Thyroid echinococcus granulosus', 'unilocular echinococcosis', 'unilocular hydatid disease', 'cystic echinococcosis'], 'used for the removal of ascarids toxocara canis and toxascaris leonina and hookworms ancylostoma caninum and uncinaria stenocephala and as an aid in removing tapeworms taenia pisiformis dipylidium caninum and echinococcus granulosus from dogs and cats')|
|('DB11560', 'MONDO:0018408', ['echinococcus granulosus', 'Echinococcus granulosus infection', 'Echinococcus granulosus infection of lung', 'Echinococcus granulosus infection of thyroid', 'echinococcus granulosus infectious disease', 'Echinococcus granulosus infectious disease of liver', 'echinococcus granulosus infectious disease of liver', 'echinococcus granulosus infectious disease of thyroid', 'Liver echinococcus granulosus', 'lung echinococcus granulosus', 'Thyroid echinococcus granulosus', 'unilocular echinococcosis', 'unilocular hydatid disease', 'cystic echinococcosis'], 'for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone')|
|('DB11560', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone')|
|('DB11563', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'sebelipase alfa is a hydrolytic lysosomal cholesteryl ester and triacylglycerolspecific enzyme indicated for the treatment of patients with a diagnosis of lysosomal acid lipase lal deficiency ')|
|('DB11568', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], 'code text here')|
|('DB11569', 'MONDO:0005393', ['Articular gout', 'gouty arthritis', 'Gouty arthropathy', 'gout'], ' ixekizumab is indicated for the treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy ')|
|('DB11569', 'MONDO:0005083', ['psoriasis'], ' ixekizumab is indicated for the treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy ')|
|('DB11570', 'MONDO:0005083', ['psoriasis'], 'indicated as an active uvb filter to prevent photodamage')|
|('DB11571', 'MONDO:0005083', ['psoriasis'], 'human thrombin is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules are accessible and control of bleeding by standard surgical techniques such as suture ligature or cautery is ineffective or impractical fda label')|
|('DB11572', 'MONDO:0005083', ['psoriasis'], 'indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques such as suture ligature or cautery is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age fda labeladditionally thrombin alfa can be used in conjunction with an absorbable gelatin sponge usp fda label')|
|('DB11572', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques such as suture ligature or cautery is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age fda labeladditionally thrombin alfa can be used in conjunction with an absorbable gelatin sponge usp fda label')|
|('DB11573', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for use as an antiperspirant ')|
|('DB11574', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'elbasvir when used in combination with db11575 as the combination product zepatier is indicated for use with or without ribavirin for the treatment of chronic hcv genotypes 1 or 4 infection in adults fda label')|
|('DB11575', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'grazoprevir is indicated in combination with db11574 as the fixed dose combination product zepatier with or without db00811 for treatment of chronic hcv genotypes 1a 1b or 4 infection in adults ')|
|('DB11577', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug was initially used as a kidney function test the main application of indigo carmine at this time is localizing and visualizing ureteral orifices during cystoscopy and ureteral catheterization procedures l2215 ')|
|('DB11580', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ravulizumab is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria pnh fda label')|
|('DB11580', 'MONDO:0018641', ['paroxysmal nocturnal hemoglobinuria'], 'ravulizumab is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria pnh fda label')|
|('DB11581', 'MONDO:0018641', ['paroxysmal nocturnal hemoglobinuria'], 'a bcl2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll with or without 17p deletion who have received at least one prior therapy fda label')|
|('DB11581', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'a bcl2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll with or without 17p deletion who have received at least one prior therapy fda label')|
|('DB11581', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'a bcl2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll with or without 17p deletion who have received at least one prior therapy fda label')|
|('DB11582', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'thiocolchicoside is a  skeletal musclerelaxant drug used in the treatment of orthopedic traumatic and rheumatologic disorders l1661 it is indicated as an adjuvant drug in the treatment of painful muscle contractures and is indicated in acute spinal pathology for adults and adolescents 16 years of age and older l1658 recent studies have examined its effect on muscle tone stiffness contractures and soreness experienced by athletes during sporting competitions l1664')|
|('DB11583', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'cetalkonium is used as a surfactant germicide fungicide mildew preventive agents in siliconebased water repellents emulsifier disinfectant topical antiinfective and antiseptic antimicrobial for pharmaceuticals for its chemical properties and its antiseptical characteristics cetalkonium can be used in a wide variety of products as part of the formulations and it is also determined to be an active antiseptic ingredient in overthecounter preparationst211')|
|('DB11583', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'cetalkonium is used as a surfactant germicide fungicide mildew preventive agents in siliconebased water repellents emulsifier disinfectant topical antiinfective and antiseptic antimicrobial for pharmaceuticals for its chemical properties and its antiseptical characteristics cetalkonium can be used in a wide variety of products as part of the formulations and it is also determined to be an active antiseptic ingredient in overthecounter preparationst211')|
|('DB11584', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'used to manage fatigue l2522 and depression l2515 a32724 l2518 l2523 used as an adjunct therapy in the management of obesity l2522')|
|('DB11585', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'drometrizole trisiloxane is used as an active ingredient in various sunscreens for the indication of protecting the skin by absorbing the damaging uv radiation of sunlight a33069 l2780 l2781 l2782 l2783 f81 f82')|
|('DB11586', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis c in adult patients with hepatitis c virus genotypes 1 or 4 and compensated liver cirrhosisl2278 hepatitis c is a liver disease caused by the hepatitis c virus the chronic state of this condition accounts for 6080 of the cases from which the risk of cirrhosis of the liver within 20 years is of around 1530l2281 the genotype 1 is the most common type of hepatitis c in the united states and the most difficult to treatl2282')|
|('DB11586', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis c in adult patients with hepatitis c virus genotypes 1 or 4 and compensated liver cirrhosisl2278 hepatitis c is a liver disease caused by the hepatitis c virus the chronic state of this condition accounts for 6080 of the cases from which the risk of cirrhosis of the liver within 20 years is of around 1530l2281 the genotype 1 is the most common type of hepatitis c in the united states and the most difficult to treatl2282')|
|('DB11586', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis c in adult patients with hepatitis c virus genotypes 1 or 4 and compensated liver cirrhosisl2278 hepatitis c is a liver disease caused by the hepatitis c virus the chronic state of this condition accounts for 6080 of the cases from which the risk of cirrhosis of the liver within 20 years is of around 1530l2281 the genotype 1 is the most common type of hepatitis c in the united states and the most difficult to treatl2282')|
|('DB11586', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis c in adult patients with hepatitis c virus genotypes 1 or 4 and compensated liver cirrhosisl2278 hepatitis c is a liver disease caused by the hepatitis c virus the chronic state of this condition accounts for 6080 of the cases from which the risk of cirrhosis of the liver within 20 years is of around 1530l2281 the genotype 1 is the most common type of hepatitis c in the united states and the most difficult to treatl2282')|
|('DB11586', 'MONDO:0021137', ['common []', 'not rare'], 'asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis c in adult patients with hepatitis c virus genotypes 1 or 4 and compensated liver cirrhosisl2278 hepatitis c is a liver disease caused by the hepatitis c virus the chronic state of this condition accounts for 6080 of the cases from which the risk of cirrhosis of the liver within 20 years is of around 1530l2281 the genotype 1 is the most common type of hepatitis c in the united states and the most difficult to treatl2282')|
|('DB11587', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'conditions characterized by bronchial congestion and bronchospasm when an expectorant or bronchodilator action is required such as acute bronchitis acute episodes of chronic bronchitis and bronchial asthma l2565 l2566')|
|('DB11587', 'MONDO:0001358', ['Bronchospasm', 'bronchial disease'], 'conditions characterized by bronchial congestion and bronchospasm when an expectorant or bronchodilator action is required such as acute bronchitis acute episodes of chronic bronchitis and bronchial asthma l2565 l2566')|
|('DB11587', 'MONDO:0003781', ['acute Bronchitis', 'chest cold', 'Chest infection', 'chronic bronchitis', 'CI - Chest infection', 'recurrent wheezy bronchitis', 'bronchitis'], 'conditions characterized by bronchial congestion and bronchospasm when an expectorant or bronchodilator action is required such as acute bronchitis acute episodes of chronic bronchitis and bronchial asthma l2565 l2566')|
|('DB11587', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'conditions characterized by bronchial congestion and bronchospasm when an expectorant or bronchodilator action is required such as acute bronchitis acute episodes of chronic bronchitis and bronchial asthma l2565 l2566')|
|('DB11588', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'used as a marker of respiratory status in spirometry tests l2557 f4food additive for pigment fixation in meat l2531')|
|('DB11589', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'indicated for use as a diagnostic tracer gas in pulmonary function tests ')|
|('DB11590', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'used as preservative in some cosmetics topical pharmaceuticals and biological drug products which includes vaccines l1671 l1672 l1673')|
|('DB11591', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'for symptomatic relief of nasal and nonnasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older fda label')|
|('DB11594', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'antiinfective topical it is used for the treatment of acute infectious dental diseases and other conditions')|
|('DB11595', 'MONDO:0005607', ['bronchitis, chronic [MONDO:patterns/chronic]', 'chronic bronchitis'], 'atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatincontaining chemotherapy with tumors expressing pdl1 in patients ineligible for cisplatincontaining chemotherapy irrespective of pdl1 have disease progression following platinum containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapyl7489atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab paclitaxel and carboplatin with no egfr or alk genomic abnormalitiesl7489 it can be used in patients with disease progression during or after platinum containing chemotherapy even if they have egfr and alk abnormalitiesl7489atezolizumab is indicated in combination with paclitaxel proteinbound to treat locally advanced or metastatic triple negative breast cancer expressing pdl1l7489finally atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancerl7489')|
|('DB11595', 'MONDO:0040679', ['transitional cell car. -uroth. [NCIT:C4030]', 'urothelial carcinoma [NCIT:C4030]', 'transitional cell carcinoma of the urinary tract [NCIT:C4030]', 'Uroepithelial carcinoma [NCIT:C4030]', 'transitional cell carcinoma of the urothelial tract [NCIT:C4030]', 'urothelial carcinoma'], 'atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatincontaining chemotherapy with tumors expressing pdl1 in patients ineligible for cisplatincontaining chemotherapy irrespective of pdl1 have disease progression following platinum containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapyl7489atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab paclitaxel and carboplatin with no egfr or alk genomic abnormalitiesl7489 it can be used in patients with disease progression during or after platinum containing chemotherapy even if they have egfr and alk abnormalitiesl7489atezolizumab is indicated in combination with paclitaxel proteinbound to treat locally advanced or metastatic triple negative breast cancer expressing pdl1l7489finally atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancerl7489')|
|('DB11595', 'MONDO:0004992', ['cancer'], 'atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatincontaining chemotherapy with tumors expressing pdl1 in patients ineligible for cisplatincontaining chemotherapy irrespective of pdl1 have disease progression following platinum containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapyl7489atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab paclitaxel and carboplatin with no egfr or alk genomic abnormalitiesl7489 it can be used in patients with disease progression during or after platinum containing chemotherapy even if they have egfr and alk abnormalitiesl7489atezolizumab is indicated in combination with paclitaxel proteinbound to treat locally advanced or metastatic triple negative breast cancer expressing pdl1l7489finally atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancerl7489')|
|('DB11595', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatincontaining chemotherapy with tumors expressing pdl1 in patients ineligible for cisplatincontaining chemotherapy irrespective of pdl1 have disease progression following platinum containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapyl7489atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab paclitaxel and carboplatin with no egfr or alk genomic abnormalitiesl7489 it can be used in patients with disease progression during or after platinum containing chemotherapy even if they have egfr and alk abnormalitiesl7489atezolizumab is indicated in combination with paclitaxel proteinbound to treat locally advanced or metastatic triple negative breast cancer expressing pdl1l7489finally atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancerl7489')|
|('DB11596', 'MONDO:0004992', ['cancer'], 'levoleucovorin is indicated for use as rescue therapy following highdose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists levoleucovorin as the product fusilev fda dosed at onehalf the usual dose of racemic dlleucovorin has an additional indication for use in combination chemotherapy with 5fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer although they should not be mixed in the same infusion as a precipitate may form')|
|('DB11596', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'levoleucovorin is indicated for use as rescue therapy following highdose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists levoleucovorin as the product fusilev fda dosed at onehalf the usual dose of racemic dlleucovorin has an additional indication for use in combination chemotherapy with 5fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer although they should not be mixed in the same infusion as a precipitate may form')|
|('DB11596', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'levoleucovorin is indicated for use as rescue therapy following highdose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists levoleucovorin as the product fusilev fda dosed at onehalf the usual dose of racemic dlleucovorin has an additional indication for use in combination chemotherapy with 5fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer although they should not be mixed in the same infusion as a precipitate may form')|
|('DB11596', 'MONDO:0005575', ['colorectal cancer'], 'levoleucovorin is indicated for use as rescue therapy following highdose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists levoleucovorin as the product fusilev fda dosed at onehalf the usual dose of racemic dlleucovorin has an additional indication for use in combination chemotherapy with 5fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer although they should not be mixed in the same infusion as a precipitate may form')|
|('DB11597', 'MONDO:0005575', ['colorectal cancer'], 'indicated for suppression of rhesus rh isoimmunization in nonsensitized rho dnegative women with an rhincompatible pregnancy or in rho dnegative individuals transfused with rh0dpositive red blood cells rbcs or blood components containing rh0dpositive rbcs also indicated in rh0dpositive nonsplenectomized adult patients with chronic immune thrombocytopenic purpura itp to raise platelet counts')|
|('DB11597', 'MONDO:0006953', ['Rh incompatibility affecting management of mother', 'rh isoimmunization'], 'indicated for suppression of rhesus rh isoimmunization in nonsensitized rho dnegative women with an rhincompatible pregnancy or in rho dnegative individuals transfused with rh0dpositive red blood cells rbcs or blood components containing rh0dpositive rbcs also indicated in rh0dpositive nonsplenectomized adult patients with chronic immune thrombocytopenic purpura itp to raise platelet counts')|
|('DB11597', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'indicated for suppression of rhesus rh isoimmunization in nonsensitized rho dnegative women with an rhincompatible pregnancy or in rho dnegative individuals transfused with rh0dpositive red blood cells rbcs or blood components containing rh0dpositive rbcs also indicated in rh0dpositive nonsplenectomized adult patients with chronic immune thrombocytopenic purpura itp to raise platelet counts')|
|('DB11598', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'antithrombin iii human is a human antithrombin at indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of perioperative and peripartum thromboembolism')|
|('DB11600', 'MONDO:0043768', ['thrombocytopenic purpura [MESH:D011696,NCIT:C26870]', 'thrombocytopenic purpura'], 'beeswax is also characterized by several therapeutic properties of great interest to us it is thought to be particularly effective in healing bruises inflammation and burns recently the interest of researchers has moved even on antimicrobial properties of beeswax although there are still few studies in the literature focused only on the action of beeswax the few studies showed an antimicrobic effectiveness of beeswax against overall staphylococcus aureus salmonella enterica candida albicans and aspergillus niger a sterile preparation of white beeswax hard paraffin and isopropyl palmitate sterile surgical bone wax is used to control bleeding from damaged bone during surgery it should not be confused with aseptic surgical wax bpc 1949 also known as horsleys wax  which contained yellow beeswax olive oil and phenol in a mercuric chloride solution and was used to control haemorrhage in bone or cranial surgery')|
|('DB11600', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'beeswax is also characterized by several therapeutic properties of great interest to us it is thought to be particularly effective in healing bruises inflammation and burns recently the interest of researchers has moved even on antimicrobial properties of beeswax although there are still few studies in the literature focused only on the action of beeswax the few studies showed an antimicrobic effectiveness of beeswax against overall staphylococcus aureus salmonella enterica candida albicans and aspergillus niger a sterile preparation of white beeswax hard paraffin and isopropyl palmitate sterile surgical bone wax is used to control bleeding from damaged bone during surgery it should not be confused with aseptic surgical wax bpc 1949 also known as horsleys wax  which contained yellow beeswax olive oil and phenol in a mercuric chloride solution and was used to control haemorrhage in bone or cranial surgery')|
|('DB11601', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated as a diagnostic agent in mantoux test used to detect infection with mycobacterium tuberculosis ')|
|('DB11602', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for alleviating surface irritation in topical ocular administrations such as artificial tear solutions hydroxyethyl cellulose is also found in topical formulations to aid in more efficient drug diffusion across the membranes ')|
|('DB11603', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'for use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine fda label')|
|('DB11603', 'MONDO:0019173', ['Lyssa', 'rabies'], 'for use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine fda label')|
|('DB11604', 'MONDO:0019173', ['Lyssa', 'rabies'], 'for use as prophylaxis against tetanus in patients who are injured and have incomplete of uncertain immunization statu fda label may also be used in the treatment of active tetanus')|
|('DB11604', 'MONDO:0005526', ['clostridial tetanus', 'Infection due to Clostridium tetani', 'tetanus'], 'for use as prophylaxis against tetanus in patients who are injured and have incomplete of uncertain immunization statu fda label may also be used in the treatment of active tetanus')|
|('DB11605', 'MONDO:0005526', ['clostridial tetanus', 'Infection due to Clostridium tetani', 'tetanus'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11605', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11605', 'MONDO:0005124', ['leprosy'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11605', 'MONDO:0005976', ['syphilitic chancre', 'syphilis'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11605', 'MONDO:0002508', ['acute gingivitis', 'chronic gingivitis', 'gingivitis'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11605', 'MONDO:0025419', ['furunculosis'], 'fda approved only for use in food historically used for indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy and syphilis it is also used orally as a stimulant antispasmodic and to increase menstrual flow topically myrrh is used for mild inflammation of the oral and pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath and loose teeth in foods and beverages myrrh is used as a flavoring component in manufacturing myrrh is used as a fragrance and fixative in cosmetics it is also used in embalming and as incense ')|
|('DB11606', 'MONDO:0025419', ['furunculosis'], 'indicated for the treatment of bleeding episodes in adults with acquired hemophilia a')|
|('DB11606', 'MONDO:0019139', ['acquired hemophilia [MONDO:patterns/acquired]', 'acquired hemophilia'], 'indicated for the treatment of bleeding episodes in adults with acquired hemophilia a')|
|('DB11607', 'MONDO:0019139', ['acquired hemophilia [MONDO:patterns/acquired]', 'acquired hemophilia'], 'indicated for the treatment and prophylaxis of bleeding in patients with haemophilia a congenital factor viii deficiency fda label')|
|('DB11608', 'MONDO:0019139', ['acquired hemophilia [MONDO:patterns/acquired]', 'acquired hemophilia'], 'indicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia b congenital factor ix deficiency')|
|('DB11608', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'indicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia b congenital factor ix deficiency')|
|('DB11608', 'MONDO:0010604', ['Congenital factor IX deficiency', 'Congenital factor IX disorder', 'deficiency, functional factor IX', 'factor IX deficiency', 'hemophilia b'], 'indicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia b congenital factor ix deficiency')|
|('DB11609', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for use in the treatment of cough when other less potent treatments have failed fda label')|
|('DB11610', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'used in combination with db11609 as an antitussive fda label')|
|('DB11611', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for the treatment of signs and symptoms of keratoconjunctivitis sicca dry eye syndrome')|
|('DB11611', 'MONDO:0004768', ['keratoconjunctivitis'], 'for the treatment of signs and symptoms of keratoconjunctivitis sicca dry eye syndrome')|
|('DB11611', 'MONDO:0006733', ['KCS', 'dry eye syndrome'], 'for the treatment of signs and symptoms of keratoconjunctivitis sicca dry eye syndrome')|
|('DB11613', 'MONDO:0004768', ['keratoconjunctivitis'], 'velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include therapy with db00811when used in combination with db08934 as the combination product epclusa velpatasvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosis fda label')|
|('DB11613', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include therapy with db00811when used in combination with db08934 as the combination product epclusa velpatasvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosis fda label')|
|('DB11613', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis c virus hcv infected patients with hcv genoptypes 16 and to treat hcv and hiv coinfected patients depending on the level of cirrhosis or decompensation combination therapy can also include therapy with db00811when used in combination with db08934 as the combination product epclusa velpatasvir is indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis or in combination with db00811 if associated with decompensated cirrhosis fda label')|
|('DB11614', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'for the symptomatic relief of nasal and nonnasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older fda label also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older')|
|('DB11614', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'for the symptomatic relief of nasal and nonnasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older fda label also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older')|
|('DB11614', 'MONDO:0024332', ['nonseasonal allergic rhinitis [NCIT:C92189-variant]', 'perennial allergic rhinitis [NCIT:C92189]', 'non-seasonal allergic rhinitis [NCIT:C92189]', 'perennial allergic rhinitis'], 'for the symptomatic relief of nasal and nonnasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older fda label also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older')|
|('DB11614', 'MONDO:0005492', ['urticaria'], 'for the symptomatic relief of nasal and nonnasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older fda label also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older')|
|('DB11619', 'MONDO:0005492', ['urticaria'], 'endometriosis with or without accompanying sterility treatment is limited to a single course of 6 months duration per lifetime l1699 l1700')|
|('DB11621', 'MONDO:0005492', ['urticaria'], 'indicated for preventing and reducing the severity of chicken pox varicella zoster virus infections in high risk individuals within 4 days of exposure to varicella zoster virus')|
|('DB11621', 'MONDO:0005700', ['varicella', 'chickenpox'], 'indicated for preventing and reducing the severity of chicken pox varicella zoster virus infections in high risk individuals within 4 days of exposure to varicella zoster virus')|
|('DB11622', 'MONDO:0005700', ['varicella', 'chickenpox'], 'no approved therapeutic indications ')|
|('DB11626', 'MONDO:0005700', ['varicella', 'chickenpox'], 'for use in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation or in palliative care for irresectable soft tissue sarcoma of the limbs fda label used in combination with melphalan via mild hyperthermic isolated limb perfusion')|
|('DB11626', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'for use in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation or in palliative care for irresectable soft tissue sarcoma of the limbs fda label used in combination with melphalan via mild hyperthermic isolated limb perfusion')|
|('DB11627', 'MONDO:0018078', ['malignant mesenchymal tumor [Orphanet:3394]', 'malignant soft tissue tumor [Orphanet:3394]', 'non-Rhabdo. soft tissue sarcoma [NCIT:C9306]', 'connective tissue sarcoma [NCIT:C9306]', 'soft tissue sarcoma [NCIT:C9306]', 'sarcoma of soft tissue [NCIT:C9306]', 'soft part sarcoma [Orphanet:3394]', 'sarcoma of the soft tissue [NCIT:C9306]', 'soft tissue sarcoma'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0000984', ['Sickle-cell thalassemia with crisis', 'Sickle-cell thalassemia without crisis', 'thalassemia Hb-S disease with crisis', 'thalassemia Hb-S disease without crisis', 'thalassemia'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0002280', ['anaemia', 'anemia'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0018660', ['hemophilia'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0021681', ['sexually transmitted disease [MESH:D012749]', 'VD, venereal disease [NCIT:C3365]', 'sexually Transmitted disorder [NCIT:C3365]', 'venereal disease (VD) [NCIT:C3365]', 'VD [NCIT:C3365]', 'STD [NCIT:C3365]', 'disease (VD), venereal [NCIT:C3365]', 'sexually transmitted disease'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0005366', ['hepatitis B infection, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis B [MESH:D019694]', 'hepatitis B, chronic [MONDO:patterns/chronic]', 'chronic hepatitis b virus infection'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11627', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'active immunization against hepatitis b virus infectionthe vaccine will not protect against infection caused by hepatitis a and nona nonb hepatitis viruses as hepatitis d caused by the delta agent does not occur in the absence of hepatitis b infection or carrier state it can be expected that hepatitis d will also be prevented by vaccination with hepatitis b virus vaccinethe vaccine can be administered at any age from birth onwards it may be used to start a primary course of vaccination or as a booster dose it may also be used to complete a primary course of vaccination started with plasmaderived or yeastderived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasmaderived or yeastderived vaccinesin areas of low prevalence of hepatitis b vaccination is strongly recommended in subjects who are at increased risk of infection these include the following groups health professionals physicians and surgeons oral surgeons and dentists nurses dental nurses dental hygienists podiatrists iv teams and operating room personnel paramedical personnel in close contact with patients staff in hemodialysis nephrology hepatology hematology and oncology units laboratory personnel handling blood and other clinical specimens blood bank and plasma fractionation workers pathologists and morgue attendants cleaning staff who handle waste in hospitals emergency and first aid workers ambulance staff dental medical and nursing students patients patients receiving frequent blood transfusion or clotting factor concentrates such as those in oncology units and those with thalassemia sicklecell anemia cirrhosis hemophilia etc patients on hemodialysis patients with type 2 diabetes personnel and residents of institutions persons with frequent andor close contacts with highrisk groups prisoners and prison staff residents and staff of institutions for the developmentally challenged those who are in contact with aggressive biting residents being at highest risk persons at increased risk due to their sexual practices males having sexual contact with other males others with multiple sexual partners or with a recent history of sexually transmitted disease persons who use injectable drugs illicitly travellers to areas of high endemicity and their close contacts household contacts of any of the above groups and of patients with acute or chronic hepatitis b infection infants born of hbsagpositive mothers chronic liver disease cld subjects with chronic liver disease subjects at risk of developing cld eg hepatitis c virus carriers persons who abuse alcohol others police fire fighters armed forces personnel morticians and embalmers those who through their work or personal lifestyle may be exposed to the hepatitis b virus in areas of both low and high prevalence vaccination should be offered to all young children and neonates at risk as well as to adult high risk groups')|
|('DB11630', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'for use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy surgery or systemic chemotherapy fda label')|
|('DB11632', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'opicapone is approved as an adjunctive therapy in adults with parkinson’s disease and endofdose motor fluctuations whose symptoms cannot be stabilized on levodopadopa decarboxylase inhibitor combinations l2336')|
|('DB11633', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], ' indicated for patients 18 years of age and older for the treatment of invasive aspergillosis fda label indicated for patients 18 years of age and older for the treatment of invasive mucormycosis fda label including patients where treatment amphotericin b is inappropriate l1482')|
|('DB11633', 'MONDO:0000240', ['invasive aspergillosis'], ' indicated for patients 18 years of age and older for the treatment of invasive aspergillosis fda label indicated for patients 18 years of age and older for the treatment of invasive mucormycosis fda label including patients where treatment amphotericin b is inappropriate l1482')|
|('DB11635', 'MONDO:0000240', ['invasive aspergillosis'], 'tocofersolan is indicated in vitamin e deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth full term newborns up to 18 years of age l2371')|
|('DB11635', 'MONDO:0021140', ['inborn []', 'congenital'], 'tocofersolan is indicated in vitamin e deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth full term newborns up to 18 years of age l2371')|
|('DB11635', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'tocofersolan is indicated in vitamin e deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth full term newborns up to 18 years of age l2371')|
|('DB11637', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis mdrtb in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability l1407')|
|('DB11638', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'for the treatment of uncomplicated plasmodium falciparum infection in adults children and infants aged 6 months and up weighing over 5 kg fda label used in combination with db13941')|
|('DB11639', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], ' indicated for the treatment of acute tibia fractures in adults as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation fda label indicated for singlelevel lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of nonoperative treatment for this condition l1391')|
|('DB11640', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'amifampridine is indicated for the symptomatic treatment of lamberteaton myasthenic syndrome lems in adultsf272 and in patients aged 6 to less than 17 years of agef4609l6250 nevertheless it is important to note that at the current time only the firdapse brand of amifampridine is indicated for the treatment of lems in adultsf272 and the ruzurgi brand of amifampridine is indicated for the treatment of lems in patients aged 6 to less than 17 yearsf4609l6250')|
|('DB11640', 'MONDO:0018556', ['Eaton-Lambert syndrome', 'Lambert-Eaton syndrome', 'LEMS', 'lambert-eaton myasthenic syndrome'], 'amifampridine is indicated for the symptomatic treatment of lamberteaton myasthenic syndrome lems in adultsf272 and in patients aged 6 to less than 17 years of agef4609l6250 nevertheless it is important to note that at the current time only the firdapse brand of amifampridine is indicated for the treatment of lems in adultsf272 and the ruzurgi brand of amifampridine is indicated for the treatment of lems in patients aged 6 to less than 17 yearsf4609l6250')|
|('DB11641', 'MONDO:0018556', ['Eaton-Lambert syndrome', 'Lambert-Eaton syndrome', 'LEMS', 'lambert-eaton myasthenic syndrome'], 'for use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinumcontaining therapy l2381 ')|
|('DB11641', 'MONDO:0006474', ['transitional carcinoma', 'transitional cell tumor', 'urothelial cell carcinoma', 'transitional cell carcinoma'], 'for use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinumcontaining therapy l2381 ')|
|('DB11642', 'MONDO:0006474', ['transitional carcinoma', 'transitional cell tumor', 'urothelial cell carcinoma', 'transitional cell carcinoma'], 'pitolisant is indicated for the treatment of narcolepsy with or without cataplexy l1471 and excessive daytime sleepiness in narcolepsy in adult patientsl8063')|
|('DB11642', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'pitolisant is indicated for the treatment of narcolepsy with or without cataplexy l1471 and excessive daytime sleepiness in narcolepsy in adult patientsl8063')|
|('DB11644', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'indicated for1 the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment in europel6247 2 the treatment of cardiomyopathy in wild type or hereditary transthyretinmediated amyloidosis in the uslabelthere is a distinction in dosage between tafamidis dosed at 61mg daily and tafamadis meglumine which is dosed at 80mg daily')|
|('DB11644', 'MONDO:0004994', ['Cardiomyopathies', 'cardiomyopathy'], 'indicated for1 the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment in europel6247 2 the treatment of cardiomyopathy in wild type or hereditary transthyretinmediated amyloidosis in the uslabelthere is a distinction in dosage between tafamidis dosed at 61mg daily and tafamadis meglumine which is dosed at 80mg daily')|
|('DB11644', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'indicated for1 the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment in europel6247 2 the treatment of cardiomyopathy in wild type or hereditary transthyretinmediated amyloidosis in the uslabelthere is a distinction in dosage between tafamidis dosed at 61mg daily and tafamadis meglumine which is dosed at 80mg daily')|
|('DB11653', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition problems with the relationship or the effects of a medication or drugl9635')|
|('DB11653', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition problems with the relationship or the effects of a medication or drugl9635')|
|('DB11660', 'MONDO:0001821', ['Lack or loss of sexual desire', 'hypoactive sexual desire disorder'], 'latanoprostene bunod opthalmic solution is indicated for the reduction of intraocular pressure in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB11660', 'MONDO:0005041', ['glaucoma'], 'latanoprostene bunod opthalmic solution is indicated for the reduction of intraocular pressure in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB11660', 'MONDO:0006875', ['ocular hypertension'], 'latanoprostene bunod opthalmic solution is indicated for the reduction of intraocular pressure in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB11672', 'MONDO:0006875', ['ocular hypertension'], 'no approved therapeutic indications ')|
|('DB11691', 'MONDO:0006875', ['ocular hypertension'], 'for the treatment of opioidinduced constipation fda label')|
|('DB11699', 'MONDO:0006875', ['ocular hypertension'], 'for the prevention of nausea and vomiting induced by cytotoxic therapy and postoperative ')|
|('DB11703', 'MONDO:0006875', ['ocular hypertension'], 'acalabrutinib is currently indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyl10241 it has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphomal10241')|
|('DB11703', 'MONDO:0018876', ['mantle cell lymphoma'], 'acalabrutinib is currently indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyl10241 it has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphomal10241')|
|('DB11703', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'acalabrutinib is currently indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyl10241 it has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphomal10241')|
|('DB11712', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis cf in patients aged 12 years or older with two copies of the f508del gene mutation or at least one mutation in the cftr gene that is responsive to this drugl6814tezacaftor when used in combination with ivacaftor and elexacaftor in the product trikafta is also indicated for the treatment of cf in patients 12 years of age and older that have at least one f508del mutation in the cftr genel9395')|
|('DB11712', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'tezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis cf in patients aged 12 years or older with two copies of the f508del gene mutation or at least one mutation in the cftr gene that is responsive to this drugl6814tezacaftor when used in combination with ivacaftor and elexacaftor in the product trikafta is also indicated for the treatment of cf in patients 12 years of age and older that have at least one f508del mutation in the cftr genel9395')|
|('DB11714', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'durvalumab is indicated for patients with urothelial carcinoma such as urinary bladder urethra or ureter cancer patients with prolonged disease progression due to failed platinumbased chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment its clinical effectiveness is especially enhanced in pdl1positive patient groups a19123 ')|
|('DB11714', 'MONDO:0040679', ['transitional cell car. -uroth. [NCIT:C4030]', 'urothelial carcinoma [NCIT:C4030]', 'transitional cell carcinoma of the urinary tract [NCIT:C4030]', 'Uroepithelial carcinoma [NCIT:C4030]', 'transitional cell carcinoma of the urothelial tract [NCIT:C4030]', 'urothelial carcinoma'], 'durvalumab is indicated for patients with urothelial carcinoma such as urinary bladder urethra or ureter cancer patients with prolonged disease progression due to failed platinumbased chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment its clinical effectiveness is especially enhanced in pdl1positive patient groups a19123 ')|
|('DB11714', 'MONDO:0008627', ['malignant tumour of ureter', 'malignant ureteral tumor', 'ureter cancer'], 'durvalumab is indicated for patients with urothelial carcinoma such as urinary bladder urethra or ureter cancer patients with prolonged disease progression due to failed platinumbased chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment its clinical effectiveness is especially enhanced in pdl1positive patient groups a19123 ')|
|('DB11718', 'MONDO:0008627', ['malignant tumour of ureter', 'malignant ureteral tumor', 'ureter cancer'], 'used in combination with binimetinib in metastatic melanoma with a braf v600e or v600k mutation as detected by an fdaapproved test l3335')|
|('DB11718', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'used in combination with binimetinib in metastatic melanoma with a braf v600e or v600k mutation as detected by an fdaapproved test l3335')|
|('DB11730', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'kisqali ribociclib is a selective cyclindependent kinase inhibitor a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclindependent kinase 4 and 6 cdk46 these proteins when overactivated can enable cancer cells to grow and divide too quickly targeting cdk46 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably')|
|('DB11730', 'MONDO:0004992', ['cancer'], 'kisqali ribociclib is a selective cyclindependent kinase inhibitor a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclindependent kinase 4 and 6 cdk46 these proteins when overactivated can enable cancer cells to grow and divide too quickly targeting cdk46 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably')|
|('DB11730', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'kisqali ribociclib is a selective cyclindependent kinase inhibitor a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclindependent kinase 4 and 6 cdk46 these proteins when overactivated can enable cancer cells to grow and divide too quickly targeting cdk46 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably')|
|('DB11731', 'MONDO:0004992', ['cancer'], 'no approved indication')|
|('DB11732', 'MONDO:0004992', ['cancer'], 'lasmiditan is indicated for the acute treatment of migraine with or without aura in adultsl9338')|
|('DB11732', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'lasmiditan is indicated for the acute treatment of migraine with or without aura in adultsl9338')|
|('DB11735', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'there are limited therapeutic uses for which galactose is formally indicated some predominant indications include a the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines t188 l2633 and b the role galactose plays as an essential element in the formation of lactulose  a synthetic disaccharide indicated for the treatment of constipation andor hepatic encephalopathy he hepatic coma l2632nevertheless there are many studies looking into a variety of possible uses for galactose including the use of the monosaccharide sugar for accelerating senescence in mice rats and drosophila a32853 a32854 the proposed association between galactose in consumed milk and ovarian cancer a32855 a32856 a possible role in the therapy of focal segmental glomerulosclerosis a32858 among various others regardless none of these proposed indications have yet been formally elucidated for practical use')|
|('DB11735', 'MONDO:0001711', ['Portal-systemic encephalopathy', 'hepatic encephalopathy'], 'there are limited therapeutic uses for which galactose is formally indicated some predominant indications include a the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines t188 l2633 and b the role galactose plays as an essential element in the formation of lactulose  a synthetic disaccharide indicated for the treatment of constipation andor hepatic encephalopathy he hepatic coma l2632nevertheless there are many studies looking into a variety of possible uses for galactose including the use of the monosaccharide sugar for accelerating senescence in mice rats and drosophila a32853 a32854 the proposed association between galactose in consumed milk and ovarian cancer a32855 a32856 a possible role in the therapy of focal segmental glomerulosclerosis a32858 among various others regardless none of these proposed indications have yet been formally elucidated for practical use')|
|('DB11735', 'MONDO:0001548', ['Hepatocerebral intoxication', 'hepatic coma'], 'there are limited therapeutic uses for which galactose is formally indicated some predominant indications include a the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines t188 l2633 and b the role galactose plays as an essential element in the formation of lactulose  a synthetic disaccharide indicated for the treatment of constipation andor hepatic encephalopathy he hepatic coma l2632nevertheless there are many studies looking into a variety of possible uses for galactose including the use of the monosaccharide sugar for accelerating senescence in mice rats and drosophila a32853 a32854 the proposed association between galactose in consumed milk and ovarian cancer a32855 a32856 a possible role in the therapy of focal segmental glomerulosclerosis a32858 among various others regardless none of these proposed indications have yet been formally elucidated for practical use')|
|('DB11735', 'MONDO:0008170', ['malignant Ovarian tumor', 'malignant tumour of ovary', 'ovarian neoplasm', 'ovary neoplasm', 'primary ovarian cancer', 'tumor of the Ovary', 'ovarian cancer'], 'there are limited therapeutic uses for which galactose is formally indicated some predominant indications include a the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines t188 l2633 and b the role galactose plays as an essential element in the formation of lactulose  a synthetic disaccharide indicated for the treatment of constipation andor hepatic encephalopathy he hepatic coma l2632nevertheless there are many studies looking into a variety of possible uses for galactose including the use of the monosaccharide sugar for accelerating senescence in mice rats and drosophila a32853 a32854 the proposed association between galactose in consumed milk and ovarian cancer a32855 a32856 a possible role in the therapy of focal segmental glomerulosclerosis a32858 among various others regardless none of these proposed indications have yet been formally elucidated for practical use')|
|('DB11735', 'MONDO:0005363', ['FGS', 'focal glomerular sclerosis', 'focal glomerulosclerosis', 'FSGS', 'focal segmental glomerulosclerosis'], 'there are limited therapeutic uses for which galactose is formally indicated some predominant indications include a the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines t188 l2633 and b the role galactose plays as an essential element in the formation of lactulose  a synthetic disaccharide indicated for the treatment of constipation andor hepatic encephalopathy he hepatic coma l2632nevertheless there are many studies looking into a variety of possible uses for galactose including the use of the monosaccharide sugar for accelerating senescence in mice rats and drosophila a32853 a32854 the proposed association between galactose in consumed milk and ovarian cancer a32855 a32856 a possible role in the therapy of focal segmental glomerulosclerosis a32858 among various others regardless none of these proposed indications have yet been formally elucidated for practical use')|
|('DB11737', 'MONDO:0005363', ['FGS', 'focal glomerular sclerosis', 'focal glomerulosclerosis', 'FSGS', 'focal segmental glomerulosclerosis'], 'icotinib hydrochloride is a novel epidermal growth factor receptor egfr–tyrosine kinase inhibitor exhibits encouraging efficacy and tolerability in patients with advanced nonsmallcell lung cancer nsclc who failed previous chemotherapy')|
|('DB11737', 'MONDO:0008903', ['lung cancer'], 'icotinib hydrochloride is a novel epidermal growth factor receptor egfr–tyrosine kinase inhibitor exhibits encouraging efficacy and tolerability in patients with advanced nonsmallcell lung cancer nsclc who failed previous chemotherapy')|
|('DB11753', 'MONDO:0008903', ['lung cancer'], 'rifamycin is indicated for the treatment of adult patients with travelers diarrhea caused by noninvasive strains of e coli the status of the disease should not be complicated by fever or blood in the stool to prevent drugresistant bacteria it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacterial4802travallers diarrhea is very common problem affecting 2060 of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad this condition is rarely life threatening but in severe cases it can produce dehydration and sepsis the most common cause of travellers diarrhea is a pathogen and from the pathogens identified bacteria is the most common cause followed by norovirus rotavirus and similar virusesa39995')|
|('DB11753', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'rifamycin is indicated for the treatment of adult patients with travelers diarrhea caused by noninvasive strains of e coli the status of the disease should not be complicated by fever or blood in the stool to prevent drugresistant bacteria it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacterial4802travallers diarrhea is very common problem affecting 2060 of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad this condition is rarely life threatening but in severe cases it can produce dehydration and sepsis the most common cause of travellers diarrhea is a pathogen and from the pathogens identified bacteria is the most common cause followed by norovirus rotavirus and similar virusesa39995')|
|('DB11753', 'MONDO:0021137', ['common []', 'not rare'], 'rifamycin is indicated for the treatment of adult patients with travelers diarrhea caused by noninvasive strains of e coli the status of the disease should not be complicated by fever or blood in the stool to prevent drugresistant bacteria it is important to mention that the use of rifamycin for this indication should be only done in cases where the infection is proven or strongly suspected to be caused by bacterial4802travallers diarrhea is very common problem affecting 2060 of the travellers and it is defined as an increase in frequency of bowel movements to three or more loose stools per day during a trip abroad this condition is rarely life threatening but in severe cases it can produce dehydration and sepsis the most common cause of travellers diarrhea is a pathogen and from the pathogens identified bacteria is the most common cause followed by norovirus rotavirus and similar virusesa39995')|
|('DB11755', 'MONDO:0021137', ['common []', 'not rare'], 'thcv does not currently have any fda health canada or ema approved indications')|
|('DB11757', 'MONDO:0021137', ['common []', 'not rare'], 'istradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of parkinsons diseasel8237')|
|('DB11760', 'MONDO:0021137', ['common []', 'not rare'], 'talazoparib is indicated for the treatment of deleterious or suspected deleterious germline brca mutated her2 negative locally advanced or metastatic breast cancer in adults fda label')|
|('DB11760', 'MONDO:0004992', ['cancer'], 'talazoparib is indicated for the treatment of deleterious or suspected deleterious germline brca mutated her2 negative locally advanced or metastatic breast cancer in adults fda label')|
|('DB11761', 'MONDO:0004992', ['cancer'], 'tenapanor is indicated for the treatment of constipationpredominant irritable bowel syndrome ibsc in adultsl8558 it is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis nct02081534 and nct02675998a185489')|
|('DB11761', 'MONDO:0005052', ['IBD', 'Irritable colon', 'irritable bowel syndrome'], 'tenapanor is indicated for the treatment of constipationpredominant irritable bowel syndrome ibsc in adultsl8558 it is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis nct02081534 and nct02675998a185489')|
|('DB11761', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'tenapanor is indicated for the treatment of constipationpredominant irritable bowel syndrome ibsc in adultsl8558 it is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis nct02081534 and nct02675998a185489')|
|('DB11767', 'MONDO:0001343', ['kidney disease []', 'disease of kidney [MONDO:patterns/disease_by_dysfunctional_structure]', 'impaired renal function disease'], 'indicated for modere to severe reactive ra in adult patients who are irresponsive respond inadequately or present intolerance to diseasemodifying antirheumatic drugs dmards or tumor necrosis factor tnf antagonists it is indicated to be used in combination with methotrexate mtx or as a monotherapy when there is intolerance to mtx or mtx administration is inappropriate')|
|('DB11767', 'MONDO:0005272', ['RA [NCIT:C2872]', 'aregenerative anemia [NCIT:C2872]', 'refractory anemia'], 'indicated for modere to severe reactive ra in adult patients who are irresponsive respond inadequately or present intolerance to diseasemodifying antirheumatic drugs dmards or tumor necrosis factor tnf antagonists it is indicated to be used in combination with methotrexate mtx or as a monotherapy when there is intolerance to mtx or mtx administration is inappropriate')|
|('DB11776', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'brodalumab has been approved for the treatment of psoriasis vulgaris psoriatic arthritis pustular psoriasis and psoriatic erythroderma ')|
|('DB11776', 'MONDO:0005083', ['psoriasis'], 'brodalumab has been approved for the treatment of psoriasis vulgaris psoriatic arthritis pustular psoriasis and psoriatic erythroderma ')|
|('DB11776', 'MONDO:0011849', ['arthritis psoriatica', 'arthropathic psoriasis', 'psoriatic arthritis'], 'brodalumab has been approved for the treatment of psoriasis vulgaris psoriatic arthritis pustular psoriasis and psoriatic erythroderma ')|
|('DB11793', 'MONDO:0005083', ['psoriasis'], 'niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy')|
|('DB11793', 'MONDO:0015686', ['serous surface papillary carcinoma [Orphanet:168829]', 'PPC [NCIT:C40022,Orphanet:168829]', 'Extra-ovarian primary peritoneal carcinoma [Orphanet:168829]', 'primary peritoneal serous carcinoma [Orphanet:168829]', 'EOPPC [Orphanet:168829]', 'primary peritoneal carcinoma [MONDO:ambiguous,NCIT:C40022]', 'primary peritoneal cancer [NCIT:C40022]', 'primary peritoneal carcinoma'], 'niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy')|
|('DB11799', 'MONDO:0015686', ['serous surface papillary carcinoma [Orphanet:168829]', 'PPC [NCIT:C40022,Orphanet:168829]', 'Extra-ovarian primary peritoneal carcinoma [Orphanet:168829]', 'primary peritoneal serous carcinoma [Orphanet:168829]', 'EOPPC [Orphanet:168829]', 'primary peritoneal carcinoma [MONDO:ambiguous,NCIT:C40022]', 'primary peritoneal cancer [NCIT:C40022]', 'primary peritoneal carcinoma'], 'bictegravir is indicated in the management of hiv1 infection in patients not previously treated with antiretroviral therapy  additionally bictegravir is indicated in the management of hiv1 infection in patients who are virologically suppressed hiv1 rna 50 cml on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication  it is used in combination with tenofovir and emtricitabine l1219 l1220')|
|('DB11799', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'bictegravir is indicated in the management of hiv1 infection in patients not previously treated with antiretroviral therapy  additionally bictegravir is indicated in the management of hiv1 infection in patients who are virologically suppressed hiv1 rna 50 cml on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication  it is used in combination with tenofovir and emtricitabine l1219 l1220')|
|('DB11817', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or who are intolerant to one or more diseasemodifying antirheumatic drugs as monotherapy or in combination with methotrexate')|
|('DB11817', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to or who are intolerant to one or more diseasemodifying antirheumatic drugs as monotherapy or in combination with methotrexate')|
|('DB11823', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'this drug is indicated in conjunction with an oral antidepressant for the treatment of treatmentresistant depression trd in adults fda labelnote esketamine is not approved as an anesthetic agent the safety and effectiveness of esketamine as an anesthetic agent have not been established to this date fda label ')|
|('DB11827', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'ertugliflozin as a monotherapy is indicated to improve the glycemic control in adult patients with type 2 diabetesfda label ertugliflozin in combination with metformin hydrochloride is indicated to improve glycemic control in patients with diabetes type 2 who are not controlled on a regimen of ertugliflozin or metformin or in patients who are already treated with both ertugliflozin and metforminl1134 the administration of ertugliflozin in combination with sitagliptin is indicated to improve glycemic control in adult patients with type 2 diabetes when treatment with ertugliflozin and sitagliptin is appropriatel1135 it is pointed out that the use of ertugliflozin has to be an adjunct therapy to the use of diet and exercisethe type 2 diabetes mellitus is characterized by insulin resistance in muscle and liver which results in the elevation of glucose levels in blood or by presence of insulin deficiency the insulin resistance is related to genetic factors obesity sedentary lifestyle orand aging this increase in the blood glucose can cause severe damage to kidney eyes and vascular systema31582')|
|('DB11827', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'ertugliflozin as a monotherapy is indicated to improve the glycemic control in adult patients with type 2 diabetesfda label ertugliflozin in combination with metformin hydrochloride is indicated to improve glycemic control in patients with diabetes type 2 who are not controlled on a regimen of ertugliflozin or metformin or in patients who are already treated with both ertugliflozin and metforminl1134 the administration of ertugliflozin in combination with sitagliptin is indicated to improve glycemic control in adult patients with type 2 diabetes when treatment with ertugliflozin and sitagliptin is appropriatel1135 it is pointed out that the use of ertugliflozin has to be an adjunct therapy to the use of diet and exercisethe type 2 diabetes mellitus is characterized by insulin resistance in muscle and liver which results in the elevation of glucose levels in blood or by presence of insulin deficiency the insulin resistance is related to genetic factors obesity sedentary lifestyle orand aging this increase in the blood glucose can cause severe damage to kidney eyes and vascular systema31582')|
|('DB11827', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ertugliflozin as a monotherapy is indicated to improve the glycemic control in adult patients with type 2 diabetesfda label ertugliflozin in combination with metformin hydrochloride is indicated to improve glycemic control in patients with diabetes type 2 who are not controlled on a regimen of ertugliflozin or metformin or in patients who are already treated with both ertugliflozin and metforminl1134 the administration of ertugliflozin in combination with sitagliptin is indicated to improve glycemic control in adult patients with type 2 diabetes when treatment with ertugliflozin and sitagliptin is appropriatel1135 it is pointed out that the use of ertugliflozin has to be an adjunct therapy to the use of diet and exercisethe type 2 diabetes mellitus is characterized by insulin resistance in muscle and liver which results in the elevation of glucose levels in blood or by presence of insulin deficiency the insulin resistance is related to genetic factors obesity sedentary lifestyle orand aging this increase in the blood glucose can cause severe damage to kidney eyes and vascular systema31582')|
|('DB11827', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ertugliflozin as a monotherapy is indicated to improve the glycemic control in adult patients with type 2 diabetesfda label ertugliflozin in combination with metformin hydrochloride is indicated to improve glycemic control in patients with diabetes type 2 who are not controlled on a regimen of ertugliflozin or metformin or in patients who are already treated with both ertugliflozin and metforminl1134 the administration of ertugliflozin in combination with sitagliptin is indicated to improve glycemic control in adult patients with type 2 diabetes when treatment with ertugliflozin and sitagliptin is appropriatel1135 it is pointed out that the use of ertugliflozin has to be an adjunct therapy to the use of diet and exercisethe type 2 diabetes mellitus is characterized by insulin resistance in muscle and liver which results in the elevation of glucose levels in blood or by presence of insulin deficiency the insulin resistance is related to genetic factors obesity sedentary lifestyle orand aging this increase in the blood glucose can cause severe damage to kidney eyes and vascular systema31582')|
|('DB11828', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use as an extended adjuvant treatment in adult patients with early stage her2overexpressedamplified breast cancer to follow adjuvant trastuzumabbased therapy fda label')|
|('DB11828', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'for use as an extended adjuvant treatment in adult patients with early stage her2overexpressedamplified breast cancer to follow adjuvant trastuzumabbased therapy fda label')|
|('DB11834', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'indicated for the treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy')|
|('DB11834', 'MONDO:0005083', ['psoriasis'], 'indicated for the treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy')|
|('DB11842', 'MONDO:0005083', ['psoriasis'], 'angiotensin ii is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock fda label')|
|('DB11855', 'MONDO:0005083', ['psoriasis'], 'revefenacin is indicated as an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease copdl4820copd is a growing disease being the third leading cause of death in the us this disease is characterized by not fully reversible airflow limitationl4821')|
|('DB11855', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'revefenacin is indicated as an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease copdl4820copd is a growing disease being the third leading cause of death in the us this disease is characterized by not fully reversible airflow limitationl4821')|
|('DB11859', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'brexanolone is a synthetic neuroactive steroid gammaaminobutyric acid a gabaa receptor positive modulator indicated for the treatment of postpartum depression ppd in adult women fda labela176080 a176083 f4063 f4066 f4072')|
|('DB11859', 'MONDO:0005929', ['Maternity blues', 'postnatal depression', 'postpartum depression'], 'brexanolone is a synthetic neuroactive steroid gammaaminobutyric acid a gabaa receptor positive modulator indicated for the treatment of postpartum depression ppd in adult women fda labela176080 a176083 f4063 f4066 f4072')|
|('DB11866', 'MONDO:0005929', ['Maternity blues', 'postnatal depression', 'postpartum depression'], 'romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatmentsl9554')|
|('DB11866', 'MONDO:0005298', ['osteoporosis'], 'romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatmentsl9554')|
|('DB11901', 'MONDO:0005298', ['osteoporosis'], 'indicated for the treatment of patients with nonmetastatic castrationresistant prostate cancer nmcrpc fda label')|
|('DB11901', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'indicated for the treatment of patients with nonmetastatic castrationresistant prostate cancer nmcrpc fda label')|
|('DB11915', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'for the treatment of tardive dyskinesia in adults fda label')|
|('DB11915', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'for the treatment of tardive dyskinesia in adults fda label')|
|('DB11921', 'MONDO:0010096', ['tardive dyskinesia [MONDO:ambiguous,OMIM:272620]', 'tardive dyskinesia'], 'deflazacort is indicated for the treatment of duchenne muscular dystrophy dmd in patients 2 years of age and olderfda label')|
|('DB11921', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'deflazacort is indicated for the treatment of duchenne muscular dystrophy dmd in patients 2 years of age and olderfda label')|
|('DB11942', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasonelabel patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors at least two immunomodulatory agents and an anti‐cd38 monoclonal antibody')|
|('DB11942', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasonelabel patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors at least two immunomodulatory agents and an anti‐cd38 monoclonal antibody')|
|('DB11943', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'delafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the grampositive organisms staphylococcus aureus including methicillinresistant and methicillinsusceptible isolates staphylococcus haemolyticus staphylococcus lugdunensis streptococcus agalactiae streptococcus anginosus group including streptococcus anginosus streptococcus intermedius and streptococcus constellatus streptococcus pyogenes and enterococcus faecalis as well as the gramnegative organisms escherichia coli enterobacter cloacae klebsiella pneumoniae and pseudomonas aeruginosa fda label')|
|('DB11945', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'indicated for the treatment of adults and pediatric patients 12 years and older with metastatic merkel cell carcinoma mcc ')|
|('DB11945', 'MONDO:0019210', ['carcinoma of Merkel cell [MONDO:patterns/carcinoma]', 'neuroendocrine carcinoma of the skin [NCIT:C9231]', 'trabecular skin carcinoma [NCIT:C9231]', 'Merkel cell carcinoma [MONDO:patterns/location,NCIT:C9231,Orphanet:79140]', 'neuroendocrine carcinoma of skin [NCIT:C9231]', 'Merkel cell tumor [NCIT:C9231]', 'Merkel cell cancer [NCIT:C9231]', 'cutaneous APUDoma [NCIT:C9231]', 'neuroendocrine skin carcinoma [NCIT:C9231]', 'cutaneous neuroendocrine carcinoma [NCIT:C9231]', 'MCC [ONCOTREE:MCC,Orphanet:79140]', 'trabecular cancer [NCIT:C9231]', 'cutaneous neuroendocrine carcinoma'], 'indicated for the treatment of adults and pediatric patients 12 years and older with metastatic merkel cell carcinoma mcc ')|
|('DB11951', 'MONDO:0005170', ['myeloma', 'myeloid neoplasm'], 'lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset andor sleep maintenancel10863')|
|('DB11951', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset andor sleep maintenancel10863')|
|('DB11952', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0004948', ['B-cell chronic lymphocytic leukaemia', 'B-cell chronic lymphocytic leukemia', 'chronic lymphatic leukaemia', 'chronic lymphatic leukemia', 'chronic lymphocytic leukaemia', 'CLL', 'lymphoplasmacytic leukaemia', 'lymphoplasmacytic leukemia', 'b-cell chronic lymphocytic leukemia'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0005059', ['leukemia'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11952', 'MONDO:0018906', ['follicular lymphoma'], 'duvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll after at least two prior therapiesl4586the cll is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells in leukemia there is an overproduction of cells that are abnormal and do not mature into blood cells and thus they just crowd out normal cells and impair their normal function in lymphocyte leukemia the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes the cll is the type of lymphocytic leukemia that develops slowly over months or yearsl4587 the sll is a very similar disease to the cll and these terms are usually referred interchangeably the only difference between these two diseases is that in cll the cells are found mostly in the blood and bone marrow while in sll the cells are mainly found in the lymph nodesl4588as well duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies this approval is still under the status of continued approval and it is restrained to confirmatory trialsl4586the follicular lymphoma is a bcell lymphoma that clusters in the lymph nodes or other tissuesl4589')|
|('DB11963', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'dacomitinib is indicated as the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon 19 deletion or exon 21 l858r substitution mutations as verified by an fdaapproved testl4812lung cancer is the leading cause of cancer death and nsclc accounts for 85 of lung cancer cases from the cases of nsclc approximately 75 of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5 the presence of a mutation in egfr accounts for more than the 60 of the nsclc cases and the overexpression of egfr is associated with frequent lymph node metastasis and poor chemosensitivitya40018 a19201')|
|('DB11963', 'MONDO:0004992', ['cancer'], 'dacomitinib is indicated as the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon 19 deletion or exon 21 l858r substitution mutations as verified by an fdaapproved testl4812lung cancer is the leading cause of cancer death and nsclc accounts for 85 of lung cancer cases from the cases of nsclc approximately 75 of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5 the presence of a mutation in egfr accounts for more than the 60 of the nsclc cases and the overexpression of egfr is associated with frequent lymph node metastasis and poor chemosensitivitya40018 a19201')|
|('DB11963', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'dacomitinib is indicated as the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon 19 deletion or exon 21 l858r substitution mutations as verified by an fdaapproved testl4812lung cancer is the leading cause of cancer death and nsclc accounts for 85 of lung cancer cases from the cases of nsclc approximately 75 of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5 the presence of a mutation in egfr accounts for more than the 60 of the nsclc cases and the overexpression of egfr is associated with frequent lymph node metastasis and poor chemosensitivitya40018 a19201')|
|('DB11963', 'MONDO:0008903', ['lung cancer'], 'dacomitinib is indicated as the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc with epidermal growth factor receptor egfr exon 19 deletion or exon 21 l858r substitution mutations as verified by an fdaapproved testl4812lung cancer is the leading cause of cancer death and nsclc accounts for 85 of lung cancer cases from the cases of nsclc approximately 75 of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5 the presence of a mutation in egfr accounts for more than the 60 of the nsclc cases and the overexpression of egfr is associated with frequent lymph node metastasis and poor chemosensitivitya40018 a19201')|
|('DB11967', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'on june 27 2018 the food and drug administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation as detected by an fdaapproved test l3335')|
|('DB11967', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'on june 27 2018 the food and drug administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation as detected by an fdaapproved test l3335')|
|('DB11978', 'MONDO:0005191', ['metastatic malignant melanoma []', 'metastatic melanoma [NCIT:C8925]', 'metastatic melanoma'], 'glasdegib in combination with cytarabine is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have comorbidities that preclude intensive induction chemotherapyl5080acute myeloid leukemia is characterized by abnormal production of myeloblasts red cells or platelets it is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adultsl4832')|
|('DB11978', 'MONDO:0015667', ['unclassified AML [Orphanet:167714]', 'acute myeloid leukemia [NCIT:C27753]', 'acute myeloid leukemia not otherwise categorized [NCIT:C27753]', 'AML, NOS [NCIT:C27753]', 'acute myeloid leukemia NOS [NCIT:C27753]', 'acute myeloid leukemia not otherwise specified [NCIT:C27753]', 'acute myeloid leukemia, NOS [NCIT:C27753]', 'unclassified acute myeloid leukemia'], 'glasdegib in combination with cytarabine is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have comorbidities that preclude intensive induction chemotherapyl5080acute myeloid leukemia is characterized by abnormal production of myeloblasts red cells or platelets it is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adultsl4832')|
|('DB11978', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'glasdegib in combination with cytarabine is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have comorbidities that preclude intensive induction chemotherapyl5080acute myeloid leukemia is characterized by abnormal production of myeloblasts red cells or platelets it is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adultsl4832')|
|('DB11978', 'MONDO:0021137', ['common []', 'not rare'], 'glasdegib in combination with cytarabine is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have comorbidities that preclude intensive induction chemotherapyl5080acute myeloid leukemia is characterized by abnormal production of myeloblasts red cells or platelets it is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adultsl4832')|
|('DB11978', 'MONDO:0010643', ['Stem cell leukaemia', 'Stem cell Leukemia', 'acute leukemia'], 'glasdegib in combination with cytarabine is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have comorbidities that preclude intensive induction chemotherapyl5080acute myeloid leukemia is characterized by abnormal production of myeloblasts red cells or platelets it is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adultsl4832')|
|('DB11979', 'MONDO:0010643', ['Stem cell leukaemia', 'Stem cell Leukemia', 'acute leukemia'], 'elagolix is a gonadotropinreleasing hormone gnrh receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis fda label')|
|('DB11979', 'MONDO:0005133', ['endometriosis'], 'elagolix is a gonadotropinreleasing hormone gnrh receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis fda label')|
|('DB11986', 'MONDO:0005133', ['endometriosis'], 'entrectinib is indicated for the treatment of metastatic ros1positive nonsmall cell lung cancer in adultsl8081 entrectinib is also indicated in adults and children over 12 years old for the treatment of ntrk gene fusionpositive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available')|
|('DB11986', 'MONDO:0004992', ['cancer'], 'entrectinib is indicated for the treatment of metastatic ros1positive nonsmall cell lung cancer in adultsl8081 entrectinib is also indicated in adults and children over 12 years old for the treatment of ntrk gene fusionpositive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available')|
|('DB11986', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'entrectinib is indicated for the treatment of metastatic ros1positive nonsmall cell lung cancer in adultsl8081 entrectinib is also indicated in adults and children over 12 years old for the treatment of ntrk gene fusionpositive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available')|
|('DB11988', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis fda label')|
|('DB11988', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis fda label')|
|('DB11989', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'for use in the treatment of chagas disease in children 212 years of age l939')|
|('DB11989', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'for use in the treatment of chagas disease in children 212 years of age l939')|
|('DB11994', 'MONDO:0001444', ['Chagas disease', 'chagas disease with digestive system involvement', 'chagas disease with nervous system involvement', 'chagas disease with other organ involvement', 'chagas disease'], 'for the treatment of osteoarthritis affecting the hip or knee l780')|
|('DB11994', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'for the treatment of osteoarthritis affecting the hip or knee l780')|
|('DB11995', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure fda label')|
|('DB11995', 'MONDO:0002049', ['thrombocytopenia'], 'indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure fda label')|
|('DB12001', 'MONDO:0002049', ['thrombocytopenia'], ' indicated in combination with fulvestrant for the treatment of women with hormone receptor hrpositive human epidermal growth factor receptor 2 her2negative advanced or metastatic breast cancer with disease progression following endocrine therapy  inidicated as monotherapy for the treatment of adult patients with hrpositive her2negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting ')|
|('DB12001', 'MONDO:0004992', ['cancer'], ' indicated in combination with fulvestrant for the treatment of women with hormone receptor hrpositive human epidermal growth factor receptor 2 her2negative advanced or metastatic breast cancer with disease progression following endocrine therapy  inidicated as monotherapy for the treatment of adult patients with hrpositive her2negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting ')|
|('DB12007', 'MONDO:0004992', ['cancer'], 'indicated for overthecounter use as a dietary supplement for increasing bone density and regulating blood fat ')|
|('DB12010', 'MONDO:0004992', ['cancer'], 'fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia itp in patients who have had insufficient response to previous therapy fda label')|
|('DB12010', 'MONDO:0002049', ['thrombocytopenia'], 'fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia itp in patients who have had insufficient response to previous therapy fda label')|
|('DB12015', 'MONDO:0002049', ['thrombocytopenia'], 'alpelisib is indicated in combination with fulvestrant to treat postmenopausal women and men with advanced or metastatic breast cancerlabel this cancer must be hormone receptor hrpositive human epidermal growth factor receptor 2 her2negative and pik3ca\xad mutatedlabel the cancer must be detected by an fdaapproved test following progression on or after an endocrinebased regimenlabel')|
|('DB12015', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'alpelisib is indicated in combination with fulvestrant to treat postmenopausal women and men with advanced or metastatic breast cancerlabel this cancer must be hormone receptor hrpositive human epidermal growth factor receptor 2 her2negative and pik3ca\xad mutatedlabel the cancer must be detected by an fdaapproved test following progression on or after an endocrinebased regimenlabel')|
|('DB12015', 'MONDO:0004992', ['cancer'], 'alpelisib is indicated in combination with fulvestrant to treat postmenopausal women and men with advanced or metastatic breast cancerlabel this cancer must be hormone receptor hrpositive human epidermal growth factor receptor 2 her2negative and pik3ca\xad mutatedlabel the cancer must be detected by an fdaapproved test following progression on or after an endocrinebased regimenlabel')|
|('DB12020', 'MONDO:0004992', ['cancer'], 'tecovirimat is indicated for the treatment of smallpox infection it can be administered in children and adults with a minimum body weight of 13 kg  fda label tecovirimat is an inhibitor of the orthopoxvirus vp37 envelope wrapping protein fda label')|
|('DB12020', 'MONDO:0004651', ['Ordinary smallpox', 'smallpox'], 'tecovirimat is indicated for the treatment of smallpox infection it can be administered in children and adults with a minimum body weight of 13 kg  fda label tecovirimat is an inhibitor of the orthopoxvirus vp37 envelope wrapping protein fda label')|
|('DB12020', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'tecovirimat is indicated for the treatment of smallpox infection it can be administered in children and adults with a minimum body weight of 13 kg  fda label tecovirimat is an inhibitor of the orthopoxvirus vp37 envelope wrapping protein fda label')|
|('DB12023', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'benralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotypel1020 the pathology of severe asthma with eosinophilic phenotype is also denotated as th2high phenotype the patients with this phenotype are characterized by the expression of il5 and il13 airway hyperresponsiveness responsiveness to inhaled corticosteroids high serum ige and eosinophilia in blood and airway in the th2high phenotype il5 presents a central role as it is responsible for eosinophil differentiation survival activation and migration to the lungsa31295')|
|('DB12023', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'benralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotypel1020 the pathology of severe asthma with eosinophilic phenotype is also denotated as th2high phenotype the patients with this phenotype are characterized by the expression of il5 and il13 airway hyperresponsiveness responsiveness to inhaled corticosteroids high serum ige and eosinophilia in blood and airway in the th2high phenotype il5 presents a central role as it is responsible for eosinophil differentiation survival activation and migration to the lungsa31295')|
|('DB12026', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'vosevi voxilaprevirdb08934db11613 is approved for use in patients with genotypes 16 who have been previously treated with an ns5a inhibitor or patients with genotypes 1a or 3 infection who have previously been treated with an hcv regimen containing db08934 without an ns5a inhibitor l935 ')|
|('DB12035', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'sarecycline is a tetracyclineclass drug indicated for the treatment of inflammatory lesions of nonnodular moderate to severe acne vulgaris in patients 9 years of age and older fda label')|
|('DB12070', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'for use in prophylaxis of cytomegalovirus cmv infection and disease in adult cmvseropositive recipients of an allogeneic hematopoietic stem cell transplant hsct fda label')|
|('DB12095', 'MONDO:0015691', ['eosinophilia', 'Eosinophilic leukocytosis', 'hypereosinophilic syndrome'], 'as a serotonin synthesis inhibitor telotristat etiprate has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome ')|
|('DB12095', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'as a serotonin synthesis inhibitor telotristat etiprate has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome ')|
|('DB12095', 'MONDO:0006689', ['carcinoid syndrome [MONDO:0007262]', 'malignant carcinoid syndrome [Orphanet:100093]', 'carcinoid syndrome'], 'as a serotonin synthesis inhibitor telotristat etiprate has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome ')|
|('DB12107', 'MONDO:0006689', ['carcinoid syndrome [MONDO:0007262]', 'malignant carcinoid syndrome [Orphanet:100093]', 'carcinoid syndrome'], 'indicated in combination with meropenem for the treatment of patients 18 years of age and older with complicated urinary tract infections cuti including pyelonephritis caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae and enterobacter cloacae species complexfda label')|
|('DB12107', 'MONDO:0006939', ['pyelonephritis'], 'indicated in combination with meropenem for the treatment of patients 18 years of age and older with complicated urinary tract infections cuti including pyelonephritis caused by the following susceptible microorganisms escherichia coli klebsiella pneumoniae and enterobacter cloacae species complexfda label')|
|('DB12129', 'MONDO:0006939', ['pyelonephritis'], 'tideglusib was initially formulated for the treatment of alzheimer and progressive supranuclear palsya31601 the raising interest for the use of tideglusib comes from the significant upregulation of gsk3 in the brain in patients with alzheimer disease its function as a degradant of βcatenin was also important as it prevents the transcription of cell survival genes all these factors have directed current research towards this kinase as a potential targeta31603 alzheimer disease is the most prevalent form of dementia the most accepted hypothesis to explain this disease is related to the presence of amyloid β which triggers a cascade that will alter the tau protein and provoke synaptic dysfunction and neuronal deatha31605 gsk3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib thus it is also under the research for the natural repair treatment of deep caries lesionsa31602 ')|
|('DB12129', 'MONDO:0004975', ['Alzheimer disease', 'Alzheimers dementia', 'alzheimer disease'], 'tideglusib was initially formulated for the treatment of alzheimer and progressive supranuclear palsya31601 the raising interest for the use of tideglusib comes from the significant upregulation of gsk3 in the brain in patients with alzheimer disease its function as a degradant of βcatenin was also important as it prevents the transcription of cell survival genes all these factors have directed current research towards this kinase as a potential targeta31603 alzheimer disease is the most prevalent form of dementia the most accepted hypothesis to explain this disease is related to the presence of amyloid β which triggers a cascade that will alter the tau protein and provoke synaptic dysfunction and neuronal deatha31605 gsk3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib thus it is also under the research for the natural repair treatment of deep caries lesionsa31602 ')|
|('DB12129', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'tideglusib was initially formulated for the treatment of alzheimer and progressive supranuclear palsya31601 the raising interest for the use of tideglusib comes from the significant upregulation of gsk3 in the brain in patients with alzheimer disease its function as a degradant of βcatenin was also important as it prevents the transcription of cell survival genes all these factors have directed current research towards this kinase as a potential targeta31603 alzheimer disease is the most prevalent form of dementia the most accepted hypothesis to explain this disease is related to the presence of amyloid β which triggers a cascade that will alter the tau protein and provoke synaptic dysfunction and neuronal deatha31605 gsk3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib thus it is also under the research for the natural repair treatment of deep caries lesionsa31602 ')|
|('DB12129', 'MONDO:0001627', ['dementia'], 'tideglusib was initially formulated for the treatment of alzheimer and progressive supranuclear palsya31601 the raising interest for the use of tideglusib comes from the significant upregulation of gsk3 in the brain in patients with alzheimer disease its function as a degradant of βcatenin was also important as it prevents the transcription of cell survival genes all these factors have directed current research towards this kinase as a potential targeta31603 alzheimer disease is the most prevalent form of dementia the most accepted hypothesis to explain this disease is related to the presence of amyloid β which triggers a cascade that will alter the tau protein and provoke synaptic dysfunction and neuronal deatha31605 gsk3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib thus it is also under the research for the natural repair treatment of deep caries lesionsa31602 ')|
|('DB12129', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tideglusib was initially formulated for the treatment of alzheimer and progressive supranuclear palsya31601 the raising interest for the use of tideglusib comes from the significant upregulation of gsk3 in the brain in patients with alzheimer disease its function as a degradant of βcatenin was also important as it prevents the transcription of cell survival genes all these factors have directed current research towards this kinase as a potential targeta31603 alzheimer disease is the most prevalent form of dementia the most accepted hypothesis to explain this disease is related to the presence of amyloid β which triggers a cascade that will alter the tau protein and provoke synaptic dysfunction and neuronal deatha31605 gsk3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib thus it is also under the research for the natural repair treatment of deep caries lesionsa31602 ')|
|('DB12130', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lorlatinib is a thirdgeneration anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki l4848 indicated for the treatment of patients with alkpositive metastatic nonsmall cell lung cancer nsclc whose disease has progressed on a the prior use of crizotinib and at least one other alk inhibitor for metastatic disease or b the prior use of alectinib as the first alk inhibitor therapy for metastatic disease or c the prior use of certinib as the first alk inhibitor therapy for metastatic disease l848 fda label ')|
|('DB12130', 'MONDO:0004992', ['cancer'], 'lorlatinib is a thirdgeneration anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki l4848 indicated for the treatment of patients with alkpositive metastatic nonsmall cell lung cancer nsclc whose disease has progressed on a the prior use of crizotinib and at least one other alk inhibitor for metastatic disease or b the prior use of alectinib as the first alk inhibitor therapy for metastatic disease or c the prior use of certinib as the first alk inhibitor therapy for metastatic disease l848 fda label ')|
|('DB12130', 'MONDO:0024883', ['metastatic tumor [NCIT:C3261]', 'metastatic neoplasm [NCIT:C3261]', 'metastatic disease [NCIT:C3261]', 'metastatic neoplasm'], 'lorlatinib is a thirdgeneration anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki l4848 indicated for the treatment of patients with alkpositive metastatic nonsmall cell lung cancer nsclc whose disease has progressed on a the prior use of crizotinib and at least one other alk inhibitor for metastatic disease or b the prior use of alectinib as the first alk inhibitor therapy for metastatic disease or c the prior use of certinib as the first alk inhibitor therapy for metastatic disease l848 fda label ')|
|('DB12140', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dilmapimod has been used in trials studying the treatment and diagnostic of nerve trauma inflammation pain neuropathic arthritis rheumatoid and coronary heart disease among others')|
|('DB12140', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'dilmapimod has been used in trials studying the treatment and diagnostic of nerve trauma inflammation pain neuropathic arthritis rheumatoid and coronary heart disease among others')|
|('DB12141', 'MONDO:0005010', ['CHD', 'coronary arteriosclerosis', 'Coronary disease', 'coronary heart disease', 'coronary artery disease'], 'gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an flt3 mutation detected by an fdaapproved test this indication was expanded for a companion diagnostic to include use with gilteritinib such as the leukostrat cdx flt3 mutation assayl4830acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression this condition produces low numbers of normal blood cells and the requirement of continuous need for transfusionsl4832 ')|
|('DB12141', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an flt3 mutation detected by an fdaapproved test this indication was expanded for a companion diagnostic to include use with gilteritinib such as the leukostrat cdx flt3 mutation assayl4830acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression this condition produces low numbers of normal blood cells and the requirement of continuous need for transfusionsl4832 ')|
|('DB12141', 'MONDO:0004992', ['cancer'], 'gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an flt3 mutation detected by an fdaapproved test this indication was expanded for a companion diagnostic to include use with gilteritinib such as the leukostrat cdx flt3 mutation assayl4830acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression this condition produces low numbers of normal blood cells and the requirement of continuous need for transfusionsl4832 ')|
|('DB12147', 'MONDO:0004992', ['cancer'], 'erdafitinib is a panfibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda labela177109 a177112 a177115 that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that hasi susceptible fgfr3 or fgfr2 genetic alterations and has fda labelii progressed during or following at least one line of prior platinumcontaining chemotherapy including within 12 months of neoadjuvant or adjuvant platinumcontaining chemotherapy fda labelthe selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible fgfr genetic alterations in tumor specimens as detected by an fdaapproved companion diagnostic like the fda approved therascreen fgfr rgq rtpcr kit as developed by qiagen fda labelthis above indication is approved under accelerated approval by the us fda based on tumor response rate fda label continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials fda label')|
|('DB12147', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'erdafitinib is a panfibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda labela177109 a177112 a177115 that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that hasi susceptible fgfr3 or fgfr2 genetic alterations and has fda labelii progressed during or following at least one line of prior platinumcontaining chemotherapy including within 12 months of neoadjuvant or adjuvant platinumcontaining chemotherapy fda labelthe selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible fgfr genetic alterations in tumor specimens as detected by an fdaapproved companion diagnostic like the fda approved therascreen fgfr rgq rtpcr kit as developed by qiagen fda labelthis above indication is approved under accelerated approval by the us fda based on tumor response rate fda label continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials fda label')|
|('DB12147', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'erdafitinib is a panfibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda labela177109 a177112 a177115 that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that hasi susceptible fgfr3 or fgfr2 genetic alterations and has fda labelii progressed during or following at least one line of prior platinumcontaining chemotherapy including within 12 months of neoadjuvant or adjuvant platinumcontaining chemotherapy fda labelthe selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible fgfr genetic alterations in tumor specimens as detected by an fdaapproved companion diagnostic like the fda approved therascreen fgfr rgq rtpcr kit as developed by qiagen fda labelthis above indication is approved under accelerated approval by the us fda based on tumor response rate fda label continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials fda label')|
|('DB12159', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'dupilumab indicated as monotherapy or in combination with topical corticosteroids for the treatment of patients aged 12 years and older with moderateto\xadsevere atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisablel7186indicated as an addon maintenance treatment in patients with moderatetosevere asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma it is not indicated for the relief of acute bronchospasm or status asthmaticusl7186indicated for the treatment of nasal polyps accompanied by inadequately controlled chronic rhinosinusitis in adult patientsl7258')|
|('DB12159', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'dupilumab indicated as monotherapy or in combination with topical corticosteroids for the treatment of patients aged 12 years and older with moderateto\xadsevere atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisablel7186indicated as an addon maintenance treatment in patients with moderatetosevere asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma it is not indicated for the relief of acute bronchospasm or status asthmaticusl7186indicated for the treatment of nasal polyps accompanied by inadequately controlled chronic rhinosinusitis in adult patientsl7258')|
|('DB12159', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'dupilumab indicated as monotherapy or in combination with topical corticosteroids for the treatment of patients aged 12 years and older with moderateto\xadsevere atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisablel7186indicated as an addon maintenance treatment in patients with moderatetosevere asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma it is not indicated for the relief of acute bronchospasm or status asthmaticusl7186indicated for the treatment of nasal polyps accompanied by inadequately controlled chronic rhinosinusitis in adult patientsl7258')|
|('DB12159', 'MONDO:0006031', ['chronic sinusitis []', 'sinusitis, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic rhinosinusitis'], 'dupilumab indicated as monotherapy or in combination with topical corticosteroids for the treatment of patients aged 12 years and older with moderateto\xadsevere atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisablel7186indicated as an addon maintenance treatment in patients with moderatetosevere asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma it is not indicated for the relief of acute bronchospasm or status asthmaticusl7186indicated for the treatment of nasal polyps accompanied by inadequately controlled chronic rhinosinusitis in adult patientsl7258')|
|('DB12161', 'MONDO:0006031', ['chronic sinusitis []', 'sinusitis, chronic [MONDO:design_pattern,MONDO:patterns/chronic]', 'chronic rhinosinusitis'], 'indicated for the treatment of chorea associated with huntington’s disease fda label ')|
|('DB12161', 'MONDO:0001595', ['chorea', 'hereditary chorea', 'choreatic disease'], 'indicated for the treatment of chorea associated with huntington’s disease fda label ')|
|('DB12240', 'MONDO:0001595', ['chorea', 'hereditary chorea', 'choreatic disease'], 'this medication is indicated to treat adults with relapsed or refractory diffuse large bcell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapieslabel')|
|('DB12240', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'this medication is indicated to treat adults with relapsed or refractory diffuse large bcell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapieslabel')|
|('DB12240', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'this medication is indicated to treat adults with relapsed or refractory diffuse large bcell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapieslabel')|
|('DB12243', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of als')|
|('DB12243', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of als')|
|('DB12243', 'MONDO:0004976', ['ALS', 'Lou Gehrigs disease', 'motor neuron disease, bulbar', 'amyotrophic lateral sclerosis'], 'indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of als')|
|('DB12245', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'this drug is indicated for the treatment of fascioliasis in patients aged 6 years old and abovefda labell5452')|
|('DB12245', 'MONDO:0004668', ['Fasciola hepatica infection', 'Infection by Fasciola', 'Liver flukes', 'Sheep liver fluke infection', 'fascioliasis'], 'this drug is indicated for the treatment of fascioliasis in patients aged 6 years old and abovefda labell5452')|
|('DB12249', 'MONDO:0004668', ['Fasciola hepatica infection', 'Infection by Fasciola', 'Liver flukes', 'Sheep liver fluke infection', 'fascioliasis'], 'the primary medical purpose for which stem bromelain sb is currently indicated for is the removal of eschar in adults with deep partial and fullthickness thermal burns fda labelbesides this official indication however it is also believed that sb may be used as a treatment for several other purposes as well including cardiovascular health osteoarthritis autoimmunity blood clotting diarrhea cancer surgery and debridement  although the specific mechanisms of action for these indications remain to be elucidated a27198')|
|('DB12249', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'the primary medical purpose for which stem bromelain sb is currently indicated for is the removal of eschar in adults with deep partial and fullthickness thermal burns fda labelbesides this official indication however it is also believed that sb may be used as a treatment for several other purposes as well including cardiovascular health osteoarthritis autoimmunity blood clotting diarrhea cancer surgery and debridement  although the specific mechanisms of action for these indications remain to be elucidated a27198')|
|('DB12267', 'MONDO:0005178', ['degenerative arthritis', 'degenerative joint disease', 'hypertrophic arthritis', 'osteoarthrosis', 'Osteoarthrosis and allied disorder', 'osteoarthritis'], 'the anaplastic lymphoma kinase positive metastatic nonsmall cell lung cancer alk nsclc represents only 35 of the nsclc cancer cases but the alk mutation overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy targeta31311 the alkrelated cases of nsclc are associated with the presence of the fusion gene eml4alk which fused the alk protein with the echinoderm microtubuleassociated protein like4 whose original function is the correct formation of microtubulesa31313 the presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth proliferation and survivala31316 crizotinib is indicated for the treatment of such cases but the presence of alk kinase domain mutations confer resistance to the treatment thus brigatinib is indicated for the treatment of patients with alk nsclc with intolerance to crizotiniba31314')|
|('DB12267', 'MONDO:0004992', ['cancer'], 'the anaplastic lymphoma kinase positive metastatic nonsmall cell lung cancer alk nsclc represents only 35 of the nsclc cancer cases but the alk mutation overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy targeta31311 the alkrelated cases of nsclc are associated with the presence of the fusion gene eml4alk which fused the alk protein with the echinoderm microtubuleassociated protein like4 whose original function is the correct formation of microtubulesa31313 the presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth proliferation and survivala31316 crizotinib is indicated for the treatment of such cases but the presence of alk kinase domain mutations confer resistance to the treatment thus brigatinib is indicated for the treatment of patients with alk nsclc with intolerance to crizotiniba31314')|
|('DB12267', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'the anaplastic lymphoma kinase positive metastatic nonsmall cell lung cancer alk nsclc represents only 35 of the nsclc cancer cases but the alk mutation overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy targeta31311 the alkrelated cases of nsclc are associated with the presence of the fusion gene eml4alk which fused the alk protein with the echinoderm microtubuleassociated protein like4 whose original function is the correct formation of microtubulesa31313 the presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth proliferation and survivala31316 crizotinib is indicated for the treatment of such cases but the presence of alk kinase domain mutations confer resistance to the treatment thus brigatinib is indicated for the treatment of patients with alk nsclc with intolerance to crizotiniba31314')|
|('DB12278', 'MONDO:0005233', ['Non-small cell lung cancer', 'non-small cell lung carcinoma', 'NSCLC', 'non-small cell lung carcinoma'], 'indicated for symptomatic treatment of urinary incontinence andor increased urinary frequency and urgency in patients with overactive bladder oab l2315  propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury a32581')|
|('DB12278', 'MONDO:0006624', ['overactive bladder [MONDO:ambiguous]', 'overactive bladder'], 'indicated for symptomatic treatment of urinary incontinence andor increased urinary frequency and urgency in patients with overactive bladder oab l2315  propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury a32581')|
|('DB12278', 'MONDO:0043797', ['spinal cord injury [MESH:D013119,MONDO:patterns/location]', 'injury of spinal cord [MONDO:design_pattern]', 'spinal cord injury'], 'indicated for symptomatic treatment of urinary incontinence andor increased urinary frequency and urgency in patients with overactive bladder oab l2315  propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury a32581')|
|('DB12281', 'MONDO:0043797', ['spinal cord injury [MESH:D013119,MONDO:patterns/location]', 'injury of spinal cord [MONDO:design_pattern]', 'spinal cord injury'], 'luspatercept is indicated for the treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusionsl9980')|
|('DB12281', 'MONDO:0002280', ['anaemia', 'anemia'], 'luspatercept is indicated for the treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusionsl9980')|
|('DB12281', 'MONDO:0019402', ['beta thalassemia'], 'luspatercept is indicated for the treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusionsl9980')|
|('DB12301', 'MONDO:0019402', ['beta thalassemia'], 'doravirine is indicated in combination with other antiretroviral agents for the treatment of hiv1 infection in adult patients with no prior antiretroviral treatment history fda label')|
|('DB12323', 'MONDO:0019402', ['beta thalassemia'], 'radotinib is indicated for the treatment of different types of cancer most notably philadelphia chromosomepositive ph chronic myeloid leukemia cml with resistance or intolerance of other bcrabl tyrosinekinase inhibitors such as patients resistant or intolerant to imatinib')|
|('DB12323', 'MONDO:0004992', ['cancer'], 'radotinib is indicated for the treatment of different types of cancer most notably philadelphia chromosomepositive ph chronic myeloid leukemia cml with resistance or intolerance of other bcrabl tyrosinekinase inhibitors such as patients resistant or intolerant to imatinib')|
|('DB12323', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'radotinib is indicated for the treatment of different types of cancer most notably philadelphia chromosomepositive ph chronic myeloid leukemia cml with resistance or intolerance of other bcrabl tyrosinekinase inhibitors such as patients resistant or intolerant to imatinib')|
|('DB12328', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12328', 'MONDO:0021137', ['common []', 'not rare'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12328', 'MONDO:0005855', ['molluscum contagiosum'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12328', 'MONDO:0005446', ['Asian Desert Cutaneous Leishmaniasis', 'diffuse cutaneous leishmaniasis', 'Leproid leishmaniasis', 'cutaneous leishmaniasis'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12328', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12328', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the only therapeutic use for which cantharidin is currently primarily indicated for is as an active ingredient in topical agents for treating common warts verruca vulgaris periungual warts plantar warts and molluscum contagiosum a32891 a32892 f32 at the same time such topical cantharidin applications have also been used for a number of offlabel indications like callus removal cutaneous leishmaniasis herpes zoster and acquired perforating dermatosis a32892 furthermore since most topical cantharidin applications are most commonly available in a 07 formulation or a more potent 1 mixture the 07 formulation is most commonly indicated for the treatment of common warts periungual warts and molluscum contagiosum while the more potent 1 mixture is typically limited only for use by healthcare professionals in a clinical setting for treating plantar warts and other more specialized offlabel conditions a32891 a32892 f32moreover there have also been studies into whether or not cantharidin could be effective at being used as an inflammatory model or in cancer treatment  either of which has yet to formally elucidate any results a32892')|
|('DB12329', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'this drug is a tetracycline class antibacterial indicated for the treatment of complicated intraabdominal infections in patients 18 years of age and older fda label')|
|('DB12332', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated as monotherapy for the treatment of patients with deleterious brca mutation germline andor somatic associated advanced ovarian cancer who have been treated with two or more chemotherapies select patients for therapy based on an fdaapproved companion diagnostic for rucaparib')|
|('DB12332', 'MONDO:0004992', ['cancer'], 'indicated as monotherapy for the treatment of patients with deleterious brca mutation germline andor somatic associated advanced ovarian cancer who have been treated with two or more chemotherapies select patients for therapy based on an fdaapproved companion diagnostic for rucaparib')|
|('DB12364', 'MONDO:0004992', ['cancer'], 'betrixaban is indicated for prophylaxis of venous thromboembolism vte in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of vte ')|
|('DB12364', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'betrixaban is indicated for prophylaxis of venous thromboembolism vte in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of vte ')|
|('DB12366', 'MONDO:0005399', ['venous thromboembolism [NCIT:C99537]', 'venous thromboembolism'], 'indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis vii mps vii sly syndrome')|
|('DB12366', 'MONDO:0009662', ['beta-glucuronidase deficiency', 'deficiency of beta-glucuronidase', 'MPS VII - Sly syndrome', 'mucopolysaccharidosis VII', 'mucopolysaccharidosis type 7'], 'indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis vii mps vii sly syndrome')|
|('DB12371', 'MONDO:0009662', ['beta-glucuronidase deficiency', 'deficiency of beta-glucuronidase', 'MPS VII - Sly syndrome', 'mucopolysaccharidosis VII', 'mucopolysaccharidosis type 7'], 'this drug is indicated for the treatment of relapsing forms of multiple sclerosis ms to include clinically isolated syndrome relapsingremitting disease and active secondary progressive disease in adults fda label')|
|('DB12371', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'this drug is indicated for the treatment of relapsing forms of multiple sclerosis ms to include clinically isolated syndrome relapsingremitting disease and active secondary progressive disease in adults fda label')|
|('DB12377', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'relebactam is indicated in combination with imipenem and cilastatin for the treatment of complicated urinary tract infections including pyelonephritis and complicated intraabdominal infections caused by susceptible organisms in adultslabel')|
|('DB12377', 'MONDO:0006939', ['pyelonephritis'], 'relebactam is indicated in combination with imipenem and cilastatin for the treatment of complicated urinary tract infections including pyelonephritis and complicated intraabdominal infections caused by susceptible organisms in adultslabel')|
|('DB12442', 'MONDO:0006939', ['pyelonephritis'], 'investigated for use as an antineoplastic agent for solid tumors advanced solid tumours or acute myeloid leukaemia ')|
|('DB12442', 'MONDO:0018874', ['acute myeloblastic leukaemia', 'acute myeloblastic leukemia', 'acute myelogenous leukaemia', 'acute myelogenous leukemia', 'acute myeloid leukaemia', 'AML - acute Myeloid Leukemia', 'Leukemia, Myelocytic, acute', 'acute myeloid leukemia'], 'investigated for use as an antineoplastic agent for solid tumors advanced solid tumours or acute myeloid leukaemia ')|
|('DB12455', 'MONDO:0006939', ['pyelonephritis'], 'omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacyclinesusceptible organisms in adultsfda label')|
|('DB12455', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacyclinesusceptible organisms in adultsfda label')|
|('DB12455', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacyclinesusceptible organisms in adultsfda label')|
|('DB12483', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'indicated for the treatment of adult patients with relapsed follicular lymphoma fl who have received at least two prior systemic therapies')|
|('DB12483', 'MONDO:0018906', ['follicular lymphoma'], 'indicated for the treatment of adult patients with relapsed follicular lymphoma fl who have received at least two prior systemic therapies')|
|('DB12498', 'MONDO:0018906', ['follicular lymphoma'], 'for the intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides mf or sézary syndrome ss after at least one prior systemic therapy this approval provides a new treatment option for patients with mf and is the first fda approval of a drug specifically for sézary syndrome fda label')|
|('DB12498', 'MONDO:0020481', ['exercise-induced delayed-onset myotonia [Orphanet:99734]', 'Fluctuating myotonia [Orphanet:99734]', 'MF [NCIT:C122789]', 'myotonia fluctuans'], 'for the intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides mf or sézary syndrome ss after at least one prior systemic therapy this approval provides a new treatment option for patients with mf and is the first fda approval of a drug specifically for sézary syndrome fda label')|
|('DB12500', 'MONDO:0020481', ['exercise-induced delayed-onset myotonia [Orphanet:99734]', 'Fluctuating myotonia [Orphanet:99734]', 'MF [NCIT:C122789]', 'myotonia fluctuans'], 'fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate2 or high riskl8090')|
|('DB12532', 'MONDO:0020481', ['exercise-induced delayed-onset myotonia [Orphanet:99734]', 'Fluctuating myotonia [Orphanet:99734]', 'MF [NCIT:C122789]', 'myotonia fluctuans'], 'oxetacaine is available as an overthecounter antacid and it is used to alleviate pain associated with gastritis peptic ulcer disease heartburn esophagitis hiatus hernia and anorexiaa33109 ')|
|('DB12532', 'MONDO:0004966', ['acute gastric mucosal erosion', 'Erosive Gastritis', 'Erosive gastropathy', 'gastritis'], 'oxetacaine is available as an overthecounter antacid and it is used to alleviate pain associated with gastritis peptic ulcer disease heartburn esophagitis hiatus hernia and anorexiaa33109 ')|
|('DB12532', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'oxetacaine is available as an overthecounter antacid and it is used to alleviate pain associated with gastritis peptic ulcer disease heartburn esophagitis hiatus hernia and anorexiaa33109 ')|
|('DB12532', 'MONDO:0001409', ['acute esophagitis', 'esophagitis'], 'oxetacaine is available as an overthecounter antacid and it is used to alleviate pain associated with gastritis peptic ulcer disease heartburn esophagitis hiatus hernia and anorexiaa33109 ')|
|('DB12532', 'MONDO:0024583', ['hernia'], 'oxetacaine is available as an overthecounter antacid and it is used to alleviate pain associated with gastritis peptic ulcer disease heartburn esophagitis hiatus hernia and anorexiaa33109 ')|
|('DB12589', 'MONDO:0024583', ['hernia'], 'investigated for usetreatment in lymphoma nonhodgkins and multiple myeloma')|
|('DB12598', 'MONDO:0024583', ['hernia'], 'used as an anticoagulant in patients with disseminative blood vessel coagulation hemorrhagic lesions and hemorrhagic tendencies it prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation ')|
|('DB12615', 'MONDO:0024583', ['hernia'], 'plazomicin is indicated for the treatment of patients 18 years of age or older with complicated urinary tract infections cuti including pyelonephritis who have limited or no alternative treatment options it should only be used to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms fda label ')|
|('DB12615', 'MONDO:0006939', ['pyelonephritis'], 'plazomicin is indicated for the treatment of patients 18 years of age or older with complicated urinary tract infections cuti including pyelonephritis who have limited or no alternative treatment options it should only be used to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms fda label ')|
|('DB12688', 'MONDO:0006939', ['pyelonephritis'], 'mxp is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia hcl who received at least two prior systemic therapies including treatment with a purine nucleoside analog the use of this drug is not recommended in patients with severe renal impairment crcl  29 mlminl4568hcl is an uncommon type of lymphocytic leukemia that starts in b cells or b lymphocytes it is characterized by an accumulation of abnormal b lymphocytes hcl is called hairy as it produces hairlike projections in the surface of the cancer cells a usual symptom in people having hcl is the presence of splenomegaly and less often hepatomegalya38877')|
|('DB12688', 'MONDO:0004110', ['Refractory Hairy cell Leukemia', 'refractory hairy cell leukemia'], 'mxp is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia hcl who received at least two prior systemic therapies including treatment with a purine nucleoside analog the use of this drug is not recommended in patients with severe renal impairment crcl  29 mlminl4568hcl is an uncommon type of lymphocytic leukemia that starts in b cells or b lymphocytes it is characterized by an accumulation of abnormal b lymphocytes hcl is called hairy as it produces hairlike projections in the surface of the cancer cells a usual symptom in people having hcl is the presence of splenomegaly and less often hepatomegalya38877')|
|('DB12688', 'MONDO:0005402', ['lymphocytic leukemia [NCIT:C7539]', 'lymphogenous leukemia [NCIT:C7539]', 'lymphoid leukemia [MONDO:ambiguous,NCIT:C7539]', 'leukemia, LYMPHOCYTIC, malignant [NCIT:C7539]', 'subacute lymphoid leukemia [DOID:10747]', 'lymphoid leukemia'], 'mxp is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia hcl who received at least two prior systemic therapies including treatment with a purine nucleoside analog the use of this drug is not recommended in patients with severe renal impairment crcl  29 mlminl4568hcl is an uncommon type of lymphocytic leukemia that starts in b cells or b lymphocytes it is characterized by an accumulation of abnormal b lymphocytes hcl is called hairy as it produces hairlike projections in the surface of the cancer cells a usual symptom in people having hcl is the presence of splenomegaly and less often hepatomegalya38877')|
|('DB12688', 'MONDO:0004992', ['cancer'], 'mxp is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia hcl who received at least two prior systemic therapies including treatment with a purine nucleoside analog the use of this drug is not recommended in patients with severe renal impairment crcl  29 mlminl4568hcl is an uncommon type of lymphocytic leukemia that starts in b cells or b lymphocytes it is characterized by an accumulation of abnormal b lymphocytes hcl is called hairy as it produces hairlike projections in the surface of the cancer cells a usual symptom in people having hcl is the presence of splenomegaly and less often hepatomegalya38877')|
|('DB12698', 'MONDO:0004992', ['cancer'], 'indicated for the treatment of human immunodeficiency virus type 1 hiv1 infection in highly treatmentexperienced adults with multidrugresistant hiv1 infection failing their current antiretroviral regimen fda labelthe approval of trogarzo was supported by a clinical trial of 40 treatmentexperienced adults with mdr hiv1 infection who persistently had elevated levels of hiv rna in their blood despite heavy antiretroviral therapy the majority of study patients had previously been treated with ≥10 antiretroviral medications l1554')|
|('DB12742', 'MONDO:0004992', ['cancer'], 'amuvatinib is a selective multitargeted tyrosine kinase inhibitor that suppresses cmet cret and the mutant forms of ckit pdgfr and flt3 amuvatinib also suppresses rad51 protein a critical component of doublestranded dna repair in cancer cells')|
|('DB12783', 'MONDO:0004992', ['cancer'], 'the primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of parkinsons disease in adults  25 years of age with the exception of druginduced parkinsonism f2 l2553at certain doses the combination product of levodopa and benserazide may also be used to treat restless legs syndrome which is sometimes associated with parkinsons disease l2553 t181there have also been some studies that have prompted the european medicines agency to confer orphan designation upon benserazide  hydrochloride as a potential therapy for beta thalassaemia f3 although studies are ongoing no evidence has been formally elucidated as of yet f3')|
|('DB12783', 'MONDO:0005391', ['WED', 'Willis-Ekbom disease', 'Wittmaack-Ekbom syndrome', 'restless legs syndrome'], 'the primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of parkinsons disease in adults  25 years of age with the exception of druginduced parkinsonism f2 l2553at certain doses the combination product of levodopa and benserazide may also be used to treat restless legs syndrome which is sometimes associated with parkinsons disease l2553 t181there have also been some studies that have prompted the european medicines agency to confer orphan designation upon benserazide  hydrochloride as a potential therapy for beta thalassaemia f3 although studies are ongoing no evidence has been formally elucidated as of yet f3')|
|('DB12783', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of parkinsons disease in adults  25 years of age with the exception of druginduced parkinsonism f2 l2553at certain doses the combination product of levodopa and benserazide may also be used to treat restless legs syndrome which is sometimes associated with parkinsons disease l2553 t181there have also been some studies that have prompted the european medicines agency to confer orphan designation upon benserazide  hydrochloride as a potential therapy for beta thalassaemia f3 although studies are ongoing no evidence has been formally elucidated as of yet f3')|
|('DB12808', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and olderl9013')|
|('DB12808', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and olderl9013')|
|('DB12825', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'lefamulin is indicated to treat adults diagnosed with communityacquired bacterial pneumonia cabp that is caused by susceptible bacteria its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms the list of susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillinsusceptible legionella pneumophila haemophilus influenza chlamydophila pneumoniae and mycoplasma pneumoniael8093')|
|('DB12825', 'MONDO:0004652', ['gram-negative pneumonia', 'Pneumonia due to other gram-negative bacteria', 'bacterial pneumonia'], 'lefamulin is indicated to treat adults diagnosed with communityacquired bacterial pneumonia cabp that is caused by susceptible bacteria its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms the list of susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillinsusceptible legionella pneumophila haemophilus influenza chlamydophila pneumoniae and mycoplasma pneumoniael8093')|
|('DB12825', 'MONDO:0005824', ['Infection by Legionella pneumophilia', 'Legionella', 'Legionella pneumonia', 'Legionnaires disease', "legionnaires' disease"], 'lefamulin is indicated to treat adults diagnosed with communityacquired bacterial pneumonia cabp that is caused by susceptible bacteria its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms the list of susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillinsusceptible legionella pneumophila haemophilus influenza chlamydophila pneumoniae and mycoplasma pneumoniael8093')|
|('DB12831', 'MONDO:0005824', ['Infection by Legionella pneumophilia', 'Legionella', 'Legionella pneumonia', 'Legionnaires disease', "legionnaires' disease"], 'no approved indication')|
|('DB12834', 'MONDO:0005824', ['Infection by Legionella pneumophilia', 'Legionella', 'Legionella pneumonia', 'Legionnaires disease', "legionnaires' disease"], 'indicated for the treatment of bacterial vaginosis in adult women  ')|
|('DB12834', 'MONDO:0005316', ['bacterial vaginosis'], 'indicated for the treatment of bacterial vaginosis in adult women  ')|
|('DB12836', 'MONDO:0005316', ['bacterial vaginosis'], 'the effects of grapiprant have been investigated in the area of analgesia and antiinflammation due to the effects that have been reported about this moleculea39816this molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritisa39835 in humans it has been researched to be used in the control of pain and inflammation associated with osteoarthritisa39844 a39843the effect of grapiprant can be explained through the function of prostaglandin e2 pge2 which is a key mediator of swelling redness and pain which are classic signs of inflammation the effect of pge2 results from its action through four receptor ep1 ep2 ep3 and ep4 from which the ep4 is the primary mediator of pge2driven inflammationa39817')|
|('DB12836', 'MONDO:0000675', ['analgesia', 'pain agnosia'], 'the effects of grapiprant have been investigated in the area of analgesia and antiinflammation due to the effects that have been reported about this moleculea39816this molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritisa39835 in humans it has been researched to be used in the control of pain and inflammation associated with osteoarthritisa39844 a39843the effect of grapiprant can be explained through the function of prostaglandin e2 pge2 which is a key mediator of swelling redness and pain which are classic signs of inflammation the effect of pge2 results from its action through four receptor ep1 ep2 ep3 and ep4 from which the ep4 is the primary mediator of pge2driven inflammationa39817')|
|('DB12836', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the effects of grapiprant have been investigated in the area of analgesia and antiinflammation due to the effects that have been reported about this moleculea39816this molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritisa39835 in humans it has been researched to be used in the control of pain and inflammation associated with osteoarthritisa39844 a39843the effect of grapiprant can be explained through the function of prostaglandin e2 pge2 which is a key mediator of swelling redness and pain which are classic signs of inflammation the effect of pge2 results from its action through four receptor ep1 ep2 ep3 and ep4 from which the ep4 is the primary mediator of pge2driven inflammationa39817')|
|('DB12836', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'the effects of grapiprant have been investigated in the area of analgesia and antiinflammation due to the effects that have been reported about this moleculea39816this molecule has been approved and widely accepted to be used in veterinary for pain reduction in arthritisa39835 in humans it has been researched to be used in the control of pain and inflammation associated with osteoarthritisa39844 a39843the effect of grapiprant can be explained through the function of prostaglandin e2 pge2 which is a key mediator of swelling redness and pain which are classic signs of inflammation the effect of pge2 results from its action through four receptor ep1 ep2 ep3 and ep4 from which the ep4 is the primary mediator of pge2driven inflammationa39817')|
|('DB12839', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'pegvaliase is indicated for the management of phenylketonuria pku in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromoll on existing management ')|
|('DB12839', 'MONDO:0009861', ['Follings disease', 'maternal phenylketonuria', 'phenylalaninemia', 'PKU', 'phenylketonuria'], 'pegvaliase is indicated for the management of phenylketonuria pku in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromoll on existing management ')|
|('DB12865', 'MONDO:0009861', ['Follings disease', 'maternal phenylketonuria', 'phenylalaninemia', 'PKU', 'phenylketonuria'], 'etelcalcetide is a calciumsensing receptor agonist indicated for secondary hyperparathyroidism hpt in adult patients with chronic kidney disease ckd on hemodialysis')|
|('DB12865', 'MONDO:0006964', ['secondary hyperparathyroidism'], 'etelcalcetide is a calciumsensing receptor agonist indicated for secondary hyperparathyroidism hpt in adult patients with chronic kidney disease ckd on hemodialysis')|
|('DB12865', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'etelcalcetide is a calciumsensing receptor agonist indicated for secondary hyperparathyroidism hpt in adult patients with chronic kidney disease ckd on hemodialysis')|
|('DB12872', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'vonicog alfa is indicated for the ondemand treatment and control of bleeding episodes in adults previously diagnosed with von willebrand diseasel1866 vonicog alfa contains only the vwf and thus its administration offers the flexibility to administer the coagulation factor viii if needed the von willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von willebrand factor vwf due to this deficiency the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding there are three types of this disease and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vwfl1867')|
|('DB12872', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'vonicog alfa is indicated for the ondemand treatment and control of bleeding episodes in adults previously diagnosed with von willebrand diseasel1866 vonicog alfa contains only the vwf and thus its administration offers the flexibility to administer the coagulation factor viii if needed the von willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von willebrand factor vwf due to this deficiency the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding there are three types of this disease and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vwfl1867')|
|('DB12909', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'factor xiii human available as the commercially available product corifact is approved by the food and drug administration for routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital fxiii deficiency fda label')|
|('DB12909', 'MONDO:0021140', ['inborn []', 'congenital'], 'factor xiii human available as the commercially available product corifact is approved by the food and drug administration for routine prophylactic treatment and perioperative management of surgical bleeding in adult and pediatric patients with congenital fxiii deficiency fda label')|
|('DB12911', 'MONDO:0021140', ['inborn []', 'congenital'], 'the primary therapeutic use for which nicoboxil is currently indicated for is as an active ingredient in combination with the capsaicinoid nonivamide compound as a topical analgesic for the temporary relief of the pain of rheumatism arthritis lumbago muscular aches sprains and strains sporting injuries and other conditions where local warmth is beneficial f11nevertheless most of the available studies regarding the use of nicoboxil and nonivamide topical analgesics focus specifically on their efficacy and safety in treating acute nonspecific low back pain typically finding the combination analgesic to be an effective safe and welltolerated medication for such an indication a32785 a32786')|
|('DB12911', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'the primary therapeutic use for which nicoboxil is currently indicated for is as an active ingredient in combination with the capsaicinoid nonivamide compound as a topical analgesic for the temporary relief of the pain of rheumatism arthritis lumbago muscular aches sprains and strains sporting injuries and other conditions where local warmth is beneficial f11nevertheless most of the available studies regarding the use of nicoboxil and nonivamide topical analgesics focus specifically on their efficacy and safety in treating acute nonspecific low back pain typically finding the combination analgesic to be an effective safe and welltolerated medication for such an indication a32785 a32786')|
|('DB12924', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ozenoxacin cream is indicated for the topical treatment of impetigo caused by staphylococcus aureus or streptococcus pyogenes in patients aged 2 months of age and older fda label')|
|('DB12924', 'MONDO:0004592', ['impetigo'], 'ozenoxacin cream is indicated for the topical treatment of impetigo caused by staphylococcus aureus or streptococcus pyogenes in patients aged 2 months of age and older fda label')|
|('DB12941', 'MONDO:0004592', ['impetigo'], 'this drug is indicated for the treatment of patients diagnosed with nonmetastatic and castrateresistant prostate cancerl10872')|
|('DB12965', 'MONDO:0004592', ['impetigo'], 'indicated for the treatment of acne for topical use or the management of dental caries for dental use ')|
|('DB12965', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'indicated for the treatment of acne for topical use or the management of dental caries for dental use ')|
|('DB12965', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'indicated for the treatment of acne for topical use or the management of dental caries for dental use ')|
|('DB12978', 'MONDO:0005276', ['Dental caries extending into pulp', 'Dental caries of smooth surface', 'Dental caries pit and fissure', 'dental caries'], 'pexidartinib is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor tgct associated with severe morbidity or functional limitations and not amenable to improvement with surgeryl7883')|
|('DB12978', 'MONDO:0002171', ['giant cell tumor'], 'pexidartinib is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor tgct associated with severe morbidity or functional limitations and not amenable to improvement with surgeryl7883')|
|('DB13007', 'MONDO:0002171', ['giant cell tumor'], 'enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor1 pd1 or programmed deathligand 1 pdl1 inhibitor and a platinumcontaining chemotherapy in the neoadjuvantadjuvant locally advanced or metastatic settingl10836')|
|('DB13007', 'MONDO:0004992', ['cancer'], 'enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor1 pd1 or programmed deathligand 1 pdl1 inhibitor and a platinumcontaining chemotherapy in the neoadjuvantadjuvant locally advanced or metastatic settingl10836')|
|('DB13025', 'MONDO:0004992', ['cancer'], 'tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia alcohol withdrawal syndrome negative symptoms of psychosis and agitation and aggression in the elderly')|
|('DB13074', 'MONDO:0004992', ['cancer'], 'indicated for the diagnosis of adult growth hormone deficiency aghd fda label')|
|('DB13092', 'MONDO:0004992', ['cancer'], 'currently under investigation for the topical treatment of ulcerative oral mucositis l797')|
|('DB13092', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'currently under investigation for the topical treatment of ulcerative oral mucositis l797')|
|('DB13092', 'MONDO:0020579', ['inflammation of mucosa []', 'mucosa inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'mucositis [NCIT:C115965]', 'mucositis'], 'currently under investigation for the topical treatment of ulcerative oral mucositis l797')|
|('DB13125', 'MONDO:0020579', ['inflammation of mucosa []', 'mucosa inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'mucositis [NCIT:C115965]', 'mucositis'], 'lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure')|
|('DB13125', 'MONDO:0002049', ['thrombocytopenia'], 'lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure')|
|('DB13133', 'MONDO:0002049', ['thrombocytopenia'], 'the vwf and factor viii complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von willebrand disease patients it is also indicated for the ondemand treatment and control of bleeding episodesl1880 the von willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von willebrand factor vwf due to this deficiency the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding there are three types of this disease and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vwfl1867')|
|('DB13133', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'the vwf and factor viii complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von willebrand disease patients it is also indicated for the ondemand treatment and control of bleeding episodesl1880 the von willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von willebrand factor vwf due to this deficiency the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding there are three types of this disease and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vwfl1867')|
|('DB13139', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'indicated for the management of copd chronic obstructive pulmonary disease also known as chronic obstructive lung disease and asthma')|
|('DB13139', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'indicated for the management of copd chronic obstructive pulmonary disease also known as chronic obstructive lung disease and asthma')|
|('DB13139', 'MONDO:0002267', ['respiratory airway obstruction', 'obstructive lung disease'], 'indicated for the management of copd chronic obstructive pulmonary disease also known as chronic obstructive lung disease and asthma')|
|('DB13139', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'indicated for the management of copd chronic obstructive pulmonary disease also known as chronic obstructive lung disease and asthma')|
|('DB13140', 'MONDO:0002267', ['respiratory airway obstruction', 'obstructive lung disease'], 'prevents recurrence of clostridium difficile infection in people 18 years or older who are either currently receiving treatment for c difficile infection or have a high risk of recurrence ')|
|('DB13142', 'MONDO:0002267', ['respiratory airway obstruction', 'obstructive lung disease'], 'calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss osteoporosis weak bones osteomalaciarickets decreased activity of the parathyroid gland hypoparathyroidism and a certain muscle disease latent tetany it may also be used in certain patients to make sure they are getting enough calcium eg women who are pregnant nursing or postmenopausal people taking certain medications such as phenytoin phenobarbital or prednisone')|
|('DB13144', 'MONDO:0002267', ['respiratory airway obstruction', 'obstructive lung disease'], 'the drug is used to reduce the risk of lifethreatening infection in patients with neutropenia particularly after cytotoxic chemotherapy lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with nonmyeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapylenograstim is also indicated to mobilise peripheral blood progenitor cells pbpcs with lenograstim alone or after myelosuppressive chemotherapy in order to accelerate haematopoietic recovery by infusion of such cells after myelosuppressive or myeloablative therapy lenograstim  is also indicated to accelerate the engraftment of these cells after their reinfusiongranocyte is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis kostmanns syndrome')|
|('DB13144', 'MONDO:0001475', ['neutropenia'], 'the drug is used to reduce the risk of lifethreatening infection in patients with neutropenia particularly after cytotoxic chemotherapy lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with nonmyeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapylenograstim is also indicated to mobilise peripheral blood progenitor cells pbpcs with lenograstim alone or after myelosuppressive chemotherapy in order to accelerate haematopoietic recovery by infusion of such cells after myelosuppressive or myeloablative therapy lenograstim  is also indicated to accelerate the engraftment of these cells after their reinfusiongranocyte is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis kostmanns syndrome')|
|('DB13144', 'MONDO:0021140', ['inborn []', 'congenital'], 'the drug is used to reduce the risk of lifethreatening infection in patients with neutropenia particularly after cytotoxic chemotherapy lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with nonmyeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapylenograstim is also indicated to mobilise peripheral blood progenitor cells pbpcs with lenograstim alone or after myelosuppressive chemotherapy in order to accelerate haematopoietic recovery by infusion of such cells after myelosuppressive or myeloablative therapy lenograstim  is also indicated to accelerate the engraftment of these cells after their reinfusiongranocyte is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis kostmanns syndrome')|
|('DB13145', 'MONDO:0021140', ['inborn []', 'congenital'], 'used in the treatment of nonsmall cell lung cancer small cell lung cancer oesophygeal cancer and head and neck cancers a20300')|
|('DB13145', 'MONDO:0004992', ['cancer'], 'used in the treatment of nonsmall cell lung cancer small cell lung cancer oesophygeal cancer and head and neck cancers a20300')|
|('DB13146', 'MONDO:0004992', ['cancer'], 'fluciclovine is indicated as a detection agent for positron emission tomography pet in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen psa levels following prior treatmenta31388 the overexpression of ltype amino acid transporters such as lat1 and lat3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growtha31389')|
|('DB13146', 'MONDO:0008315', ['hereditary prostate cancer', 'malignant tumor of the prostate', 'NGP - new growth of prostate', 'prostate cancer, familial', 'prostate neoplasm', 'prostatic cancer', 'prostatic neoplasm', 'tumor of the prostate', 'prostate cancer'], 'fluciclovine is indicated as a detection agent for positron emission tomography pet in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen psa levels following prior treatmenta31388 the overexpression of ltype amino acid transporters such as lat1 and lat3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growtha31389')|
|('DB13146', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'fluciclovine is indicated as a detection agent for positron emission tomography pet in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen psa levels following prior treatmenta31388 the overexpression of ltype amino acid transporters such as lat1 and lat3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growtha31389')|
|('DB13147', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'please refer to db00085')|
|('DB13148', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated in adults and children aged 12 years and above with hereditary factor x deficiency for ondemand treatment and control of bleeding episodes or for perioperative management of bleeding in patients with mild hereditary factor x deficiency fda label ')|
|('DB13148', 'MONDO:0002247', ['factor X deficiency'], 'indicated in adults and children aged 12 years and above with hereditary factor x deficiency for ondemand treatment and control of bleeding episodes or for perioperative management of bleeding in patients with mild hereditary factor x deficiency fda label ')|
|('DB13149', 'MONDO:0002247', ['factor X deficiency'], 'for use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin k antagonist therapy fda label protein s is administered as part of a cocktail containing several other coagulation factors')|
|('DB13150', 'MONDO:0002247', ['factor X deficiency'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13150', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13150', 'MONDO:0021140', ['inborn []', 'congenital'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13150', 'MONDO:0018660', ['hemophilia'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13150', 'MONDO:0002244', ['deficiency, stable [DOID:2215,MTHICD9_2006:286.3]', 'factor VII deficiency [DOID:2215]', 'factor vii deficiency'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13150', 'MONDO:0013792', ['intracerebral hemorrhage'], 'may be administered in cases of uncontrolled bleeding  factor vii alone can be used in the treatment of congenital hemophilia a or b  acquired hemophilia congenital factor vii deficiency and glanzmanns thrombasthenia off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage  brands for human factor vii are currently only in combination with other vitamin k coagulation factors and can be used to reverse vitamin k antagonist activity in patients with acute major bleeds or for urgent surgeryinvasive procedures ')|
|('DB13151', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for use in the control of bleeding episodes perioperative management and routine prophylaxis against bleeding episodes in hemophilia a and b patients with inhibitors fda label it is not indicated in the absence of factor viii or ix inhibitors')|
|('DB13152', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'factor ix is used to treat christmas disease factor ix deficiency is treated by injection factor ix produced from human plasma tranexamic acid may be of value in patients undergoing surgery who have inherited factor ix deficiency in order to reduce the perioperative risk of bleeding')|
|('DB13152', 'MONDO:0021152', ['inherited'], 'factor ix is used to treat christmas disease factor ix deficiency is treated by injection factor ix produced from human plasma tranexamic acid may be of value in patients undergoing surgery who have inherited factor ix deficiency in order to reduce the perioperative risk of bleeding')|
|('DB13153', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'levomenol has been known to elicit a number of potentially beneficial pharmacological effects including antiirritant antiinflammatory and antimicrobial actions bisabolol is also demonstrated to enhance the percutaneous absorption of certain molecules')|
|('DB13154', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used as an intermediate in organic synthesis of dyes and drugslocal antibacterial agent in root canal therapy as topical antiseptic in ointments')|
|('DB13155', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'as medication esculin is sometimes used as a vasoprotective agentesculin is also used in a microbiology laboratory to aid in the identification of bacterial species especially enterococci and listeria as all strains of group d streptococci hydrolyze æsculin in 40 bile')|
|('DB13155', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'as medication esculin is sometimes used as a vasoprotective agentesculin is also used in a microbiology laboratory to aid in the identification of bacterial species especially enterococci and listeria as all strains of group d streptococci hydrolyze æsculin in 40 bile')|
|('DB13156', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus type 1 and type ii and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser ')|
|('DB13156', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus type 1 and type ii and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser ')|
|('DB13157', 'MONDO:0005647', ['Anogenital Human papilloma Virus Infectious Disease', 'Anogenital warts', 'genital wart virus infectious disease', 'Genital warts', 'venereal wart', 'anogenital human papillomavirus infection'], 'sodium lauryl sulfoacetate is not an active pharmacological ingredient in pharmaceutical preparations and so has no official indication')|
|('DB13157', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'sodium lauryl sulfoacetate is not an active pharmacological ingredient in pharmaceutical preparations and so has no official indication')|
|('DB13158', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'in dermatology topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitisin ophthalmology clobetasone butyrate 01 eye drops have been shown to be safe and effective in the treatment of dry eyes in sjögrens syndrome')|
|('DB13158', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'in dermatology topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitisin ophthalmology clobetasone butyrate 01 eye drops have been shown to be safe and effective in the treatment of dry eyes in sjögrens syndrome')|
|('DB13161', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the treatment of spinal muscular atrophy sma in pediatric and adult patients ')|
|('DB13161', 'MONDO:0001516', ['spinal muscular atrophy'], 'indicated for the treatment of spinal muscular atrophy sma in pediatric and adult patients ')|
|('DB13163', 'MONDO:0001516', ['spinal muscular atrophy'], 'terpin hydrate is used in the treatment of acute and chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious and inflammatory diseases of the upper respiratory tract')|
|('DB13163', 'MONDO:0005249', ['acute pneumonia', 'pneumonia'], 'terpin hydrate is used in the treatment of acute and chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious and inflammatory diseases of the upper respiratory tract')|
|('DB13163', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'terpin hydrate is used in the treatment of acute and chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious and inflammatory diseases of the upper respiratory tract')|
|('DB13164', 'MONDO:0005002', ['chronic obstructive airway disease', 'chronic obstructive lung disease', 'COLD', 'COPD', 'chronic obstructive pulmonary disease'], 'for use in treatment of metastatic t790m mutation positive nonsmall cell lung cancer a19196')|
|('DB13164', 'MONDO:0004992', ['cancer'], 'for use in treatment of metastatic t790m mutation positive nonsmall cell lung cancer a19196')|
|('DB13165', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ripasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension it is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema ')|
|('DB13165', 'MONDO:0005041', ['glaucoma'], 'ripasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension it is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema ')|
|('DB13165', 'MONDO:0006875', ['ocular hypertension'], 'ripasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension it is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema ')|
|('DB13165', 'MONDO:0005266', ['Retinal abnormality - diabetes-related', 'diabetic retinopathy'], 'ripasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension it is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema ')|
|('DB13167', 'MONDO:0005266', ['Retinal abnormality - diabetes-related', 'diabetic retinopathy'], 'alclofenac is indicated in rheumatology in particular for the treatment of rheumatoid arthritis ankylosing spondylitis and as an analgesic in painful arthritic pathologies')|
|('DB13167', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'alclofenac is indicated in rheumatology in particular for the treatment of rheumatoid arthritis ankylosing spondylitis and as an analgesic in painful arthritic pathologies')|
|('DB13167', 'MONDO:0003937', ['spondylitis'], 'alclofenac is indicated in rheumatology in particular for the treatment of rheumatoid arthritis ankylosing spondylitis and as an analgesic in painful arthritic pathologies')|
|('DB13168', 'MONDO:0003937', ['spondylitis'], 'there are no current pharmacotherapeutic products based on omega6 fatty acids ')|
|('DB13170', 'MONDO:0003937', ['spondylitis'], 'plecanatide stimulates intestinal fluid secretions in the gastrointestinal tract to support regular bowel function plecanatide taken orally once daily works locally in the upper gi tract to stimulate secretion of intestinal fluid and support regular bowel function')|
|('DB13173', 'MONDO:0003937', ['spondylitis'], 'cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease to decelerate the progressive motor function decline in patients 3 years of age and older cln2 disease is a form of batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death l755 it is caused by the lack the lysosomal enzyme tripeptidyl peptidase1 tpp1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system')|
|('DB13173', 'MONDO:0015674', ['late infantile neuronal ceroid lipofuscinosis []', 'LINCL [Orphanet:168491]', 'late infantile NCL [Orphanet:168491]', 'late-infantile neuronal ceroid lipofuscinosis []', 'Jansky-Bielschowsky disease [Orphanet:168491]', 'late infantile neuronal ceroid lipofuscinosis'], 'cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease to decelerate the progressive motor function decline in patients 3 years of age and older cln2 disease is a form of batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death l755 it is caused by the lack the lysosomal enzyme tripeptidyl peptidase1 tpp1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system')|
|('DB13173', 'MONDO:0008769', ['CLN2', 'neuronal ceroid lipofuscinosis 2 variable age at onset', 'neuronal ceroid lipofuscinosis 2'], 'cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease to decelerate the progressive motor function decline in patients 3 years of age and older cln2 disease is a form of batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death l755 it is caused by the lack the lysosomal enzyme tripeptidyl peptidase1 tpp1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system')|
|('DB13173', 'MONDO:0019262', ['batten disease [MONDO:0000439,Orphanet:79264]', 'Spielmeyer-Vogt disease [Orphanet:79264]', 'juvenile neuronal ceroid lipofuscinosis [DOID:0050756]', 'JNCL [Orphanet:79264]', 'juvenile NCL [Orphanet:79264]', 'juvenile neuronal ceroid lipofuscinosis'], 'cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease to decelerate the progressive motor function decline in patients 3 years of age and older cln2 disease is a form of batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death l755 it is caused by the lack the lysosomal enzyme tripeptidyl peptidase1 tpp1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system')|
|('DB13173', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 cln2 disease to decelerate the progressive motor function decline in patients 3 years of age and older cln2 disease is a form of batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death l755 it is caused by the lack the lysosomal enzyme tripeptidyl peptidase1 tpp1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system')|
|('DB13174', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'no approved indication')|
|('DB13175', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'no approved indication')|
|('DB13178', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'inositol may be used in food without any limitation as a drug inositol is used as a nutrient supplement in special dietary foods and infant formulal2561 as it presents a relevant role in ensuring oocyte fertility inositol has been studied for its use in the management of polycystic ovariesa32751 inositol is also being researched for the treatment of diabetesa32766 prevention of metabolic syndromea32768 aid agent for weight lossa32769 treatment of depression psychiatric disorder and anxiety disordera32770 and for prevention of cancera32771')|
|('DB13178', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'inositol may be used in food without any limitation as a drug inositol is used as a nutrient supplement in special dietary foods and infant formulal2561 as it presents a relevant role in ensuring oocyte fertility inositol has been studied for its use in the management of polycystic ovariesa32751 inositol is also being researched for the treatment of diabetesa32766 prevention of metabolic syndromea32768 aid agent for weight lossa32769 treatment of depression psychiatric disorder and anxiety disordera32770 and for prevention of cancera32771')|
|('DB13178', 'MONDO:0002025', ['psychiatric disorder'], 'inositol may be used in food without any limitation as a drug inositol is used as a nutrient supplement in special dietary foods and infant formulal2561 as it presents a relevant role in ensuring oocyte fertility inositol has been studied for its use in the management of polycystic ovariesa32751 inositol is also being researched for the treatment of diabetesa32766 prevention of metabolic syndromea32768 aid agent for weight lossa32769 treatment of depression psychiatric disorder and anxiety disordera32770 and for prevention of cancera32771')|
|('DB13178', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'inositol may be used in food without any limitation as a drug inositol is used as a nutrient supplement in special dietary foods and infant formulal2561 as it presents a relevant role in ensuring oocyte fertility inositol has been studied for its use in the management of polycystic ovariesa32751 inositol is also being researched for the treatment of diabetesa32766 prevention of metabolic syndromea32768 aid agent for weight lossa32769 treatment of depression psychiatric disorder and anxiety disordera32770 and for prevention of cancera32771')|
|('DB13180', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'for use as part of electrolyte supplementation in total parenteral nutrition fda label')|
|('DB13185', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'used as a performance enhancing drug illicitly in athletes ')|
|('DB13191', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate atp for muscular activity like contractionsgiven this utility of phosphocreatine to recycle atp the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements  such as in ischemic stroke and other cerebrovascular diseases it is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications although it is administered intravenously for cardiovascular conditions in some countriesadditionally because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics ')|
|('DB13191', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate atp for muscular activity like contractionsgiven this utility of phosphocreatine to recycle atp the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements  such as in ischemic stroke and other cerebrovascular diseases it is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications although it is administered intravenously for cardiovascular conditions in some countriesadditionally because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics ')|
|('DB13192', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the human antihemophilic factor is indicated for the cases of hemophilia a also known as classical hemophilia for the prevention and control of hemorrhagic episodesl1055 if surgery is needed in patients with hemophilia a there is a need of correction of the clotting abnormality in this cases the human antihemophilic factor may be administered followed by intermittent maintenance dosesl1053 the hemophilia a is characterized by the deficiency of the coagulation factor viii that results in prolonged blood flow after injury or surgery as well as recurrent bleedingt56')|
|('DB13192', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'the human antihemophilic factor is indicated for the cases of hemophilia a also known as classical hemophilia for the prevention and control of hemorrhagic episodesl1055 if surgery is needed in patients with hemophilia a there is a need of correction of the clotting abnormality in this cases the human antihemophilic factor may be administered followed by intermittent maintenance dosesl1053 the hemophilia a is characterized by the deficiency of the coagulation factor viii that results in prolonged blood flow after injury or surgery as well as recurrent bleedingt56')|
|('DB13192', 'MONDO:0018660', ['hemophilia'], 'the human antihemophilic factor is indicated for the cases of hemophilia a also known as classical hemophilia for the prevention and control of hemorrhagic episodesl1055 if surgery is needed in patients with hemophilia a there is a need of correction of the clotting abnormality in this cases the human antihemophilic factor may be administered followed by intermittent maintenance dosesl1053 the hemophilia a is characterized by the deficiency of the coagulation factor viii that results in prolonged blood flow after injury or surgery as well as recurrent bleedingt56')|
|('DB13192', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'the human antihemophilic factor is indicated for the cases of hemophilia a also known as classical hemophilia for the prevention and control of hemorrhagic episodesl1055 if surgery is needed in patients with hemophilia a there is a need of correction of the clotting abnormality in this cases the human antihemophilic factor may be administered followed by intermittent maintenance dosesl1053 the hemophilia a is characterized by the deficiency of the coagulation factor viii that results in prolonged blood flow after injury or surgery as well as recurrent bleedingt56')|
|('DB13198', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'used as a pancreatic enzyme replacement in pancreatic insufficiency l2357  it is intended to mimic naturally produced human pepsin l2360pepsin powder is prepared from the gastric mucosa of pigs cattle or sheep l2367 in the laboratory it is primarily used for the unspecific hydrolysis of proteins and peptides in acidic media in addition it provides limited hydrolysis of native immunoglobulins yielding biologically active fragments l2353in certain supplements pepsin may be combined with betaine and hcl hydrochloric acid to aid in digestion in various gastrointestinal conditions l2360 l2352')|
|('DB13200', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes l2441 ')|
|('DB13200', 'MONDO:0001475', ['neutropenia'], 'indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes l2441 ')|
|('DB13200', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes l2441 ')|
|('DB13209', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'indicated for overthecounter use as an antacid ')|
|('DB13231', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'indicated for use as the nutritional supplement ')|
|('DB13235', 'MONDO:0011996', ['chronic granulocytic leukaemia', 'chronic granulocytic leukemia', 'chronic myelogenous leukaemia', 'chronic myelogenous leukemia', 'chronic myeloid leukaemia', 'CML', 'CML - chronic Myelogenous Leukemia', 'Myeloid Leukemia, chronic', 'chronic myelogenous leukemia, bcr-abl1 positive'], 'in the industry sodium perborate is used as a disinfectant it is also part of the ingredients for detergents bleach powders and personal care formulations in cosmetic products perboric acid and mainly its salt are used as an oxidizing agent for dyeing or permanent wavingf66 in dentistry sodium perborate monohydrate is used as an aid for the removal of phlegm mucus or other secretions associated with an occasional sore in the mouth for cleansing minor wounds for temporary cleanse of canker sore or for the removal of foreign materials in minor woundsl2770in ophthalmic preparations sodium perborate is used as a preservative for products used for dry eye this use is approved as this compound rapidly degrades to harmless byproductst203')|
|('DB13235', 'MONDO:0005318', ['canker sore [NCIT:C62546]', 'aphthous ulcer [NCIT:C62546]', 'canker sore'], 'in the industry sodium perborate is used as a disinfectant it is also part of the ingredients for detergents bleach powders and personal care formulations in cosmetic products perboric acid and mainly its salt are used as an oxidizing agent for dyeing or permanent wavingf66 in dentistry sodium perborate monohydrate is used as an aid for the removal of phlegm mucus or other secretions associated with an occasional sore in the mouth for cleansing minor wounds for temporary cleanse of canker sore or for the removal of foreign materials in minor woundsl2770in ophthalmic preparations sodium perborate is used as a preservative for products used for dry eye this use is approved as this compound rapidly degrades to harmless byproductst203')|
|('DB13249', 'MONDO:0005318', ['canker sore [NCIT:C62546]', 'aphthous ulcer [NCIT:C62546]', 'canker sore'], 'magnesium silicate is used to absorb moisture prevent caking and to improve the feel of a product in the pharmaceutical companies it is used as a dietary supplement as part of the formulation ingredients in drug production in antacid and antiulcer preparations as a component of antiepileptic drugs in antifungal topical agents and in the treatment of acne and as a facial moisturizerl2603 when complexed with arginine magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammalst186')|
|('DB13249', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'magnesium silicate is used to absorb moisture prevent caking and to improve the feel of a product in the pharmaceutical companies it is used as a dietary supplement as part of the formulation ingredients in drug production in antacid and antiulcer preparations as a component of antiepileptic drugs in antifungal topical agents and in the treatment of acne and as a facial moisturizerl2603 when complexed with arginine magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammalst186')|
|('DB13249', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'magnesium silicate is used to absorb moisture prevent caking and to improve the feel of a product in the pharmaceutical companies it is used as a dietary supplement as part of the formulation ingredients in drug production in antacid and antiulcer preparations as a component of antiepileptic drugs in antifungal topical agents and in the treatment of acne and as a facial moisturizerl2603 when complexed with arginine magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammalst186')|
|('DB13257', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the prevention and treatment of iron deficiency anemia l2252')|
|('DB13257', 'MONDO:0001356', ['iron deficiency anemia'], 'for the prevention and treatment of iron deficiency anemia l2252')|
|('DB13268', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'acetarsol has been used for the treatment of different diseases such as syphilis amoebiasis yaws trypanosomiasis and malarial2624 acetarsol was used commonly for the treatment of vaginitis due to trichomonas vaginalis and candida albicansa32839 a32841 when orally administered acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitisl2626protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom protozoa which is formed by a great diversity of organismsl2627')|
|('DB13268', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'acetarsol has been used for the treatment of different diseases such as syphilis amoebiasis yaws trypanosomiasis and malarial2624 acetarsol was used commonly for the treatment of vaginitis due to trichomonas vaginalis and candida albicansa32839 a32841 when orally administered acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitisl2626protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom protozoa which is formed by a great diversity of organismsl2627')|
|('DB13268', 'MONDO:0000940', ['trypanosomiasis'], 'acetarsol has been used for the treatment of different diseases such as syphilis amoebiasis yaws trypanosomiasis and malarial2624 acetarsol was used commonly for the treatment of vaginitis due to trichomonas vaginalis and candida albicansa32839 a32841 when orally administered acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitisl2626protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom protozoa which is formed by a great diversity of organismsl2627')|
|('DB13268', 'MONDO:0002234', ['vaginitis'], 'acetarsol has been used for the treatment of different diseases such as syphilis amoebiasis yaws trypanosomiasis and malarial2624 acetarsol was used commonly for the treatment of vaginitis due to trichomonas vaginalis and candida albicansa32839 a32841 when orally administered acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitisl2626protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom protozoa which is formed by a great diversity of organismsl2627')|
|('DB13268', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'acetarsol has been used for the treatment of different diseases such as syphilis amoebiasis yaws trypanosomiasis and malarial2624 acetarsol was used commonly for the treatment of vaginitis due to trichomonas vaginalis and candida albicansa32839 a32841 when orally administered acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitisl2626protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom protozoa which is formed by a great diversity of organismsl2627')|
|('DB13269', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'dichlorobenzyl alcohol in combination with db13908 is available in overthecounter products used for symptomatic relief of acute sore throat and postoperative sore throata27155')|
|('DB13269', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'dichlorobenzyl alcohol in combination with db13908 is available in overthecounter products used for symptomatic relief of acute sore throat and postoperative sore throata27155')|
|('DB13293', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'ipecac is indicated as an emetic agent for the induction of vomiting in poisoning victims who ingested systemic poison in order to prevent absorption of the chemicals through the gastrointestinal tract in low doses ipecac was also used as an expectorantl2753reports have suggested that ipecac was vastly used in patients with eating disorders to produce vomitingt49')|
|('DB13306', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'chlorquinaldol was used historically as a topical antiseptic agent for skin infectionsf4549 it maintains use in european countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infectionsf4552')|
|('DB13345', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'dihydroergocristine is used in some countries such as brasil as a single agent for the treatment of cerebral and peripheric vascular eventsl2649 to know more about dihydroergocristine as part of the ergoloid mesylate mixture please visit db01049')|
|('DB13346', 'MONDO:0002258', ['acute pharyngitis', 'acute sore throat', 'chronic pharyn/nasopharyngitis', 'chronic pharyngitis', 'chronic pharyngitis and nasopharyngitis', 'chronic sore throat', 'Inflamed throat', 'Persistent sore throat', 'Pharyngeal disorder', 'Pharyngitis - acute', 'Sore throat - chronic', 'pharyngitis'], 'indicated for the treatment of various skin conditions such as atopic eczema and other inflammatory dermatoses ')|
|('DB13346', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the treatment of various skin conditions such as atopic eczema and other inflammatory dermatoses ')|
|('DB13421', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'edoxudine was used in europe in the form of a topical antiviral for the treatment of human herpes keratitisa32643 human herpes keratitis is an inflammation of the cornea in the eye caused by herpes simplex virus infection this infection is a cause of significant morbidity whose incidence is significantly increased in the presence of recurrent infection and it can even produce corneal blindnessa32645edoxudine 3 cream was also indicated for the treatment of dermal herpes simplex virusa32643 this virus can produce an infection ubiquitously and it is highly contagious there are two types of herpes virus type 1 that is mainly transmitted by oraltooral contact and type 2 that is sexually transmittedl2411')|
|('DB13421', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'edoxudine was used in europe in the form of a topical antiviral for the treatment of human herpes keratitisa32643 human herpes keratitis is an inflammation of the cornea in the eye caused by herpes simplex virus infection this infection is a cause of significant morbidity whose incidence is significantly increased in the presence of recurrent infection and it can even produce corneal blindnessa32645edoxudine 3 cream was also indicated for the treatment of dermal herpes simplex virusa32643 this virus can produce an infection ubiquitously and it is highly contagious there are two types of herpes virus type 1 that is mainly transmitted by oraltooral contact and type 2 that is sexually transmittedl2411')|
|('DB13444', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicatedf55 the intravascular administration of ioxitalamate is contraindicated as it may present significant side effectsf54')|
|('DB13456', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'midecamycin was used for the treatment of infections in the oral cavity upper and lower respiratory tracts and skin and soft tissue infections the alone use of midecamycin was mainly used in europe or japant207 ')|
|('DB13501', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'prior to the withdrawal of bendazac from various international regions of use due to concerns for hepatotoxicity a39891 a39892 a39893 l4778 the chemical had demonstrated potential usefulness predominantly as the prescription medication bendazac lysine for the indication of managing the level of vision in patients with mild to moderate cataracts to facilitate delaying the need for surgical intervention a39863 a39869 a39890elsewhere bendazac may still be available in a limited capacity as a nonprescription topical cream product for treating conditions like local pain inflammation dermatitis eczema pruritis hives insect bites burns erythema and others l4780  although such products may also be facing general discontinuation l4781')|
|('DB13501', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'prior to the withdrawal of bendazac from various international regions of use due to concerns for hepatotoxicity a39891 a39892 a39893 l4778 the chemical had demonstrated potential usefulness predominantly as the prescription medication bendazac lysine for the indication of managing the level of vision in patients with mild to moderate cataracts to facilitate delaying the need for surgical intervention a39863 a39869 a39890elsewhere bendazac may still be available in a limited capacity as a nonprescription topical cream product for treating conditions like local pain inflammation dermatitis eczema pruritis hives insect bites burns erythema and others l4780  although such products may also be facing general discontinuation l4781')|
|('DB13503', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'tyrothricin is used as an over the counter topical antibiotic')|
|('DB13518', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for the management of gastric reflux reflux oesophagitis hiatus hernia heartburn including heartburn of pregnancy and similar gastric distress f46')|
|('DB13518', 'MONDO:0006896', ['Peptic esophagitis', 'Peptic reflux disease', 'reflux esophagitis', 'Reflux oesophagitis', 'peptic esophagitis'], 'indicated for the management of gastric reflux reflux oesophagitis hiatus hernia heartburn including heartburn of pregnancy and similar gastric distress f46')|
|('DB13518', 'MONDO:0024583', ['hernia'], 'indicated for the management of gastric reflux reflux oesophagitis hiatus hernia heartburn including heartburn of pregnancy and similar gastric distress f46')|
|('DB13583', 'MONDO:0024583', ['hernia'], 'mephenesin was used for the treatment of muscle spasticity in diseases like parkinsons or multiple sclerosis')|
|('DB13583', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'mephenesin was used for the treatment of muscle spasticity in diseases like parkinsons or multiple sclerosis')|
|('DB13595', 'MONDO:0024583', ['hernia'], 'almasilate is indicated for use as an antacid for the neutralization of excess stomach acid f25 it is subsequently also used for the symptomatic treatment of diseases where it is necessary to neutralize acid in the stomach for example for treating stomach and duodenal ulcers or heartburn and stomach conditions caused by excess stomach acid f25')|
|('DB13615', 'MONDO:0024583', ['hernia'], 'indicated in children adolescents and young adults for the treatment of highgrade resectable nonmetastatic osteosarcoma after macroscopically complete surgical resection typically in combination with postoperative multiagent chemotherapy l1203')|
|('DB13615', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'indicated in children adolescents and young adults for the treatment of highgrade resectable nonmetastatic osteosarcoma after macroscopically complete surgical resection typically in combination with postoperative multiagent chemotherapy l1203')|
|('DB13620', 'MONDO:0009807', ['bone tissue neoplasm', 'Osteogenic sarcoma', 'osteoid sarcoma', 'Skeletal sarcoma', 'osteosarcoma'], 'because of potassium’s wideranging roles in the body low intakes can increase the risk of illness l2655potassium supplements are indicated to prevent hypokalemia in patients who would be at particular risk if hypokalemia were to develop eg digitalis treated patients with significant cardiac arrhythmias potassium deficiency occurs when the rate of loss through renal excretion andor loss from the gastrointestinal tract is higher than the rate of potassium intake in addition to serving as a preventative supplement potassium gluconate also serves as a treatment for decreased potassium levels l2655 l2651 l2657')|
|('DB13620', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'because of potassium’s wideranging roles in the body low intakes can increase the risk of illness l2655potassium supplements are indicated to prevent hypokalemia in patients who would be at particular risk if hypokalemia were to develop eg digitalis treated patients with significant cardiac arrhythmias potassium deficiency occurs when the rate of loss through renal excretion andor loss from the gastrointestinal tract is higher than the rate of potassium intake in addition to serving as a preventative supplement potassium gluconate also serves as a treatment for decreased potassium levels l2655 l2651 l2657')|
|('DB13620', 'MONDO:0006919', ['potassium deficiency'], 'because of potassium’s wideranging roles in the body low intakes can increase the risk of illness l2655potassium supplements are indicated to prevent hypokalemia in patients who would be at particular risk if hypokalemia were to develop eg digitalis treated patients with significant cardiac arrhythmias potassium deficiency occurs when the rate of loss through renal excretion andor loss from the gastrointestinal tract is higher than the rate of potassium intake in addition to serving as a preventative supplement potassium gluconate also serves as a treatment for decreased potassium levels l2655 l2651 l2657')|
|('DB13707', 'MONDO:0006919', ['potassium deficiency'], ' it acts as an emulsifier and ph control agent in food products l2590 l2598in the laboratory it is used while performing the karl fischer equation which is used to determine the water content of various substances f18 l2590')|
|('DB13720', 'MONDO:0006919', ['potassium deficiency'], 'used in the treatment of peptic ulcer gastric hyperacidity and hypermotility in gastritis and pylorospasm and in the treatment of hyperhidrosis excessive perspiration')|
|('DB13720', 'MONDO:0001428', ['pylorospasm'], 'used in the treatment of peptic ulcer gastric hyperacidity and hypermotility in gastritis and pylorospasm and in the treatment of hyperhidrosis excessive perspiration')|
|('DB13746', 'MONDO:0001428', ['pylorospasm'], 'bioallethrin was used for lice and scabies infestation other pyrethroids are now used in place of bioallethrin')|
|('DB13746', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'bioallethrin was used for lice and scabies infestation other pyrethroids are now used in place of bioallethrin')|
|('DB13747', 'MONDO:0004525', ['Infestation by Sarcoptes scabiei', 'Infestation by Sarcoptes scabiei var hominis', 'Sarcoptic itch', 'scabies'], 'trolamine is used as an alkalizing agent surfactant and counterion in cosmetic and pharmaceutical formulations a27174 it is not considered to be an active pharmacological ingredient and so has no official indication')|
|('DB13747', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'trolamine is used as an alkalizing agent surfactant and counterion in cosmetic and pharmaceutical formulations a27174 it is not considered to be an active pharmacological ingredient and so has no official indication')|
|('DB13749', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'magnesium gluconate is a mineral supplement which is used to prevent and treat low levels of magnesium magnesium is very important for the normal physiologic functioning of cells nerves muscles bones and the heart generally a wellbalanced diet provides the necessary amounts of magnesium for homeostasis however certain conditions causing chronic magnesium deficiency may decrease levels of magnesium these conditions include treatment with diuretics a poor diet alcoholism or other medical conditions eg severe diarrheavomiting stomachintestinal absorption problems poorly controlled diabetes l2600')|
|('DB13749', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'magnesium gluconate is a mineral supplement which is used to prevent and treat low levels of magnesium magnesium is very important for the normal physiologic functioning of cells nerves muscles bones and the heart generally a wellbalanced diet provides the necessary amounts of magnesium for homeostasis however certain conditions causing chronic magnesium deficiency may decrease levels of magnesium these conditions include treatment with diuretics a poor diet alcoholism or other medical conditions eg severe diarrheavomiting stomachintestinal absorption problems poorly controlled diabetes l2600')|
|('DB13751', 'MONDO:0007079', ['alcoholism', 'alcohol dependence'], 'glycyrrhizic acid is widely applied in foods as a natural sweetener as a therapeutic agent is has been used in a vast variety of formulations as it is reported to be antiinflammatory antiulcer antiallergic antioxidant antitumor antidiabetic and hepatoprotective due to this properties its indications have been treatment of premenstrual syndrome treatment of viral infections antilipidemic and antihyperglycemica33063 it is also known to be used as a remedy for peptic ulcer and other stomach diseasest205')|
|('DB13751', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'glycyrrhizic acid is widely applied in foods as a natural sweetener as a therapeutic agent is has been used in a vast variety of formulations as it is reported to be antiinflammatory antiulcer antiallergic antioxidant antitumor antidiabetic and hepatoprotective due to this properties its indications have been treatment of premenstrual syndrome treatment of viral infections antilipidemic and antihyperglycemica33063 it is also known to be used as a remedy for peptic ulcer and other stomach diseasest205')|
|('DB13761', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tilactase is indicated for the symptomatic treatment of lactose intolerance in infants and older patients requiring a parenteral nutrition or fluid dietl2338lactose intolerance occurs when there is an existence of an inability to break down lactose which is commonly found in dairy products this inability occurs when the lactase levels are reduced and thus there is no via to digest and break down the lactose the undigested lactose moves into the large intestine where normal flora bacteria can interact with it and cause bloating gas and diarrheaa32592 ')|
|('DB13761', 'MONDO:0009116', ['LM - Lactose malabsorption', 'lactose intolerance'], 'tilactase is indicated for the symptomatic treatment of lactose intolerance in infants and older patients requiring a parenteral nutrition or fluid dietl2338lactose intolerance occurs when there is an existence of an inability to break down lactose which is commonly found in dairy products this inability occurs when the lactase levels are reduced and thus there is no via to digest and break down the lactose the undigested lactose moves into the large intestine where normal flora bacteria can interact with it and cause bloating gas and diarrheaa32592 ')|
|('DB13783', 'MONDO:0009116', ['LM - Lactose malabsorption', 'lactose intolerance'], 'acemetacin is not fda canada or ema approved but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis osteoarthritis low back pain and postsurgical painl1045 it is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis treatment of ankylosing spondylitis treatment of irritation in the joints and spinal column caused by degenerative disorders treatment of inflammatory softtissue rheumatism syndrome and painful swelling and inflammation caused by injuryl1044 l1046')|
|('DB13783', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'acemetacin is not fda canada or ema approved but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis osteoarthritis low back pain and postsurgical painl1045 it is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis treatment of ankylosing spondylitis treatment of irritation in the joints and spinal column caused by degenerative disorders treatment of inflammatory softtissue rheumatism syndrome and painful swelling and inflammation caused by injuryl1044 l1046')|
|('DB13783', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'acemetacin is not fda canada or ema approved but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis osteoarthritis low back pain and postsurgical painl1045 it is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis treatment of ankylosing spondylitis treatment of irritation in the joints and spinal column caused by degenerative disorders treatment of inflammatory softtissue rheumatism syndrome and painful swelling and inflammation caused by injuryl1044 l1046')|
|('DB13783', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'acemetacin is not fda canada or ema approved but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis osteoarthritis low back pain and postsurgical painl1045 it is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis treatment of ankylosing spondylitis treatment of irritation in the joints and spinal column caused by degenerative disorders treatment of inflammatory softtissue rheumatism syndrome and painful swelling and inflammation caused by injuryl1044 l1046')|
|('DB13800', 'MONDO:0005306', ['Bekhterev syndrome', 'Bekhterevs disease', 'Marie-Strumpell disease', 'ankylosing spondylitis'], 'this new application of calcium is intended for use as a food fortifier to fortify foods like sauces condiments beer beverages soft drinks milk and milk products soy milk and soy products with calcium nutrition l2765 calcium levulinate can be used alone or with calcium lactate calcium chloride and other compounds either for pharmaceutical tablets capsules or injections preparation l2765 in essence calcium levulinate is ultimately a relatively new calcium supplementation option l2767')|
|('DB13800', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this new application of calcium is intended for use as a food fortifier to fortify foods like sauces condiments beer beverages soft drinks milk and milk products soy milk and soy products with calcium nutrition l2765 calcium levulinate can be used alone or with calcium lactate calcium chloride and other compounds either for pharmaceutical tablets capsules or injections preparation l2765 in essence calcium levulinate is ultimately a relatively new calcium supplementation option l2767')|
|('DB13813', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'no approved therapeutic indications ')|
|('DB13853', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'the most typical uses for which anethol trithione is currently indicated for includes increasing salivary secretion in patients experiencing dry mouth or being used as an adjunctive therapy for cholecystitis gallstone indigestion and acutechronic hepatitis a32614 a32616 l2377in addition although some studies have suggested that anethol trithione also possesses a certain capacity to inhibit tumorigenesis as a potential cancer therapy medication the specific mechanism of action for this effect remains to be elucidated a32619 with certain national cancer institutes listing the agent as a substance that is being studied in the treatment of cancer l2373')|
|('DB13853', 'MONDO:0002155', ['acute and chronic cholecystitis', 'acute cholecystitis', 'acute on chronic cholecystitis', 'chronic cholecystitis', 'cholecystitis'], 'the most typical uses for which anethol trithione is currently indicated for includes increasing salivary secretion in patients experiencing dry mouth or being used as an adjunctive therapy for cholecystitis gallstone indigestion and acutechronic hepatitis a32614 a32616 l2377in addition although some studies have suggested that anethol trithione also possesses a certain capacity to inhibit tumorigenesis as a potential cancer therapy medication the specific mechanism of action for this effect remains to be elucidated a32619 with certain national cancer institutes listing the agent as a substance that is being studied in the treatment of cancer l2373')|
|('DB13853', 'MONDO:0002268', ['dyspepsia, indigestion [DOID:2321]', 'indigestion [CSP2005:1249-7609,DOID:2321]', 'dyspepsia'], 'the most typical uses for which anethol trithione is currently indicated for includes increasing salivary secretion in patients experiencing dry mouth or being used as an adjunctive therapy for cholecystitis gallstone indigestion and acutechronic hepatitis a32614 a32616 l2377in addition although some studies have suggested that anethol trithione also possesses a certain capacity to inhibit tumorigenesis as a potential cancer therapy medication the specific mechanism of action for this effect remains to be elucidated a32619 with certain national cancer institutes listing the agent as a substance that is being studied in the treatment of cancer l2373')|
|('DB13853', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'the most typical uses for which anethol trithione is currently indicated for includes increasing salivary secretion in patients experiencing dry mouth or being used as an adjunctive therapy for cholecystitis gallstone indigestion and acutechronic hepatitis a32614 a32616 l2377in addition although some studies have suggested that anethol trithione also possesses a certain capacity to inhibit tumorigenesis as a potential cancer therapy medication the specific mechanism of action for this effect remains to be elucidated a32619 with certain national cancer institutes listing the agent as a substance that is being studied in the treatment of cancer l2373')|
|('DB13853', 'MONDO:0004992', ['cancer'], 'the most typical uses for which anethol trithione is currently indicated for includes increasing salivary secretion in patients experiencing dry mouth or being used as an adjunctive therapy for cholecystitis gallstone indigestion and acutechronic hepatitis a32614 a32616 l2377in addition although some studies have suggested that anethol trithione also possesses a certain capacity to inhibit tumorigenesis as a potential cancer therapy medication the specific mechanism of action for this effect remains to be elucidated a32619 with certain national cancer institutes listing the agent as a substance that is being studied in the treatment of cancer l2373')|
|('DB13854', 'MONDO:0004992', ['cancer'], 'indicated as a dietary supplement for overthecounter uses ')|
|('DB13867', 'MONDO:0004992', ['cancer'], 'fluticasones 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxisfda labelf4364as well as inflammatory and pruritic dermatosesf4355 a db00588 nasal spray is indicated for managing nonallergic rhinitisf4358 while the db08906 nasal spray is indicated for treating season and perennial allergic rhinitisf4361a177130')|
|('DB13867', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'fluticasones 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxisfda labelf4364as well as inflammatory and pruritic dermatosesf4355 a db00588 nasal spray is indicated for managing nonallergic rhinitisf4358 while the db08906 nasal spray is indicated for treating season and perennial allergic rhinitisf4361a177130')|
|('DB13872', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the treatment of shortterm insomnia l927')|
|('DB13872', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for the treatment of shortterm insomnia l927')|
|('DB13873', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'for use as an adjunctive therapy to diet to a reduce triglyceride levels in adult patients with severe hypertriglyceridemia and b reduce elevated total cholesterol lowdensitylipoprotein ldlc triglycerides and apolipoprotein b and to increase highdensitylipoprotein hdlc in adult patients with primary hypercholesterolemia or mixed dyslipidemia fredrickson types iia and iib fda label')|
|('DB13874', 'MONDO:0013600', ['insomnia [MONDO:ambiguous]', 'insomnia'], 'indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia aml with an isocitrate dehydrogenase2 idh2 mutation')|
|('DB13874', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia aml with an isocitrate dehydrogenase2 idh2 mutation')|
|('DB13878', 'MONDO:0004643', ['leukaemia myelogenous', 'leukemia myelogenous', 'myeloid granulocytic leukaemia', 'myeloid granulocytic leukemia', 'myeloid leukaemia', 'Non-Lymphocytic Leukemia', 'myeloid leukemia'], 'indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis childpugha mavyret is also indicated for the treatment of adult patients with hcv genotype 1 infection who previously have been treated with a regimen containing an hcv ns5a inhibitoror an ns34a protease inhibitor pi but not both fda label ')|
|('DB13878', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis childpugha mavyret is also indicated for the treatment of adult patients with hcv genotype 1 infection who previously have been treated with a regimen containing an hcv ns5a inhibitoror an ns34a protease inhibitor pi but not both fda label ')|
|('DB13878', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis childpugha mavyret is also indicated for the treatment of adult patients with hcv genotype 1 infection who previously have been treated with a regimen containing an hcv ns5a inhibitoror an ns34a protease inhibitor pi but not both fda label ')|
|('DB13879', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis childpugha mavyret is also indicated for the treatment of adult patients with hcv genotype 1 infection who previously have been treated with a regimen containing an hcv ns5a inhibitoror an ns34a protease inhibitor pi but not both fda label ')|
|('DB13879', 'MONDO:0005354', ['hepatitis C infection, chronic [MONDO:patterns/chronic]', 'hepatitis C, chronic [MONDO:patterns/chronic]', 'chronic Hepatitis C [MESH:D019698]', 'chronic hepatitis c virus infection'], 'indicated for the treatment of adult patients with chronic hepatitis c virus hcv genotype 1 2 3 4 5 or 6 infection without cirrhosis or with compensated cirrhosis childpugha mavyret is also indicated for the treatment of adult patients with hcv genotype 1 infection who previously have been treated with a regimen containing an hcv ns5a inhibitoror an ns34a protease inhibitor pi but not both fda label ')|
|('DB13881', 'MONDO:0005155', ['Cirrhosis', 'cirrhosis of liver', 'cirrhosis of liver'], 'indicated for the treatment of patients up to 25 years of age with bcell precursor acute lymphoblastic leukemia all that is refractory or in second or later relapse fda label ')|
|('DB13881', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'indicated for the treatment of patients up to 25 years of age with bcell precursor acute lymphoblastic leukemia all that is refractory or in second or later relapse fda label ')|
|('DB13882', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'indicated for the temporary relief of aches and pains in muscles tendons and joints ')|
|('DB13883', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'this particular antivenin is indicated only for the treatment of envenomation caused by bites from eastern coral snakes micrurus fulvius fulvius and texas coral snakes micrurus fulvius tenere fda label l2176 the agent will not neutralize the venom of arizona sonoran coral snakes micruroides euryxanthus or that of south american species fda label l2176')|
|('DB13884', 'MONDO:0001018', ['lymphoblastic leukaemia', 'lymphoblastic leukemia', 'lymphocytic leukaemia', 'lymphoid leukemia', 'lymphoblastic leukemia'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0018660', ['hemophilia'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0021137', ['common []', 'not rare'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0021152', ['inherited'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0010604', ['Congenital factor IX deficiency', 'Congenital factor IX disorder', 'deficiency, functional factor IX', 'factor IX deficiency', 'hemophilia b'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13884', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'under the ema and fda rixrfp is indicated in the treatment of hemophilia bl2306 for health canada rixfrp is also indicated to prevent or reduce bleeding episodesl2305hemophilia b is the second most common type of hemophilia it is a rare inherited bleeding disorder caused by reduced or absent levels of factor ix fix the fix is a vitamin kdependent plasma protease that when activated is involved in the blood coagulation cascadea32551 the hemophilia b is caused by mutations in the fix gene which can cause different phenotypes the severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgerya32552')|
|('DB13886', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'it is used to prevent cytomegalovirus cmv disease after organ transplant l2225cytomegalovirus immune globulin intravenous human is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney lung liver pancreas and heart fda label in transplants of these organs other than the kidney from cmv seropositive donors into seronegative recipients prophylactic cmvigiv should be considered in combination with ganciclovir fda label')|
|('DB13891', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'crofab is indicated for the management of adult and pediatric patients with north american crotalid envenomation the term crotalid is used to describe the crotalinae subfamily formerly known as crotalidae of venomous snakes which includes rattlesnakes copperheads and cottonmouthswater moccasins fda label')|
|('DB13892', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'crofab is indicated for the management of adult and pediatric patients with north american crotalid envenomation the term crotalid is used to describe the crotalinae subfamily formerly known as crotalidae of venomous snakes which includes rattlesnakes copperheads and cottonmouthswater moccasins fda label')|
|('DB13893', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'indicated for north american crotalid envenomation by crotalinae rattlesnakes eg cottonmouthswater moccasins copperheads rattlesnakes fda label l2874')|
|('DB13894', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'crofab is a sheepderived antivenin indicated for the management of adult and pediatric patients with north american crotalid envenomation fda label')|
|('DB13896', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'this medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery fda label elsewhere the ema notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic stage iiib iiic and ivm1a with no bone brain lung or other visceral diseases l2209')|
|('DB13896', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'this medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery fda label elsewhere the ema notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic stage iiib iiic and ivm1a with no bone brain lung or other visceral diseases l2209')|
|('DB13897', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin e immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype e in adults and pediatric patients fda label')|
|('DB13898', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin c immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype c in adults and pediatric patients fda label')|
|('DB13899', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin g immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype g in adults and pediatric patients fda label')|
|('DB13900', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin a immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype a in adults and pediatric patients fda label')|
|('DB13901', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin f immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype f in adults and pediatric patients fda label')|
|('DB13902', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin d immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype d in adults and pediatric patients fda label')|
|('DB13903', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'equine botulinum neurotoxin b immune fab2 is indicted for use in documented or suspected exposure to botulinum toxin serotype b in adults and pediatric patients fda label')|
|('DB13905', 'MONDO:0005105', ['malignant melanoma', 'Naevocarcinoma', 'melanoma'], 'indicated for treatment of clinical signs of scorpion envenomation l2195 l2196')|
|('DB13905', 'MONDO:0018755', ['toxic effect of venom of scorpion []', 'poisoning caused by scorpion venom []', 'poisoning due to scorpion venom []', 'scorpion envenomation'], 'indicated for treatment of clinical signs of scorpion envenomation l2195 l2196')|
|('DB13906', 'MONDO:0018755', ['toxic effect of venom of scorpion []', 'poisoning caused by scorpion venom []', 'poisoning due to scorpion venom []', 'scorpion envenomation'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13906', 'MONDO:0004980', ['allergic dermatitis', 'Atopic dermatitis', 'atopic eczema', 'Atopic neurodermatitis', 'Besniers prurigo', 'atopic eczema'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13906', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13906', 'MONDO:0011438', ['Acne varioliformis', 'acne vulgaris', 'frontalis acne', 'acne'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13906', 'MONDO:0043771', ['dermatitis radiation [NCIT:C3349]', 'radiation dermatitis [NCIT:C3349]', 'radiation-induced dermatitis [NCIT:C3349]', 'radiodermatitis [NCIT:C3349]', 'radiodermatitis'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13906', 'MONDO:0005326', ['sunburn'], 'indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions including contact or atopic dermatitis eczema dermatitis and acne urticata first and seconddegree burns radiation dermatitis and sunburn ')|
|('DB13908', 'MONDO:0043771', ['dermatitis radiation [NCIT:C3349]', 'radiation dermatitis [NCIT:C3349]', 'radiation-induced dermatitis [NCIT:C3349]', 'radiodermatitis [NCIT:C3349]', 'radiodermatitis'], 'sore throat minor mouth and throat infections l2570 l2571 a32773')|
|('DB13909', 'MONDO:0043771', ['dermatitis radiation [NCIT:C3349]', 'radiation dermatitis [NCIT:C3349]', 'radiation-induced dermatitis [NCIT:C3349]', 'radiodermatitis [NCIT:C3349]', 'radiodermatitis'], 'the most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a nonprescription internal deodorant product for the purpose of deodorizing flatulence and stools l2309 l2312 a32566additionally there are also various nonprescription over the counter bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent  usually for soft tissue surgery in otorhinolaryngology andor dermatologic settings a32567 a32568 a32569 a32570moreover in the past bismuth subgallate may have seen some use as a treatment for helicobacter pylori infection a32571 in contrast contemporary firstline therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication ease of administration and patient compliance')|
|('DB13909', 'MONDO:0021137', ['common []', 'not rare'], 'the most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a nonprescription internal deodorant product for the purpose of deodorizing flatulence and stools l2309 l2312 a32566additionally there are also various nonprescription over the counter bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent  usually for soft tissue surgery in otorhinolaryngology andor dermatologic settings a32567 a32568 a32569 a32570moreover in the past bismuth subgallate may have seen some use as a treatment for helicobacter pylori infection a32571 in contrast contemporary firstline therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication ease of administration and patient compliance')|
|('DB13909', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'the most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a nonprescription internal deodorant product for the purpose of deodorizing flatulence and stools l2309 l2312 a32566additionally there are also various nonprescription over the counter bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent  usually for soft tissue surgery in otorhinolaryngology andor dermatologic settings a32567 a32568 a32569 a32570moreover in the past bismuth subgallate may have seen some use as a treatment for helicobacter pylori infection a32571 in contrast contemporary firstline therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication ease of administration and patient compliance')|
|('DB13911', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'for use in dental disclosing products allowing for highlighting of bacterial placques')|
|('DB13913', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'no therapeutic indications ')|
|('DB13914', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'volixibat is an investigational drug that has not been approved for use in any conditions')|
|('DB13914', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'volixibat is an investigational drug that has not been approved for use in any conditions')|
|('DB13915', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the treatment of adult patients with relapsed or refractory large bcell lymphoma after two or more lines of systemic therapy including diffuse large bcell lymphoma dlbcl not otherwise specified primary mediastinal large bcell lymphoma high grade bcell lymphoma and dlbcl arising from follicular lymphoma ')|
|('DB13915', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'indicated for the treatment of adult patients with relapsed or refractory large bcell lymphoma after two or more lines of systemic therapy including diffuse large bcell lymphoma dlbcl not otherwise specified primary mediastinal large bcell lymphoma high grade bcell lymphoma and dlbcl arising from follicular lymphoma ')|
|('DB13915', 'MONDO:0018906', ['follicular lymphoma'], 'indicated for the treatment of adult patients with relapsed or refractory large bcell lymphoma after two or more lines of systemic therapy including diffuse large bcell lymphoma dlbcl not otherwise specified primary mediastinal large bcell lymphoma high grade bcell lymphoma and dlbcl arising from follicular lymphoma ')|
|('DB13923', 'MONDO:0005062', ['lymphoid cancer', 'lymphoma'], 'the main function of emicizumab is the prevention of bleeding episodes thus emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia a with or without factor viii inhibitorsl4657hemophilia a is a deficiency of coagulation factor viii which causes a serious bleeding disorder the standard treatment is done with the administration of recombinant or serumderiver factor viii which induces the formation of antifactor viii alloantibodies factor viii inhibitors and renders the standard treatment ineffectivea31286')|
|('DB13923', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'the main function of emicizumab is the prevention of bleeding episodes thus emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia a with or without factor viii inhibitorsl4657hemophilia a is a deficiency of coagulation factor viii which causes a serious bleeding disorder the standard treatment is done with the administration of recombinant or serumderiver factor viii which induces the formation of antifactor viii alloantibodies factor viii inhibitors and renders the standard treatment ineffectivea31286')|
|('DB13924', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'shingrix vaccine is indicated for the prevention of herpes zoster shingles in adults aged 50 years and older')|
|('DB13924', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'shingrix vaccine is indicated for the prevention of herpes zoster shingles in adults aged 50 years and older')|
|('DB13925', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'dotatate gallium 68 is one of the most prominent radiopharmaceuticals used in imaging with positron emission tomography it binds to the somatostatin2 receptor which is usually overexpressed in many neuroendocrine tumors in both adult and pediatric patientsa31362 the neuroendocrine tumors are bening or malignant tumors produced in the hormone producing cells of the neuroendocrine systeml1048 ')|
|('DB13926', 'MONDO:0005609', ['herpes zona', 'Shingles', 'herpes zoster'], 'cenegermin is indicated for the treatment of moderate persistent epithelial defect or severe corneal ulcer neurotrophic keratitis in adults fda label f1502 ')|
|('DB13926', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'cenegermin is indicated for the treatment of moderate persistent epithelial defect or severe corneal ulcer neurotrophic keratitis in adults fda label f1502 ')|
|('DB13926', 'MONDO:0003085', ['keratitis'], 'cenegermin is indicated for the treatment of moderate persistent epithelial defect or severe corneal ulcer neurotrophic keratitis in adults fda label f1502 ')|
|('DB13928', 'MONDO:0003085', ['keratitis'], 'semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus and is used as an adjunct to diet and exercisel8678l8681 it is important to note that semaglutide is not a suitable firstline drug for diabetes that has not been controlled by diet and exercisein addition it has not been studied in patients with pancreatitis  semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosisl8678')|
|('DB13928', 'MONDO:0005148', ['NIDDM', 'non-insulin-dependent diabetes mellitus', 'type 2 diabetes', 'type II diabetes mellitus', 'type 2 diabetes mellitus'], 'semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus and is used as an adjunct to diet and exercisel8678l8681 it is important to note that semaglutide is not a suitable firstline drug for diabetes that has not been controlled by diet and exercisein addition it has not been studied in patients with pancreatitis  semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosisl8678')|
|('DB13928', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus and is used as an adjunct to diet and exercisel8678l8681 it is important to note that semaglutide is not a suitable firstline drug for diabetes that has not been controlled by diet and exercisein addition it has not been studied in patients with pancreatitis  semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosisl8678')|
|('DB13928', 'MONDO:0004982', ['pancreatitis'], 'semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus and is used as an adjunct to diet and exercisel8678l8681 it is important to note that semaglutide is not a suitable firstline drug for diabetes that has not been controlled by diet and exercisein addition it has not been studied in patients with pancreatitis  semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosisl8678')|
|('DB13931', 'MONDO:0004982', ['pancreatitis'], 'netarsudil is indicated for the reduction of elevated intraocular pressure iop in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB13931', 'MONDO:0005041', ['glaucoma'], 'netarsudil is indicated for the reduction of elevated intraocular pressure iop in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB13931', 'MONDO:0006875', ['ocular hypertension'], 'netarsudil is indicated for the reduction of elevated intraocular pressure iop in patients with openangle glaucoma or ocular hypertension fda label')|
|('DB13932', 'MONDO:0006875', ['ocular hypertension'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13932', 'MONDO:0019118', ['Retinal Dystrophy', 'inherited retinal dystrophy'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13932', 'MONDO:0008765', ['amaurosis congenita of Leber II', 'LCA2', 'leber congenital amaurosis 2'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13932', 'MONDO:0018998', ['LCA', 'Lebers amaurosis', 'Lebers congenital amaurosis', 'Lebers disease', 'leber congenital amaurosis'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13932', 'MONDO:0021152', ['inherited'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13932', 'MONDO:0004580', ['degeneration of retina', 'retinal degeneration'], 'vnrzyl is indicated for the treatment of children and adult patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy the administration of vnrzyl is conditioned to the physician determination of the presence of viable retinal cellsfda label the rpe65 represents the lca2 form of the lebers congenital amaurosis lca lca is a group of inherited conditionts that involves retinal degeneration and severe vision loss in early childhood leading to total blindness by 3040 years old the lca2 form is associated with a mutation that interferes with the isomerohydrolase activity of the retinal pigment epithelium the isomerohydrolase activity transforms the transretinyl esters to 11cisretinal which is the natural ligand and chromophore of the opsins of rod and cones photoreceptors in the presence of rpe65 mutations the opsins cannot capture light or transduce it into electrical responses to initiate visiona31480')|
|('DB13933', 'MONDO:0008765', ['amaurosis congenita of Leber II', 'LCA2', 'leber congenital amaurosis 2'], 'nonacog beta pegol is indicated for the use in adults and children with hemophilia b for control and prevention of bleeding episodes routine prophylaxis and perioperative managementl1100 in the ema approval it is also indicated for ondemand treatment of bleeding episodesl1099 hemophilia b is characterized by a deficiency in the coagulation factor ix which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing hemophilia b patients present more frequent bleeding episodes during childhood and adolescence than in adulthoodt56')|
|('DB13933', 'MONDO:0010604', ['Congenital factor IX deficiency', 'Congenital factor IX disorder', 'deficiency, functional factor IX', 'factor IX deficiency', 'hemophilia b'], 'nonacog beta pegol is indicated for the use in adults and children with hemophilia b for control and prevention of bleeding episodes routine prophylaxis and perioperative managementl1100 in the ema approval it is also indicated for ondemand treatment of bleeding episodesl1099 hemophilia b is characterized by a deficiency in the coagulation factor ix which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing hemophilia b patients present more frequent bleeding episodes during childhood and adolescence than in adulthoodt56')|
|('DB13933', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'nonacog beta pegol is indicated for the use in adults and children with hemophilia b for control and prevention of bleeding episodes routine prophylaxis and perioperative managementl1100 in the ema approval it is also indicated for ondemand treatment of bleeding episodesl1099 hemophilia b is characterized by a deficiency in the coagulation factor ix which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing hemophilia b patients present more frequent bleeding episodes during childhood and adolescence than in adulthoodt56')|
|('DB13941', 'MONDO:0010604', ['Congenital factor IX deficiency', 'Congenital factor IX disorder', 'deficiency, functional factor IX', 'factor IX deficiency', 'hemophilia b'], 'for the treatment of uncomplicated plasmodium falciparum infection in adults children and infants aged 6 months and up weighing over 5 kg fda label used in combination with db11638')|
|('DB13943', 'MONDO:0010604', ['Congenital factor IX deficiency', 'Congenital factor IX disorder', 'deficiency, functional factor IX', 'factor IX deficiency', 'hemophilia b'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13943', 'MONDO:0002146', ['hypogonadism'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13943', 'MONDO:0009047', ['Cryptorchism', 'Undescended testicle', 'undescended testicles', 'Undescended testis', 'cryptorchidism'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13943', 'MONDO:0010107', ['testicular regression syndrome [MONDO:Lexical,OMIM:273250]', 'ETRS [Orphanet:983]', 'embryonic testicular regression syndrome [Orphanet:983]', 'TRS [MONDO:Lexical,OMIM:273250,Orphanet:983]', 'vanishing testes syndrome [Orphanet:983]', 'vanishing testis syndrome [Orphanet:983]', 'testicular regression syndrome'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13943', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13943', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone these conditions are 1 primary hypogonadism defined as the testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy and 2 hypogonadotropic hypogonadism characterized by idiopathic gonadotropin lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiationl1153')|
|('DB13944', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0002146', ['hypogonadism'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0009047', ['Cryptorchism', 'Undescended testicle', 'undescended testicles', 'Undescended testis', 'cryptorchidism'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0010107', ['testicular regression syndrome [MONDO:Lexical,OMIM:273250]', 'ETRS [Orphanet:983]', 'embryonic testicular regression syndrome [Orphanet:983]', 'TRS [MONDO:Lexical,OMIM:273250,Orphanet:983]', 'vanishing testes syndrome [Orphanet:983]', 'vanishing testis syndrome [Orphanet:983]', 'testicular regression syndrome'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0006823', ['Hypogonadotropic Hypogonadism', 'Klinefelter syndrome', 'XXY syndrome', 'XXY trisomy', 'klinefelter syndrome'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0004992', ['cancer'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0017169', ['men syndromes [NCIT:C6432]', 'multiple endocrine neoplasia syndrome [NCIT:C6432]', 'men syndrome [NCIT:C6432]', 'men [NCIT:C6432,Orphanet:276161]', 'multiple endocrine neoplasia syndrome(s) [NCIT:C6432]', 'multiple endocrine neoplasia [NCIT:C6432]', 'multiple endocrine adenomatosis [NCIT:C6432]', 'multiple endocrine neoplasia'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13944', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone some of the treated conditions are 1 primary hypogonadism defined as testicular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomy 2 hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormonereleasing hormone deficiency or due to a pituitaryhypothalamic injury from tumors trauma or radiation in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy 3 to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder if the conditions 1 and 2 occur prior to puberty the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after pubertyfda labelin females testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal it has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormoneresponsive tumorfda labeltestosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism f1941 the use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with lateonset hypogonadism and males less than 18 years old have not yet been established f1941 moreover subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like nonfatal myocardial infarction nonfatal stroke and cardiovascular death f1941')|
|('DB13946', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'testosterone undecanoate is indicated for replacement therapy in adult males with conditions that are linked with an absence or deficiency in endogenous testosterone production f4247fda label')|
|('DB13949', 'MONDO:0005098', ['CVA, cerebrovascular accident [NCIT:C3390]', 'cerebrovascular accident [NCIT:C3390]', 'cerebral infarction [NCIT:C3390]', 'syndrome, stroke [NCIT:C3390]', 'stroke [NCIT:C3390]', 'stroke syndrome [NCIT:C3390]', 'CVA [NCIT:C3390]', 'cerebrovascular accident, (CVA) [NCIT:C3390]', 'undetermined stroke [NCIT:C3390]', 'stroke disorder'], 'for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis as ferric citrate')|
|('DB13949', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis as ferric citrate')|
|('DB13952', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'femring is indicated for the treatment of vasomotor and urogenital symptoms associated with menopause use of femring estradiol acetate has been shown to improve symptoms caused by atrophy of the vagina such as dryness burning pruritus and dyspareunia andor the lower urinary tract urinary urgency and dysuria')|
|('DB13952', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'femring is indicated for the treatment of vasomotor and urogenital symptoms associated with menopause use of femring estradiol acetate has been shown to improve symptoms caused by atrophy of the vagina such as dryness burning pruritus and dyspareunia andor the lower urinary tract urinary urgency and dysuria')|
|('DB13953', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'estradiol benzoate is not currently available in any fda or health canada approved products')|
|('DB13954', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'depoestradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism')|
|('DB13954', 'MONDO:0002146', ['hypogonadism'], 'depoestradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism')|
|('DB13955', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'estradiol dienanthate is not currently available in any fda or health canada approved products')|
|('DB13956', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'estradiol valerate is commercially available as an intramuscular injection as the product delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only estradiol valerate is also available in combination with db09123 as the commercially available product natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding')|
|('DB13956', 'MONDO:0002146', ['hypogonadism'], 'estradiol valerate is commercially available as an intramuscular injection as the product delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only estradiol valerate is also available in combination with db09123 as the commercially available product natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding')|
|('DB13956', 'MONDO:0005387', ['hypergonadotropic hypogonadism', 'premature menopause', 'premature ovarian insufficiency', 'primary ovarian insufficiency', 'primary ovarian failure'], 'estradiol valerate is commercially available as an intramuscular injection as the product delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only estradiol valerate is also available in combination with db09123 as the commercially available product natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding')|
|('DB13956', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'estradiol valerate is commercially available as an intramuscular injection as the product delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause for the treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure and for the treatment of advanced androgendependent carcinoma of the prostate for palliation only estradiol valerate is also available in combination with db09123 as the commercially available product natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding')|
|('DB13959', 'MONDO:0004993', ['epithelial cancer', 'epithelioma', 'malignant Epithelioma', 'carcinoma'], 'when incorporated as an active ingredient in combination with other active components like fish oils soya oil and olive oil as a prescription medication smoflipid medium chain triglycerides mcts constitute a therapy indicated for supplying energy calories and essential fatty acids to adult patients as part of a parenteral nutrition regimen when oral or enteral nutrition is impossible insufficient or contraindicated f126 f127however given the predominant indication of mcts for acting as a source of calories and essential fatty acids the use of mcts alone or as a component part of various unique individual patienttailored composite regimen therapies mcts are also ultimately indicated for a wide range of health conditions that involve energy deficiency malnutrition or disturbances in the ordinary absorption of dietary fats a33175 f128 such conditions can include crohns disease waldmann disease weight maintenance in aids cachexia and various disturbances in patient bile secretion like cholestasis disturbances in hepaticintestinal circulation of bile acids intestinal dysbacteriosis or in pancreatic lipase secretion like pancreatic failure in the course of cystic fibrosis a33175 f128 ')|
|('DB13959', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'when incorporated as an active ingredient in combination with other active components like fish oils soya oil and olive oil as a prescription medication smoflipid medium chain triglycerides mcts constitute a therapy indicated for supplying energy calories and essential fatty acids to adult patients as part of a parenteral nutrition regimen when oral or enteral nutrition is impossible insufficient or contraindicated f126 f127however given the predominant indication of mcts for acting as a source of calories and essential fatty acids the use of mcts alone or as a component part of various unique individual patienttailored composite regimen therapies mcts are also ultimately indicated for a wide range of health conditions that involve energy deficiency malnutrition or disturbances in the ordinary absorption of dietary fats a33175 f128 such conditions can include crohns disease waldmann disease weight maintenance in aids cachexia and various disturbances in patient bile secretion like cholestasis disturbances in hepaticintestinal circulation of bile acids intestinal dysbacteriosis or in pancreatic lipase secretion like pancreatic failure in the course of cystic fibrosis a33175 f128 ')|
|('DB13959', 'MONDO:0001751', ['bile occlusion', 'Obstruction of bile duct', 'cholestasis'], 'when incorporated as an active ingredient in combination with other active components like fish oils soya oil and olive oil as a prescription medication smoflipid medium chain triglycerides mcts constitute a therapy indicated for supplying energy calories and essential fatty acids to adult patients as part of a parenteral nutrition regimen when oral or enteral nutrition is impossible insufficient or contraindicated f126 f127however given the predominant indication of mcts for acting as a source of calories and essential fatty acids the use of mcts alone or as a component part of various unique individual patienttailored composite regimen therapies mcts are also ultimately indicated for a wide range of health conditions that involve energy deficiency malnutrition or disturbances in the ordinary absorption of dietary fats a33175 f128 such conditions can include crohns disease waldmann disease weight maintenance in aids cachexia and various disturbances in patient bile secretion like cholestasis disturbances in hepaticintestinal circulation of bile acids intestinal dysbacteriosis or in pancreatic lipase secretion like pancreatic failure in the course of cystic fibrosis a33175 f128 ')|
|('DB13959', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'when incorporated as an active ingredient in combination with other active components like fish oils soya oil and olive oil as a prescription medication smoflipid medium chain triglycerides mcts constitute a therapy indicated for supplying energy calories and essential fatty acids to adult patients as part of a parenteral nutrition regimen when oral or enteral nutrition is impossible insufficient or contraindicated f126 f127however given the predominant indication of mcts for acting as a source of calories and essential fatty acids the use of mcts alone or as a component part of various unique individual patienttailored composite regimen therapies mcts are also ultimately indicated for a wide range of health conditions that involve energy deficiency malnutrition or disturbances in the ordinary absorption of dietary fats a33175 f128 such conditions can include crohns disease waldmann disease weight maintenance in aids cachexia and various disturbances in patient bile secretion like cholestasis disturbances in hepaticintestinal circulation of bile acids intestinal dysbacteriosis or in pancreatic lipase secretion like pancreatic failure in the course of cystic fibrosis a33175 f128 ')|
|('DB13960', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'bronopol as an active ingredient is registered as a commercial biocide and preservative in many industrial processes registered biocidal uses include pulp and paper mills water cooling towers waste water treatment evaporative condensers heat exchangers food pasteurizing plants metalworking fluids and oilfield applications f2317 in addition preservative uses include household products eg dishwashing liquids laundry products latex emulsions polymer lattices pigments leather and milk samples for analysis f2317 bronopol is also formulated into granular domestic enduse products in the form of cat litter f2317')|
|('DB13961', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'under fda approval fish oil pharmaceuticals are typically products consisting of a combination of the omega3fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe 500 mgdl hypertriglyceridemia fda label f36under ema approval such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega3fatty acids epa and dha are indicated specifically for a adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy ie statins antiplatelet medicinal products beta blockers ace inhibitors and b as a supplement to diet when dietary measures alone are insufficient to produce an adequate response particularly with type iv hypertriglyceridemia in monotherapy or type iibiii in combination with statins when control of triglycerides is insufficient l2661 in addition prescribing information for ema approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high 500 mgdl triglyceride levels in adult patients much like similar fda approved indications f37 fda label')|
|('DB13961', 'MONDO:0005347', ['hypertriglyceridemia [MONDO:ambiguous]', 'hypertriglyceridemia'], 'under fda approval fish oil pharmaceuticals are typically products consisting of a combination of the omega3fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe 500 mgdl hypertriglyceridemia fda label f36under ema approval such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega3fatty acids epa and dha are indicated specifically for a adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy ie statins antiplatelet medicinal products beta blockers ace inhibitors and b as a supplement to diet when dietary measures alone are insufficient to produce an adequate response particularly with type iv hypertriglyceridemia in monotherapy or type iibiii in combination with statins when control of triglycerides is insufficient l2661 in addition prescribing information for ema approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high 500 mgdl triglyceride levels in adult patients much like similar fda approved indications f37 fda label')|
|('DB13961', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'under fda approval fish oil pharmaceuticals are typically products consisting of a combination of the omega3fatty acids eicosapentaenoic acid epa and docosahexaenoic acid dha and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe 500 mgdl hypertriglyceridemia fda label f36under ema approval such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega3fatty acids epa and dha are indicated specifically for a adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy ie statins antiplatelet medicinal products beta blockers ace inhibitors and b as a supplement to diet when dietary measures alone are insufficient to produce an adequate response particularly with type iv hypertriglyceridemia in monotherapy or type iibiii in combination with statins when control of triglycerides is insufficient l2661 in addition prescribing information for ema approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high 500 mgdl triglyceride levels in adult patients much like similar fda approved indications f37 fda label')|
|('DB13964', 'MONDO:0005068', ['heart attack', 'Myocardial infarct', 'myocardial infarction'], 'peanut oil is widely used in food and it is even the component for the adulteration of olive oilt41 it is used in overthecounter ear drops to help lubricate the ear waxf124 it was also used as an ingredient in cleansing soaps in emollient cream preparations or in laxativesl2892 f125peanut oil is also used usually to solubilize drugs with poor water solubility as part of the oral formulationt224when orally administered peanut oil has as well been researched and used to prevent heart diseases and lower cholesterol levels as well as to aid in weight loss and decrease appetitel2897')|
|('DB13964', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'peanut oil is widely used in food and it is even the component for the adulteration of olive oilt41 it is used in overthecounter ear drops to help lubricate the ear waxf124 it was also used as an ingredient in cleansing soaps in emollient cream preparations or in laxativesl2892 f125peanut oil is also used usually to solubilize drugs with poor water solubility as part of the oral formulationt224when orally administered peanut oil has as well been researched and used to prevent heart diseases and lower cholesterol levels as well as to aid in weight loss and decrease appetitel2897')|
|('DB13965', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'no approved therapeutic indications ')|
|('DB13966', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the primary medical indication for which isopropyl myristate is formally used as an active ingredient in a patient care product is as a nonprescription pediculicide rinse a32330')|
|('DB13967', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'patent blue is used for marking lymphatic vessels and arterial territories as well as for sentinel lymph node prior to biopsy in patients with operable breast cancer and clinically negative lymph nodes in combination with a radiotracera32575patent blue is also used in the textile paper agriculture and cosmetic industrya32574')|
|('DB13967', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'patent blue is used for marking lymphatic vessels and arterial territories as well as for sentinel lymph node prior to biopsy in patients with operable breast cancer and clinically negative lymph nodes in combination with a radiotracera32575patent blue is also used in the textile paper agriculture and cosmetic industrya32574')|
|('DB13968', 'MONDO:0007254', ['breast tumor', 'malignant neoplasm of breast', 'malignant tumor of the breast', 'mammary cancer', 'mammary tumor', 'primary breast cancer', 'breast cancer'], 'ppfh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy it is also used as a substitution therapy in emergency cases of factor deficiencies for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy ppfh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpural2264ppfh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cellsl2261')|
|('DB13968', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'ppfh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy it is also used as a substitution therapy in emergency cases of factor deficiencies for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy ppfh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpural2264ppfh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cellsl2261')|
|('DB13973', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'indicated for in the management of acute graft versus host disease agvhd in pediatric patients acute gvhd should be refractory to treatment with systemic corticosteroid therapy andor other immunosuppressive agents remestemcell may be used for grades c and d of the disease in any organ remestemcell may also be used in the management of grade b agvhd involving any visceral organ including the gi tract and the liver but excluding skin l1310')|
|('DB13973', 'MONDO:0020546', ['fulminant graft versus host disease [NCIT:C4980]', 'graft versus host disease, acute [MONDO:patterns/acute]', 'GVHD, acute [NCIT:C4980]', 'acute graft versus host disease'], 'indicated for in the management of acute graft versus host disease agvhd in pediatric patients acute gvhd should be refractory to treatment with systemic corticosteroid therapy andor other immunosuppressive agents remestemcell may be used for grades c and d of the disease in any organ remestemcell may also be used in the management of grade b agvhd involving any visceral organ including the gi tract and the liver but excluding skin l1310')|
|('DB13975', 'MONDO:0020546', ['fulminant graft versus host disease [NCIT:C4980]', 'graft versus host disease, acute [MONDO:patterns/acute]', 'GVHD, acute [NCIT:C4980]', 'acute graft versus host disease'], 'treatment of menopausal symptoms and menstrual dysfunction l2307')|
|('DB13979', 'MONDO:0020546', ['fulminant graft versus host disease [NCIT:C4980]', 'graft versus host disease, acute [MONDO:patterns/acute]', 'GVHD, acute [NCIT:C4980]', 'acute graft versus host disease'], 'besilesomab is radiolabelled with sodium pertechnetate tc99m solution to develop technetium tc99m besilesomab solution this solution is indicated in adults for scintigraphic imaging  in conjunction with other appropriate imaging modalities when possible  in determining the location of inflammationinfection in peripheral bone in adults with suspected osteomyelitis fda label when utilized as such this medicinal product is for diagnostic use only fda label')|
|('DB13979', 'MONDO:0005246', ['osteomyelitis'], 'besilesomab is radiolabelled with sodium pertechnetate tc99m solution to develop technetium tc99m besilesomab solution this solution is indicated in adults for scintigraphic imaging  in conjunction with other appropriate imaging modalities when possible  in determining the location of inflammationinfection in peripheral bone in adults with suspected osteomyelitis fda label when utilized as such this medicinal product is for diagnostic use only fda label')|
|('DB13985', 'MONDO:0005246', ['osteomyelitis'], 'indicated for the treatment of somatostatin receptorpositive gastroenteropancreatic neuroendocrine tumors gepnets including foregut midgut and hindgut neuroendocrine tumors in adults fda label')|
|('DB13987', 'MONDO:0005246', ['osteomyelitis'], 'when employed as an ingredient in toothpaste formulations strontium chloride is predominantly indicated for treating teeth hypersensitivity a33167 a33168 l2882 f118')|
|('DB13995', 'MONDO:0005246', ['osteomyelitis'], 'ferric pyrophosphate citrate is indicated for the treatment of iron loss or iron deficiency to maintain hemoglobin and to reduce the prescribed dose of erythropoiesisstimulating agent esa required to maintain desired hemoglobin levelsl1423 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB13995', 'MONDO:0002875', ['ectoparasitism', 'parasitic ectoparasitic infectious disease'], 'ferric pyrophosphate citrate is indicated for the treatment of iron loss or iron deficiency to maintain hemoglobin and to reduce the prescribed dose of erythropoiesisstimulating agent esa required to maintain desired hemoglobin levelsl1423 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB13995', 'MONDO:0002049', ['thrombocytopenia'], 'ferric pyrophosphate citrate is indicated for the treatment of iron loss or iron deficiency to maintain hemoglobin and to reduce the prescribed dose of erythropoiesisstimulating agent esa required to maintain desired hemoglobin levelsl1423 iron deficiency appears when the dietary intake does not meet the bodys requirement or when there is chronic external blood loss during acute blood loss body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis but when the altered homeostasis remains for weeks to months then some supplement is needed some causes of iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia and gastrointestinal hemorrhagea31984')|
|('DB13997', 'MONDO:0002049', ['thrombocytopenia'], 'for the treatment of influenza a and b virus infection l1473 l1475 fda label in patients 12 and older who have been symptomatic for no more than 48 hours clinical trials of this drug did not include subjects 65 years of age and older to determine whether they respond in a different way than younger subjects fda label')|
|('DB13997', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of influenza a and b virus infection l1473 l1475 fda label in patients 12 and older who have been symptomatic for no more than 48 hours clinical trials of this drug did not include subjects 65 years of age and older to determine whether they respond in a different way than younger subjects fda label')|
|('DB13998', 'MONDO:0005812', ['flu', 'Influenza with non-respiratory manifestation', 'influenza with non-respiratory manifestation', 'Influenza with other manifestations', 'influenza'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB13998', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB13998', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB13998', 'MONDO:0002241', ['FXIIID [MONDO:cjm]', 'factor xiii deficiency'], 'for the treatment of hemophilia a von willebrand disease and factor xiii deficiency')|
|('DB13999', 'MONDO:0019565', ['vascular hemophilia', 'vascular pseudohemophilia', 'von Willebrand disease', 'von Willebrand disorder', 'von Willebrands-Jurgens disease', 'von Willebrand-Jrgens disease', 'hereditary von willebrand disease'], 'moroctocog alfa is approved by health canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia a congenital factor viii deficiency or classic hemophiliamoroctocog alfa is also approved by the european medicines agency for the treatment and prophylaxis of bleeding in patients with haemophilia a congenital factor viii deficiency')|
|('DB13999', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'moroctocog alfa is approved by health canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia a congenital factor viii deficiency or classic hemophiliamoroctocog alfa is also approved by the european medicines agency for the treatment and prophylaxis of bleeding in patients with haemophilia a congenital factor viii deficiency')|
|('DB13999', 'MONDO:0021140', ['inborn []', 'congenital'], 'moroctocog alfa is approved by health canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia a congenital factor viii deficiency or classic hemophiliamoroctocog alfa is also approved by the european medicines agency for the treatment and prophylaxis of bleeding in patients with haemophilia a congenital factor viii deficiency')|
|('DB14001', 'MONDO:0021140', ['inborn []', 'congenital'], 'the primary healthrelated use for which alphatocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166similarly more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alphatocopherol succinates capability to act as an anticancer therapy or as a regulator of inflammation l2699 a32958 a32959')|
|('DB14001', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'the primary healthrelated use for which alphatocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166similarly more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alphatocopherol succinates capability to act as an anticancer therapy or as a regulator of inflammation l2699 a32958 a32959')|
|('DB14001', 'MONDO:0008692', ['familial hypobetalipoproteinemia', 'microsomal triglyceride transfer protein deficiency disease', 'abetalipoproteinemia'], 'the primary healthrelated use for which alphatocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166similarly more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alphatocopherol succinates capability to act as an anticancer therapy or as a regulator of inflammation l2699 a32958 a32959')|
|('DB14001', 'MONDO:0004992', ['cancer'], 'the primary healthrelated use for which alphatocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166similarly more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alphatocopherol succinates capability to act as an anticancer therapy or as a regulator of inflammation l2699 a32958 a32959')|
|('DB14001', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'the primary healthrelated use for which alphatocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166similarly more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alphatocopherol succinates capability to act as an anticancer therapy or as a regulator of inflammation l2699 a32958 a32959')|
|('DB14002', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'in addition to any following information owing to dalphatocopherol acetates closely related chemical nature with alphatocopherol acetate please also refer to the drug information page for alphatocopherol acetate for further datavitamin e known for its antioxidant activities is protective against cardiovascular disease and some forms of cancer and has also demonstrated immuneenhancing effects it may be of limited benefit in some with asthma and rheumatoid arthritis it may be helpful in some neurological diseases including alzheimers some eye disorders including cataracts and diabetes and premenstrual syndrome it may also help protect skin from ultraviolet irradiation although claims that it reverses skin aging enhances male fertility and exercise performance are poorly supported it may help relieve some muscle cramps')|
|('DB14002', 'MONDO:0004995', ['disease of subdivision of hemolymphoid system', 'cardiovascular disease'], 'in addition to any following information owing to dalphatocopherol acetates closely related chemical nature with alphatocopherol acetate please also refer to the drug information page for alphatocopherol acetate for further datavitamin e known for its antioxidant activities is protective against cardiovascular disease and some forms of cancer and has also demonstrated immuneenhancing effects it may be of limited benefit in some with asthma and rheumatoid arthritis it may be helpful in some neurological diseases including alzheimers some eye disorders including cataracts and diabetes and premenstrual syndrome it may also help protect skin from ultraviolet irradiation although claims that it reverses skin aging enhances male fertility and exercise performance are poorly supported it may help relieve some muscle cramps')|
|('DB14002', 'MONDO:0004992', ['cancer'], 'in addition to any following information owing to dalphatocopherol acetates closely related chemical nature with alphatocopherol acetate please also refer to the drug information page for alphatocopherol acetate for further datavitamin e known for its antioxidant activities is protective against cardiovascular disease and some forms of cancer and has also demonstrated immuneenhancing effects it may be of limited benefit in some with asthma and rheumatoid arthritis it may be helpful in some neurological diseases including alzheimers some eye disorders including cataracts and diabetes and premenstrual syndrome it may also help protect skin from ultraviolet irradiation although claims that it reverses skin aging enhances male fertility and exercise performance are poorly supported it may help relieve some muscle cramps')|
|('DB14002', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'in addition to any following information owing to dalphatocopherol acetates closely related chemical nature with alphatocopherol acetate please also refer to the drug information page for alphatocopherol acetate for further datavitamin e known for its antioxidant activities is protective against cardiovascular disease and some forms of cancer and has also demonstrated immuneenhancing effects it may be of limited benefit in some with asthma and rheumatoid arthritis it may be helpful in some neurological diseases including alzheimers some eye disorders including cataracts and diabetes and premenstrual syndrome it may also help protect skin from ultraviolet irradiation although claims that it reverses skin aging enhances male fertility and exercise performance are poorly supported it may help relieve some muscle cramps')|
|('DB14002', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'in addition to any following information owing to dalphatocopherol acetates closely related chemical nature with alphatocopherol acetate please also refer to the drug information page for alphatocopherol acetate for further datavitamin e known for its antioxidant activities is protective against cardiovascular disease and some forms of cancer and has also demonstrated immuneenhancing effects it may be of limited benefit in some with asthma and rheumatoid arthritis it may be helpful in some neurological diseases including alzheimers some eye disorders including cataracts and diabetes and premenstrual syndrome it may also help protect skin from ultraviolet irradiation although claims that it reverses skin aging enhances male fertility and exercise performance are poorly supported it may help relieve some muscle cramps')|
|('DB14003', 'MONDO:0008383', ['Arthritis or polyarthritis, rheumatic', 'atrophic Arthritis', 'rheumatoid arthritis'], 'the primary healthrelated use for which alphatocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166')|
|('DB14003', 'MONDO:0021136', ['rare (European definition) []', 'rare'], 'the primary healthrelated use for which alphatocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166')|
|('DB14003', 'MONDO:0008692', ['familial hypobetalipoproteinemia', 'microsomal triglyceride transfer protein deficiency disease', 'abetalipoproteinemia'], 'the primary healthrelated use for which alphatocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166')|
|('DB14003', 'MONDO:0004992', ['cancer'], 'the primary healthrelated use for which alphatocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin e deficiency at the same time vitamin e deficiency is generally quite rare but may occur in premature babies of very low birth weight  1500 grams individuals with fatmalabsorption disorders as fat is required for the digestive tract to absorb vitamin e or individuals with abetalipoproteinemia  a rare inherited disorder that causes poor absorption of dietary fat  who require extremely large doses of supplemental vitamin e daily around 100 mgkg or 510 gday l2120 in all such cases alphatocopherol is largely the preferred form of vitamin e to be administeredelsewhere vitamin es chemical profile as a fatsoluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin e possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer and more t166 none of these ongoing studies have yet to elucidate any formally significant evidence however t166')|
|('DB14004', 'MONDO:0004992', ['cancer'], 'moderatesevere plaque psoriasis l1858 fda label')|
|('DB14004', 'MONDO:0005083', ['psoriasis'], 'moderatesevere plaque psoriasis l1858 fda label')|
|('DB14005', 'MONDO:0005083', ['psoriasis'], 'dimethicone is approved as a transdermal drug delivery system dimethicone 410 is part of the simethicone element in dow corning q72242 lva which is an antifoaml2163 l2166 some otcs containing dimethicone are used to relieve the discomfort of infant gas caused by air swallowing or certain formulas or foodl2170 to prevent and help rash to protect and relieve chapped or cracked skinl2171 and as an antilice agentl1769')|
|('DB14005', 'MONDO:0008893', ['C syndrome [OMIM:211750]', 'OTCS [Orphanet:1308]', 'trigonocephaly C syndrome [Orphanet:1308]', 'Opitz trigonocephaly C syndrome [Orphanet:1308]', 'Opitz trigonocephaly syndrome [OMIM:211750,Orphanet:1308]', 'Opitz C trigonocephaly [Orphanet:1308]', 'c syndrome'], 'dimethicone is approved as a transdermal drug delivery system dimethicone 410 is part of the simethicone element in dow corning q72242 lva which is an antifoaml2163 l2166 some otcs containing dimethicone are used to relieve the discomfort of infant gas caused by air swallowing or certain formulas or foodl2170 to prevent and help rash to protect and relieve chapped or cracked skinl2171 and as an antilice agentl1769')|
|('DB14005', 'MONDO:0100014', ['AIR []', 'retina autoimmune disease [MONDO:design_pattern,MONDO:patterns/location]', 'autoimmune disease of retina [MONDO:design_pattern]', 'autoimmune retinopathy'], 'dimethicone is approved as a transdermal drug delivery system dimethicone 410 is part of the simethicone element in dow corning q72242 lva which is an antifoaml2163 l2166 some otcs containing dimethicone are used to relieve the discomfort of infant gas caused by air swallowing or certain formulas or foodl2170 to prevent and help rash to protect and relieve chapped or cracked skinl2171 and as an antilice agentl1769')|
|('DB14005', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'dimethicone is approved as a transdermal drug delivery system dimethicone 410 is part of the simethicone element in dow corning q72242 lva which is an antifoaml2163 l2166 some otcs containing dimethicone are used to relieve the discomfort of infant gas caused by air swallowing or certain formulas or foodl2170 to prevent and help rash to protect and relieve chapped or cracked skinl2171 and as an antilice agentl1769')|
|('DB14006', 'MONDO:0006547', ['exanthema', 'Rash', 'exanthem'], 'the oral gel is indicated for the relief of pain and discomfort of common mouth ulcers cold sores denture sore spots infant teething and mouth ulcers and sore spots due to orthodontic devices in children l2135')|
|('DB14006', 'MONDO:0021137', ['common []', 'not rare'], 'the oral gel is indicated for the relief of pain and discomfort of common mouth ulcers cold sores denture sore spots infant teething and mouth ulcers and sore spots due to orthodontic devices in children l2135')|
|('DB14006', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'the oral gel is indicated for the relief of pain and discomfort of common mouth ulcers cold sores denture sore spots infant teething and mouth ulcers and sore spots due to orthodontic devices in children l2135')|
|('DB14007', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'dtpa is widely used in industry and medicine as a medical agent it is approved for its use in medical imaging and for the decorporation of internally deposited radionuclidesa32501 it is fda approved for the treatment of individuals with known or suspected internal contamination with plutonium americium or curium to increase the rates of eliminationl2243due to the pharmacokinetic elimination by the kidneys pentetic acid conjugated with technetium tc99m is being used clinically to estimate physiological parameters such as glomerular filtration rat and effective renal plasma flowt168')|
|('DB14011', 'MONDO:0043839', ['ulcerative [NCIT:C3426]', 'ulceration [NCIT:C3426]', 'ulcers [MESH:D014456]', 'ulcer [MESH:D014456]', 'ulcer disease'], 'in canada sativex has received a notice of compliance noc for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis ms who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy sativex has also received a notice of compliance with conditions nocc for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis ms and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit patients should be advised of the conditional nature of the authorizations with conditions')|
|('DB14011', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'in canada sativex has received a notice of compliance noc for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis ms who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy sativex has also received a notice of compliance with conditions nocc for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis ms and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit patients should be advised of the conditional nature of the authorizations with conditions')|
|('DB14011', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'in canada sativex has received a notice of compliance noc for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis ms who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy sativex has also received a notice of compliance with conditions nocc for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis ms and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit patients should be advised of the conditional nature of the authorizations with conditions')|
|('DB14012', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'this drug is indicated for the treatment of xlinked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons l2347')|
|('DB14012', 'MONDO:0000313', ['hypophosphatemia'], 'this drug is indicated for the treatment of xlinked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons l2347')|
|('DB14012', 'MONDO:0005381', ['bone disease'], 'this drug is indicated for the treatment of xlinked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons l2347')|
|('DB14018', 'MONDO:0005381', ['bone disease'], 'bromotheophylline is used as a diuretic and also in combination with db00316 it is used for the relief of temporary water weight gain bloating swelling and full feeling associated with the premenstrual and menstrual periodsl2737')|
|('DB14019', 'MONDO:0005381', ['bone disease'], 'indicated in combination palonosetron as the drug akynzeo and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy including but not limited to highly emetogenic chemotherapy fda labelthe following are indications listed on the ema label f29prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatinbased cancer chemotherapy f29prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy f29')|
|('DB14019', 'MONDO:0004992', ['cancer'], 'indicated in combination palonosetron as the drug akynzeo and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy including but not limited to highly emetogenic chemotherapy fda labelthe following are indications listed on the ema label f29prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatinbased cancer chemotherapy f29prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy f29')|
|('DB14020', 'MONDO:0004992', ['cancer'], 'no approved therapeutic indications ')|
|('DB14033', 'MONDO:0004992', ['cancer'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0006939', ['pyelonephritis'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0006032', ['cystitis'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0021108', ['inflammation of meninx []', 'meninx inflammation [MONDO:patterns/inflammatory_disease_by_site]', 'meningitis [NCIT:C26828]', 'meningitis'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0005441', ['otitis media'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0005808', ['adult inclusion conjunctivitis', 'Chlamydial conjunctivitis', 'Inclusion blennorrhoea', 'inclusion blenorrhea', 'inclusion conjunctivitis'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0001797', ['Ulcus molle, skin', 'chancroid'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14033', 'MONDO:0005136', ['induced malaria', 'malaria'], 'acute recurrent or chronic urinary tract infections primarily pyelonephritis pyelitis and cystitis due to susceptible organisms usually escherichia coli klebsiellaenterobacter staphylococcus proteus mirabilis and less frequently proteus vulgaris in the absence of obstructive uropathy or foreign bodies l2804meningococcal meningitis where the organism has been demonstrated to be susceptible haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin l2804meningococcal meningitis prophylaxis l2804acute otitis media due to haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin see appropriate labeling for prescribing information l2804trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum when used as adjunctive therapy l2804currently the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides especially in the treatment of chronic and recurrent urinary tract infections l2804')|
|('DB14039', 'MONDO:0005136', ['induced malaria', 'malaria'], 'erenumab is indicated for the preventative treatment of migraine in adults fda label')|
|('DB14040', 'MONDO:0005136', ['induced malaria', 'malaria'], 'use of eptinezumab is intended for migraine prevention a33105 a33106 a33108')|
|('DB14041', 'MONDO:0005136', ['induced malaria', 'malaria'], 'the ongoing trials for fremanezumab are for episodic and chronic migraine prevention and also for cluster headache a33114')|
|('DB14041', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'the ongoing trials for fremanezumab are for episodic and chronic migraine prevention and also for cluster headache a33114')|
|('DB14042', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'galcanezumab is a humanized monoclonal antibody that is indicated for migraine prophylaxis and treatment of episodic cluster headaches in adults by binding endogenous human calcitonin generelated peptide cgrpa33112label')|
|('DB14048', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'sodium zirconium cyclosilicate is a potassium binder indicated for the treatment of hyperkalemia in adult patients fda label f130')|
|('DB14050', 'MONDO:0043537', ['cluster headache syndrome [MESH:D003027]', 'cluster headache [NCIT:C117077]', 'cluster headache syndrome'], 'cannabidivarin does not currently have any fda or health canada approved indications however in october 2017 cbdv was given orphan designation by the european medicines agency for use in rett syndrome l2952 and again in february 2018 for treatment of fragile x syndrome l2951')|
|('DB14050', 'MONDO:0010383', ['FRAGILE X MENTAL RETARDATION SYNDROME', 'MARKER X SYNDROME', 'MARTIN-BELL SYNDROME', 'fragile x syndrome'], 'cannabidivarin does not currently have any fda or health canada approved indications however in october 2017 cbdv was given orphan designation by the european medicines agency for use in rett syndrome l2952 and again in february 2018 for treatment of fragile x syndrome l2951')|
|('DB14051', 'MONDO:0010383', ['FRAGILE X MENTAL RETARDATION SYNDROME', 'MARKER X SYNDROME', 'MARTIN-BELL SYNDROME', 'fragile x syndrome'], 'malacidin a is being investigated for its antibiotic action and has potential for use as an antibacterial agent in the future a33312')|
|('DB14051', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'malacidin a is being investigated for its antibiotic action and has potential for use as an antibacterial agent in the future a33312')|
|('DB14052', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'malacidin b is being investigated for its antibiotic action and has potential for use as an antibacterial agent in the future a33312')|
|('DB14074', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'icaridin is indicated for use to repel insects such as mosquitoes biting flies ticks chiggers and fleas via topical use or over clothing l4617 ')|
|('DB14100', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'indicated for the repair of single or multiple symptomatic fullthickness cartilage defects of the knee with or without bone involvement in adults')|
|('DB14112', 'MONDO:0002595', ['vaccinia'], 'cnj016 vaccinia immune globulin intravenous human vigiv is indicated for the treatment andor modification of a eczema vaccinatum b progressive vaccinia c severe generalized vaccinia d vaccinia infections in individuals who have skin conditions such as burns impetigo varicellazoster or poison ivy or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions or e aberrant infections induced by vaccinia virus that include its accidental implantation in eyes except in cases of isolated keratitis mouth or other areas where vaccinia infection would constitute a special hazard fda label')|
|('DB14112', 'MONDO:0004592', ['impetigo'], 'cnj016 vaccinia immune globulin intravenous human vigiv is indicated for the treatment andor modification of a eczema vaccinatum b progressive vaccinia c severe generalized vaccinia d vaccinia infections in individuals who have skin conditions such as burns impetigo varicellazoster or poison ivy or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions or e aberrant infections induced by vaccinia virus that include its accidental implantation in eyes except in cases of isolated keratitis mouth or other areas where vaccinia infection would constitute a special hazard fda label')|
|('DB14126', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'tenofovir has been shown to be effective against hiv herpes simplex virus2 and hepatitis b virusa178330to know more about the specific product indications please visit the information in the orally available forms of tenofovir tenofovir alafenamide and tenofovir disoproxil')|
|('DB14126', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'tenofovir has been shown to be effective against hiv herpes simplex virus2 and hepatitis b virusa178330to know more about the specific product indications please visit the information in the orally available forms of tenofovir tenofovir alafenamide and tenofovir disoproxil')|
|('DB14131', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'basic fibroblast growth factor is not currently approved for any fda or health canada approved indications ')|
|('DB14132', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'when used in combination with db01075 as the antiemetic db00985 8chlorotheophylline  is indicated for the prevention and treatment of nausea vomiting or vertigo of motion sickness')|
|('DB14146', 'MONDO:0002251', ['acute and subacute liver necrosis', 'acute hepatitis', 'acute/subac. necrosis of liver', 'animal hepatitis', 'chronic hepatitis', 'chronic persistent hepatitis', 'hepatitis'], 'loxicodegol was developed as an opioid analgesic with low abuse potential for use in treating chronic pain l3263 an application has been filed for fda approval of loxicodegol for use in treating chronic lower back pain')|
|('DB14146', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'loxicodegol was developed as an opioid analgesic with low abuse potential for use in treating chronic pain l3263 an application has been filed for fda approval of loxicodegol for use in treating chronic lower back pain')|
|('DB14165', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14166', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14167', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14168', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14169', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14170', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14171', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'used in allergenic testing')|
|('DB14175', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'alphaamyl cinnamaldehyde is used in allergenic testing')|
|('DB14176', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'benzylparaben is used in allergenic testing')|
|('DB14177', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'propylparaben is used in allergenic testing')|
|('DB14183', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'geraniol is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14183', 'MONDO:0006525', ['allergic contact dermatitis'], 'geraniol is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14184', 'MONDO:0006525', ['allergic contact dermatitis'], 'cinnamaldehyde is approved by the fda for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14185', 'MONDO:0006525', ['allergic contact dermatitis'], 'aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders')|
|('DB14185', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders')|
|('DB14186', 'MONDO:0005090', ['schizophrenia-1', 'schizophrenia'], 'cinnamyl alcohol is approved by the fda for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14186', 'MONDO:0006525', ['allergic contact dermatitis'], 'cinnamyl alcohol is approved by the fda for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14187', 'MONDO:0006525', ['allergic contact dermatitis'], 'hydroxycitronellal is approved by the fda for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14188', 'MONDO:0006525', ['allergic contact dermatitis'], 'isoeugenol is approved by the fda for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14189', 'MONDO:0006525', ['allergic contact dermatitis'], 'ethylenediamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14190', 'MONDO:0006525', ['allergic contact dermatitis'], 'ptertbutylphenolformaldehyde resin low molecular weight is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14191', 'MONDO:0006525', ['allergic contact dermatitis'], 'diphenylguanidine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14193', 'MONDO:0006525', ['allergic contact dermatitis'], 'ditiocarb zinc is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14194', 'MONDO:0006525', ['allergic contact dermatitis'], 'zinc dibutyldithiocarbamate is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14195', 'MONDO:0006525', ['allergic contact dermatitis'], '4isopropylaminodiphenylamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14196', 'MONDO:0006525', ['allergic contact dermatitis'], 'ncyclohexylnphenyl14phenylenediamine is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14197', 'MONDO:0006525', ['allergic contact dermatitis'], 'methylchloroisothiazolinone is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14198', 'MONDO:0006525', ['allergic contact dermatitis'], 'quaternium15 is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14199', 'MONDO:0006525', ['allergic contact dermatitis'], 'bromothalonil is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14200', 'MONDO:0006525', ['allergic contact dermatitis'], 'thiohexam is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14201', 'MONDO:0006525', ['allergic contact dermatitis'], '22dibenzothiazyl disulfide is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis acd in persons 6 years of age and older')|
|('DB14233', 'MONDO:0006525', ['allergic contact dermatitis'], 'for use as a source of calories for patients requiring parenteral nutrition')|
|('DB14478', 'MONDO:0006525', ['allergic contact dermatitis'], 'when in complex with iodine indicated for inducing antisepsis for prevention of infection in minor cuts scrapes and burns ')|
|('DB14481', 'MONDO:0006525', ['allergic contact dermatitis'], 'for use as an over the counter calcium and phosphate supplement antacid or a source of calcium and phosphate in toothpaste fda label l851')|
|('DB14487', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14487', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14487', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14488', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used in preventing and treating irondeficiency anemia')|
|('DB14488', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB14489', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used in preventing and treating irondeficiency anemia')|
|('DB14489', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB14490', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used in preventing and treating irondeficiency anemia')|
|('DB14490', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB14491', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'used in preventing and treating irondeficiency anemia')|
|('DB14491', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB14498', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions ')|
|('DB14499', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions ')|
|('DB14500', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0020598', ['malabsorption [NCIT:C3214]', 'malabsorption syndrome [NCIT:C3214]', 'malabsorption syndrome'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0006919', ['potassium deficiency'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0008223', ['familial hypokalemic periodic paralysis', 'familial periodic paralysis', 'Hypokalemic familial periodic paralysis', 'Hypokalemic periodic paralysis', 'periodic hypokalemic paralysis', 'Periodic paralysis I', 'Westphal disease', 'hypokalemic periodic paralysis'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0001909', ['renal tubular acidosis'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14500', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'general uses of potassiumpotassium is indicated to treat a variety of conditions firstly it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption decreased intake or excess sodium intake  the causes of potassium deficiency are numerous the following indications for potassium are not comprehensive but include the main indications for which this nutrient is used various products and preparations contain potassiumpotassium chloridepotassium chloride is one of the main preparations of potassium used in a clinical setting the oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis in patients who have failed conservative management with potassiumrich foods or diuretic dose titrationsl8744 the injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrationsl8768finally the extendedrelease tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis to treat digitalis intoxication and to manage patients with hypokalemic familial periodic paralysis it is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomesl8771potassium chloride with dextrose and sodium chloride this liquid preparation is is indicated in a clinical setting as a source of water calories and electrolytesl8747 potassium acetate solution is meant as an alternative to potassium chloride replenishing potassium and added to large volume infusion fluids for intravenous injectionl8759potassium citratethe potassium citrate preparation is used for the management of renal tubular acidosis rta with calcium stones nephrolithiasis calcium oxalate stones by any cause and uric acid nephrolithiasis with or without calcium stones this regimen also includes adequate water intake leading to a urine out put of 2 lday or more and sodium restrictionl8753')|
|('DB14501', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'used in preventing and treating irondeficiency anemia')|
|('DB14501', 'MONDO:0002280', ['anaemia', 'anemia'], 'used in preventing and treating irondeficiency anemia')|
|('DB14502', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'used to treat constipation or to clean the bowel before a colonoscopy fda label')|
|('DB14503', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'used to treat constipation or to clean the bowel before a colonoscopy fda label')|
|('DB14505', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'no fda or emaapproved therapeutic indications on its own')|
|('DB14507', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'lithium is used as a mood stabilizer and is used for treatment of depression and mania it is often used in bipolar disorder treatment')|
|('DB14509', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'lithium is used as a mood stabilizer and is indicated for the treatment of manic episodes and maintenance of bipolar disorderfda label')|
|('DB14512', 'MONDO:0008171', ['kidney stones', 'Stone - kidney/ureter', 'nephrolithiasis'], 'there are 3 formulations of mometasone furoate with various indications the inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsfda label the nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years treating nasal polyps in patients ≥18 years and prophylaxis of seasonal allergic rhinitis in patients ≥12 yearsf4292 the ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 yearsf4295')|
|('DB14512', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'there are 3 formulations of mometasone furoate with various indications the inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsfda label the nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years treating nasal polyps in patients ≥18 years and prophylaxis of seasonal allergic rhinitis in patients ≥12 yearsf4292 the ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 yearsf4295')|
|('DB14512', 'MONDO:0011786', ['atopic rhinitis', 'hay fever', 'Non-seasonal allergic rhinitis', 'Perenial allergic rhinitis', 'pollenosis', 'seasonal allergic rhinitis', 'allergic rhinitis'], 'there are 3 formulations of mometasone furoate with various indications the inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsfda label the nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years treating nasal polyps in patients ≥18 years and prophylaxis of seasonal allergic rhinitis in patients ≥12 yearsf4292 the ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 yearsf4295')|
|('DB14512', 'MONDO:0005324', ['seasonal allergic rhinitis [NCIT:C92188]', 'hay fever [NCIT:C92188]', 'seasonal allergic rhinitis'], 'there are 3 formulations of mometasone furoate with various indications the inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsfda label the nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years treating nasal polyps in patients ≥18 years and prophylaxis of seasonal allergic rhinitis in patients ≥12 yearsf4292 the ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 yearsf4295')|
|('DB14512', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'there are 3 formulations of mometasone furoate with various indications the inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsfda label the nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years treating nasal polyps in patients ≥18 years and prophylaxis of seasonal allergic rhinitis in patients ≥12 yearsf4292 the ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 yearsf4295')|
|('DB14513', 'MONDO:0002406', ['eczema', 'skin inflammation', 'dermatitis'], 'healthy levels of magnesium can be achieved through a well balanced diet but if food sources are insufficient magnesium supplements can be used to prevent and treat magnesium deficienciesl2601in medicine various magnesium salts may be used in laxative and antacid productsa19349 for example magnesium citrate is a available overthecounter and may be used to manage occasional constipationl10349 magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemial10355 magnesium sulfate is also indicated to prevent seizures in pregnant women with preeclampsia and to manage seizures associated with eclampsiaa188087l10355')|
|('DB14513', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'healthy levels of magnesium can be achieved through a well balanced diet but if food sources are insufficient magnesium supplements can be used to prevent and treat magnesium deficienciesl2601in medicine various magnesium salts may be used in laxative and antacid productsa19349 for example magnesium citrate is a available overthecounter and may be used to manage occasional constipationl10349 magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemial10355 magnesium sulfate is also indicated to prevent seizures in pregnant women with preeclampsia and to manage seizures associated with eclampsiaa188087l10355')|
|('DB14513', 'MONDO:0005081', ['gestational hypertension', 'hypertension induced by pregnancy', 'pre-eclamptic toxaemia', 'preeclampsia', 'preeclampsia/eclampsia', 'pregnancy associated hypertension', 'pregnancy toxemia', 'proteinuric hypertension of pregnancy', 'toxaemia of pregnancy', 'preeclampsia'], 'healthy levels of magnesium can be achieved through a well balanced diet but if food sources are insufficient magnesium supplements can be used to prevent and treat magnesium deficienciesl2601in medicine various magnesium salts may be used in laxative and antacid productsa19349 for example magnesium citrate is a available overthecounter and may be used to manage occasional constipationl10349 magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemial10355 magnesium sulfate is also indicated to prevent seizures in pregnant women with preeclampsia and to manage seizures associated with eclampsiaa188087l10355')|
|('DB14520', 'MONDO:0005081', ['gestational hypertension', 'hypertension induced by pregnancy', 'pre-eclamptic toxaemia', 'preeclampsia', 'preeclampsia/eclampsia', 'pregnancy associated hypertension', 'pregnancy toxemia', 'proteinuric hypertension of pregnancy', 'toxaemia of pregnancy', 'preeclampsia'], 'for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis as ferric citrate')|
|('DB14520', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis as ferric citrate')|
|('DB14526', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB14527', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB14528', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB14529', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB14530', 'MONDO:0005300', ['chronic kidney failure', 'chronic renal disease', 'chronic renal failure syndrome', 'CKD', 'CRF', 'renal failure - chronic', 'chronic kidney disease'], 'indicated for use as a supplement to intravenous solutions given for total parenteral nutrition tpn to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms fda label')|
|('DB14533', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14533', 'MONDO:0021178', ['traumatic injury [NCIT:C3671]', 'wound [NCIT:C3671]', 'trauma [NCIT:C3671]', 'injury [NCIT:C3671]', 'injury'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14533', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'zinc can be used for the treatment and prevention of zinc deficiencyits consequences including stunted growth and acute diarrhea in children and slowed wound healing it is also utilized for boosting the immune system treating the common cold and recurrent ear infections as well as preventing lower respiratory tract infections l2172  ')|
|('DB14538', 'MONDO:0005709', ['acute coryza', 'acute Nasopharyngitis', 'acute nasopharyngitis', 'acute rhinitis', 'Acute viral rhinopharyngitis', 'Nasopharyngitis - acute', 'Nasopharyngitis, acute', 'rhino-sinusitis', 'common cold'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14538', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14538', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14538', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14538', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14539', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14539', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14539', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14539', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14540', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14540', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14540', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14540', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14541', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14541', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14541', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14541', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14542', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14542', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14542', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14542', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14543', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14543', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14543', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14543', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14544', 'MONDO:0005292', ['colitis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14544', 'MONDO:0004670', ['lupus', 'lupus erythematosus'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14544', 'MONDO:0005083', ['psoriasis'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14544', 'MONDO:0004979', ['bronchial hyperreactivity', 'chronic obstructive asthma', 'chronic obstructive asthma with acute exacerbation', 'chronic obstructive asthma with status asthmaticus', 'Exercise induced asthma', 'exercise-induced asthma', 'asthma'], 'for the relief of the inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses also used to treat endocrine hormonal disorders adrenal insufficiency addisons disease it is also used to treat many immune and allergic disorders such as arthritis lupus severe psoriasis severe asthma ulcerative colitis and crohns disease')|
|('DB14562', 'MONDO:0005292', ['colitis'], 'andexanet alfa is indicated for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding l3725 andexxa has not been shown to be effective for and is not indicated for the treatment of bleeding related to any factor xa inhibitors other than apixaban and rivaroxaban l3725')|
|('DB14562', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'andexanet alfa is indicated for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding l3725 andexxa has not been shown to be effective for and is not indicated for the treatment of bleeding related to any factor xa inhibitors other than apixaban and rivaroxaban l3725')|
|('DB14568', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'ivosidenib is approved for use in the treatment of relapsed or refractory aml with a susceptible idh1 mutation as detected by an fdaapproved test fda label')|
|('DB14582', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'patisirant is indicated for the treatment of hereditary transthyretinmediated amyloidosis in adults fda labelit is administered with premedication to reduce complications fda label these include an intravenous corticosteroid equivalent to 10 mg of dexamethasone 500 mg of oral acetaminophen an intravenous histamine h1 blocker equivalent to 50 mg of diphenhydramine and an intravenous histamine h2 blocker equivalent to 50 mg of ranitidine')|
|('DB14582', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'patisirant is indicated for the treatment of hereditary transthyretinmediated amyloidosis in adults fda labelit is administered with premedication to reduce complications fda label these include an intravenous corticosteroid equivalent to 10 mg of dexamethasone 500 mg of oral acetaminophen an intravenous histamine h1 blocker equivalent to 50 mg of diphenhydramine and an intravenous histamine h2 blocker equivalent to 50 mg of ranitidine')|
|('DB14583', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'segesterone acetate in combination with ethinyl estradiol is indicated for use by females of reproductive potential to prevent pregnancy as a combination hormonal contraceptive chc it induces contraception for thirteen 28day cycles 1 year following vaginal administration the vaginal system must remain in place continuously for 3 weeks 21 days followed by a 1week 7day vaginal systemfree interval the use in females with a body mass index of 29 kgm2 has not been adequately evaluated fda label')|
|('DB14583', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'segesterone acetate in combination with ethinyl estradiol is indicated for use by females of reproductive potential to prevent pregnancy as a combination hormonal contraceptive chc it induces contraception for thirteen 28day cycles 1 year following vaginal administration the vaginal system must remain in place continuously for 3 weeks 21 days followed by a 1week 7day vaginal systemfree interval the use in females with a body mass index of 29 kgm2 has not been adequately evaluated fda label')|
|('DB14597', 'MONDO:0019395', ['HS [Orphanet:84085]', 'HAS [Orphanet:84085]', 'non-neurogenic neurogenic bladder [Orphanet:84085]', 'occult neuropathic bladder [Orphanet:84085]', 'Hinman-Allen syndrome [Orphanet:84085]', 'hinman syndrome'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14597', 'MONDO:0019623', ['HANE', 'Hereditary angioedema', 'Hereditary angioneurotic edema', 'hereditary angioedema'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14597', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14597', 'MONDO:0021152', ['inherited'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14597', 'MONDO:0010953', ['FACE', 'FANCE', 'fanconi anemia complementation group e'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14597', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'lanadelumab is indicated for the prophylaxis treatment to prevent attacks in patients 12 years and older with hereditary angioedemal4537the hereditary angioedema hea is an autosomal dominant disorder resulted from the presence of c1 deficiency some reports have indicated a high prevalence of cases that result from spontaneous mutations which can be inherited this condition is manifested by attacks of subcutaneous or submucosal edema in the face larynx gi tract limbs or genitalia from all the types of attacks the most serious is the laryngeal as it can compromise the airway the rest of the attacks are accompanied by pain and considerable dysfunctiona38679 ')|
|('DB14600', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB14600', 'MONDO:0018019', ['saturnism [Orphanet:330015]', 'Lead intoxication [Orphanet:330015]', 'plumbism [Orphanet:330015]', 'lead poisoning'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB14600', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for the reduction of blood levels and depot stores of lead in lead poisoning acute and chronic and lead encephalopathy in both pediatric populations and adults')|
|('DB14635', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'no approved therapeutic indications ')|
|('DB14638', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'diloxanide is used alone as a primary agent in the treatment of asymptomatic cyst passers intestinal amebiasis caused by entamoeba histolytica diloxanide may also be used concurrently or sequentially with other agents such as the nitroimidazoles eg metronidazole in the treatment of invasive or extraintestinal forms of amebiasis')|
|('DB14638', 'MONDO:0005644', ['amoebiasis', 'entamoebiasis', 'amebiasis'], 'diloxanide is used alone as a primary agent in the treatment of asymptomatic cyst passers intestinal amebiasis caused by entamoeba histolytica diloxanide may also be used concurrently or sequentially with other agents such as the nitroimidazoles eg metronidazole in the treatment of invasive or extraintestinal forms of amebiasis')|
|('DB14655', 'MONDO:0005560', ['encephalopathy', 'brain disease'], 'for use in females for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal')|
|('DB14655', 'MONDO:0004992', ['cancer'], 'for use in females for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal')|
|('DB14683', 'MONDO:0004992', ['cancer'], 'commonly used in cosmetic products for the skin and hair a19503')|
|('DB14684', 'MONDO:0004992', ['cancer'], 'polycarbophil is used to treat constipation and to help maintain regular bowel movements')|
|('DB14700', 'MONDO:0004992', ['cancer'], 'indicated for use in previously treated adults and adolescents 12 years of age and above with hemophilia a congenital factor viii deficiency forondemand treatment and control of bleeding episodes fda label perioperative management of bleeding fda label and routine prophylaxis to reduce the frequency of bleeding episodes fda label')|
|('DB14700', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'indicated for use in previously treated adults and adolescents 12 years of age and above with hemophilia a congenital factor viii deficiency forondemand treatment and control of bleeding episodes fda label perioperative management of bleeding fda label and routine prophylaxis to reduce the frequency of bleeding episodes fda label')|
|('DB14700', 'MONDO:0021140', ['inborn []', 'congenital'], 'indicated for use in previously treated adults and adolescents 12 years of age and above with hemophilia a congenital factor viii deficiency forondemand treatment and control of bleeding episodes fda label perioperative management of bleeding fda label and routine prophylaxis to reduce the frequency of bleeding episodes fda label')|
|('DB14707', 'MONDO:0021140', ['inborn []', 'congenital'], 'this drug is a programmed death receptor1 pd1 blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation fda label a39201')|
|('DB14707', 'MONDO:0005096', ['epidermoid carcinoma', 'malignant squamous cell tumor', 'squamous carcinoma', 'squamous cell cancer', 'squamous cell Epithelioma', 'squamous cell carcinoma'], 'this drug is a programmed death receptor1 pd1 blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation fda label a39201')|
|('DB14712', 'MONDO:0005096', ['epidermoid carcinoma', 'malignant squamous cell tumor', 'squamous carcinoma', 'squamous cell cancer', 'squamous cell Epithelioma', 'squamous cell carcinoma'], 'elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency adascid in pediatric and adult patientsl4654 this condition was previously treated by the use of pegamedase bovine as part of an enzyme replacement therapyl4655adascid is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme the patients suffering from this disease often present a compromised immune system this condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infectionsl4656')|
|('DB14712', 'MONDO:0021152', ['inherited'], 'elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency adascid in pediatric and adult patientsl4654 this condition was previously treated by the use of pegamedase bovine as part of an enzyme replacement therapyl4655adascid is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme the patients suffering from this disease often present a compromised immune system this condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infectionsl4656')|
|('DB14713', 'MONDO:0021152', ['inherited'], 'inotersen is a transthyretindirected antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults fda label f1938  ')|
|('DB14713', 'MONDO:0001824', ['polyneuropathy'], 'inotersen is a transthyretindirected antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults fda label f1938  ')|
|('DB14713', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'inotersen is a transthyretindirected antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults fda label f1938  ')|
|('DB14723', 'MONDO:0019065', ['amyloid disease', 'amyloidosis'], 'larotrectinib is a tyrosine kinase inhibitor that is currently indicated for the treatment of adult and pediatric patients with solid tumors that either a have a neurotrophic receptor tyrosine kinase ntrk gene fusion without a known acquired resistance mutation b are metastatic or where surgical resection is likely to result in severe morbidity and c have no satisfactory alternative treatments or that have progressed following treatment fda labelat the moment these uses of larotrectinib are only approved under the auspices of an accelerated approval by the us fda based on overall response rate and duration of response and continuation of support for these indications may be contingent upon the verification and description of continued clinical benefit in confirmatory trials fda label ')|
|('DB14723', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'larotrectinib is a tyrosine kinase inhibitor that is currently indicated for the treatment of adult and pediatric patients with solid tumors that either a have a neurotrophic receptor tyrosine kinase ntrk gene fusion without a known acquired resistance mutation b are metastatic or where surgical resection is likely to result in severe morbidity and c have no satisfactory alternative treatments or that have progressed following treatment fda labelat the moment these uses of larotrectinib are only approved under the auspices of an accelerated approval by the us fda based on overall response rate and duration of response and continuation of support for these indications may be contingent upon the verification and description of continued clinical benefit in confirmatory trials fda label ')|
|('DB14724', 'MONDO:0021141', ['not genetically inherited [Orphanet:409941]', 'acquired'], 'emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis hlh with refractory recurrent or progressive disease or intolerance to conventional hlh therapyl4840the hlh condition is a hyperinflammatory status characterized by the overwhelming activation of normal t lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death as part of the condition profile there have been reports proving a massive overexpression of interferongamma which is thought to drive the immune hyperactivation leading to organ failurea38676 this condition is usually developed and present the symptomatic profile within the first months or years of life these symptoms consist of fever enlarged liver or spleen and a lower number of blood cellsl4840')|
|('DB14724', 'MONDO:0015541', ['familial hemophagocytic lymphohistiocytosis [MONDO:cjm]', 'primary hemophagocytic lymphohistiocytosis [Orphanet:158038]', 'genetic hemophagocytic syndrome [MONDO:patterns/genetic]', 'genetic hemophagocytic lymphohistiocytosis [Orphanet:158038]', 'genetic hemophagocytic lymphohistiocytosis'], 'emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis hlh with refractory recurrent or progressive disease or intolerance to conventional hlh therapyl4840the hlh condition is a hyperinflammatory status characterized by the overwhelming activation of normal t lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death as part of the condition profile there have been reports proving a massive overexpression of interferongamma which is thought to drive the immune hyperactivation leading to organ failurea38676 this condition is usually developed and present the symptomatic profile within the first months or years of life these symptoms consist of fever enlarged liver or spleen and a lower number of blood cellsl4840')|
|('DB14724', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis hlh with refractory recurrent or progressive disease or intolerance to conventional hlh therapyl4840the hlh condition is a hyperinflammatory status characterized by the overwhelming activation of normal t lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death as part of the condition profile there have been reports proving a massive overexpression of interferongamma which is thought to drive the immune hyperactivation leading to organ failurea38676 this condition is usually developed and present the symptomatic profile within the first months or years of life these symptoms consist of fever enlarged liver or spleen and a lower number of blood cellsl4840')|
|('DB14730', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'this drug is is an asparagine specific enzyme indicated as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years fda labelthe pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with bcell lineage all l4890 the fda approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 01 uml when administering calaspargase 2500 um2 intravenously at 3week intervals ')|
|('DB14730', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'this drug is is an asparagine specific enzyme indicated as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years fda labelthe pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with bcell lineage all l4890 the fda approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 01 uml when administering calaspargase 2500 um2 intravenously at 3week intervals ')|
|('DB14731', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm bpdcn in adults and pediatric patients over 2 years old this treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantationl4893bpdcn is a rare hematologic malignancy derived from plasmacytoid dendritic cells it is characterized by the significantly increased expression of cells expressing cd4cd56cd123 and other markers restricted to plasmacytoid dendritic cells and a lack of expression of lymphoid natural killer or myeloid lineageassociated antigensa40274 a key feature of the malignant cells is the overexpression of cd123 also known as interleukin3 receptor and the constant requirement of il3 for survivall4897')|
|('DB14731', 'MONDO:0019467', ['blastic plasmacytoid Dendritic cell neoplasm [NCIT:C7203]', 'monomorphic NK-cell lymphoma [GARD:0010556,NCIT:C7203,Orphanet:86870]', 'blastic NK-cell lymphoma [NCIT:C7203,Orphanet:86870]', 'blastic natural Killer leukemia/lymphoma [NCIT:C7203]', 'agranular CD4+ CD56+ hematodermic neoplasm/tumor [NCIT:C7203]', 'primary cutaneous CD4+/CD56+ hematolymphoid neoplasm [NCIT:C7203]', 'early plasmacytoid Dendritic cell leukemia/lymphoma [NCIT:C7203]', 'CD4+/CD56+ hematodermic neoplasm [GARD:0010556,NCIT:C7203]', 'blastic plasmacytoid dendritic cell neoplasm [Orphanet:86870]', 'BPDCN [Orphanet:86870]', 'agranular CD4+ natural Killer cell leukemia [NCIT:C7203]', 'lymphoblastoid variant of NK-cell lymphoma [GARD:0010556,Orphanet:86870]', 'cd4+/cd56+ hematodermic neoplasm'], 'tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm bpdcn in adults and pediatric patients over 2 years old this treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantationl4893bpdcn is a rare hematologic malignancy derived from plasmacytoid dendritic cells it is characterized by the significantly increased expression of cells expressing cd4cd56cd123 and other markers restricted to plasmacytoid dendritic cells and a lack of expression of lymphoid natural killer or myeloid lineageassociated antigensa40274 a key feature of the malignant cells is the overexpression of cd123 also known as interleukin3 receptor and the constant requirement of il3 for survivall4897')|
|('DB14731', 'MONDO:0044881', ['malignant hematopoietic neoplasm [NCIT:C27134]', 'hematopoietic neoplasms including Lymphomas [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm [NCIT:C27134]', 'hematological tumor [NCIT:C27134]', 'hematopoietic cancer [NCIT:C27134]', 'hematological neoplasm [NCIT:C27134]', 'hematologic neoplasm [NCIT:C27134]', 'hematopoietic malignancy, NOS [NCIT:C27134]', 'HEMOLYMPHORETICULAR tumor, malignant [NCIT:C27134]', 'hematopoietic, Including myeloma [NCIT:C27134]', 'hematopoietic neoplasm [NCIT:C27134]', 'hematologic cancer [NCIT:C27134]', 'hematologic malignancy [NCIT:C27134]', 'hematopoietic and lymphoid neoplasms [NCIT:C27134]', 'hematopoietic tumor [NCIT:C27134]', 'malignant hematologic neoplasm [NCIT:C27134]', 'hematopoietic cell tumor [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm'], 'tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm bpdcn in adults and pediatric patients over 2 years old this treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantationl4893bpdcn is a rare hematologic malignancy derived from plasmacytoid dendritic cells it is characterized by the significantly increased expression of cells expressing cd4cd56cd123 and other markers restricted to plasmacytoid dendritic cells and a lack of expression of lymphoid natural killer or myeloid lineageassociated antigensa40274 a key feature of the malignant cells is the overexpression of cd123 also known as interleukin3 receptor and the constant requirement of il3 for survivall4897')|
|('DB14732', 'MONDO:0044881', ['malignant hematopoietic neoplasm [NCIT:C27134]', 'hematopoietic neoplasms including Lymphomas [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm [NCIT:C27134]', 'hematological tumor [NCIT:C27134]', 'hematopoietic cancer [NCIT:C27134]', 'hematological neoplasm [NCIT:C27134]', 'hematologic neoplasm [NCIT:C27134]', 'hematopoietic malignancy, NOS [NCIT:C27134]', 'HEMOLYMPHORETICULAR tumor, malignant [NCIT:C27134]', 'hematopoietic, Including myeloma [NCIT:C27134]', 'hematopoietic neoplasm [NCIT:C27134]', 'hematologic cancer [NCIT:C27134]', 'hematologic malignancy [NCIT:C27134]', 'hematopoietic and lymphoid neoplasms [NCIT:C27134]', 'hematopoietic tumor [NCIT:C27134]', 'malignant hematologic neoplasm [NCIT:C27134]', 'hematopoietic cell tumor [NCIT:C27134]', 'hematopoietic and lymphoid cell neoplasm'], 'current and ongoing research suggests queuine is a natural biochemical compound that can be found endogenously in the human body and plays an essential role in the generation of other critical bodily chemicals including tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipids and others a173830 a173833 a173851 such research subsequently proposes that if queuine could be utilized as a pharmaceutic that it may be considered a socalled putative longevity vitamin indicated for agedelaying andor prolonged survival functionality perhaps via maintaining the ongoing generation of the aforementioned bodily chemicals for the human body a173830 a173833 a173851  ')|
|('DB14732', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'current and ongoing research suggests queuine is a natural biochemical compound that can be found endogenously in the human body and plays an essential role in the generation of other critical bodily chemicals including tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipids and others a173830 a173833 a173851 such research subsequently proposes that if queuine could be utilized as a pharmaceutic that it may be considered a socalled putative longevity vitamin indicated for agedelaying andor prolonged survival functionality perhaps via maintaining the ongoing generation of the aforementioned bodily chemicals for the human body a173830 a173833 a173851  ')|
|('DB14738', 'MONDO:0012833', ['CAN', 'Crouzon-dermoskeletal syndrome', 'Crouzonodermoskeletal syndrome', 'crouzon syndrome-acanthosis nigricans syndrome'], 'turoctocog alfa pegol n8gp is indicated for use in adults and children of all ages with hemophilia a congenital factor viii deficiency for routine prophylaxis in reducing the frequency of bleeding episodes ondemand treatment and control of bleeding episodes and the perioperative management of bleeding f3649')|
|('DB14738', 'MONDO:0004967', ['acute lymphoblastic leukaemia', 'acute lymphoblastic leukemia', 'acute lymphocytic leukaemia', 'ALL', 'precursor lymphoblastic lymphoma/leukemia', 'acute lymphoblastic leukemia'], 'turoctocog alfa pegol n8gp is indicated for use in adults and children of all ages with hemophilia a congenital factor viii deficiency for routine prophylaxis in reducing the frequency of bleeding episodes ondemand treatment and control of bleeding episodes and the perioperative management of bleeding f3649')|
|('DB14738', 'MONDO:0010602', ['classic hemophilia A', 'Congenital factor VIII disorder', 'Hemophilia A', 'Subhemophilia', 'hemophilia a'], 'turoctocog alfa pegol n8gp is indicated for use in adults and children of all ages with hemophilia a congenital factor viii deficiency for routine prophylaxis in reducing the frequency of bleeding episodes ondemand treatment and control of bleeding episodes and the perioperative management of bleeding f3649')|
|('DB14738', 'MONDO:0021140', ['inborn []', 'congenital'], 'turoctocog alfa pegol n8gp is indicated for use in adults and children of all ages with hemophilia a congenital factor viii deficiency for routine prophylaxis in reducing the frequency of bleeding episodes ondemand treatment and control of bleeding episodes and the perioperative management of bleeding f3649')|
|('DB14751', 'MONDO:0021140', ['inborn []', 'congenital'], 'mecasermin rinfabate was approved for treatment of severe primary insulinlike growth factor igf deficiency or in patients with gh gene deletion who have developed antibodies to growth hormone gha176020severe primary igf1 deficiency is defined byfda labela height standard deviation sd score less than or equal to 3 sd below normalb basal igf1 sd score less than or equal to 3 sd below normalc normal or above normal levels of growth hormonein 2007 insmed mecasermin rinfabates manufacturer made an agreement with tercica mecasermins manufacturer that mecasermin would no longer be available for this indication but could be developed for non short stature conditions such as severe insulin resistance myotonic muscular dystrophy and hiv associated adipose redistribution syndromea176125')|
|('DB14751', 'MONDO:0020121', ['muscular dystrophy'], 'mecasermin rinfabate was approved for treatment of severe primary insulinlike growth factor igf deficiency or in patients with gh gene deletion who have developed antibodies to growth hormone gha176020severe primary igf1 deficiency is defined byfda labela height standard deviation sd score less than or equal to 3 sd below normalb basal igf1 sd score less than or equal to 3 sd below normalc normal or above normal levels of growth hormonein 2007 insmed mecasermin rinfabates manufacturer made an agreement with tercica mecasermins manufacturer that mecasermin would no longer be available for this indication but could be developed for non short stature conditions such as severe insulin resistance myotonic muscular dystrophy and hiv associated adipose redistribution syndromea176125')|
|('DB14753', 'MONDO:0020121', ['muscular dystrophy'], 'used in the treatment of nonprogressive blastomycosis of the skin and other mycoses')|
|('DB14754', 'MONDO:0020121', ['muscular dystrophy'], 'solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy but is not a treatment for the underlying airway obstruction in apnea patientsfda labela176534a176744')|
|('DB14754', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy but is not a treatment for the underlying airway obstruction in apnea patientsfda labela176534a176744')|
|('DB14762', 'MONDO:0021107', ['Narcolepsy, without cataplexy', 'paroxysmal sleep', 'narcolepsy'], 'this drug is for the treatment of moderatetosevere plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease processfda label')|
|('DB14762', 'MONDO:0005083', ['psoriasis'], 'this drug is for the treatment of moderatetosevere plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease processfda label')|
|('DB14783', 'MONDO:0005083', ['psoriasis'], 'diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis ms in adults specifically active secondary progressive disease and clinically isolated syndrome as well as relapsingremitting msl9623l9629l9632')|
|('DB14783', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis ms in adults specifically active secondary progressive disease and clinically isolated syndrome as well as relapsingremitting msl9623l9629l9632')|
|('DB14864', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degenerationa187208l9089')|
|('DB14879', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'cefiderocol is indicated for the treatment of complicated urinary tract infections with or without pyelonephritisfda label')|
|('DB14962', 'MONDO:0005301', ['Generalized multiple sclerosis', 'insular sclerosis', 'multiple sclerosis'], 'trastuzumab deruxtecan is indicated for the treatment of adult patients with her2 positive breast cancer that is unresectable or metastatic and was previously treated with at least 2 antiher2based regimens while the cancer was metastaticl10842continued approval will depend on the results of clinical trial results confirming its clinical benefitl10842')|
|('DB14962', 'MONDO:0004992', ['cancer'], 'trastuzumab deruxtecan is indicated for the treatment of adult patients with her2 positive breast cancer that is unresectable or metastatic and was previously treated with at least 2 antiher2based regimens while the cancer was metastaticl10842continued approval will depend on the results of clinical trial results confirming its clinical benefitl10842')|
|('DB14975', 'MONDO:0004992', ['cancer'], 'voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 12 years and abovel10397')|
|('DB15035', 'MONDO:0004992', ['cancer'], 'zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyl10163')|
|('DB15035', 'MONDO:0018876', ['mantle cell lymphoma'], 'zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyl10163')|
|('DB15066', 'MONDO:0018876', ['mantle cell lymphoma'], 'givosiran is indicated for the treatment of adults with acute hepatic porphyrial10202')|
|('DB15091', 'MONDO:0018876', ['mantle cell lymphoma'], 'upadacitinib is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexatel10896for patients who do not responded well or are intolerant to one or more diseasemodifying antirheumatic drugs dmards upadacitinib may be used as monotherapy or in combination with methotrexate mtxl10899')|
|('DB15091', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'upadacitinib is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexatel10896for patients who do not responded well or are intolerant to one or more diseasemodifying antirheumatic drugs dmards upadacitinib may be used as monotherapy or in combination with methotrexate mtxl10899')|
|('DB15271', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'crizanlizumab is indicated to reduce the frequency of vasoocclusive crisis in patients with sickle cell diseases who are ≥16 years oldl10097')|
|('DB15328', 'MONDO:0005578', ['Inflammatory disorder of joint', 'arthritis'], 'ubrogepant is indicated for the acute treatment of migraine with or without aura in adultsl10926')|
|('DB15328', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'ubrogepant is indicated for the acute treatment of migraine with or without aura in adultsl10926')|
|('DB15444', 'MONDO:0005277', ['migraine disorder', 'migraine variant', 'migraine with or without aura', 'migraine disorder'], 'elexacaftor in combination with ivacaftor and tezacaftor as the combination product trikaftasuptmsup is indicated for the treatment of cystic fibrosis cf in patients 12 years of age and older who have at least one f508del mutation in the ctfr genel9395')|
|('DB15444', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'elexacaftor in combination with ivacaftor and tezacaftor as the combination product trikaftasuptmsup is indicated for the treatment of cystic fibrosis cf in patients 12 years of age and older who have at least one f508del mutation in the ctfr genel9395')|
|('DB15465', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'benzyhydrocodone is indicated in combination with acetaminophen for the shortterm management of acute pain requiring opioid therapyl4894')|
|('DB15466', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'tallimustine was being investigated for its use in treating tumorsa182036a182039 derivatives of tallimustine with similar dna binding ability and reduced myelotoxicity are being investigated for their antitumor activitya182039')|
|('DB15489', 'MONDO:0009061', ['CF', 'mucoviscidosis', 'cystic fibrosis'], 'mexazolam is indicated for the treatment of anxiety with or without psychoneurotic conditionsa184910')|
|('DB15489', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'mexazolam is indicated for the treatment of anxiety with or without psychoneurotic conditionsa184910')|
|('DB15494', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'edotreotide gallium ga68 is a radioactive diagnostic compound used in positron emission tomography pet for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adultsl8597')|
|('DB15528', 'MONDO:0011918', ['anxiety [OMIM:607834]', 'anxiety'], 'onasemnogene abeparvovec is indicated for the treatment of pediatric patients less than 2 years of age neonatal and infant patients with spinal muscular atrophy sma with biallelic mutations in the survival motor neuron 1 smn1 genel9194')|
|('DB15528', 'MONDO:0001516', ['spinal muscular atrophy'], 'onasemnogene abeparvovec is indicated for the treatment of pediatric patients less than 2 years of age neonatal and infant patients with spinal muscular atrophy sma with biallelic mutations in the survival motor neuron 1 smn1 genel9194')|
|('DB15566', 'MONDO:0001516', ['spinal muscular atrophy'], 'prednisolone acetate is indicated as an antiinflammatory or immunosuppressive agent for allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic or infectious conditionsl9449 prednisolone acetate is also indicated in organ transplant patients as well as endocrine or neoplastic conditionsl9449')|
|('DB15568', 'MONDO:0001516', ['spinal muscular atrophy'], 'mrtx849 is an experimental kras inhibitor being investigated for the treatment of kras g12c mutant lung and colon adenocarcinomasa187559')|
|('DB15569', 'MONDO:0001516', ['spinal muscular atrophy'], 'amg510 is being investigated for the treatment of kras g12c mutant non small cell lung cancer colorectal cancer and appendix cancera187547')|
|('DB15569', 'MONDO:0004992', ['cancer'], 'amg510 is being investigated for the treatment of kras g12c mutant non small cell lung cancer colorectal cancer and appendix cancera187547')|
|('DB15593', 'MONDO:0004992', ['cancer'], 'golodirsen is indicated to treat duchenne muscular dystrophy dmd in patients with a confirmed mutation of the dmd gene that would benefit from exon 53 skipping continued fda approval of this drug is contingent upon the results of clinical trials to confirm its benefitl10755l10758')|
|('DB15593', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'golodirsen is indicated to treat duchenne muscular dystrophy dmd in patients with a confirmed mutation of the dmd gene that would benefit from exon 53 skipping continued fda approval of this drug is contingent upon the results of clinical trials to confirm its benefitl10755l10758')|
|('DB15594', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'this drug is indicated for selectively staining the internal limiting membrane ilml10830')|
|('DB15595', 'MONDO:0010679', ['Muscular dystrophy, Duchenne', 'duchenne muscular dystrophy'], 'ebola zaire vaccine is indicated for active immunization of individuals 18 years of age or older to protect against ebola virus disease evd caused by zaire ebolavirusl10857')|
|('DB15595', 'MONDO:0005737', ['Ebola virus disease', 'ebola hemorrhagic fever'], 'ebola zaire vaccine is indicated for active immunization of individuals 18 years of age or older to protect against ebola virus disease evd caused by zaire ebolavirusl10857')|
